trm_lvl_id,pmid,page,original_strings_caught_from_tt,mesh_term,mesh_code,atc_code,risk_score,tid,global,global_n,global_pcdsfartl,mesh_term_f,txt_id
1,10438259,2,age,Age Factors,D000367,NA,0,746,any,2,000000000,Age Factors,NA
2,10438259,2,aspirin use,Aspirin,D001241,NA,0,746,any,2,000000000,Aspirin,NA
3,10438259,2,aspirin use;no beta-blocker use,Adrenergic beta-Antagonists,D000319,NA,0,746,any,2,000000000,Adrenergic beta-Antagonists,NA
4,10438259,2,diabetes,Diabetes Mellitus,D003920,NA,0,746,any,2,000000000,Diabetes Mellitus,NA
5,10438259,2,family history^,Medical History Taking,D008487,NA,0,746,family history,6,000010000,Medical History Taking,NA
6,10438259,2,HDL cholesterol,Lipoproteins,D008074,NA,0,746,any,2,000000000,Lipoproteins,NA
7,10438259,2,hdl cholesterolÂ§;5151 mg/dl ldl cholesterol ||,Lipoproteins,D008074,NA,0,746,any,2,000000000,Lipoproteins,NA
8,10438259,2,hdl cholesterolÂ§;531.5 mg/dl triglycerides^,Lipoproteins,D008074,NA,0,746,any,2,000000000,Lipoproteins,NA
9,10438259,2,Hypertension,Hypertension,D006973,NA,0,746,any,2,000000000,Hypertension,NA
10,10438259,2,prior myocardial infarction,Myocardial Infarction,D009203,NA,0,746,previous,8,100000000,Myocardial Infarction,NA
11,10438259,2,race,Racial Groups,D044469,NA,0,746,any,2,000000000,Racial Groups,NA
12,10438259,2,Smoker,Cigarette Smoking,D000073865,NA,0,746,any,2,000000000,Cigarette Smoking,NA
13,10438259,2,smoking;current,Cigarette Smoking,D000073865,NA,0,746,current,3,010000000,Cigarette Smoking,NA
14,10636365,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,226
15,10789602,NA,enrollment in the first or second cohort,unclassifible,NA,NA,0,0,any,2,000000000,unclassifible,NA
16,10789602,NA,number of baseline Raynaud phenomenon attacks,unclassifible,NA,NA,0,0,any,2,000000000,unclassifible,NA
17,10789602,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,254
18,10789602,NA,whether bio feedback control was learned to criterion,unclassifible,NA,NA,0,0,any,2,000000000,unclassifible,NA
19,10789602,NA,whether randomization was to the preferred treatment,unclassifible,NA,NA,0,0,any,2,000000000,unclassifible,NA
20,10789664,NA,Age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
21,10789664,NA,patients with vs without diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
22,10789664,NA,Race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
23,11104295,NA,Medical History: digital blood pressure responses to cooling,Blood Pressure,D001794,NA,0,0,previous,8,100000000,Blood Pressure,NA
24,11419425,2,acute coronary syndrome,Acute Coronary Syndrome,D054058,NA,0,1830,any,2,000000000,Acute Coronary Syndrome,NA
25,11419425,2,age;<65 yr,Age Factors,D000367,NA,0,1830,any,2,000000000,Age Factors,NA
26,11419425,2,age;>=65 yr,Age Factors,D000367,NA,0,1830,any,2,000000000,Age Factors,NA
27,11419425,2,clopidogrel given before procedure,Fibrinolytic Agents,D005343,NA,0,1830,any,2,000000000,Fibrinolytic Agents,NA
28,11419425,2,clopidogrel given before procedure;no,Fibrinolytic Agents,D005343,NA,0,1830,any,2,000000000,Fibrinolytic Agents,NA
29,11419425,2,clopidogrel given before procedure;yes,Fibrinolytic Agents,D005343,NA,0,1830,any,2,000000000,Fibrinolytic Agents,NA
30,11419425,2,diabetes,Diabetes Mellitus,D003920,NA,0,1830,any,2,000000000,Diabetes Mellitus,NA
31,11419425,2,diabetes;no,Diabetes Mellitus,D003920,NA,0,1830,any,2,000000000,Diabetes Mellitus,NA
32,11419425,2,diabetes;yes,Diabetes Mellitus,D003920,NA,0,1830,any,2,000000000,Diabetes Mellitus,NA
33,11419425,2,indication for stent,Stents,D015607,NA,0,1830,any,2,000000000,Stents,NA
34,11419425,2,indication for stent;other,Stents,D015607,NA,0,1830,any,2,000000000,Stents,NA
35,11419425,2,location of treatment center,Geographic Locations,D005842,NA,0,1830,any,2,000000000,Geographic Locations,NA
36,11419425,2,location of treatment center;other,Geographic Locations,D005842,NA,0,1830,any,2,000000000,Geographic Locations,NA
37,11419425,2,location of treatment center;united states,Geographic Locations,D005842,NA,0,1830,any,2,000000000,Geographic Locations,NA
38,11419425,2,sex,Gender Identity,D005783,NA,0,1830,any,2,000000000,Gender Identity,NA
39,11419425,2,sex;female,Gender Identity,D005783,NA,0,1830,any,2,000000000,Gender Identity,NA
40,11419425,2,sex;male,Gender Identity,D005783,NA,0,1830,any,2,000000000,Gender Identity,NA
41,11419426,NA,Age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
42,11419426,NA,Cardiogenic shock,"Shock, Cardiogenic",D012770,NA,0,0,any,2,000000000,"Shock, Cardiogenic",NA
43,11419426,NA,Diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
44,11419426,NA,Onset of chest pain,Chest Pain,D002637,NA,0,0,any,2,000000000,Chest Pain,NA
45,11419426,NA,Sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
46,11419426,NA,Target vessel diameter,unclassifiable,NA,NA,0,0,any,2,000000000,unclassifiable,NA
47,11419426,NA,Type of MI,Myocardial Infarction,D009203,NA,0,0,type,12,000000010,Myocardial Infarction,NA
48,11442551,2,;all randomized women,Gender Identity,D005783,NA,0,1726,any,2,000000000,Gender Identity,NA
49,11442551,2,";post-menopausal with hormone replacementÂ therapy (asa 6,091/placebo 5957)",Estrogen Replacement Therapy,D015914,NA,0,1726,any,2,000000000,Estrogen Replacement Therapy,NA
50,11442551,2,";post-menopausal without hormone replacementÂ therapy (asa 3,261/placebo 3264)",Estrogen Replacement Therapy,D015914,NA,0,1726,any,2,000000000,Estrogen Replacement Therapy,NA
51,11442551,2,;pre-menopausal with hormone replacementÂ therapy (asa 530/placebo 481),Estrogen Replacement Therapy,D015914,NA,0,1726,any,2,000000000,Estrogen Replacement Therapy,NA
52,11442551,2,;pre-menopausal without hormone replacementÂ therapy (asa 4626/placebo 4703),Estrogen Replacement Therapy,D015914,NA,0,1726,any,2,000000000,Estrogen Replacement Therapy,NA
53,11527638,1,ace inhibitors,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,1826,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
54,11527638,1,age (yrs),Age Factors,D000367,NA,0,1826,any,2,000000000,Age Factors,NA
55,11527638,1,age (yrs);<50,Age Factors,D000367,NA,0,1826,any,2,000000000,Age Factors,NA
56,11527638,1,age (yrs);>80,Age Factors,D000367,NA,0,1826,any,2,000000000,Age Factors,NA
57,11527638,1,age (yrs);50-59,Age Factors,D000367,NA,0,1826,any,2,000000000,Age Factors,NA
58,11527638,1,age (yrs);60-69,Age Factors,D000367,NA,0,1826,any,2,000000000,Age Factors,NA
59,11527638,1,age (yrs);70-79,Age Factors,D000367,NA,0,1826,any,2,000000000,Age Factors,NA
60,11527638,1,diabetes etiology,Diabetes Mellitus,D003920,NA,0,1826,aetiological,1,000001000,Diabetes Mellitus,NA
61,11527638,1,hypertension,Hypertension,D006973,NA,0,1826,any,2,000000000,Hypertension,NA
62,11527638,1,male,Gender Identity,D005783,NA,0,1826,any,2,000000000,Gender Identity,NA
63,11527638,1,n,Age Factors,D000367,NA,0,1826,any,2,000000000,Age Factors,NA
64,11527638,1,nonwhite,Racial Groups,D044469,NA,0,1826,any,2,000000000,Racial Groups,NA
65,11527638,1,prior mi,Myocardial Infarction,D009203,NA,0,1826,previous,8,100000000,Myocardial Infarction,NA
66,11918909,NA,history of  previous myocardial infarction,Myocardial Infarction,D009203,NA,0,0,previous,8,100000000,Myocardial Infarction,274
67,11918909,NA,revascularisation procedure,Myocardial Revascularization,D009204,NA,0,0,any,2,000000000,Myocardial Revascularization,NA
68,11937179,NA,Medical History: Diabetes,Diabetes Mellitus,D003920,NA,0,0,previous,8,100000000,Diabetes Mellitus,50
69,11948888,NA,angina type,Angina Pectoris,D000787,NA,0,0,type,12,000000010,Angina Pectoris,59
70,12086367,NA,study center,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,262
71,12205648,2,dementia,Dementia,D003704,NA,0,656,severity,11,000100000,Dementia,NA
72,12243636,NA,isolated systolic hypertension,Hypertension,D006973,NA,0,0,any,2,000000000,Hypertension,278
73,12409542,NA,Patient Variable: Gender,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,237
74,12456232,3,fasting plasma insulin,Insulin,D007328,NA,0,1436,any,2,000000000,Insulin,NA
75,12466506,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
76,12466506,NA,cad,Coronary Artery Disease,D003324,NA,0,0,any,2,000000000,Coronary Artery Disease,NA
77,12466506,NA,duration of af,Atrial Fibrillation,D001281,NA,0,0,duration,5,001000000,Atrial Fibrillation,NA
78,12466506,NA,heart failure,Heart Failure,D006333,NA,0,0,any,2,000000000,Heart Failure,NA
79,12466506,NA,hypertension,Hypertension,D006973,NA,0,0,any,2,000000000,Hypertension,NA
80,12466506,NA,lvef,Stroke Volume,D013318,NA,0,0,any,2,000000000,Stroke Volume,NA
81,12466506,NA,rhythm at randomisation,"Arrhythmias, Cardiac",D001145,NA,0,0,type,12,000000010,"Arrhythmias, Cardiac",NA
82,12466506,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
83,12466506,NA,type of episode of af,Atrial Fibrillation,D001281,NA,0,0,type,12,000000010,Atrial Fibrillation,NA
84,12479763,NA,DIABETES,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
85,12479763,NA,participants less than 65 and 65 years or older,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
86,12479763,NA,post hoc subgroups presence or absence of CHD at baseline,Coronary Artery Disease,D003324,NA,0,0,any,2,000000000,Coronary Artery Disease,NA
87,12479763,NA,RACE,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
88,12479763,NA,"subgroups, (1) men and women, (2) participants less than 65 and 65 years or older, (3) black and nonblack participants, and (4) diabetic and nondiabetic participants, and the post hoc subgroups presence or absence of CHD at baseline",Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
89,12479764,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
90,12479764,NA,Age-Years,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
91,12479764,NA,chd,Coronary Artery Disease,D003324,NA,0,0,any,2,000000000,Coronary Artery Disease,NA
92,12479764,NA,chd and ldl<130,complex,NA,NA,0,0,any,2,000000000,complex,NA
93,12479764,NA,composite NO CHD and LDL high,complex,NA,NA,0,0,any,2,000000000,complex,NA
94,12479764,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
95,12479764,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
96,12479764,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
97,12505224,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,89
98,12505224,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,250
99,12505224,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,250
100,12601075,2,age,Age Factors,D000367,NA,0,4,any,2,000000000,Age Factors,NA
101,12601075,2,factor v leiden or prothrombin mutation,Thrombophilia,D019851,NA,0,4,any,2,000000000,Thrombophilia,NA
102,12601075,2,factor v leiden or prothrombin mutation;present,Thrombophilia,D019851,NA,0,4,any,2,000000000,Thrombophilia,NA
103,12601075,2,no. of previous venous thromboembolic events,Venous Thromboembolism,D054556,NA,0,4,previous,8,100000000,Venous Thromboembolism,NA
104,12601075,2,sex,Gender Identity,D005783,NA,0,4,any,2,000000000,Gender Identity,NA
105,12601075,2,time since cessation of full-dose warfarin therapy,Anticoagulants,D000925,NA,0,4,any,2,000000000,Anticoagulants,NA
106,12803733,2,HbA1c,Glycated Hemoglobin A,D006442,NA,0,1584,any,2,000000000,Glycated Hemoglobin A,NA
107,12803733,2,hba1c strata,Glycated Hemoglobin A,D006442,NA,0,1584,any,2,000000000,Glycated Hemoglobin A,NA
108,12803733,3,HbA1c,Glycated Hemoglobin A,D006442,NA,0,1213,any,2,000000000,Glycated Hemoglobin A,NA
109,12803733,3,hba1c strata,Glycated Hemoglobin A,D006442,NA,0,1213,any,2,000000000,Glycated Hemoglobin A,NA
110,12803733,4,HbA1c,Glycated Hemoglobin A,D006442,NA,0,1746,any,2,000000000,Glycated Hemoglobin A,NA
111,12803733,4,hba1c strata,Glycated Hemoglobin A,D006442,NA,0,1746,any,2,000000000,Glycated Hemoglobin A,NA
112,12803733,5,HbA1c,Glycated Hemoglobin A,D006442,NA,0,161,any,2,000000000,Glycated Hemoglobin A,NA
113,12803733,5,hba1c strata,Glycated Hemoglobin A,D006442,NA,0,161,any,2,000000000,Glycated Hemoglobin A,NA
114,12860578,NA,calcium channel blocker,Calcium Channel Blockers,D002121,NA,0,0,any,2,000000000,Calcium Channel Blockers,191
115,12899584,2,;patients with clinically evident vascular disease,Vascular Diseases,D014652,NA,0,1333,any,2,000000000,Vascular Diseases,NA
116,12899584,2,;patients without clinically evident vascular disease,Vascular Diseases,D014652,NA,0,1333,any,2,000000000,Vascular Diseases,NA
117,12925554,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
118,12925554,NA,Age-Years,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
119,12925554,NA,chd,Coronary Artery Disease,D003324,NA,0,0,any,2,000000000,Coronary Artery Disease,NA
120,12925554,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
121,12925554,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
122,12925554,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
123,14506118,NA,patients with elevated levels of cardiac troponin T or to those with ST-segment depression,Troponin,D014336,NA,0,0,any,2,000000000,Troponin,112
124,14657064,2,"age, y",Age Factors,D000367,NA,0,1097,any,2,000000000,Age Factors,NA
125,14657064,2,congestive heart failure,Heart Failure,D006333,NA,0,1097,any,2,000000000,Heart Failure,NA
126,14657064,2,diabetes,Diabetes Mellitus,D003920,NA,0,1097,any,2,000000000,Diabetes Mellitus,NA
127,14657064,2,Hypercholesterolemia,Hypercholesterolemia,D006937,NA,0,1097,any,2,000000000,Hypercholesterolemia,NA
128,14657064,2,left ventricular hypertrophy,"Hypertrophy, Left Ventricular",D017379,NA,0,1097,any,2,000000000,"Hypertrophy, Left Ventricular",NA
129,14657064,2,myocardial infarction,Myocardial Infarction,D009203,NA,0,1097,any,2,000000000,Myocardial Infarction,NA
130,14657064,2,race/ethnicity,Racial Groups,D044469,NA,0,1097,any,2,000000000,Racial Groups,NA
131,14657064,2,revascularization,Myocardial Revascularization,D009204,NA,0,1097,any,2,000000000,Myocardial Revascularization,NA
132,14657064,2,sex,Gender Identity,D005783,NA,0,1097,any,2,000000000,Gender Identity,NA
133,14657064,2,us resident,Racial Groups,D044469,NA,0,1097,any,2,000000000,Racial Groups,NA
134,14661009,NA,"According to the analysis of the subgroup with the use of other concomitant drugs, the cardiovascularevent–inhibiting effects of candesartan were also significant in patients receiving conventional dru",unclassifiable,NA,NA,0,0,any,2,000000000,unclassifiable,NA
135,14687444,NA,ACR functional class,"Arthritis, Rheumatoid",D001172,NA,0,0,severity,11,000100000,"Arthritis, Rheumatoid",NA
136,14687444,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,91
137,14687444,NA,joint,"Arthritis, Rheumatoid",D001172,NA,0,0,any,2,000000000,"Arthritis, Rheumatoid",NA
138,14687444,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,90
139,14687444,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,90
140,14687444,NA,tertiles of patient global assessmentof disease status,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,90
141,14724302,2,age,Age Factors,D000367,NA,0,227,any,2,000000000,Age Factors,NA
142,14724302,2,age;<70 yr,Age Factors,D000367,NA,0,227,any,2,000000000,Age Factors,NA
143,14724302,2,age;>70 yr,Age Factors,D000367,NA,0,227,any,2,000000000,Age Factors,NA
144,14724302,2,angina class iii or iv prior myocardial infarction,Myocardial Infarction,D009203,NA,0,227,previous severity,9,100100000,Myocardial Infarction,NA
145,14724302,2,angina class iii or iv prior myocardial infarction;no,Myocardial Infarction,D009203,NA,0,227,previous severity,9,100100000,Myocardial Infarction,NA
146,14724302,2,angina class iii or iv prior myocardial infarction;yes,Myocardial Infarction,D009203,NA,0,227,previous severity,9,100100000,Myocardial Infarction,NA
147,14724302,2,diabetes,Diabetes Mellitus,D003920,NA,0,227,any,2,000000000,Diabetes Mellitus,NA
148,14724302,2,diabetes;no,Diabetes Mellitus,D003920,NA,0,227,any,2,000000000,Diabetes Mellitus,NA
149,14724302,2,diabetes;yes,Diabetes Mellitus,D003920,NA,0,227,any,2,000000000,Diabetes Mellitus,NA
150,14724302,2,intervention in complex lesions,Coronary Artery Disease,D003324,NA,0,227,severity,11,000100000,Coronary Artery Disease,NA
151,14724302,2,intervention in complex lesions;no,Coronary Artery Disease,D003324,NA,0,227,severity,11,000100000,Coronary Artery Disease,NA
152,14724302,2,intervention in complex lesions;yes,Coronary Artery Disease,D003324,NA,0,227,severity,11,000100000,Coronary Artery Disease,NA
153,14724302,2,sex,Gender Identity,D005783,NA,0,227,any,2,000000000,Gender Identity,NA
154,14724302,2,sex;female,Gender Identity,D005783,NA,0,227,any,2,000000000,Gender Identity,NA
155,14724302,2,sex;male,Gender Identity,D005783,NA,0,227,any,2,000000000,Gender Identity,NA
156,14996776,NA,Age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
157,14996776,NA,Body mass index,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,NA
158,14996776,NA,"High-density lipoprotein, mg/dl",Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,NA
159,14996776,NA,History of diabetes mellitus,Diabetes Mellitus,D003920,NA,0,0,previous,8,100000000,Diabetes Mellitus,NA
160,14996776,NA,History of hypertension,Hypertension,D006973,NA,0,0,previous,8,100000000,Hypertension,NA
161,14996776,NA,History of statin use,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,0,previous,8,100000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
162,14996776,NA,"Low-density lipoprotein, mg/dl",Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,NA
163,14996776,NA,Metabolic syndrome,Metabolic Syndrome,D024821,NA,0,0,any,2,000000000,Metabolic Syndrome,NA
164,14996776,NA,Race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
165,14996776,NA,Sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
166,14996776,NA,Smoking status,Cigarette Smoking,D000073865,NA,0,0,any,2,000000000,Cigarette Smoking,NA
167,15028365,1,age,Age Factors,D000367,NA,0,1693,any,2,000000000,Age Factors,NA
168,15028365,1,alcohol intake,Alcohol Drinking,D000428,NA,0,1693,any,2,000000000,Alcohol Drinking,NA
169,15028365,1,angina,Angina Pectoris,D000787,NA,0,1693,any,2,000000000,Angina Pectoris,NA
170,15028365,1,BMI,Body Mass Index,D015992,NA,0,1693,any,2,000000000,Body Mass Index,NA
171,15028365,1,diabetes,Diabetes Mellitus,D003920,NA,0,1693,any,2,000000000,Diabetes Mellitus,NA
172,15028365,1,diastolic bp,Blood Pressure,D001794,NA,0,1693,any,2,000000000,Blood Pressure,NA
173,15028365,1,ecg-lvh (cornell),"Hypertrophy, Left Ventricular",D017379,NA,0,1693,any,2,000000000,"Hypertrophy, Left Ventricular",NA
174,15028365,1,ecg-lvh (sokolow-lyon),"Hypertrophy, Left Ventricular",D017379,NA,0,1693,any,2,000000000,"Hypertrophy, Left Ventricular",NA
175,15028365,1,exercise status,Exercise,D015444,NA,0,1693,any,2,000000000,Exercise,NA
176,15028365,1,gender,Gender Identity,D005783,NA,0,1693,any,2,000000000,Gender Identity,NA
177,15028365,1,HDL cholesterol,Lipoproteins,D008074,NA,0,1693,any,2,000000000,Lipoproteins,NA
178,15028365,1,heart failure,Heart Failure,D006333,NA,0,1693,any,2,000000000,Heart Failure,NA
179,15028365,1,ihd,Coronary Artery Disease,D003324,NA,0,1693,any,2,000000000,Coronary Artery Disease,NA
180,15028365,1,ish,Hypertension,D006973,NA,0,1693,type,12,000000010,Hypertension,NA
181,15028365,1,mi,Myocardial Infarction,D009203,NA,0,1693,any,2,000000000,Myocardial Infarction,NA
182,15028365,1,microalbuminuria,Albuminuria,D000419,NA,0,1693,any,2,000000000,Albuminuria,NA
183,15028365,1,race,Racial Groups,D044469,NA,0,1693,any,2,000000000,Racial Groups,NA
184,15028365,1,Smoker,Cigarette Smoking,D000073865,NA,0,1693,any,2,000000000,Cigarette Smoking,NA
185,15028365,1,stroke,Stroke,D020521,NA,0,1693,any,2,000000000,Stroke,NA
186,15028365,1,systolic bp,Blood Pressure,D001794,NA,0,1693,any,2,000000000,Blood Pressure,NA
187,15028365,1,total cholesterol,Lipoproteins,D008074,NA,0,1693,any,2,000000000,Lipoproteins,NA
188,15028365,2,race,Racial Groups,D044469,NA,0,1577,any,2,000000000,Racial Groups,NA
189,15028365,2,stroke,Stroke,D020521,NA,0,1577,any,2,000000000,Stroke,NA
190,15028365,2,u.s. non-black patients,Racial Groups,D044469,NA,0,1577,any,2,000000000,Racial Groups,NA
191,15028365,2,worldwide non-black patients,Racial Groups,D044469,NA,0,1577,any,2,000000000,Racial Groups,NA
192,15103313,NA,Patient Variable: Weekly Drink Consumption,Alcohol Drinking,D000428,NA,0,0,any,2,000000000,Alcohol Drinking,50
193,15238590,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
194,15238590,NA,inclusion criteria,unclassifiable,NA,NA,0,0,any,2,000000000,unclassifiable,NA
195,15238590,NA,killip,Myocardial Infarction,D009203,NA,0,0,severity,11,000100000,Myocardial Infarction,NA
196,15238590,NA,prior cabg,Coronary Artery Bypass,D001026,NA,0,0,previous,8,100000000,Coronary Artery Bypass,NA
197,15238590,NA,prior PCI,Percutaneous Coronary Intervention,D062645,NA,0,0,previous,8,100000000,Percutaneous Coronary Intervention,NA
198,15238590,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
199,15238590,NA,smoking,Cigarette Smoking,D000073865,NA,0,0,any,2,000000000,Cigarette Smoking,NA
200,15238590,NA,study cite,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,NA
201,15337732,2,age,Age Factors,D000367,NA,0,691,any,2,000000000,Age Factors,NA
202,15337732,2,"c-reactive protein, mg/l",C-Reactive Protein,D002097,NA,0,691,any,2,000000000,C-Reactive Protein,NA
203,15337732,2,diabetes,Diabetes Mellitus,D003920,NA,0,691,any,2,000000000,Diabetes Mellitus,NA
204,15337732,2,HDL cholesterol,Lipoproteins,D008074,NA,0,691,any,2,000000000,Lipoproteins,NA
205,15337732,2,index diagnosis;non-st-segment elevation acs,Acute Coronary Syndrome,D054058,NA,0,691,any,2,000000000,Acute Coronary Syndrome,NA
206,15337732,2,"ldl cholesterol, mg/dl",Lipoproteins,D008074,NA,0,691,any,2,000000000,Lipoproteins,NA
207,15337732,2,pci for index event,Percutaneous Coronary Intervention,D062645,NA,0,691,any,2,000000000,Percutaneous Coronary Intervention,NA
208,15337732,2,sex,Gender Identity,D005783,NA,0,691,any,2,000000000,Gender Identity,NA
209,15337732,2,ST segment elevation myocardial infarction,Myocardial Infarction,D009203,NA,0,691,any,2,000000000,Myocardial Infarction,NA
210,15381674,2,Diabetes,Diabetes Mellitus,D003920,NA,0,11,any,2,000000000,Diabetes Mellitus,NA
211,15451146,2,age,Age Factors,D000367,NA,0,957,any,2,000000000,Age Factors,NA
212,15451146,2,diabetes,Diabetes Mellitus,D003920,NA,0,957,any,2,000000000,Diabetes Mellitus,NA
213,15451146,2,elevated troponin,Troponin,D014336,NA,0,957,any,2,000000000,Troponin,NA
214,15451146,2,male female,Gender Identity,D005783,NA,0,957,any,2,000000000,Gender Identity,NA
215,15451146,2,no prior aspirin,Aspirin,D001241,NA,0,957,previous,8,100000000,Aspirin,NA
216,15451146,2,no st depression or elevation,ST Elevation Myocardial Infarction,D000072657,NA,0,957,any,2,000000000,ST Elevation Myocardial Infarction,NA
217,15451146,2,non-diabetics,Diabetes Mellitus,D003920,NA,0,957,any,2,000000000,Diabetes Mellitus,NA
218,15451146,2,normal troponin,Troponin,D014336,NA,0,957,any,2,000000000,Troponin,NA
219,15451146,2,prior aspirin,Aspirin,D001241,NA,0,957,previous,8,100000000,Aspirin,NA
220,15451146,2,st depression or elevation,ST Elevation Myocardial Infarction,D000072657,NA,0,957,any,2,000000000,ST Elevation Myocardial Infarction,NA
221,15451146,2,timi risk score 0-2,Thrombosis,D013927,NA,0,957,severity,11,000100100,Thrombosis,NA
222,15451146,2,timi risk score 3-7,Thrombosis,D013927,NA,0,957,severity,11,000100100,Thrombosis,NA
223,15531767,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,160
224,15531767,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,159
225,15531767,NA,history of myocardial infarction,Myocardial Infarction,D009203,NA,0,0,previous,8,100000000,Myocardial Infarction,159
226,15531767,NA,left ventricular function,Stroke Volume,D013318,NA,0,0,any,2,000000000,Stroke Volume,159
227,15531767,NA,previous revascularization procedure,Myocardial Revascularization,D009204,NA,0,0,previous,8,100000000,Myocardial Revascularization,159
228,15531767,NA,previous use of diuretic agents,Diuretics,D004232,NA,0,0,previous,8,100000000,Diuretics,159
229,15531767,NA,previous use of lipid-lowering drugs,lipid modifying agents,NA,C10,0,0,previous,8,100000000,lipid modifying agents,159
230,15531767,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,159
231,15531767,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,159
232,15531767,NA,the serum cholesterol or creatinine concentration,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,159
233,15537681,2,presence or absence of metabolic syndrome or type 2 diabetes mellitus.,Metabolic Diseases,D008659,NA,0,562,type,12,000000010,Metabolic Diseases,NA
234,15579515,2,NKF stage,Renal Insufficiency,D051437,NA,0,365,severity,11,000100000,Renal Insufficiency,NA
235,15590586,2,;45-54,Age Factors,D000367,NA,0,1386,any,2,000000000,Age Factors,NA
236,15590586,2,;55-64,Age Factors,D000367,NA,0,1386,any,2,000000000,Age Factors,NA
237,15590586,2,;65+,Age Factors,D000367,NA,0,1386,any,2,000000000,Age Factors,NA
238,15590586,3,;45-54,Age Factors,D000367,NA,0,794,any,2,000000000,Age Factors,NA
239,15590586,3,;55-64,Age Factors,D000367,NA,0,794,any,2,000000000,Age Factors,NA
240,15590586,3,;65+,Age Factors,D000367,NA,0,794,any,2,000000000,Age Factors,NA
241,15590586,4,Smoker,Cigarette Smoking,D000073865,NA,0,1183,any,2,000000000,Cigarette Smoking,NA
242,15659722,2,;beta-blocker,Adrenergic beta-Antagonists,D000319,NA,0,196,any,2,000000000,Adrenergic beta-Antagonists,NA
243,15659722,2,;diabetes,Diabetes Mellitus,D003920,NA,0,196,any,2,000000000,Diabetes Mellitus,NA
244,15659722,2,;lvef<30%,Stroke Volume,D013318,NA,0,196,any,2,000000000,Stroke Volume,NA
245,15659722,2,;lvef>30%,Stroke Volume,D013318,NA,0,196,any,2,000000000,Stroke Volume,NA
246,15659722,2,;no beta-blocker,Adrenergic beta-Antagonists,D000319,NA,0,196,any,2,000000000,Adrenergic beta-Antagonists,NA
247,15659722,2,;no diabetes,Diabetes Mellitus,D003920,NA,0,196,any,2,000000000,Diabetes Mellitus,NA
248,15659722,2,;nonwhite race,Racial Groups,D044469,NA,0,196,any,2,000000000,Racial Groups,NA
249,15659722,2,age,Age Factors,D000367,NA,0,196,any,2,000000000,Age Factors,NA
250,15659722,2,Cause of heart failure,Heart Failure,D006333,NA,0,196,aetiological,1,000001000,Heart Failure,NA
251,15659722,2,diabetes â€” no. (%),Diabetes Mellitus,D003920,NA,0,196,any,2,000000000,Diabetes Mellitus,NA
252,15659722,2,heart failure,Heart Failure,D006333,NA,0,196,severity,11,000100000,Heart Failure,NA
253,15659722,2,male female,Gender Identity,D005783,NA,0,196,any,2,000000000,Gender Identity,NA
254,15659722,2,nonwhite race â€” no. (%) ejection fraction,Racial Groups,D044469,NA,0,196,any,2,000000000,Racial Groups,NA
255,15734614,NA,Medical History: Prior Atrial Fibrillation,Atrial Fibrillation,D001281,NA,0,0,previous,8,100000000,Atrial Fibrillation,70
256,15734767,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
257,15734767,NA,Age-Years,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
258,15734767,NA,angina class or provious mi,Angina Pectoris,D000787,NA,0,0,severity,11,000100000,Angina Pectoris,NA
259,15734767,NA,angina/myocardial infarction,Angina Pectoris,D000787,NA,0,0,any,2,000000000,Angina Pectoris,NA
260,15734767,NA,complex lesion,Coronary Artery Disease,D003324,NA,0,0,any,2,000000000,Coronary Artery Disease,NA
261,15734767,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
262,15734767,NA,intervention in complex lesions,Coronary Artery Disease,D003324,NA,0,0,any,2,000000000,Coronary Artery Disease,NA
263,15734767,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
264,15753114,2,age;>65 yr,Age Factors,D000367,NA,0,1169,any,2,000000000,Age Factors,NA
265,15753114,2,age;45-54 yr,Age Factors,D000367,NA,0,1169,any,2,000000000,Age Factors,NA
266,15753114,2,age;55-64 yr,Age Factors,D000367,NA,0,1169,any,2,000000000,Age Factors,NA
267,15753114,2,blood pressure,Blood Pressure,D001794,NA,0,1169,any,2,000000000,Blood Pressure,NA
268,15753114,2,body-mass indexf,Body Mass Index,D015992,NA,0,1169,any,2,000000000,Body Mass Index,NA
269,15753114,2,hypertension!,Hypertension,D006973,NA,0,1169,any,2,000000000,Hypertension,NA
270,15753114,2,Menopausal status,Menopause,D008593,NA,0,1169,any,2,000000000,Menopause,NA
271,15753114,2,menopause and hrt,Estrogen Replacement Therapy,D015914,NA,0,1169,any,2,000000000,Estrogen Replacement Therapy,NA
272,15753114,2,"menopause and hrt;postmenopausal, current hrt",Estrogen Replacement Therapy,D015914,NA,0,1169,current,3,010000000,Estrogen Replacement Therapy,NA
273,15753114,2,"menopause and hrt;postmenopausal, no hrt",Estrogen Replacement Therapy,D015914,NA,0,1169,any,2,000000000,Estrogen Replacement Therapy,NA
274,15753114,2,Smoker,Cigarette Smoking,D000073865,NA,0,1169,any,2,000000000,Cigarette Smoking,NA
275,15753114,2,smoking status;current,Water Pipe Smoking,D000073867,NA,0,1169,current,3,010000000,Water Pipe Smoking,NA
276,15753114,2,smoking status;current,Cigarette Smoking,D000073865,NA,0,1169,current,3,010000000,Cigarette Smoking,NA
277,15753114,2,smoking status;past or never,Cigarette Smoking,D000073865,NA,0,1169,previous,8,100000000,Cigarette Smoking,NA
278,15758000,2,age;< 65 yr,Age Factors,D000367,NA,0,1346,any,2,000000000,Age Factors,NA
279,15758000,2,age;>65 yr,Age Factors,D000367,NA,0,1346,any,2,000000000,Age Factors,NA
280,15758000,2,infarct location,Infarction,D007238,NA,0,1346,location,7,000000001,Infarction,NA
281,15758000,2,infarct location;nonanterior,Infarction,D007238,NA,0,1346,location,7,000000001,Infarction,NA
282,15758000,2,predominant type of heparin,"Heparin, Low-Molecular-Weight",D006495,NA,0,1346,type,12,000000010,"Heparin, Low-Molecular-Weight",NA
283,15758000,2,predominant type of heparin;low-molecular-weight,"Heparin, Low-Molecular-Weight",D006495,NA,0,1346,type,12,000000010,"Heparin, Low-Molecular-Weight",NA
284,15758000,2,sex,Gender Identity,D005783,NA,0,1346,any,2,000000000,Gender Identity,NA
285,15758000,2,types of fibrinolytic agent,Fibrinolytic Agents,D005343,NA,0,1346,type,12,000000010,Fibrinolytic Agents,NA
286,15758000,2,types of fibrinolytic agent;fibrin-specific,Fibrinolytic Agents,D005343,NA,0,1346,type,12,000000010,Fibrinolytic Agents,NA
287,15758000,2,types of fibrinolytic agent;non-fibrin-specific,Fibrin,D005337,NA,0,1346,type,12,000000010,Fibrin,NA
288,15781429,2,;tg >3.1,Lipoproteins,D008074,NA,0,34,any,2,000000000,Lipoproteins,NA
289,15781429,2,;tg<=3.1,Lipoproteins,D008074,NA,0,34,any,2,000000000,Lipoproteins,NA
290,15811979,NA,Patient Variable: Race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,182
291,15851647,2,by diabetes status,Diabetes Mellitus,D003920,NA,0,1618,any,2,000000000,Diabetes Mellitus,NA
292,15851647,2,"by gfr stratum for all participants, ml/min per 1.73 mâ€™!",Glomerular Filtration Rate,D005919,NA,0,1618,any,2,000000000,Glomerular Filtration Rate,NA
293,15851647,2,"by gfr stratum for diabetic participants, mt/min per 1.73 mâ€™Â§",complex,none,NA,0,1618,any,2,000000000,complex,NA
294,15851647,2,"by gfr stratum tor all participants, ml/min per 1.73 m^!",Glomerular Filtration Rate,D005919,NA,0,1618,any,2,000000000,Glomerular Filtration Rate,NA
295,15851647,3,by baseline diabetic status,Diabetes Mellitus,D003920,NA,0,1473,any,2,000000000,Diabetes Mellitus,NA
296,15851647,3,by baseline diabetic status;nondiabetic participants!,Diabetes Mellitus,D003920,NA,0,1473,any,2,000000000,Diabetes Mellitus,NA
297,15851647,3,"by gfr stratum for all participants, ml/min per 1.73 mâ€™!",Glomerular Filtration Rate,D005919,NA,0,1473,any,2,000000000,Glomerular Filtration Rate,NA
298,15851647,3,"by gfr stratum tor all participants, ml/min per 1.73 m^!",Glomerular Filtration Rate,D005919,NA,0,1473,any,2,000000000,Glomerular Filtration Rate,NA
299,15851647,3,"by gfr stratum tor diabetic participants, ml/min per 1.73 mâ€™Â§",Glomerular Filtration Rate,D005919,NA,0,1473,any,2,000000000,Glomerular Filtration Rate,NA
300,15864235,NA,CHD risk,Coronary Artery Disease,D003324,NA,0,0,risk score,10,000000100,Coronary Artery Disease,135
301,15883637,2,age group,Age Factors,D000367,NA,0,1189,any,2,000000000,Age Factors,NA
302,15899106,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,216
303,15899106,NA,LDL,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,215
304,15899106,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,215
305,15899106,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,215
306,15924587,2,age:,Age Factors,D000367,NA,0,417,any,2,000000000,Age Factors,NA
307,15924587,2,age:;<65 yrs,Age Factors,D000367,NA,0,417,any,2,000000000,Age Factors,NA
308,15924587,2,age:;>65 yrs sex:,complex,none,NA,0,417,any,2,000000000,complex,NA
309,15924587,2,age:;female,Gender Identity,D005783,NA,0,417,any,2,000000000,Gender Identity,NA
310,15924587,2,age:;male,Gender Identity,D005783,NA,0,417,any,2,000000000,Gender Identity,NA
311,15924587,2,baseline ldl-c:,Lipoproteins,D008074,NA,0,417,any,2,000000000,Lipoproteins,NA
312,15924587,2,baseline ldl-c:;<3.4 mmol/l,Lipoproteins,D008074,NA,0,417,any,2,000000000,Lipoproteins,NA
313,15924587,2,baseline ldl-c:;>3.4 mmol/l,Lipoproteins,D008074,NA,0,417,any,2,000000000,Lipoproteins,NA
314,15924587,2,body mass index:,Body Mass Index,D015992,NA,0,417,any,2,000000000,Body Mass Index,NA
315,15924587,2,body mass index:;<27.2 kg/m2,Body Mass Index,D015992,NA,0,417,any,2,000000000,Body Mass Index,NA
316,15924587,2,body mass index:;>27.2 kg/m2 hypertension:,Body Mass Index,D015992,NA,0,417,any,2,000000000,Body Mass Index,NA
317,15924587,2,body mass index:;no,Body Mass Index,D015992,NA,0,417,any,2,000000000,Body Mass Index,NA
318,15924587,2,body mass index:;yes,Body Mass Index,D015992,NA,0,417,any,2,000000000,Body Mass Index,NA
319,15924587,2,diabetes mellitus:,Diabetes Mellitus,D003920,NA,0,417,any,2,000000000,Diabetes Mellitus,NA
320,15924587,2,diabetes mellitus:;no,Diabetes Mellitus,D003920,NA,0,417,any,2,000000000,Diabetes Mellitus,NA
321,15924587,2,diabetes mellitus:;yes,Diabetes Mellitus,D003920,NA,0,417,any,2,000000000,Diabetes Mellitus,NA
322,15924587,2,male female,Gender Identity,D005783,NA,0,417,any,2,000000000,Gender Identity,NA
323,15924587,2,treatment stratum^:,Atorvastatin,D000069059,NA,0,417,any,2,000000000,Atorvastatin,NA
324,15924587,2,treatment stratum^:;atv 10 mg,Atorvastatin,D000069059,NA,0,417,any,2,000000000,Atorvastatin,NA
325,15924587,2,treatment stratum^:;atv 20 mg study protocol,Atorvastatin,D000069059,NA,0,417,any,2,000000000,Atorvastatin,NA
326,15924587,NA,Age-Years,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
327,15924587,NA,"Age, y",Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
328,15924587,NA,Baseline LDL-C,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,NA
329,15924587,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,NA
330,15924587,NA,Body mass index,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,NA
331,15924587,NA,Concomitant statin use,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,0,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
332,15924587,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
333,15924587,NA,Diabetes mellitus,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
334,15924587,NA,hypertension,Hypertension,D006973,NA,0,0,any,2,000000000,Hypertension,NA
335,15924587,NA,Hypertension,Hypertension,D006973,NA,0,0,any,2,000000000,Hypertension,NA
336,15924587,NA,ldl,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,NA
337,15924587,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
338,15924587,NA,Sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
339,15998890,2,"age, y;>65",Age Factors,D000367,NA,0,1085,any,2,000000000,Age Factors,NA
340,15998890,2,"age, y;45-54",Age Factors,D000367,NA,0,1085,any,2,000000000,Age Factors,NA
341,15998890,2,"age, y;55-64",Age Factors,D000367,NA,0,1085,any,2,000000000,Age Factors,NA
342,15998890,2,"alcohol use, drinks/wk*",Alcohol Drinking,D000428,NA,0,1085,any,2,000000000,Alcohol Drinking,NA
343,15998890,2,bmi,Body Mass Index,D015992,NA,0,1085,any,2,000000000,Body Mass Index,NA
344,15998890,2,family history of cancerf,Neoplasms,D009369,NA,0,1085,family history,6,000010000,Neoplasms,NA
345,15998890,2,Menopausal status,Menopause,D008593,NA,0,1085,any,2,000000000,Menopause,NA
346,15998890,2,menopausal status and use of ht,Estrogen Replacement Therapy,D015914,NA,0,1085,any,2,000000000,Estrogen Replacement Therapy,NA
347,15998890,2,menopausal status and use of ht;postmenopausal and current ht,Estrogen Replacement Therapy,D015914,NA,0,1085,current,3,010000000,Estrogen Replacement Therapy,NA
348,15998890,2,menopausal status and use of ht;postmenopausal and no ht,Estrogen Replacement Therapy,D015914,NA,0,1085,any,2,000000000,Estrogen Replacement Therapy,NA
349,15998890,2,"physical activity, kcal/wk*",Exercise,D015444,NA,0,1085,any,2,000000000,Exercise,NA
350,15998890,2,Smoker,Cigarette Smoking,D000073865,NA,0,1085,any,2,000000000,Cigarette Smoking,NA
351,15998890,2,smoking*;current,Pipe Smoking,D000073868,NA,0,1085,current,3,010000000,Pipe Smoking,NA
352,15998890,2,smoking*;past,Cigarette Smoking,D000073865,NA,0,1085,previous,8,100000000,Cigarette Smoking,NA
353,16053964,NA,serum digoxin concentration,Diuretics,D004232,NA,0,0,any,2,000000000,Diuretics,NA
354,16116047,3,higher risk (n=4911),Hypertension,D006973,NA,0,1000,risk score,10,000000100,Hypertension,NA
355,16116047,3,lower risk (n=4282),Hypertension,D006973,NA,0,1000,risk score,10,000000100,Hypertension,NA
356,16139123,NA,Medical History: Aspirin Use at Baseline,Aspirin,D001241,NA,0,0,previous,8,100000000,Aspirin,50
357,16214597,2,;none,Vascular Diseases,D014652,NA,0,1367,previous,8,100000000,Vascular Diseases,NA
358,16214597,2,;other chd,Coronary Artery Disease,D003324,NA,0,1367,any,2,000000000,Coronary Artery Disease,NA
359,16214597,2,ldl cholesterol (mmol/l):;«3-5,Lipoproteins,D008074,NA,0,1367,any,2,000000000,Lipoproteins,NA
360,16214597,2,;post-mi,Myocardial Infarction,D009203,NA,0,1367,any,2,000000000,Myocardial Infarction,NA
361,16214597,2,age (years):,Age Factors,D000367,NA,0,1367,any,2,000000000,Age Factors,NA
362,16214597,2,age (years):;^65,Age Factors,D000367,NA,0,1367,any,2,000000000,Age Factors,NA
363,16214597,2,age (years):;=s65,Age Factors,D000367,NA,0,1367,any,2,000000000,Age Factors,NA
364,16214597,2,age (years):;>65,Age Factors,D000367,NA,0,1367,any,2,000000000,Age Factors,NA
365,16214597,2,diastolic blood pressure (mm hg):,Blood Pressure,D001794,NA,0,1367,any,2,000000000,Blood Pressure,NA
366,16214597,2,diastolic blood pressure (mm hg):;^90,Blood Pressure,D001794,NA,0,1367,any,2,000000000,Blood Pressure,NA
367,16214597,2,diastolic blood pressure (mm hg):;>90,Blood Pressure,D001794,NA,0,1367,any,2,000000000,Blood Pressure,NA
368,16214597,2,groups,Coronary Artery Disease,D003324,NA,0,1367,previous,8,100000000,Coronary Artery Disease,NA
369,16214597,2,HDL cholesterol,Lipoproteins,D008074,NA,0,1367,any,2,000000000,Lipoproteins,NA
370,16214597,2,hdl cholesterol (mmol/l):,Lipoproteins,D008074,NA,0,1367,any,2,000000000,Lipoproteins,NA
371,16214597,2,hdl cholesterol (mmol/l):;>1-1,Lipoproteins,D008074,NA,0,1367,any,2,000000000,Lipoproteins,NA
372,16214597,2,hdl cholesterol (mmol/l):;>o-9-ii,Lipoproteins,D008074,NA,0,1367,any,2,000000000,Lipoproteins,NA
373,16214597,2,hdl cholesterol (mmol/l):;sso-9,Lipoproteins,D008074,NA,0,1367,any,2,000000000,Lipoproteins,NA
374,16214597,2,history of diabetes:,Diabetes Mellitus,D003920,NA,0,1367,previous,8,100000000,Diabetes Mellitus,NA
375,16214597,2,history of diabetes:;no,Diabetes Mellitus,D003920,NA,0,1367,previous,8,100000000,Diabetes Mellitus,NA
376,16214597,2,history of diabetes:;yes,Diabetes Mellitus,D003920,NA,0,1367,previous,8,100000000,Diabetes Mellitus,NA
377,16214597,2,ldl cholesterol (mmol/l):,Lipoproteins,D008074,NA,0,1367,any,2,000000000,Lipoproteins,NA
378,16214597,2,ldl cholesterol (mmol/l):;>3-5-45,Lipoproteins,D008074,NA,0,1367,any,2,000000000,Lipoproteins,NA
379,16214597,2,ldl cholesterol (mmol/l):;>4-5,Lipoproteins,D008074,NA,0,1367,any,2,000000000,Lipoproteins,NA
380,16214597,2,previous disease:,Medical History Taking,D008487,NA,0,1367,previous,8,100000000,Medical History Taking,NA
381,16214597,2,previous disease:;post-mi,Myocardial Infarction,D009203,NA,0,1367,previous,8,100000000,Myocardial Infarction,NA
382,16214597,2,sex:,Gender Identity,D005783,NA,0,1367,any,2,000000000,Gender Identity,NA
383,16214597,2,sex:;female,Gender Identity,D005783,NA,0,1367,any,2,000000000,Gender Identity,NA
384,16214597,2,sex:;male,Gender Identity,D005783,NA,0,1367,any,2,000000000,Gender Identity,NA
385,16214597,2,total cholesterol (mmol/l):,Lipoproteins,D008074,NA,0,1367,any,2,000000000,Lipoproteins,NA
386,16214597,2,total cholesterol (mmol/l):;^5-2,Lipoproteins,D008074,NA,0,1367,any,2,000000000,Lipoproteins,NA
387,16214597,2,total cholesterol (mmol/l):;>5-2-65,Lipoproteins,D008074,NA,0,1367,any,2,000000000,Lipoproteins,NA
388,16214597,2,total cholesterol (mmol/l):;>6-5,Lipoproteins,D008074,NA,0,1367,any,2,000000000,Lipoproteins,NA
389,16214597,2,treated hypertension:,Hypertension,D006973,NA,0,1367,any,2,000000000,Hypertension,NA
390,16214597,2,treated hypertension:;no,Hypertension,D006973,NA,0,1367,any,2,000000000,Hypertension,NA
391,16214597,2,treated hypertension:;yes,Hypertension,D006973,NA,0,1367,any,2,000000000,Hypertension,NA
392,16214597,2,triglycerides (mmol/l):,Lipoproteins,D008074,NA,0,1367,any,2,000000000,Lipoproteins,NA
393,16214597,2,triglycerides (mmol/l):;^1-4,Lipoproteins,D008074,NA,0,1367,any,2,000000000,Lipoproteins,NA
394,16214597,2,triglycerides (mmol/l):;>1-4-20,Lipoproteins,D008074,NA,0,1367,any,2,000000000,Lipoproteins,NA
395,16214597,2,triglycerides (mmol/l):;>2 0,Lipoproteins,D008074,NA,0,1367,any,2,000000000,Lipoproteins,NA
396,16214597,2,triglycerides (mmol/l):;>20,Lipoproteins,D008074,NA,0,1367,any,2,000000000,Lipoproteins,NA
397,16214597,2,triglycerides (mmol/l):;overall,Lipoproteins,D008074,NA,0,1367,any,2,000000000,Lipoproteins,NA
398,16214597,3,diastolic blood pressure (mm hg):;s£90,Blood Pressure,D001794,NA,0,959,any,2,000000000,Blood Pressure,NA
399,16214597,3,;post-mi,Myocardial Infarction,D009203,NA,0,959,any,2,000000000,Myocardial Infarction,NA
400,16214597,3,age (years):,Age Factors,D000367,NA,0,959,any,2,000000000,Age Factors,NA
401,16214597,3,age (years):;^65,Age Factors,D000367,NA,0,959,any,2,000000000,Age Factors,NA
402,16214597,3,age (years):;>65,Age Factors,D000367,NA,0,959,any,2,000000000,Age Factors,NA
403,16214597,3,ldl cholesterol (mmol/l):;«3-5,Lipoproteins,D008074,NA,0,959,any,2,000000000,Lipoproteins,NA
404,16214597,3,diastolic blood pressure (mm hg):,Blood Pressure,D001794,NA,0,959,any,2,000000000,Blood Pressure,NA
405,16214597,3,diastolic blood pressure (mm hg):;>90,Blood Pressure,D001794,NA,0,959,any,2,000000000,Blood Pressure,NA
406,16214597,3,diastolic blood pressure (mm hg):;sÂ£90,Blood Pressure,D001794,NA,0,959,any,2,000000000,Blood Pressure,NA
407,16214597,3,HDL cholesterol,Lipoproteins,D008074,NA,0,959,any,2,000000000,Lipoproteins,NA
408,16214597,3,hdl cholesterol (mmol/l):,Lipoproteins,D008074,NA,0,959,any,2,000000000,Lipoproteins,NA
409,16214597,3,hdl cholesterol (mmol/l):;>11,Lipoproteins,D008074,NA,0,959,any,2,000000000,Lipoproteins,NA
410,16214597,3,hdl cholesterol (mmol/l):;>o-9-i-i,Lipoproteins,D008074,NA,0,959,any,2,000000000,Lipoproteins,NA
411,16214597,3,history of diabetes:,Diabetes Mellitus,D003920,NA,0,959,previous,8,100000000,Diabetes Mellitus,NA
412,16214597,3,history of diabetes:;no,Diabetes Mellitus,D003920,NA,0,959,previous,8,100000000,Diabetes Mellitus,NA
413,16214597,3,history of diabetes:;yes,Diabetes Mellitus,D003920,NA,0,959,previous,8,100000000,Diabetes Mellitus,NA
414,16214597,3,ldl cholesterol (mmol/l):,Lipoproteins,D008074,NA,0,959,any,2,000000000,Lipoproteins,NA
415,16214597,3,ldl cholesterol (mmol/l):;>3-5-4-5,Lipoproteins,D008074,NA,0,959,any,2,000000000,Lipoproteins,NA
416,16214597,3,ldl cholesterol (mmol/l):;>4-5,Lipoproteins,D008074,NA,0,959,any,2,000000000,Lipoproteins,NA
417,16214597,3,previous disease:,History of Medicine,D006666,NA,0,959,previous,8,100000000,History of Medicine,NA
418,16214597,3,previous disease:;none,History of Medicine,D006666,NA,0,959,previous,8,100000000,History of Medicine,NA
419,16214597,3,previous disease:;other chd,Cardiovascular Diseases,D002318,NA,0,959,previous,8,100000000,Cardiovascular Diseases,NA
420,16214597,3,previous disease:;post-mi,Myocardial Infarction,D009203,NA,0,959,previous,8,100000000,Myocardial Infarction,NA
421,16214597,3,sex:,Gender Identity,D005783,NA,0,959,any,2,000000000,Gender Identity,NA
422,16214597,3,sex:;female,Gender Identity,D005783,NA,0,959,any,2,000000000,Gender Identity,NA
423,16214597,3,sex:;male,Gender Identity,D005783,NA,0,959,any,2,000000000,Gender Identity,NA
424,16214597,3,total cholesterol (mmol/l):,Lipoproteins,D008074,NA,0,959,any,2,000000000,Lipoproteins,NA
425,16214597,3,total cholesterol (mmol/l):;^5-2,Lipoproteins,D008074,NA,0,959,any,2,000000000,Lipoproteins,NA
426,16214597,3,total cholesterol (mmol/l):;>52-65,Lipoproteins,D008074,NA,0,959,any,2,000000000,Lipoproteins,NA
427,16214597,3,total cholesterol (mmol/l):;>6-5,Lipoproteins,D008074,NA,0,959,any,2,000000000,Lipoproteins,NA
428,16214597,3,treated hypertension:,Hypertension,D006973,NA,0,959,any,2,000000000,Hypertension,NA
429,16214597,3,treated hypertension:;no,Hypertension,D006973,NA,0,959,any,2,000000000,Hypertension,NA
430,16214597,3,treated hypertension:;yes,Hypertension,D006973,NA,0,959,any,2,000000000,Hypertension,NA
431,16214597,3,triglycerides (mmol/l):,Lipoproteins,D008074,NA,0,959,any,2,000000000,Lipoproteins,NA
432,16214597,3,triglycerides (mmol/l):;>1-4-20,Lipoproteins,D008074,NA,0,959,any,2,000000000,Lipoproteins,NA
433,16214597,3,triglycerides (mmol/l):;>2 0,Lipoproteins,D008074,NA,0,959,any,2,000000000,Lipoproteins,NA
434,16214597,3,triglycerides (mmol/l):;overall,Lipoproteins,D008074,NA,0,959,any,2,000000000,Lipoproteins,NA
435,16214597,3,triglycerides (mmol/l):;ssi-4,Lipoproteins,D008074,NA,0,959,any,2,000000000,Lipoproteins,NA
436,16214597,3,hdl cholesterol (mmol/l):;«s0-9,Lipoproteins,D008074,NA,0,959,any,2,000000000,Lipoproteins,NA
437,16214597,NA,Age-Years,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
438,16214597,NA,dbp,Blood Pressure,D001794,NA,0,0,any,2,000000000,Blood Pressure,NA
439,16214597,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
440,16214597,NA,hdl,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,NA
441,16214597,NA,hypertension,Hypertension,D006973,NA,0,0,any,2,000000000,Hypertension,NA
442,16214597,NA,ldl,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,NA
443,16214597,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
444,16214597,NA,total cholesterol,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,NA
445,16214597,NA,trig,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,NA
446,16258899,NA,did or did not have erosive disease at baseline,"Arthritis, Rheumatoid",D001172,NA,0,0,any,2,000000000,"Arthritis, Rheumatoid",49
447,16271642,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
448,16271642,NA,ecg at entry,Electrocardiography,D004562,NA,0,0,any,2,000000000,Electrocardiography,NA
449,16271642,NA,Eligible for CLARITY trial,unclassifiable,NA,NA,0,0,any,2,000000000,unclassifiable,NA
450,16271642,NA,Fibrinolytic agent given,Fibrinolytic Agents,D005343,NA,0,0,any,2,000000000,Fibrinolytic Agents,NA
451,16271642,NA,Heart rate (bpm),Heart Rate,D006339,NA,0,0,any,2,000000000,Heart Rate,NA
452,16271642,NA,killip,Myocardial Infarction,D009203,NA,0,0,severity,11,000100000,Myocardial Infarction,NA
453,16271642,NA,Metoprolol allocation,unclassifiable,NA,NA,0,0,any,2,000000000,unclassifiable,NA
454,16271642,NA,mi duration,Myocardial Infarction,D009203,NA,0,0,duration,5,001000000,Myocardial Infarction,NA
455,16271642,NA,previou mi,Myocardial Infarction,D009203,NA,0,0,any,2,000000000,Myocardial Infarction,NA
456,16271642,NA,previous aspirin,Aspirin,D001241,NA,0,0,previous,8,100000000,Aspirin,NA
457,16271642,NA,previous mi,Myocardial Infarction,D009203,NA,0,0,previous,8,100000000,Myocardial Infarction,NA
458,16271642,NA,Prognostic index (3 equal groups),unclassifiable,NA,NA,0,0,any,2,000000000,unclassifiable,NA
459,16271642,NA,sbp,Blood Pressure,D001794,NA,0,0,any,2,000000000,Blood Pressure,NA
460,16271642,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
461,16271643,NA,"Age, y",Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
462,16271643,NA,Fibrinolytic agent given,Fibrinolytic Agents,D005343,NA,0,0,any,2,000000000,Fibrinolytic Agents,NA
463,16271643,NA,Heart rate (bpm),Heart Rate,D006339,NA,0,0,any,2,000000000,Heart Rate,NA
464,16271643,NA,Killip class,Myocardial Infarction,D009203,NA,0,0,severity,11,000100000,Myocardial Infarction,NA
465,16271643,NA,Sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
466,16271643,NA,Systolic blood pressure (mm Hg),Blood Pressure,D001794,NA,0,0,any,2,000000000,Blood Pressure,NA
467,16271643,NA,"Time since onset (h), duration",Myocardial Infarction,D009203,NA,0,0,duration,5,001000000,Myocardial Infarction,NA
468,16278257,NA,Medical History: Baseline Nasal Congestion Score,unclassifiable,NA,NA,0,0,previous,8,100000000,unclassifiable,165
469,16304073,NA,[ECG changes and biomarkers OR age and ECG OR age ad biomarkers OR all 3 OR biomarkers only],complex,none,NA,0,0,any,2,000000000,complex,NA
470,16304073,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
471,16304073,NA,inclusion criteria,unclassifiable,NA,NA,0,0,any,2,000000000,unclassifiable,NA
472,16304073,NA,kilip class,Heart Failure,D006333,NA,0,0,severity,11,000100000,Heart Failure,NA
473,16304073,NA,killip,Myocardial Infarction,D009203,NA,0,0,severity,11,000100000,Myocardial Infarction,NA
474,16304073,NA,prior cabg,Coronary Artery Bypass,D001026,NA,0,0,previous,8,100000000,Coronary Artery Bypass,NA
475,16304073,NA,prior CABG,Coronary Artery Bypass,D001026,NA,0,0,previous,8,100000000,Coronary Artery Bypass,NA
476,16304073,NA,prior PCI,Percutaneous Coronary Intervention,D062645,NA,0,0,previous,8,100000000,Percutaneous Coronary Intervention,NA
477,16304073,NA,region,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,NA
478,16304073,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
479,16304073,NA,smoking,Cigarette Smoking,D000073865,NA,0,0,any,2,000000000,Cigarette Smoking,NA
480,16304073,NA,study cite,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,NA
481,16339095,NA,corticosteroid refractory versus not refractory.,unclassifiable,NA,NA,0,0,severity,11,000100000,unclassifiable,256
482,16351668,2,age,Age Factors,D000367,NA,0,1789,any,2,000000000,Age Factors,NA
483,16351668,2,baseline ldl-c,Lipoproteins,D008074,NA,0,1789,any,2,000000000,Lipoproteins,NA
484,16351668,2,body mass index,Body Mass Index,D015992,NA,0,1789,any,2,000000000,Body Mass Index,NA
485,16351668,2,diabetes mellitus,Diabetes Mellitus,D003920,NA,0,1789,any,2,000000000,Diabetes Mellitus,NA
486,16351668,2,female,Gender Identity,D005783,NA,0,1789,any,2,000000000,Gender Identity,NA
487,16351668,2,hypertension,Hypertension,D006973,NA,0,1789,any,2,000000000,Hypertension,NA
488,16351668,2,male,Gender Identity,D005783,NA,0,1789,any,2,000000000,Gender Identity,NA
489,16351668,2,race,Racial Groups,D044469,NA,0,1789,any,2,000000000,Racial Groups,NA
490,16380589,2,";age, years >65",Age Factors,D000367,NA,0,724,any,2,000000000,Age Factors,NA
491,16380589,2,";age, yearsÂ  <65",Age Factors,D000367,NA,0,724,any,2,000000000,Age Factors,NA
492,16380589,2,;preoperative beta-blocker use no,Adrenergic beta-Antagonists,D000319,NA,0,724,any,2,000000000,Adrenergic beta-Antagonists,NA
493,16380589,2,;preoperative beta-blocker use yes,Adrenergic beta-Antagonists,D000319,NA,0,724,any,2,000000000,Adrenergic beta-Antagonists,NA
494,16380589,2,;type of surgery valve replacement/ repair with or without cabg,Cardiac Surgical Procedures,D006348,NA,0,724,type,12,000000010,Cardiac Surgical Procedures,NA
495,16399150,NA,psoriatic arthritis,"Arthritis, Psoriatic",D015535,NA,0,0,any,2,000000000,"Arthritis, Psoriatic",68
496,16488800,NA,Age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
497,16488800,NA,Country,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,NA
498,16488800,NA,Diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
499,16488800,NA,First medical contact,Patient Admission,D010343,NA,0,0,any,2,000000000,Patient Admission,NA
500,16488800,NA,Infarct location,Infarction,D007238,NA,0,0,location,7,000000001,Infarction,NA
501,16488800,NA,Kilip Class,Myocardial Infarction,D009203,NA,0,0,severity,11,000100000,Myocardial Infarction,NA
502,16488800,NA,Previous coronary artery bypass graft,Coronary Artery Bypass,D001026,NA,0,0,previous,8,100000000,Coronary Artery Bypass,NA
503,16488800,NA,Previous infarction,Myocardial Infarction,D009203,NA,0,0,previous,8,100000000,Myocardial Infarction,NA
504,16488800,NA,Previous PCI,Percutaneous Coronary Intervention,D062645,NA,0,0,previous,8,100000000,Percutaneous Coronary Intervention,NA
505,16488800,NA,Sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
506,16488800,NA,Stent placement,Stents,D015607,NA,0,0,any,2,000000000,Stents,NA
507,16488800,NA,Time from randomisation to 1st balloon inflation (h),"Angioplasty, Balloon, Coronary",D015906,NA,0,0,any,2,000000000,"Angioplasty, Balloon, Coronary",NA
508,16488800,NA,Time from symptoms onset to 1st balloon inflation (h),"Angioplasty, Balloon, Coronary",D015906,NA,0,0,any,2,000000000,"Angioplasty, Balloon, Coronary",NA
509,16488800,NA,Time to randomisation from symptom onset (h),Duration of Therapy,D000081206,NA,0,0,duration,5,001000000,Duration of Therapy,NA
510,16495392,2,";patients with mild pain (womac pain score, 125-300)",Pain,D010146,NA,0,672,severity,11,000100000,Pain,NA
511,16495392,2,";patients with moderate-to-severe pain (womac pain score, 301-400)",Pain,D010146,NA,0,672,severity,11,000100000,Pain,NA
512,16495392,2,Patients with mild pain,Pain,D010146,NA,0,672,severity,11,000100000,Pain,NA
513,16495392,2,Patients with moderate tosevere pain,Pain,D010146,NA,0,672,severity,11,000100000,Pain,NA
514,16533938,2,clopidogrel pretreatment duration,Platelet Aggregation Inhibitors,D010975,NA,0,1544,duration,5,001000000,Platelet Aggregation Inhibitors,NA
515,16533938,2,diabetes,Diabetes Mellitus,D003920,NA,0,1544,any,2,000000000,Diabetes Mellitus,NA
516,16533938,2,troponin level,Troponin,D014336,NA,0,1544,any,2,000000000,Troponin,NA
517,16537662,2,;at clinic diastolic pressure <85 mm hg,Blood Pressure,D001794,NA,0,374,any,2,000000000,Blood Pressure,NA
518,16537662,2,;at clinic diastolic pressure >85 mm hg,Blood Pressure,D001794,NA,0,374,any,2,000000000,Blood Pressure,NA
519,16537662,2,;at clinic systolic pressure <135 mm hg,Blood Pressure,D001794,NA,0,374,any,2,000000000,Blood Pressure,NA
520,16537662,2,;at clinic systolic pressure >135 mm hg,Blood Pressure,D001794,NA,0,374,any,2,000000000,Blood Pressure,NA
521,16537662,2,;at home diastolic pressure < 82 mm hg,Blood Pressure,D001794,NA,0,374,any,2,000000000,Blood Pressure,NA
522,16537662,2,;at home diastolic pressure >82 mm hg,Blood Pressure,D001794,NA,0,374,any,2,000000000,Blood Pressure,NA
523,16537662,2,;at home systolic pressure <132 mm hg,Blood Pressure,D001794,NA,0,374,any,2,000000000,Blood Pressure,NA
524,16537662,2,;at home systolic pressure >132 mm hg,Blood Pressure,D001794,NA,0,374,any,2,000000000,Blood Pressure,NA
525,16537662,2,age,Age Factors,D000367,NA,0,374,any,2,000000000,Age Factors,NA
526,16537662,2,bmi,Body Mass Index,D015992,NA,0,374,any,2,000000000,Body Mass Index,NA
527,16537662,2,male female,Gender Identity,D005783,NA,0,374,any,2,000000000,Gender Identity,NA
528,16537662,2,race,Racial Groups,D044469,NA,0,374,any,2,000000000,Racial Groups,NA
529,16537662,2,weight,Body Weight,D001835,NA,0,374,any,2,000000000,Body Weight,NA
530,16537665,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
531,16537665,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
532,16537665,NA,Fibrinolytic agent given,Fibrinolytic Agents,D005343,NA,0,0,any,2,000000000,Fibrinolytic Agents,NA
533,16537665,NA,infarct location,Infarction,D007238,NA,0,0,location,7,000000001,Infarction,NA
534,16537665,NA,previou mi,Myocardial Infarction,D009203,NA,0,0,any,2,000000000,Myocardial Infarction,NA
535,16537665,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
536,16537665,NA,time to treatment,Time-to-Treatment,D061665,NA,0,0,any,2,000000000,Time-to-Treatment,NA
537,16572114,2,race,Racial Groups,D044469,NA,0,1665,any,2,000000000,Racial Groups,NA
538,16651474,1,;non-black,Racial Groups,D044469,NA,0,170,any,2,000000000,Racial Groups,NA
539,16651474,1,;non-diabetic,Diabetes Mellitus,D003920,NA,0,170,any,2,000000000,Diabetes Mellitus,NA
540,16651474,1,age,Age Factors,D000367,NA,0,170,any,2,000000000,Age Factors,NA
541,16651474,1,diabetes,Diabetes Mellitus,D003920,NA,0,170,any,2,000000000,Diabetes Mellitus,NA
542,16651474,1,male female,Gender Identity,D005783,NA,0,170,any,2,000000000,Gender Identity,NA
543,16651474,1,race,Racial Groups,D044469,NA,0,170,any,2,000000000,Racial Groups,NA
544,16709304,2,;entire cohort gender,Gender Identity,D005783,NA,0,530,any,2,000000000,Gender Identity,NA
545,16709304,2,age,Age Factors,D000367,NA,0,530,any,2,000000000,Age Factors,NA
546,16709304,2,age;< 65 years,Age Factors,D000367,NA,0,530,any,2,000000000,Age Factors,NA
547,16709304,2,age;> 160mg/dl chd status,Coronary Artery Disease,D003324,NA,0,530,any,2,000000000,Coronary Artery Disease,NA
548,16709304,2,age;chd,Coronary Artery Disease,D003324,NA,0,530,any,2,000000000,Coronary Artery Disease,NA
549,16709304,2,age;no chd,Coronary Artery Disease,D003324,NA,0,530,any,2,000000000,Coronary Artery Disease,NA
550,16709304,2,race,Racial Groups,D044469,NA,0,530,any,2,000000000,Racial Groups,NA
551,16709304,2,race;non-caucasian,Racial Groups,D044469,NA,0,530,any,2,000000000,Racial Groups,NA
552,16709304,2,race;non-caucasian eze/simva,Racial Groups,D044469,NA,0,530,any,2,000000000,Racial Groups,NA
553,16709304,3,age,Age Factors,D000367,NA,0,49,any,2,000000000,Age Factors,NA
554,16709304,3,age;< 160 mg/dl eze/simva,lipid modifying agents,NA,C10,0,49,any,2,000000000,lipid modifying agents,NA
555,16709304,3,age;< 160 mg/dl simva,lipid modifying agents,NA,C10,0,49,any,2,000000000,lipid modifying agents,NA
556,16709304,3,age;< 65 years,Age Factors,D000367,NA,0,49,any,2,000000000,Age Factors,NA
557,16709304,3,age;< 65 years eze/simva,Age Factors,D000367,NA,0,49,any,2,000000000,Age Factors,NA
558,16709304,3,age;< 65 years simva,Age Factors,D000367,NA,0,49,any,2,000000000,Age Factors,NA
559,16709304,3,age;> 160 mg/dl eze/simva,lipid modifying agents,NA,C10,0,49,any,2,000000000,lipid modifying agents,NA
560,16709304,3,age;> 160 mg/dl simva,lipid modifying agents,NA,C10,0,49,any,2,000000000,lipid modifying agents,NA
561,16709304,3,age;> 65 years eze/simva baseline ldl-c,complex,none,NA,0,49,any,2,000000000,complex,NA
562,16709304,3,age;> 65 years simva,Age Factors,D000367,NA,0,49,any,2,000000000,Age Factors,NA
563,16709304,3,chd status,Coronary Artery Disease,D003324,NA,0,49,any,2,000000000,Coronary Artery Disease,NA
564,16709304,3,chd status Â§,Coronary Artery Disease,D003324,NA,0,49,any,2,000000000,Coronary Artery Disease,NA
565,16709304,3,chd status;chd eze/simva,complex,none,NA,0,49,any,2,000000000,complex,NA
566,16709304,3,chd status;chd simva,complex,none,NA,0,49,any,2,000000000,complex,NA
567,16709304,3,chd status;no chd eze/simva,complex,none,NA,0,49,any,2,000000000,complex,NA
568,16709304,3,chd status;no chd simva,complex,none,NA,0,49,any,2,000000000,complex,NA
569,16709304,3,entire cohort;eze/simva gender,complex,none,NA,0,49,any,2,000000000,complex,NA
570,16709304,3,entire cohort;female eze/simva,complex,none,NA,0,49,any,2,000000000,complex,NA
571,16709304,3,entire cohort;female simva,complex,none,NA,0,49,any,2,000000000,complex,NA
572,16709304,3,entire cohort;male eze/simva,complex,none,NA,0,49,any,2,000000000,complex,NA
573,16709304,3,entire cohort;male simva,complex,none,NA,0,49,any,2,000000000,complex,NA
574,16709304,3,entire cohort;simva,lipid modifying agents,NA,C10,0,49,any,2,000000000,lipid modifying agents,NA
575,16709304,3,race,Racial Groups,D044469,NA,0,49,any,2,000000000,Racial Groups,NA
576,16709304,3,race;caucasian eze/simva,complex,none,NA,0,49,any,2,000000000,complex,NA
577,16709304,3,race;caucasian simva,complex,none,NA,0,49,any,2,000000000,complex,NA
578,16709304,3,race;non-caucasian,Racial Groups,D044469,NA,0,49,any,2,000000000,Racial Groups,NA
579,16709304,3,race;non-caucasian eze/simva,Racial Groups,D044469,NA,0,49,any,2,000000000,Racial Groups,NA
580,16709304,3,race;non-caucasian simva,complex,none,NA,0,49,any,2,000000000,complex,NA
581,16709304,4,age,Age Factors,D000367,NA,0,1128,any,2,000000000,Age Factors,NA
582,16709304,4,age;< 65 years,Age Factors,D000367,NA,0,1128,any,2,000000000,Age Factors,NA
583,16709304,4,baseline ldl-c,Lipoproteins,D008074,NA,0,1128,any,2,000000000,Lipoproteins,NA
584,16709304,4,chd status,Coronary Artery Disease,D003324,NA,0,1128,any,2,000000000,Coronary Artery Disease,NA
585,16709304,4,chd status Â§,Coronary Artery Disease,D003324,NA,0,1128,any,2,000000000,Coronary Artery Disease,NA
586,16709304,4,gender,Gender Identity,D005783,NA,0,1128,any,2,000000000,Gender Identity,NA
587,16709304,4,race,Racial Groups,D044469,NA,0,1128,any,2,000000000,Racial Groups,NA
588,16714187,NA,Age-Years,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
589,16714187,NA,history of IHD,Coronary Artery Disease,D003324,NA,0,0,previous,8,100000000,Coronary Artery Disease,NA
590,16714187,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
591,16714187,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
592,16714187,NA,type of cerebral ischaemia,Stroke,D020521,NA,0,0,current,3,010000010,Stroke,NA
593,16801465,2,egfr <45.0 (vs egfr >75),Glomerular Filtration Rate,D005919,NA,0,1298,any,2,000000000,Glomerular Filtration Rate,NA
594,16801465,2,egfr >75,Glomerular Filtration Rate,D005919,NA,0,1298,any,2,000000000,Glomerular Filtration Rate,NA
595,16801465,2,egfr 45.0-59.9 (vs egfr >75),Glomerular Filtration Rate,D005919,NA,0,1298,any,2,000000000,Glomerular Filtration Rate,NA
596,16801465,2,egfr 60.0-74.9 (vs egfr >75),Glomerular Filtration Rate,D005919,NA,0,1298,any,2,000000000,Glomerular Filtration Rate,NA
597,16860168,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,235
598,16905022,2,";revascularisation but no antiplatelets, lipid-lowering agents, or p blockers",complex,none,NA,0,872,any,2,000000000,complex,NA
599,16905022,2,;revascularisation+antiplatelets+ lipid-lowering agents+p blockers,complex,none,NA,0,872,any,2,000000000,complex,NA
600,16905022,2,;with antiplatelets,Platelet Aggregation Inhibitors,D010975,NA,0,872,any,2,000000000,Platelet Aggregation Inhibitors,NA
601,16905022,2,;with lipid-lowering agents,Hypolipidemic Agents,D000960,NA,0,872,any,2,000000000,Hypolipidemic Agents,NA
602,16905022,2,;with p blockers,beta blocking agents,NA,C07,0,872,any,2,000000000,beta blocking agents,NA
603,16905022,2,;with revascularisation,Myocardial Revascularization,D009204,NA,0,872,any,2,000000000,Myocardial Revascularization,NA
604,16905022,2,;without antiplatelets,Platelet Aggregation Inhibitors,D010975,NA,0,872,any,2,000000000,Platelet Aggregation Inhibitors,NA
605,16905022,2,;without lipid-lowering agents,Hypolipidemic Agents,D000960,NA,0,872,any,2,000000000,Hypolipidemic Agents,NA
606,16905022,2,;without p blockers,beta blocking agents,NA,C07,0,872,any,2,000000000,beta blocking agents,NA
607,16905022,2,;without revascularsation,Myocardial Revascularization,D009204,NA,0,872,any,2,000000000,Myocardial Revascularization,NA
608,17001471,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,134
609,17001471,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,133
610,17001471,NA,HOMA-IR; HOMA-I,Insulin Resistance,D007333,NA,0,0,any,2,000000000,Insulin Resistance,133
611,17001471,NA,metabolic syndrome status,Metabolic Syndrome,D024821,NA,0,0,any,2,000000000,Metabolic Syndrome,133
612,17001471,NA,previous OHA status,Hypoglycemic Agents,D007004,NA,0,0,previous,8,100000000,Hypoglycemic Agents,133
613,17001471,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,133
614,17001471,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,133
615,17010793,NA,pre_treatment,unclassifiable,NA,NA,0,0,any,2,000000000,unclassifiable,NA
616,17011942,2,age,Age Factors,D000367,NA,0,1519,any,2,000000000,Age Factors,NA
617,17011942,2,body-mass index,Body Mass Index,D015992,NA,0,1519,any,2,000000000,Body Mass Index,NA
618,17011942,2,current/past smoker,Cigarette Smoking,D000073865,NA,0,1519,previous,8,110000000,Cigarette Smoking,NA
619,17011942,2,diabetes,Diabetes Mellitus,D003920,NA,0,1519,any,2,000000000,Diabetes Mellitus,NA
620,17011942,2,HDL cholesterol,Lipoproteins,D008074,NA,0,1519,any,2,000000000,Lipoproteins,NA
621,17011942,2,Hypertension,Hypertension,D006973,NA,0,1519,any,2,000000000,Hypertension,NA
622,17011942,2,ldl cholesterol,Lipoproteins,D008074,NA,0,1519,any,2,000000000,Lipoproteins,NA
623,17011942,2,sex,Gender Identity,D005783,NA,0,1519,any,2,000000000,Gender Identity,NA
624,17011942,2,total cholesterol,Lipoproteins,D008074,NA,0,1519,any,2,000000000,Lipoproteins,NA
625,17011942,2,triglycerides,Lipoproteins,D008074,NA,0,1519,any,2,000000000,Lipoproteins,NA
626,17022864,NA,Ezetimibe/Simvastatin and Rosuvastatin,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,0,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,124
627,17058629,2,diabetes mellitus,Diabetes Mellitus,D003920,NA,0,521,any,2,000000000,Diabetes Mellitus,NA
628,17058629,2,metabolic syndrome*,Metabolic Syndrome,D024821,NA,0,521,any,2,000000000,Metabolic Syndrome,NA
629,17058629,2,neither pbo + statin eze + statin,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,521,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
630,17060377,2,age groups,Age Factors,D000367,NA,0,575,any,2,000000000,Age Factors,NA
631,17060377,3,;age <70 y (n 1220),Age Factors,D000367,NA,0,1420,any,2,000000000,Age Factors,NA
632,17065671,2,age ^65,Age Factors,D000367,NA,0,245,any,2,000000000,Age Factors,NA
633,17065671,2,age <65,Age Factors,D000367,NA,0,245,any,2,000000000,Age Factors,NA
634,17097378,2,age,Age Factors,D000367,NA,0,831,any,2,000000000,Age Factors,NA
635,17097378,2,baseline % bsa involvement,Body Surface Area,D001830,NA,0,831,any,2,000000000,Body Surface Area,NA
636,17097378,2,dissatisfied with/stopped >= 2 prior systemic therapies because of side effects,complex,none,NA,0,831,previous,8,100000000,complex,NA
637,17097378,2,dissatisfied with/stopped >=Â 1 prior systemic therapy because of side effects,complex,none,NA,0,831,previous,8,100000000,complex,NA
638,17097378,2,"prior therapy, %",Biological Therapy,D001691,NA,0,831,previous,8,100000000,Biological Therapy,NA
639,17097378,2,"prior therapy, %;acitretin",antipsoriatics,NA,D05,0,831,previous,8,100000000,antipsoriatics,NA
640,17097378,2,"prior therapy, %;biologic agents",Biological Therapy,D001691,NA,0,831,previous,8,100000000,Biological Therapy,NA
641,17097378,2,"prior therapy, %;cyclosporin",Cyclosporins,D003524,NA,0,831,previous,8,100000000,Cyclosporins,NA
642,17097378,2,"prior therapy, %;methotrexate",Immunosuppressive Agents,D007166,NA,0,831,previous,8,100000000,Immunosuppressive Agents,NA
643,17097378,2,"prior therapy, %;puva",PUVA Therapy,D011701,NA,0,831,previous,8,100000000,PUVA Therapy,NA
644,17097378,2,"prior therapy, %;uvb",Ultraviolet Therapy,D014467,NA,0,831,previous,8,100000000,Ultraviolet Therapy,NA
645,17097378,2,prior use of >= 2 systemic therapies,Psoriasis,D011565,NA,0,831,previous,8,100000000,Psoriasis,NA
646,17097378,2,prior use of >= 2 systemic therapies,Psoriasis,D011565,NA,0,831,previous severity,9,100100000,Psoriasis,NA
647,17097378,2,prior use of >= 2 systemic therapies,Psoriasis,D011565,NA,0,831,severity,11,000100000,Psoriasis,NA
648,17097378,2,prior use of biologic agents,Biological Therapy,D001691,NA,0,831,previous,8,100000000,Biological Therapy,NA
649,17113426,2,age,Age Factors,D000367,NA,0,911,any,2,000000000,Age Factors,NA
650,17113426,2,diabetes,Diabetes Mellitus,D003920,NA,0,911,any,2,000000000,Diabetes Mellitus,NA
651,17113426,2,disease,"Arthritis, Rheumatoid",D001172,NA,0,911,any,2,000000000,"Arthritis, Rheumatoid",NA
652,17113426,2,disease,Osteoarthritis,D010003,NA,0,911,any,2,000000000,Osteoarthritis,NA
653,17113426,2,disease;osteoarthritis,Osteoarthritis,D010003,NA,0,911,any,2,000000000,Osteoarthritis,NA
654,17113426,2,disease;rheumatoid arthritis,"Arthritis, Rheumatoid",D001172,NA,0,911,any,2,000000000,"Arthritis, Rheumatoid",NA
655,17113426,2,established ascvd,Cardiovascular Diseases,D002318,NA,0,911,any,2,000000000,Cardiovascular Diseases,NA
656,17113426,2,established ascvd or >2 cv risk factors,Cardiovascular Diseases,D002318,NA,0,911,risk score,10,000000100,Cardiovascular Diseases,NA
657,17113426,2,etoricoxib dose,"antiinflammatory and antirheumatic products, non-steroids",NA,M01A,0,911,any,2,000000000,"antiinflammatory and antirheumatic products, non-steroids",NA
658,17113426,2,male female,Gender Identity,D005783,NA,0,911,any,2,000000000,Gender Identity,NA
659,17113426,2,race,Racial Groups,D044469,NA,0,911,any,2,000000000,Racial Groups,NA
660,17124018,NA,cK MB/troponin,Troponin,D014336,NA,0,0,any,2,000000000,Troponin,NA
661,17124018,NA,GP IIb/IIIa inhibitor,unclassifiable,NA,NA,0,0,any,2,000000000,unclassifiable,NA
662,17124018,NA,"Randomization to angiography or intervention, thirds",Coronary Angiography,D017023,NA,0,0,any,2,000000000,Coronary Angiography,NA
663,17124018,NA,ST-segment deviation,ST Elevation Myocardial Infarction,D000072657,NA,0,0,any,2,000000000,ST Elevation Myocardial Infarction,NA
664,17124018,NA,Thienopyridine before angiography or PCI,Thienopyridines,D058924,NA,0,0,any,2,000000000,Thienopyridines,NA
665,17124018,NA,TIMI score,Thrombosis,D013927,NA,1,0,any,2,000000000,Thrombosis,NA
666,17124018,NA,Treatment strategy,Coronary Artery Bypass,D001026,NA,0,0,previous,8,100000000,Coronary Artery Bypass,NA
667,17145742,2,<140 mg/dl,Glucose,D005947,NA,0,31,any,2,000000000,Glucose,NA
668,17145742,2,<30,Body Mass Index,D015992,NA,0,31,any,2,000000000,Body Mass Index,NA
669,17145742,2,<50 yr,Age Factors,D000367,NA,0,31,any,2,000000000,Age Factors,NA
670,17145742,2,<82.0 kg,Body Weight,D001835,NA,0,31,any,2,000000000,Body Weight,NA
671,17145742,2,<99 cm,Waist Circumference,D055105,NA,0,31,any,2,000000000,Waist Circumference,NA
672,17145742,2,>60 yr,Age Factors,D000367,NA,0,31,any,2,000000000,Age Factors,NA
673,17145742,2,age,Age Factors,D000367,NA,0,31,any,2,000000000,Age Factors,NA
674,17145742,2,baseline fasting plasma glucose,Glucose,D005947,NA,0,31,any,2,000000000,Glucose,NA
675,17145742,2,bmi,Body Mass Index,D015992,NA,0,31,any,2,000000000,Body Mass Index,NA
676,17145742,2,region,Geographic Locations,D005842,NA,0,31,any,2,000000000,Geographic Locations,NA
677,17145742,2,sex,Gender Identity,D005783,NA,0,31,any,2,000000000,Gender Identity,NA
678,17145742,2,waist circumference,Waist Circumference,D055105,NA,0,31,any,2,000000000,Waist Circumference,NA
679,17145742,2,weight,Body Weight,D001835,NA,0,31,any,2,000000000,Body Weight,NA
680,17157112,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,234
681,17157112,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,233
682,17157112,NA,diabetes duration,Diabetes Mellitus,D003920,NA,0,0,duration,5,001000000,Diabetes Mellitus,233
683,17157112,NA,HbA1c,Glycated Hemoglobin A,D006442,NA,0,0,any,2,000000000,Glycated Hemoglobin A,233
684,17157112,NA,HOMA-IR; HOMA-I,Insulin Resistance,D007333,NA,0,0,any,2,000000000,Insulin Resistance,233
685,17157112,NA,metabolic syndrome status,Metabolic Syndrome,D024821,NA,0,0,any,2,000000000,Metabolic Syndrome,233
686,17157112,NA,previous OHA status,Hypoglycemic Agents,D007004,NA,0,0,previous,8,100000000,Hypoglycemic Agents,233
687,17157112,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,233
688,17157112,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,233
689,17190893,NA,Baseline BMD T score at femoral neck,Osteoporosis,D010024,NA,0,0,severity,2,000000000,Osteoporosis,NA
690,17190893,NA,Prevalent vertebral fracture,"Fractures, Bone",D050723,NA,0,0,any,2,000000000,"Fractures, Bone",NA
691,17239798,NA,stroke type,Stroke,D020521,NA,0,0,type,12,000000010,Stroke,146
692,17244641,2,age < 75 years,Age Factors,D000367,NA,0,324,any,2,000000000,Age Factors,NA
693,17244641,2,age >= 75 years,Age Factors,D000367,NA,0,324,any,2,000000000,Age Factors,NA
694,17244641,2,"anterior infarction,",Myocardial Infarction,D009203,NA,0,324,any,2,000000000,Myocardial Infarction,NA
695,17244641,2,"non anterior infarction,",Infarction,D007238,NA,0,324,location,7,000000001,Infarction,NA
696,17244641,NA,Age-Years,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
697,17244641,NA,infarction location,Geographic Locations,D005842,NA,0,0,location,7,000000001,Geographic Locations,NA
698,17244641,NA,time of presentation [early versus late],unclassifiable,NA,NA,0,0,severity,11,000100000,unclassifiable,NA
699,17259484,2,;bmi >= 35,Body Mass Index,D015992,NA,0,343,any,2,000000000,Body Mass Index,NA
700,17304660,2,age,Age Factors,D000367,NA,0,1589,any,2,000000000,Age Factors,NA
701,17304660,2,baseline aspirin use strata,Aspirin,D001241,NA,0,1589,any,2,000000000,Aspirin,NA
702,17304660,2,continued use of gastroprotective agents gpa,Gastrointestinal Agents,D005765,NA,0,1589,any,2,000000000,Gastrointestinal Agents,NA
703,17304660,2,gender,Gender Identity,D005783,NA,0,1589,any,2,000000000,Gender Identity,NA
704,17304660,2,new use of gastroprotective agents gpa,Gastrointestinal Agents,D005765,NA,0,1589,any,2,000000000,Gastrointestinal Agents,NA
705,17304660,2,race,Racial Groups,D044469,NA,0,1589,any,2,000000000,Racial Groups,NA
706,17304660,2,race;non-caucasian,Racial Groups,D044469,NA,0,1589,any,2,000000000,Racial Groups,NA
707,17368152,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
708,17368152,NA,Age-Years,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,230
709,17368152,NA,Antithrombin crossovers,Antithrombins,D000991,NA,0,0,any,2,000000000,Antithrombins,NA
710,17368152,NA,Antithrombins,Antithrombins,D000991,NA,0,0,any,2,000000000,Antithrombins,230
711,17368152,NA,CrCl ?60 mL per min,Glomerular Filtration Rate,D005919,NA,0,0,any,2,000000000,Glomerular Filtration Rate,NA
712,17368152,NA,Creatinine clearance,Glomerular Filtration Rate,D005919,NA,0,0,any,2,000000000,Glomerular Filtration Rate,230
713,17368152,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
714,17368152,NA,Diabetes Mellitus,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,230
715,17368152,NA,Drug-Eluting Stents,Drug-Eluting Stents,D054855,NA,0,0,any,2,000000000,Drug-Eluting Stents,230
716,17368152,NA,Geographic Locations,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,230
717,17368152,NA,"Myocardial Infarction, ST segment elevation (finding)",ST Elevation Myocardial Infarction,D000072657,NA,0,0,any,2,000000000,ST Elevation Myocardial Infarction,230
718,17368152,NA,Percutaneous Coronary Intervention,Percutaneous Coronary Intervention,D062645,NA,0,0,any,2,000000000,Percutaneous Coronary Intervention,230
719,17368152,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
720,17368152,NA,Racial group,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,230
721,17368152,NA,"Randomisation to PCI, tertiles",Percutaneous Coronary Intervention,D062645,NA,0,0,any,2,000000000,Percutaneous Coronary Intervention,NA
722,17368152,NA,region,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,NA
723,17368152,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,230
723,17368152,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
724,17368152,NA,ST deviation,ST Elevation Myocardial Infarction,D000072657,NA,0,0,any,2,000000000,ST Elevation Myocardial Infarction,NA
725,17368152,NA,thienopyridine,Thienopyridines,D058924,NA,0,0,any,2,000000000,Thienopyridines,230
726,17368152,NA,Thienopyridine administration,Thienopyridines,D058924,NA,0,0,any,2,000000000,Thienopyridines,NA
727,17368152,NA,Thrombolysis in Myocardial Infarction Flow,Thrombosis,D013927,NA,0,0,any,2,000000000,Thrombosis,230
728,17368152,NA,TIMI risk score,Thrombosis,D013927,NA,1,0,risk score,10,000000100,Thrombosis,NA
729,17368152,NA,Troponin,Troponin,D014336,NA,0,0,any,2,000000000,Troponin,230
730,17368152,NA,Troponin raised,Troponin,D014336,NA,0,0,any,2,000000000,Troponin,NA
731,17368152,NA,Upstream IIb/IIIa inhibitor,unclassifiable,NA,NA,0,0,any,2,000000000,unclassifiable,230
731,17368152,NA,Upstream IIb/IIIa inhibitor,unclassifiable,NA,NA,0,0,any,2,000000000,unclassifiable,NA
732,17368152,NA,"DES implanted BMS only implanted (n=1666) 7·4% 7·2% 1·03 (0·73–1·46)
No stent implanted",Drug-Eluting Stents,D054855,NA,0,0,any,2,000000000,Drug-Eluting Stents,NA
733,17384434,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,116
734,17384434,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,NA
735,17384434,NA,hypertension,Hypertension,D006973,NA,0,0,any,2,000000000,Hypertension,NA
736,17384434,NA,lipoprotein,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,NA
737,17384434,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
738,17384434,NA,region,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,NA
739,17384434,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
740,17384437,1,?-Blocker Use Yes No,Adrenergic beta-Antagonists,D000319,NA,0,111,any,2,000000000,Adrenergic beta-Antagonists,NA
741,17384437,1,<1.3,Glomerular Filtration Rate,D005919,NA,0,1471,any,2,000000000,Glomerular Filtration Rate,NA
742,17384437,1,<120,Blood Pressure,D001794,NA,0,1471,any,2,000000000,Blood Pressure,NA
743,17384437,1,<2.8,Arginine Vasopressin,D001127,NA,0,1471,any,2,000000000,Arginine Vasopressin,NA
744,17384437,1,<26,Blood Urea Nitrogen,D001806,NA,0,1471,any,2,000000000,Blood Urea Nitrogen,NA
745,17384437,1,<28,Stroke Volume,D013318,NA,0,1471,any,2,000000000,Stroke Volume,NA
746,17384437,1,<65,Age Factors,D000367,NA,0,1471,any,2,000000000,Age Factors,NA
747,17384437,1,<698,"Natriuretic Peptide, Brain",D020097,NA,0,1471,any,2,000000000,"Natriuretic Peptide, Brain",NA
748,17384437,1,>1.3,Glomerular Filtration Rate,D005919,NA,0,1471,any,2,000000000,Glomerular Filtration Rate,NA
749,17384437,1,>120,Blood Pressure,D001794,NA,0,1471,any,2,000000000,Blood Pressure,NA
750,17384437,1,>2.8,Arginine Vasopressin,D001127,NA,0,1471,any,2,000000000,Arginine Vasopressin,NA
751,17384437,1,>26,Blood Urea Nitrogen,D001806,NA,0,1471,any,2,000000000,Blood Urea Nitrogen,NA
752,17384437,1,>28,Stroke Volume,D013318,NA,0,1471,any,2,000000000,Stroke Volume,NA
753,17384437,1,>65,Age Factors,D000367,NA,0,1471,any,2,000000000,Age Factors,NA
754,17384437,1,>698,"Natriuretic Peptide, Brain",D020097,NA,0,1471,any,2,000000000,"Natriuretic Peptide, Brain",NA
755,17384437,1,ACE Inhibitor or ARB Use Yes No,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,111,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
756,17384437,1,age,Age Factors,D000367,NA,0,111,any,2,000000000,Age Factors,NA
757,17384437,1,Aldosterone use,Steroids,D013256,S02B,0,111,any,2,000000000,Steroids,NA
758,17384437,1,"B-Natriuretic Peptide, pg/mL >698 ?698","Natriuretic Peptide, Brain",D020097,NA,0,111,any,2,000000000,"Natriuretic Peptide, Brain",NA
759,17384437,1,Cause of heart failure Non-ischaemic (n=2087) ischaemic (n=4418),Heart Failure,D006333,NA,0,111,aetiological,1,000001000,Heart Failure,NA
760,17384437,1,Congestion Not Severe,Dyspnea,D004417,NA,0,111,severity,11,000100000,Dyspnea,NA
761,17384437,1,"Congestion Not Severe,Severe",Dyspnea,D004417,NA,0,111,severity,11,000100000,Dyspnea,NA
762,17384437,1,Congestion Severe,Dyspnea,D004417,NA,0,111,severity,11,000100000,Dyspnea,NA
763,17384437,1,"Dyspnea
Frequent or Continuous
None or Seldom",Dyspnea,D004417,NA,0,111,severity,11,000100000,Dyspnea,NA
764,17384437,1,eastern europe,Geographic Locations,D005842,NA,0,1471,any,2,000000000,Geographic Locations,NA
765,17384437,1,"Ejection Fraction, %",Stroke Volume,D013318,NA,0,111,any,2,000000000,Stroke Volume,NA
766,17384437,1,Etiology Ischemic Nonischemic,Ischemia,D007511,NA,0,111,aetiological,1,000001000,Ischemia,NA
767,17384437,1,female,Gender Identity,D005783,NA,0,1471,any,2,000000000,Gender Identity,NA
768,17384437,1,frequent or continuous,Dyspnea,D004417,NA,0,1471,any,2,000000000,Dyspnea,NA
769,17384437,1,iii,Heart Failure,D006333,NA,0,1471,severity,11,000100000,Heart Failure,NA
770,17384437,1,ischemic,Ischemia,D007511,NA,0,1471,aetiological,1,000001000,Ischemia,NA
771,17384437,1,iv,Heart Failure,D006333,NA,0,1471,severity,11,000100000,Heart Failure,NA
772,17384437,1,male,Gender Identity,D005783,NA,0,1471,any,2,000000000,Gender Identity,NA
773,17384437,1,male female,Gender Identity,D005783,NA,0,111,any,2,000000000,Gender Identity,NA
774,17384437,1,no,NA,NA,C07,0,1471,any,2,000000000,NA,NA
775,17384437,1,none or seldom,Dyspnea,D004417,NA,0,1471,any,2,000000000,Dyspnea,NA
776,17384437,1,nonischemic,Ischemia,D007511,NA,0,1471,aetiological,1,000001000,Ischemia,NA
777,17384437,1,north america,Geographic Locations,D005842,NA,0,1471,any,2,000000000,Geographic Locations,NA
778,17384437,1,not severe,Dyspnea,D004417,NA,0,1471,any,2,000000000,Dyspnea,NA
779,17384437,1,NYHA class,Heart Failure,D006333,NA,0,111,severity,11,000100000,Heart Failure,NA
780,17384437,1,"pulmonary arterial hypertension, etiology",Pulmonary Arterial Hypertension,D000081029,NA,0,111,aetiological,1,000001000,Pulmonary Arterial Hypertension,NA
781,17384437,1,race,Racial Groups,D044469,NA,0,111,any,2,000000000,Racial Groups,NA
782,17384437,1,sbp,Blood Pressure,D001794,NA,0,111,any,2,000000000,Blood Pressure,NA
783,17384437,1,"Serum Sodium, mEq/L >137 ?137",Sodium,D012964,NA,0,111,any,2,000000000,Sodium,NA
784,17384437,1,"Serum Urea Nitrogen, mg/dL >26 ?26",Blood Urea Nitrogen,D001806,NA,0,111,any,2,000000000,Blood Urea Nitrogen,NA
785,17384437,1,severe,Dyspnea,D004417,NA,0,1471,any,2,000000000,Dyspnea,NA
786,17384437,1,south america,Geographic Locations,D005842,NA,0,1471,any,2,000000000,Geographic Locations,NA
787,17384437,1,western europe,Geographic Locations,D005842,NA,0,1471,any,2,000000000,Geographic Locations,NA
788,17384437,1,white,Racial Groups,D044469,NA,0,1471,any,2,000000000,Racial Groups,NA
789,17384437,1,yes,NA,NA,C07,0,1471,any,2,000000000,NA,NA
790,17384437,fig1,"AVP, pg/mL >2.8 ?2.8",Arginine Vasopressin,D001127,NA,0,1471,any,2,000000000,Arginine Vasopressin,NA
791,17384437,fig1,Cause of heart failure Non-ischaemic (n=2087) ischaemic (n=4418),Heart Failure,D006333,NA,0,1471,aetiological,1,000001000,Heart Failure,NA
792,17384437,fig1,Serum creatinine,Glomerular Filtration Rate,D005919,NA,0,1471,any,2,000000000,Glomerular Filtration Rate,NA
793,17384437,fig2,sbp,Blood Pressure,D001794,NA,0,1471,any,2,000000000,Blood Pressure,NA
794,17384437,NA,ace inhibitor or arb,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,0,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
795,17384437,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
796,17384437,NA,aldosterone,Steroids,D013256,NA,0,0,any,2,000000000,Steroids,NA
797,17384437,NA,avp,Arginine Vasopressin,D001127,NA,0,0,any,2,000000000,Arginine Vasopressin,NA
798,17384437,NA,Beta blocker use,Adrenergic beta-Antagonists,D000319,NA,0,0,any,2,000000000,Adrenergic beta-Antagonists,NA
799,17384437,NA,bnp,"Natriuretic Peptide, Brain",D020097,NA,0,0,any,2,000000000,"Natriuretic Peptide, Brain",NA
800,17384437,NA,congestion,Dyspnea,D004417,NA,0,0,any,2,000000000,Dyspnea,NA
801,17384437,NA,creatinine,Glomerular Filtration Rate,D005919,NA,0,0,any,2,000000000,Glomerular Filtration Rate,NA
802,17384437,NA,dyspnea,Dyspnea,D004417,NA,0,0,any,2,000000000,Dyspnea,NA
803,17384437,NA,etiology,Heart Failure,D006333,NA,0,0,aetiological,1,000001000,Heart Failure,NA
804,17384437,NA,lvef,Stroke Volume,D013318,NA,0,0,any,2,000000000,Stroke Volume,NA
805,17384437,NA,nitrogen,Blood Urea Nitrogen,D001806,NA,0,0,any,2,000000000,Blood Urea Nitrogen,NA
806,17384437,NA,nyha class,Heart Failure,D006333,NA,0,0,severity,11,000100000,Heart Failure,NA
807,17384437,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
808,17384437,NA,region,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,NA
809,17384437,NA,sbp,Blood Pressure,D001794,NA,0,0,any,2,000000000,Blood Pressure,NA
810,17384437,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
811,17384437,NA,sodium,Sodium,D012964,NA,0,0,any,2,000000000,Sodium,NA
812,17392541,NA,Patient Variable: Age at randomisation,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,37
813,17398308,2,age (years),Age Factors,D000367,NA,0,1768,any,2,000000000,Age Factors,NA
814,17398308,2,bmi,Body Mass Index,D015992,NA,0,1768,any,2,000000000,Body Mass Index,NA
815,17398308,2,diabetes,Diabetes Mellitus,D003920,NA,0,1768,any,2,000000000,Diabetes Mellitus,NA
816,17398308,2,diabetes;present,Diabetes Mellitus,D003920,NA,0,1768,current,3,010000000,Diabetes Mellitus,NA
817,17398308,2,HDL cholesterol,Lipoproteins,D008074,NA,0,1768,any,2,000000000,Lipoproteins,NA
818,17398308,2,Hypertension,Hypertension,D006973,NA,0,1768,any,2,000000000,Hypertension,NA
819,17398308,2,hypertension;present,Hypertension,D006973,NA,0,1768,current,3,010000000,Hypertension,NA
820,17398308,2,ldl-cholesterol (,Lipoproteins,D008074,NA,0,1768,any,2,000000000,Lipoproteins,NA
821,17398308,2,previous cad,Coronary Artery Disease,D003324,NA,0,1768,previous,8,100000000,Coronary Artery Disease,NA
822,17398308,2,previous cad;present,Coronary Artery Disease,D003324,NA,0,1768,previous,8,110000000,Coronary Artery Disease,NA
823,17398308,2,sex,Gender Identity,D005783,NA,0,1768,any,2,000000000,Gender Identity,NA
824,17398308,2,smoking;smoker,Cigarette Smoking,D000073865,NA,0,1768,any,2,000000000,Cigarette Smoking,NA
825,17398308,2,total cholesterol (mmol/l),Lipoproteins,D008074,NA,0,1768,any,2,000000000,Lipoproteins,NA
826,17398308,2,triglyceride (mm,Lipoproteins,D008074,NA,0,1768,any,2,000000000,Lipoproteins,NA
827,17448820,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
828,17448820,NA,Age-Years,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
829,17448820,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
830,17448820,NA,National Institutes of Health Stroke Scale (NIHSS),Stroke,D020521,NA,0,0,any,2,000000000,Stroke,NA
831,17448820,NA,nihss score,Stroke,D020521,NA,0,0,any,2,000000000,Stroke,NA
832,17448820,NA,obesity,Obesity,D009765,NA,0,0,any,2,000000000,Obesity,NA
833,17448820,NA,previous stroke,Stroke,D020521,NA,0,0,previous,8,100000000,Stroke,NA
834,17448820,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
835,17448820,NA,stroke,Stroke,D020521,NA,0,0,any,2,000000000,Stroke,NA
836,17448820,NA,stroke prophylaxis,unclassifiable,NA,NA,0,0,any,2,000000000,unclassifiable,NA
837,17451425,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,173
838,17451425,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,NA
839,17451425,NA,HbA1c,Glycated Hemoglobin A,D006442,NA,0,0,any,2,000000000,Glycated Hemoglobin A,NA
840,17451425,NA,history of hypertension,Hypertension,D006973,NA,0,0,previous,8,100000000,Hypertension,NA
841,17451425,NA,hypercholesterolaemia history,Lipoproteins,D008074,NA,0,0,previous,8,100000000,Lipoproteins,NA
842,17451425,NA,LDL,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,NA
843,17451425,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
844,17451425,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
845,17470824,2,patients not receiving corticosteroids at baseline,Steroids,D013256,NA,0,427,any,2,000000000,Steroids,NA
846,17470824,2,patients not receiving immunosuppressive agents at baseline,Immunosuppressive Agents,D007166,NA,0,427,any,2,000000000,Immunosuppressive Agents,NA
847,17470824,2,patients receiving corticosteroids at baseline,Steroids,D013256,NA,0,427,any,2,000000000,Steroids,NA
848,17470824,2,patients receiving immunosuppressive agents at baseline,Immunosuppressive Agents,D007166,NA,0,427,any,2,000000000,Immunosuppressive Agents,NA
849,17470824,2,patients who received indeterminate results on test for antibodies to infliximabt,complex,none,NA,0,427,any,2,000000000,complex,NA
850,17470824,2,patients who received negative results on test for antibodies to infliximabt,complex,none,NA,0,427,any,2,000000000,complex,NA
851,17470824,2,patients who received positive results on test for antibodies to infliximabt,complex,none,NA,0,427,any,2,000000000,complex,NA
852,17470824,2,patients with baseline crp concentration <10 mg/l,C-Reactive Protein,D002097,NA,0,427,any,2,000000000,C-Reactive Protein,NA
853,17470824,2,patients with baseline crp concentration >=10 mg/l,C-Reactive Protein,D002097,NA,0,427,any,2,000000000,C-Reactive Protein,NA
854,17470824,2,patients with previous intolerance of infliximab,Tumor Necrosis Factor Inhibitors,D000079424,NA,0,427,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
855,17470824,2,patients with previous loss of response to and intolerance of infliximab*,Tumor Necrosis Factor Inhibitors,D000079424,NA,0,427,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
856,17470824,2,patients with previous loss of response to infliximab,Tumor Necrosis Factor Inhibitors,D000079424,NA,0,427,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
857,17560879,1,";crp (mg/l), median ± sd",C-Reactive Protein,D002097,NA,0,784,any,2,000000000,C-Reactive Protein,NA
858,17560879,1,";tg (mg/dl), median ± sd",Lipoproteins,D008074,NA,0,784,any,2,000000000,Lipoproteins,NA
859,17560879,1,;<65,Age Factors,D000367,NA,0,784,any,2,000000000,Age Factors,NA
860,17560879,1,;>65,Age Factors,D000367,NA,0,784,any,2,000000000,Age Factors,NA
861,17560879,1,;age (yrs),Age Factors,D000367,NA,0,784,any,2,000000000,Age Factors,NA
862,17560879,1,;apolipoprotein b (mg/dl),Apolipoprotein A-I,D016632,NA,0,784,any,2,000000000,Apolipoprotein A-I,NA
863,17560879,1,;body mass index (kg/nr),Body Mass Index,D015992,NA,0,784,any,2,000000000,Body Mass Index,NA
864,17560879,1,;caucasian (%),Racial Groups,D044469,NA,0,784,any,2,000000000,Racial Groups,NA
865,17560879,1,;caucasian (%),Racial Groups,D044469,NA,0,784,type,12,000000010,Racial Groups,NA
866,17560879,1,;coronary heart disease (%),Coronary Artery Disease,D003324,NA,0,784,any,2,000000000,Coronary Artery Disease,NA
867,17560879,1,;coronary heart disease (%),Coronary Artery Disease,D003324,NA,0,784,type,12,000000010,Coronary Artery Disease,NA
868,17560879,1,";crp (mg/l), median Â± sd",C-Reactive Protein,D002097,NA,0,784,any,2,000000000,C-Reactive Protein,NA
869,17560879,1,;diabetes mellitus (%),Diabetes Mellitus,D003920,NA,0,784,any,2,000000000,Diabetes Mellitus,NA
870,17560879,1,;diabetes mellitus (%),Diabetes Mellitus,D003920,NA,0,784,type,12,000000010,Diabetes Mellitus,NA
871,17560879,1,;hdl (mg/dl),Lipoproteins,D008074,NA,0,784,any,2,000000000,Lipoproteins,NA
872,17560879,1,;ldl cholesterol (mg/dl),Lipoproteins,D008074,NA,0,784,any,2,000000000,Lipoproteins,NA
873,17560879,1,;men (%),Gender Identity,D005783,NA,0,784,any,2,000000000,Gender Identity,NA
874,17560879,1,;men (%),Gender Identity,D005783,NA,0,784,type,12,000000010,Gender Identity,NA
875,17560879,1,;metabolic syndrome (%),Metabolic Syndrome,D024821,NA,0,784,any,2,000000000,Metabolic Syndrome,NA
876,17560879,1,;metabolic syndrome (%),Metabolic Syndrome,D024821,NA,0,784,type,12,000000010,Metabolic Syndrome,NA
877,17560879,1,";tg (mg/dl), median Â± sd",Lipoproteins,D008074,NA,0,784,any,2,000000000,Lipoproteins,NA
878,17560879,1,;total cholesterol (mg/dl),Lipoproteins,D008074,NA,0,784,any,2,000000000,Lipoproteins,NA
879,17560879,1,age,Age Factors,D000367,NA,0,784,any,2,000000000,Age Factors,NA
880,17560879,1,atorvastatin factorial study,Atorvastatin,D000069059,NA,0,784,any,2,000000000,Atorvastatin,NA
881,17560879,1,pooled simvastatin factorial studies,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,784,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
882,17560879,2,atovarstatin,Atorvastatin,D000069059,NA,0,287,any,2,000000000,Atorvastatin,NA
883,17560879,2,ezetimibe/simvastatin,lipid modifying agents,NA,C10,0,287,any,2,000000000,lipid modifying agents,NA
884,17560879,2,simvastatin,lipid modifying agents,NA,C10,0,287,any,2,000000000,lipid modifying agents,NA
885,17560879,NA,Age-Years,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
886,17560879,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,NA
887,17560879,NA,chd,Coronary Artery Disease,D003324,NA,0,0,any,2,000000000,Coronary Artery Disease,NA
888,17560879,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
889,17560879,NA,Metabolic Syndrome,Metabolic Syndrome,D024821,NA,0,0,any,2,000000000,Metabolic Syndrome,NA
890,17560879,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
891,17560879,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
892,17586303,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,261
893,17586303,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,259
894,17586303,NA,egfr,Renal Insufficiency,D051437,NA,0,0,any,2,000000000,Renal Insufficiency,259
895,17586303,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,259
896,17605774,2,";ics(tiotropium n = 126, placebo n = 113)",Steroids,D013256,NA,0,16,any,2,000000000,Steroids,NA
897,17605774,2,";ics; no laba(tiotropium n = 76, placebo n = 65)",Steroids,D013256,R03,0,16,any,2,000000000,Steroids,NA
898,17605774,2,";laba plus ics(tiotropium n = 50, placebo n = 48)",drugs for obstructive airway diseases,NA,R03,0,16,any,2,000000000,drugs for obstructive airway diseases,NA
899,17605774,2,";no laba; no ics(tiotropium n = 59, placebo n = 63)",Steroids,D013256,NA,0,16,any,2,000000000,Steroids,NA
900,17634458,2,glucocorticoids at baseline,Steroids,D013256,NA,0,1820,any,2,000000000,Steroids,NA
901,17634458,2,immunosuppressive agents at baseline,Tumor Necrosis Factor Inhibitors,D000079424,NA,0,1820,any,2,000000000,Tumor Necrosis Factor Inhibitors,NA
902,17634458,2,no glucocorticoids at baseline,Steroids,D013256,NA,0,1820,any,2,000000000,Steroids,NA
903,17634458,2,no immunosuppressive agents at baseline,Immunosuppressive Agents,D007166,NA,0,1820,any,2,000000000,Immunosuppressive Agents,NA
904,17634458,2,no previous treatment with infliximab,Tumor Necrosis Factor Inhibitors,D000079424,NA,0,1820,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
905,17634458,2,previous treatment with infliximab,Tumor Necrosis Factor Inhibitors,D000079424,NA,0,1820,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
906,17634458,2,with baseline crp level of>10 mg/liter,C-Reactive Protein,D002097,NA,0,1820,any,2,000000000,C-Reactive Protein,NA
907,17634459,2,Certolizumab Pegol,Immunosuppressive Agents,D007166,NA,0,10,any,2,000000000,Immunosuppressive Agents,NA
908,17634459,2,Certolizumab Pegol and high crp,complex,none,NA,0,10,any,2,000000000,complex,NA
909,17634459,2,placebo and high crp,C-Reactive Protein,D002097,NA,0,10,any,2,000000000,C-Reactive Protein,NA
910,17723125,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
911,17723125,NA,cancer surgery,unclassifiable,NA,NA,0,0,any,2,000000000,unclassifiable,NA
912,17723125,NA,duration of surgery,"Surgical Procedures, Operative",D013514,NA,0,0,duration,5,001000000,"Surgical Procedures, Operative",NA
913,17723125,NA,number of risk factors for venous thromboembolism,Embolism and Thrombosis,D016769,NA,0,0,risk score,10,000000100,Embolism and Thrombosis,NA
914,17723125,NA,obese,Obesity,D009765,NA,0,0,any,2,000000000,Obesity,NA
915,17723125,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
916,17723125,NA,type of surgery,"Specialties, Surgical",D013043,NA,0,0,type,12,000000010,"Specialties, Surgical",NA
917,17765963,2,age (years),Age Factors,D000367,NA,0,1006,any,2,000000000,Age Factors,NA
918,17765963,2,combined micro- and macrovascular complications,complex,NA,NA,0,1006,any,2,000000000,complex,NA
919,17765963,2,hba1c (%),Glycated Hemoglobin A,D006442,NA,0,1006,any,2,000000000,Glycated Hemoglobin A,NA
920,17765963,2,history of macrovascular disease,Cardiovascular Diseases,D002318,NA,0,1006,previous,8,100000000,Cardiovascular Diseases,NA
921,17765963,2,history of microvascular disease,Microvessels,D055806,NA,0,1006,previous,8,100000000,Microvessels,NA
922,17765963,2,Hypertension,Hypertension,D006973,NA,0,1006,any,2,000000000,Hypertension,NA
923,17765963,2,sbp (mm hg),Blood Pressure,D001794,NA,0,1006,any,2,000000000,Blood Pressure,NA
924,17765963,2,sex,Gender Identity,D005783,NA,0,1006,any,2,000000000,Gender Identity,NA
925,17765963,2,Treatment with anti-platelet drugs No Yes,Platelet Aggregation Inhibitors,D010975,NA,0,1006,any,2,000000000,Platelet Aggregation Inhibitors,NA
926,17765963,2,treatment with anti-platelet drugs;combined macro+micro,Platelet Aggregation Inhibitors,D010975,NA,0,1006,any,2,000000000,Platelet Aggregation Inhibitors,NA
927,17765963,2,treatment with any bp lowering drugs,Antihypertensive Agents,D000959,NA,0,1006,any,2,000000000,Antihypertensive Agents,NA
928,17765963,2,treatment with open-label perindopril,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,1006,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
929,17765963,2,treatment with statins,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,1006,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
930,17804843,2,conversion to sinus rhythm in <5 days,"Arrhythmias, Cardiac",D001145,NA,0,517,type,12,000000010,"Arrhythmias, Cardiac",NA
931,17804843,2,heart failure criteria met,Heart Failure,D006333,NA,0,517,any,2,000000000,Heart Failure,NA
932,17804843,2,Hypertension,Hypertension,D006973,NA,0,517,any,2,000000000,Hypertension,NA
933,17804843,2,left atrial diameter,Heart Atria,D006325,NA,0,517,any,2,000000000,Heart Atria,NA
934,17804843,2,previous use of amiodarone,Amiodarone,D000638,NA,0,517,previous,8,100000000,Amiodarone,NA
935,17804843,2,previous use of antiarrhythmic drugs,Anti-Arrhythmia Agents,D000889,NA,0,517,previous,8,100000000,Anti-Arrhythmia Agents,NA
936,17804843,2,structural heart disease,Heart Valve Diseases,D006349,NA,0,517,any,2,000000000,Heart Valve Diseases,NA
937,17846352,2,black non-hispanic,Racial Groups,D044469,NA,0,1115,any,2,000000000,Racial Groups,NA
938,17846352,2,non black hispanic,Racial Groups,D044469,NA,0,1115,any,2,000000000,Racial Groups,NA
939,17846352,2,race,Racial Groups,D044469,NA,0,1115,any,2,000000000,Racial Groups,NA
940,17846352,2,white non-hispanic,Racial Groups,D044469,NA,0,1115,any,2,000000000,Racial Groups,NA
941,17846352,3,black non-hispanic,Racial Groups,D044469,NA,0,1549,any,2,000000000,Racial Groups,NA
942,17846352,3,non black hispanic,Racial Groups,D044469,NA,0,1549,any,2,000000000,Racial Groups,NA
943,17846352,3,non white hispanic,Racial Groups,D044469,NA,0,1549,any,2,000000000,Racial Groups,NA
944,17878242,1,age,Age Factors,D000367,NA,0,496,any,2,000000000,Age Factors,NA
945,17965424,2,age,Age Factors,D000367,NA,0,456,any,2,000000000,Age Factors,NA
946,17965424,2,baseline aspirin use strata,Aspirin,D001241,NA,0,456,any,2,000000000,Aspirin,NA
947,17965424,2,continued use of gpa,Gastrointestinal Agents,D005765,NA,0,456,any,2,000000000,Gastrointestinal Agents,NA
948,17965424,2,gender,Gender Identity,D005783,NA,0,456,any,2,000000000,Gender Identity,NA
949,17965424,2,new use of gpa,Gastrointestinal Agents,D005765,NA,0,456,any,2,000000000,Gastrointestinal Agents,NA
950,17965424,2,race,Racial Groups,D044469,NA,0,456,any,2,000000000,Racial Groups,NA
951,17965424,2,race;non-caucasian,Racial Groups,D044469,NA,0,456,any,2,000000000,Racial Groups,NA
952,17969365,NA,previous mi,Myocardial Infarction,D009203,NA,0,0,previous,8,100000000,Myocardial Infarction,NA
953,17969365,NA,previous stroke,Stroke,D020521,NA,0,0,previous,8,100000000,Stroke,NA
954,17980928,3,insulin glargineÂ Â±Â oad,Hypoglycemic Agents,D007004,NA,0,553,any,2,000000000,Hypoglycemic Agents,NA
955,17980928,3,insulin glargineÂ Â±Â oadÂ +Â >bd prandial,Insulin,D007328,NA,0,553,any,2,000000000,Insulin,NA
956,17980928,3,insulin glargineÂ Â±Â oadÂ +Â bd prandial,Insulin,D007328,NA,0,553,any,2,000000000,Insulin,NA
957,17980928,3,insulin glargineÂ Â±Â oadÂ +Â od prandial,Insulin,D007328,NA,0,553,any,2,000000000,Insulin,NA
958,17988947,NA,Beta-blocker,Adrenergic beta-Antagonists,D000319,NA,0,0,any,2,000000000,Adrenergic beta-Antagonists,8
959,18000186,2,;with metabolic syndrome,Metabolic Syndrome,D024821,NA,0,1711,any,2,000000000,Metabolic Syndrome,NA
960,18000186,2,;without metabolic syndrome,Metabolic Syndrome,D024821,NA,0,1711,any,2,000000000,Metabolic Syndrome,NA
961,18032739,NA,baseline NIHSS score,Stroke,D020521,NA,0,0,severity,2,000000000,Stroke,NA
962,18034842,NA,obese,Obesity,D009765,NA,0,0,any,2,000000000,Obesity,136
963,18056903,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
964,18056903,NA,Age-Years,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
965,18056903,NA,Antithrombin crossovers,Antithrombins,D000991,NA,0,0,any,2,000000000,Antithrombins,NA
966,18056903,NA,Antithrombins,Antithrombins,D000991,NA,0,0,any,2,000000000,Antithrombins,NA
967,18056903,NA,Creatine kinase MB/troponin I or T,Troponin,D014336,NA,0,0,any,2,000000000,Troponin,NA
968,18056903,NA,creatinine,Glomerular Filtration Rate,D005919,NA,0,0,any,2,000000000,Glomerular Filtration Rate,NA
969,18056903,NA,Creatinine clearance,Glomerular Filtration Rate,D005919,NA,0,0,any,2,000000000,Glomerular Filtration Rate,NA
970,18056903,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
971,18056903,NA,Diabetes Mellitus,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
972,18056903,NA,Geographic Locations,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,NA
973,18056903,NA,"Myocardial Infarction, ST segment elevation (finding)",ST Elevation Myocardial Infarction,D000072657,NA,0,0,any,2,000000000,ST Elevation Myocardial Infarction,NA
974,18056903,NA,PCI CABG surgery Medical therapy,Coronary Artery Bypass,D001026,NA,0,0,previous,8,100000000,Coronary Artery Bypass,NA
975,18056903,NA,Percutaneous Coronary Intervention,Percutaneous Coronary Intervention,D062645,NA,0,0,any,2,000000000,Percutaneous Coronary Intervention,NA
976,18056903,NA,Racial group,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
977,18056903,NA,Randomization to angiography or intervention,Coronary Angiography,D017023,NA,0,0,any,2,000000000,Coronary Angiography,NA
978,18056903,NA,region,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,NA
979,18056903,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
980,18056903,NA,ST deviation,ST Elevation Myocardial Infarction,D000072657,NA,0,0,any,2,000000000,ST Elevation Myocardial Infarction,NA
981,18056903,NA,thienopyridine,Thienopyridines,D058924,NA,0,0,any,2,000000000,Thienopyridines,NA
982,18056903,NA,Thienopyridine administration,Thienopyridines,D058924,NA,0,0,any,2,000000000,Thienopyridines,NA
983,18056903,NA,Thrombolysis in Myocardial Infarction Flow,Thrombosis,D013927,NA,0,0,any,2,000000000,Thrombosis,NA
984,18056903,NA,TIMI risk score,Thrombosis,D013927,NA,1,0,risk score,10,000000100,Thrombosis,NA
985,18056903,NA,Troponin,Troponin,D014336,NA,0,0,any,2,000000000,Troponin,NA
986,18056903,NA,Upstream IIb/IIIa inhibitor,unclassifiable,NA,NA,0,0,any,2,000000000,unclassifiable,NA
987,18094675,2,hemoglobin (gl^-1)Â for baseline hemoglobin < 120 gl^-1,Hemoglobins,D006454,NA,0,626,any,2,000000000,Hemoglobins,NA
988,18094675,2,hemoglobin (gl^-1)for combined hemoglobin groups,Hemoglobins,D006454,NA,0,626,any,2,000000000,Hemoglobins,NA
989,18094675,3,baseline hemoglobin,Hemoglobins,D006454,NA,0,979,any,2,000000000,Hemoglobins,NA
990,18172039,3,;> 50 years,Age Factors,D000367,NA,0,699,any,2,000000000,Age Factors,NA
991,18172039,3,;> 55 years,Age Factors,D000367,NA,0,699,any,2,000000000,Age Factors,NA
992,18172039,3,;> 60 years,Age Factors,D000367,NA,0,699,any,2,000000000,Age Factors,NA
993,18172039,3,;> 60 years 47 / 1425 (7.4),Age Factors,D000367,NA,0,699,any,2,000000000,Age Factors,NA
994,18172039,3,;>60 years,Age Factors,D000367,NA,0,699,any,2,000000000,Age Factors,NA
995,18199798,2,;dd,Genetic Profile,D000076610,NA,0,859,any,2,000000000,Genetic Profile,NA
996,18199798,2,;id,Genetic Profile,D000076610,NA,0,859,any,2,000000000,Genetic Profile,NA
997,18199798,2,;ii,Genetic Profile,D000076610,NA,0,859,any,2,000000000,Genetic Profile,NA
998,18199798,2,ACE genotype,complex,none,NA,0,859,type,12,000000010,complex,NA
999,18223031,NA,gender,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
1000,18227370,2,;non-black participants,Racial Groups,D044469,NA,0,1356,any,2,000000000,Racial Groups,NA
1001,18227370,2,race,Racial Groups,D044469,NA,0,1356,any,2,000000000,Racial Groups,NA
1002,18227370,2,With  no metabolic syndrome,Metabolic Syndrome,D024821,NA,0,1356,any,2,000000000,Metabolic Syndrome,NA
1003,18227370,2,With metabolic syndrome,Metabolic Syndrome,D024821,NA,0,1356,any,2,000000000,Metabolic Syndrome,NA
1004,18227370,2,With no metabolic syndrome,Metabolic Syndrome,D024821,NA,0,1356,any,2,000000000,Metabolic Syndrome,NA
1005,18227370,2,Without metabolic syndrome,Metabolic Syndrome,D024821,NA,0,1356,any,2,000000000,Metabolic Syndrome,NA
1006,18227370,3,;non-black participants,Racial Groups,D044469,NA,0,663,any,2,000000000,Racial Groups,NA
1007,18227370,3,race,Racial Groups,D044469,NA,0,663,any,2,000000000,Racial Groups,NA
1008,18227370,3,With  no metabolic syndrome,Metabolic Syndrome,D024821,NA,0,663,any,2,000000000,Metabolic Syndrome,NA
1009,18227370,3,With metabolic syndrome,Metabolic Syndrome,D024821,NA,0,663,any,2,000000000,Metabolic Syndrome,NA
1010,18227370,3,With no metabolic syndrome,Metabolic Syndrome,D024821,NA,0,663,any,2,000000000,Metabolic Syndrome,NA
1011,18227370,3,Without metabolic syndrome,Metabolic Syndrome,D024821,NA,0,663,any,2,000000000,Metabolic Syndrome,NA
1012,18227370,4,;non-black participants,Racial Groups,D044469,NA,0,1633,any,2,000000000,Racial Groups,NA
1013,18227370,4,race,Racial Groups,D044469,NA,0,1633,any,2,000000000,Racial Groups,NA
1014,18227370,4,With  no metabolic syndrome,Metabolic Syndrome,D024821,NA,0,1633,any,2,000000000,Metabolic Syndrome,NA
1015,18227370,4,With metabolic syndrome,Metabolic Syndrome,D024821,NA,0,1633,any,2,000000000,Metabolic Syndrome,NA
1016,18227370,4,With no metabolic syndrome,Metabolic Syndrome,D024821,NA,0,1633,any,2,000000000,Metabolic Syndrome,NA
1017,18227370,4,Without metabolic syndrome,Metabolic Syndrome,D024821,NA,0,1633,any,2,000000000,Metabolic Syndrome,NA
1018,18227370,5,With  no metabolic syndrome,Metabolic Syndrome,D024821,NA,0,1379,any,2,000000000,Metabolic Syndrome,NA
1019,18227370,5,With metabolic syndrome,Metabolic Syndrome,D024821,NA,0,1379,any,2,000000000,Metabolic Syndrome,NA
1020,18227370,5,With no metabolic syndrome,Metabolic Syndrome,D024821,NA,0,1379,any,2,000000000,Metabolic Syndrome,NA
1021,18227370,5,Without metabolic syndrome,Metabolic Syndrome,D024821,NA,0,1379,any,2,000000000,Metabolic Syndrome,NA
1022,18259029,2,men,Gender Identity,D005783,NA,0,1453,any,2,000000000,Gender Identity,NA
1023,18259029,2,men (n=2112),Gender Identity,D005783,NA,0,1453,any,2,000000000,Gender Identity,NA
1024,18259029,2,men (n=2118),Gender Identity,D005783,NA,0,1453,any,2,000000000,Gender Identity,NA
1025,18259029,2,women,Gender Identity,D005783,NA,0,1453,any,2,000000000,Gender Identity,NA
1026,18259029,2,women (n=2476),Gender Identity,D005783,NA,0,1453,any,2,000000000,Gender Identity,NA
1027,18259029,2,women (n=2487) events,Gender Identity,D005783,NA,0,1453,any,2,000000000,Gender Identity,NA
1028,18284434,2,patients aged <65,Age Factors,D000367,NA,0,337,any,2,000000000,Age Factors,NA
1029,18284434,2,patients aged 65,Age Factors,D000367,NA,0,337,any,2,000000000,Age Factors,NA
1030,18326958,2,;less severe hypertension,Hypertension,D006973,NA,0,240,severity,11,000100000,Hypertension,NA
1031,18326958,2,;more severe hypertension,Hypertension,D006973,NA,0,240,severity,11,000100000,Hypertension,NA
1032,18339679,2,;newly diagnosed asthma (n),Asthma,D001249,NA,0,1220,any,2,000000000,Asthma,NA
1033,18339679,2,"age (years);,55",Age Factors,D000367,NA,0,1220,any,2,000000000,Age Factors,NA
1034,18339679,2,age (years);55-64.9,Age Factors,D000367,NA,0,1220,any,2,000000000,Age Factors,NA
1035,18339679,2,age (years);65+,Age Factors,D000367,NA,0,1220,any,2,000000000,Age Factors,NA
1036,18339679,2,bmi (kg/m2),Body Mass Index,D015992,NA,0,1220,any,2,000000000,Body Mass Index,NA
1037,18339679,2,exercise,Exercise,D015444,NA,0,1220,any,2,000000000,Exercise,NA
1038,18339679,2,postmenopausal hormone use,Estrogen Replacement Therapy,D015914,NA,0,1220,any,2,000000000,Estrogen Replacement Therapy,NA
1039,18339679,2,postmenopausal hormone use;current,Estrogen Replacement Therapy,D015914,NA,0,1220,current,3,010000000,Estrogen Replacement Therapy,NA
1040,18339679,2,postmenopausal hormone use;past,Estrogen Replacement Therapy,D015914,NA,0,1220,previous,8,100000000,Estrogen Replacement Therapy,NA
1041,18339679,2,Smoker,Cigarette Smoking,D000073865,NA,0,1220,any,2,000000000,Cigarette Smoking,NA
1042,18339679,2,smoking status;current,Cigarette Smoking,D000073865,NA,0,1220,current,3,010000000,Cigarette Smoking,NA
1043,18339679,2,smoking status;past,Cigarette Smoking,D000073865,NA,0,1220,previous,8,100000000,Cigarette Smoking,NA
1044,18339679,2,vitamin e,Vitamin E,D014810,NA,0,1220,any,2,000000000,Vitamin E,NA
1045,18370800,NA,Medical History: Metabolic Syndrome at baseline,Metabolic Syndrome,D024821,NA,0,0,previous,8,100000000,Metabolic Syndrome,45
1046,18371559,1,syncope,Syncope,D013575,NA,0,1629,any,2,000000000,Syncope,NA
1047,18375982,2,;no prior mi,Myocardial Infarction,D009203,NA,0,1450,previous,8,100000000,Myocardial Infarction,NA
1048,18375982,2,;prior mi,Myocardial Infarction,D009203,NA,0,1450,previous,8,100000000,Myocardial Infarction,NA
1049,18375982,NA,Age-Years,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
1050,18375982,NA,arrhythmia,"Arrhythmias, Cardiac",D001145,NA,0,0,any,2,000000000,"Arrhythmias, Cardiac",NA
1051,18375982,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
1052,18375982,NA,heart rate,Heart Rate,D006339,NA,0,0,any,2,000000000,Heart Rate,NA
1053,18375982,NA,killip class,Heart Failure,D006333,NA,0,0,severity,11,000100000,Heart Failure,NA
1054,18375982,NA,PCI,Percutaneous Coronary Intervention,D062645,NA,0,0,any,2,000000000,Percutaneous Coronary Intervention,NA
1055,18375982,NA,peripheral vascular disease,Peripheral Vascular Diseases,D016491,NA,0,0,any,2,000000000,Peripheral Vascular Diseases,NA
1056,18375982,NA,prior MI,Myocardial Infarction,D009203,NA,0,0,previous,8,100000000,Myocardial Infarction,NA
1057,18375982,NA,prior stroke or TIA,Cerebrovascular Disorders,D002561,NA,0,0,previous,8,100000000,Cerebrovascular Disorders,NA
1058,18375982,NA,region,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,NA
1059,18375982,NA,renal function,Renal Insufficiency,D051437,NA,0,0,any,2,000000000,Renal Insufficiency,NA
1060,18375982,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
1061,18375982,NA,smoking,Cigarette Smoking,D000073865,NA,0,0,any,2,000000000,Cigarette Smoking,NA
1062,18381571,NA,menopause,Menopause,D008593,NA,0,0,any,2,000000000,Menopause,225
1063,18398080,2,age,Age Factors,D000367,NA,0,893,any,2,000000000,Age Factors,NA
1064,18398080,2,crp (mg/dl) <1.7,C-Reactive Protein,D002097,NA,0,893,any,2,000000000,C-Reactive Protein,NA
1065,18398080,2,current smoker yes,Cigarette Smoking,D000073865,NA,0,893,current,3,010000000,Cigarette Smoking,NA
1066,18398080,2,egfr <78,Glomerular Filtration Rate,D005919,NA,0,893,any,2,000000000,Glomerular Filtration Rate,NA
1067,18398080,2,gender male,Gender Identity,D005783,NA,0,893,any,2,000000000,Gender Identity,NA
1068,18398080,2,ldl-c (mg/dl) <100,Lipoproteins,D008074,NA,0,893,any,2,000000000,Lipoproteins,NA
1069,18398080,2,male female,Gender Identity,D005783,NA,0,893,any,2,000000000,Gender Identity,NA
1070,18398080,2,non-hdl (mg/dl) <130,Lipoproteins,D008074,NA,0,893,any,2,000000000,Lipoproteins,NA
1071,18398080,2,sbp (mmhg) <120,Blood Pressure,D001794,NA,0,893,any,2,000000000,Blood Pressure,NA
1072,18398081,NA,who had received induction therapy with corticosteroids,"Steroids, Brominated",D013257,NA,0,0,any,2,000000000,"Steroids, Brominated",148
1073,18451347,2,primary prevention subgroup,unclassifiable,NA,NA,0,NA,severity,11,000100000,unclassifiable,NA
1074,18451347,2,secondary prevention subgroup,unclassifiable,NA,NA,0,NA,severity,11,000100000,unclassifiable,NA
1075,18458145,NA,HbA1c,Glycated Hemoglobin A,D006442,NA,0,0,any,2,000000000,Glycated Hemoglobin A,52
1076,18479744,2,epidural/spinal anaesthesia,"Anesthesia, Epidural",D000767,NA,0,720,any,2,000000000,"Anesthesia, Epidural",NA
1077,18479744,2,intraperitoneal surgery,"Surgical Procedures, Operative",D013514,NA,0,720,any,2,000000000,"Surgical Procedures, Operative",NA
1078,18479744,2,number of cardiac risk factors,Heart Disease Risk Factors,D000082742,NA,0,720,risk score,10,000000100,Heart Disease Risk Factors,NA
1079,18479744,2,orthopaedic surgery,Orthopedic Procedures,D019637,NA,0,720,any,2,000000000,Orthopedic Procedures,NA
1080,18479744,2,other anaesthesia,Anesthesia,D000758,NA,0,720,any,2,000000000,Anesthesia,NA
1081,18479744,2,other surgery,"Surgical Procedures, Operative",D013514,NA,0,720,any,2,000000000,"Surgical Procedures, Operative",NA
1082,18479744,2,vascular surgery,Vascular Surgical Procedures,D014656,NA,0,720,any,2,000000000,Vascular Surgical Procedures,NA
1083,18479744,NA,cardiac risk factors,Heart Disease Risk Factors,D000082742,NA,0,0,risk score,10,000000100,Heart Disease Risk Factors,NA
1084,18479744,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
1085,18479744,NA,"type of anaesthesia [epidural/special, other].",Anesthesia,D000758,NA,0,0,type,12,000000010,Anesthesia,NA
1086,18479744,NA,"type of surgery [vascular, orthopaedic, abdominal]","Specialties, Surgical",D013043,NA,0,0,type,12,000000010,"Specialties, Surgical",NA
1087,18498915,2,age,Age Factors,D000367,NA,0,1104,any,2,000000000,Age Factors,NA
1088,18498915,2,body mass index*,Body Mass Index,D015992,NA,0,1104,any,2,000000000,Body Mass Index,NA
1089,18498915,2,body mass index+,Body Mass Index,D015992,NA,0,1104,any,2,000000000,Body Mass Index,NA
1090,18498915,2,race,Racial Groups,D044469,NA,0,1104,any,2,000000000,Racial Groups,NA
1091,18498915,2,sex,Gender Identity,D005783,NA,0,1104,any,2,000000000,Gender Identity,NA
1092,18498915,2,Smoker,Cigarette Smoking,D000073865,NA,0,1104,any,2,000000000,Cigarette Smoking,NA
1093,18498915,2,smoking status;current nonsmoker,Cigarette Smoking,D000073865,NA,0,1104,current,3,010000000,Cigarette Smoking,NA
1094,18498915,2,smoking status;current nonsmokers,Cigarette Smoking,D000073865,NA,0,1104,current,3,010000000,Cigarette Smoking,NA
1095,18498915,3,age,Age Factors,D000367,NA,0,1537,any,2,000000000,Age Factors,NA
1096,18498915,3,body mass index*,Body Mass Index,D015992,NA,0,1537,any,2,000000000,Body Mass Index,NA
1097,18498915,3,body mass index+,Body Mass Index,D015992,NA,0,1537,any,2,000000000,Body Mass Index,NA
1098,18498915,3,diabetes,Diabetes Mellitus,D003920,NA,0,1537,any,2,000000000,Diabetes Mellitus,NA
1099,18498915,3,diabetes status,Diabetes Mellitus,D003920,NA,0,1537,any,2,000000000,Diabetes Mellitus,NA
1100,18498915,3,diabetes status;nondiabetic,Diabetes Mellitus,D003920,NA,0,1537,any,2,000000000,Diabetes Mellitus,NA
1101,18498915,3,race,Racial Groups,D044469,NA,0,1537,any,2,000000000,Racial Groups,NA
1102,18498915,3,sex,Gender Identity,D005783,NA,0,1537,any,2,000000000,Gender Identity,NA
1103,18498915,3,Smoker,Cigarette Smoking,D000073865,NA,0,1537,any,2,000000000,Cigarette Smoking,NA
1104,18498915,3,smoking status;current nonsmoker,Cigarette Smoking,D000073865,NA,0,1537,current,3,010000000,Cigarette Smoking,NA
1105,18498915,3,smoking status;current nonsmokers,Cigarette Smoking,D000073865,NA,0,1537,current,3,010000000,Cigarette Smoking,NA
1106,18499565,2,geographic location,Geographic Locations,D005842,NA,0,1046,any,2,000000000,Geographic Locations,NA
1107,18499565,2,infarct location,Infarction,D007238,NA,0,1046,location,7,000000001,Infarction,NA
1108,18499565,2,male female,Gender Identity,D005783,NA,0,1046,any,2,000000000,Gender Identity,NA
1109,18499565,2,not anterior,Infarction,D007238,NA,0,1046,location,7,000000001,Infarction,NA
1110,18499565,2,previous myocardial infarction,Myocardial Infarction,D009203,NA,0,1046,previous,8,100010000,Myocardial Infarction,NA
1111,18499565,2,rest of the world,Geographic Locations,D005842,NA,0,1046,any,2,000000000,Geographic Locations,NA
1112,18511702,2,% predicted fev1,Pulmonary Ventilation,D012123,NA,0,479,any,2,000000000,Pulmonary Ventilation,NA
1113,18511702,2,age,Age Factors,D000367,NA,0,479,any,2,000000000,Age Factors,NA
1114,18511702,2,baseline sgrq total score,Quality of Life,D011788,NA,0,479,severity,11,000100000,Quality of Life,NA
1115,18511702,2,baseline SGRQ total score,Quality of Life,D011788,NA,0,479,severity,11,000100000,Quality of Life,NA
1116,18511702,2,body mass index,Body Mass Index,D015992,NA,0,479,any,2,000000000,Body Mass Index,NA
1117,18511702,2,exacerbations in previous year,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,479,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
1118,18511702,2,exacerbations in the year before study,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,479,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
1119,18511702,2,precent predicted FEV1,Pulmonary Ventilation,D012123,NA,0,479,any,2,000000000,Pulmonary Ventilation,NA
1120,18511702,2,region,Geographic Locations,D005842,NA,0,479,any,2,000000000,Geographic Locations,NA
1121,18511702,2,sex,Gender Identity,D005783,NA,0,479,any,2,000000000,Gender Identity,NA
1122,18511702,2,Smoker,Cigarette Smoking,D000073865,NA,0,479,any,2,000000000,Cigarette Smoking,NA
1123,18514551,NA,NA,unclassifiable,NA,NA,0,0,any,2,000000000,unclassifiable,3
1124,18537526,2,diabetes status,Diabetes Mellitus,D003920,NA,0,1509,any,2,000000000,Diabetes Mellitus,NA
1125,18537526,2,diabetes status;with dm,Diabetes Mellitus,D003920,NA,0,1509,any,2,000000000,Diabetes Mellitus,NA
1126,18537526,2,diabetes status;without dm,Diabetes Mellitus,D003920,NA,0,1509,any,2,000000000,Diabetes Mellitus,NA
1127,18539916,2,age,Age Factors,D000367,NA,0,653,any,2,000000000,Age Factors,NA
1128,18539916,2,body-mass index,Body Mass Index,D015992,NA,0,653,any,2,000000000,Body Mass Index,NA
1129,18539916,2,Fasting plasma glucose,Glucose,D005947,NA,0,653,any,2,000000000,Glucose,NA
1130,18539916,2,glycated hemoglobin,Glycated Hemoglobin A,D006442,NA,0,653,any,2,000000000,Glycated Hemoglobin A,NA
1131,18539916,2,history of macrovascular disease,Cardiovascular Diseases,D002318,NA,0,653,previous,8,100000000,Cardiovascular Diseases,NA
1132,18539916,2,history of microvascular disease,Microvessels,D055806,NA,0,653,previous,8,100000000,Microvessels,NA
1133,18539916,2,sex,Gender Identity,D005783,NA,0,653,any,2,000000000,Gender Identity,NA
1134,18539916,2,systolic blood pressure,Blood Pressure,D001794,NA,0,653,any,2,000000000,Blood Pressure,NA
1135,18539916,2,treatment with antiplatelet drugs,Platelet Aggregation Inhibitors,D010975,NA,0,653,any,2,000000000,Platelet Aggregation Inhibitors,NA
1136,18539916,2,treatment with statins,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,653,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
1137,18539917,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
1138,18539917,NA,hba1c,Glycated Hemoglobin A,D006442,NA,0,0,any,2,000000000,Glycated Hemoglobin A,NA
1139,18539917,NA,previous cardiovascular event,Cardiovascular Diseases,D002318,NA,0,0,previous,8,100000000,Cardiovascular Diseases,NA
1140,18539917,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
1141,18539917,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
1142,18549913,NA,"Serum uric acid, mg/dl",Uric Acid,D014527,NA,0,0,any,2,000000000,Uric Acid,NA
1143,18593517,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
1144,18593517,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,225
1145,18593517,NA,sbp,Blood Pressure,D001794,NA,0,0,any,2,000000000,Blood Pressure,NA
1146,18597830,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,NA
1147,18600389,NA,"Age, y",Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
1148,18600389,NA,BMI,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,NA
1149,18600389,NA,H. pylori infection,Helicobacter pylori,D016480,NA,0,0,any,2,000000000,Helicobacter pylori,NA
1150,18600389,NA,Hiatus hernia,"Hernia, Hiatal",D006551,NA,0,0,any,2,000000000,"Hernia, Hiatal",NA
1151,18600389,NA,Pepsinogen I/II ratio,Pepsinogens,D010435,NA,0,0,any,2,000000000,Pepsinogens,NA
1152,18600389,NA,Sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
1153,18615004,2,Genotype,Genetic Profile,D000076610,NA,0,960,type,12,000000010,Genetic Profile,NA
1154,18657652,2,prior myocardial infarction,Myocardial Infarction,D009203,NA,0,1093,previous,8,100000000,Myocardial Infarction,NA
1155,18667204,2,;high triglyceride low high density lipoprotein,Lipoproteins,D008074,NA,0,1260,any,2,000000000,Lipoproteins,NA
1156,18676075,2,;gfr <60,Glomerular Filtration Rate,D005919,NA,0,1708,any,2,000000000,Glomerular Filtration Rate,NA
1157,18676075,2,;gfr >Â 90,Glomerular Filtration Rate,D005919,NA,0,1708,any,2,000000000,Glomerular Filtration Rate,NA
1158,18676075,2,;gfr 60 - 89,Glomerular Filtration Rate,D005919,NA,0,1708,any,2,000000000,Glomerular Filtration Rate,NA
1159,18753638,2,ace-inhibitor use,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,1396,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
1160,18753638,2,age,Age Factors,D000367,NA,0,1396,any,2,000000000,Age Factors,NA
1161,18753638,2,alcohol use,Alcohol Drinking,D000428,NA,0,1396,any,2,000000000,Alcohol Drinking,NA
1162,18753638,2,diabetes mellitus,Diabetes Mellitus,D003920,NA,0,1396,any,2,000000000,Diabetes Mellitus,NA
1163,18753638,2,ethnic group;native latin,Racial Groups,D044469,NA,0,1396,any,2,000000000,Racial Groups,NA
1164,18753638,2,medical history of hypertension,Hypertension,D006973,NA,0,1396,previous,8,100000000,Hypertension,NA
1165,18753638,2,medical history;other atherosclerotic event,Atherosclerosis,D050197,NA,0,1396,previous,8,100000000,Atherosclerosis,NA
1166,18753638,2,medical history;previous stroke or tia,Cerebrovascular Disorders,D002561,NA,0,1396,previous,8,100000000,Cerebrovascular Disorders,NA
1167,18753638,2,obesity,Obesity,D009765,NA,0,1396,any,2,000000000,Obesity,NA
1168,18753638,2,prespecified analysis;any recurrent stroke,Stroke,D020521,NA,0,1396,previous severity,9,110100000,Stroke,NA
1169,18753638,2,race,Racial Groups,D044469,NA,0,1396,any,2,000000000,Racial Groups,NA
1170,18753638,2,randomization to placebo or telmisartan;telmisartan,Angiotensin Receptor Antagonists,D057911,NA,0,1396,any,2,000000000,Angiotensin Receptor Antagonists,NA
1171,18753638,2,sbp,Blood Pressure,D001794,NA,0,1396,any,2,000000000,Blood Pressure,NA
1172,18753638,2,sex,Gender Identity,D005783,NA,0,1396,any,2,000000000,Gender Identity,NA
1173,18753638,2,statin use,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,1396,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
1174,18753638,2,stroke risk score,Stroke,D020521,NA,0,1396,severity,11,000100100,Stroke,NA
1175,18753638,2,stroke risk score;>10-14 (moderate risk),Stroke,D020521,NA,0,1396,severity,11,000100100,Stroke,NA
1176,18753638,2,stroke risk score;>14 (high risk),Stroke,D020521,NA,0,1396,severity,11,000100100,Stroke,NA
1177,18753638,2,stroke risk score;0-10 (low risk),Stroke,D020521,NA,0,1396,severity,11,000100100,Stroke,NA
1178,18753638,2,time since qualifying stroke event,unclassifiable,NA,NA,0,1396,any,2,000000000,unclassifiable,NA
1179,18753638,2,toast classification of qualifying stroke,Stroke,D020521,NA,0,1396,severity,11,000100010,Stroke,NA
1180,18753638,2,toast classification of qualifying stroke;large-artery atherosclerosis,Stroke,D020521,NA,0,1396,severity,11,000100010,Stroke,NA
1181,18753638,2,toast classification of qualifying stroke;small-artery occlusion,Stroke,D020521,NA,0,1396,severity,11,000100010,Stroke,NA
1182,18753638,2,"toast classification of qualifying stroke;undetermined, other, or cardioembolism",Stroke,D020521,NA,0,1396,severity,11,000100010,Stroke,NA
1183,18753639,2,;all recurrent strokes,Stroke,D020521,NA,0,595,current,3,010000000,Stroke,NA
1184,18753639,2,diabetes mellitus,Diabetes Mellitus,D003920,NA,0,595,any,2,000000000,Diabetes Mellitus,NA
1185,18753639,2,sbp,Blood Pressure,D001794,NA,0,595,any,2,000000000,Blood Pressure,NA
1186,18753639,2,stroke risk score,Stroke,D020521,NA,0,595,severity,11,000100100,Stroke,NA
1187,18753639,2,stroke risk score;high risk (>14),Stroke,D020521,NA,0,595,severity,11,000100100,Stroke,NA
1188,18753639,2,stroke risk score;low risk (0-10),Stroke,D020521,NA,0,595,severity,11,000100100,Stroke,NA
1189,18753639,2,stroke risk score;moderate risk (>10-14),Stroke,D020521,NA,0,595,severity,11,000100100,Stroke,NA
1190,18753639,2,use of ace inhibitor,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,595,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
1191,18753639,3,diabetes mellitus,Diabetes Mellitus,D003920,NA,0,943,any,2,000000000,Diabetes Mellitus,NA
1192,18753639,3,sbp,Blood Pressure,D001794,NA,0,943,any,2,000000000,Blood Pressure,NA
1193,18753639,3,stroke risk score,Stroke,D020521,NA,0,943,severity,11,000100100,Stroke,NA
1194,18753639,3,stroke risk score;high risk (>14),Stroke,D020521,NA,0,943,severity,11,000100100,Stroke,NA
1195,18753639,3,stroke risk score;low risk (0-10),Stroke,D020521,NA,0,943,severity,11,000100100,Stroke,NA
1196,18753639,3,stroke risk score;moderate risk (>10-14),Stroke,D020521,NA,0,943,severity,11,000100100,Stroke,NA
1197,18753639,3,time from onset of qualifying stroke to randomization,Stroke,D020521,NA,0,943,any,2,000000000,Stroke,NA
1198,18753639,3,use of ace inhibitor,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,943,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
1199,18757089,2,';total cholesterol >4'97 mmol/lt',Lipoproteins,D008074,NA,0,835,any,2,000000000,Lipoproteins,NA
1200,18757089,2,;age <70 years (median),Age Factors,D000367,NA,0,835,any,2,000000000,Age Factors,NA
1201,18757089,2,;age >70 years (median),Age Factors,D000367,NA,0,835,any,2,000000000,Age Factors,NA
1202,18757089,2,;diabetes,Diabetes Mellitus,D003920,NA,0,835,any,2,000000000,Diabetes Mellitus,NA
1203,18757089,2,;ischaemic cause,Ischemia,D007511,NA,0,835,aetiological,1,000001000,Ischemia,NA
1204,18757089,2,;lvef <40%,Stroke Volume,D013318,NA,0,835,any,2,000000000,Stroke Volume,NA
1205,18757089,2,;lvef >40%,Stroke Volume,D013318,NA,0,835,any,2,000000000,Stroke Volume,NA
1206,18757089,2,;no diabetes,Diabetes Mellitus,D003920,NA,0,835,any,2,000000000,Diabetes Mellitus,NA
1207,18757089,2,;non-ischaemic cause,Ischemia,D007511,NA,0,835,aetiological,1,000001000,Ischemia,NA
1208,18757089,2,;total cholesterol <4 97 mmol/lt,Lipoproteins,D008074,NA,0,835,any,2,000000000,Lipoproteins,NA
1209,18757089,2,NYHA class,Heart Failure,D006333,NA,0,835,severity,11,000100000,Heart Failure,NA
1210,18757090,2,;age <69 years (median),Age Factors,D000367,NA,0,1049,any,2,000000000,Age Factors,NA
1211,18757090,2,;age >69 years (median),Age Factors,D000367,NA,0,1049,any,2,000000000,Age Factors,NA
1212,18757090,2,;diabetes,Diabetes Mellitus,D003920,NA,0,1049,any,2,000000000,Diabetes Mellitus,NA
1213,18757090,2,;ischaemic cause,Ischemia,D007511,NA,0,1049,aetiological,1,000001000,Ischemia,NA
1214,18757090,2,;lvef <40%,Stroke Volume,D013318,NA,0,1049,any,2,000000000,Stroke Volume,NA
1215,18757090,2,;lvef >40%,Stroke Volume,D013318,NA,0,1049,any,2,000000000,Stroke Volume,NA
1216,18757090,2,;no diabetes,Diabetes Mellitus,D003920,NA,0,1049,any,2,000000000,Diabetes Mellitus,NA
1217,18757090,2,;non-ischaemic cause,Ischemia,D007511,NA,0,1049,aetiological,1,000001000,Ischemia,NA
1218,18757090,2,;total cholesterol <4-87 mmol/lt,Lipoproteins,D008074,NA,0,1049,any,2,000000000,Lipoproteins,NA
1219,18757090,2,;total cholesterol >4-87 mmol/lt,Lipoproteins,D008074,NA,0,1049,any,2,000000000,Lipoproteins,NA
1220,18757090,2,NYHA class,Heart Failure,D006333,NA,0,1049,severity,11,000100000,Heart Failure,NA
1221,18813219,NA,Patient Variable: Race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,39
1222,18813219,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,284
1223,18821708,2,disease severity,"Arthritis, Rheumatoid",D001172,NA,0,164,severity,11,000100000,"Arthritis, Rheumatoid",NA
1224,18835953,2,a1c,Glycated Hemoglobin A,D006442,NA,0,856,any,2,000000000,Glycated Hemoglobin A,NA
1225,18835953,2,age;>65 years,Age Factors,D000367,NA,0,856,any,2,000000000,Age Factors,NA
1226,18835953,2,age;45-54 years,Age Factors,D000367,NA,0,856,any,2,000000000,Age Factors,NA
1227,18835953,2,age;55-64 years,Age Factors,D000367,NA,0,856,any,2,000000000,Age Factors,NA
1228,18835953,2,bmi,Body Mass Index,D015992,NA,0,856,any,2,000000000,Body Mass Index,NA
1229,18835953,2,exercise > once weekly?,Exercise,D015444,NA,0,856,any,2,000000000,Exercise,NA
1230,18835953,2,family history ol diabetes?,Diabetes Mellitus,D003920,NA,0,856,family history,6,000010000,Diabetes Mellitus,NA
1231,18835953,2,HDL cholesterol,Lipoproteins,D008074,NA,0,856,any,2,000000000,Lipoproteins,NA
1232,18835953,2,hscrp,C-Reactive Protein,D002097,NA,0,856,any,2,000000000,C-Reactive Protein,NA
1233,18835953,2,hyperlipidemia,Hypercholesterolemia,D006937,NA,0,856,any,2,000000000,Hypercholesterolemia,NA
1234,18835953,2,hypertension,Hypertension,D006973,NA,0,856,any,2,000000000,Hypertension,NA
1235,18835953,2,LDL cholesterol,Lipoproteins,D008074,NA,0,856,any,2,000000000,Lipoproteins,NA
1236,18835953,2,Menopausal status,Menopause,D008593,NA,0,856,any,2,000000000,Menopause,NA
1237,18835953,2,menopause and ht,Estrogen Replacement Therapy,D015914,NA,0,856,any,2,000000000,Estrogen Replacement Therapy,NA
1238,18835953,2,"menopause and ht;poslmenopausal, ht",Estrogen Replacement Therapy,D015914,NA,0,856,any,2,000000000,Estrogen Replacement Therapy,NA
1239,18835953,2,"menopause and ht;poslmenopausal, no ht",Estrogen Replacement Therapy,D015914,NA,0,856,any,2,000000000,Estrogen Replacement Therapy,NA
1240,18835953,2,non-hdl cholesterol,Lipoproteins,D008074,NA,0,856,any,2,000000000,Lipoproteins,NA
1241,18835953,2,tolal cholesterol-to-hdl cholesterol ratio,Lipoproteins,D008074,NA,0,856,any,2,000000000,Lipoproteins,NA
1242,18835953,2,total cholesterol,Lipoproteins,D008074,NA,0,856,any,2,000000000,Lipoproteins,NA
1243,18836213,2,age (years),Age Factors,D000367,NA,0,641,any,2,000000000,Age Factors,NA
1244,18836213,2,bmi,Body Mass Index,D015992,NA,0,641,any,2,000000000,Body Mass Index,NA
1245,18836213,2,bmi;anticholinergic,Cholinergic Antagonists,D018680,NA,0,641,any,2,000000000,Cholinergic Antagonists,NA
1246,18836213,2,bmi;ics,Steroids,D013256,NA,0,641,any,2,000000000,Steroids,NA
1247,18836213,2,bmi;laba + ics,Adrenergic beta-2 Receptor Agonists,D058666,NA,0,641,any,2,000000000,Adrenergic beta-2 Receptor Agonists,NA
1248,18836213,2,gender,Gender Identity,D005783,NA,0,641,any,2,000000000,Gender Identity,NA
1249,18836213,2,gold stage,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,641,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
1250,18836213,2,gold stage;i/ii,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,641,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
1251,18836213,2,race,Racial Groups,D044469,NA,0,641,any,2,000000000,Racial Groups,NA
1252,18836213,2,region,Geographic Locations,D005842,NA,0,641,any,2,000000000,Geographic Locations,NA
1253,18836213,2,Smoker,Cigarette Smoking,D000073865,NA,0,641,any,2,000000000,Cigarette Smoking,NA
1254,18836213,2,smoking status;current,Cigarette Smoking,D000073865,NA,0,641,current,3,010000000,Cigarette Smoking,NA
1255,18836213,2,smoking status;former,Cigarette Smoking,D000073865,NA,0,641,previous,8,100000000,Cigarette Smoking,NA
1256,18836213,3,gold stage;i/ii,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1625,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
1257,18836213,3,Smoker,Cigarette Smoking,D000073865,NA,0,1625,any,2,000000000,Cigarette Smoking,NA
1258,18852398,NA,hba1c,Glycated Hemoglobin A,D006442,NA,0,0,any,2,000000000,Glycated Hemoglobin A,149
1259,18926433,NA,natriuretic peptide levels,"Natriuretic Peptide, Brain",D020097,NA,0,0,any,2,000000000,"Natriuretic Peptide, Brain",145
1260,18972097,1,apoa-i,Apolipoprotein A-I,D016632,NA,0,670,any,2,000000000,Apolipoprotein A-I,NA
1261,18972097,1,cholesterol,Lipoproteins,D008074,NA,0,670,any,2,000000000,Lipoproteins,NA
1262,18972097,1,HDL cholesterol,Lipoproteins,D008074,NA,0,670,any,2,000000000,Lipoproteins,NA
1263,18972097,1,ldlc,Lipoproteins,D008074,NA,0,670,any,2,000000000,Lipoproteins,NA
1264,18972097,1,non-hdlc,Lipoproteins,D008074,NA,0,670,any,2,000000000,Lipoproteins,NA
1265,18972097,1,tc:hdlc,Lipoproteins,D008074,NA,0,670,any,2,000000000,Lipoproteins,NA
1266,18975369,NA,renal function,Renal Insufficiency,D051437,NA,0,0,any,2,000000000,Renal Insufficiency,NA
1267,19001024,NA,Medical History: Ejection Fraction data,Stroke Volume,D013318,NA,0,0,previous,8,100000000,Stroke Volume,NA
1268,19001508,2,age,Age Factors,D000367,NA,0,1143,any,2,000000000,Age Factors,NA
1269,19001508,2,diabetes,Diabetes Mellitus,D003920,NA,0,1143,any,2,000000000,Diabetes Mellitus,NA
1270,19001508,2,ejection fraction,Stroke Volume,D013318,NA,0,1143,any,2,000000000,Stroke Volume,NA
1271,19001508,2,geographic region,Geographic Locations,D005842,NA,0,1143,any,2,000000000,Geographic Locations,NA
1272,19001508,2,hospitalization for heart failure within 6 mo,Heart Failure,D006333,NA,0,1143,severity,11,000100000,Heart Failure,NA
1273,19001508,2,sex,Gender Identity,D005783,NA,0,1143,any,2,000000000,Gender Identity,NA
1274,19001508,2,use of ace inhibitor,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,1143,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
1275,19001508,2,use of beta-blocker,Adrenergic beta-Antagonists,D000319,NA,0,1143,any,2,000000000,Adrenergic beta-Antagonists,NA
1276,19026303,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,107
1277,19026303,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,NA
1278,19026303,NA,cholesterol,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,NA
1279,19026303,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
1280,19026303,NA,hdl,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,NA
1281,19026303,NA,metabolic syndrome,Metabolic Syndrome,D024821,NA,0,0,any,2,000000000,Metabolic Syndrome,NA
1282,19026303,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
1283,19026303,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
1284,19026303,NA,triglyceride,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,NA
1285,19042161,NA,severe AD,Alzheimer Disease,D000544,NA,0,0,severity,11,000100000,Alzheimer Disease,65
1286,19052124,NA,"Age, y",Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
1287,19052124,NA,Diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
1288,19052124,NA,Sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
1289,19097665,2,race,Racial Groups,D044469,NA,0,231,any,2,000000000,Racial Groups,NA
1290,19097665,3,2-h postprandial c-peptide (ng/ml),C-Peptide,D002096,NA,0,1827,any,2,000000000,C-Peptide,NA
1291,19097665,3,2-h postprandial insulin (miu/ml),Insulin,D007328,NA,0,1827,any,2,000000000,Insulin,NA
1292,19097665,3,2-h postprandial proinsulin (pmol/l),Proinsulin,D011384,NA,0,1827,any,2,000000000,Proinsulin,NA
1293,19097665,3,composite index of insulin sensitivity (isi),Insulin Resistance,D007333,NA,0,1827,location,7,000000001,Insulin Resistance,NA
1294,19097665,3,fasting c-peptide (ng/ml),C-Peptide,D002096,NA,0,1827,any,2,000000000,C-Peptide,NA
1295,19097665,3,fasting insulin (miu/ml),Insulin,D007328,NA,0,1827,any,2,000000000,Insulin,NA
1296,19097665,3,fasting proinsulin (pmol/l),Proinsulin,D011384,NA,0,1827,any,2,000000000,Proinsulin,NA
1297,19097665,3,homa-b,Insulin Resistance,D007333,NA,0,1827,any,2,000000000,Insulin Resistance,NA
1298,19097665,3,homa-ir,Insulin Resistance,D007333,NA,0,1827,any,2,000000000,Insulin Resistance,NA
1299,19097665,3,insulinogenic index (dinsulino_3o min/dglucoseo-3o min),Insulin,D007328,NA,0,1827,any,2,000000000,Insulin,NA
1300,19097665,3,quicki,Insulin Resistance,D007333,NA,0,1827,any,2,000000000,Insulin Resistance,NA
1301,19104004,3,blood pressure,Blood Pressure,D001794,NA,0,1326,any,2,000000000,Blood Pressure,NA
1302,19104004,3,blood pressure;controlld,Blood Pressure,D001794,NA,0,1326,any,2,000000000,Blood Pressure,NA
1303,19104004,3,blood pressure;uncontrolled,Blood Pressure,D001794,NA,0,1326,any,2,000000000,Blood Pressure,NA
1304,19104004,3,BMI,Body Mass Index,D015992,NA,0,1326,any,2,000000000,Body Mass Index,NA
1305,19104004,3,diabetes,Diabetes Mellitus,D003920,NA,0,1326,any,2,000000000,Diabetes Mellitus,NA
1306,19104004,3,diabetes;dm,Diabetes Mellitus,D003920,NA,0,1326,any,2,000000000,Diabetes Mellitus,NA
1307,19104004,3,diabetes;non-dm,Diabetes Mellitus,D003920,NA,0,1326,any,2,000000000,Diabetes Mellitus,NA
1308,19104004,3,sex,Gender Identity,D005783,NA,0,1326,any,2,000000000,Gender Identity,NA
1309,19104004,3,Smoker,Cigarette Smoking,D000073865,NA,0,1326,any,2,000000000,Cigarette Smoking,NA
1310,19104004,3,smoking;current/past,Cigarette Smoking,D000073865,NA,0,1326,previous,8,110000000,Cigarette Smoking,NA
1311,19125778,2,age (years),Age Factors,D000367,NA,0,923,any,2,000000000,Age Factors,NA
1312,19125778,2,age (years);<65 (n â€” 367),Age Factors,D000367,NA,0,923,any,2,000000000,Age Factors,NA
1313,19125778,2,age (years);>65 (n â€” 128),Age Factors,D000367,NA,0,923,any,2,000000000,Age Factors,NA
1314,19125778,2,age (years);>75 (n â€” 18),Age Factors,D000367,NA,0,923,any,2,000000000,Age Factors,NA
1315,19125778,2,baseline body mass index,Body Mass Index,D015992,NA,0,923,any,2,000000000,Body Mass Index,NA
1316,19125778,2,baseline hba1c,Glycated Hemoglobin A,D006442,NA,0,923,any,2,000000000,Glycated Hemoglobin A,NA
1317,19125778,2,baseline hba1c;<8.0 (n â€” 243),Glycated Hemoglobin A,D006442,NA,0,923,any,2,000000000,Glycated Hemoglobin A,NA
1318,19125778,2,baseline hba1c;>8.0 (n â€” 252),Glycated Hemoglobin A,D006442,NA,0,923,any,2,000000000,Glycated Hemoglobin A,NA
1319,19125778,2,ethnicity;hispanic or latino (n â€” 248),Racial Groups,D044469,NA,0,923,any,2,000000000,Racial Groups,NA
1320,19125778,2,race,Racial Groups,D044469,NA,0,923,any,2,000000000,Racial Groups,NA
1321,19125778,2,sex,Gender Identity,D005783,NA,0,923,any,2,000000000,Gender Identity,NA
1322,19125992,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,206
1323,19125992,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,207
1324,19125992,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,207
1325,19125992,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,207
1326,19139391,2,age,Age Factors,D000367,NA,0,747,any,2,000000000,Age Factors,NA
1327,19166691,2,BMI (Body mass index),Body Mass Index,D015992,NA,0,366,any,2,000000000,Body Mass Index,NA
1328,19166691,2,DM (Diabetes mellitus),Diabetes Mellitus,D003920,NA,0,366,any,2,000000000,Diabetes Mellitus,NA
1329,19166691,2,HDL-C high density lipoprotein cholesterol,Lipoproteins,D008074,NA,0,366,any,2,000000000,Lipoproteins,NA
1330,19166691,2,LDL-C LDL cholesterol,Lipoproteins,D008074,NA,0,366,any,2,000000000,Lipoproteins,NA
1331,19166691,2,TG triglycerides,Lipoproteins,D008074,NA,0,366,any,2,000000000,Lipoproteins,NA
1332,19190658,2,mean sitting systolic blood pressure from baseline,Blood Pressure,D001794,NA,0,612,any,2,000000000,Blood Pressure,NA
1333,19201775,2,baseline cd-related antibiotic use,Anti-Bacterial Agents,D000900,NA,0,763,any,2,000000000,Anti-Bacterial Agents,NA
1334,19201775,2,baseline immunosuppressant use,Immunosuppressive Agents,D007166,NA,0,763,any,2,000000000,Immunosuppressive Agents,NA
1335,19201775,2,no baseline cd-related antibiotic use,Anti-Bacterial Agents,D000900,NA,0,763,any,2,000000000,Anti-Bacterial Agents,NA
1336,19201775,2,no baseline immunosuppressant use,Immunosuppressive Agents,D007166,NA,0,763,any,2,000000000,Immunosuppressive Agents,NA
1337,19210140,2,baseline HbA1c,Glycated Hemoglobin A,D006442,NA,0,904,any,2,000000000,Glycated Hemoglobin A,NA
1338,19210298,NA,Erosive oesophagitis GRADE,unclassifiable,NA,NA,0,0,any,2,000000000,unclassifiable,NA
1339,19213680,NA,ace/arb,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,0,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
1340,19213680,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,163
1341,19213680,NA,Beta-blocker,Adrenergic beta-Antagonists,D000319,NA,0,0,any,2,000000000,Adrenergic beta-Antagonists,NA
1342,19213680,NA,cvd,Cardiovascular Diseases,D002318,NA,0,0,any,2,000000000,Cardiovascular Diseases,NA
1343,19213680,NA,heart failure,Heart Failure,D006333,NA,0,0,any,2,000000000,Heart Failure,NA
1344,19213680,NA,lvef,Stroke Volume,D013318,NA,0,0,any,2,000000000,Stroke Volume,NA
1345,19213680,NA,presence of af or flutter,Atrial Fibrillation,D001281,NA,0,0,any,2,000000000,Atrial Fibrillation,NA
1346,19213680,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
1347,19225038,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,97
1348,19225038,NA,treatment or prevention,unclassifible,NA,NA,0,0,any,2,000000000,unclassifible,156
1349,19332455,2,age,Age Factors,D000367,NA,0,1348,any,2,000000000,Age Factors,NA
1350,19332455,2,diabetes,Diabetes Mellitus,D003920,NA,0,1348,any,2,000000000,Diabetes Mellitus,NA
1351,19332455,2,early clopidogrel intended,Fibrinolytic Agents,D005343,NA,0,1348,any,2,000000000,Fibrinolytic Agents,NA
1352,19332455,2,heparin use,"Heparin, Low-Molecular-Weight",D006495,NA,0,1348,any,2,000000000,"Heparin, Low-Molecular-Weight",NA
1353,19332455,2,heparin use;low-molecular-weight only,"Heparin, Low-Molecular-Weight",D006495,NA,0,1348,any,2,000000000,"Heparin, Low-Molecular-Weight",NA
1354,19332455,2,region of the world,Geographic Locations,D005842,NA,0,1348,any,2,000000000,Geographic Locations,NA
1355,19332455,2,sex,Gender Identity,D005783,NA,0,1348,any,2,000000000,Gender Identity,NA
1356,19332455,2,timi risk score,Thrombosis,D013927,NA,1,1348,severity,11,000100000,Thrombosis,NA
1357,19332455,2,timi risk score;intermediate (3-4),Thrombosis,D013927,NA,1,1348,severity,11,000100000,Thrombosis,NA
1358,19332455,2,troponin,Troponin,D014336,NA,0,1348,any,2,000000000,Troponin,NA
1359,19332467,2,age,Age Factors,D000367,NA,0,1124,any,2,000000000,Age Factors,NA
1360,19332467,2,diabetes,Diabetes Mellitus,D003920,NA,0,1124,any,2,000000000,Diabetes Mellitus,NA
1361,19332467,2,history of mi,Myocardial Infarction,D009203,NA,0,1124,previous,8,100010000,Myocardial Infarction,NA
1362,19332467,2,infarct localization,Infarction,D007238,NA,0,1124,location,7,000000001,Infarction,NA
1363,19332467,2,infarct localization;non-anterior,Infarction,D007238,NA,0,1124,location,7,000000001,Infarction,NA
1364,19332467,2,interval clopidogrel to pci,Fibrinolytic Agents,D005343,NA,0,1124,any,2,000000000,Fibrinolytic Agents,NA
1365,19332467,2,interval pain onset to admission,Pain,D010146,NA,0,1124,any,2,000000000,Pain,NA
1366,19332467,2,interval study drug to pci,Percutaneous Coronary Intervention,D062645,NA,0,1124,duration,5,001000000,Percutaneous Coronary Intervention,NA
1367,19332467,2,sex,Gender Identity,D005783,NA,0,1124,any,2,000000000,Gender Identity,NA
1368,19336502,3,age,Age Factors,D000367,NA,0,1587,any,2,000000000,Age Factors,NA
1369,19336502,3,atrial fibrillation,Atrial Fibrillation,D001281,NA,0,1587,type,12,000000010,Atrial Fibrillation,NA
1370,19336502,3,atrial fibrillation;permanent,Atrial Fibrillation,D001281,NA,0,1587,type,12,000000010,Atrial Fibrillation,NA
1371,19336502,3,atrial fibrillation;persistent or paroxysmal,Atrial Fibrillation,D001281,NA,0,1587,type,12,000000010,Atrial Fibrillation,NA
1372,19336502,3,chads2 score,Stroke,D020521,NA,1,1587,any,2,000000000,Stroke,NA
1373,19336502,3,congestive heart failure,Heart Failure,D006333,NA,0,1587,any,2,000000000,Heart Failure,NA
1374,19336502,3,diabetes,Diabetes Mellitus,D003920,NA,0,1587,any,2,000000000,Diabetes Mellitus,NA
1375,19336502,3,Hypertension,Hypertension,D006973,NA,0,1587,any,2,000000000,Hypertension,NA
1376,19336502,3,mi or cad,Coronary Artery Disease,D003324,NA,0,1587,any,2,000000000,Coronary Artery Disease,NA
1377,19336502,3,reason for enrollment in active a;risk of bleeding,unclassifiable,NA,NA,0,1587,risk score,10,000000100,unclassifiable,NA
1378,19336502,3,region,Geographic Locations,D005842,NA,0,1587,any,2,000000000,Geographic Locations,NA
1379,19336502,3,region;south africa,Geographic Locations,D005842,NA,0,1587,any,2,000000000,Geographic Locations,NA
1380,19336502,3,region;western europe and israel,Geographic Locations,D005842,NA,0,1587,any,2,000000000,Geographic Locations,NA
1381,19336502,3,sex,Gender Identity,D005783,NA,0,1587,any,2,000000000,Gender Identity,NA
1382,19336502,3,stroke or tia,Stroke,D020521,NA,0,1587,any,2,000000000,Stroke,NA
1383,19336502,3,systolic blood pressure,Blood Pressure,D001794,NA,0,1587,any,2,000000000,Blood Pressure,NA
1384,19336502,3,vka therapy,Anticoagulants,D000925,NA,0,1587,any,2,000000000,Anticoagulants,NA
1385,19336502,4,age,Age Factors,D000367,NA,0,1223,any,2,000000000,Age Factors,NA
1386,19336502,4,atrial fibrillation,Atrial Fibrillation,D001281,NA,0,1223,any,2,000000000,Atrial Fibrillation,NA
1387,19336502,4,atrial fibrillation;permanent,Atrial Fibrillation,D001281,NA,0,1223,type,12,000000010,Atrial Fibrillation,NA
1388,19336502,4,atrial fibrillation;persistent or paroxysmal,Atrial Fibrillation,D001281,NA,0,1223,type,12,000000010,Atrial Fibrillation,NA
1389,19336502,4,chads2 score,Stroke,D020521,NA,0,1223,severity,11,000100100,Stroke,NA
1390,19336502,4,congestive heart failure,Heart Failure,D006333,NA,0,1223,any,2,000000000,Heart Failure,NA
1391,19336502,4,diabetes,Diabetes Mellitus,D003920,NA,0,1223,any,2,000000000,Diabetes Mellitus,NA
1392,19336502,4,Hypertension,Hypertension,D006973,NA,0,1223,any,2,000000000,Hypertension,NA
1393,19336502,4,mi or cad,Coronary Artery Disease,D003324,NA,0,1223,any,2,000000000,Coronary Artery Disease,NA
1394,19336502,4,reason for enrollment in active a;risk of bleeding,Hemorrhage,D006470,NA,0,1223,risk score,10,000000100,Hemorrhage,NA
1395,19336502,4,region,Geographic Locations,D005842,NA,0,1223,any,2,000000000,Geographic Locations,NA
1396,19336502,4,region;south africa,Geographic Locations,D005842,NA,0,1223,any,2,000000000,Geographic Locations,NA
1397,19336502,4,region;western europe and israel,Geographic Locations,D005842,NA,0,1223,any,2,000000000,Geographic Locations,NA
1398,19336502,4,sex,Gender Identity,D005783,NA,0,1223,any,2,000000000,Gender Identity,NA
1399,19336502,4,stroke or tia,Stroke,D020521,NA,0,1223,any,2,000000000,Stroke,NA
1400,19336502,4,systolic blood pressure,Blood Pressure,D001794,NA,0,1223,any,2,000000000,Blood Pressure,NA
1401,19349325,2,diabetes mellitus,Diabetes Mellitus,D003920,NA,0,1675,any,2,000000000,Diabetes Mellitus,NA
1402,19349325,2,no diabetes mellitus,Diabetes Mellitus,D003920,NA,0,1675,any,2,000000000,Diabetes Mellitus,NA
1403,19362675,NA,treatment or prevention,unclassifible,NA,NA,0,0,any,2,000000000,unclassifible,157
1404,19369667,2,af alone,Atrial Fibrillation,D001281,NA,0,617,type,12,000000010,Atrial Fibrillation,NA
1405,19369667,2,age,Age Factors,D000367,NA,0,617,any,2,000000000,Age Factors,NA
1406,19369667,2,"hf, lvd, or both",Heart Failure,D006333,NA,0,617,any,2,000000000,Heart Failure,NA
1407,19369667,2,use of ace inhibitor,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,617,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
1408,19369667,2,use of antiarrhythmic agent,Anti-Arrhythmia Agents,D000889,NA,0,617,any,2,000000000,Anti-Arrhythmia Agents,NA
1409,19369667,2,use of antiarrhythmic agent;amiodarone,Amiodarone,D000638,C01,0,617,any,2,000000000,Amiodarone,NA
1410,19369667,2,use of beta-blockers,Adrenergic beta-Antagonists,D000319,NA,0,617,any,2,000000000,Adrenergic beta-Antagonists,NA
1411,19389561,2,"ranolazine (n = 1,789)",cardiac therapy,NA,C01,0,586,any,2,000000000,cardiac therapy,NA
1412,19389561,3,History of chronic angina. Recent ACS,Angina Pectoris,D000787,NA,0,1017,previous,8,100000000,Angina Pectoris,NA
1413,19409693,2,age group,Age Factors,D000367,NA,0,1340,any,2,000000000,Age Factors,NA
1414,19409693,2,bmi,Body Mass Index,D015992,NA,0,1340,any,2,000000000,Body Mass Index,NA
1415,19409693,2,bph-luts severity,Prostatic Hyperplasia,D011470,NA,0,1340,severity,11,000100000,Prostatic Hyperplasia,NA
1416,19409693,2,bph-luts severity;moderate (ipss <20) (n=393),Prostatic Diseases,D011469,NA,0,1340,severity,11,000100000,Prostatic Diseases,NA
1417,19409693,2,bph-luts severity;severe (ipss >20) (n = 185),Prostatic Diseases,D011469,NA,0,1340,severity,11,000100000,Prostatic Diseases,NA
1418,19409693,2,prior a-blocker use,Adrenergic alpha-Antagonists,D000317,NA,0,1340,previous,8,100000000,Adrenergic alpha-Antagonists,NA
1419,19409693,2,prior ed therapy,Erectile Dysfunction,D007172,NA,0,1340,previous,8,100000000,Erectile Dysfunction,NA
1420,19409693,2,psa,Prostate-Specific Antigen,D017430,NA,0,1340,any,2,000000000,Prostate-Specific Antigen,NA
1421,19423108,2,;moderate ckd,Renal Insufficiency,D051437,NA,0,550,severity,11,000100000,Renal Insufficiency,NA
1422,19423108,2,;normal/mild ckd,Renal Insufficiency,D051437,NA,0,550,severity,11,000100000,Renal Insufficiency,NA
1423,19443528,2,bmi kg/Â m^2,Body Mass Index,D015992,NA,0,1330,any,2,000000000,Body Mass Index,NA
1424,19447387,2,;igm(n = 4565),Glucose Intolerance,D018149,NA,0,1687,any,2,000000000,Glucose Intolerance,NA
1425,19447387,2,;ng,Glucose Intolerance,D018149,NA,0,1687,any,2,000000000,Glucose Intolerance,NA
1426,19447387,2,";ng (n = 14,080)",Glucose Intolerance,D018149,NA,0,1687,any,2,000000000,Glucose Intolerance,NA
1427,19447387,3,;igm,Glucose Intolerance,D018149,NA,0,590,any,2,000000000,Glucose Intolerance,NA
1428,19447387,3,;ng,Glucose Intolerance,D018149,NA,0,590,any,2,000000000,Glucose Intolerance,NA
1429,19447387,3,";ng (n = 14,080)",Glucose Intolerance,D018149,NA,0,590,any,2,000000000,Glucose Intolerance,NA
1430,19447387,3,;ng vs igm,Glucose Intolerance,D018149,NA,0,590,any,2,000000000,Glucose Intolerance,NA
1431,19470885,2,age,Age Factors,D000367,NA,0,561,any,2,000000000,Age Factors,NA
1432,19470885,2,baseline 6-mlnute walk distance:,Exercise,D015444,NA,0,561,any,2,000000000,Exercise,NA
1433,19470885,2,baseline who function class,Pulmonary Arterial Hypertension,D000081029,NA,0,561,severity,11,000100000,Pulmonary Arterial Hypertension,NA
1434,19470885,2,bosentan use:,Antihypertensive Agents,D000959,NA,0,561,any,2,000000000,Antihypertensive Agents,NA
1435,19470885,2,gender:,Gender Identity,D005783,NA,0,561,any,2,000000000,Gender Identity,NA
1436,19470885,2,pah etiology:;connective-tissue disease,Pulmonary Arterial Hypertension,D000081029,NA,0,561,aetiological,1,000001000,Pulmonary Arterial Hypertension,NA
1437,19470885,2,pah etiology:;idiopathic,Pulmonary Arterial Hypertension,D000081029,NA,0,561,aetiological,1,000001000,Pulmonary Arterial Hypertension,NA
1438,19470885,2,pah etiology:;others,Pulmonary Arterial Hypertension,D000081029,NA,0,561,aetiological,1,000001000,Pulmonary Arterial Hypertension,NA
1439,19470885,2,pah etiology:;repaired s-p shunts,Cardiovascular Abnormalities,D018376,NA,0,561,any,2,000000000,Cardiovascular Abnormalities,NA
1440,19470885,2,"pulmonary arterial hypertension, etiology",Pulmonary Arterial Hypertension,D000081029,NA,0,561,aetiological,1,000001000,Pulmonary Arterial Hypertension,NA
1441,19476470,NA,prior OAD therapy (monotherapy or dualtherapy),Hypoglycemic Agents,D007004,NA,0,0,previous,8,100000000,Hypoglycemic Agents,127
1442,19478198,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,51
1443,19478198,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,51
1444,19478198,NA,diabetes duration,Diabetes Mellitus,D003920,NA,0,0,duration,5,001000000,Diabetes Mellitus,51
1445,19478198,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,51
1446,19478198,NA,region,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,51
1447,19478198,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,51
1448,19508464,NA,Medical History:  triglyceride level at baseline,Lipoproteins,D008074,NA,0,0,previous,8,100000000,Lipoproteins,265
1449,19515181,2,Baseline HbA1c,Glycated Hemoglobin A,D006442,NA,0,819,any,2,000000000,Glycated Hemoglobin A,NA
1450,19515181,2,Metformin,Hypoglycemic Agents,D007004,NA,0,819,any,2,000000000,Hypoglycemic Agents,NA
1451,19515181,2,SAXA,Hypoglycemic Agents,D007004,NA,0,819,any,2,000000000,Hypoglycemic Agents,NA
1452,19531054,NA,subjects who previously received monotherapy or dual therapy,Hypoglycemic Agents,D007004,NA,0,0,previous,8,100000000,Hypoglycemic Agents,47
1453,19560810,1,number of previous tnfa inhibitors,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,1570,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
1454,19560810,1,reason for discontinuation of previous tnfa inhibitor,Tumor Necrosis Factor Inhibitors,D000079424,NA,0,1570,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
1455,19566934,NA,COPD gold stage,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,0,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",55
1456,19567517,2,age (yr),Age Factors,D000367,NA,0,220,any,2,000000000,Age Factors,NA
1457,19567517,2,bmi (kg/m2),Body Mass Index,D015992,NA,0,220,any,2,000000000,Body Mass Index,NA
1458,19567517,2,crcl (ml/min),Glomerular Filtration Rate,D005919,NA,0,220,any,2,000000000,Glomerular Filtration Rate,NA
1459,19567517,2,femoral neck t-scoreÂ and vfx status,Osteoporosis,D010024,NA,0,220,severity,11,000100000,Osteoporosis,NA
1460,19567517,2,prior bp use,bisphosphonates,NA,M05BA,0,220,previous,8,100000000,bisphosphonates,NA
1461,19567517,2,race,Racial Groups,D044469,NA,0,220,any,2,000000000,Racial Groups,NA
1462,19567517,2,region,Geographic Locations,D005842,NA,0,220,any,2,000000000,Geographic Locations,NA
1463,19567517,2,Smoker,Cigarette Smoking,D000073865,NA,0,220,any,2,000000000,Cigarette Smoking,NA
1464,19567517,2,total hip bmd (g/cm2),Osteoporosis,D010024,NA,0,220,severity,11,000100000,Osteoporosis,NA
1465,19567517,2,weight (kg),Body Weight,D001835,NA,0,220,any,2,000000000,Body Weight,NA
1466,19614786,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,239
1467,19614786,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,122
1468,19614786,NA,diabetes duration,Diabetes Mellitus,D003920,NA,0,0,duration,5,001000000,Diabetes Mellitus,122
1469,19614786,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,122
1470,19614786,NA,region,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,122
1471,19614786,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,122
1472,19614946,3,insulin glusiline add on therapy,Racial Groups,D044469,NA,0,96,any,2,000000000,Racial Groups,NA
1473,19614946,3,insulin glusiline monotherapy,Racial Groups,D044469,NA,0,96,any,2,000000000,Racial Groups,NA
1474,19632710,NA,"ACQ scores, severity",Asthma,D001249,NA,0,0,severity,11,000100000,Asthma,142
1475,19632710,NA,lung function (FEV1 bronchodilator reversibility,Bronchodilator Agents,D001993,NA,0,0,any,2,000000000,Bronchodilator Agents,141
1476,19650752,2,HbA1c at baseline,Glycated Hemoglobin A,D006442,NA,0,881,any,2,000000000,Glycated Hemoglobin A,NA
1477,19660610,2,;highest tg tertile,Lipoproteins,D008074,NA,0,97,any,2,000000000,Lipoproteins,NA
1478,19660610,2,;lowest tg tertile,Lipoproteins,D008074,NA,0,97,any,2,000000000,Lipoproteins,NA
1479,19660610,2,;middle tg tertile,Lipoproteins,D008074,NA,0,97,any,2,000000000,Lipoproteins,NA
1480,19660610,2,stratified by triglyceride (TG) tertiles,Lipoproteins,D008074,NA,0,97,any,2,000000000,Lipoproteins,NA
1481,19674165,NA,tamsulosin,Tamsulosin,D000077409,NA,0,0,any,2,000000000,Tamsulosin,108
1482,19683639,2,Age (years) <75 =75,Age Factors,D000367,NA,0,1241,any,2,000000000,Age Factors,NA
1483,19683639,2,Age (years) <75 Ã¢â€°Â¥75,Age Factors,D000367,NA,0,1241,any,2,000000000,Age Factors,NA
1484,19683639,2,Atrial fibrillation pattern Paroxysmal Persistent Permanent,Atrial Fibrillation,D001281,NA,0,1241,type,12,000000010,Atrial Fibrillation,NA
1485,19683639,2,Sex Female Male,Gender Identity,D005783,NA,0,1241,any,2,000000000,Gender Identity,NA
1486,19688336,2,mmse <23,Mental Status and Dementia Tests,D000073216,NA,0,854,any,2,000000000,Mental Status and Dementia Tests,NA
1487,19688336,2,mmse >28,Mental Status and Dementia Tests,D000073216,NA,0,854,any,2,000000000,Mental Status and Dementia Tests,NA
1488,19688336,2,mmse 24-27,Mental Status and Dementia Tests,D000073216,NA,0,854,any,2,000000000,Mental Status and Dementia Tests,NA
1489,19704100,2,;1 (497),Heart Failure,D006333,NA,0,1504,risk score,10,000000100,Heart Failure,NA
1490,19704100,2,;ii (497),Heart Failure,D006333,NA,0,1504,risk score,10,000000100,Heart Failure,NA
1491,19704100,2,;iii (496),Heart Failure,D006333,NA,0,1504,risk score,10,000000100,Heart Failure,NA
1492,19704100,2,;iv (496),Heart Failure,D006333,NA,0,1504,risk score,10,000000100,Heart Failure,NA
1493,19704100,2,;v (497),Heart Failure,D006333,NA,0,1504,risk score,10,000000100,Heart Failure,NA
1494,19716598,2,gold stage ii,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,563,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
1495,19716598,2,gold stage iii,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,563,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
1496,19716598,2,gold stage iv,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,563,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
1497,19717850,2,age <68 years3,Age Factors,D000367,NA,0,1081,any,2,000000000,Age Factors,NA
1498,19717850,2,diabetes,Diabetes Mellitus,D003920,NA,0,1081,any,2,000000000,Diabetes Mellitus,NA
1499,19717850,2,egfr <60 (ml/min/1.73 m2),Glomerular Filtration Rate,D005919,NA,0,1081,any,2,000000000,Glomerular Filtration Rate,NA
1500,19717850,2,history of paroxysmal af,Atrial Fibrillation,D001281,NA,0,1081,previous,8,100000010,Atrial Fibrillation,NA
1501,19717850,2,ischemic aetiology,Ischemia,D007511,NA,0,1081,aetiological,1,000001000,Ischemia,NA
1502,19717850,2,lvef <33%,Stroke Volume,D013318,NA,0,1081,any,2,000000000,Stroke Volume,NA
1503,19717850,2,lvef >33%,Stroke Volume,D013318,NA,0,1081,any,2,000000000,Stroke Volume,NA
1504,19717850,2,no diabetes,Diabetes Mellitus,D003920,NA,0,1081,any,2,000000000,Diabetes Mellitus,NA
1505,19717850,2,no history of paroxysmal af,Atrial Fibrillation,D001281,NA,0,1081,previous,8,100000110,Atrial Fibrillation,NA
1506,19717850,2,non-ischaemic aetiology,Ischemia,D007511,NA,0,1081,aetiological,1,000001000,Ischemia,NA
1507,19717850,2,nyha lll-iv,Heart Failure,D006333,NA,0,1081,severity,11,000100000,Heart Failure,NA
1508,19717850,2,total cholesterol3 <194 mg/dl,Lipoproteins,D008074,NA,0,1081,any,2,000000000,Lipoproteins,NA
1509,19726772,2,;>70 yr,Age Factors,D000367,NA,0,1744,any,2,000000000,Age Factors,NA
1510,19726772,2,baseline high-sensitivity crp,C-Reactive Protein,D002097,NA,0,1744,any,2,000000000,C-Reactive Protein,NA
1511,19726772,2,baseline ldl cholesterol,Lipoproteins,D008074,NA,0,1744,any,2,000000000,Lipoproteins,NA
1512,19726772,2,baseline total cholesterol,Lipoproteins,D008074,NA,0,1744,any,2,000000000,Lipoproteins,NA
1513,19726772,2,cardiac risk,Cardiovascular Diseases,D002318,NA,0,1744,risk score,10,000000100,Cardiovascular Diseases,NA
1514,19726772,2,cardiac risk;intermediate,Cardiovascular Diseases,D002318,NA,0,1744,risk score,10,000000100,Cardiovascular Diseases,NA
1515,19726772,2,Temporary discontinuation of study drug,other,NA,NA,0,1744,any,2,000000000,other,NA
1516,19726772,2,type of surgery,"Specialties, Surgical",D013043,NA,0,1744,type,12,000000010,"Specialties, Surgical",NA
1517,19726772,2,type of surgery;endovascular,"Specialties, Surgical",D013043,NA,0,1744,type,12,000000010,"Specialties, Surgical",NA
1518,19726772,NA,Age-Years,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
1519,19726772,NA,cardiac risk,Cardiovascular Diseases,D002318,NA,0,0,risk score,10,000000100,Cardiovascular Diseases,NA
1520,19726772,NA,crp,C-Reactive Protein,D002097,NA,0,0,any,2,000000000,C-Reactive Protein,NA
1521,19726772,NA,ldl,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,NA
1522,19726772,NA,total cholesteror,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,NA
1523,19726772,NA,type of surgery,"Specialties, Surgical",D013043,NA,0,0,type,12,000000010,"Specialties, Surgical",NA
1524,19751115,2,;age < 65 years,Age Factors,D000367,NA,0,643,any,2,000000000,Age Factors,NA
1525,19751115,2,;age >= 65 years,Age Factors,D000367,NA,0,643,any,2,000000000,Age Factors,NA
1526,19752419,NA,Baseline center point thickness,unclassifiable,NA,NA,0,0,any,2,000000000,unclassifiable,NA
1527,19752419,NA,Baseline visual acuity letter score (Snellen equivalent),unclassifiable,NA,NA,0,0,any,2,000000000,unclassifiable,NA
1528,19752419,NA,Duration of macular edema at baseline,Macular Edema,D008269,NA,0,0,duration,5,001000000,Macular Edema,NA
1529,19752419,NA,Pseudophakic at baseline,unclassifiable,NA,NA,0,0,any,2,000000000,unclassifiable,NA
1530,19758359,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,184
1531,19758359,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,210
1532,19758359,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,210
1533,19758359,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,210
1534,19776408,NA,UPDRS scores,Parkinson Disease,D010300,NA,0,0,severity,11,000100000,Parkinson Disease,223
1535,19793357,NA,Patient Variable: Age at randomisation,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,56
1536,19847908,2,;age <51 gadolinium lesion >1 n=72,Age Factors,D000367,NA,0,238,any,2,000000000,Age Factors,NA
1537,19847908,2,;age <51 gadolinium lesion=0 n=143,complex,none,NA,0,238,any,2,000000000,complex,NA
1538,19847908,2,;age >51 gadolinium lesion >1 n=37,complex,none,NA,0,238,any,2,000000000,complex,NA
1539,19847908,2,;age >51 gadolinium lesion=0 n=187,complex,none,NA,0,238,any,2,000000000,complex,NA
1540,19847908,NA,Age-Years,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
1541,19847908,NA,gadolinium,Gadolinium,D005682,NA,0,0,any,2,000000000,Gadolinium,NA
1542,19850248,2,age,Age Factors,D000367,NA,0,941,any,2,000000000,Age Factors,NA
1543,19850248,2,baseline killip class,Heart Failure,D006333,NA,0,941,severity,11,000100000,Heart Failure,NA
1544,19850248,2,enrollment in lmwh,Fibrinolytic Agents,D005343,NA,0,941,any,2,000000000,Fibrinolytic Agents,NA
1545,19850248,2,gender,Gender Identity,D005783,NA,0,941,any,2,000000000,Gender Identity,NA
1546,19850248,2,geographic location,Geographic Locations,D005842,NA,0,941,any,2,000000000,Geographic Locations,NA
1547,19850248,2,geographic location;rest of the world,Geographic Locations,D005842,NA,0,941,any,2,000000000,Geographic Locations,NA
1548,19850248,2,high risk,unclassifiable,none,NA,0,941,risk score,10,000000100,unclassifiable,NA
1549,19850248,2,history of diabetes mellitus,Diabetes Mellitus,D003920,NA,0,941,previous,8,100000000,Diabetes Mellitus,NA
1550,19850248,2,infarct location,Infarction,D007238,NA,0,941,location,7,000000001,Infarction,NA
1551,19850248,2,infarct location;not anterior,Infarction,D007238,NA,0,941,location,7,000000001,Infarction,NA
1552,19850248,2,pci delay due to low risk,Percutaneous Coronary Intervention,D062645,NA,0,941,severity,11,000100100,Percutaneous Coronary Intervention,NA
1553,19850248,2,previous ml,Myocardial Infarction,D009203,NA,0,941,previous,8,100000000,Myocardial Infarction,NA
1554,19850248,2,time of qualifying ecg to balloon inflation (hrs),"Angioplasty, Balloon, Coronary",D015906,NA,0,941,duration,5,001000000,"Angioplasty, Balloon, Coronary",NA
1555,19850248,2,time of symptom onset to balloon inflation (hrs),"Angioplasty, Balloon, Coronary",D015906,NA,0,941,duration,5,001000000,"Angioplasty, Balloon, Coronary",NA
1556,19850248,2,time of symptom onset to balloon inflation (hrs);tertile 1 index pci performed,Percutaneous Coronary Intervention,D062645,NA,0,941,any,2,000000000,Percutaneous Coronary Intervention,NA
1557,19850248,2,time of symptom onset to randomization (hrs),Percutaneous Coronary Intervention,D062645,NA,0,941,any,2,000000000,Percutaneous Coronary Intervention,NA
1558,19850248,3,age,Age Factors,D000367,NA,0,714,any,2,000000000,Age Factors,NA
1559,19850248,3,age (yrs);<75 baseline killip class,Heart Failure,D006333,NA,0,714,severity,11,000100000,Heart Failure,NA
1560,19850248,3,enrollment in lmwh,Fibrinolytic Agents,D005343,NA,0,714,any,2,000000000,Fibrinolytic Agents,NA
1561,19850248,3,gender,Gender Identity,D005783,NA,0,714,any,2,000000000,Gender Identity,NA
1562,19850248,3,geographic location,Geographic Locations,D005842,NA,0,714,any,2,000000000,Geographic Locations,NA
1563,19850248,3,geographic location;rest of the world,Geographic Locations,D005842,NA,0,714,any,2,000000000,Geographic Locations,NA
1564,19850248,3,high risk,unclassifiable,none,NA,0,714,risk score,10,000000100,unclassifiable,NA
1565,19850248,3,history of diabetes mellitus,Diabetes Mellitus,D003920,NA,0,714,previous,8,100000000,Diabetes Mellitus,NA
1566,19850248,3,index pci performed,Percutaneous Coronary Intervention,D062645,NA,0,714,any,2,000000000,Percutaneous Coronary Intervention,NA
1567,19850248,3,infarct location,Infarction,D007238,NA,0,714,location,7,000000001,Infarction,NA
1568,19850248,3,pci delay due to low risk,Percutaneous Coronary Intervention,D062645,NA,0,714,severity,11,000100100,Percutaneous Coronary Intervention,NA
1569,19850248,3,previous ml,Myocardial Infarction,D009203,NA,0,714,previous,8,100000000,Myocardial Infarction,NA
1570,19850248,3,sites;hub,unclassifiable,none,NA,0,714,location,7,000000001,unclassifiable,NA
1571,19850248,3,time of qualifying ecg to balloon inflation (hrs),"Angioplasty, Balloon, Coronary",D015906,NA,0,714,duration,5,001000000,"Angioplasty, Balloon, Coronary",NA
1572,19850248,3,time of symptom onset to balloon inflation (hrs),"Angioplasty, Balloon, Coronary",D015906,NA,0,714,duration,5,001000000,"Angioplasty, Balloon, Coronary",NA
1573,19850249,1,timi =2,Thrombosis,D013927,NA,0,832,severity,11,000100100,Thrombosis,NA
1574,19850249,1,timi =3,Thrombosis,D013927,NA,0,832,severity,11,000100100,Thrombosis,NA
1575,19850249,1,timi =3 and spoke,Thrombosis,D013927,NA,0,832,severity,11,000100100,Thrombosis,NA
1576,19850249,1,timi =3 and spoke and time =2 h,Thrombosis,D013927,NA,0,832,severity,11,000100100,Thrombosis,NA
1577,19850249,1,timi =3 and spoke and time =3 h,Thrombosis,D013927,NA,0,832,severity,11,000100100,Thrombosis,NA
1578,19850249,1,timi =3 and spoke and time =4 h,Thrombosis,D013927,NA,0,832,severity,11,000100100,Thrombosis,NA
1579,19850249,1,timi =3 and spoke and time =5 h,Thrombosis,D013927,NA,0,832,severity,11,000100100,Thrombosis,NA
1580,19850249,1,timi =4,Thrombosis,D013927,NA,0,832,severity,11,000100100,Thrombosis,NA
1581,19850249,1,timi =5,Thrombosis,D013927,NA,0,832,severity,11,000100100,Thrombosis,NA
1582,19850249,1,timi Ã¢â€°Â¥2,Thrombosis,D013927,NA,0,832,severity,11,000100100,Thrombosis,NA
1583,19850249,1,timi Ã¢â€°Â¥3,Thrombosis,D013927,NA,0,832,severity,11,000100100,Thrombosis,NA
1584,19850249,1,timi Ã¢â€°Â¥3 and spoke,Thrombosis,D013927,NA,0,832,severity,11,000100100,Thrombosis,NA
1585,19850249,1,timi Ã¢â€°Â¥3 and spoke and time Ã¢â€°Â¤2 h,Thrombosis,D013927,NA,0,832,severity,11,000100100,Thrombosis,NA
1586,19850249,1,timi Ã¢â€°Â¥3 and spoke and time Ã¢â€°Â¤3 h,Thrombosis,D013927,NA,0,832,severity,11,000100100,Thrombosis,NA
1587,19850249,1,timi Ã¢â€°Â¥3 and spoke and time Ã¢â€°Â¤4 h,Thrombosis,D013927,NA,0,832,severity,11,000100100,Thrombosis,NA
1588,19850249,1,timi Ã¢â€°Â¥3 and spoke and time Ã¢â€°Â¤5 h,Thrombosis,D013927,NA,0,832,severity,11,000100100,Thrombosis,NA
1589,19850249,1,timi Ã¢â€°Â¥4,Thrombosis,D013927,NA,0,832,severity,11,000100100,Thrombosis,NA
1590,19850249,1,timi Ã¢â€°Â¥5,Thrombosis,D013927,NA,0,832,severity,11,000100100,Thrombosis,NA
1591,19850249,2,timi =2,Thrombosis,D013927,NA,0,987,severity,11,000100100,Thrombosis,NA
1592,19850249,2,timi =3,Thrombosis,D013927,NA,0,987,severity,11,000100100,Thrombosis,NA
1593,19850249,2,timi =3 and spoke,Thrombosis,D013927,NA,0,987,severity,11,000100100,Thrombosis,NA
1594,19850249,2,timi =3 and spoke and time =2 h,Thrombosis,D013927,NA,0,987,severity,11,000100100,Thrombosis,NA
1595,19850249,2,timi =3 and spoke and time =3 h,Thrombosis,D013927,NA,0,987,severity,11,000100100,Thrombosis,NA
1596,19850249,2,timi =3 and spoke and time =4 h,Thrombosis,D013927,NA,0,987,severity,11,000100100,Thrombosis,NA
1597,19850249,2,timi =3 and spoke and time =5 h,Thrombosis,D013927,NA,0,987,severity,11,000100100,Thrombosis,NA
1598,19850249,2,timi =4,Thrombosis,D013927,NA,0,987,severity,11,000100100,Thrombosis,NA
1599,19850249,2,timi =5,Thrombosis,D013927,NA,0,987,severity,11,000100100,Thrombosis,NA
1600,19850249,2,timi Ã¢â€°Â¥2,Thrombosis,D013927,NA,0,987,severity,11,000100100,Thrombosis,NA
1601,19850249,2,timi Ã¢â€°Â¥3,Thrombosis,D013927,NA,0,987,severity,11,000100100,Thrombosis,NA
1602,19850249,2,timi Ã¢â€°Â¥3 and spoke,Thrombosis,D013927,NA,0,987,severity,11,000100100,Thrombosis,NA
1603,19850249,2,timi Ã¢â€°Â¥3 and spoke and time Ã¢â€°Â¤2 h,Thrombosis,D013927,NA,0,987,severity,11,000100100,Thrombosis,NA
1604,19850249,2,timi Ã¢â€°Â¥3 and spoke and time Ã¢â€°Â¤3 h,Thrombosis,D013927,NA,0,987,severity,11,000100100,Thrombosis,NA
1605,19850249,2,timi Ã¢â€°Â¥3 and spoke and time Ã¢â€°Â¤4 h,Thrombosis,D013927,NA,0,987,severity,11,000100100,Thrombosis,NA
1606,19850249,2,timi Ã¢â€°Â¥3 and spoke and time Ã¢â€°Â¤5 h,Thrombosis,D013927,NA,0,987,severity,11,000100100,Thrombosis,NA
1607,19850249,2,timi Ã¢â€°Â¥4,Thrombosis,D013927,NA,0,987,severity,11,000100100,Thrombosis,NA
1608,19850249,2,timi Ã¢â€°Â¥5,Thrombosis,D013927,NA,0,987,severity,11,000100100,Thrombosis,NA
1609,19850525,2,age (years),Age Factors,D000367,NA,0,165,any,2,000000000,Age Factors,NA
1610,19850525,2,arial flutter or fibrillation,Atrial Fibrillation,D001281,NA,0,165,any,2,000000000,Atrial Fibrillation,NA
1611,19850525,2,history of stroke,Stroke,D020521,NA,0,165,previous,8,100000000,Stroke,NA
1612,19850525,2,Hypertension,Hypertension,D006973,NA,0,165,any,2,000000000,Hypertension,NA
1613,19850525,2,nihss at baseline,Stroke,D020521,NA,0,165,severity,11,000100000,Stroke,NA
1614,19850525,2,previous chronic use of antiplatelet drugs,Platelet Aggregation Inhibitors,D010975,NA,0,165,previous,8,100000000,Platelet Aggregation Inhibitors,NA
1615,19850525,2,previous diabetes,Diabetes Mellitus,D003920,NA,0,165,previous,8,100000000,Diabetes Mellitus,NA
1616,19850525,2,sex,Gender Identity,D005783,NA,0,165,any,2,000000000,Gender Identity,NA
1617,19850525,2,Smoker,Cigarette Smoking,D000073865,NA,0,165,any,2,000000000,Cigarette Smoking,NA
1618,19850525,2,time to treatment initiation (min),Stroke,D020521,NA,0,165,duration,5,001000000,Stroke,NA
1619,19864452,NA,baselineHbA1c,Glycated Hemoglobin A,D006442,NA,0,0,any,2,000000000,Glycated Hemoglobin A,179
1620,19864452,NA,HOMA-2  values,Insulin Resistance,D007333,NA,0,0,any,2,000000000,Insulin Resistance,178
1621,19915217,NA,"carotid intima-media thickness, risk",Cardiovascular Diseases,D002318,NA,0,0,risk score,10,000000100,Cardiovascular Diseases,241
1622,19915217,NA,crp,C-Reactive Protein,D002097,NA,0,0,any,2,000000000,C-Reactive Protein,241
1623,19915217,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,241
1624,19915217,NA,HDL,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,241
1625,19915217,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,242
1626,19915221,2,stable angina,"Angina, Stable",D060050,NA,0,765,any,2,000000000,"Angina, Stable",NA
1627,19915221,2,STEMI,Myocardial Infarction,D009203,NA,0,765,any,2,000000000,Myocardial Infarction,NA
1628,19915221,2,unstable angina with non STEMI,Myocardial Infarction,D009203,NA,0,765,any,2,000000000,Myocardial Infarction,NA
1629,19915222,NA,troponin level,Troponin,D014336,NA,0,0,any,2,000000000,Troponin,192
1630,19917887,NA,cause of heart failure (ischaemic versus non-ischaemic),Heart Failure,D006333,NA,0,0,aetiological,1,000001000,Heart Failure,NA
1631,19917887,NA,kilip II versus III,Heart Failure,D006333,NA,0,0,severity,11,000100000,Heart Failure,NA
1632,19917888,2,;hs-crp <2.0 g/l,C-Reactive Protein,D002097,NA,0,823,any,2,000000000,C-Reactive Protein,NA
1633,19917888,2,;hs-crp <2.0 mg/l,C-Reactive Protein,D002097,NA,0,823,any,2,000000000,C-Reactive Protein,NA
1634,19917888,2,;hs-crp >2.0 mg/l,C-Reactive Protein,D002097,NA,0,823,any,2,000000000,C-Reactive Protein,NA
1635,19917888,3,;hs-crp <2.0 mg/l,C-Reactive Protein,D002097,NA,0,1747,any,2,000000000,C-Reactive Protein,NA
1636,19917888,3,;hs-crp >2.0 mg/l,C-Reactive Protein,D002097,NA,0,1747,any,2,000000000,C-Reactive Protein,NA
1637,19929994,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,106
1638,19933596,NA,Location,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,NA
1639,19933596,NA,Race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
1640,20010618,NA,stage-1 or stage-2 hypertension,Hypertension,D006973,NA,0,0,severity,2,000000000,Hypertension,85
1641,20092585,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,181
1642,20092585,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,180
1643,20092585,NA,diabetes duration,Diabetes Mellitus,D003920,NA,0,0,duration,5,001000000,Diabetes Mellitus,180
1644,20092585,NA,HbA1c,Glycated Hemoglobin A,D006442,NA,0,0,any,2,000000000,Glycated Hemoglobin A,180
1645,20092585,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,180
1646,20092585,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,180
1647,20136164,1,type 2 diabetes,Diabetes Mellitus,D003920,NA,0,1119,type,12,000000010,Diabetes Mellitus,NA
1648,20136164,2,type 2 diabetes,Diabetes Mellitus,D003920,NA,0,797,type,12,000000010,Diabetes Mellitus,NA
1649,20136164,3,type 2 diabetes,Diabetes Mellitus,D003920,NA,0,1514,type,12,000000010,Diabetes Mellitus,NA
1650,20136164,4,type 2 diabetes,Diabetes Mellitus,D003920,NA,0,1663,type,12,000000010,Diabetes Mellitus,NA
1651,20136164,5,type 2 diabetes,Diabetes Mellitus,D003920,NA,0,360,type,12,000000010,Diabetes Mellitus,NA
1652,20136164,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,99
1653,20151997,2,apo b/apo a-l,Apolipoprotein A-I,D016632,NA,0,524,any,2,000000000,Apolipoprotein A-I,NA
1654,20151997,2,apolipoprotein a-i*,Apolipoprotein A-I,D016632,NA,0,524,any,2,000000000,Apolipoprotein A-I,NA
1655,20151997,2,apolipoprotein b^,Apolipoprotein A-I,D016632,NA,0,524,any,2,000000000,Apolipoprotein A-I,NA
1656,20151997,2,hdl-c,Lipoproteins,D008074,NA,0,524,any,2,000000000,Lipoproteins,NA
1657,20151997,2,hs-crp,C-Reactive Protein,D002097,NA,0,524,any,2,000000000,C-Reactive Protein,NA
1658,20151997,2,ldl-c,Lipoproteins,D008074,NA,0,524,any,2,000000000,Lipoproteins,NA
1659,20151997,2,ldl-c/hdl-c,Lipoproteins,D008074,NA,0,524,any,2,000000000,Lipoproteins,NA
1660,20151997,2,mets w/o t2dm,Diabetes Mellitus,D003920,NA,0,524,any,2,000000000,Diabetes Mellitus,NA
1661,20151997,2,neither t2dm nor mets,Diabetes Mellitus,D003920,NA,0,524,any,2,000000000,Diabetes Mellitus,NA
1662,20151997,2,non-hdl-c,Lipoproteins,D008074,NA,0,524,any,2,000000000,Lipoproteins,NA
1663,20151997,2,non-hdl-c/hdl-c,Lipoproteins,D008074,NA,0,524,any,2,000000000,Lipoproteins,NA
1664,20151997,2,t2dm,Diabetes Mellitus,D003920,NA,0,524,any,2,000000000,Diabetes Mellitus,NA
1665,20151997,2,total cholesterol,Lipoproteins,D008074,NA,0,524,any,2,000000000,Lipoproteins,NA
1666,20151997,2,total cholesterol/hdl-c,Lipoproteins,D008074,NA,0,524,any,2,000000000,Lipoproteins,NA
1667,20151997,2,triglycerides,Lipoproteins,D008074,NA,0,524,any,2,000000000,Lipoproteins,NA
1668,20163842,2,;mild edÂ Â (n = 58),Erectile Dysfunction,D007172,NA,0,1296,severity,11,000100000,Erectile Dysfunction,NA
1669,20163842,2,;mild edÂ (n = 50),Erectile Dysfunction,D007172,NA,0,1296,severity,11,000100000,Erectile Dysfunction,NA
1670,20163842,2,;moderate-to-severe edÂ (n = 46),Erectile Dysfunction,D007172,NA,0,1296,severity,11,000100000,Erectile Dysfunction,NA
1671,20163842,2,;moderate-to-severe edÂ (n = 53),Erectile Dysfunction,D007172,NA,0,1296,severity,11,000100000,Erectile Dysfunction,NA
1672,20163842,2,;moderate-to-severe edÂ (n = 58),Erectile Dysfunction,D007172,NA,0,1296,severity,11,000100000,Erectile Dysfunction,NA
1673,20163842,2,;moderate-to-severe edÂ (n = 62),Erectile Dysfunction,D007172,NA,0,1296,severity,11,000100000,Erectile Dysfunction,NA
1674,20185012,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,110
1675,20185012,NA,Atherosclerosis,Atherosclerosis,D050197,NA,0,0,any,2,000000000,Atherosclerosis,NA
1676,20185012,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,NA
1677,20185012,NA,crp,C-Reactive Protein,D002097,NA,0,0,any,2,000000000,C-Reactive Protein,NA
1678,20185012,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
1679,20185012,NA,hdl,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,NA
1680,20185012,NA,ldl,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,NA
1681,20185012,NA,metabolic syndrome,Metabolic Syndrome,D024821,NA,0,0,any,2,000000000,Metabolic Syndrome,NA
1682,20185012,NA,region,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,NA
1683,20185012,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
1684,20185012,NA,triglyceride,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,NA
1685,20185426,NA,patients who were not receiving any maintenance respiratory medications,unclassifiable,NA,NA,0,0,any,2,000000000,unclassifiable,231
1686,20200926,2,;morphometric vertebral,Spine,D013131,NA,0,19,any,2,000000000,Spine,NA
1687,20200926,2,;nonvertebral,Spine,D013131,NA,0,19,any,2,000000000,Spine,NA
1688,20200926,NA,femoral neck t-score,Osteoporosis,D010024,NA,0,0,severity,2,000000000,Osteoporosis,19
1689,20200926,NA,vertebral fracture,"Fractures, Bone",D050723,NA,0,0,any,2,000000000,"Fractures, Bone",19
1690,20228402,2,ace inhibitor treatment,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,213,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
1691,20228402,2,age,Age Factors,D000367,NA,0,213,any,2,000000000,Age Factors,NA
1692,20228402,2,blood pressure control*,Blood Pressure,D001794,NA,0,213,any,2,000000000,Blood Pressure,NA
1693,20228402,2,body mass index,Body Mass Index,D015992,NA,0,213,any,2,000000000,Body Mass Index,NA
1694,20228402,2,body mass index[kg/m^],Body Mass Index,D015992,NA,0,213,any,2,000000000,Body Mass Index,NA
1695,20228402,2,body mass index[kg/m^];<25,Body Mass Index,D015992,NA,0,213,any,2,000000000,Body Mass Index,NA
1696,20228402,2,body mass index[kg/m^];>25-30,Body Mass Index,D015992,NA,0,213,any,2,000000000,Body Mass Index,NA
1697,20228402,2,body mass index[kg/m^];>30-35,Body Mass Index,D015992,NA,0,213,any,2,000000000,Body Mass Index,NA
1698,20228402,2,body mass index[kg/m^];>35,Body Mass Index,D015992,NA,0,213,any,2,000000000,Body Mass Index,NA
1699,20228402,2,body mass index[kh/m^],Body Mass Index,D015992,NA,0,213,any,2,000000000,Body Mass Index,NA
1700,20228402,2,body mass index[kh/m^];<25,Body Mass Index,D015992,NA,0,213,any,2,000000000,Body Mass Index,NA
1701,20228402,2,body mass index[kh/m^];>25-30,Body Mass Index,D015992,NA,0,213,any,2,000000000,Body Mass Index,NA
1702,20228402,2,body mass index[kh/m^];>30-35,Body Mass Index,D015992,NA,0,213,any,2,000000000,Body Mass Index,NA
1703,20228402,2,body mass index[kh/m^];>35,Body Mass Index,D015992,NA,0,213,any,2,000000000,Body Mass Index,NA
1704,20228402,2,Fasting plasma glucose,Glucose,D005947,NA,0,213,any,2,000000000,Glucose,NA
1705,20228402,2,Hypertension,Hypertension,D006973,NA,0,213,any,2,000000000,Hypertension,NA
1706,20228402,2,Prior CVD,Cardiovascular Diseases,D002318,NA,0,213,previous,8,100000000,Cardiovascular Diseases,NA
1707,20228402,2,race,Racial Groups,D044469,NA,0,213,any,2,000000000,Racial Groups,NA
1708,20228402,2,race;other,Racial Groups,D044469,NA,0,213,any,2,000000000,Racial Groups,NA
1709,20228402,2,region,Geographic Locations,D005842,NA,0,213,any,2,000000000,Geographic Locations,NA
1710,20228402,2,region;other,Geographic Locations,D005842,NA,0,213,any,2,000000000,Geographic Locations,NA
1711,20228402,2,sex,Gender Identity,D005783,NA,0,213,any,2,000000000,Gender Identity,NA
1712,20228402,2,waist circumference,Waist Circumference,D055105,NA,0,213,any,2,000000000,Waist Circumference,NA
1713,20228402,2,waist circumference[cm{female)/cm{male)],Waist Circumference,D055105,NA,0,213,any,2,000000000,Waist Circumference,NA
1714,20228402,2,waist circumference[cm{female)/cm{male)];<88/102,Waist Circumference,D055105,NA,0,213,any,2,000000000,Waist Circumference,NA
1715,20228402,2,waist circumference[cm{female)/cm{male)];>88/102,Waist Circumference,D055105,NA,0,213,any,2,000000000,Waist Circumference,NA
1716,20228402,3,ace inhibitor treatment,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,1489,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
1717,20228402,3,age,Age Factors,D000367,NA,0,1489,any,2,000000000,Age Factors,NA
1718,20228402,3,blood pressure control*,Blood Pressure,D001794,NA,0,1489,any,2,000000000,Blood Pressure,NA
1719,20228402,3,body mass index,Body Mass Index,D015992,NA,0,1489,any,2,000000000,Body Mass Index,NA
1720,20228402,3,body mass index[kg/m^],Body Mass Index,D015992,NA,0,1489,any,2,000000000,Body Mass Index,NA
1721,20228402,3,body mass index[kg/m^];<25,Body Mass Index,D015992,NA,0,1489,any,2,000000000,Body Mass Index,NA
1722,20228402,3,body mass index[kg/m^];>25-30,Body Mass Index,D015992,NA,0,1489,any,2,000000000,Body Mass Index,NA
1723,20228402,3,body mass index[kg/m^];>30-35,Body Mass Index,D015992,NA,0,1489,any,2,000000000,Body Mass Index,NA
1724,20228402,3,body mass index[kg/m^];>35,Body Mass Index,D015992,NA,0,1489,any,2,000000000,Body Mass Index,NA
1725,20228402,3,body mass index[kh/m^],Body Mass Index,D015992,NA,0,1489,any,2,000000000,Body Mass Index,NA
1726,20228402,3,body mass index[kh/m^];<25,Body Mass Index,D015992,NA,0,1489,any,2,000000000,Body Mass Index,NA
1727,20228402,3,body mass index[kh/m^];>25-30,Body Mass Index,D015992,NA,0,1489,any,2,000000000,Body Mass Index,NA
1728,20228402,3,body mass index[kh/m^];>30-35,Body Mass Index,D015992,NA,0,1489,any,2,000000000,Body Mass Index,NA
1729,20228402,3,body mass index[kh/m^];>35,Body Mass Index,D015992,NA,0,1489,any,2,000000000,Body Mass Index,NA
1730,20228402,3,Fasting plasma glucose,Glucose,D005947,NA,0,1489,any,2,000000000,Glucose,NA
1731,20228402,3,Hypertension,Hypertension,D006973,NA,0,1489,any,2,000000000,Hypertension,NA
1732,20228402,3,Prior CVD,Cardiovascular Diseases,D002318,NA,0,1489,previous,8,100000000,Cardiovascular Diseases,NA
1733,20228402,3,race,Racial Groups,D044469,NA,0,1489,any,2,000000000,Racial Groups,NA
1734,20228402,3,race;other,Racial Groups,D044469,NA,0,1489,any,2,000000000,Racial Groups,NA
1735,20228402,3,region,Geographic Locations,D005842,NA,0,1489,any,2,000000000,Geographic Locations,NA
1736,20228402,3,region;other,Geographic Locations,D005842,NA,0,1489,any,2,000000000,Geographic Locations,NA
1737,20228402,3,sex,Gender Identity,D005783,NA,0,1489,any,2,000000000,Gender Identity,NA
1738,20228402,3,waist circumference,Waist Circumference,D055105,NA,0,1489,any,2,000000000,Waist Circumference,NA
1739,20228402,3,waist circumference[cm{female)/cm{male)],Waist Circumference,D055105,NA,0,1489,any,2,000000000,Waist Circumference,NA
1740,20228402,3,waist circumference[cm{female)/cm{male)];<88/102,Waist Circumference,D055105,NA,0,1489,any,2,000000000,Waist Circumference,NA
1741,20228402,3,waist circumference[cm{female)/cm{male)];>88/102,Waist Circumference,D055105,NA,0,1489,any,2,000000000,Waist Circumference,NA
1742,20228402,4,'2hr prandial glucose\'*â€™',Glucose,D005947,NA,0,403,any,2,000000000,Glucose,NA
1743,20228402,4,ace inhibitor treatment,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,403,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
1744,20228402,4,age,Age Factors,D000367,NA,0,403,any,2,000000000,Age Factors,NA
1745,20228402,4,blood pressure control*,Blood Pressure,D001794,NA,0,403,any,2,000000000,Blood Pressure,NA
1746,20228402,4,body mass index,Body Mass Index,D015992,NA,0,403,any,2,000000000,Body Mass Index,NA
1747,20228402,4,body mass index[kg/m^],Body Mass Index,D015992,NA,0,403,any,2,000000000,Body Mass Index,NA
1748,20228402,4,body mass index[kg/m^];<25,Body Mass Index,D015992,NA,0,403,any,2,000000000,Body Mass Index,NA
1749,20228402,4,body mass index[kg/m^];>25-30,Body Mass Index,D015992,NA,0,403,any,2,000000000,Body Mass Index,NA
1750,20228402,4,body mass index[kg/m^];>30-35,Body Mass Index,D015992,NA,0,403,any,2,000000000,Body Mass Index,NA
1751,20228402,4,body mass index[kg/m^];>35,Body Mass Index,D015992,NA,0,403,any,2,000000000,Body Mass Index,NA
1752,20228402,4,body mass index[kh/m^],Body Mass Index,D015992,NA,0,403,any,2,000000000,Body Mass Index,NA
1753,20228402,4,body mass index[kh/m^];<25,Body Mass Index,D015992,NA,0,403,any,2,000000000,Body Mass Index,NA
1754,20228402,4,body mass index[kh/m^];>25-30,Body Mass Index,D015992,NA,0,403,any,2,000000000,Body Mass Index,NA
1755,20228402,4,body mass index[kh/m^];>30-35,Body Mass Index,D015992,NA,0,403,any,2,000000000,Body Mass Index,NA
1756,20228402,4,body mass index[kh/m^];>35,Body Mass Index,D015992,NA,0,403,any,2,000000000,Body Mass Index,NA
1757,20228402,4,Fasting plasma glucose,Glucose,D005947,NA,0,403,any,2,000000000,Glucose,NA
1758,20228402,4,fasting plasma glucose*,Glucose,D005947,NA,0,403,any,2,000000000,Glucose,NA
1759,20228402,4,Hypertension,Hypertension,D006973,NA,0,403,any,2,000000000,Hypertension,NA
1760,20228402,4,Prior CVD,Cardiovascular Diseases,D002318,NA,0,403,previous,8,100000000,Cardiovascular Diseases,NA
1761,20228402,4,race,Racial Groups,D044469,NA,0,403,any,2,000000000,Racial Groups,NA
1762,20228402,4,race;other,Racial Groups,D044469,NA,0,403,any,2,000000000,Racial Groups,NA
1763,20228402,4,region,Geographic Locations,D005842,NA,0,403,any,2,000000000,Geographic Locations,NA
1764,20228402,4,region;other,Geographic Locations,D005842,NA,0,403,any,2,000000000,Geographic Locations,NA
1765,20228402,4,sex,Gender Identity,D005783,NA,0,403,any,2,000000000,Gender Identity,NA
1766,20228402,4,waist circumference,Waist Circumference,D055105,NA,0,403,any,2,000000000,Waist Circumference,NA
1767,20228402,4,waist circumference[cm{female)/cm{male)],Waist Circumference,D055105,NA,0,403,any,2,000000000,Waist Circumference,NA
1768,20228402,4,waist circumference[cm{female)/cm{male)];<88/102,Waist Circumference,D055105,NA,0,403,any,2,000000000,Waist Circumference,NA
1769,20228402,4,waist circumference[cm{female)/cm{male)];>88/102,Waist Circumference,D055105,NA,0,403,any,2,000000000,Waist Circumference,NA
1770,20228403,2,ace inhibitor treatment,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,844,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
1771,20228403,2,age,Age Factors,D000367,NA,0,844,any,2,000000000,Age Factors,NA
1772,20228403,2,blood pressure control*,Blood Pressure,D001794,NA,0,844,any,2,000000000,Blood Pressure,NA
1773,20228403,2,body mass index[kg/m^],Body Mass Index,D015992,NA,0,844,any,2,000000000,Body Mass Index,NA
1774,20228403,2,body mass index[kg/m^];<25,Body Mass Index,D015992,NA,0,844,any,2,000000000,Body Mass Index,NA
1775,20228403,2,body mass index[kg/m^];>25-30,Body Mass Index,D015992,NA,0,844,any,2,000000000,Body Mass Index,NA
1776,20228403,2,body mass index[kg/m^];>30-35,Body Mass Index,D015992,NA,0,844,any,2,000000000,Body Mass Index,NA
1777,20228403,2,body mass index[kg/m^];>35,Body Mass Index,D015992,NA,0,844,any,2,000000000,Body Mass Index,NA
1778,20228403,2,Fasting plasma glucose,Glucose,D005947,NA,0,844,any,2,000000000,Glucose,NA
1779,20228403,2,Hypertension,Hypertension,D006973,NA,0,844,any,2,000000000,Hypertension,NA
1780,20228403,2,Prior CVD,Cardiovascular Diseases,D002318,NA,0,844,previous,8,100000000,Cardiovascular Diseases,NA
1781,20228403,2,race,Racial Groups,D044469,NA,0,844,any,2,000000000,Racial Groups,NA
1782,20228403,2,race;other,Racial Groups,D044469,NA,0,844,any,2,000000000,Racial Groups,NA
1783,20228403,2,region,Geographic Locations,D005842,NA,0,844,any,2,000000000,Geographic Locations,NA
1784,20228403,2,region;other,Geographic Locations,D005842,NA,0,844,any,2,000000000,Geographic Locations,NA
1785,20228403,2,sex,Gender Identity,D005783,NA,0,844,any,2,000000000,Gender Identity,NA
1786,20228403,2,waist circumference[cm(female)/cm(male)],Waist Circumference,D055105,NA,0,844,any,2,000000000,Waist Circumference,NA
1787,20228403,2,waist circumference[cm(female)/cm(male)];<88/102,Waist Circumference,D055105,NA,0,844,any,2,000000000,Waist Circumference,NA
1788,20228403,2,waist circumference[cm(female)/cm(male)];>88/102,Waist Circumference,D055105,NA,0,844,any,2,000000000,Waist Circumference,NA
1789,20228403,3,ace inhibitor treatment,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,1351,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
1790,20228403,3,age,Age Factors,D000367,NA,0,1351,any,2,000000000,Age Factors,NA
1791,20228403,3,blood pressure control*,Blood Pressure,D001794,NA,0,1351,any,2,000000000,Blood Pressure,NA
1792,20228403,3,body mass index[kg/m^],Body Mass Index,D015992,NA,0,1351,any,2,000000000,Body Mass Index,NA
1793,20228403,3,body mass index[kg/m^];<25,Body Mass Index,D015992,NA,0,1351,any,2,000000000,Body Mass Index,NA
1794,20228403,3,body mass index[kg/m^];>25-30,Body Mass Index,D015992,NA,0,1351,any,2,000000000,Body Mass Index,NA
1795,20228403,3,body mass index[kg/m^];>30-35,Body Mass Index,D015992,NA,0,1351,any,2,000000000,Body Mass Index,NA
1796,20228403,3,body mass index[kg/m^];>35,Body Mass Index,D015992,NA,0,1351,any,2,000000000,Body Mass Index,NA
1797,20228403,3,Fasting plasma glucose,Glucose,D005947,NA,0,1351,any,2,000000000,Glucose,NA
1798,20228403,3,fasting plasma glucose*,Glucose,D005947,NA,0,1351,any,2,000000000,Glucose,NA
1799,20228403,3,Hypertension,Hypertension,D006973,NA,0,1351,any,2,000000000,Hypertension,NA
1800,20228403,3,Prior CVD,Cardiovascular Diseases,D002318,NA,0,1351,previous,8,100000000,Cardiovascular Diseases,NA
1801,20228403,3,race,Racial Groups,D044469,NA,0,1351,any,2,000000000,Racial Groups,NA
1802,20228403,3,race;other,Racial Groups,D044469,NA,0,1351,any,2,000000000,Racial Groups,NA
1803,20228403,3,region,Geographic Locations,D005842,NA,0,1351,any,2,000000000,Geographic Locations,NA
1804,20228403,3,region;other,Geographic Locations,D005842,NA,0,1351,any,2,000000000,Geographic Locations,NA
1805,20228403,3,sex,Gender Identity,D005783,NA,0,1351,any,2,000000000,Gender Identity,NA
1806,20228403,3,waist circumference[cm(female)/cm(male)],Waist Circumference,D055105,NA,0,1351,any,2,000000000,Waist Circumference,NA
1807,20228403,3,waist circumference[cm(female)/cm(male)];<88/102,Waist Circumference,D055105,NA,0,1351,any,2,000000000,Waist Circumference,NA
1808,20228403,3,waist circumference[cm(female)/cm(male)];>88/102,Waist Circumference,D055105,NA,0,1351,any,2,000000000,Waist Circumference,NA
1809,20228403,4,ace inhibitor treatment,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,855,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
1810,20228403,4,age,Age Factors,D000367,NA,0,855,any,2,000000000,Age Factors,NA
1811,20228403,4,age;<60 years,Age Factors,D000367,NA,0,855,any,2,000000000,Age Factors,NA
1812,20228403,4,age;>60-67 years,Age Factors,D000367,NA,0,855,any,2,000000000,Age Factors,NA
1813,20228403,4,age;>67 years,Age Factors,D000367,NA,0,855,any,2,000000000,Age Factors,NA
1814,20228403,4,blood pressure control*,Blood Pressure,D001794,NA,0,855,any,2,000000000,Blood Pressure,NA
1815,20228403,4,body mass index[kg/m^],Body Mass Index,D015992,NA,0,855,any,2,000000000,Body Mass Index,NA
1816,20228403,4,body mass index[kg/m^];<25,Body Mass Index,D015992,NA,0,855,any,2,000000000,Body Mass Index,NA
1817,20228403,4,body mass index[kg/m^];>25-30,Body Mass Index,D015992,NA,0,855,any,2,000000000,Body Mass Index,NA
1818,20228403,4,body mass index[kg/m^];>30-35,Body Mass Index,D015992,NA,0,855,any,2,000000000,Body Mass Index,NA
1819,20228403,4,body mass index[kg/m^];>35,Body Mass Index,D015992,NA,0,855,any,2,000000000,Body Mass Index,NA
1820,20228403,4,Fasting plasma glucose,Glucose,D005947,NA,0,855,any,2,000000000,Glucose,NA
1821,20228403,4,Hypertension,Hypertension,D006973,NA,0,855,any,2,000000000,Hypertension,NA
1822,20228403,4,Prior CVD,Cardiovascular Diseases,D002318,NA,0,855,previous,8,100000000,Cardiovascular Diseases,NA
1823,20228403,4,race,Racial Groups,D044469,NA,0,855,any,2,000000000,Racial Groups,NA
1824,20228403,4,race;other,Racial Groups,D044469,NA,0,855,any,2,000000000,Racial Groups,NA
1825,20228403,4,region,Geographic Locations,D005842,NA,0,855,any,2,000000000,Geographic Locations,NA
1826,20228403,4,region;other,Geographic Locations,D005842,NA,0,855,any,2,000000000,Geographic Locations,NA
1827,20228403,4,sex,Gender Identity,D005783,NA,0,855,any,2,000000000,Gender Identity,NA
1828,20228403,4,waist circumference[cm(female)/cm(male)],Waist Circumference,D055105,NA,0,855,any,2,000000000,Waist Circumference,NA
1829,20228403,4,waist circumference[cm(female)/cm(male)];<88/102,Waist Circumference,D055105,NA,0,855,any,2,000000000,Waist Circumference,NA
1830,20228403,4,waist circumference[cm(female)/cm(male)];>88/102,Waist Circumference,D055105,NA,0,855,any,2,000000000,Waist Circumference,NA
1831,20228404,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
1832,20228404,NA,glycemia group,Glucose Intolerance,D018149,NA,0,0,any,2,000000000,Glucose Intolerance,NA
1833,20228404,NA,hba1c,Glycated Hemoglobin A,D006442,NA,0,0,any,2,000000000,Glycated Hemoglobin A,NA
1834,20228404,NA,hdl,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,NA
1835,20228404,NA,ldl,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,NA
1836,20228404,NA,previous cardiovascular event,Cardiovascular Diseases,D002318,NA,0,0,previous,8,100000000,Cardiovascular Diseases,NA
1837,20228404,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
1838,20228404,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
1839,20228404,NA,triglycerides,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,NA
1840,20385930,2,ace inhibitor or arb,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,755,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
1841,20385930,2,angiography during index hospitalization,Gender Identity,D005783,NA,0,755,any,2,000000000,Gender Identity,NA
1842,20385930,2,pci during index hospitalization,Percutaneous Coronary Intervention,D062645,NA,0,755,any,2,000000000,Percutaneous Coronary Intervention,NA
1843,20385930,2,statin,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,755,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
1844,20385930,3,men,Gender Identity,D005783,NA,0,1086,any,2,000000000,Gender Identity,NA
1845,20385930,3,women,Gender Identity,D005783,NA,0,1086,any,2,000000000,Gender Identity,NA
1846,20393175,2,'duration of crohn\'s disease (yrs)',Crohn Disease,D003424,NA,0,704,duration,5,001000000,Crohn Disease,NA
1847,20393175,2,age (yrs),Age Factors,D000367,NA,0,704,any,2,000000000,Age Factors,NA
1848,20393175,2,age (yrs);30 to < 40,Age Factors,D000367,NA,0,704,any,2,000000000,Age Factors,NA
1849,20393175,2,age (yrs);40 to <50,Age Factors,D000367,NA,0,704,any,2,000000000,Age Factors,NA
1850,20393175,2,baseline 5-asa,intestinal antiinflammatory agents,NA,A07E,0,704,any,2,000000000,intestinal antiinflammatory agents,NA
1851,20393175,2,baseline 5-asa;no use of 5-asa compounds,intestinal antiinflammatory agents,NA,A07E,0,704,any,2,000000000,intestinal antiinflammatory agents,NA
1852,20393175,2,baseline 5-asa;use 5-asa compounds,intestinal antiinflammatory agents,NA,A07E,0,704,any,2,000000000,intestinal antiinflammatory agents,NA
1853,20393175,2,baseline corticosteroid use (mg),Steroids,D013256,NA,0,704,any,2,000000000,Steroids,NA
1854,20393175,2,baseline crp (mg/dl),C-Reactive Protein,D002097,NA,0,704,any,2,000000000,C-Reactive Protein,NA
1855,20393175,2,center location,Geographic Locations,D005842,NA,0,704,any,2,000000000,Geographic Locations,NA
1856,20393175,2,crohnâ€™s disease related surgery,"Surgical Procedures, Operative",D013514,NA,0,704,previous,8,100000000,"Surgical Procedures, Operative",NA
1857,20393175,2,crohnâ€™s disease related surgery;with previous surgery,"Surgical Procedures, Operative",D013514,NA,0,704,previous,8,100000000,"Surgical Procedures, Operative",NA
1858,20393175,2,crohnâ€™s disease related surgery;without previous surgery,"Surgical Procedures, Operative",D013514,NA,0,704,previous,8,100000000,"Surgical Procedures, Operative",NA
1859,20393175,2,duration of crohnâ€™s disease (yrs),Crohn Disease,D003424,NA,0,704,duration,5,001000000,Crohn Disease,NA
1860,20393175,2,gender,Gender Identity,D005783,NA,0,704,any,2,000000000,Gender Identity,NA
1861,20393175,2,race,Racial Groups,D044469,NA,0,704,any,2,000000000,Racial Groups,NA
1862,20393175,2,race;non-caucasian,Racial Groups,D044469,NA,0,704,any,2,000000000,Racial Groups,NA
1863,20393175,2,Smoker,Cigarette Smoking,D000073865,NA,0,704,any,2,000000000,Cigarette Smoking,NA
1864,20393175,2,weight (kg),Body Weight,D001835,NA,0,704,any,2,000000000,Body Weight,NA
1865,20393175,2,y C-reactive protein;,C-Reactive Protein,D002097,NA,0,704,any,2,000000000,C-Reactive Protein,NA
1866,20393175,3,'duration of crohn\'s disease (yrs)',Crohn Disease,D003424,NA,0,1275,duration,5,001000000,Crohn Disease,NA
1867,20393175,3,age (yrs),Age Factors,D000367,NA,0,1275,any,2,000000000,Age Factors,NA
1868,20393175,3,baseline 5-asa,intestinal antiinflammatory agents,NA,A07E,0,1275,any,2,000000000,intestinal antiinflammatory agents,NA
1869,20393175,3,baseline 5-asa;no use of 5-asa compounds,intestinal antiinflammatory agents,NA,A07E,0,1275,any,2,000000000,intestinal antiinflammatory agents,NA
1870,20393175,3,baseline 5-asa;use 5-asa compounds,intestinal antiinflammatory agents,NA,A07E,0,1275,any,2,000000000,intestinal antiinflammatory agents,NA
1871,20393175,3,baseline corticosteroid use (mg),Steroids,D013256,NA,0,1275,any,2,000000000,Steroids,NA
1872,20393175,3,baseline crp (mg/dl),C-Reactive Protein,D002097,NA,0,1275,any,2,000000000,C-Reactive Protein,NA
1873,20393175,3,center location,Geographic Locations,D005842,NA,0,1275,any,2,000000000,Geographic Locations,NA
1874,20393175,3,crohnâ€™s disease related surgery,complex,none,NA,0,1275,any,2,000000000,complex,NA
1875,20393175,3,crohnâ€™s disease related surgery;with previous surgery,"Surgical Procedures, Operative",D013514,NA,0,1275,previous,8,100000000,"Surgical Procedures, Operative",NA
1876,20393175,3,crohnâ€™s disease related surgery;without previous surgery,"Surgical Procedures, Operative",D013514,NA,0,1275,previous,8,100000000,"Surgical Procedures, Operative",NA
1877,20393175,3,duration of crohnâ€™s disease (yrs),Crohn Disease,D003424,NA,0,1275,duration,5,001000000,Crohn Disease,NA
1878,20393175,3,gender,Gender Identity,D005783,NA,0,1275,any,2,000000000,Gender Identity,NA
1879,20393175,3,race,Racial Groups,D044469,NA,0,1275,any,2,000000000,Racial Groups,NA
1880,20393175,3,race;non-caucasian,Racial Groups,D044469,NA,0,1275,any,2,000000000,Racial Groups,NA
1881,20393175,3,Smoker,Cigarette Smoking,D000073865,NA,0,1275,any,2,000000000,Cigarette Smoking,NA
1882,20393175,3,weight (kg),Body Weight,D001835,NA,0,1275,any,2,000000000,Body Weight,NA
1883,20393175,3,y C-reactive protein;,C-Reactive Protein,D002097,NA,0,1275,any,2,000000000,C-Reactive Protein,NA
1884,20393175,4,'duration of crohn\'s disease (yrs)',Crohn Disease,D003424,NA,0,301,duration,5,001000000,Crohn Disease,NA
1885,20393175,4,age (yrs),Age Factors,D000367,NA,0,301,any,2,000000000,Age Factors,NA
1886,20393175,4,baseline 5-asa,intestinal antiinflammatory agents,NA,A07E,0,301,any,2,000000000,intestinal antiinflammatory agents,NA
1887,20393175,4,baseline 5-asa;no use of 5-asa compounds,intestinal antiinflammatory agents,NA,A07E,0,301,any,2,000000000,intestinal antiinflammatory agents,NA
1888,20393175,4,baseline 5-asa;use 5-asa compounds,intestinal antiinflammatory agents,NA,A07E,0,301,any,2,000000000,intestinal antiinflammatory agents,NA
1889,20393175,4,baseline corticosteroid use (mg),Steroids,D013256,NA,0,301,any,2,000000000,Steroids,NA
1890,20393175,4,baseline corticosteroid use (mg);with corticosteroid treatment > 20,Steroids,D013256,NA,0,301,any,2,000000000,Steroids,NA
1891,20393175,4,center location,Geographic Locations,D005842,NA,0,301,any,2,000000000,Geographic Locations,NA
1892,20393175,4,center location;europe/lsrael,Geographic Locations,D005842,NA,0,301,any,2,000000000,Geographic Locations,NA
1893,20393175,4,crohnâ€™s disease related surgery,complex,none,NA,0,301,any,2,000000000,complex,NA
1894,20393175,4,crohnâ€™s disease related surgery;with previous surgery,"Surgical Procedures, Operative",D013514,NA,0,301,previous,8,100000000,"Surgical Procedures, Operative",NA
1895,20393175,4,crohnâ€™s disease related surgery;without previous surgery,"Surgical Procedures, Operative",D013514,NA,0,301,previous,8,100000000,"Surgical Procedures, Operative",NA
1896,20393175,4,duration of crohnâ€™s disease (yrs),Crohn Disease,D003424,NA,0,301,duration,5,001000000,Crohn Disease,NA
1897,20393175,4,gender,Gender Identity,D005783,NA,0,301,any,2,000000000,Gender Identity,NA
1898,20393175,4,race,Racial Groups,D044469,NA,0,301,any,2,000000000,Racial Groups,NA
1899,20393175,4,race;non-caucasian,Racial Groups,D044469,NA,0,301,any,2,000000000,Racial Groups,NA
1900,20393175,4,Smoker,Cigarette Smoking,D000073865,NA,0,301,any,2,000000000,Cigarette Smoking,NA
1901,20393175,4,weight (kg),Body Weight,D001835,NA,0,301,any,2,000000000,Body Weight,NA
1902,20393175,4,y C-reactive protein;,C-Reactive Protein,D002097,NA,0,301,any,2,000000000,C-Reactive Protein,NA
1903,20400762,1,age (years),Age Factors,D000367,NA,0,642,any,2,000000000,Age Factors,NA
1904,20400762,1,diabetes,Diabetes Mellitus,D003920,NA,0,642,any,2,000000000,Diabetes Mellitus,NA
1905,20400762,1,diabetes;dm,Diabetes Mellitus,D003920,NA,0,642,any,2,000000000,Diabetes Mellitus,NA
1906,20400762,1,diabetes;no dm,Diabetes Mellitus,D003920,NA,0,642,any,2,000000000,Diabetes Mellitus,NA
1907,20400762,1,diabetes;no prior ml,Myocardial Infarction,D009203,NA,0,642,previous,8,100010000,Myocardial Infarction,NA
1908,20400762,1,diabetes;prior ml,Myocardial Infarction,D009203,NA,0,642,previous,8,100010000,Myocardial Infarction,NA
1909,20400762,1,fibrinolytic,Fibrinolytic Agents,D005343,NA,0,642,any,2,000000000,Fibrinolytic Agents,NA
1910,20400762,1,fibrinolytic;fibrin-specilic,Fibrinolytic Agents,D005343,NA,0,642,any,2,000000000,Fibrinolytic Agents,NA
1911,20400762,1,fibrinolytic;streptokinase,Fibrinolytic Agents,D005343,NA,0,642,any,2,000000000,Fibrinolytic Agents,NA
1912,20400762,1,location,Infarction,D007238,NA,0,642,location,7,000000001,Infarction,NA
1913,20400762,1,location;other,Infarction,D007238,NA,0,642,location,7,000000001,Infarction,NA
1914,20400762,1,sex,Gender Identity,D005783,NA,0,642,any,2,000000000,Gender Identity,NA
1915,20400762,1,time to rx,Myocardial Infarction,D009203,NA,0,642,duration,5,001000000,Myocardial Infarction,NA
1916,20409909,NA,BMI,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,NA
1917,20409909,NA,Diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
1918,20409909,NA,Elderly,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
1919,20409909,NA,Isolated systolic hypertension,Hypertension,D006973,NA,0,0,type,2,000000000,Hypertension,NA
1920,20409909,NA,Race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
1921,20418083,2,men,Gender Identity,D005783,NA,0,1142,any,2,000000000,Gender Identity,NA
1922,20418083,2,women,Gender Identity,D005783,NA,0,1142,any,2,000000000,Gender Identity,NA
1923,20429821,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,84
1924,20429821,NA,Patient Variable: BMI at baseline,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,29
1925,20436046,2,"left ventricular ejection fraction <=0.40 and nyha class ii, iii at baseline",Stroke Volume,D013318,NA,0,1484,severity,11,000100000,Stroke Volume,NA
1926,20436046,2,NYHA class,Heart Failure,D006333,NA,0,1484,severity,11,000100000,Heart Failure,NA
1927,20463178,2,inhaled corticosteroid use,Steroids,D013256,NA,0,1036,any,2,000000000,Steroids,NA
1928,20469975,2,male female,Gender Identity,D005783,NA,0,207,any,2,000000000,Gender Identity,NA
1929,20484828,1,no peripheral artery disease baseline,Peripheral Vascular Diseases,D016491,NA,0,1263,any,2,000000000,Peripheral Vascular Diseases,NA
1930,20484828,1,peripheral artery diseaseÂ at baseline,Peripheral Vascular Diseases,D016491,NA,0,1263,any,2,000000000,Peripheral Vascular Diseases,NA
1931,20487050,2,baseline ldl,Lipoproteins,D008074,NA,0,1044,any,2,000000000,Lipoproteins,NA
1932,20487050,2,primary vs secondary prevention,unclassifiable,NA,NA,0,1044,any,2,000000000,unclassifiable,NA
1933,20488885,NA,baseline seropositivity,"Arthritis, Rheumatoid",D001172,NA,0,0,risk score,10,000000100,"Arthritis, Rheumatoid",76
1934,20488885,NA,baselineDAS28-ESR,"Arthritis, Rheumatoid",D001172,NA,0,0,any,2,000000000,"Arthritis, Rheumatoid",NA
1935,20488885,NA,duration of RA,"Arthritis, Rheumatoid",D001172,NA,0,0,duration,5,001000000,"Arthritis, Rheumatoid",NA
1936,20491747,2,no prior in<U+FB02>iximab use,Tumor Necrosis Factor Inhibitors,D000079424,NA,0,46,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
1937,20491747,2,no prior inÃ¯Â¬â€šiximab use,Tumor Necrosis Factor Inhibitors,D000079424,NA,0,46,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
1938,20491747,2,prior in<U+FB02>iximab use,Immunosuppressive Agents,D007166,NA,0,46,previous,8,100000000,Immunosuppressive Agents,NA
1939,20491747,2,prior inÃ¯Â¬â€šiximab use,Immunosuppressive Agents,D007166,NA,0,46,previous,8,100000000,Immunosuppressive Agents,NA
1940,20522841,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,247
1941,20522841,NA,COPD severity,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,0,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",246
1942,20522841,NA,Inhaled Corticosteroids,Adrenal Cortex Hormones,D000305,NA,0,0,any,2,000000000,Adrenal Cortex Hormones,246
1943,20522841,NA,smoking status,Cigarette Smoking,D000073865,NA,0,0,any,2,000000000,Cigarette Smoking,246
1944,20582594,2,age,Age Factors,D000367,NA,0,1274,any,2,000000000,Age Factors,NA
1945,20582594,2,diabetes,Diabetes Mellitus,D003920,NA,0,1274,any,2,000000000,Diabetes Mellitus,NA
1946,20582594,2,history of mi,Myocardial Infarction,D009203,NA,0,1274,previous,8,100010000,Myocardial Infarction,NA
1947,20582594,2,infarct localization,Infarction,D007238,NA,0,1274,location,7,000000001,Infarction,NA
1948,20582594,2,infarct localization;non-anterior,Infarction,D007238,NA,0,1274,location,7,000000001,Infarction,NA
1949,20582594,2,interval clopidogrel to pci,Fibrinolytic Agents,D005343,NA,0,1274,any,2,000000000,Fibrinolytic Agents,NA
1950,20582594,2,interval pain onset to admission,Pain,D010146,NA,0,1274,any,2,000000000,Pain,NA
1951,20582594,2,interval study drug to pci,Percutaneous Coronary Intervention,D062645,NA,0,1274,any,2,000000000,Percutaneous Coronary Intervention,NA
1952,20582594,2,sex,Gender Identity,D005783,NA,0,1274,any,2,000000000,Gender Identity,NA
1953,20582993,NA,"Age, y",Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
1954,20582993,NA,Concomitant MAO-B inhibitor use,monoamine oxidase b inhibitors,NA,N04BD,0,0,any,2,000000000,monoamine oxidase b inhibitors,NA
1955,20582993,NA,"Disease duration, y",Parkinson Disease,D010300,NA,0,0,duration,5,001000000,Parkinson Disease,NA
1956,20582993,NA,not On dopamine agonist,dopamine agonists,NA,N04BC,0,0,any,2,000000000,dopamine agonists,NA
1957,20582993,NA,On dopamine agonist,dopamine agonists,NA,N04BC,0,0,any,2,000000000,dopamine agonists,NA
1958,20582993,NA,Sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
1959,20582993,NA,"Weight, kg",Body Weight,D001835,NA,0,0,any,2,000000000,Body Weight,NA
1960,20593911,NA,"Age, y",Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
1961,20593911,NA,Diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
1962,20593911,NA,Hypertension severity,Hypertension,D006973,NA,0,0,severity,11,000100000,Hypertension,NA
1963,20593911,NA,Sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
1964,20620037,NA,laba,"lama, long-acting beta agonist",NA,R03,0,0,any,2,000000000,"lama, long-acting beta agonist",219
1965,20621900,2,age,Age Factors,D000367,NA,0,1150,any,2,000000000,Age Factors,NA
1966,20621900,2,male female,Gender Identity,D005783,NA,0,1150,any,2,000000000,Gender Identity,NA
1967,20670726,NA,Patient Variable: Age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,83
1968,20678674,2,Hypertension,Hypertension,D006973,NA,0,1755,severity,11,000100000,Hypertension,NA
1969,20678878,2,;all grafts,unclassifiable,none,NA,0,634,any,2,000000000,unclassifiable,NA
1970,20678878,2,;venous,Vascular Grafting,D058017,NA,0,634,type,12,000000010,Vascular Grafting,NA
1971,20678878,2,mobility level,Exercise,D015444,NA,0,634,any,2,000000000,Exercise,NA
1972,20685748,2,age;<55,Age Factors,D000367,NA,0,1512,any,2,000000000,Age Factors,NA
1973,20685748,2,age;55e64,Age Factors,D000367,NA,0,1512,any,2,000000000,Age Factors,NA
1974,20685748,2,age;65e74,Age Factors,D000367,NA,0,1512,any,2,000000000,Age Factors,NA
1975,20685748,2,baseline cv treatment,cardiac therapy,NA,C01,0,1512,any,2,000000000,cardiac therapy,NA
1976,20685748,2,baseline fev1,Pulmonary Ventilation,D012123,NA,0,1512,any,2,000000000,Pulmonary Ventilation,NA
1977,20685748,2,baseline short-acting anticholinergics,Cholinergic Antagonists,D018680,NA,0,1512,duration,5,001000000,Cholinergic Antagonists,NA
1978,20685748,2,male female,Gender Identity,D005783,NA,0,1512,any,2,000000000,Gender Identity,NA
1979,20685748,2,prior mi,Myocardial Infarction,D009203,NA,0,1512,previous,8,100010000,Myocardial Infarction,NA
1980,20685748,2,Smoker,Cigarette Smoking,D000073865,NA,0,1512,any,2,000000000,Cigarette Smoking,NA
1981,20685748,2,smoking status;current,Cigarette Smoking,D000073865,NA,0,1512,current,3,010000000,Cigarette Smoking,NA
1982,20685748,2,smoking status;former,Cigarette Smoking,D000073865,NA,0,1512,previous,8,100000000,Cigarette Smoking,NA
1983,20707767,NA,Medical History: Severe overactive bladder,Urinary Bladder Diseases,D001745,NA,0,0,previous severity,9,100100000,Urinary Bladder Diseases,42
1984,20723849,NA,Medical History: CADILLAC Risk,Cardiovascular Diseases,D002318,NA,0,0,previous,8,100000100,Cardiovascular Diseases,94
1985,20724648,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,201
1986,20724648,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,200
1987,20724648,NA,HbA1c,Glycated Hemoglobin A,D006442,NA,0,0,any,2,000000000,Glycated Hemoglobin A,200
1988,20724648,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,200
1989,20724648,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,200
1990,20801500,2,age,Age Factors,D000367,NA,0,1278,any,2,000000000,Age Factors,NA
1991,20801500,2,baseline heart rate,Heart Rate,D006339,NA,0,1278,any,2,000000000,Heart Rate,NA
1992,20801500,2,cause of heart failure,Heart Failure,D006333,NA,0,1278,aetiological,1,000001000,Heart Failure,NA
1993,20801500,2,Cause of heart failure Non-ischaemic (n=2087) ischaemic (n=4418),Heart Failure,D006333,NA,0,1278,aetiological,1,000001000,Heart Failure,NA
1994,20801500,2,cause of heart failure;non-ischaemic (n=2087),Ischemia,D007511,NA,0,1278,any,2,000000000,Ischemia,NA
1995,20801500,2,diabetes,Diabetes Mellitus,D003920,NA,0,1278,any,2,000000000,Diabetes Mellitus,NA
1996,20801500,2,diabetes;history of diabetes (n=1979),Diabetes Mellitus,D003920,NA,0,1278,previous,8,100000000,Diabetes Mellitus,NA
1997,20801500,2,diabetes;no history of diabetes (n=4526),Diabetes Mellitus,D003920,NA,0,1278,previous,8,100000000,Diabetes Mellitus,NA
1998,20801500,2,hypertension,Hypertension,D006973,NA,0,1278,any,2,000000000,Hypertension,NA
1999,20801500,2,nyha class,Heart Failure,D006333,NA,0,1278,severity,11,000100000,Heart Failure,NA
2000,20801500,2,p blockers,beta blocking agents,NA,C07,0,1278,any,2,000000000,beta blocking agents,NA
2001,20801500,2,p blockers;no p-blocker intake at randomisation (n=685),beta blocking agents,NA,C07,0,1278,any,2,000000000,beta blocking agents,NA
2002,20801500,2,p blockers;p-blocker intake at randomisation (n=5820),beta blocking agents,NA,C07,0,1278,any,2,000000000,beta blocking agents,NA
2003,20801500,2,sex,Gender Identity,D005783,NA,0,1278,any,2,000000000,Gender Identity,NA
2004,20801500,NA,Age-Years,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
2005,20801500,NA,beta blocker,Adrenergic beta-Antagonists,D000319,NA,0,0,any,2,000000000,Adrenergic beta-Antagonists,NA
2006,20801500,NA,cause of heart failure (non-ischaemic/ischaemic),Heart Failure,D006333,NA,0,0,aetiological,1,000001000,Heart Failure,NA
2007,20801500,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
2008,20801500,NA,heart rate,Heart Rate,D006339,NA,0,0,any,2,000000000,Heart Rate,NA
2009,20801500,NA,hypertension,Hypertension,D006973,NA,0,0,any,2,000000000,Hypertension,NA
2010,20801500,NA,nyha class,Heart Failure,D006333,NA,0,0,severity,11,000100000,Heart Failure,NA
2011,20801500,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
2012,20883926,2,baseline Coenzyme Q10 Concentration;tertile 1,Ubiquinone,D014451,NA,0,NA,any,2,000000000,Ubiquinone,NA
2013,20883926,2,baseline Coenzyme Q10 Concentration;tertile 2,Ubiquinone,D014451,NA,0,NA,any,2,000000000,Ubiquinone,NA
2014,20883926,2,baseline Coenzyme Q10 Concentration;tertile 3,Ubiquinone,D014451,NA,0,NA,any,2,000000000,Ubiquinone,NA
2015,20883926,3,baseline Coenzyme Q10 Concentration;tertile 1,Ubiquinone,D014451,NA,0,NA,any,2,000000000,Ubiquinone,NA
2016,20883926,3,baseline Coenzyme Q10 Concentration;tertile 2,Ubiquinone,D014451,NA,0,NA,any,2,000000000,Ubiquinone,NA
2017,20883926,3,baseline Coenzyme Q10 Concentration;tertile 3,Ubiquinone,D014451,NA,0,NA,any,2,000000000,Ubiquinone,NA
2018,20925534,2,Concomitant Aspirin,Aspirin,D001241,NA,0,1573,any,2,000000000,Aspirin,NA
2019,20925534,2,Concomitant Clopidogrel,Fibrinolytic Agents,D005343,NA,0,1573,any,2,000000000,Fibrinolytic Agents,NA
2020,20925534,2,Concomitant Statin,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,1573,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
2021,20925534,2,diabetes,Diabetes Mellitus,D003920,NA,0,1573,any,2,000000000,Diabetes Mellitus,NA
2022,20925534,2,Diabetes,Diabetes Mellitus,D003920,NA,0,1573,any,2,000000000,Diabetes Mellitus,NA
2023,20925534,2,H. pylori Negative,Helicobacter pylori,D016480,NA,0,1573,any,2,000000000,Helicobacter pylori,NA
2024,20925534,2,H. pylori Positive or Indeterminate,Helicobacter pylori,D016480,NA,0,1573,any,2,000000000,Helicobacter pylori,NA
2025,20925534,2,helicobacter pylori negative,Helicobacter pylori,D016480,NA,0,1573,any,2,000000000,Helicobacter pylori,NA
2026,20925534,2,History of PAD Negative,Peripheral Vascular Diseases,D016491,NA,0,1573,any,2,000000000,Peripheral Vascular Diseases,NA
2027,20925534,2,Hypercholesterolemia,Hypercholesterolemia,D006937,NA,0,1573,any,2,000000000,Hypercholesterolemia,NA
2028,20925534,2,Hypertension,Hypertension,D006973,NA,0,1573,any,2,000000000,Hypertension,NA
2029,20925534,2,male female,Gender Identity,D005783,NA,0,1573,any,2,000000000,Gender Identity,NA
2030,20925534,2,No Aspirin Use,Aspirin,D001241,NA,0,1573,any,2,000000000,Aspirin,NA
2031,20925534,2,No Clopidogrel Use,Fibrinolytic Agents,D005343,NA,0,1573,any,2,000000000,Fibrinolytic Agents,NA
2032,20925534,2,no diabetes,Diabetes Mellitus,D003920,NA,0,1573,any,2,000000000,Diabetes Mellitus,NA
2033,20925534,2,No Diabetes,Diabetes Mellitus,D003920,NA,0,1573,any,2,000000000,Diabetes Mellitus,NA
2034,20925534,2,no hypercholesterolaemia,Hypercholesterolemia,D006937,NA,0,1573,any,2,000000000,Hypercholesterolemia,NA
2035,20925534,2,No Hypercholesterolemia,Hypercholesterolemia,D006937,NA,0,1573,any,2,000000000,Hypercholesterolemia,NA
2036,20925534,2,No Hypertension,Hypertension,D006973,NA,0,1573,any,2,000000000,Hypertension,NA
2037,20925534,2,no nsaid,Anti-Inflammatory Agents,D000893,NA,0,1573,any,2,000000000,Anti-Inflammatory Agents,NA
2038,20925534,2,No NSAIDs Used,Anti-Inflammatory Agents,D000893,NA,0,1573,any,2,000000000,Anti-Inflammatory Agents,NA
2039,20925534,2,No Other Risk Factor,Risk Factors,D012307,NA,0,1573,any,2,000000000,Risk Factors,NA
2040,20925534,2,no risk factors,Risk Factors,D012307,NA,0,1573,any,2,000000000,Risk Factors,NA
2041,20925534,2,no statin,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,1573,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
2042,20925534,2,No Statin Use,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,1573,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
2043,20925534,2,NSAIDs Used,Anti-Inflammatory Agents,D000893,NA,0,1573,any,2,000000000,Anti-Inflammatory Agents,NA
2044,20925534,2,Other Risk Factors,Risk Factors,D012307,NA,0,1573,risk score,10,000000100,Risk Factors,NA
2045,20925534,2,other risk factros,Risk Factors,D012307,NA,0,1573,risk score,10,000000100,Risk Factors,NA
2046,20925534,2,Peripheral artery disease Yes No,Peripheral Vascular Diseases,D016491,NA,0,1573,any,2,000000000,Peripheral Vascular Diseases,NA
2047,20925534,2,race,Racial Groups,D044469,NA,0,1573,any,2,000000000,Racial Groups,NA
2048,20925534,3,age less or equal to 70,Age Factors,D000367,NA,0,110,any,2,000000000,Age Factors,NA
2049,20925534,3,age over 70,Age Factors,D000367,NA,0,110,any,2,000000000,Age Factors,NA
2050,20925534,3,aspirin use,Aspirin,D001241,NA,0,110,any,2,000000000,Aspirin,NA
2051,20925534,3,clopidogrel use,Fibrinolytic Agents,D005343,NA,0,110,any,2,000000000,Fibrinolytic Agents,NA
2052,20925534,3,concomitant statin,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,110,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
2053,20925534,3,diabetes,Diabetes Mellitus,D003920,NA,0,110,any,2,000000000,Diabetes Mellitus,NA
2054,20925534,3,Diabetes,Diabetes Mellitus,D003920,NA,0,110,any,2,000000000,Diabetes Mellitus,NA
2055,20925534,3,H. pylori Negative,Helicobacter pylori,D016480,NA,0,110,any,2,000000000,Helicobacter pylori,NA
2056,20925534,3,helicobacter pylori negative,Helicobacter pylori,D016480,NA,0,110,any,2,000000000,Helicobacter pylori,NA
2057,20925534,3,helicobacter pylori positive or indeterminate,Helicobacter pylori,D016480,NA,0,110,any,2,000000000,Helicobacter pylori,NA
2058,20925534,3,history of pad,Peripheral Vascular Diseases,D016491,NA,0,110,previous,8,100000000,Peripheral Vascular Diseases,NA
2059,20925534,3,no aspirin,Aspirin,D001241,NA,0,110,any,2,000000000,Aspirin,NA
2060,20925534,3,no clopidogrel,Fibrinolytic Agents,D005343,NA,0,110,any,2,000000000,Fibrinolytic Agents,NA
2061,20925534,3,no diabetes,Diabetes Mellitus,D003920,NA,0,110,any,2,000000000,Diabetes Mellitus,NA
2062,20925534,3,No Diabetes,Diabetes Mellitus,D003920,NA,0,110,any,2,000000000,Diabetes Mellitus,NA
2063,20925534,3,no hypercholesterolaemia,Hypercholesterolemia,D006937,NA,0,110,any,2,000000000,Hypercholesterolemia,NA
2064,20925534,3,No Hypercholesterolemia,Hypercholesterolemia,D006937,NA,0,110,any,2,000000000,Hypercholesterolemia,NA
2065,20925534,3,no hypertensive disease,Hypertension,D006973,NA,0,110,any,2,000000000,Hypertension,NA
2066,20925534,3,no nsaid,Anti-Inflammatory Agents,D000893,NA,0,110,any,2,000000000,Anti-Inflammatory Agents,NA
2067,20925534,3,No NSAIDs Used,Anti-Inflammatory Agents,D000893,NA,0,110,any,2,000000000,Anti-Inflammatory Agents,NA
2068,20925534,3,No Other Risk Factor,Risk Factors,D012307,NA,0,110,risk score,10,000000100,Risk Factors,NA
2069,20925534,3,no pad,Peripheral Vascular Diseases,D016491,NA,0,110,any,2,000000000,Peripheral Vascular Diseases,NA
2070,20925534,3,no risk factors,Risk Factors,D012307,NA,0,110,risk score,10,000000100,Risk Factors,NA
2071,20925534,3,no statin,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,110,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
2072,20925534,3,No Statin Use,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,110,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
2073,20925534,3,nsaid used,Anti-Inflammatory Agents,D000893,NA,0,110,any,2,000000000,Anti-Inflammatory Agents,NA
2074,20925534,3,Other Risk Factors,Risk Factors,D012307,NA,0,110,risk score,10,000000100,Risk Factors,NA
2075,20925534,3,other risk factros,Risk Factors,D012307,NA,0,110,risk score,10,000000100,Risk Factors,NA
2076,20937671,2,seropositive (rf +ve and/or acpa +ve) subgroup,Rheumatoid Factor,D012217,NA,0,90,any,2,000000000,Rheumatoid Factor,NA
2077,20953684,2,;non-diabetic,Diabetes Mellitus,D003920,NA,0,1676,any,2,000000000,Diabetes Mellitus,NA
2078,20953684,2,diabetes,Diabetes Mellitus,D003920,NA,0,1676,any,2,000000000,Diabetes Mellitus,NA
2079,20979470,2,;poor,Metabolism,D008660,NA,0,970,any,2,000000000,Metabolism,NA
2080,20979470,2,metabolizer phenotype,Phenotype,D010641,NA,0,970,type,12,000000010,Phenotype,NA
2081,20979470,3,;poor,Metabolism,D008660,NA,0,219,any,2,000000000,Metabolism,NA
2082,20979470,3,metabolizer phenotype,Phenotype,D010641,NA,0,219,type,12,000000010,Phenotype,NA
2083,21045096,NA,Apolipoprotein E carrier,Apolipoprotein A-I,D016632,NA,0,0,any,2,000000000,Apolipoprotein A-I,NA
2084,21045096,NA,Cholinesterase inhibitor use,Mental Status and Dementia Tests,D000073216,V03AB29,0,0,any,2,000000000,Mental Status and Dementia Tests,NA
2085,21045096,NA,Clinical dementia rating score,Mental Status and Dementia Tests,D000073216,NA,0,0,any,2,000000000,Mental Status and Dementia Tests,NA
2086,21060071,2,;non-diabetic,Diabetes Mellitus,D003920,NA,0,1219,any,2,000000000,Diabetes Mellitus,NA
2087,21060071,2,diabetes,Diabetes Mellitus,D003920,NA,0,1219,any,2,000000000,Diabetes Mellitus,NA
2088,21109344,NA,nocturia at baseline,Nocturia,D053158,NA,0,0,any,2,000000000,Nocturia,10
2089,21118495,NA,triglycerides,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,158
2090,21174145,2,hyperlipidaemia,Hypercholesterolemia,D006937,NA,0,1805,any,2,000000000,Hypercholesterolemia,NA
2091,21174145,2,T2DM,Diabetes Mellitus,D003920,NA,0,1805,any,2,000000000,Diabetes Mellitus,NA
2092,21174145,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,266
2093,21209123,2,aminosalicylates,intestinal antiinflammatory agents,NA,A07E,0,347,any,2,000000000,intestinal antiinflammatory agents,NA
2094,21209123,2,extensive colitis,Colitis,D003092,NA,0,347,severity,11,000100000,Colitis,NA
2095,21209123,2,imm + corticosteroid,Steroids,D013256,NA,0,347,any,2,000000000,Steroids,NA
2096,21209123,2,immÂ (without corticosteroid),Immunotherapy,D007167,NA,0,347,any,2,000000000,Immunotherapy,NA
2097,21209123,2,mayo>=10,"Colitis, Ulcerative",D003093,NA,0,347,severity,11,000100000,"Colitis, Ulcerative",NA
2098,21209123,2,no aminosalicylates,Anti-Bacterial Agents,D000900,NA,0,347,any,2,000000000,Anti-Bacterial Agents,NA
2099,21209123,2,no corticosteroid + no imm,Steroids,D013256,NA,0,347,any,2,000000000,Steroids,NA
2100,21209123,2,no extensive colitis,Colitis,D003092,NA,0,347,severity,11,000100000,Colitis,NA
2101,21209123,2,weight < 70.0 kg,Body Weight,D001835,NA,0,347,any,2,000000000,Body Weight,NA
2102,21209123,2,"weight >=70.0 kg, <82.0 kg",Body Weight,D001835,NA,0,347,any,2,000000000,Body Weight,NA
2103,21209123,2,weight >=82.0 kg,Body Weight,D001835,NA,0,347,any,2,000000000,Body Weight,NA
2104,21209123,2,y C-reactive protein;,C-Reactive Protein,D002097,NA,0,347,any,2,000000000,C-Reactive Protein,NA
2105,21216833,2,baseline Coenzyme Q10 Concentration;tertile 1,Osteoprotegerin,D053244,NA,0,NA,any,2,000000000,Osteoprotegerin,NA
2106,21216833,2,baseline Coenzyme Q10 Concentration;tertile 2,Osteoprotegerin,D053244,NA,0,NA,any,2,000000000,Osteoprotegerin,NA
2107,21216833,2,baseline Coenzyme Q10 Concentration;tertile 3,Osteoprotegerin,D053244,NA,0,NA,any,2,000000000,Osteoprotegerin,NA
2108,21224838,NA,Nocturnal heartburn severity,Heartburn,D006356,NA,0,0,severity,11,000100000,Heartburn,NA
2109,21227674,2,presence of cardiovascular risk factors,Heart Disease Risk Factors,D000082742,NA,0,1052,risk score,10,000000100,Heart Disease Risk Factors,NA
2110,21235696,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,268
2111,21235696,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,269
2112,21235696,NA,diabetes duration,Diabetes Mellitus,D003920,NA,0,0,duration,5,001000000,Diabetes Mellitus,269
2113,21235696,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,269
2114,21235696,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,269
2115,21315217,NA,implantable cardioverter-defibrillator,"Defibrillators, Implantable",D017147,NA,0,0,any,2,000000000,"Defibrillators, Implantable",69
2116,21320109,NA,Antiepileptic drug type at baseline,Anticonvulsants,D000927,NA,0,0,type,12,000000010,Anticonvulsants,NA
2117,21332627,2,;esrd,Renal Insufficiency,D051437,NA,0,114,severity,11,000100000,Renal Insufficiency,NA
2118,21332627,2,;moderate renal impairment,Renal Insufficiency,D051437,NA,0,114,severity,11,000100000,Renal Insufficiency,NA
2119,21332627,2,;severe renal impairment,Renal Insufficiency,D051437,NA,0,114,severity,11,000100000,Renal Insufficiency,NA
2120,21332627,3,;esrd,Renal Insufficiency,D051437,NA,0,1112,severity,11,000100000,Renal Insufficiency,NA
2121,21332627,3,;moderate renal impairment,Renal Insufficiency,D051437,NA,0,1112,severity,11,000100000,Renal Insufficiency,NA
2122,21332627,3,;severe renal impairment,Renal Insufficiency,D051437,NA,0,1112,severity,11,000100000,Renal Insufficiency,NA
2123,21332630,2,"age, years",Age Factors,D000367,NA,0,490,any,2,000000000,Age Factors,NA
2124,21332630,2,"bmi, kg/mâ€™",Body Mass Index,D015992,NA,0,490,any,2,000000000,Body Mass Index,NA
2125,21332630,2,ipss,Prostatism,D053448,NA,0,490,severity,11,000100000,Prostatism,NA
2126,21332630,2,ipss hrql,Prostatism,D053448,NA,0,490,severity,11,000100000,Prostatism,NA
2127,21332630,2,previous treatment?,drugs used in benign prostatic hypertrophy,NA,G04C,0,490,previous,8,100000000,drugs used in benign prostatic hypertrophy,NA
2128,21332630,2,"psa level, ng/ml",Prostate-Specific Antigen,D017430,NA,0,490,any,2,000000000,Prostate-Specific Antigen,NA
2129,21332630,2,qmaxi rn l/s,Urodynamics,D014563,NA,0,490,any,2,000000000,Urodynamics,NA
2130,21332630,2,race,Racial Groups,D044469,NA,0,490,any,2,000000000,Racial Groups,NA
2131,21332630,2,race;non-white,Racial Groups,D044469,NA,0,490,any,2,000000000,Racial Groups,NA
2132,21388309,NA,Diastolic blood pressure,Blood Pressure,D001794,NA,0,0,any,2,000000000,Blood Pressure,NA
2133,21388309,NA,Estimated glomerular filtration rate,Renal Insufficiency,D051437,NA,0,0,any,2,000000000,Renal Insufficiency,NA
2134,21388309,NA,Glycated hemoglobin,Glycated Hemoglobin A,D006442,NA,0,0,any,2,000000000,Glycated Hemoglobin A,NA
2135,21388309,NA,Systolic blood pressure,Blood Pressure,D001794,NA,0,0,any,2,000000000,Blood Pressure,NA
2136,21388309,NA,Urine albumin-to-creatinine ratio,Albuminuria,D000419,NA,0,0,any,2,000000000,Albuminuria,NA
2137,21410627,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,251
2138,21410627,NA,baseline homeostasis model assessment of insulin resistance,Insulin Resistance,D007333,NA,0,0,any,2,000000000,Insulin Resistance,NA
2139,21410627,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,NA
2140,21410627,NA,baseline HOMA-ß,Insulin Resistance,D007333,NA,0,0,any,2,000000000,Insulin Resistance,NA
2141,21410627,NA,diabetes duration,Diabetes Mellitus,D003920,NA,0,0,duration,5,001000000,Diabetes Mellitus,NA
2142,21410627,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
2143,21410627,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
2144,21411557,NA,"For new vertebral fractures the higher-risk subgroups included women with the following: 1) two or more preexisting vertebral fractures of any degree of deformity, or one or more vertebral fracture of moderate or severe deformity, or both (prevalent vertebral fracture status); 2) a femoral neck BMD T-score of 2.5 or less; or 3) both multiple and/or moderate or severe vertebral deformities and a femoral neck BMD T-score of 2.5 or less. For hip fractures the higher-risk subgroups included women: 1) 75 yr old or older; 2) with a femoral neck BMD T-score of 2.5 or less; or 3) 75 yr old or older and with a femoral neck BMD T-score of 2.5 or less. Women who did not have the risk factor(s) specified were included in the lower-risk subgroups.",unclassifiable,NA,NA,0,0,severity,11,000100100,unclassifiable,NA
2145,21428765,2,age,Age Factors,D000367,NA,0,1191,any,2,000000000,Age Factors,NA
2146,21428765,2,BMI,Body Mass Index,D015992,NA,0,1191,any,2,000000000,Body Mass Index,NA
2147,21428765,2,copd severity stage (gold),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1191,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
2148,21428765,2,copd severity stage (gold);stage iv,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1191,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
2149,21428765,2,male female,Gender Identity,D005783,NA,0,1191,any,2,000000000,Gender Identity,NA
2150,21428765,2,Smoker,Cigarette Smoking,D000073865,NA,0,1191,any,2,000000000,Cigarette Smoking,NA
2151,21428765,2,stages of COPD,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1191,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
2152,21428765,2,use of inhaled glucocorticoids at baseline,Adrenergic beta-2 Receptor Agonists,D058666,NA,0,1191,any,2,000000000,Adrenergic beta-2 Receptor Agonists,NA
2153,21428766,2,age,Age Factors,D000367,NA,0,800,any,2,000000000,Age Factors,NA
2154,21428766,2,BMI,Body Mass Index,D015992,NA,0,800,any,2,000000000,Body Mass Index,NA
2155,21428766,2,fasting plasma glucose,Glucose,D005947,NA,0,800,any,2,000000000,Glucose,NA
2156,21428766,2,glucose test,Glucose Tolerance Test,D005951,NA,0,800,any,2,000000000,Glucose Tolerance Test,NA
2157,21428766,2,glucose test;ifg and igt,Glucose Intolerance,D018149,NA,0,800,any,2,000000000,Glucose Intolerance,NA
2158,21428766,2,race,Racial Groups,D044469,NA,0,800,any,2,000000000,Racial Groups,NA
2159,21428766,2,race or ethnic group,Racial Groups,D044469,NA,0,800,any,2,000000000,Racial Groups,NA
2160,21428766,2,race or ethnic group;white,Racial Groups,D044469,NA,0,800,any,2,000000000,Racial Groups,NA
2161,21428766,2,sex,Gender Identity,D005783,NA,0,800,any,2,000000000,Gender Identity,NA
2162,21428766,2,sex;female,Gender Identity,D005783,NA,0,800,any,2,000000000,Gender Identity,NA
2163,21428766,2,sex;male,Gender Identity,D005783,NA,0,800,any,2,000000000,Gender Identity,NA
2164,21428766,2,waist circumference,Waist Circumference,D055105,NA,0,800,any,2,000000000,Waist Circumference,NA
2165,21464051,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
2166,21464051,NA,angina,Angina Pectoris,D000787,NA,0,0,any,2,000000000,Angina Pectoris,225
2167,21464051,NA,crp,C-Reactive Protein,D002097,NA,0,0,any,2,000000000,C-Reactive Protein,NA
2168,21464051,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
2169,21464051,NA,glycoprotein IIb/IIIa inhibitors,complex,NA,NA,0,0,any,2,000000000,complex,NA
2170,21464051,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
2171,21464051,NA,single-vessel versus multivessel intervention,Coronary Artery Disease,D003324,NA,0,0,any,2,000000000,Coronary Artery Disease,NA
2172,21474646,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,224
2173,21474646,NA,dl,complex,NA,NA,0,0,any,2,000000000,complex,NA
2174,21474646,NA,fvc,Vital Capacity,D014797,NA,0,0,any,2,000000000,Vital Capacity,NA
2175,21474646,NA,region,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,NA
2176,21474646,NA,smoke history,Cigarette Smoking,D000073865,NA,0,0,previous,8,100000000,Cigarette Smoking,NA
2177,21491487,NA,CKD,Kidney Diseases,D007674,NA,0,0,any,2,000000000,Kidney Diseases,NA
2178,21502549,2,;hormone-refractory prostate carcinoma,Neoplasms,D009369,NA,0,1472,location,7,000000001,Neoplasms,NA
2179,21502549,2,;pancreatic cancer,Neoplasms,D009369,NA,0,1472,location,7,000000001,Neoplasms,NA
2180,21502969,NA,Patient Variable: Ethnicity,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,240
2181,21509444,NA,HbA1c,Glycated Hemoglobin A,D006442,NA,0,0,any,2,000000000,Glycated Hemoglobin A,208
2182,21542001,NA,Back pain,Pain,D010146,NA,0,0,any,2,000000000,Pain,NA
2183,21542001,NA,vertebral fracture,"Fractures, Bone",D050723,NA,0,0,any,2,000000000,"Fractures, Bone",NA
2184,21586508,2,dose of ICS,Steroids,D013256,NA,0,936,any,2,000000000,Steroids,NA
2185,21596364,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,222
2186,21596364,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
2187,21596364,NA,ldl,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,NA
2188,21596364,NA,metabolic syndrome,Metabolic Syndrome,D024821,NA,0,0,any,2,000000000,Metabolic Syndrome,NA
2189,21596364,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
2190,21596364,NA,risk of atherosclerotic vascular disease,Atherosclerosis,D050197,NA,0,0,risk score,10,000000100,Atherosclerosis,NA
2191,21596364,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
2192,21596364,NA,triglyceride,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,NA
2193,21607551,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,243
2194,21627828,2,region,Geographic Locations,D005842,NA,0,1226,any,2,000000000,Geographic Locations,NA
2195,21642014,3,country,Geographic Locations,D005842,NA,0,1857,any,2,000000000,Geographic Locations,NA
2196,21642014,3,country;australia,Geographic Locations,D005842,NA,0,1857,any,2,000000000,Geographic Locations,NA
2197,21642014,3,country;austria,Geographic Locations,D005842,NA,0,1857,any,2,000000000,Geographic Locations,NA
2198,21642014,3,country;belgium,Geographic Locations,D005842,NA,0,1857,any,2,000000000,Geographic Locations,NA
2199,21642014,3,country;brazil,Geographic Locations,D005842,NA,0,1857,any,2,000000000,Geographic Locations,NA
2200,21642014,3,country;canada,Geographic Locations,D005842,NA,0,1857,any,2,000000000,Geographic Locations,NA
2201,21642014,3,country;czech republic,Geographic Locations,D005842,NA,0,1857,any,2,000000000,Geographic Locations,NA
2202,21642014,3,country;estonia,Geographic Locations,D005842,NA,0,1857,any,2,000000000,Geographic Locations,NA
2203,21642014,3,country;germany,Geographic Locations,D005842,NA,0,1857,any,2,000000000,Geographic Locations,NA
2204,21642014,3,country;hungary,Geographic Locations,D005842,NA,0,1857,any,2,000000000,Geographic Locations,NA
2205,21642014,3,country;israel,Geographic Locations,D005842,NA,0,1857,any,2,000000000,Geographic Locations,NA
2206,21642014,3,country;italy,Geographic Locations,D005842,NA,0,1857,any,2,000000000,Geographic Locations,NA
2207,21642014,3,country;latvia,Geographic Locations,D005842,NA,0,1857,any,2,000000000,Geographic Locations,NA
2208,21642014,3,country;new zealand,Geographic Locations,D005842,NA,0,1857,any,2,000000000,Geographic Locations,NA
2209,21642014,3,country;poland,Geographic Locations,D005842,NA,0,1857,any,2,000000000,Geographic Locations,NA
2210,21642014,3,country;romania,Geographic Locations,D005842,NA,0,1857,any,2,000000000,Geographic Locations,NA
2211,21642014,3,country;russia,Geographic Locations,D005842,NA,0,1857,any,2,000000000,Geographic Locations,NA
2212,21642014,3,country;ukraine,Geographic Locations,D005842,NA,0,1857,any,2,000000000,Geographic Locations,NA
2213,21642014,3,country;united states,Geographic Locations,D005842,NA,0,1857,any,2,000000000,Geographic Locations,NA
2214,21642014,3,geographic region,Geographic Locations,D005842,NA,0,1857,any,2,000000000,Geographic Locations,NA
2215,21642014,3,geographic region;europe (zone 1),Geographic Locations,D005842,NA,0,1857,any,2,000000000,Geographic Locations,NA
2216,21642014,3,geographic region;europe (zone 2),Geographic Locations,D005842,NA,0,1857,any,2,000000000,Geographic Locations,NA
2217,21642014,3,geographic region;north america,Geographic Locations,D005842,NA,0,1857,any,2,000000000,Geographic Locations,NA
2218,21642014,3,geographic region;rest of world,Geographic Locations,D005842,NA,0,1857,any,2,000000000,Geographic Locations,NA
2219,21642014,NA,Age-Years,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
2220,21642014,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,NA
2221,21642014,NA,CDAI score,"Arthritis, Rheumatoid",D001172,NA,0,0,any,2,000000000,"Arthritis, Rheumatoid",NA
2222,21642014,NA,crp,C-Reactive Protein,D002097,NA,0,0,any,2,000000000,C-Reactive Protein,NA
2223,21642014,NA,disease duration,Crohn Disease,D003424,NA,0,0,duration,5,001000000,Crohn Disease,NA
2224,21642014,NA,disease location,Crohn Disease,D003424,NA,0,0,location,7,000000001,Crohn Disease,NA
2225,21642014,NA,previous corticosteroid use,Steroids,D013256,NA,0,0,previous,8,100000000,Steroids,NA
2226,21642014,NA,previous immunosupressant or corticosteroid use,complex,NA,NA,0,0,previous,8,100000000,complex,NA
2227,21642014,NA,previous immunosupressant use,Immunosuppressive Agents,D007166,NA,0,0,previous,8,100000000,Immunosuppressive Agents,NA
2228,21642014,NA,prior surgery,"Surgical Procedures, Operative",D013514,NA,0,0,previous,8,100000000,"Surgical Procedures, Operative",NA
2229,21642014,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
2230,21642014,NA,region,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,NA
2231,21642014,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
2232,21642014,NA,smoking,Cigarette Smoking,D000073865,NA,0,0,any,2,000000000,Cigarette Smoking,NA
2233,21645018,2,remission by: baseline duration of steroid,Steroids,D013256,NA,0,297,duration,5,001000000,Steroids,NA
2234,21645018,2,remission by: baseline steroid doses,Steroids,D013256,NA,0,297,any,2,000000000,Steroids,NA
2235,21673005,2,;migraine with aura,Migraine Disorders,D008881,NA,0,915,any,2,000000000,Migraine Disorders,NA
2236,21673005,2,;migraine without aura,Migraine Disorders,D008881,NA,0,915,any,2,000000000,Migraine Disorders,NA
2237,21673005,2,;no history of migraine,Neoplasms,D009369,NA,0,915,previous,8,100000000,Neoplasms,NA
2238,21673005,2,;prior migraine,Migraine Disorders,D008881,NA,0,915,previous,8,100000000,Migraine Disorders,NA
2239,21680990,NA,Patient Variable: Ethnicity,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,252
2240,21682834,2,;postmenopausal,Menopause,D008593,NA,0,639,any,2,000000000,Menopause,NA
2241,21682834,2,male female,Gender Identity,D005783,NA,0,639,any,2,000000000,Gender Identity,NA
2242,21682834,2,Menopausal status,Menopause,D008593,NA,0,639,any,2,000000000,Menopause,NA
2243,21732835,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
2244,21732835,NA,cad,Coronary Artery Disease,D003324,NA,0,0,any,2,000000000,Coronary Artery Disease,NA
2245,21732835,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
2246,21732835,NA,Diuretic at randomization,Diuretics,D004232,NA,0,0,any,2,000000000,Diuretics,NA
2247,21732835,NA,egfr,Renal Insufficiency,D051437,NA,0,0,any,2,000000000,Renal Insufficiency,NA
2248,21732835,NA,Inotrope at randomization,unclassifiable,NA,NA,0,0,any,2,000000000,unclassifiable,NA
2249,21732835,NA,lvef,Stroke Volume,D013318,NA,0,0,any,2,000000000,Stroke Volume,NA
2250,21732835,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
2251,21732835,NA,region,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,NA
2252,21732835,NA,sbp,Blood Pressure,D001794,NA,0,0,any,2,000000000,Blood Pressure,NA
2253,21732835,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
2254,21732835,NA,Study-drug bolus,unclassifiable,NA,NA,0,0,any,2,000000000,unclassifiable,NA
2255,21732835,NA,Vasodilator at randomization,Vasodilator Agents,D014665,NA,0,0,any,2,000000000,Vasodilator Agents,NA
2256,21777884,NA,Diabetes Mellitus,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
2257,21777884,NA,diabetes type,Diabetes Mellitus,D003920,NA,0,0,type,12,000000010,Diabetes Mellitus,NA
2258,21777884,NA,diabetic,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
2259,21777884,NA,"insulin treatted diabets, non insulin treated diabetes.",Insulin,D007328,NA,0,0,any,2,000000000,Insulin,NA
2260,21780946,2,;antiplatelet therapy dual,Platelet Aggregation Inhibitors,D010975,NA,0,128,any,2,000000000,Platelet Aggregation Inhibitors,NA
2261,21780946,2,acs treatment,Acute Coronary Syndrome,D054058,NA,0,128,any,2,000000000,Acute Coronary Syndrome,NA
2262,21780946,2,acs treatment;cabg,Coronary Artery Bypass,D001026,NA,0,128,any,2,000000000,Coronary Artery Bypass,NA
2263,21780946,2,acs treatment;pci,Percutaneous Coronary Intervention,D062645,NA,0,128,any,2,000000000,Percutaneous Coronary Intervention,NA
2264,21780946,2,acs type,Acute Coronary Syndrome,D054058,NA,0,128,type,12,000000010,Acute Coronary Syndrome,NA
2265,21780946,2,acs type;non-stemi,Myocardial Infarction,D009203,NA,0,128,type,12,000000010,Myocardial Infarction,NA
2266,21780946,2,acs type;stemi,Myocardial Infarction,D009203,NA,0,128,type,12,000000010,Myocardial Infarction,NA
2267,21780946,2,age;<65,Age Factors,D000367,NA,0,128,any,2,000000000,Age Factors,NA
2268,21780946,2,apixaban dose (or matching placebo);2.5 mg bid,apixaban,C522181,NA,0,128,any,2,000000000,apixaban,NA
2269,21780946,2,apixaban dose (or matching placebo);5 mg bid,apixaban,C522181,NA,0,128,any,2,000000000,apixaban,NA
2270,21780946,2,bmi,Body Mass Index,D015992,NA,0,128,any,2,000000000,Body Mass Index,NA
2271,21780946,2,diabetes mellitus,Diabetes Mellitus,D003920,NA,0,128,any,2,000000000,Diabetes Mellitus,NA
2272,21780946,2,geographic region,Geographic Locations,D005842,NA,0,128,any,2,000000000,Geographic Locations,NA
2273,21780946,2,heart failure,Heart Failure,D006333,NA,0,128,any,2,000000000,Heart Failure,NA
2274,21780946,2,history of stroke,Stroke,D020521,NA,0,128,previous,8,100000000,Stroke,NA
2275,21780946,2,level of renal impairment,Renal Insufficiency,D051437,NA,0,128,severity,11,000100000,Renal Insufficiency,NA
2276,21780946,2,level of renal impairment;mild,Renal Insufficiency,D051437,NA,0,128,severity,11,000100000,Renal Insufficiency,NA
2277,21780946,2,level of renal impairment;severe or moderate,Renal Insufficiency,D051437,NA,0,128,severity,11,000100000,Renal Insufficiency,NA
2278,21780946,2,race,Racial Groups,D044469,NA,0,128,any,2,000000000,Racial Groups,NA
2279,21780946,2,sex,Gender Identity,D005783,NA,0,128,any,2,000000000,Gender Identity,NA
2280,21781152,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,54
2281,21815708,1,age,Age Factors,D000367,NA,0,1167,any,2,000000000,Age Factors,NA
2282,21815708,1,male female,Gender Identity,D005783,NA,0,1167,any,2,000000000,Gender Identity,NA
2283,21815708,2,age,Age Factors,D000367,NA,0,1835,any,2,000000000,Age Factors,NA
2284,21815708,2,male female,Gender Identity,D005783,NA,0,1835,any,2,000000000,Gender Identity,NA
2285,21816478,2,atorvastatin users,Atorvastatin,D000069059,NA,0,945,any,2,000000000,Atorvastatin,NA
2286,21816478,2,coronary heart disease,Coronary Artery Disease,D003324,NA,0,945,any,2,000000000,Coronary Artery Disease,NA
2287,21816478,2,diabetes mellitus,Diabetes Mellitus,D003920,NA,0,945,any,2,000000000,Diabetes Mellitus,NA
2288,21871706,2,baseline ed severity**:,Erectile Dysfunction,D007172,NA,0,735,severity,11,000100000,Erectile Dysfunction,NA
2289,21871706,2,baseline ed severity**:;mild (n1 = 83)1,Erectile Dysfunction,D007172,NA,0,735,severity,11,000100000,Erectile Dysfunction,NA
2290,21871706,2,baseline ed severity**:;moderate (n1 = 36),Erectile Dysfunction,D007172,NA,0,735,severity,11,000100000,Erectile Dysfunction,NA
2291,21871706,2,baseline ed severity**:;severe (n1 = 56),Erectile Dysfunction,D007172,NA,0,735,severity,11,000100000,Erectile Dysfunction,NA
2292,21871706,2,baseline luts severity*:,Lower Urinary Tract Symptoms,D059411,NA,0,735,severity,11,000100000,Lower Urinary Tract Symptoms,NA
2293,21871706,2,baseline luts severity*:;moderate (n1 = 187),Lower Urinary Tract Symptoms,D059411,NA,0,735,severity,11,000100000,Lower Urinary Tract Symptoms,NA
2294,21871706,2,baseline luts severity*:;severe (n1 = 115),Lower Urinary Tract Symptoms,D059411,NA,0,735,severity,11,000100000,Lower Urinary Tract Symptoms,NA
2295,21883438,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,227
2296,21925996,3,Mean sitting diastolic blood pressure,Blood Pressure,D001794,NA,0,1619,any,2,000000000,Blood Pressure,NA
2297,21925996,3,Mean sitting systolic blood pressure,Blood Pressure,D001794,NA,0,1619,any,2,000000000,Blood Pressure,NA
2298,21925996,4,"nonobese (body mass index [BMI] <30 kg/m"")",Body Mass Index,D015992,NA,0,1460,severity,11,000100000,Body Mass Index,NA
2299,21925996,4,obese (BMI >30 kg/nr),Body Mass Index,D015992,NA,0,1460,severity,11,000100000,Body Mass Index,NA
2300,21925996,4,With Metabolic syndrome (MetS),Metabolic Syndrome,D024821,NA,0,1460,any,2,000000000,Metabolic Syndrome,NA
2301,21925996,4,Without Metabolic syndrome,Metabolic Syndrome,D024821,NA,0,1460,any,2,000000000,Metabolic Syndrome,NA
2302,21939839,NA,Medical History: Week 8 Mayo Endoscopy Subscore,Collateral Circulation,D003097,NA,0,0,previous severity,9,100100000,Collateral Circulation,169
2303,21974759,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,95
2304,21974760,NA,24-hour ambulatory blood pressure monitoring (ABPM),Blood Pressure,D001794,NA,0,0,any,2,000000000,Blood Pressure,144
2305,21976367,NA,Age (years),Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
2306,21976367,NA,Body mass index (kg/m2),Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,NA
2307,21976367,NA,Estimated creatinine clearance (mL/min),Glomerular Filtration Rate,D005919,NA,0,0,any,2,000000000,Glomerular Filtration Rate,NA
2308,21976367,NA,Femoral neck BMD T-score,Osteoporosis,D010024,NA,0,0,any,2,000000000,Osteoporosis,NA
2309,21976367,NA,Prevalent vertebral fracture,"Fractures, Bone",D050723,NA,0,0,any,2,000000000,"Fractures, Bone",NA
2310,21976367,NA,Prior nonvertebral fracture,"Fractures, Bone",D050723,NA,0,0,previous,8,100000000,"Fractures, Bone",NA
2311,21976367,NA,Prior use of osteoporosis medications,Osteoporosis,D010024,NA,0,0,previous,8,100000000,Osteoporosis,NA
2312,21976367,NA,Race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
2313,21976367,NA,Region,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,NA
2314,22052584,2,;mild impairment (60 to <90 ml/minute),Glomerular Filtration Rate,D005919,NA,0,908,severity,11,000100000,Glomerular Filtration Rate,NA
2315,22052584,2,;moderate or severe impairmentÂ (<60 ml/minute),Glomerular Filtration Rate,D005919,NA,0,908,severity,11,000100000,Glomerular Filtration Rate,NA
2316,22052584,2,;normal (90 ml/minute),Glomerular Filtration Rate,D005919,NA,0,908,severity,11,000100000,Glomerular Filtration Rate,NA
2317,22052584,2,Baseline renal function,Glomerular Filtration Rate,D005919,NA,0,908,any,2,000000000,Glomerular Filtration Rate,NA
2318,22077816,NA,Age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
2319,22077816,NA,Aspirin dose,Aspirin,D001241,NA,0,0,any,2,000000000,Aspirin,NA
2320,22077816,NA,CABG,Coronary Artery Bypass,D001026,NA,0,0,previous,8,100000000,Coronary Artery Bypass,NA
2321,22077816,NA,Current tobacco use,Cigarette Smoking,D000073865,NA,0,0,previous,8,110000000,Cigarette Smoking,NA
2322,22077816,NA,Diabetes,Diabetes Mellitus,D003920,NA,0,0,previous,8,100000000,Diabetes Mellitus,NA
2323,22077816,NA,Hyperlipidemia,Hypercholesterolemia,D006937,NA,0,0,previous,8,100000000,Hypercholesterolemia,NA
2324,22077816,NA,Hypertension,Hypertension,D006973,NA,0,0,previous,8,100000000,Hypertension,NA
2325,22077816,NA,Intent to use DTI,unclassifiable,NA,NA,0,0,any,2,000000000,unclassifiable,NA
2326,22077816,NA,Intent to use GP IIb/IIIa,Glycoproteins,D006023,NA,0,0,any,2,000000000,Glycoproteins,NA
2327,22077816,NA,MI medical history,Myocardial Infarction,D009203,NA,0,0,previous,8,100000000,Myocardial Infarction,NA
2328,22077816,NA,PCI,Percutaneous Coronary Intervention,D062645,NA,0,0,previous,8,100000000,Percutaneous Coronary Intervention,NA
2329,22077816,NA,Peripheral artery disease,Peripheral Vascular Diseases,D016491,NA,0,0,previous,8,100000000,Peripheral Vascular Diseases,NA
2330,22077816,NA,Race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
2331,22077816,NA,Region,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,NA
2332,22077816,NA,Renal function (ml/min),Renal Insufficiency,D051437,NA,0,0,any,2,000000000,Renal Insufficiency,NA
2333,22077816,NA,Sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
2334,22077816,NA,ST-segment depression,ST Elevation Myocardial Infarction,D000072657,NA,0,0,any,2,000000000,ST Elevation Myocardial Infarction,NA
2335,22077816,NA,Stroke,Stroke,D020521,NA,0,0,any,2,000000000,Stroke,NA
2336,22077816,NA,Thienopyridine use,Thienopyridines,D058924,NA,0,0,any,2,000000000,Thienopyridines,NA
2337,22077816,NA,TIMI score,Thrombosis,D013927,NA,1,0,any,2,000000000,Thrombosis,NA
2338,22077816,NA,Troponin or CKMB value,Troponin,D014336,NA,0,0,any,2,000000000,Troponin,NA
2339,22077816,NA,Weight,Body Weight,D001835,NA,0,0,any,2,000000000,Body Weight,NA
2340,22081481,NA,region,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,121
2341,22085343,1,ace inhibitor or arb,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,1639,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
2342,22085343,1,age,Age Factors,D000367,NA,0,1639,any,2,000000000,Age Factors,NA
2343,22085343,1,aspirin or other antiplatelet or anticoagulant agent,Platelet Aggregation Inhibitors,D010975,NA,0,1639,any,2,000000000,Platelet Aggregation Inhibitors,NA
2344,22085343,1,beta-blocker,Adrenergic beta-Antagonists,D000319,NA,0,1639,any,2,000000000,Adrenergic beta-Antagonists,NA
2345,22085343,1,cabg,Coronary Artery Bypass,D001026,NA,0,1639,previous,8,100000000,Coronary Artery Bypass,NA
2346,22085343,1,duration of prior statin therapy^,Simvastatin,D019821,NA,0,1639,previous,8,101000000,Simvastatin,NA
2347,22085343,1,glucose â€” mg/dl,Glucose,D005947,NA,0,1639,any,2,000000000,Glucose,NA
2348,22085343,1,glycated hemoglobin â€” %,Glycated Hemoglobin A,D006442,NA,0,1639,any,2,000000000,Glycated Hemoglobin A,NA
2349,22085343,1,history of diabetes,Diabetes Mellitus,D003920,NA,0,1639,previous,8,100000000,Diabetes Mellitus,NA
2350,22085343,1,history of hypertension,Hypertension,D006973,NA,0,1639,previous,8,100000000,Hypertension,NA
2351,22085343,1,history of myocardial infarction,Myocardial Infarction,D009203,NA,0,1639,previous,8,100010000,Myocardial Infarction,NA
2352,22085343,1,insulin â€” /tu/ml,Insulin,D007328,NA,0,1639,any,2,000000000,Insulin,NA
2353,22085343,1,laboratory values in patients with history of diabetes,Diabetes Mellitus,D003920,NA,0,1639,previous,8,100000000,Diabetes Mellitus,NA
2354,22085343,1,metabolic syndrome,Metabolic Syndrome,D024821,NA,0,1639,any,2,000000000,Metabolic Syndrome,NA
2355,22085343,1,pci,Percutaneous Coronary Intervention,D062645,NA,0,1639,severity,11,000100000,Percutaneous Coronary Intervention,NA
2356,22085343,1,peripheral vascular disease,Peripheral Vascular Diseases,D016491,NA,0,1639,any,2,000000000,Peripheral Vascular Diseases,NA
2357,22085343,1,presenting history or diagnosis â€” no. (%),Peripheral Vascular Diseases,D016491,NA,0,1639,previous,8,100000000,Peripheral Vascular Diseases,NA
2358,22085343,1,previous use of niacin or niaspanÂ§,Niacin,D009525,NA,0,1639,previous,8,100000000,Niacin,NA
2359,22085343,1,race,Racial Groups,D044469,NA,0,1639,any,2,000000000,Racial Groups,NA
2360,22085343,1,sex â€” no. (%),Gender Identity,D005783,NA,0,1639,any,2,000000000,Gender Identity,NA
2361,22085343,1,statin,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,1639,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
2362,22085343,1,stroke or cerebrovascular disease,Stroke,D020521,NA,0,1639,any,2,000000000,Stroke,NA
2363,22087680,NA,induction group,Cyclophosphamide,D003520,NA,0,0,any,2,000000000,Cyclophosphamide,NA
2364,22087680,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
2365,22087680,NA,region,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,NA
2366,22087680,NA,REGION,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,NA
2367,22087680,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
2368,22087680,NA,Subgroups induction treatment [cyclophosphamide versus mycophenolate mofetil],unclassifiable,NA,NA,0,0,any,2,000000000,unclassifiable,NA
2369,22142350,NA,"(1) baseline number of migraine attacks per month; (2) number of sumatriptan/naproxen sodium doses per migraine attack; (3) number of sumatriptan/naproxen sodium doses per month; and (4) total number of sumatriptan/naproxen sodium doses. For the primary BP end points, a separate MMRM analysis with corresponding 95% CIs was computed within each of the subgroups within the subpopulations defined by each of the 4 criteria above.",Migraine Disorders,D008881,NA,0,0,any,2,000000000,Migraine Disorders,263
2370,22142350,NA,number of sumatriptan ? naproxen sodium doses per migraine,sumatriptan,NA,N02CC01,0,0,any,2,000000000,sumatriptan,114
2371,22177371,2,age,Age Factors,D000367,NA,0,1389,any,2,000000000,Age Factors,NA
2372,22177371,2,"albuterol reversibility, %",Bronchodilator Agents,D001993,NA,0,1389,type,12,000000010,Bronchodilator Agents,NA
2373,22177371,2,"bmi, kg/m2",Body Mass Index,D015992,NA,0,1389,any,2,000000000,Body Mass Index,NA
2374,22177371,2,copd severity (gold 20087),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1389,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
2375,22177371,2,sex,Gender Identity,D005783,NA,0,1389,any,2,000000000,Gender Identity,NA
2376,22177371,2,Smoker,Cigarette Smoking,D000073865,NA,0,1389,any,2,000000000,Cigarette Smoking,NA
2377,22177371,2,use of ics,Adrenergic beta-2 Receptor Agonists,D058666,NA,0,1389,any,2,000000000,Adrenergic beta-2 Receptor Agonists,NA
2378,22177371,2,waist-hip ratio,Waist-Hip Ratio,D049629,NA,0,1389,any,2,000000000,Waist-Hip Ratio,NA
2379,22234149,2,age (years)*,Age Factors,D000367,NA,0,1548,any,2,000000000,Age Factors,NA
2380,22234149,2,framingham 10-year cv risk score,Cardiovascular Diseases,D002318,NA,0,1548,severity,11,000100100,Cardiovascular Diseases,NA
2381,22234149,2,gender,Gender Identity,D005783,NA,0,1548,any,2,000000000,Gender Identity,NA
2382,22234149,2,investigator-reported hypoglycaemia*,Hypoglycemia,D007003,NA,0,1548,any,2,000000000,Hypoglycemia,NA
2383,22234149,2,race,Racial Groups,D044469,NA,0,1548,any,2,000000000,Racial Groups,NA
2384,22235820,2,male female,Gender Identity,D005783,NA,0,1080,any,2,000000000,Gender Identity,NA
2385,22235820,3,age,Age Factors,D000367,NA,0,659,any,2,000000000,Age Factors,NA
2386,22235820,3,diabetes,Diabetes Mellitus,D003920,NA,0,659,any,2,000000000,Diabetes Mellitus,NA
2387,22235820,3,male female,Gender Identity,D005783,NA,0,659,any,2,000000000,Gender Identity,NA
2388,22235820,3,race,Racial Groups,D044469,NA,0,659,any,2,000000000,Racial Groups,NA
2389,22248871,2,african american,Racial Groups,D044469,NA,0,627,any,2,000000000,Racial Groups,NA
2390,22248871,2,caucasian,Racial Groups,D044469,NA,0,627,any,2,000000000,Racial Groups,NA
2391,22259009,2,;change from baseline stage 3 ckd,Renal Insufficiency,D051437,NA,0,68,severity,11,000100000,Renal Insufficiency,NA
2392,22259009,2,;change from baseline stage 4 ckd,Renal Insufficiency,D051437,NA,0,68,severity,11,000100000,Renal Insufficiency,NA
2393,22297243,NA,previous a-blocker therapy,Adrenergic alpha-Antagonists,D000317,NA,0,0,previous,8,100000000,Adrenergic alpha-Antagonists,81
2394,22305835,2,;age < 75 years,Age Factors,D000367,NA,0,1187,any,2,000000000,Age Factors,NA
2395,22305835,2,;age >75 years,Age Factors,D000367,NA,0,1187,any,2,000000000,Age Factors,NA
2396,22305835,2,;diabetic (no),Diabetes Mellitus,D003920,NA,0,1187,any,2,000000000,Diabetes Mellitus,NA
2397,22305835,2,;diabetic (yes),Diabetes Mellitus,D003920,NA,0,1187,any,2,000000000,Diabetes Mellitus,NA
2398,22305835,2,;gfr <60,Glomerular Filtration Rate,D005919,NA,0,1187,any,2,000000000,Glomerular Filtration Rate,NA
2399,22305835,2,;gfr >60,Glomerular Filtration Rate,D005919,NA,0,1187,any,2,000000000,Glomerular Filtration Rate,NA
2400,22305835,2,;prior thienopyridine (-),Thienopyridines,D058924,NA,0,1187,previous,8,100000000,Thienopyridines,NA
2401,22305835,2,;prior thienopyridine (+),Thienopyridines,D058924,NA,0,1187,previous,8,100000000,Thienopyridines,NA
2402,22305835,2,;troponin (-),Troponin,D014336,NA,0,1187,any,2,000000000,Troponin,NA
2403,22305835,2,;troponin (+),Troponin,D014336,NA,0,1187,any,2,000000000,Troponin,NA
2404,22311004,NA,Low-renin (baseline PRA <0.65 ng/mL/h) and normal-high renin,agents acting on the renin-angiotensin system,NA,C09,0,0,any,2,000000000,agents acting on the renin-angiotensin system,155
2405,22335737,1,DVT location,Venous Thromboembolism,D054556,NA,0,317,location,7,000000001,Venous Thromboembolism,NA
2406,22335737,1,Outcome according to no. of risk factors for VTE,Venous Thromboembolism,D054556,NA,0,317,risk score,10,000000100,Venous Thromboembolism,NA
2407,22335737,1,Outcome according to primary cancer site no./total no. (%) Lung Pancreas Stomach Colon or rectum Bladder Ovary,Neoplasms,D009369,NA,0,317,location,7,000000001,Neoplasms,NA
2408,22335737,1,Outcome according to stage of cancer no./total no. (%) Metastatic  Locally advanced,Neoplasm Staging,D009367,NA,0,317,any,2,000000000,Neoplasm Staging,NA
2409,22335737,1,PE symptomatic vs incidental,Venous Thromboembolism,D054556,NA,0,317,type,12,000000010,Venous Thromboembolism,NA
2410,22337213,2,"Anti-dsDNA <30 lU/mL,>30 lU/mL",Autoantibodies,D001323,NA,0,29,any,2,000000000,Autoantibodies,NA
2411,22337213,2,Antimalarial use Yes No,Antimalarials,D000962,NA,0,29,any,2,000000000,Antimalarials,NA
2412,22337213,2,Immunosuppressive use	Yes No,Immunosuppressive Agents,D007166,NA,0,29,any,2,000000000,Immunosuppressive Agents,NA
2413,22337213,2,"Steroid dose <=7.5 mg/d,>7.5 mg/d",Steroids,D013256,NA,0,29,any,2,000000000,Steroids,NA
2414,22337213,2,Steroids yes No,Steroids,D013256,NA,0,29,any,2,000000000,Steroids,NA
2415,22354934,NA,baseline troponin elevation,Troponin,D014336,NA,0,0,any,2,000000000,Troponin,NA
2416,22354934,NA,resence orabsence of CKD,Kidney Diseases,D007674,NA,0,0,any,2,000000000,Kidney Diseases,NA
2417,22369287,2,age (years),Age Factors,D000367,NA,0,311,any,2,000000000,Age Factors,NA
2418,22369287,2,bmi at baseline (kg/m2 ),Body Mass Index,D015992,NA,0,311,any,2,000000000,Body Mass Index,NA
2419,22369287,2,duration of diabetes (months),Diabetes Mellitus,D003920,NA,0,311,duration,5,001000000,Diabetes Mellitus,NA
2420,22369287,2,duration of metformin therapy (months),Hypoglycemic Agents,D007004,NA,0,311,duration,5,001000000,Hypoglycemic Agents,NA
2421,22369287,2,gender,Gender Identity,D005783,NA,0,311,any,2,000000000,Gender Identity,NA
2422,22369287,2,"hba1c at baseline, %",Glycated Hemoglobin A,D006442,NA,0,311,any,2,000000000,Glycated Hemoglobin A,NA
2423,22371186,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,63
2424,22371186,NA,renal function,Renal Insufficiency,D051437,NA,0,0,any,2,000000000,Renal Insufficiency,62
2425,22371186,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,62
2426,22371186,NA,weight,Body Weight,D001835,NA,0,0,any,2,000000000,Body Weight,62
2427,22378566,2,;no mtx at baseline,Immunosuppressive Agents,D007166,NA,0,1553,previous,8,100000000,Immunosuppressive Agents,NA
2428,22378566,2,mtx at baseline,Immunosuppressive Agents,D007166,NA,0,1553,previous,8,100000000,Immunosuppressive Agents,NA
2429,22396585,2,;diabetes bl,Diabetes Mellitus,D003920,NA,0,1678,any,2,000000000,Diabetes Mellitus,NA
2430,22396585,2,;idm,Diabetes Mellitus,D003920,NA,0,1678,any,2,000000000,Diabetes Mellitus,NA
2431,22396585,2,;no diabetes,Diabetes Mellitus,D003920,NA,0,1678,any,2,000000000,Diabetes Mellitus,NA
2432,22405352,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,270
2433,22405352,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,271
2434,22405352,NA,diabetes duration,Diabetes Mellitus,D003920,NA,0,0,duration,5,001000000,Diabetes Mellitus,271
2435,22405352,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,271
2436,22405352,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,271
2437,22419732,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,270
2438,22419732,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,260
2439,22419732,NA,diabetes duration,Diabetes Mellitus,D003920,NA,0,0,duration,5,001000000,Diabetes Mellitus,260
2440,22419732,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,260
2441,22419732,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,260
2442,22432932,NA,Medical History: FEV1 at baseline,Pulmonary Ventilation,D012123,NA,0,0,previous,8,100000000,Pulmonary Ventilation,236
2443,22443427,2,age,Age Factors,D000367,NA,0,857,any,2,000000000,Age Factors,NA
2444,22443427,2,aspirin at enrollment,Aspirin,D001241,NA,0,857,any,2,000000000,Aspirin,NA
2445,22443427,2,body weight,Body Weight,D001835,NA,0,857,any,2,000000000,Body Weight,NA
2446,22443427,2,diabetes,Diabetes Mellitus,D003920,NA,0,857,any,2,000000000,Diabetes Mellitus,NA
2447,22443427,2,egfr (mumin/1.73 m2),Glomerular Filtration Rate,D005919,NA,0,857,any,2,000000000,Glomerular Filtration Rate,NA
2448,22443427,2,history of stroke,Stroke,D020521,NA,0,857,previous,8,100000000,Stroke,NA
2449,22443427,2,Peripheral artery disease Yes No,Peripheral Vascular Diseases,D016491,NA,0,857,any,2,000000000,Peripheral Vascular Diseases,NA
2450,22443427,2,qualifying atherosclerosis,Atherosclerosis,D050197,NA,0,857,any,2,000000000,Atherosclerosis,NA
2451,22443427,2,qualifying atherosclerosis;mi,Myocardial Infarction,D009203,NA,0,857,any,2,000000000,Myocardial Infarction,NA
2452,22443427,2,qualifying atherosclerosis;pad,Peripheral Vascular Diseases,D016491,NA,0,857,any,2,000000000,Peripheral Vascular Diseases,NA
2453,22443427,2,region,Geographic Locations,D005842,NA,0,857,any,2,000000000,Geographic Locations,NA
2454,22443427,2,region;australia/nz,Geographic Locations,D005842,NA,0,857,any,2,000000000,Geographic Locations,NA
2455,22443427,2,sex,Gender Identity,D005783,NA,0,857,any,2,000000000,Gender Identity,NA
2456,22443427,2,Smoker,Cigarette Smoking,D000073865,NA,0,857,any,2,000000000,Cigarette Smoking,NA
2457,22443427,2,stroke,Stroke,D020521,NA,0,857,any,2,000000000,Stroke,NA
2458,22443427,2,thienopyridine at enrollment,Thienopyridines,D058924,NA,0,857,any,2,000000000,Thienopyridines,NA
2459,22443427,3,age,Age Factors,D000367,NA,0,834,any,2,000000000,Age Factors,NA
2460,22443427,3,aspirin at enrollment,Aspirin,D001241,NA,0,834,any,2,000000000,Aspirin,NA
2461,22443427,3,body weight,Body Weight,D001835,NA,0,834,any,2,000000000,Body Weight,NA
2462,22443427,3,diabetes,Diabetes Mellitus,D003920,NA,0,834,any,2,000000000,Diabetes Mellitus,NA
2463,22443427,3,estimated glomerular filtration,Glomerular Filtration Rate,D005919,NA,0,834,any,2,000000000,Glomerular Filtration Rate,NA
2464,22443427,3,history of stroke,Stroke,D020521,NA,0,834,previous,8,100000000,Stroke,NA
2465,22443427,3,Peripheral artery disease Yes No,Peripheral Vascular Diseases,D016491,NA,0,834,any,2,000000000,Peripheral Vascular Diseases,NA
2466,22443427,3,qualifying atherosclerosis,Atherosclerosis,D050197,NA,0,834,any,2,000000000,Atherosclerosis,NA
2467,22443427,3,qualifying atherosclerosis;mi,Myocardial Infarction,D009203,NA,0,834,any,2,000000000,Myocardial Infarction,NA
2468,22443427,3,qualifying atherosclerosis;stroke,Stroke,D020521,NA,0,834,any,2,000000000,Stroke,NA
2469,22443427,3,region,Geographic Locations,D005842,NA,0,834,any,2,000000000,Geographic Locations,NA
2470,22443427,3,region;australia/nz,Geographic Locations,D005842,NA,0,834,any,2,000000000,Geographic Locations,NA
2471,22443427,3,sex,Gender Identity,D005783,NA,0,834,any,2,000000000,Gender Identity,NA
2472,22443427,3,Smoker,Cigarette Smoking,D000073865,NA,0,834,any,2,000000000,Cigarette Smoking,NA
2473,22443427,3,stroke,Stroke,D020521,NA,0,834,any,2,000000000,Stroke,NA
2474,22443427,3,thienopyridine at enrollment,Thienopyridines,D058924,NA,0,834,any,2,000000000,Thienopyridines,NA
2475,22470539,2,genotype,Genetic Profile,D000076610,NA,0,1198,any,2,000000000,Genetic Profile,NA
2476,22490878,1,;mild reduction in egfr,Glomerular Filtration Rate,D005919,NA,0,839,any,2,000000000,Glomerular Filtration Rate,NA
2477,22490878,1,;moderate/severe reduction in egfr,Glomerular Filtration Rate,D005919,NA,0,839,severity,11,000100000,Glomerular Filtration Rate,NA
2478,22490878,1,;normal or increased egfr,Glomerular Filtration Rate,D005919,NA,0,839,any,2,000000000,Glomerular Filtration Rate,NA
2479,22490878,2,egfr,Glomerular Filtration Rate,D005919,NA,0,824,any,2,000000000,Glomerular Filtration Rate,NA
2480,22490878,3,egfr,Glomerular Filtration Rate,D005919,NA,0,1249,any,2,000000000,Glomerular Filtration Rate,NA
2481,22491018,NA,genotype,Genetic Profile,D000076610,NA,0,0,type,12,000000010,Genetic Profile,185
2482,22503610,NA,cvd,Cardiovascular Diseases,D002318,NA,0,0,any,2,000000000,Cardiovascular Diseases,NA
2483,22503610,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
2484,22504093,2,Baseline high sensitivity C-reactive protein,C-Reactive Protein,D002097,NA,0,727,any,2,000000000,C-Reactive Protein,NA
2485,22504093,2,concomitant immunosuppressant use,Immunosuppressive Agents,D007166,NA,0,727,any,2,000000000,Immunosuppressive Agents,NA
2486,22504093,2,"Prior therapy, anti-TNF",Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,727,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
2487,22504093,2,"Prior therapy, corticosteroid failure",Steroids,D013256,S02B,0,727,previous,8,100000000,Steroids,NA
2488,22509859,1,a1c (%),Glycated Hemoglobin A,D006442,NA,0,127,any,2,000000000,Glycated Hemoglobin A,NA
2489,22509859,1,age (yrs),Age Factors,D000367,NA,0,127,any,2,000000000,Age Factors,NA
2490,22509859,1,black/african-american,Racial Groups,D044469,NA,0,127,any,2,000000000,Racial Groups,NA
2491,22509859,1,bmi (kg/m^),Body Mass Index,D015992,NA,0,127,any,2,000000000,Body Mass Index,NA
2492,22509859,1,final a1c (%),Glycated Hemoglobin A,D006442,NA,0,127,any,2,000000000,Glycated Hemoglobin A,NA
2493,22509859,1,fpg data';';black/african-american,Racial Groups,D044469,NA,0,127,any,2,000000000,Racial Groups,NA
2494,22509859,1,fpg data';';hispanic/latino,Racial Groups,D044469,NA,0,127,any,2,000000000,Racial Groups,NA
2495,22509859,1,fpg data';';non-hispanic/latino,Racial Groups,D044469,NA,0,127,any,2,000000000,Racial Groups,NA
2496,22509859,1,fpg data';';white,Racial Groups,D044469,NA,0,127,any,2,000000000,Racial Groups,NA
2497,22509859,1,"gender (m/f), (%)",Gender Identity,D005783,NA,0,127,any,2,000000000,Gender Identity,NA
2498,22509859,1,hispanic/latino,Racial Groups,D044469,NA,0,127,any,2,000000000,Racial Groups,NA
2499,22509859,1,n,Racial Groups,D044469,NA,0,127,any,2,000000000,Racial Groups,NA
2500,22509859,1,non-hispanic/latino,Racial Groups,D044469,NA,0,127,any,2,000000000,Racial Groups,NA
2501,22509859,1,weight (kg),Body Weight,D001835,NA,0,127,any,2,000000000,Body Weight,NA
2502,22509859,1,white,Racial Groups,D044469,NA,0,127,any,2,000000000,Racial Groups,NA
2503,22544891,2,copd severity,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1196,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
2504,22544891,2,copd severity;moderate,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1196,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
2505,22544891,2,copd severity;severe or very severe,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1196,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
2506,22544891,2,ics use,Steroids,D013256,NA,0,1196,any,2,000000000,Steroids,NA
2507,22544891,2,ics use;ics non-users,Steroids,D013256,NA,0,1196,any,2,000000000,Steroids,NA
2508,22544891,2,ics use;ics users,Steroids,D013256,NA,0,1196,any,2,000000000,Steroids,NA
2509,22544891,2,Smoker,Cigarette Smoking,D000073865,NA,0,1196,any,2,000000000,Cigarette Smoking,NA
2510,22573644,2,diet diet + pravastatin,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,1853,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
2511,22573644,2,metsyn,Metabolic Syndrome,D024821,NA,0,1853,any,2,000000000,Metabolic Syndrome,NA
2512,22573644,2,metsyn with ldl >156.9 mg/dl,Metabolic Syndrome,D024821,NA,0,1853,any,2,000000000,Metabolic Syndrome,NA
2513,22573644,2,non-metsyn,Metabolic Syndrome,D024821,NA,0,1853,any,2,000000000,Metabolic Syndrome,NA
2514,22576673,2,";patients with ra, as, or psa (n = 280)",Rheumatic Diseases,D012216,NA,0,342,any,2,000000000,Rheumatic Diseases,NA
2515,22576673,2,";patients without ra, as, or psa (n = 18,609)",Rheumatic Diseases,D012216,NA,0,342,any,2,000000000,Rheumatic Diseases,NA
2516,22672586,2,a1c<6.4% (median),Glycated Hemoglobin A,D006442,NA,0,891,any,2,000000000,Glycated Hemoglobin A,NA
2517,22672586,2,age,Age Factors,D000367,NA,0,891,any,2,000000000,Age Factors,NA
2518,22672586,2,BMI,Body Mass Index,D015992,NA,0,891,any,2,000000000,Body Mass Index,NA
2519,22672586,2,male female,Gender Identity,D005783,NA,0,891,any,2,000000000,Gender Identity,NA
2520,22672586,2,metformin,Hypoglycemic Agents,D007004,NA,0,891,any,2,000000000,Hypoglycemic Agents,NA
2521,22686416,2,a1c<6.4% (median),Glycated Hemoglobin A,D006442,NA,0,503,any,2,000000000,Glycated Hemoglobin A,NA
2522,22686416,2,ace-i/arb,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,503,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
2523,22686416,2,ifg/igt,Glucose Intolerance,D018149,NA,0,503,any,2,000000000,Glucose Intolerance,NA
2524,22686416,2,metformin,Hypoglycemic Agents,D007004,NA,0,503,any,2,000000000,Hypoglycemic Agents,NA
2525,22686416,2,new dm,Diabetes Mellitus,D003920,NA,0,503,duration,5,001000000,Diabetes Mellitus,NA
2526,22686416,2,no ace-i/arb,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,503,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
2527,22686416,2,no metformin,Hypoglycemic Agents,D007004,NA,0,503,any,2,000000000,Hypoglycemic Agents,NA
2528,22686416,2,no prior cv event,Cardiovascular Diseases,D002318,NA,0,503,previous,8,100000000,Cardiovascular Diseases,NA
2529,22686416,2,no statin use,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,503,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
2530,22686416,2,omega 3 allocation,"Fatty Acids, Omega-3",D015525,NA,0,503,any,2,000000000,"Fatty Acids, Omega-3",NA
2531,22686416,2,prior cv event,Cardiovascular Diseases,D002318,NA,0,503,previous,8,100000000,Cardiovascular Diseases,NA
2532,22686416,2,prior dm,Diabetes Mellitus,D003920,NA,0,503,previous,8,100000000,Diabetes Mellitus,NA
2533,22686416,2,statin use,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,503,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
2534,22704916,NA,duration of Crohn's disease,Crohn Disease,D003424,NA,0,0,duration,5,001000000,Crohn Disease,93
2535,22704916,NA,Medical History: Disease Duration,"Arthritis, Rheumatoid",D001172,NA,0,0,previous,8,101000000,"Arthritis, Rheumatoid",27
2536,22738922,NA,Total periventricular WML score,complex,NA,NA,0,0,any,2,000000000,complex,225
2537,22740508,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
2538,22740508,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,225
2539,22740508,NA,egfr,Renal Insufficiency,D051437,NA,0,0,any,2,000000000,Renal Insufficiency,NA
2540,22740508,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
2541,22748821,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,119
2542,22748821,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,120
2543,22799613,1,black (n = 166),Racial Groups,D044469,NA,0,92,any,2,000000000,Racial Groups,NA
2544,22799613,1,black (n = 174),Racial Groups,D044469,NA,0,92,any,2,000000000,Racial Groups,NA
2545,22799613,1,black (n = 181),Racial Groups,D044469,NA,0,92,any,2,000000000,Racial Groups,NA
2546,22799613,1,black (n = 183),Racial Groups,D044469,NA,0,92,any,2,000000000,Racial Groups,NA
2547,22799613,1,non-black (n = 371),Racial Groups,D044469,NA,0,92,any,2,000000000,Racial Groups,NA
2548,22799613,1,non-black (n = 397),Racial Groups,D044469,NA,0,92,any,2,000000000,Racial Groups,NA
2549,22799613,1,non-black (n = 408),Racial Groups,D044469,NA,0,92,any,2,000000000,Racial Groups,NA
2550,22799613,1,non-black (n = 422),Racial Groups,D044469,NA,0,92,any,2,000000000,Racial Groups,NA
2551,22799613,2,black,Racial Groups,D044469,NA,0,731,any,2,000000000,Racial Groups,NA
2552,22799613,2,non-black,Racial Groups,D044469,NA,0,731,any,2,000000000,Racial Groups,NA
2553,22873530,2,age,Age Factors,D000367,NA,0,888,any,2,000000000,Age Factors,NA
2554,22873530,2,anti-ccp,Anti-Citrullinated Protein Antibodies,D000075422,NA,0,888,any,2,000000000,Anti-Citrullinated Protein Antibodies,NA
2555,22873530,2,anti-ccp;dmard-biologic ir,Antirheumatic Agents,D018501,NA,0,888,disease response,4,000000000,Antirheumatic Agents,NA
2556,22873530,2,gender,Gender Identity,D005783,NA,0,888,any,2,000000000,Gender Identity,NA
2557,22873530,2,region,Geographic Locations,D005842,NA,0,888,any,2,000000000,Geographic Locations,NA
2558,22873530,2,rheumatoid factor,Rheumatoid Factor,D012217,NA,0,888,any,2,000000000,Rheumatoid Factor,NA
2559,22913890,NA,Patient Variable: Ethnicity,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,98
2560,22913891,3,"age, years",Age Factors,D000367,NA,0,1306,any,2,000000000,Age Factors,NA
2561,22913891,3,"body mass index, kg/m2",Body Mass Index,D015992,NA,0,1306,any,2,000000000,Body Mass Index,NA
2562,22913891,3,"body mass index, kg/m2;<10 (n = 1480)",Body Mass Index,D015992,NA,0,1306,any,2,000000000,Body Mass Index,NA
2563,22913891,3,"body mass index, kg/m2;>=10 (n = 586)",Body Mass Index,D015992,NA,0,1306,any,2,000000000,Body Mass Index,NA
2564,22913891,3,"body mass index, kg/m2;>=20 to <25 (n = 168)",Body Mass Index,D015992,NA,0,1306,any,2,000000000,Body Mass Index,NA
2565,22913891,3,"body mass index, kg/m2;>=25 to <30 (n = 667)",Body Mass Index,D015992,NA,0,1306,any,2,000000000,Body Mass Index,NA
2566,22913891,3,"body mass index, kg/m2;>=30 to <35 (n = 673)",Body Mass Index,D015992,NA,0,1306,any,2,000000000,Body Mass Index,NA
2567,22913891,3,"body mass index, kg/m2;>=35 (n = 555)",Body Mass Index,D015992,NA,0,1306,any,2,000000000,Body Mass Index,NA
2568,22913891,3,race,Racial Groups,D044469,NA,0,1306,any,2,000000000,Racial Groups,NA
2569,22913891,3,race;<10 (n = 1480),Racial Groups,D044469,NA,0,1306,any,2,000000000,Racial Groups,NA
2570,22913891,3,race;<65 (n = 1613),Racial Groups,D044469,NA,0,1306,any,2,000000000,Racial Groups,NA
2571,22913891,3,race;>=10 (n = 586),Racial Groups,D044469,NA,0,1306,any,2,000000000,Racial Groups,NA
2572,22913891,3,race;>=20 to <25 (n = 168),Racial Groups,D044469,NA,0,1306,any,2,000000000,Racial Groups,NA
2573,22913891,3,race;>=25 to <30 (n = 667),Racial Groups,D044469,NA,0,1306,any,2,000000000,Racial Groups,NA
2574,22913891,3,race;>=30 to <35 (n = 673),Racial Groups,D044469,NA,0,1306,any,2,000000000,Racial Groups,NA
2575,22913891,3,race;>=35 (n = 555),Racial Groups,D044469,NA,0,1306,any,2,000000000,Racial Groups,NA
2576,22913891,3,race;>=65 (n = 454),Racial Groups,D044469,NA,0,1306,any,2,000000000,Racial Groups,NA
2577,22913891,3,sex,Gender Identity,D005783,NA,0,1306,any,2,000000000,Gender Identity,NA
2578,22913891,3,sex;<65 (n = 1613),Gender Identity,D005783,NA,0,1306,any,2,000000000,Gender Identity,NA
2579,22913891,3,sex;>=65 (n = 454),Gender Identity,D005783,NA,0,1306,any,2,000000000,Gender Identity,NA
2580,22913891,4,"body mass index, kg/m2",Body Mass Index,D015992,NA,0,1139,any,2,000000000,Body Mass Index,NA
2581,22913891,4,"body mass index, kg/m2;<10 (n = 1480)",Body Mass Index,D015992,NA,0,1139,any,2,000000000,Body Mass Index,NA
2582,22913891,4,"body mass index, kg/m2;>=10 (n = 586)",Body Mass Index,D015992,NA,0,1139,any,2,000000000,Body Mass Index,NA
2583,22913891,4,"body mass index, kg/m2;>=20 to <25 (n = 168)",Body Mass Index,D015992,NA,0,1139,any,2,000000000,Body Mass Index,NA
2584,22913891,4,"body mass index, kg/m2;>=25 to <30 (n = 667)",Body Mass Index,D015992,NA,0,1139,any,2,000000000,Body Mass Index,NA
2585,22913891,4,"body mass index, kg/m2;>=30 to <35 (n = 673)",Body Mass Index,D015992,NA,0,1139,any,2,000000000,Body Mass Index,NA
2586,22913891,4,"body mass index, kg/m2;>=35 (n = 555)",Body Mass Index,D015992,NA,0,1139,any,2,000000000,Body Mass Index,NA
2587,22913891,4,"duration of diabetes, years",Diabetes Mellitus,D003920,NA,0,1139,duration,5,001000000,Diabetes Mellitus,NA
2588,22913891,4,race;<10 (n = 1480),Racial Groups,D044469,NA,0,1139,any,2,000000000,Racial Groups,NA
2589,22913891,4,race;<65 (n = 1613),Racial Groups,D044469,NA,0,1139,any,2,000000000,Racial Groups,NA
2590,22913891,4,race;>=10 (n = 586),Racial Groups,D044469,NA,0,1139,any,2,000000000,Racial Groups,NA
2591,22913891,4,race;>=20 to <25 (n = 168),Racial Groups,D044469,NA,0,1139,any,2,000000000,Racial Groups,NA
2592,22913891,4,race;>=25 to <30 (n = 667),Racial Groups,D044469,NA,0,1139,any,2,000000000,Racial Groups,NA
2593,22913891,4,race;>=30 to <35 (n = 673),Racial Groups,D044469,NA,0,1139,any,2,000000000,Racial Groups,NA
2594,22913891,4,race;>=35 (n = 555),Racial Groups,D044469,NA,0,1139,any,2,000000000,Racial Groups,NA
2595,22913891,4,race;>=65 (n = 454),Racial Groups,D044469,NA,0,1139,any,2,000000000,Racial Groups,NA
2596,22913891,5,"age, years",Age Factors,D000367,NA,0,1173,any,2,000000000,Age Factors,NA
2597,22913891,5,"body mass index, kg/m2",Body Mass Index,D015992,NA,0,1173,any,2,000000000,Body Mass Index,NA
2598,22913891,5,"body mass index, kg/m2;<10 (n = 1480)",Body Mass Index,D015992,NA,0,1173,any,2,000000000,Body Mass Index,NA
2599,22913891,5,"body mass index, kg/m2;>=10 (n = 586)",Body Mass Index,D015992,NA,0,1173,any,2,000000000,Body Mass Index,NA
2600,22913891,5,"body mass index, kg/m2;>=20 to <25 (n = 168)",Body Mass Index,D015992,NA,0,1173,any,2,000000000,Body Mass Index,NA
2601,22913891,5,"body mass index, kg/m2;>=25 to <30 (n = 667)",Body Mass Index,D015992,NA,0,1173,any,2,000000000,Body Mass Index,NA
2602,22913891,5,"body mass index, kg/m2;>=30 to <35 (n = 673)",Body Mass Index,D015992,NA,0,1173,any,2,000000000,Body Mass Index,NA
2603,22913891,5,"body mass index, kg/m2;>=35 (n = 555)",Body Mass Index,D015992,NA,0,1173,any,2,000000000,Body Mass Index,NA
2604,22913891,5,sex,Gender Identity,D005783,NA,0,1173,any,2,000000000,Gender Identity,NA
2605,22913891,5,sex;<65 (n = 1613),Gender Identity,D005783,NA,0,1173,any,2,000000000,Gender Identity,NA
2606,22913891,5,sex;>=65 (n = 454),Gender Identity,D005783,NA,0,1173,any,2,000000000,Gender Identity,NA
2607,22913891,6,"body mass index, kg/m2",Body Mass Index,D015992,NA,0,1195,any,2,000000000,Body Mass Index,NA
2608,22913891,6,"body mass index, kg/m2;<10 (n = 1480)",Body Mass Index,D015992,NA,0,1195,any,2,000000000,Body Mass Index,NA
2609,22913891,6,"body mass index, kg/m2;>=10 (n = 586)",Body Mass Index,D015992,NA,0,1195,any,2,000000000,Body Mass Index,NA
2610,22913891,6,"body mass index, kg/m2;>=20 to <25 (n = 168)",Body Mass Index,D015992,NA,0,1195,any,2,000000000,Body Mass Index,NA
2611,22913891,6,"body mass index, kg/m2;>=25 to <30 (n = 667)",Body Mass Index,D015992,NA,0,1195,any,2,000000000,Body Mass Index,NA
2612,22913891,6,"body mass index, kg/m2;>=30 to <35 (n = 673)",Body Mass Index,D015992,NA,0,1195,any,2,000000000,Body Mass Index,NA
2613,22913891,6,"body mass index, kg/m2;>=35 (n = 555)",Body Mass Index,D015992,NA,0,1195,any,2,000000000,Body Mass Index,NA
2614,22913891,6,"duration of diabetes, years",Diabetes Mellitus,D003920,NA,0,1195,duration,5,001000000,Diabetes Mellitus,NA
2615,22913891,6,race,Racial Groups,D044469,NA,0,1195,any,2,000000000,Racial Groups,NA
2616,22913891,6,race;<10 (n = 1480),Racial Groups,D044469,NA,0,1195,any,2,000000000,Racial Groups,NA
2617,22913891,6,race;<65 (n = 1613),Racial Groups,D044469,NA,0,1195,any,2,000000000,Racial Groups,NA
2618,22913891,6,race;>=10 (n = 586),Racial Groups,D044469,NA,0,1195,any,2,000000000,Racial Groups,NA
2619,22913891,6,race;>=20 to <25 (n = 168),Racial Groups,D044469,NA,0,1195,any,2,000000000,Racial Groups,NA
2620,22913891,6,race;>=25 to <30 (n = 667),Racial Groups,D044469,NA,0,1195,any,2,000000000,Racial Groups,NA
2621,22913891,6,race;>=30 to <35 (n = 673),Racial Groups,D044469,NA,0,1195,any,2,000000000,Racial Groups,NA
2622,22913891,6,race;>=35 (n = 555),Racial Groups,D044469,NA,0,1195,any,2,000000000,Racial Groups,NA
2623,22913891,6,race;>=65 (n = 454),Racial Groups,D044469,NA,0,1195,any,2,000000000,Racial Groups,NA
2624,22913893,2,;with diabetes,Diabetes Mellitus,D003920,NA,0,1610,any,2,000000000,Diabetes Mellitus,NA
2625,22913893,2,;without diabetes,Diabetes Mellitus,D003920,NA,0,1610,any,2,000000000,Diabetes Mellitus,NA
2626,22931315,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
2627,22931315,NA,aspirin at index stroke,Aspirin,D001241,NA,0,0,any,2,000000000,Aspirin,NA
2628,22931315,NA,history of diabetes,Diabetes Mellitus,D003920,NA,0,0,previous,8,100000000,Diabetes Mellitus,NA
2629,22931315,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
2630,22931315,NA,region,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,NA
2631,22931315,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
2632,22932716,2,age,Age Factors,D000367,NA,0,1607,any,2,000000000,Age Factors,NA
2633,22932716,2,diabetes,Diabetes Mellitus,D003920,NA,0,1607,any,2,000000000,Diabetes Mellitus,NA
2634,22932716,2,egfr (ml/min/1.73m2),Glomerular Filtration Rate,D005919,NA,0,1607,any,2,000000000,Glomerular Filtration Rate,NA
2635,22932716,2,mi,Myocardial Infarction,D009203,NA,0,1607,any,2,000000000,Myocardial Infarction,NA
2636,22932716,2,planned thienopyridine at enrollment,Thienopyridines,D058924,NA,0,1607,any,2,000000000,Thienopyridines,NA
2637,22932716,2,prior stent,Stents,D015607,NA,0,1607,previous,8,100000000,Stents,NA
2638,22932716,2,prior stroke or tia,Stroke,D020521,NA,0,1607,previous,8,100000000,Stroke,NA
2639,22932716,2,qualifying myocardial infarction,Myocardial Infarction,D009203,NA,0,1607,any,2,000000000,Myocardial Infarction,NA
2640,22932716,2,qualifying myocardial infarction;stemi,Myocardial Infarction,D009203,NA,0,1607,any,2,000000000,Myocardial Infarction,NA
2641,22932716,2,region,Geographic Locations,D005842,NA,0,1607,any,2,000000000,Geographic Locations,NA
2642,22932716,2,region;australia/nz,Geographic Locations,D005842,NA,0,1607,any,2,000000000,Geographic Locations,NA
2643,22932716,2,sex,Gender Identity,D005783,NA,0,1607,any,2,000000000,Gender Identity,NA
2644,22932716,2,weight,Body Weight,D001835,NA,0,1607,any,2,000000000,Body Weight,NA
2645,22939358,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
2646,22939358,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,NA
2647,22939358,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
2648,22939358,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
2649,22939358,NA,renal function,Renal Insufficiency,D051437,NA,0,0,any,2,000000000,Renal Insufficiency,NA
2650,22939358,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
2651,23020650,2,;gold ii,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,314,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
2652,23020650,2,;gold iii-iv,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,314,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
2653,23020650,2,bdi total score (baseline),Dyspnea,D004417,NA,0,314,severity,11,000100000,Dyspnea,NA
2654,23020650,2,sgrq total score (baseline),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,314,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
2655,23020650,2,sgrq total score (week 12 locf),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,314,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
2656,23040786,2,moderate copd,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1057,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
2657,23040786,2,severe copd,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1057,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
2658,23040830,2,absorption marker level,Lipoproteins,D008074,NA,0,967,any,2,000000000,Lipoproteins,NA
2659,23048052,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
2660,23048052,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
2661,23048052,NA,EGFR,Renal Insufficiency,D051437,NA,0,0,any,2,000000000,Renal Insufficiency,NA
2662,23048052,NA,Intervention type,Geographic Locations,D005842,NA,0,0,type,12,000000010,Geographic Locations,NA
2663,23048052,NA,lvef,Stroke Volume,D013318,NA,0,0,any,2,000000000,Stroke Volume,NA
2664,23048052,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
2665,23048052,NA,Study type,unclassifiable,NA,NA,0,0,type,12,000000010,unclassifiable,NA
2666,23078148,NA,ICS use prior to study entry,"Steroids, Brominated",D013257,NA,0,0,previous,8,100000000,"Steroids, Brominated",177
2667,23110471,1,;chronic cvd,Cardiovascular Diseases,D002318,NA,0,1490,any,2,000000000,Cardiovascular Diseases,NA
2668,23110471,1,;ckd,Kidney Diseases,D007674,NA,0,1490,any,2,000000000,Kidney Diseases,NA
2669,23110471,1,;diabetes,Diabetes Mellitus,D003920,NA,0,1490,any,2,000000000,Diabetes Mellitus,NA
2670,23110471,1,ckd,Kidney Diseases,D007674,NA,0,1490,any,2,000000000,Kidney Diseases,NA
2671,23110471,1,diabetes,Diabetes Mellitus,D003920,NA,0,1490,any,2,000000000,Diabetes Mellitus,NA
2672,23110471,3,;ckd,Kidney Diseases,D007674,NA,0,1146,any,2,000000000,Kidney Diseases,NA
2673,23110471,3,;diabetes,Diabetes Mellitus,D003920,NA,0,1146,any,2,000000000,Diabetes Mellitus,NA
2674,23110471,3,chronic cvd,Cardiovascular Diseases,D002318,NA,0,1146,any,2,000000000,Cardiovascular Diseases,NA
2675,23110471,3,ckd,Kidney Diseases,D007674,NA,0,1146,any,2,000000000,Kidney Diseases,NA
2676,23110471,3,diabetes,Diabetes Mellitus,D003920,NA,0,1146,any,2,000000000,Diabetes Mellitus,NA
2677,23113482,NA,total testosterone,Testosterone,D013739,NA,0,0,any,2,000000000,Testosterone,NA
2678,23116881,NA,Baseline HbA1c,Glycated Hemoglobin A,D006442,NA,0,0,any,2,000000000,Glycated Hemoglobin A,NA
2679,23117723,NA,Medical History: Ischemic Stroke,Stroke,D020521,NA,0,0,previous,8,100000000,Stroke,244
2680,23128104,2,age;age: <70 years (n=960),Age Factors,D000367,NA,0,348,any,2,000000000,Age Factors,NA
2681,23128104,2,cardiac valve surgery,Heart Valve Prosthesis,D006350,NA,0,348,any,2,000000000,Heart Valve Prosthesis,NA
2682,23128104,2,country;country: argentina (n=342),Geographic Locations,D005842,NA,0,348,any,2,000000000,Geographic Locations,NA
2683,23128104,2,country;italy (n=728),Geographic Locations,D005842,NA,0,348,any,2,000000000,Geographic Locations,NA
2684,23128104,2,cross-clamp time,unclassifiable,NA,NA,0,348,any,2,000000000,unclassifiable,NA
2685,23128104,2,ejection fraction,Stroke Volume,D013318,NA,0,348,any,2,000000000,Stroke Volume,NA
2686,23128104,2,ejection fraction;ejection fraction: <50% (n=288),Stroke Volume,D013318,NA,0,348,any,2,000000000,Stroke Volume,NA
2687,23128104,2,habitual fish intake,"Fish Proteins, Dietary",D000078504,NA,0,348,any,2,000000000,"Fish Proteins, Dietary",NA
2688,23128104,2,Hypertension,Hypertension,D006973,NA,0,348,any,2,000000000,Hypertension,NA
2689,23128104,2,left atrial diameter,Heart Atria,D006325,NA,0,348,any,2,000000000,Heart Atria,NA
2690,23128104,2,left atrial diameter;left atrial diameter: <42 mm (n=480),Heart Atria,D006325,NA,0,348,any,2,000000000,Heart Atria,NA
2691,23128104,2,nyha class 2-4,Heart Failure,D006333,NA,0,348,severity,11,000100000,Heart Failure,NA
2692,23128104,2,off-pump time,unclassifiable,NA,NA,0,348,any,2,000000000,unclassifiable,NA
2693,23128104,2,peri-op ace inhibitiors/arbs,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,348,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
2694,23128104,2,peri-op amiodarone,Amiodarone,D000638,C01,0,348,any,2,000000000,Amiodarone,NA
2695,23128104,2,peri-op beta-blockers,Adrenergic beta-Antagonists,D000319,NA,0,348,any,2,000000000,Adrenergic beta-Antagonists,NA
2696,23128104,2,peri-op statins,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,348,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
2697,23128104,2,phospholipid omega-3 levels,Fatty Acids,D005227,NA,0,348,any,2,000000000,Fatty Acids,NA
2698,23128104,2,serum potassium,Sodium,D012964,NA,0,348,any,2,000000000,Sodium,NA
2699,23128104,2,sex,Gender Identity,D005783,NA,0,348,any,2,000000000,Gender Identity,NA
2700,23129601,2,% change median baseline crp >2mg/l,C-Reactive Protein,D002097,NA,0,776,any,2,000000000,C-Reactive Protein,NA
2701,23129601,2,baseline crp <2mg/l,C-Reactive Protein,D002097,NA,0,776,any,2,000000000,C-Reactive Protein,NA
2702,23134522,NA,sbp,Blood Pressure,D001794,NA,0,0,any,2,000000000,Blood Pressure,NA
2703,23134522,NA,smoking,Cigarette Smoking,D000073865,NA,0,0,any,2,000000000,Cigarette Smoking,NA
2704,23216615,2,age,Age Factors,D000367,NA,0,694,any,2,000000000,Age Factors,NA
2705,23216615,2,age;<65 yr,Age Factors,D000367,NA,0,694,any,2,000000000,Age Factors,NA
2706,23216615,2,index event;dvt only,Venous Thromboembolism,D054556,NA,0,694,type,12,000000010,Venous Thromboembolism,NA
2707,23216615,2,index event;pe (with or without dvt),Venous Thromboembolism,D054556,NA,0,694,type,12,000000010,Venous Thromboembolism,NA
2708,23216615,2,level of renal impairment,Renal Insufficiency,D051437,NA,0,694,severity,11,000100000,Renal Insufficiency,NA
2709,23216615,2,level of renal impairment;mild,Renal Insufficiency,D051437,NA,0,694,severity,11,000100000,Renal Insufficiency,NA
2710,23216615,2,level of renal impairment;normal renal function,Renal Insufficiency,D051437,NA,0,694,severity,11,000100000,Renal Insufficiency,NA
2711,23216615,2,level of renal impairment;severe or moderate,Renal Insufficiency,D051437,NA,0,694,severity,11,000100000,Renal Insufficiency,NA
2712,23216615,2,sex,Gender Identity,D005783,NA,0,694,any,2,000000000,Gender Identity,NA
2713,23216615,2,weight,Body Weight,D001835,NA,0,694,any,2,000000000,Body Weight,NA
2714,23219284,NA,Patient Variable: BMI,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,36
2715,23238658,NA,Retinal severity change,Retinal Diseases,D012164,NA,0,0,severity,11,000100000,Retinal Diseases,NA
2716,23307827,2,Baseline walk distance,Exercise,D015444,NA,0,382,any,2,000000000,Exercise,NA
2717,23307827,2,Baseline WHO class,Pulmonary Arterial Hypertension,D000081029,NA,0,382,severity,11,000100000,Pulmonary Arterial Hypertension,NA
2718,23307827,2,Etiology,etiology,Q000209,NA,0,382,aetiological,1,000001000,etiology,NA
2719,23307827,2,Sex,Gender Identity,D005783,NA,0,382,any,2,000000000,Gender Identity,NA
2720,23325525,1,af pattern,Atrial Fibrillation,D001281,NA,0,1442,any,2,000000000,Atrial Fibrillation,NA
2721,23325525,1,af pattern;paroxysmal,Atrial Fibrillation,D001281,NA,0,1442,type,12,000000010,Atrial Fibrillation,NA
2722,23325525,1,af pattern;permanent,Atrial Fibrillation,D001281,NA,0,1442,type,12,000000010,Atrial Fibrillation,NA
2723,23325525,1,af pattern;persistent,Atrial Fibrillation,D001281,NA,0,1442,type,12,000000010,Atrial Fibrillation,NA
2724,23325525,1,age,Age Factors,D000367,NA,0,1442,any,2,000000000,Age Factors,NA
2725,23325525,1,chads2,Stroke,D020521,NA,1,1442,severity,11,000100000,Stroke,NA
2726,23325525,1,gender,Gender Identity,D005783,NA,0,1442,any,2,000000000,Gender Identity,NA
2727,23325525,1,laa length,Atrial Appendage,D020517,NA,0,1442,any,2,000000000,Atrial Appendage,NA
2728,23325525,1,laa ostium,Atrial Appendage,D020517,NA,0,1442,any,2,000000000,Atrial Appendage,NA
2729,23325525,1,lvef,Stroke Volume,D013318,NA,0,1442,any,2,000000000,Stroke Volume,NA
2730,23339726,2,albuminuria,Albuminuria,D000419,NA,0,1543,any,2,000000000,Albuminuria,NA
2731,23396280,2,Ischaemic Stroke,Stroke,D020521,NA,0,328,any,2,000000000,Stroke,NA
2732,23425163,2,active cancer,Neoplasms,D009369,NA,0,564,any,2,000000000,Neoplasms,NA
2733,23425163,2,age category,Age Factors,D000367,NA,0,564,any,2,000000000,Age Factors,NA
2734,23425163,2,age category;>75 years,Age Factors,D000367,NA,0,564,any,2,000000000,Age Factors,NA
2735,23425163,2,Coronary heart disease,Coronary Artery Disease,D003324,NA,0,564,any,2,000000000,Coronary Artery Disease,NA
2736,23425163,2,creatine clearance category;>80 ml/min,Glomerular Filtration Rate,D005919,NA,0,564,any,2,000000000,Glomerular Filtration Rate,NA
2737,23425163,2,creatine clearance category;30 to <50 ml/min,Glomerular Filtration Rate,D005919,NA,0,564,any,2,000000000,Glomerular Filtration Rate,NA
2738,23425163,2,creatine clearance category;50 to <60 ml/min,Glomerular Filtration Rate,D005919,NA,0,564,any,2,000000000,Glomerular Filtration Rate,NA
2739,23425163,2,Creatinine,Glomerular Filtration Rate,D005919,NA,0,564,any,2,000000000,Glomerular Filtration Rate,NA
2740,23425163,2,gender,Gender Identity,D005783,NA,0,564,any,2,000000000,Gender Identity,NA
2741,23425163,2,geographical region,Geographic Locations,D005842,NA,0,564,any,2,000000000,Geographic Locations,NA
2742,23425163,2,history of >1 previous vte (excluding index event),Venous Thromboembolism,D054556,NA,0,564,previous,8,100000000,Venous Thromboembolism,NA
2743,23425163,2,history of non-hemor-rhagic stroke,Stroke,D020521,NA,0,564,previous,8,100000000,Stroke,NA
2744,23425163,2,qualifying index event as pe,Pulmonary Embolism,D011655,NA,0,564,any,2,000000000,Pulmonary Embolism,NA
2745,23425163,2,race,Racial Groups,D044469,NA,0,564,any,2,000000000,Racial Groups,NA
2746,23425163,2,Smoker,Cigarette Smoking,D000073865,NA,0,564,any,2,000000000,Cigarette Smoking,NA
2747,23425163,2,smoking history;currently smokes,Cigarette Smoking,D000073865,NA,0,564,current,3,010000000,Cigarette Smoking,NA
2748,23425163,2,smoking history;never smoked,Cigarette Smoking,D000073865,NA,0,564,any,2,000000000,Cigarette Smoking,NA
2749,23425163,2,subgroup w.r.t. re-cover;re-cover 1 dabigatran,Anticoagulants,D000925,NA,0,564,any,2,000000000,Anticoagulants,NA
2750,23425163,2,subgroup w.r.t. re-cover;re-cover 1 warfarin,Anticoagulants,D000925,NA,0,564,any,2,000000000,Anticoagulants,NA
2751,23425163,2,symptomatic pe,Pulmonary Embolism,D011655,NA,0,564,any,2,000000000,Pulmonary Embolism,NA
2752,23425163,2,weight category,Body Weight,D001835,NA,0,564,any,2,000000000,Body Weight,NA
2753,23425163,2,weight category;>80 ml/min,Body Weight,D001835,NA,0,564,any,2,000000000,Body Weight,NA
2754,23425163,2,weight category;0 to <30 ml/min,Body Weight,D001835,NA,0,564,any,2,000000000,Body Weight,NA
2755,23425163,2,weight category;30 to <50 ml/min,Body Weight,D001835,NA,0,564,any,2,000000000,Body Weight,NA
2756,23425163,2,weight category;50 to <80 ml/min,Body Weight,D001835,NA,0,564,any,2,000000000,Body Weight,NA
2757,23425163,3,age category,Age Factors,D000367,NA,0,1026,any,2,000000000,Age Factors,NA
2758,23425163,3,age category;>75 years,Age Factors,D000367,NA,0,1026,any,2,000000000,Age Factors,NA
2759,23425163,3,creatine clearance category;>80 ml/min,Glomerular Filtration Rate,D005919,NA,0,1026,any,2,000000000,Glomerular Filtration Rate,NA
2760,23425163,3,creatine clearance category;30 to <50 ml/min,Glomerular Filtration Rate,D005919,NA,0,1026,any,2,000000000,Glomerular Filtration Rate,NA
2761,23425163,3,creatine clearance category;50 to <60 ml/min,Glomerular Filtration Rate,D005919,NA,0,1026,any,2,000000000,Glomerular Filtration Rate,NA
2762,23425163,3,Creatinine,Glomerular Filtration Rate,D005919,NA,0,1026,any,2,000000000,Glomerular Filtration Rate,NA
2763,23425163,3,gender,Gender Identity,D005783,NA,0,1026,any,2,000000000,Gender Identity,NA
2764,23425163,3,geographical region,Geographic Locations,D005842,NA,0,1026,any,2,000000000,Geographic Locations,NA
2765,23425163,3,geographical region;rest of the world,Geographic Locations,D005842,NA,0,1026,any,2,000000000,Geographic Locations,NA
2766,23425163,3,qualifying index event as pe,Pulmonary Embolism,D011655,NA,0,1026,any,2,000000000,Pulmonary Embolism,NA
2767,23425163,3,race,Racial Groups,D044469,NA,0,1026,any,2,000000000,Racial Groups,NA
2768,23425163,3,Smoker,Cigarette Smoking,D000073865,NA,0,1026,any,2,000000000,Cigarette Smoking,NA
2769,23425163,3,smoking history;currently smokes,Cigarette Smoking,D000073865,NA,0,1026,current,3,010000000,Cigarette Smoking,NA
2770,23425163,3,smoking history;never smoke,Cigarette Smoking,D000073865,NA,0,1026,any,2,000000000,Cigarette Smoking,NA
2771,23425163,3,subgroup w.r.t. re-cover;re-cover 1 dabigatran,Anticoagulants,D000925,NA,0,1026,any,2,000000000,Anticoagulants,NA
2772,23425163,3,subgroup w.r.t. re-cover;re-cover 1 warfarin,Fibrinolytic Agents,D005343,NA,0,1026,any,2,000000000,Fibrinolytic Agents,NA
2773,23425163,3,weight category,Body Weight,D001835,NA,0,1026,any,2,000000000,Body Weight,NA
2774,23425163,3,weight category;>80 ml/min,Body Weight,D001835,NA,0,1026,any,2,000000000,Body Weight,NA
2775,23425163,3,weight category;0 to <30 ml/min,Body Weight,D001835,NA,0,1026,any,2,000000000,Body Weight,NA
2776,23425163,3,weight category;30 to <50 ml/min,Body Weight,D001835,NA,0,1026,any,2,000000000,Body Weight,NA
2777,23425163,3,weight category;50 to <80 ml/min,Body Weight,D001835,NA,0,1026,any,2,000000000,Body Weight,NA
2778,23432142,NA,NA,unclassifiable,NA,NA,0,0,any,2,000000000,unclassifiable,138
2779,23436336,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
2780,23436336,NA,region,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,NA
2781,23436336,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
2782,23451835,2,"Body Mass Index, kg/m2, <25, 25 to <30, >=30",Body Mass Index,D015992,NA,0,1698,any,2,000000000,Body Mass Index,NA
2783,23471469,2,;high subgroup,Eosinophilia,D004802,NA,0,273,any,2,000000000,Eosinophilia,NA
2784,23471469,2,;low subgroup,Eosinophilia,D004802,NA,0,273,any,2,000000000,Eosinophilia,NA
2785,23471469,2,eosinophils,Eosinophilia,D004802,NA,0,273,any,2,000000000,Eosinophilia,NA
2786,23471469,2,periostin,"POSTN protein, human",C512835,NA,0,273,any,2,000000000,"POSTN protein, human",NA
2787,23473396,2,age,Age Factors,D000367,NA,0,262,any,2,000000000,Age Factors,NA
2788,23473396,2,age;<75 yr,Age Factors,D000367,NA,0,262,any,2,000000000,Age Factors,NA
2789,23473396,2,age;>75 yr,Age Factors,D000367,NA,0,262,any,2,000000000,Age Factors,NA
2790,23473396,2,diabetes,Diabetes Mellitus,D003920,NA,0,262,any,2,000000000,Diabetes Mellitus,NA
2791,23473396,2,Hypertension,Hypertension,D006973,NA,0,262,any,2,000000000,Hypertension,NA
2792,23473396,2,infarct location,Infarction,D007238,NA,0,262,location,7,000000001,Infarction,NA
2793,23473396,2,infarct location;other,Infarction,D007238,NA,0,262,location,7,000000001,Infarction,NA
2794,23473396,2,killip class,Myocardial Infarction,D009203,NA,0,262,severity,11,000100000,Myocardial Infarction,NA
2795,23473396,2,killip class;i,Myocardial Infarction,D009203,NA,0,262,severity,11,000100000,Myocardial Infarction,NA
2796,23473396,2,killip class;ii-iv,Myocardial Infarction,D009203,NA,0,262,severity,11,000100000,Myocardial Infarction,NA
2797,23473396,2,sex,Gender Identity,D005783,NA,0,262,any,2,000000000,Gender Identity,NA
2798,23473396,2,systolic blood pressure,Blood Pressure,D001794,NA,0,262,any,2,000000000,Blood Pressure,NA
2799,23473396,2,timi risk score,Thrombosis,D013927,NA,0,262,severity,11,000100100,Thrombosis,NA
2800,23473396,2,timi risk score;<5,Thrombosis,D013927,NA,0,262,severity,11,000100100,Thrombosis,NA
2801,23473396,2,timi risk score;>5,Thrombosis,D013927,NA,0,262,severity,11,000100100,Thrombosis,NA
2802,23473396,2,weight,Body Weight,D001835,NA,0,262,any,2,000000000,Body Weight,NA
2803,23500237,2,age years,Age Factors,D000367,NA,0,1580,any,2,000000000,Age Factors,NA
2804,23500237,2,antianginal medication usage,Cardiovascular Agents,D002317,NA,0,1580,any,2,000000000,Cardiovascular Agents,NA
2805,23500237,2,"belarus,russia, ukraine",Geographic Locations,D005842,NA,0,1580,any,2,000000000,Geographic Locations,NA
2806,23500237,2,"gender, male , female",Gender Identity,D005783,NA,0,1580,any,2,000000000,Gender Identity,NA
2807,23500237,2,hba1c >Â median,Glycated Hemoglobin A,D006442,NA,0,1580,any,2,000000000,Glycated Hemoglobin A,NA
2808,23500237,2,history of CABG yes no,Coronary Artery Bypass,D001026,NA,0,1580,previous,8,100000000,Coronary Artery Bypass,NA
2809,23500237,2,history of PCI yes no,Percutaneous Coronary Intervention,D062645,NA,0,1580,previous,8,100000000,Percutaneous Coronary Intervention,NA
2810,23501976,NA,Patients  With  Peripheral  Artery  Disease,Peripheral Vascular Diseases,D016491,NA,0,0,any,2,000000000,Peripheral Vascular Diseases,NA
2811,23519546,NA,Age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
2812,23519546,NA,"Body weight, kg",Body Weight,D001835,NA,0,0,any,2,000000000,Body Weight,NA
2813,23519546,NA,Concurrent medication,Losartan,D019808,NA,0,0,current,3,010000000,Losartan,NA
2814,23519546,NA,Concurrent medication,Lisinopril,D017706,NA,0,0,current,3,010000000,Lisinopril,NA
2815,23519546,NA,Diastolic BP,Blood Pressure,D001794,NA,0,0,any,2,000000000,Blood Pressure,NA
2816,23519546,NA,Race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
2817,23529173,NA,gender,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
2818,23564916,3,ace-i/arb,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,449,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
2819,23564916,3,age,Age Factors,D000367,NA,0,449,any,2,000000000,Age Factors,NA
2820,23564916,3,diabetes,Diabetes Mellitus,D003920,NA,0,449,any,2,000000000,Diabetes Mellitus,NA
2821,23564916,3,fascng plasma glucose a medan,Glucose,D005947,NA,0,449,any,2,000000000,Glucose,NA
2822,23564916,3,fastng plasma glucose < median,Glucose,D005947,NA,0,449,any,2,000000000,Glucose,NA
2823,23564916,3,hba1c < median,Glycated Hemoglobin A,D006442,NA,0,449,any,2,000000000,Glycated Hemoglobin A,NA
2824,23564916,3,hba1c >Â median,Glycated Hemoglobin A,D006442,NA,0,449,any,2,000000000,Glycated Hemoglobin A,NA
2825,23564916,3,hbalc < medan,Glycated Hemoglobin A,D006442,NA,0,449,any,2,000000000,Glycated Hemoglobin A,NA
2826,23564916,3,hbalca median,Glycated Hemoglobin A,D006442,NA,0,449,any,2,000000000,Glycated Hemoglobin A,NA
2827,23564916,3,male female,Gender Identity,D005783,NA,0,449,any,2,000000000,Gender Identity,NA
2828,23564916,3,maximum cimt < median,Carotid Intima-Media Thickness,D059168,NA,0,449,any,2,000000000,Carotid Intima-Media Thickness,NA
2829,23564916,3,maximum cimt >Â median,Carotid Intima-Media Thickness,D059168,NA,0,449,any,2,000000000,Carotid Intima-Media Thickness,NA
2830,23564916,3,maximum cimt a med an,Carotid Intima-Media Thickness,D059168,NA,0,449,any,2,000000000,Carotid Intima-Media Thickness,NA
2831,23564916,3,no ace-i/arb,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,449,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
2832,23564916,3,no diabetes,Diabetes Mellitus,D003920,NA,0,449,any,2,000000000,Diabetes Mellitus,NA
2833,23564916,3,no previous cv event,Cardiovascular Diseases,D002318,NA,0,449,previous,8,100000000,Cardiovascular Diseases,NA
2834,23564916,3,no statin,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,449,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
2835,23564916,3,previous cv event,Cardiovascular Diseases,D002318,NA,0,449,previous,8,100000000,Cardiovascular Diseases,NA
2836,23564916,3,stalin,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,449,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
2837,23564916,3,statin,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,449,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
2838,23564916,3,tnglycendes < median,Lipoproteins,D008074,NA,0,449,any,2,000000000,Lipoproteins,NA
2839,23564916,3,tngtycendes a median,Lipoproteins,D008074,NA,0,449,any,2,000000000,Lipoproteins,NA
2840,23564916,3,triglycerides < median,Lipoproteins,D008074,NA,0,449,any,2,000000000,Lipoproteins,NA
2841,23564916,3,triglycerides >Â median,Lipoproteins,D008074,NA,0,449,any,2,000000000,Lipoproteins,NA
2842,23564916,4,ace-i/arb,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,1712,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
2843,23564916,4,age,Age Factors,D000367,NA,0,1712,any,2,000000000,Age Factors,NA
2844,23564916,4,diabetes,Diabetes Mellitus,D003920,NA,0,1712,any,2,000000000,Diabetes Mellitus,NA
2845,23564916,4,fasting plasma glucose < median,Glucose,D005947,NA,0,1712,any,2,000000000,Glucose,NA
2846,23564916,4,fasting plasma glucose >Â median,Glucose,D005947,NA,0,1712,any,2,000000000,Glucose,NA
2847,23564916,4,hba1c < median,Glycated Hemoglobin A,D006442,NA,0,1712,any,2,000000000,Glycated Hemoglobin A,NA
2848,23564916,4,hba1c >Â median,Glycated Hemoglobin A,D006442,NA,0,1712,any,2,000000000,Glycated Hemoglobin A,NA
2849,23564916,4,hbalc < medan,Glycated Hemoglobin A,D006442,NA,0,1712,any,2,000000000,Glycated Hemoglobin A,NA
2850,23564916,4,male female,Gender Identity,D005783,NA,0,1712,any,2,000000000,Gender Identity,NA
2851,23564916,4,maximum cimt < median,Carotid Intima-Media Thickness,D059168,NA,0,1712,any,2,000000000,Carotid Intima-Media Thickness,NA
2852,23564916,4,maximum cimt >Â median,Carotid Intima-Media Thickness,D059168,NA,0,1712,any,2,000000000,Carotid Intima-Media Thickness,NA
2853,23564916,4,maximum cimt a med an,Carotid Intima-Media Thickness,D059168,NA,0,1712,any,2,000000000,Carotid Intima-Media Thickness,NA
2854,23564916,4,no ace-i/arb,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,1712,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
2855,23564916,4,no diabetes,Diabetes Mellitus,D003920,NA,0,1712,any,2,000000000,Diabetes Mellitus,NA
2856,23564916,4,no previous cv event,Cardiovascular Diseases,D002318,NA,0,1712,previous,8,100000000,Cardiovascular Diseases,NA
2857,23564916,4,no statin,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,1712,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
2858,23564916,4,previous cv event,Cardiovascular Diseases,D002318,NA,0,1712,previous,8,100000000,Cardiovascular Diseases,NA
2859,23564916,4,stalin,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,1712,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
2860,23564916,4,statin,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,1712,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
2861,23564916,4,tnglycendes < median,Lipoproteins,D008074,NA,0,1712,any,2,000000000,Lipoproteins,NA
2862,23564916,4,tngtycendes a median,Lipoproteins,D008074,NA,0,1712,any,2,000000000,Lipoproteins,NA
2863,23564916,4,triglycerides < median,Lipoproteins,D008074,NA,0,1712,any,2,000000000,Lipoproteins,NA
2864,23564916,4,triglycerides >Â median,Lipoproteins,D008074,NA,0,1712,any,2,000000000,Lipoproteins,NA
2865,23656980,2,a1c < median,Glycated Hemoglobin A,D006442,NA,0,607,any,2,000000000,Glycated Hemoglobin A,NA
2866,23656980,2,a1c >= median,Glycated Hemoglobin A,D006442,NA,0,607,any,2,000000000,Glycated Hemoglobin A,NA
2867,23656980,2,age < median,Age Factors,D000367,NA,0,607,any,2,000000000,Age Factors,NA
2868,23656980,2,age >- median,Age Factors,D000367,NA,0,607,any,2,000000000,Age Factors,NA
2869,23656980,2,alcohol <= 2/wk,Alcohol Drinking,D000428,NA,0,607,any,2,000000000,Alcohol Drinking,NA
2870,23656980,2,alcohol > 2/wk,Alcohol Drinking,D000428,NA,0,607,any,2,000000000,Alcohol Drinking,NA
2871,23656980,2,depression,Depression,D003863,NA,0,607,any,2,000000000,Depression,NA
2872,23656980,2,diabetes,Diabetes Mellitus,D003920,NA,0,607,any,2,000000000,Diabetes Mellitus,NA
2873,23656980,2,grip strength < meidan,Hand Strength,D018737,NA,0,607,any,2,000000000,Hand Strength,NA
2874,23656980,2,grip strength >= median,Hand Strength,D018737,NA,0,607,any,2,000000000,Hand Strength,NA
2875,23656980,2,no diabetes,Diabetes Mellitus,D003920,NA,0,607,any,2,000000000,Diabetes Mellitus,NA
2876,23656980,2,urine acr < median,Albuminuria,D000419,NA,0,607,any,2,000000000,Albuminuria,NA
2877,23656980,2,urine acr >= median,Albuminuria,D000419,NA,0,607,any,2,000000000,Albuminuria,NA
2878,23656980,2,waist/hip < median,Waist-Hip Ratio,D049629,NA,0,607,any,2,000000000,Waist-Hip Ratio,NA
2879,23656980,2,waisvhip >= median,Waist-Hip Ratio,D049629,NA,0,607,any,2,000000000,Waist-Hip Ratio,NA
2880,23672632,NA,Patient Variable: Ethnicity,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,101
2881,23706759,2,;a1c at baseline <9.0%,Glycated Hemoglobin A,D006442,NA,0,1462,any,2,000000000,Glycated Hemoglobin A,NA
2882,23706759,2,age (years),Age Factors,D000367,NA,0,1462,any,2,000000000,Age Factors,NA
2883,23706759,2,frailty status,Frailty,D000073496,NA,0,1462,any,2,000000000,Frailty,NA
2884,23706759,2,frailty status;frail,Frailty,D000073496,NA,0,1462,any,2,000000000,Frailty,NA
2885,23706759,2,frailty status;non-frail,Frailty,D000073496,NA,0,1462,any,2,000000000,Frailty,NA
2886,23726159,2,age (p=0.53),Age Factors,D000367,NA,0,1714,any,2,000000000,Age Factors,NA
2887,23726159,2,baseline sbp (p=0.78),Blood Pressure,D001794,NA,0,1714,any,2,000000000,Blood Pressure,NA
2888,23726159,2,baseline sbp (p=0.78);sbp,Blood Pressure,D001794,NA,0,1714,any,2,000000000,Blood Pressure,NA
2889,23726159,2,history of diabetes (p=0.64),Diabetes Mellitus,D003920,NA,0,1714,previous,8,100000000,Diabetes Mellitus,NA
2890,23726159,2,history of diabetes (p=0.64);diabetes (n=1106),Diabetes Mellitus,D003920,NA,0,1714,previous,8,100000000,Diabetes Mellitus,NA
2891,23726159,2,history of diabetes (p=0.64);non-diabetic (n=1914),Diabetes Mellitus,D003920,NA,0,1714,any,2,000000000,Diabetes Mellitus,NA
2892,23726159,2,race,Racial Groups,D044469,NA,0,1714,any,2,000000000,Racial Groups,NA
2893,23726159,2,region of residence (p=0.09),Geographic Locations,D005842,NA,0,1714,any,2,000000000,Geographic Locations,NA
2894,23726159,2,region of residence (p=0.09);spain (n=366),Geographic Locations,D005842,NA,0,1714,any,2,000000000,Geographic Locations,NA
2895,23726159,2,sex (p=0.50),Gender Identity,D005783,NA,0,1714,any,2,000000000,Gender Identity,NA
2896,23733198,2,ala carriers,Genetic Profile,D000076610,NA,0,1814,any,2,000000000,Genetic Profile,NA
2897,23733198,2,pro/pro homozygotes,Genetic Profile,D000076610,NA,0,1814,any,2,000000000,Genetic Profile,NA
2898,23735746,2,baseline corticosteroid use,Steroids,D013256,NA,0,649,any,2,000000000,Steroids,NA
2899,23735746,2,baseline corticosteroid use;budesonide,Steroids,D013256,NA,0,649,any,2,000000000,Steroids,NA
2900,23735746,2,baseline corticosteroid use;none,Steroids,D013256,NA,0,649,any,2,000000000,Steroids,NA
2901,23743487,NA,serum sodium,Sodium,D012964,NA,0,0,any,2,000000000,Sodium,NA
2902,23765873,NA,BASFI score,Spondylitis,D013166,NA,0,0,any,2,000000000,Spondylitis,NA
2903,23765873,NA,crp,C-Reactive Protein,D002097,NA,0,0,any,2,000000000,C-Reactive Protein,6
2904,23765873,NA,HLA-B27 status,complex,NA,NA,0,0,any,2,000000000,complex,NA
2905,23765873,NA,IL-6 level,complex,NA,NA,0,0,any,2,000000000,complex,NA
2906,23765873,NA,Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) score,Spondylitis,D013166,NA,0,0,any,2,000000000,Spondylitis,NA
2907,23765873,NA,peripheral arthritis,Arthritis,D001168,NA,0,0,any,2,000000000,Arthritis,129
2908,23769296,NA,NA,unclassifiable,NA,NA,0,0,any,2,000000000,unclassifiable,272
2909,23812596,2,impaired cognitive function (spmsq >2). n-350 n (%) participants with the event of interest,Cognition,D003071,NA,0,216,severity,11,000100000,Cognition,NA
2910,23812596,2,normal cognitive function (spmsq <2). n-1.616 n (%) participants with the event of interest,Cognition,D003071,NA,0,216,severity,11,000100000,Cognition,NA
2911,23861303,NA,crp,C-Reactive Protein,D002097,NA,0,0,any,2,000000000,C-Reactive Protein,17
2912,23909985,2,;a1c at baseline <9.0%,Glycated Hemoglobin A,D006442,NA,0,802,any,2,000000000,Glycated Hemoglobin A,NA
2913,23909985,2,;a1c at baseline =9.0%,Glycated Hemoglobin A,D006442,NA,0,802,any,2,000000000,Glycated Hemoglobin A,NA
2914,23909985,2,;a1c at baseline Ã¢â€°Â¥9.0%,Glycated Hemoglobin A,D006442,NA,0,802,any,2,000000000,Glycated Hemoglobin A,NA
2915,23963895,2,patients with egfr >90 ml/min/1.73m2,Glomerular Filtration Rate,D005919,NA,0,363,any,2,000000000,Glomerular Filtration Rate,NA
2916,23963895,2,patients with egfr 2>30 to <60 ml/min/1.73m2,Glomerular Filtration Rate,D005919,NA,0,363,any,2,000000000,Glomerular Filtration Rate,NA
2917,23963895,2,patients with egfr 2>60 to <90 ml/min/1.73m2,Glomerular Filtration Rate,D005919,NA,0,363,any,2,000000000,Glomerular Filtration Rate,NA
2918,23964932,2,age,Age Factors,D000367,NA,0,858,any,2,000000000,Age Factors,NA
2919,23964932,2,baseline composite mayo clinic score,"Colitis, Ulcerative",D003093,NA,0,858,severity,11,000100001,"Colitis, Ulcerative",NA
2920,23964932,2,baseline composite mayo clinic score,Collagen Diseases,D003095,NA,0,858,severity,11,000100001,Collagen Diseases,NA
2921,23964932,2,baseline composite mayo clinic score,Collagen,D003094,NA,0,858,severity,11,000100001,Collagen,NA
2922,23964932,2,baseline composite mayo clinic score,Collapse Therapy,D003096,NA,0,858,severity,11,000100001,Collapse Therapy,NA
2923,23964932,2,duration of ulcerative colitis,"Colitis, Ulcerative",D003093,NA,0,858,duration,5,001000000,"Colitis, Ulcerative",NA
2924,23964932,2,extent of disease,Colitis,D003092,NA,0,858,type,12,000000010,Colitis,NA
2925,23964932,2,extent of disease;extensive colitis,Colitis,D003092,NA,0,858,severity,11,000100000,Colitis,NA
2926,23964932,2,extent of disease;left sided colitis,Colitis,D003092,NA,0,858,any,2,000000000,Colitis,NA
2927,23964932,2,extent of disease;pancolitis,Colitis,D003092,NA,0,858,any,2,000000000,Colitis,NA
2928,23964932,2,fecal calprotectin,Leukocyte L1 Antigen Complex,D039841,NA,0,NA,any,2,000000000,Leukocyte L1 Antigen Complex,NA
2929,23964932,2,prior treatment history;any prior anti-tnf treatment failure,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,858,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
2930,23964932,2,prior treatment history;prior corticosteroid failure only,Steroids,D013256,NA,0,858,previous,8,100000000,Steroids,NA
2931,23964932,2,prior treatment history;prior immunnosupressive failure but no anti-tnf failure,complex,none,NA,0,858,previous,8,100000000,complex,NA
2932,23964932,2,sex,Gender Identity,D005783,NA,0,858,any,2,000000000,Gender Identity,NA
2933,23964932,2,stratification variables;concomitant corticosteroid use,Steroids,D013256,NA,0,858,any,2,000000000,Steroids,NA
2934,23964932,2,stratification variables;concomitant immunosuppressive and/or prior anti-tnf use,Immunosuppressive Agents,D007166,NA,0,858,previous,8,100000000,Immunosuppressive Agents,NA
2935,23964932,2,stratification variables;no concomitant cortcosteroid use,Steroids,D013256,NA,0,858,any,2,000000000,Steroids,NA
2936,23964932,2,stratification variables;no concomitant immunosuppressive and/or prior anti-tnf use,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,858,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
2937,23984728,NA,pah etiology,Pulmonary Arterial Hypertension,D000081029,NA,0,0,aetiological,1,000001000,Pulmonary Arterial Hypertension,NA
2938,23984728,NA,pah therapy at baseline,Pulmonary Arterial Hypertension,D000081029,NA,0,0,any,2,000000000,Pulmonary Arterial Hypertension,NA
2939,23984728,NA,"PAH type (connective tissue disease, congenital shunts, idiopathic)",Pulmonary Arterial Hypertension,D000081029,NA,0,0,type,12,000000010,Pulmonary Arterial Hypertension,NA
2940,23984728,NA,pulmonary arterial hypertension therapy at baseline,Pulmonary Arterial Hypertension,D000081029,NA,0,0,any,2,000000000,Pulmonary Arterial Hypertension,NA
2941,23984728,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
2942,23984728,NA,region,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,NA
2943,23984728,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
2944,23992601,2,age,Age Factors,D000367,NA,0,813,any,2,000000000,Age Factors,NA
2945,23992601,2,atherosclerosis,Atherosclerosis,D050197,NA,0,813,any,2,000000000,Atherosclerosis,NA
2946,23992601,2,atherosclerosis;multiple risk factors,Atherosclerosis,D050197,NA,0,813,risk score,10,000000100,Atherosclerosis,NA
2947,23992601,2,baseline glycatedÂ hemoglobin,Glycated Hemoglobin A,D006442,NA,0,813,any,2,000000000,Glycated Hemoglobin A,NA
2948,23992601,2,baseline insulin,Insulin,D007328,NA,0,813,any,2,000000000,Insulin,NA
2949,23992601,2,baseline metformin,Hypoglycemic Agents,D007004,NA,0,813,any,2,000000000,Hypoglycemic Agents,NA
2950,23992601,2,baseline microalbumin:,Albuminuria,D000419,NA,0,813,any,2,000000000,Albuminuria,NA
2951,23992601,2,baseline sulfonylurea,Hypoglycemic Agents,D007004,NA,0,813,any,2,000000000,Hypoglycemic Agents,NA
2952,23992601,2,baselineÂ thiazolidinedione,Hypoglycemic Agents,D007004,NA,0,813,any,2,000000000,Hypoglycemic Agents,NA
2953,23992601,2,body-mass index,Body Mass Index,D015992,NA,0,813,any,2,000000000,Body Mass Index,NA
2954,23992601,2,creatinine ratio,Albuminuria,D000419,NA,0,813,any,2,000000000,Albuminuria,NA
2955,23992601,2,duration of diabetes,Diabetes Mellitus,D003920,NA,0,813,duration,5,001000000,Diabetes Mellitus,NA
2956,23992601,2,estimated gfr,Glomerular Filtration Rate,D005919,NA,0,813,any,2,000000000,Glomerular Filtration Rate,NA
2957,23992601,2,prior heart failure,Heart Failure,D006333,NA,0,813,previous,8,100000000,Heart Failure,NA
2958,23992601,2,race,Racial Groups,D044469,NA,0,813,any,2,000000000,Racial Groups,NA
2959,23992601,2,region,Geographic Locations,D005842,NA,0,813,any,2,000000000,Geographic Locations,NA
2960,23992601,2,sex,Gender Identity,D005783,NA,0,813,any,2,000000000,Gender Identity,NA
2961,23992601,3,baseline acei/arb,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,193,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
2962,23992601,3,baseline aspirin,Aspirin,D001241,NA,0,193,any,2,000000000,Aspirin,NA
2963,23992601,3,baseline ccb,Calcium Channel Blockers,D002121,NA,0,193,any,2,000000000,Calcium Channel Blockers,NA
2964,23992601,3,baseline diuretic,Diuretics,D004232,NA,0,193,any,2,000000000,Diuretics,NA
2965,23992601,3,baseline statin,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,193,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
2966,23992601,3,prior hypertension,Hypertension,D006973,NA,0,193,previous,8,100000000,Hypertension,NA
2967,23992601,3,Smoker,Cigarette Smoking,D000073865,NA,0,193,any,2,000000000,Cigarette Smoking,NA
2968,23992601,3,weight,Body Weight,D001835,NA,0,193,any,2,000000000,Body Weight,NA
2969,23992602,2,age,Age Factors,D000367,NA,0,572,any,2,000000000,Age Factors,NA
2970,23992602,2,baseline bmi,Body Mass Index,D015992,NA,0,572,any,2,000000000,Body Mass Index,NA
2971,23992602,2,biguanide use at baseline,Hypoglycemic Agents,D007004,NA,0,572,any,2,000000000,Hypoglycemic Agents,NA
2972,23992602,2,duration of diabetes,Diabetes Mellitus,D003920,NA,0,572,duration,5,001000000,Diabetes Mellitus,NA
2973,23992602,2,Fasting plasma glucose,Glucose,D005947,NA,0,572,any,2,000000000,Glucose,NA
2974,23992602,2,geographic region,Geographic Locations,D005842,NA,0,572,any,2,000000000,Geographic Locations,NA
2975,23992602,2,history of chf before index event,Heart Failure,D006333,NA,0,572,previous,8,100000000,Heart Failure,NA
2976,23992602,2,history of pci or cabg before index event,Coronary Artery Bypass,D001026,NA,0,572,previous,8,100000000,Coronary Artery Bypass,NA
2977,23992602,2,index event;unstable angina,Angina Pectoris,D000787,NA,0,572,any,2,000000000,Angina Pectoris,NA
2978,23992602,2,insulin use at baseline,Insulin,D007328,NA,0,572,any,2,000000000,Insulin,NA
2979,23992602,2,"Medical history
Previous stroke or TIA
Other atherosclerotic event
Neither, Medical History
Hypertension N(%)
Diabetes N(%)
Atrial Fibrillation N(%)
Hospitalization for Heart Failure N(%)
Myocardial Infarction N(%)
Stroke N(%)
Coronary artery bypass surgery N(%)
Percutaneous coronary intervention N(%)",unclassifiable,none,NA,0,572,previous,8,100000000,unclassifiable,NA
2980,23992602,2,race,Racial Groups,D044469,NA,0,572,any,2,000000000,Racial Groups,NA
2981,23992602,2,race;non-white,Racial Groups,D044469,NA,0,572,any,2,000000000,Racial Groups,NA
2982,23992602,2,renal function,Renal Insufficiency,D051437,NA,0,572,any,2,000000000,Renal Insufficiency,NA
2983,23992602,2,renal function;moderate or severe impairment,Renal Insufficiency,D051437,NA,0,572,severity,11,000100000,Renal Insufficiency,NA
2984,23992602,2,renal function;normalfunction or mild impairment,Renal Insufficiency,D051437,NA,0,572,severity,11,000100000,Renal Insufficiency,NA
2985,23992602,2,sex,Gender Identity,D005783,NA,0,572,any,2,000000000,Gender Identity,NA
2986,23992602,2,Smoker,Cigarette Smoking,D000073865,NA,0,572,any,2,000000000,Cigarette Smoking,NA
2987,23992602,2,sulfonylurea use at baseline,Hypoglycemic Agents,D007004,NA,0,572,any,2,000000000,Hypoglycemic Agents,NA
2988,23992602,2,thiazolidinedione use at baseline,Hypoglycemic Agents,D007004,NA,0,572,any,2,000000000,Hypoglycemic Agents,NA
2989,24062327,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,212
2990,24062327,NA,concomitant use of OADs,Hypoglycemic Agents,D007004,NA,0,0,previous,8,100000010,Hypoglycemic Agents,212
2991,24062327,NA,HbA1c,Glycated Hemoglobin A,D006442,NA,0,0,any,2,000000000,Glycated Hemoglobin A,212
2992,24062327,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,212
2993,24062327,NA,region,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,212
2994,24062327,NA,renal function,Renal Insufficiency,D051437,NA,0,0,any,2,000000000,Renal Insufficiency,66
2995,24062327,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,212
2996,24062327,NA,time since diabetes diagnosis,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,212
2997,24062327,NA,type of basal insulin,Insulin,D007328,NA,0,0,type,12,000000010,Insulin,212
2998,24063830,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,87
2999,24063830,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
3000,24063830,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
3001,24063830,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
3002,24067431,2,baseline chronic kidney disease stage,Renal Insufficiency,D051437,NA,0,1153,severity,11,000100000,Renal Insufficiency,NA
3003,24067881,2,Previous anti-TNF alpha,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,1456,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
3004,24076283,2,age;>70 yrs,Age Factors,D000367,NA,0,192,any,2,000000000,Age Factors,NA
3005,24076283,2,baseline ecrcl,Glomerular Filtration Rate,D005919,NA,0,192,any,2,000000000,Glomerular Filtration Rate,NA
3006,24076283,2,baseline ecrcl;<60 ml/min,Glomerular Filtration Rate,D005919,NA,0,192,any,2,000000000,Glomerular Filtration Rate,NA
3007,24076283,2,baseline ecrcl;>60 ml/min,Glomerular Filtration Rate,D005919,NA,0,192,any,2,000000000,Glomerular Filtration Rate,NA
3008,24076283,2,baseline lvef,Stroke Volume,D013318,NA,0,192,any,2,000000000,Stroke Volume,NA
3009,24076283,2,ci-aki risk score,Renal Insufficiency,D051437,NA,1,192,severity,11,000100000,Renal Insufficiency,NA
3010,24076283,2,diabetes mellitus,Diabetes Mellitus,D003920,NA,0,192,any,2,000000000,Diabetes Mellitus,NA
3011,24076283,2,high risk,Acute Kidney Injury,D058186,NA,1,192,severity,11,000100000,Acute Kidney Injury,NA
3012,24076283,2,sex,Gender Identity,D005783,NA,0,192,any,2,000000000,Gender Identity,NA
3013,24084625,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
3014,24084625,NA,Age-Years,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
3015,24084625,NA,creatine phosphokinase tertile,Creatine Kinase,D003402,NA,0,0,any,2,000000000,Creatine Kinase,NA
3016,24084625,NA,creatinine kinase,unclassifiable,NA,NA,0,0,any,2,000000000,unclassifiable,NA
3017,24084625,NA,killip,Myocardial Infarction,D009203,NA,0,0,severity,11,000100000,Myocardial Infarction,NA
3018,24084625,NA,killip class (heart failure severity),Heart Failure,D006333,NA,0,0,severity,11,000100000,Heart Failure,NA
3019,24084625,NA,lvef,Stroke Volume,D013318,NA,0,0,any,2,000000000,Stroke Volume,NA
3020,24084625,NA,timi,Thrombosis,D013927,NA,0,0,any,2,000000000,Thrombosis,NA
3021,24084625,NA,timi flow,Myocardial Infarction,D009203,NA,0,0,any,2,000000000,Myocardial Infarction,NA
3022,24084625,NA,white blood cell count,unclassifiable,NA,NA,0,0,any,2,000000000,unclassifiable,NA
3023,24084625,NA,white blood count,unclassifiable,NA,NA,0,0,any,2,000000000,unclassifiable,NA
3024,24097439,2,acute coronary syndrome,Acute Coronary Syndrome,D054058,NA,0,1681,any,2,000000000,Acute Coronary Syndrome,NA
3025,24097439,2,age;Â£65 yo (n=2739),Age Factors,D000367,NA,0,1681,any,2,000000000,Age Factors,NA
3026,24097439,2,age;<65 yo (n=2306),Age Factors,D000367,NA,0,1681,any,2,000000000,Age Factors,NA
3027,24097439,2,bifurcation,Coronary Vessels,D003331,NA,0,1681,type,12,000000010,Coronary Vessels,NA
3028,24097439,2,diabetes,Diabetes Mellitus,D003920,NA,0,1681,any,2,000000000,Diabetes Mellitus,NA
3029,24097439,2,ejection fraction,Stroke Volume,D013318,NA,0,1681,any,2,000000000,Stroke Volume,NA
3030,24097439,2,male female,Gender Identity,D005783,NA,0,1681,any,2,000000000,Gender Identity,NA
3031,24097439,2,multivessel stenting,Coronary Artery Disease,D003324,NA,0,1681,any,2,000000000,Coronary Artery Disease,NA
3032,24097439,2,type of des,Drug-Eluting Stents,D054855,NA,0,1681,type,12,000000010,Drug-Eluting Stents,NA
3033,24097439,2,type of des;new des (n=1727),Drug-Eluting Stents,D054855,NA,0,1681,type,12,000000010,Drug-Eluting Stents,NA
3034,24097439,2,type of des;older des (n=3318),Drug-Eluting Stents,D054855,NA,0,1681,previous,8,100000010,Drug-Eluting Stents,NA
3035,24119319,2,age group,Age Factors,D000367,NA,0,1232,any,2,000000000,Age Factors,NA
3036,24119319,2,alcohol consumption at baseline,Alcohol Drinking,D000428,NA,0,1232,any,2,000000000,Alcohol Drinking,NA
3037,24119319,2,antihypertensive use,Antihypertensive Agents,D000959,NA,0,1232,any,2,000000000,Antihypertensive Agents,NA
3038,24119319,2,bmi,Body Mass Index,D015992,NA,0,1232,any,2,000000000,Body Mass Index,NA
3039,24119319,2,cardiac disorder,Cardiovascular Diseases,D002318,NA,0,1232,any,2,000000000,Cardiovascular Diseases,NA
3040,24119319,2,cardiovascular disorder,Cardiovascular Diseases,D002318,NA,0,1232,any,2,000000000,Cardiovascular Diseases,NA
3041,24119319,2,diabetes mellitus,Diabetes Mellitus,D003920,NA,0,1232,any,2,000000000,Diabetes Mellitus,NA
3042,24119319,2,ed duration,Erectile Dysfunction,D007172,NA,0,1232,duration,5,001000000,Erectile Dysfunction,NA
3043,24119319,2,ethnicity;nonwhite,Racial Groups,D044469,NA,0,1232,any,2,000000000,Racial Groups,NA
3044,24119319,2,hyperlipidemia,Hypercholesterolemia,D006937,NA,0,1232,any,2,000000000,Hypercholesterolemia,NA
3045,24119319,2,Hypertension,Hypertension,D006973,NA,0,1232,any,2,000000000,Hypertension,NA
3046,24119319,2,race,Racial Groups,D044469,NA,0,1232,any,2,000000000,Racial Groups,NA
3047,24119319,2,smoker at baseline,Cigarette Smoking,D000073865,NA,0,1232,any,2,000000000,Cigarette Smoking,NA
3048,24119319,2,statin use,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,1232,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
3049,24120253,3,COPD severity,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1350,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
3050,24120253,3,geographic region,Geographic Locations,D005842,NA,0,1350,any,2,000000000,Geographic Locations,NA
3051,24120253,3,Geographic region,Geographic Locations,D005842,NA,0,1350,any,2,000000000,Geographic Locations,NA
3052,24120253,3,Inhaled corticosteroids or long acting beta agonist,Steroids,D013256,R03,0,1350,any,2,000000000,Steroids,NA
3053,24120253,4,COPD severity,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,430,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
3054,24120253,4,geographic region,Geographic Locations,D005842,NA,0,430,any,2,000000000,Geographic Locations,NA
3055,24120253,4,Geographic region,Geographic Locations,D005842,NA,0,430,any,2,000000000,Geographic Locations,NA
3056,24120253,4,pre-/concomitant treatment,complex,none,NA,0,430,previous,8,100000000,complex,NA
3057,24141036,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
3058,24141036,NA,at-risk/higher-risk subjects,unclassifiable,NA,NA,0,0,risk score,10,000000100,unclassifiable,NA
3059,24141036,NA,baseline serum C-telopeptide of type I collagen  tertile,unclassifiable,NA,NA,0,0,type,12,000000010,unclassifiable,NA
3060,24141036,NA,previous osteoporotic fractures,"Fractures, Bone",D050723,NA,0,0,previous,8,100000000,"Fractures, Bone",NA
3061,24141036,NA,prior alendronate treatment,Alendronate,D019386,NA,0,0,previous,8,100000000,Alendronate,NA
3062,24156566,2,age in years,Age Factors,D000367,NA,0,466,any,2,000000000,Age Factors,NA
3063,24156566,2,COPD severity moderate or mild Severe or very severe COPD,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,466,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
3064,24156566,2,gender male female,Gender Identity,D005783,NA,0,466,any,2,000000000,Gender Identity,NA
3065,24156566,2,use of inhaled corticosteroids yes no,Steroids,D013256,NA,0,466,any,2,000000000,Steroids,NA
3066,24199686,NA,HbA1c,Glycated Hemoglobin A,D006442,NA,0,0,any,2,000000000,Glycated Hemoglobin A,143
3067,24206457,2,age < 65 years old,Age Factors,D000367,NA,0,1630,any,2,000000000,Age Factors,NA
3068,24206457,2,albuminuria,Albuminuria,D000419,NA,0,1630,any,2,000000000,Albuminuria,NA
3069,24206457,2,egfr < 60 ml/min/1.73m2,Glomerular Filtration Rate,D005919,NA,0,1630,any,2,000000000,Glomerular Filtration Rate,NA
3070,24206457,2,previously on acei+arb,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,1630,previous,8,100000000,Angiotensin-Converting Enzyme Inhibitors,NA
3071,24206457,2,race,Racial Groups,D044469,NA,0,1630,any,2,000000000,Racial Groups,NA
3072,24206457,2,race;black and other,Racial Groups,D044469,NA,0,1630,any,2,000000000,Racial Groups,NA
3073,24245566,2,age,Age Factors,D000367,NA,0,75,any,2,000000000,Age Factors,NA
3074,24245566,2,diabetes,Diabetes Mellitus,D003920,NA,0,75,any,2,000000000,Diabetes Mellitus,NA
3075,24245566,2,estimated gfr,Glomerular Filtration Rate,D005919,NA,0,75,any,2,000000000,Glomerular Filtration Rate,NA
3076,24245566,2,global ischemia,Ischemia,D007511,NA,0,75,any,2,000000000,Ischemia,NA
3077,24245566,2,maximal diameter stenosis,Renal Artery Obstruction,D012078,NA,0,75,severity,11,000100000,Renal Artery Obstruction,NA
3078,24245566,2,race,Racial Groups,D044469,NA,0,75,any,2,000000000,Racial Groups,NA
3079,24245566,2,sbp,Blood Pressure,D001794,NA,0,75,any,2,000000000,Blood Pressure,NA
3080,24245566,2,Serum creatinine,Glomerular Filtration Rate,D005919,NA,0,75,any,2,000000000,Glomerular Filtration Rate,NA
3081,24245566,2,sex,Gender Identity,D005783,NA,0,75,any,2,000000000,Gender Identity,NA
3082,24247616,2,<65,Age Factors,D000367,NA,0,451,any,2,000000000,Age Factors,NA
3083,24247616,2,baseline lipid therapy,lipid modifying agents,NA,C10,0,451,any,2,000000000,lipid modifying agents,NA
3084,24247616,2,diabetes,Diabetes Mellitus,D003920,NA,0,451,any,2,000000000,Diabetes Mellitus,NA
3085,24247616,2,heart failure,Heart Failure,D006333,NA,0,451,any,2,000000000,Heart Failure,NA
3086,24247616,2,male female,Gender Identity,D005783,NA,0,451,any,2,000000000,Gender Identity,NA
3087,24247616,2,mi,Myocardial Infarction,D009203,NA,0,451,any,2,000000000,Myocardial Infarction,NA
3088,24247616,2,PCI Postindex event,Percutaneous Coronary Intervention,D062645,NA,0,451,any,2,000000000,Percutaneous Coronary Intervention,NA
3089,24247616,2,Smoker,Cigarette Smoking,D000073865,NA,0,451,any,2,000000000,Cigarette Smoking,NA
3090,24247616,2,stemi,Myocardial Infarction,D009203,NA,0,451,any,2,000000000,Myocardial Infarction,NA
3091,24247616,2,unstable angina,Angina Pectoris,D000787,NA,0,451,any,2,000000000,Angina Pectoris,NA
3092,24247616,3,<65,Age Factors,D000367,NA,0,1255,any,2,000000000,Age Factors,NA
3093,24247616,3,baseline lipid therapy,lipid modifying agents,NA,C10,0,1255,any,2,000000000,lipid modifying agents,NA
3094,24247616,3,diabetes,Diabetes Mellitus,D003920,NA,0,1255,any,2,000000000,Diabetes Mellitus,NA
3095,24247616,3,heart failure,Heart Failure,D006333,NA,0,1255,any,2,000000000,Heart Failure,NA
3096,24247616,3,male female,Gender Identity,D005783,NA,0,1255,any,2,000000000,Gender Identity,NA
3097,24247616,3,mi,Myocardial Infarction,D009203,NA,0,1255,any,2,000000000,Myocardial Infarction,NA
3098,24247616,3,PCI Postindex event,Percutaneous Coronary Intervention,D062645,NA,0,1255,any,2,000000000,Percutaneous Coronary Intervention,NA
3099,24247616,3,Smoker,Cigarette Smoking,D000073865,NA,0,1255,any,2,000000000,Cigarette Smoking,NA
3100,24247616,3,stemi,Myocardial Infarction,D009203,NA,0,1255,any,2,000000000,Myocardial Infarction,NA
3101,24247616,3,unstable angina,Angina Pectoris,D000787,NA,0,1255,any,2,000000000,Angina Pectoris,NA
3102,24253831,3,age (yr),Age Factors,D000367,NA,0,662,any,2,000000000,Age Factors,NA
3103,24253831,3,"baseline fev, (l)",Pulmonary Ventilation,D012123,NA,0,662,any,2,000000000,Pulmonary Ventilation,NA
3104,24253831,3,grouped region,Geographic Locations,D005842,NA,0,662,any,2,000000000,Geographic Locations,NA
3105,24253831,3,grouped region;australasia,Geographic Locations,D005842,NA,0,662,any,2,000000000,Geographic Locations,NA
3106,24253831,3,sex,Gender Identity,D005783,NA,0,662,any,2,000000000,Gender Identity,NA
3107,24283598,2,age,Age Factors,D000367,NA,0,1840,any,2,000000000,Age Factors,NA
3108,24283598,2,aspirin at baseline,Aspirin,D001241,NA,0,1840,any,2,000000000,Aspirin,NA
3109,24283598,2,male female,Gender Identity,D005783,NA,0,1840,any,2,000000000,Gender Identity,NA
3110,24283598,2,no aspirin at baseline,Aspirin,D001241,NA,0,1840,any,2,000000000,Aspirin,NA
3111,24283598,2,non-black,Racial Groups,D044469,NA,0,1840,any,2,000000000,Racial Groups,NA
3112,24283598,2,race,Racial Groups,D044469,NA,0,1840,any,2,000000000,Racial Groups,NA
3113,24283598,2,smoker,Cigarette Smoking,D000073865,NA,0,1840,any,2,000000000,Cigarette Smoking,NA
3114,24313916,NA,body weight,Body Weight,D001835,NA,0,0,any,2,000000000,Body Weight,128
3115,24339179,2,;no prior tnf inhibitor exposure,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,70,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
3116,24339179,2,;prior tnf inhibitor exposure,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,70,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
3117,24383720,2,copd severity,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,186,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
3118,24383720,2,copd severity;moderate,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,186,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
3119,24383720,2,copd severity;severe,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,186,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
3120,24383720,2,ethnicity;chinese,Racial Groups,D044469,NA,0,186,any,2,000000000,Racial Groups,NA
3121,24383720,2,ics use,Steroids,D013256,NA,0,186,any,2,000000000,Steroids,NA
3122,24383720,2,race,Racial Groups,D044469,NA,0,186,any,2,000000000,Racial Groups,NA
3123,24383720,2,saba reversibility,Steroids,D013256,NA,0,186,any,2,000000000,Steroids,NA
3124,24383720,2,Smoker,Cigarette Smoking,D000073865,NA,0,186,any,2,000000000,Cigarette Smoking,NA
3125,24400655,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,205
3126,24400655,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,205
3127,24400655,NA,HbA1c,Glycated Hemoglobin A,D006442,NA,0,0,any,2,000000000,Glycated Hemoglobin A,204
3128,24400655,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,205
3129,24400655,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,205
3130,24411003,1,dosage of atorvastatin,complex,NA,NA,0,860,any,2,000000000,complex,NA
3131,24504810,NA,Prior treatment status,Lupus Nephritis,D008181,NA,0,0,previous,8,100000000,Lupus Nephritis,NA
3132,24504810,NA,Race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
3133,24561125,NA,using or not using antihypertensive therapy,Antihypertensive Agents,D000959,NA,0,0,any,2,000000000,Antihypertensive Agents,152
3134,24596459,2,age: <65 years,Age Factors,D000367,NA,0,1021,any,2,000000000,Age Factors,NA
3135,24596459,2,age: >65 years,Age Factors,D000367,NA,0,1021,any,2,000000000,Age Factors,NA
3136,24596459,2,bmi: <30.0 kg/m2,Body Mass Index,D015992,NA,0,1021,any,2,000000000,Body Mass Index,NA
3137,24596459,2,bmi: >30.0 kg/m2,Body Mass Index,D015992,NA,0,1021,any,2,000000000,Body Mass Index,NA
3138,24596459,2,ics use at baseline: no,Steroids,D013256,NA,0,1021,any,2,000000000,Steroids,NA
3139,24596459,2,ics use at baseline: yes,Steroids,D013256,NA,0,1021,any,2,000000000,Steroids,NA
3140,24596459,2,male female,Gender Identity,D005783,NA,0,1021,any,2,000000000,Gender Identity,NA
3141,24596459,2,moderate or less airflow limitation,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1021,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
3142,24596459,2,severe or worse airflow limitation,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1021,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
3143,24596459,2,Smoker,Cigarette Smoking,D000073865,NA,0,1021,any,2,000000000,Cigarette Smoking,NA
3144,24622369,NA,HbA1c,Glycated Hemoglobin A,D006442,NA,0,0,any,2,000000000,Glycated Hemoglobin A,273
3145,24646104,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,147
3146,24664227,2,age,Age Factors,D000367,NA,0,602,any,2,000000000,Age Factors,NA
3147,24664227,2,bl h/y: unilateral,Parkinson Disease,D010300,NA,0,602,severity,11,000100000,Parkinson Disease,NA
3148,24664227,2,bl updrs: high,Parkinson Disease,D010300,NA,0,602,severity,11,000100000,Parkinson Disease,NA
3149,24664227,2,bl updrs: low,Parkinson Disease,D010300,NA,0,602,severity,11,000100000,Parkinson Disease,NA
3150,24664227,2,male female,Gender Identity,D005783,NA,0,602,any,2,000000000,Gender Identity,NA
3151,24716680,3,age,Age Factors,D000367,NA,0,502,any,2,000000000,Age Factors,NA
3152,24716680,3,BMI,Body Mass Index,D015992,NA,0,502,any,2,000000000,Body Mass Index,NA
3153,24716680,3,diabetes mellitus,Diabetes Mellitus,D003920,NA,0,502,any,2,000000000,Diabetes Mellitus,NA
3154,24716680,3,"diabetes mellitus;yes, insulin-treated",Insulin,D007328,NA,0,502,any,2,000000000,Insulin,NA
3155,24716680,3,"diabetes mellitus;yes, non-insulin-treated",Insulin,D007328,NA,0,502,any,2,000000000,Insulin,NA
3156,24716680,3,ejection fraction based on local reading,Stroke Volume,D013318,NA,0,502,any,2,000000000,Stroke Volume,NA
3157,24716680,3,estimated gfr,Glomerular Filtration Rate,D005919,NA,0,502,any,2,000000000,Glomerular Filtration Rate,NA
3158,24716680,3,gender,Gender Identity,D005783,NA,0,502,any,2,000000000,Gender Identity,NA
3159,24716680,3,geographic region,Geographic Locations,D005842,NA,0,502,any,2,000000000,Geographic Locations,NA
3160,24716680,3,heart rate,Heart Rate,D006339,NA,0,502,any,2,000000000,Heart Rate,NA
3161,24716680,3,Hypertension,Hypertension,D006973,NA,0,502,any,2,000000000,Hypertension,NA
3162,24716680,3,new york heart association congestive heart failure class,Heart Failure,D006333,NA,0,502,severity,11,000100000,Heart Failure,NA
3163,24716680,3,prior myocardial infarction,Myocardial Infarction,D009203,NA,0,502,previous,8,100000000,Myocardial Infarction,NA
3164,24716680,3,pulse pressure,Blood Pressure,D001794,NA,0,502,any,2,000000000,Blood Pressure,NA
3165,24716680,3,racial category*,Racial Groups,D044469,NA,0,502,any,2,000000000,Racial Groups,NA
3166,24716680,3,randomization stratum;hospitalized for heart failure during that time period,Heart Failure,D006333,NA,0,502,any,2,000000000,Heart Failure,NA
3167,24716680,3,randomization stratum;not hospitalized for heart failure in the year prior to study enrollment,Heart Failure,D006333,NA,0,502,previous,8,100000000,Heart Failure,NA
3168,24716680,3,systolic blood pressure,Blood Pressure,D001794,NA,0,502,any,2,000000000,Blood Pressure,NA
3169,24716680,3,use of blood pressure lowering medication*,Antihypertensive Agents,D000959,NA,0,502,any,2,000000000,Antihypertensive Agents,NA
3170,24716680,3,use of cardiac medication*,cardiac therapy,NA,C01,0,502,any,2,000000000,cardiac therapy,NA
3171,24716680,3,use of statins,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,502,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
3172,24727254,2,;fgf-23 high/ egfr <60,Fibroblast Growth Factors,D005346,NA,0,1417,any,2,000000000,Fibroblast Growth Factors,NA
3173,24727254,2,;fgf-23 high/ egfr >60,Fibroblast Growth Factors,D005346,NA,0,1417,any,2,000000000,Fibroblast Growth Factors,NA
3174,24727254,2,;fgf-23 low/ egfr <60,Fibroblast Growth Factors,D005346,NA,0,1417,any,2,000000000,Fibroblast Growth Factors,NA
3175,24727254,2,;fgf-23 low/ egfr >60,Fibroblast Growth Factors,D005346,NA,0,1417,any,2,000000000,Fibroblast Growth Factors,NA
3176,24727254,3,risk categories,Fibroblast Growth Factors,D005346,NA,0,568,risk score,10,000000100,Fibroblast Growth Factors,NA
3177,24727254,3,risk categories;fgf-23 high/ <1 elevated biomarkers,Fibroblast Growth Factors,D005346,NA,0,568,risk score,10,000000100,Fibroblast Growth Factors,NA
3178,24727254,3,risk categories;fgf-23 high/ >2 elevated biomarkers,Fibroblast Growth Factors,D005346,NA,0,568,risk score,10,000000100,Fibroblast Growth Factors,NA
3179,24727254,3,risk categories;fgf-23 low/ <1 elevated biomarkers,Fibroblast Growth Factors,D005346,NA,0,568,risk score,10,000000100,Fibroblast Growth Factors,NA
3180,24727254,3,risk categories;fgf-23 low/ >2 elevated biomarkers,Fibroblast Growth Factors,D005346,NA,0,568,risk score,10,000000100,Fibroblast Growth Factors,NA
3181,24727258,2,6 minute walk distance,Exercise,D015444,NA,0,1061,any,2,000000000,Exercise,NA
3182,24742013,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,11
3183,24742013,NA,Patient Variable: Age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,43
3184,24780614,2,acute reperfusion,Reperfusion,D015424,NA,0,1565,any,2,000000000,Reperfusion,NA
3185,24780614,2,age,Age Factors,D000367,NA,0,1565,any,2,000000000,Age Factors,NA
3186,24780614,2,anterior or non- anterior ml,Myocardial Infarction,D009203,NA,0,1565,any,2,000000000,Myocardial Infarction,NA
3187,24780614,2,cardiac enzyates raised,Biomarkers,D015415,NA,0,1565,any,2,000000000,Biomarkers,NA
3188,24780614,2,diabetes,Diabetes Mellitus,D003920,NA,0,1565,any,2,000000000,Diabetes Mellitus,NA
3189,24780614,2,egfr,Glomerular Filtration Rate,D005919,NA,0,1565,any,2,000000000,Glomerular Filtration Rate,NA
3190,24780614,2,heart rate,Heart Rate,D006339,NA,0,1565,any,2,000000000,Heart Rate,NA
3191,24780614,2,heart rate (median 73.0},Heart Rate,D006339,NA,0,1565,any,2,000000000,Heart Rate,NA
3192,24780614,2,history of atrial fibrillation,Atrial Fibrillation,D001281,NA,0,1565,previous,8,100000000,Atrial Fibrillation,NA
3193,24780614,2,history of atrial Fibrillation,Atrial Fibrillation,D001281,NA,0,1565,previous,8,100000000,Atrial Fibrillation,NA
3194,24780614,2,Hypertension,Hypertension,D006973,NA,0,1565,any,2,000000000,Hypertension,NA
3195,24780614,2,male female,Gender Identity,D005783,NA,0,1565,any,2,000000000,Gender Identity,NA
3196,24780614,2,previous ml,Myocardial Infarction,D009203,NA,0,1565,previous,8,100000000,Myocardial Infarction,NA
3197,24780614,2,prior acbi or arb use,Angiotensin Receptor Antagonists,D057911,NA,0,1565,previous,8,100000000,Angiotensin Receptor Antagonists,NA
3198,24780614,2,prior bb plus acbi plus arb use,complex,none,NA,0,1565,previous,8,100000000,complex,NA
3199,24780614,2,pulse pressure,Blood Pressure,D001794,NA,0,1565,any,2,000000000,Blood Pressure,NA
3200,24780614,2,pulse pressure (median 50.0],Blood Pressure,D001794,NA,0,1565,any,2,000000000,Blood Pressure,NA
3201,24780614,2,systolic blood pressure (median 125.0),Blood Pressure,D001794,NA,0,1565,any,2,000000000,Blood Pressure,NA
3202,24780614,2,use of pci or thrombolysis within one day of randomization;thrombolysis,complex,NA,NA,0,1565,any,2,000000000,complex,NA
3203,24780614,3,anterior or nonanterior MI,Myocardial Infarction,D009203,NA,0,520,type,12,000000010,Myocardial Infarction,NA
3204,24780614,3,cardiac enzymes raised,Troponin,D014336,NA,0,520,any,2,000000000,Troponin,NA
3205,24780614,3,egfr,Glomerular Filtration Rate,D005919,NA,0,520,any,2,000000000,Glomerular Filtration Rate,NA
3206,24780614,3,heart rate,Heart Rate,D006339,NA,0,520,any,2,000000000,Heart Rate,NA
3207,24780614,3,heart rate (median 73.0},Heart Rate,D006339,NA,0,520,any,2,000000000,Heart Rate,NA
3208,24780614,3,history of diabetes,Diabetes Mellitus,D003920,NA,0,520,previous,8,100000000,Diabetes Mellitus,NA
3209,24780614,3,PCI or thrombolysis,complex,none,NA,0,520,any,2,000000000,complex,NA
3210,24780614,3,prior betabocker or acei,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,520,previous,8,100000000,Angiotensin-Converting Enzyme Inhibitors,NA
3211,24780614,3,prior MI,Myocardial Infarction,D009203,NA,0,520,previous,8,100000000,Myocardial Infarction,NA
3212,24780614,3,prior use of betablocker and acei and arb,cardiac therapy,NA,C01,0,520,previous,8,100000000,cardiac therapy,NA
3213,24780614,3,pulse pressure,Blood Pressure,D001794,NA,0,520,any,2,000000000,Blood Pressure,NA
3214,24780614,3,pulse pressure (median 50.0],Blood Pressure,D001794,NA,0,520,any,2,000000000,Blood Pressure,NA
3215,24780614,3,timing of acute reperfusion,Reperfusion,D015424,NA,0,520,any,2,000000000,Reperfusion,NA
3216,24780614,3,timing of dose administration following onset of symptoms,Symptom Flare Up,D000067251,NA,0,520,any,2,000000000,Symptom Flare Up,NA
3217,24795251,NA,ckd stage,Renal Insufficiency,D051437,NA,0,0,severity,11,000100000,Renal Insufficiency,7
3218,24825642,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,220
3219,24825642,NA,amily history of premature coronary heart disease,Coronary Artery Disease,D003324,NA,0,0,previous,8,100000000,Coronary Artery Disease,NA
3220,24825642,NA,baseline LDL,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,NA
3221,24825642,NA,baseline triglyceridelevel,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,NA
3222,24825642,NA,baselinePCSK9 level(splitbymedian),Proprotein Convertases,D043484,NA,0,0,any,2,000000000,Proprotein Convertases,221
3223,24825642,NA,BMI,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,221
3224,24825642,NA,glucose tolerance status,Glucose Intolerance,D018149,NA,0,0,any,2,000000000,Glucose Intolerance,221
3225,24825642,NA,having 2 or more baseline coronary heart disease risk factors,Coronary Artery Disease,D003324,NA,0,0,risk score,10,000000100,Coronary Artery Disease,NA
3226,24825642,NA,hypertension,Hypertension,D006973,NA,0,0,any,2,000000000,Hypertension,221
3227,24825642,NA,National Cholesterol Education Program high risk,Lipoproteins,D008074,NA,0,0,risk score,10,000000100,Lipoproteins,NA
3228,24825642,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,221
3229,24825642,NA,region,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,221
3230,24825642,NA,smoking status,Cigarette Smoking,D000073865,NA,0,0,any,2,000000000,Cigarette Smoking,221
3231,24839241,2,age groups,Age Factors,D000367,NA,0,974,any,2,000000000,Age Factors,NA
3232,24839241,2,BMI,Body Mass Index,D015992,NA,0,974,any,2,000000000,Body Mass Index,NA
3233,24839241,2,calcium level,Hypercalcemia,D006934,NA,0,974,any,2,000000000,Hypercalcemia,NA
3234,24839241,2,charlson,Comorbidity,D015897,NA,0,974,severity,11,000100000,Comorbidity,NA
3235,24839241,2,eq-5d mobility,Exercise,D015444,NA,0,974,any,2,000000000,Exercise,NA
3236,24839241,2,eq-5d mobility;walking,Exercise,D015444,NA,0,974,any,2,000000000,Exercise,NA
3237,24839241,2,fracture,"Fractures, Bone",D050723,NA,0,974,any,2,000000000,"Fractures, Bone",NA
3238,24839241,2,fracture;hip fracture only,"Fractures, Bone",D050723,NA,0,974,any,2,000000000,"Fractures, Bone",NA
3239,24839241,2,hip fracture,"Fractures, Cartilage",D050724,NA,0,974,any,2,000000000,"Fractures, Cartilage",NA
3240,24839241,2,hip fracture;intertrochanteric,Papillomavirus E7 Proteins,D050725,NA,0,974,any,2,000000000,Papillomavirus E7 Proteins,NA
3241,24839241,2,mental status,Mental Status and Dementia Tests,D000073216,NA,0,974,any,2,000000000,Mental Status and Dementia Tests,NA
3242,24839241,2,Prior use of osteoporosis medications,drugs affecting bone structure and mineralization,NA,M05B,0,974,previous,8,100000000,drugs affecting bone structure and mineralization,NA
3243,24839241,2,race,Racial Groups,D044469,NA,0,974,any,2,000000000,Racial Groups,NA
3244,24839241,2,region,Geographic Locations,D005842,NA,0,974,any,2,000000000,Geographic Locations,NA
3245,24839241,2,sex,Gender Identity,D005783,NA,0,974,any,2,000000000,Gender Identity,NA
3246,24839241,2,t-score at femoral neck,Osteoporosis,D010024,NA,0,974,severity,11,000100000,Osteoporosis,NA
3247,24839241,2,time-to-first infusion,"Infusions, Intravenous",D007262,NA,0,974,any,2,000000000,"Infusions, Intravenous",NA
3248,24842697,2,;amlodipine vs chlorthalidone obese,Obesity,D009765,NA,0,1004,any,2,000000000,Obesity,NA
3249,24842697,2,;amlodipine vs chlorthalidone overweight,Overweight,D050177,NA,0,1004,any,2,000000000,Overweight,NA
3250,24842697,2,;lisinopril vs chlorthalidone obese,Obesity,D009765,NA,0,1004,any,2,000000000,Obesity,NA
3251,24842697,2,;lisinopril vs chlorthalidone overweight,Overweight,D050177,NA,0,1004,any,2,000000000,Overweight,NA
3252,24842697,3,;amlodipine vs chlorthalidone obese,Obesity,D009765,NA,0,1658,any,2,000000000,Obesity,NA
3253,24842697,3,;amlodipine vs chlorthalidone overweight,Overweight,D050177,NA,0,1658,any,2,000000000,Overweight,NA
3254,24842697,3,;lisinopril vs chlorthalidone obese,Obesity,D009765,NA,0,1658,any,2,000000000,Obesity,NA
3255,24842697,3,;lisinopril vs chlorthalidone overweight,Overweight,D050177,NA,0,1658,any,2,000000000,Overweight,NA
3256,24859203,NA,concomitant corticosteroid,Adrenal Cortex Hormones,D000305,S02B,0,0,any,2,000000000,Adrenal Cortex Hormones,NA
3257,24859203,NA,concomitant immunosupressant,Immunosuppressive Agents,D007166,NA,0,0,any,2,000000000,Immunosuppressive Agents,NA
3258,24859203,NA,TNF antagonist,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,0,disease response,4,000000000,Tumor Necrosis Factor Inhibitors,74
3259,24898834,2,age <65 years,Age Factors,D000367,NA,0,406,any,2,000000000,Age Factors,NA
3260,24898834,2,age >65 years,Age Factors,D000367,NA,0,406,any,2,000000000,Age Factors,NA
3261,24898834,2,depression,Mental Status and Dementia Tests,D000073216,NA,0,406,any,2,000000000,Mental Status and Dementia Tests,NA
3262,24898834,2,diabetes,Diabetes Mellitus,D003920,NA,0,406,any,2,000000000,Diabetes Mellitus,NA
3263,24898834,2,education <8 years,Educational Status,D004522,NA,0,406,any,2,000000000,Educational Status,NA
3264,24898834,2,education >12 years,Educational Status,D004522,NA,0,406,any,2,000000000,Educational Status,NA
3265,24898834,2,education 8-12 years,Educational Status,D004522,NA,0,406,any,2,000000000,Educational Status,NA
3266,24898834,2,hba >median,Glycated Hemoglobin A,D006442,NA,0,406,any,2,000000000,Glycated Hemoglobin A,NA
3267,24898834,2,hbak > median,Glycated Hemoglobin A,D006442,NA,0,406,any,2,000000000,Glycated Hemoglobin A,NA
3268,24898834,2,hbak>median,Glycated Hemoglobin A,D006442,NA,0,406,any,2,000000000,Glycated Hemoglobin A,NA
3269,24898834,2,hbalc > median,Glycated Hemoglobin A,D006442,NA,0,406,any,2,000000000,Glycated Hemoglobin A,NA
3270,24898834,2,hbalc<median,Glycated Hemoglobin A,D006442,NA,0,406,any,2,000000000,Glycated Hemoglobin A,NA
3271,24898834,2,Insulin glargine,Insulin,D007328,NA,0,406,any,2,000000000,Insulin,NA
3272,24898834,2,male female,Gender Identity,D005783,NA,0,406,any,2,000000000,Gender Identity,NA
3273,24898834,2,no depression,Mental Status and Dementia Tests,D000073216,NA,0,406,any,2,000000000,Mental Status and Dementia Tests,NA
3274,24898834,2,no diabetes,Diabetes Mellitus,D003920,NA,0,406,any,2,000000000,Diabetes Mellitus,NA
3275,24898834,2,omega-3 fatty acid,Fatty Acids,D005227,NA,0,406,any,2,000000000,Fatty Acids,NA
3276,24898834,3,age <65 years,Age Factors,D000367,NA,0,1449,any,2,000000000,Age Factors,NA
3277,24898834,3,age >65 years,Age Factors,D000367,NA,0,1449,any,2,000000000,Age Factors,NA
3278,24898834,3,depression,Mental Status and Dementia Tests,D000073216,NA,0,1449,any,2,000000000,Mental Status and Dementia Tests,NA
3279,24898834,3,diabetes,Diabetes Mellitus,D003920,NA,0,1449,any,2,000000000,Diabetes Mellitus,NA
3280,24898834,3,education <8 years,Educational Status,D004522,NA,0,1449,any,2,000000000,Educational Status,NA
3281,24898834,3,education >12 years,Educational Status,D004522,NA,0,1449,any,2,000000000,Educational Status,NA
3282,24898834,3,education 8-12 years,Educational Status,D004522,NA,0,1449,any,2,000000000,Educational Status,NA
3283,24898834,3,hbalc <median,Glycated Hemoglobin A,D006442,NA,0,1449,any,2,000000000,Glycated Hemoglobin A,NA
3284,24898834,3,hbalc > median,Glycated Hemoglobin A,D006442,NA,0,1449,any,2,000000000,Glycated Hemoglobin A,NA
3285,24898834,3,hbalc<median,Glycated Hemoglobin A,D006442,NA,0,1449,any,2,000000000,Glycated Hemoglobin A,NA
3286,24898834,3,hbalc>median,Glycated Hemoglobin A,D006442,NA,0,1449,any,2,000000000,Glycated Hemoglobin A,NA
3287,24898834,3,Insulin glargine,Insulin,D007328,NA,0,1449,any,2,000000000,Insulin,NA
3288,24898834,3,male female,Gender Identity,D005783,NA,0,1449,any,2,000000000,Gender Identity,NA
3289,24898834,3,no depression,Mental Status and Dementia Tests,D000073216,NA,0,1449,any,2,000000000,Mental Status and Dementia Tests,NA
3290,24898834,3,no diabetes,Diabetes Mellitus,D003920,NA,0,1449,any,2,000000000,Diabetes Mellitus,NA
3291,24907147,4,disease severity,"Arthritis, Rheumatoid",D001172,NA,0,1054,severity,11,000100000,"Arthritis, Rheumatoid",NA
3292,24907147,5,disease severity,"Arthritis, Rheumatoid",D001172,NA,0,1559,severity,11,000100000,"Arthritis, Rheumatoid",NA
3293,24907147,5,Disease severity,"Arthritis, Rheumatoid",D001172,NA,0,1559,severity,11,000100000,"Arthritis, Rheumatoid",NA
3294,24918789,2,;1st tertile (<=87 mg/dl [<= 2.3 mmol/l])b,Lipoproteins,D008074,NA,0,1007,any,2,000000000,Lipoproteins,NA
3295,24918789,2,;2nd tertile (>87 to <=120 mg/dl [>2.3 to <=3.1 mmol/l])c,Lipoproteins,D008074,NA,0,1007,any,2,000000000,Lipoproteins,NA
3296,24918789,2,;3rd tertile (>120 mg/dl [>3.1 mmol/l])d,Lipoproteins,D008074,NA,0,1007,any,2,000000000,Lipoproteins,NA
3297,24942540,NA,inadequate response to anti-TNF agents,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,0,disease response,4,000000000,Tumor Necrosis Factor Inhibitors,NA
3298,24942540,NA,methotrexate,Immunosuppressive Agents,D007166,NA,0,0,any,2,000000000,Immunosuppressive Agents,75
3299,24942540,NA,other DMARDS,Antirheumatic Agents,D018501,NA,0,0,previous,8,100000000,Antirheumatic Agents,NA
3300,24962242,NA,antiepileptic drugs,Anticonvulsants,D000927,NA,0,0,any,2,000000000,Anticonvulsants,170
3301,24962242,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,170
3302,24962242,NA,region,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,171
3303,24962242,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,170
3304,24966672,2,;non-tiotropium,Bronchodilator Agents,D001993,NA,0,1291,any,2,000000000,Bronchodilator Agents,NA
3305,24966672,2,;tiotropium,Bronchodilator Agents,D001993,NA,0,1291,any,2,000000000,Bronchodilator Agents,NA
3306,24966672,2,non-tiotropium,Bronchodilator Agents,D001993,NA,0,1291,any,2,000000000,Bronchodilator Agents,NA
3307,24966672,2,tiotropium,Bronchodilator Agents,D001993,NA,0,1291,any,2,000000000,Bronchodilator Agents,NA
3308,24966672,3,;non-tiotropium,Bronchodilator Agents,D001993,NA,0,882,any,2,000000000,Bronchodilator Agents,NA
3309,24966672,3,;tiotropium,Bronchodilator Agents,D001993,NA,0,882,any,2,000000000,Bronchodilator Agents,NA
3310,24966672,3,non-tiotropium,Bronchodilator Agents,D001993,NA,0,882,any,2,000000000,Bronchodilator Agents,NA
3311,24966672,3,tiotropium,Bronchodilator Agents,D001993,NA,0,882,any,2,000000000,Bronchodilator Agents,NA
3312,25002161,2,age,Age Factors,D000367,NA,0,1806,any,2,000000000,Age Factors,NA
3313,25002161,2,diabetes,Diabetes Mellitus,D003920,NA,0,1806,any,2,000000000,Diabetes Mellitus,NA
3314,25002161,2,male female,Gender Identity,D005783,NA,0,1806,any,2,000000000,Gender Identity,NA
3315,25002161,2,no diabetes,Diabetes Mellitus,D003920,NA,0,1806,any,2,000000000,Diabetes Mellitus,NA
3316,25002161,2,non-black,Racial Groups,D044469,NA,0,1806,any,2,000000000,Racial Groups,NA
3317,25002161,2,race,Racial Groups,D044469,NA,0,1806,any,2,000000000,Racial Groups,NA
3318,25005327,NA,rheumatoud arthritis disese severity,"Arthritis, Rheumatoid",D001172,NA,0,0,severity,11,000100000,"Arthritis, Rheumatoid",12
3319,25031188,2,age<65 years old,Age Factors,D000367,NA,0,1237,any,2,000000000,Age Factors,NA
3320,25031188,2,age>= 65 years old,Age Factors,D000367,NA,0,1237,any,2,000000000,Age Factors,NA
3321,25031188,2,bmi >=25kg/m2,Body Mass Index,D015992,NA,0,1237,any,2,000000000,Body Mass Index,NA
3322,25031188,2,bmi<25kg/m2,Body Mass Index,D015992,NA,0,1237,any,2,000000000,Body Mass Index,NA
3323,25031188,2,family history of diabetes (-),Diabetes Mellitus,D003920,NA,0,1237,family history,6,000010000,Diabetes Mellitus,NA
3324,25031188,2,family history of diabetes (+),Diabetes Mellitus,D003920,NA,0,1237,family history,6,000010000,Diabetes Mellitus,NA
3325,25031188,2,fbs <100 mg/dl,Glycemic Control,D000085002,NA,0,1237,any,2,000000000,Glycemic Control,NA
3326,25031188,2,fbs >=100 mg/dl,Glycemic Control,D000085002,NA,0,1237,any,2,000000000,Glycemic Control,NA
3327,25031188,2,male female,Gender Identity,D005783,NA,0,1237,any,2,000000000,Gender Identity,NA
3328,25031188,2,with acei/arb,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,1237,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
3329,25031188,2,with beta blocker,Adrenergic beta-Antagonists,D000319,NA,0,1237,any,2,000000000,Adrenergic beta-Antagonists,NA
3330,25031188,2,without acei/arb,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,1237,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
3331,25031188,2,without beta blocker,Adrenergic beta-Antagonists,D000319,NA,0,1237,any,2,000000000,Adrenergic beta-Antagonists,NA
3332,25037988,2,;acs,Acute Coronary Syndrome,D054058,NA,0,281,any,2,000000000,Acute Coronary Syndrome,NA
3333,25037988,2,;age >75,Age Factors,D000367,NA,0,281,any,2,000000000,Age Factors,NA
3334,25037988,2,;aqc<75,Age Factors,D000367,NA,0,281,any,2,000000000,Age Factors,NA
3335,25037988,2,;bmi <30,Body Mass Index,D015992,NA,0,281,any,2,000000000,Body Mass Index,NA
3336,25037988,2,;bmi >30,Body Mass Index,D015992,NA,0,281,any,2,000000000,Body Mass Index,NA
3337,25037988,2,;diabetes,Diabetes Mellitus,D003920,NA,0,281,any,2,000000000,Diabetes Mellitus,NA
3338,25037988,2,;no acs,Acute Coronary Syndrome,D054058,NA,0,281,any,2,000000000,Acute Coronary Syndrome,NA
3339,25037988,2,;no diabetes,Diabetes Mellitus,D003920,NA,0,281,any,2,000000000,Diabetes Mellitus,NA
3340,25037988,2,;no smoking,Cigarette Smoking,D000073865,NA,0,281,any,2,000000000,Cigarette Smoking,NA
3341,25037988,2,;number of stent=1,Stents,D015607,NA,0,281,any,2,000000000,Stents,NA
3342,25037988,2,;number stent >2,Stents,D015607,NA,0,281,any,2,000000000,Stents,NA
3343,25037988,2,male female,Gender Identity,D005783,NA,0,281,any,2,000000000,Gender Identity,NA
3344,25037988,2,Smoker,Cigarette Smoking,D000073865,NA,0,281,any,2,000000000,Cigarette Smoking,NA
3345,25037988,3,;acs,Acute Coronary Syndrome,D054058,NA,0,569,any,2,000000000,Acute Coronary Syndrome,NA
3346,25037988,3,;age >75,Age Factors,D000367,NA,0,569,any,2,000000000,Age Factors,NA
3347,25037988,3,;aqc<75,Age Factors,D000367,NA,0,569,any,2,000000000,Age Factors,NA
3348,25037988,3,;bmi <30,Body Mass Index,D015992,NA,0,569,any,2,000000000,Body Mass Index,NA
3349,25037988,3,;bmi >30,Body Mass Index,D015992,NA,0,569,any,2,000000000,Body Mass Index,NA
3350,25037988,3,;diabetes,Diabetes Mellitus,D003920,NA,0,569,any,2,000000000,Diabetes Mellitus,NA
3351,25037988,3,;no acs,Acute Coronary Syndrome,D054058,NA,0,569,any,2,000000000,Acute Coronary Syndrome,NA
3352,25037988,3,;no diabetes,Diabetes Mellitus,D003920,NA,0,569,any,2,000000000,Diabetes Mellitus,NA
3353,25037988,3,;no smoking,Cigarette Smoking,D000073865,NA,0,569,any,2,000000000,Cigarette Smoking,NA
3354,25037988,3,;number of stent=1,Stents,D015607,NA,0,569,any,2,000000000,Stents,NA
3355,25037988,3,;number stent >2,Stents,D015607,NA,0,569,any,2,000000000,Stents,NA
3356,25037988,3,male female,Gender Identity,D005783,NA,0,569,any,2,000000000,Gender Identity,NA
3357,25037988,3,Smoker,Cigarette Smoking,D000073865,NA,0,569,any,2,000000000,Cigarette Smoking,NA
3358,25045258,2,non-tiotropium,Bronchodilator Agents,D001993,NA,0,552,any,2,000000000,Bronchodilator Agents,NA
3359,25045258,2,tiotropium,Bronchodilator Agents,D001993,NA,0,552,any,2,000000000,Bronchodilator Agents,NA
3360,25046337,2,age,Age Factors,D000367,NA,0,108,any,2,000000000,Age Factors,NA
3361,25046337,2,baseline urticaria activity score,Urticaria,D014581,NA,0,108,severity,11,000100000,Urticaria,NA
3362,25046337,2,baseline weekly itch severity score,Pruritus,D011537,NA,0,108,severity,11,000100000,Pruritus,NA
3363,25046337,2,body weiqht,Body Weight,D001835,NA,0,108,any,2,000000000,Body Weight,NA
3364,25046337,2,duration of disease before baseline,Urticaria,D014581,NA,0,108,previous,8,101000000,Urticaria,NA
3365,25046337,2,level of thyroperoxidase antibody at baseline,Autoantibodies,D001323,NA,0,108,any,2,000000000,Autoantibodies,NA
3366,25046337,2,male female,Gender Identity,D005783,NA,0,108,any,2,000000000,Gender Identity,NA
3367,25046337,2,presence of angioedema at baseline,Angioedema,D000799,NA,0,108,any,2,000000000,Angioedema,NA
3368,25046337,2,previous number of ciu/csu medications,Histamine Antagonists,D006633,NA,0,108,previous,8,100000000,Histamine Antagonists,NA
3369,25046337,2,previous use of systemic steroids for ciu/csu,Steroids,D013256,NA,0,108,previous,8,100000000,Steroids,NA
3370,25046337,2,race,Racial Groups,D044469,NA,0,108,any,2,000000000,Racial Groups,NA
3371,25046337,2,region,Geographic Locations,D005842,NA,0,108,any,2,000000000,Geographic Locations,NA
3372,25046337,2,region;non-united states,Geographic Locations,D005842,NA,0,108,any,2,000000000,Geographic Locations,NA
3373,25047021,1,tofacitinib-treated patients in the long-term extension study population,Immunosuppressive Agents,D007166,NA,0,566,any,2,000000000,Immunosuppressive Agents,NA
3374,25047021,1,tofacitinib-treated patients in the pooled phase II study population,Immunosuppressive Agents,D007166,NA,0,566,any,2,000000000,Immunosuppressive Agents,NA
3375,25047021,1,tofacitinib-treated patients in the pooled phase III study population,Immunosuppressive Agents,D007166,NA,0,566,any,2,000000000,Immunosuppressive Agents,NA
3376,25111880,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,131
3377,25111880,NA,BMI,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,132
3378,25111880,NA,femoral neck,Osteoporosis,D010024,NA,0,0,any,2,000000000,Osteoporosis,NA
3379,25111880,NA,total hip BMD,Osteoporosis,D010024,NA,0,0,any,2,000000000,Osteoporosis,NA
3380,25161043,2,age,Age Factors,D000367,NA,0,362,any,2,000000000,Age Factors,NA
3381,25161043,2,infarct location (interactsn$: p=0.29),Infarction,D007238,NA,0,362,location,7,000000001,Infarction,NA
3382,25161043,2,killip class (interaction: p=0.62),Myocardial Infarction,D009203,NA,0,362,severity,11,000100000,Myocardial Infarction,NA
3383,25161043,2,killip class (interaction: p=0.62);ii - iv (%),Myocardial Infarction,D009203,NA,0,362,severity,11,000100000,Myocardial Infarction,NA
3384,25161043,2,previous ml (interaction: p=0.09),Myocardial Infarction,D009203,NA,0,362,previous,8,100010000,Myocardial Infarction,NA
3385,25161043,2,sex (interaction: p=0.59),Gender Identity,D005783,NA,0,362,any,2,000000000,Gender Identity,NA
3386,25161043,2,systolic blood pressure [mmhg] (interaction: p=0.56);140 to <160 (%),Blood Pressure,D001794,NA,0,362,any,2,000000000,Blood Pressure,NA
3387,25161043,2,timi risk score (interaction: p=0.49),Thrombosis,D013927,NA,1,362,severity,11,000100000,Thrombosis,NA
3388,25175921,2,'gpifo\'llia inhibitor use before angography,Platelet Aggregation Inhibitors,D010975,NA,0,1446,previous,8,100000000,Platelet Aggregation Inhibitors,NA
3389,25175921,2,age,Age Factors,D000367,NA,0,1446,any,2,000000000,Age Factors,NA
3390,25175921,2,diabetes,Diabetes Mellitus,D003920,NA,0,1446,any,2,000000000,Diabetes Mellitus,NA
3391,25175921,2,gpifeellla inhibitor use before angography,complex,none,NA,0,1446,previous,8,100000000,complex,NA
3392,25175921,2,"heparin, â€˜ondaparinux or brvalirudin use between rxjex event","Heparin, Low-Molecular-Weight",D006495,NA,0,1446,any,2,000000000,"Heparin, Low-Molecular-Weight",NA
3393,25175921,2,highest killip classiciation pre-pci,Percutaneous Coronary Intervention,D062645,NA,0,1446,previous severity,9,100100000,Percutaneous Coronary Intervention,NA
3394,25175921,2,index event;stemi,Myocardial Infarction,D009203,NA,0,1446,any,2,000000000,Myocardial Infarction,NA
3395,25175921,2,location of ml,Myocardial Infarction,D009203,NA,0,1446,location,7,000000001,Myocardial Infarction,NA
3396,25175921,2,location of ml;non-anterior,Myocardial Infarction,D009203,NA,0,1446,location,7,000000001,Myocardial Infarction,NA
3397,25175921,2,morphine use for index event/pci,Analgesics,D000700,NA,0,1446,any,2,000000000,Analgesics,NA
3398,25175921,2,previous ml,Myocardial Infarction,D009203,NA,0,1446,previous,8,100000000,Myocardial Infarction,NA
3399,25175921,2,prior asa use,Aspirin,D001241,NA,0,1446,previous,8,100000000,Aspirin,NA
3400,25175921,2,prior cabg,Coronary Artery Bypass,D001026,NA,0,1446,previous,8,100000000,Coronary Artery Bypass,NA
3401,25175921,2,prior pci,Percutaneous Coronary Intervention,D062645,NA,0,1446,previous,8,100000000,Percutaneous Coronary Intervention,NA
3402,25175921,2,sex,Gender Identity,D005783,NA,0,1446,any,2,000000000,Gender Identity,NA
3403,25175921,2,tim 1 nsk score,Thrombosis,D013927,NA,0,1446,severity,11,000100100,Thrombosis,NA
3404,25175921,2,tlmi risk score,Myocardial Infarction,D009203,NA,0,1446,severity,11,000100100,Myocardial Infarction,NA
3405,25175921,3,'gpifo'llia inhibitor use before angography',complex,none,NA,0,1240,previous,8,100000000,complex,NA
3406,25175921,3,'gpifo\'llia inhibitor use before angography,Platelet Aggregation Inhibitors,D010975,NA,0,1240,previous,8,100000000,Platelet Aggregation Inhibitors,NA
3407,25175921,3,age,Age Factors,D000367,NA,0,1240,any,2,000000000,Age Factors,NA
3408,25175921,3,diabetes,Diabetes Mellitus,D003920,NA,0,1240,any,2,000000000,Diabetes Mellitus,NA
3409,25175921,3,"heparin, fondaparinux or brvalirudin use between -oex event","Heparin, Low-Molecular-Weight",D006495,NA,0,1240,any,2,000000000,"Heparin, Low-Molecular-Weight",NA
3410,25175921,3,highest killip classiciation pre-pci,Percutaneous Coronary Intervention,D062645,NA,0,1240,previous severity,9,100100000,Percutaneous Coronary Intervention,NA
3411,25175921,3,index event;stemi,Myocardial Infarction,D009203,NA,0,1240,any,2,000000000,Myocardial Infarction,NA
3412,25175921,3,location of ml,Myocardial Infarction,D009203,NA,0,1240,location,7,000000001,Myocardial Infarction,NA
3413,25175921,3,location of ml;non-anterior,Myocardial Infarction,D009203,NA,0,1240,location,7,000000001,Myocardial Infarction,NA
3414,25175921,3,morphine use for index event/pci,complex,none,NA,0,1240,any,2,000000000,complex,NA
3415,25175921,3,previous ml,Myocardial Infarction,D009203,NA,0,1240,previous,8,100010000,Myocardial Infarction,NA
3416,25175921,3,prior asa use,Aspirin,D001241,NA,0,1240,previous,8,100000000,Aspirin,NA
3417,25175921,3,prior cabg,Coronary Artery Bypass,D001026,NA,0,1240,previous,8,100000000,Coronary Artery Bypass,NA
3418,25175921,3,prior pci,Percutaneous Coronary Intervention,D062645,NA,0,1240,previous,8,100000000,Percutaneous Coronary Intervention,NA
3419,25175921,3,sex,Gender Identity,D005783,NA,0,1240,any,2,000000000,Gender Identity,NA
3420,25175921,3,tim 1 nsk score,Thrombosis,D013927,NA,0,1240,severity,11,000100100,Thrombosis,NA
3421,25175921,3,tlmi risk score,Myocardial Infarction,D009203,NA,0,1240,severity,11,000100100,Myocardial Infarction,NA
3422,25176136,2,age,Age Factors,D000367,NA,0,651,any,2,000000000,Age Factors,NA
3423,25176136,2,angina class at baseline,Angina Pectoris,D000787,NA,0,651,severity,11,000100000,Angina Pectoris,NA
3424,25176136,2,angina class at baseline;class >ii,Angina Pectoris,D000787,NA,0,651,severity,11,000100000,Angina Pectoris,NA
3425,25176136,2,angina class at baseline;class i or no symptoms,Angina Pectoris,D000787,NA,0,651,severity,11,000100000,Angina Pectoris,NA
3426,25176136,2,beta-blocker use at randomization,Adrenergic beta-Antagonists,D000319,NA,0,651,any,2,000000000,Adrenergic beta-Antagonists,NA
3427,25176136,2,heart rate,Heart Rate,D006339,NA,0,651,any,2,000000000,Heart Rate,NA
3428,25176136,2,history of diabetes,Diabetes Mellitus,D003920,NA,0,651,previous,8,100000000,Diabetes Mellitus,NA
3429,25176136,2,previous coronary revascularization,Myocardial Revascularization,D009204,NA,0,651,previous,8,100000000,Myocardial Revascularization,NA
3430,25176136,2,previous myocardial infarction,Myocardial Infarction,D009203,NA,0,651,previous,8,100010000,Myocardial Infarction,NA
3431,25176136,2,sex,Gender Identity,D005783,NA,0,651,any,2,000000000,Gender Identity,NA
3432,25176136,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
3433,25176136,NA,angina severity,Angina Pectoris,D000787,NA,0,0,severity,11,000100000,Angina Pectoris,NA
3434,25176136,NA,beta-blocker use,Adrenergic beta-Antagonists,D000319,NA,0,0,any,2,000000000,Adrenergic beta-Antagonists,NA
3435,25176136,NA,Canadian Cardiovascular Society Class),Angina Pectoris,D000787,NA,0,0,severity,11,000100000,Angina Pectoris,NA
3436,25176136,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
3437,25176136,NA,heart rate,Heart Rate,D006339,NA,0,0,any,2,000000000,Heart Rate,NA
3438,25176136,NA,previous coronary revascularisation,Myocardial Revascularization,D009204,NA,0,0,previous,8,100000000,Myocardial Revascularization,NA
3439,25176136,NA,previous mi,Myocardial Infarction,D009203,NA,0,0,previous,8,100000000,Myocardial Infarction,NA
3440,25176136,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
3441,25182247,2,delayed cardioversion,Electric Countershock,D004554,NA,0,NA,any,2,000000000,Electric Countershock,NA
3442,25182247,2,early cardioversion,Electric Countershock,D004554,NA,0,NA,any,2,000000000,Electric Countershock,NA
3443,25189213,2,albuminuria,Albuminuria,D000419,NA,0,1397,any,2,000000000,Albuminuria,NA
3444,25189213,2,"Baseline anti-hyperglycemic medications, Sulfonylurea",Hypoglycemic Agents,D007004,NA,0,1397,any,2,000000000,Hypoglycemic Agents,NA
3445,25189213,2,baseline calcium,Calcium Channel Blockers,D002121,NA,0,1397,any,2,000000000,Calcium Channel Blockers,NA
3446,25189213,2,baselineÂ acei/arb,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,1397,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
3447,25189213,2,baselineÂ beta-blocker,Adrenergic beta-Antagonists,D000319,NA,0,1397,any,2,000000000,Adrenergic beta-Antagonists,NA
3448,25189213,2,baselineÂ diuretic,Diuretics,D004232,NA,0,1397,any,2,000000000,Diuretics,NA
3449,25189213,2,baselineÂ hba1c,Glycated Hemoglobin A,D006442,NA,0,1397,any,2,000000000,Glycated Hemoglobin A,NA
3450,25189213,2,baselineÂ insulin,Insulin,D007328,NA,0,1397,any,2,000000000,Insulin,NA
3451,25189213,2,baselineÂ metformin,Hypoglycemic Agents,D007004,NA,0,1397,any,2,000000000,Hypoglycemic Agents,NA
3452,25189213,2,baselineÂ statin,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,1397,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
3453,25189213,2,beta-blockers,Adrenergic beta-Antagonists,D000319,NA,0,1397,any,2,000000000,Adrenergic beta-Antagonists,NA
3454,25189213,2,"body-mass index - kg/m2, median (iqr)",Body Mass Index,D015992,NA,0,1397,any,2,000000000,Body Mass Index,NA
3455,25189213,2,"body-mass index > 30, n(%)",Body Mass Index,D015992,NA,0,1397,any,2,000000000,Body Mass Index,NA
3456,25189213,2,body-mass index >30,Body Mass Index,D015992,NA,0,1397,any,2,000000000,Body Mass Index,NA
3457,25189213,2,creatinine ratio 30-300,Albuminuria,D000419,NA,0,1397,any,2,000000000,Albuminuria,NA
3458,25189213,2,diabetes,Diabetes Mellitus,D003920,NA,0,1397,duration,5,001000000,Diabetes Mellitus,NA
3459,25189213,2,disease,Heart Failure,D006333,NA,0,1397,risk score,10,000000100,Heart Failure,NA
3460,25189213,2,diuretics,Diuretics,D004232,NA,0,1397,any,2,000000000,Diuretics,NA
3461,25189213,2,duration of diabetes,Diabetes Mellitus,D003920,NA,0,1397,duration,5,001000000,Diabetes Mellitus,NA
3462,25189213,2,glomerularÂ filtration rate 30-60,Glomerular Filtration Rate,D005919,NA,0,1397,any,2,000000000,Glomerular Filtration Rate,NA
3463,25189213,2,metformin,Hypoglycemic Agents,D007004,NA,0,1397,any,2,000000000,Hypoglycemic Agents,NA
3464,25189213,2,prior heart failure,Heart Failure,D006333,NA,0,1397,previous,8,100000000,Heart Failure,NA
3465,25189213,2,sex,Gender Identity,D005783,NA,0,1397,any,2,000000000,Gender Identity,NA
3466,25189213,2,state;risk factors,Heart Failure,D006333,NA,0,1397,risk score,10,000000100,Heart Failure,NA
3467,25189213,2,statins,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,1397,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
3468,25199059,NA,more severe eosinophilia,Eosinophilia,D004802,NA,0,0,severity,11,000100000,Eosinophilia,73
3469,25229335,NA,Chronic kidney disease,Kidney Diseases,D007674,NA,0,0,any,2,000000000,Kidney Diseases,4
3470,25248764,2,"baseline post-bronchodilator % predicted fev, < 30%",Bronchodilator Agents,D001993,NA,0,1011,any,2,000000000,Bronchodilator Agents,NA
3471,25248764,2,"baseline post-bronchodilator % predicted fev, > 30% and concurrent tiotropium use",Bronchodilator Agents,D001993,NA,0,1011,current,3,010000000,Bronchodilator Agents,NA
3472,25248764,2,"baseline post-bronchodilator % predicted fev, > 30% and no prior ics use",complex,none,NA,0,1011,previous,8,100000000,complex,NA
3473,25248764,2,"baseline post-bronchodilator % predicted fev, > 30% and prior ics use",complex,none,NA,0,1011,previous,8,100000000,complex,NA
3474,25248764,2,"moderate/severe exacerbations, itt population; n (%)","Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1011,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
3475,25248764,2,"severe exacerbations, itt population; n (%)","Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1011,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
3476,25271206,2,empagliflozin,Hypoglycemic Agents,D007004,NA,0,1048,any,2,000000000,Hypoglycemic Agents,NA
3477,25277614,2,antiarrhythmic drug,Anti-Arrhythmia Agents,D000889,NA,0,40,any,2,000000000,Anti-Arrhythmia Agents,NA
3478,25277614,2,body mass index,Body Mass Index,D015992,NA,0,40,any,2,000000000,Body Mass Index,NA
3479,25277614,2,coronary heart disease,Coronary Artery Disease,D003324,NA,0,40,any,2,000000000,Coronary Artery Disease,NA
3480,25277614,2,diabetes,Diabetes Mellitus,D003920,NA,0,40,any,2,000000000,Diabetes Mellitus,NA
3481,25277614,2,duration of atrial fibrillation,Atrial Fibrillation,D001281,NA,0,40,duration,5,001000000,Atrial Fibrillation,NA
3482,25277614,2,left atrial diameter,Heart Atria,D006325,NA,0,40,any,2,000000000,Heart Atria,NA
3483,25277614,2,sex,Gender Identity,D005783,NA,0,40,any,2,000000000,Gender Identity,NA
3484,25277614,2,waist circumference,Waist Circumference,D055105,NA,0,40,any,2,000000000,Waist Circumference,NA
3485,25282519,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
3486,25282519,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,NA
3487,25282519,NA,ezetemibe use,complex,NA,NA,0,0,any,2,000000000,complex,NA
3488,25282519,NA,genotype,Genetic Profile,D000076610,NA,0,0,type,12,000000010,Genetic Profile,164
3489,25282519,NA,intensive statin therapy versus non-intensive statin therapy,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,0,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
3490,25282519,NA,ldl,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,NA
3491,25282519,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
3492,25329038,NA,Diuretics,Diuretics,D004232,NA,0,0,any,2,000000000,Diuretics,NA
3493,25329038,NA,"sbp, dbp",Blood Pressure,D001794,NA,0,0,any,2,000000000,Blood Pressure,183
3494,25352655,2,Glycosylated HbA1c,Glycated Hemoglobin A,D006442,NA,0,1526,any,2,000000000,Glycated Hemoglobin A,NA
3495,25352655,3,age,Age Factors,D000367,NA,0,1435,any,2,000000000,Age Factors,NA
3496,25354738,2,;japanese subpopulation,Racial Groups,D044469,NA,0,36,any,2,000000000,Racial Groups,NA
3497,25354738,2,;overall population,Racial Groups,D044469,NA,0,36,any,2,000000000,Racial Groups,NA
3498,25367713,NA,DAS28 (CRP),"Arthritis, Rheumatoid",D001172,NA,0,0,severity,11,000100000,"Arthritis, Rheumatoid",224
3499,25367713,NA,erosion,complex,NA,NA,0,0,any,2,000000000,complex,NA
3500,25367713,NA,Health Assessment Questionnaire-Disability Index,complex,NA,NA,0,0,any,2,000000000,complex,NA
3501,25367713,NA,Osteitis,Osteitis,D010000,NA,0,0,any,2,000000000,Osteitis,NA
3502,25367713,NA,pain,Pain,D010146,NA,0,0,any,2,000000000,Pain,NA
3503,25367713,NA,rheumatoid arthritis duration,"Arthritis, Rheumatoid",D001172,NA,0,0,duration,5,001000000,"Arthritis, Rheumatoid",NA
3504,25367713,NA,Synovitis,Synovitis,D013585,NA,0,0,any,2,000000000,Synovitis,NA
3505,25399274,2,af pattern,Atrial Fibrillation,D001281,NA,0,185,any,2,000000000,Atrial Fibrillation,NA
3506,25399274,2,af pattern;paroxysmal,Atrial Fibrillation,D001281,NA,0,185,type,12,000000010,Atrial Fibrillation,NA
3507,25399274,2,af pattern;permanent,Atrial Fibrillation,D001281,NA,0,185,type,12,000000010,Atrial Fibrillation,NA
3508,25399274,2,af pattern;persistent,Atrial Fibrillation,D001281,NA,0,185,type,12,000000010,Atrial Fibrillation,NA
3509,25399274,2,age,Age Factors,D000367,NA,0,185,any,2,000000000,Age Factors,NA
3510,25399274,2,chads2 score,Stroke,D020521,NA,0,185,severity,11,000100100,Stroke,NA
3511,25399274,2,history of tia or stroke,Stroke,D020521,NA,0,185,previous,8,100000000,Stroke,NA
3512,25399274,2,laa length,Atrial Appendage,D020517,NA,0,185,any,2,000000000,Atrial Appendage,NA
3513,25399274,2,laa ostium,Atrial Appendage,D020517,NA,0,185,any,2,000000000,Atrial Appendage,NA
3514,25399274,2,lv ejection fraction,Stroke Volume,D013318,NA,0,185,any,2,000000000,Stroke Volume,NA
3515,25399274,2,prior years taking warfarin,Anticoagulants,D000925,NA,0,185,duration,5,001000000,Anticoagulants,NA
3516,25399274,2,sex,Gender Identity,D005783,NA,0,185,any,2,000000000,Gender Identity,NA
3517,25399658,NA,ace/arb,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,0,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
3518,25399658,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,224
3519,25399658,NA,aspirin,Aspirin,D001241,NA,0,0,any,2,000000000,Aspirin,NA
3520,25399658,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,NA
3521,25399658,NA,cabg history,Coronary Artery Bypass,D001026,NA,0,0,previous,8,100000000,Coronary Artery Bypass,NA
3522,25399658,NA,Clinical or Lesion RF for ST,complex,NA,NA,0,0,any,2,000000000,complex,NA
3523,25399658,NA,des type,Drug-Eluting Stents,D054855,NA,0,0,type,12,000000010,Drug-Eluting Stents,NA
3524,25399658,NA,diabetes history,Diabetes Mellitus,D003920,NA,0,0,previous,8,100000000,Diabetes Mellitus,NA
3525,25399658,NA,heart failure,Heart Failure,D006333,NA,0,0,any,2,000000000,Heart Failure,NA
3526,25399658,NA,mi history,Myocardial Infarction,D009203,NA,0,0,previous,8,100000000,Myocardial Infarction,NA
3527,25399658,NA,pci history,Percutaneous Coronary Intervention,D062645,NA,0,0,previous,8,100000000,Percutaneous Coronary Intervention,NA
3528,25399658,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
3529,25399658,NA,region,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,NA
3530,25399658,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
3531,25399658,NA,smoke history,Cigarette Smoking,D000073865,NA,0,0,previous,8,100000000,Cigarette Smoking,NA
3532,25399658,NA,Thienopyridine Type,Thienopyridines,D058924,NA,0,0,type,12,000000010,Thienopyridines,NA
3533,25406305,2,Russia/Georgia,Geographic Locations,D005842,NA,0,1284,any,2,000000000,Geographic Locations,NA
3534,25414932,1,Baseline body weight,Body Weight,D001835,NA,0,1463,any,2,000000000,Body Weight,NA
3535,25414932,1,Baseline FPG,Glycemic Control,D000085002,NA,0,1463,any,2,000000000,Glycemic Control,NA
3536,25414932,1,Baseline HbA1c level,Glycated Hemoglobin A,D006442,NA,0,1463,any,2,000000000,Glycated Hemoglobin A,NA
3537,25414932,1,CVD history,Cardiovascular Diseases,D002318,NA,0,1463,any,2,000000000,Cardiovascular Diseases,NA
3538,25414932,1,HbA1c level achieved,Glycated Hemoglobin A,D006442,NA,0,1463,any,2,000000000,Glycated Hemoglobin A,NA
3539,25414932,1,no CVD history,Cardiovascular Diseases,D002318,NA,0,1463,any,2,000000000,Cardiovascular Diseases,NA
3540,25455006,2,;* non-black*,Racial Groups,D044469,NA,0,1269,any,2,000000000,Racial Groups,NA
3541,25455006,2,male female,Gender Identity,D005783,NA,0,1269,any,2,000000000,Gender Identity,NA
3542,25455006,2,men;non-black,Racial Groups,D044469,NA,0,1269,any,2,000000000,Racial Groups,NA
3543,25455006,2,race,Racial Groups,D044469,NA,0,1269,any,2,000000000,Racial Groups,NA
3544,25455006,2,women;age <65 years,complex,none,NA,0,1269,any,2,000000000,complex,NA
3545,25455006,2,women;age 65+ years,complex,none,NA,0,1269,any,2,000000000,complex,NA
3546,25455006,2,women;atrial fibrillation,complex,none,NA,0,1269,any,2,000000000,complex,NA
3547,25455006,2,women;diabetes,complex,none,NA,0,1269,any,2,000000000,complex,NA
3548,25455006,2,women;no atrial fibrillation,complex,none,NA,0,1269,any,2,000000000,complex,NA
3549,25455006,2,women;no diabetes,complex,none,NA,0,1269,any,2,000000000,complex,NA
3550,25457902,NA,"PAH causes (CTD, congenital shunt, idiopathic/other)",Pulmonary Arterial Hypertension,D000081029,NA,0,0,aetiological,1,000001000,Pulmonary Arterial Hypertension,NA
3551,25457902,NA,pah etiology,Pulmonary Arterial Hypertension,D000081029,NA,0,0,aetiological,1,000001000,Pulmonary Arterial Hypertension,NA
3552,25457902,NA,pah therapy at baseline,Pulmonary Arterial Hypertension,D000081029,NA,0,0,any,2,000000000,Pulmonary Arterial Hypertension,NA
3553,25457902,NA,pulmonary arterial hypertension therapies at baseline,Pulmonary Arterial Hypertension,D000081029,NA,0,0,any,2,000000000,Pulmonary Arterial Hypertension,NA
3554,25457902,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
3555,25457902,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
3556,25457902,NA,who fc,Pulmonary Arterial Hypertension,D000081029,NA,0,0,severity,11,000100000,Pulmonary Arterial Hypertension,NA
3557,25457902,NA,WHO functional class,Pulmonary Arterial Hypertension,D000081029,NA,0,0,severity,11,000100000,Pulmonary Arterial Hypertension,NA
3558,25465416,2,;asa < 150 mg,Aspirin,D001241,NA,0,33,any,2,000000000,Aspirin,NA
3559,25465416,2,;asa > 150 mg,Aspirin,D001241,NA,0,33,any,2,000000000,Aspirin,NA
3560,25465416,2,;des,Drug-Eluting Stents,D054855,NA,0,33,any,2,000000000,Drug-Eluting Stents,NA
3561,25465416,2,;diabetes,Diabetes Mellitus,D003920,NA,0,33,any,2,000000000,Diabetes Mellitus,NA
3562,25465416,2,;hx stroke/tia,"Ischemic Attack, Transient",D002546,NA,0,33,any,2,000000000,"Ischemic Attack, Transient",NA
3563,25465416,2,;mi <3 months*,Myocardial Infarction,D009203,NA,0,33,any,2,000000000,Myocardial Infarction,NA
3564,25465416,2,;mi >3 months*,Myocardial Infarction,D009203,NA,0,33,any,2,000000000,Myocardial Infarction,NA
3565,25465416,2,;no des,Drug-Eluting Stents,D054855,NA,0,33,any,2,000000000,Drug-Eluting Stents,NA
3566,25465416,2,;no diabetes,Diabetes Mellitus,D003920,NA,0,33,any,2,000000000,Diabetes Mellitus,NA
3567,25465416,2,;no prior stemi,Myocardial Infarction,D009203,NA,0,33,previous,8,100010000,Myocardial Infarction,NA
3568,25465416,2,;no smoking,Cigarette Smoking,D000073865,NA,0,33,any,2,000000000,Cigarette Smoking,NA
3569,25465416,2,;no stroke/tia,Stroke,D020521,NA,0,33,previous,8,100000000,Stroke,NA
3570,25465416,2,;not rando. in na*,Geographic Locations,D005842,NA,0,33,any,2,000000000,Geographic Locations,NA
3571,25465416,2,;prior stemi,Myocardial Infarction,D009203,NA,0,33,previous,8,100010000,Myocardial Infarction,NA
3572,25465416,2,;rando. in na**,Geographic Locations,D005842,NA,0,33,any,2,000000000,Geographic Locations,NA
3573,25465416,2,Smoker,Cigarette Smoking,D000073865,NA,0,33,any,2,000000000,Cigarette Smoking,NA
3574,25465417,2,thienopyridine yes no,Thienopyridines,D058924,NA,0,588,any,2,000000000,Thienopyridines,NA
3575,25468945,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
3576,25468945,NA,baseline egfr,Glomerular Filtration Rate,D005919,NA,0,0,any,2,000000000,Glomerular Filtration Rate,NA
3577,25468945,NA,baseline hba1c,Glycated Hemoglobin A,D006442,NA,0,0,any,2,000000000,Glycated Hemoglobin A,NA
3578,25468945,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,NA
3579,25468945,NA,gender,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
3580,25468945,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
3581,25475110,2,Women <65 years,Age Factors,D000367,NA,0,1071,any,2,000000000,Age Factors,NA
3582,25475110,2,Women >65 years,Gender Identity,D005783,NA,0,1071,any,2,000000000,Gender Identity,NA
3583,25490706,2,;<64,Age Factors,D000367,NA,0,1611,any,2,000000000,Age Factors,NA
3584,25490706,2,bmi,Body Mass Index,D015992,NA,0,1611,any,2,000000000,Body Mass Index,NA
3585,25490706,2,male female,Gender Identity,D005783,NA,0,1611,any,2,000000000,Gender Identity,NA
3586,25490706,2,post-bronchodilator FEV1% predicted in Global Initiative for Chronic Obstructive Lung Diseases [GOLD] stages,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1611,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
3587,25490706,2,previous pneumonia,Pneumonia,D011014,NA,0,1611,previous,8,100000000,Pneumonia,NA
3588,25490706,2,Smoker,Cigarette Smoking,D000073865,NA,0,1611,any,2,000000000,Cigarette Smoking,NA
3589,25523533,2,baseline hs-crp tertiles (mg/i],C-Reactive Protein,D002097,NA,0,79,any,2,000000000,C-Reactive Protein,NA
3590,25552421,2,;egfr < 30 ml/min/1.73 m2,Glomerular Filtration Rate,D005919,NA,0,758,any,2,000000000,Glomerular Filtration Rate,NA
3591,25552421,2,;egfr <30,Glomerular Filtration Rate,D005919,NA,0,758,any,2,000000000,Glomerular Filtration Rate,NA
3592,25552421,2,;egfr >50 ml/min/1.73 m2,Glomerular Filtration Rate,D005919,NA,0,758,any,2,000000000,Glomerular Filtration Rate,NA
3593,25552421,2,;egfr 30-50,Glomerular Filtration Rate,D005919,NA,0,758,any,2,000000000,Glomerular Filtration Rate,NA
3594,25552421,2,;egfr 30â€“50 ml/min/1.73 m2,Glomerular Filtration Rate,D005919,NA,0,758,any,2,000000000,Glomerular Filtration Rate,NA
3595,25552421,2,;egfr>50,Glomerular Filtration Rate,D005919,NA,0,758,any,2,000000000,Glomerular Filtration Rate,NA
3596,25552421,3,;egfr < 30 ml/min/1.73 m2,Glomerular Filtration Rate,D005919,NA,0,243,any,2,000000000,Glomerular Filtration Rate,NA
3597,25552421,3,;egfr <30,Glomerular Filtration Rate,D005919,NA,0,243,any,2,000000000,Glomerular Filtration Rate,NA
3598,25552421,3,;egfr >50 ml/min/1.73 m2,Glomerular Filtration Rate,D005919,NA,0,243,any,2,000000000,Glomerular Filtration Rate,NA
3599,25552421,3,;egfr 30-50,Glomerular Filtration Rate,D005919,NA,0,243,any,2,000000000,Glomerular Filtration Rate,NA
3600,25552421,3,;egfr 30â€“50 ml/min/1.73 m2,Glomerular Filtration Rate,D005919,NA,0,243,any,2,000000000,Glomerular Filtration Rate,NA
3601,25552421,3,;egfr>50,Glomerular Filtration Rate,D005919,NA,0,243,any,2,000000000,Glomerular Filtration Rate,NA
3602,25573406,2,ics usage,Steroids,D013256,NA,0,1443,any,2,000000000,Steroids,NA
3603,25592197,2,baseline glycosylated hemoglobin,Glycated Hemoglobin A,D006442,NA,0,351,any,2,000000000,Glycated Hemoglobin A,NA
3604,25619410,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,14
3605,25629790,2,age,Age Factors,D000367,NA,0,1825,any,2,000000000,Age Factors,NA
3606,25629790,2,renal impairment stage,Glomerular Filtration Rate,D005919,NA,0,1825,severity,11,000100000,Glomerular Filtration Rate,NA
3607,25629790,2,type of basal insulin,Insulin,D007328,NA,0,1825,type,12,000000010,Insulin,NA
3608,25637937,2,age,Age Factors,D000367,NA,0,1403,any,2,000000000,Age Factors,NA
3609,25637937,2,"bmi, kg/m2",Body Mass Index,D015992,NA,0,1403,any,2,000000000,Body Mass Index,NA
3610,25637937,2,"bnp, pg/ml","Natriuretic Peptide, Brain",D020097,NA,0,1403,any,2,000000000,"Natriuretic Peptide, Brain",NA
3611,25637937,2,"dbp, mmhg",Blood Pressure,D001794,NA,0,1403,any,2,000000000,Blood Pressure,NA
3612,25637937,2,diabetes mellitus,Diabetes Mellitus,D003920,NA,0,1403,any,2,000000000,Diabetes Mellitus,NA
3613,25637937,2,"egfr, ml/min/1.73 m2",Glomerular Filtration Rate,D005919,NA,0,1403,any,2,000000000,Glomerular Filtration Rate,NA
3614,25637937,2,gender,Gender Identity,D005783,NA,0,1403,any,2,000000000,Gender Identity,NA
3615,25637937,2,"hscrp, mg/l",C-Reactive Protein,D002097,NA,0,1403,any,2,000000000,C-Reactive Protein,NA
3616,25637937,2,"lvef, %",Stroke Volume,D013318,NA,0,1403,any,2,000000000,Stroke Volume,NA
3617,25637937,2,lvh,"Hypertrophy, Left Ventricular",D017379,NA,0,1403,any,2,000000000,"Hypertrophy, Left Ventricular",NA
3618,25637937,2,"sbp, mmhg",Blood Pressure,D001794,NA,0,1403,any,2,000000000,Blood Pressure,NA
3619,25637937,2,spironolactone,Diuretics,D004232,NA,0,1403,any,2,000000000,Diuretics,NA
3620,25657183,NA,Medical History: Type of prior stroke,Stroke,D020521,NA,0,0,previous,8,100000010,Stroke,187
3621,25670362,2,age,Age Factors,D000367,NA,0,1591,any,2,000000000,Age Factors,NA
3622,25670362,2,age;gender,Gender Identity,D005783,NA,0,1591,any,2,000000000,Gender Identity,NA
3623,25670362,2,baseline fc-ldl-c,Lipoproteins,D008074,NA,0,1591,any,2,000000000,Lipoproteins,NA
3624,25670362,2,baseline hdl-c,Lipoproteins,D008074,NA,0,1591,any,2,000000000,Lipoproteins,NA
3625,25670362,2,baseline tg,Lipoproteins,D008074,NA,0,1591,any,2,000000000,Lipoproteins,NA
3626,25670362,2,diabetes status,Diabetes Mellitus,D003920,NA,0,1591,any,2,000000000,Diabetes Mellitus,NA
3627,25670362,2,gender,Gender Identity,D005783,NA,0,1591,any,2,000000000,Gender Identity,NA
3628,25670362,2,HDL cholesterol,Lipoproteins,D008074,NA,0,1591,any,2,000000000,Lipoproteins,NA
3629,25670362,2,race,Racial Groups,D044469,NA,0,1591,any,2,000000000,Racial Groups,NA
3630,25670362,2,type of concomitant statin,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,1591,type,12,000000010,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
3631,25670362,2,type of concomitant statin;rosuvastatin,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,1591,type,12,000000010,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
3632,25670362,2,use of concomitant lipid-modifying therapy,lipid modifying agents in combination with other drugs,NA,C10BX,0,1591,any,2,000000000,lipid modifying agents in combination with other drugs,NA
3633,25670362,2,use of concomitant lipid-modifying therapy;statin + ezetimibe,lipid modifying agents in combination with other drugs,NA,C10BX,0,1591,any,2,000000000,lipid modifying agents in combination with other drugs,NA
3634,25670362,2,use of concomitant lipid-modifying therapy;statin + fibrate or niacin,lipid modifying agents in combination with other drugs,NA,C10BX,0,1591,any,2,000000000,lipid modifying agents in combination with other drugs,NA
3635,25670362,2,use of concomitant lipid-modifying therapy;statin only,lipid modifying agents in combination with other drugs,NA,C10BX,0,1591,any,2,000000000,lipid modifying agents in combination with other drugs,NA
3636,25670362,3,age,Age Factors,D000367,NA,0,369,any,2,000000000,Age Factors,NA
3637,25670362,3,age;gender,Gender Identity,D005783,NA,0,369,any,2,000000000,Gender Identity,NA
3638,25670362,3,baseline fc-ldl-c,Lipoproteins,D008074,NA,0,369,any,2,000000000,Lipoproteins,NA
3639,25670362,3,baseline tg,Lipoproteins,D008074,NA,0,369,any,2,000000000,Lipoproteins,NA
3640,25670362,3,diabetes status,Diabetes Mellitus,D003920,NA,0,369,any,2,000000000,Diabetes Mellitus,NA
3641,25670362,3,gender,Gender Identity,D005783,NA,0,369,any,2,000000000,Gender Identity,NA
3642,25670362,3,HDL cholesterol,Lipoproteins,D008074,NA,0,369,any,2,000000000,Lipoproteins,NA
3643,25670362,3,race,Racial Groups,D044469,NA,0,369,any,2,000000000,Racial Groups,NA
3644,25670362,3,type of concomitant statin,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,369,type,12,000000010,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
3645,25670362,3,type of concomitant statin;atorvastatin,Atorvastatin,D000069059,NA,0,369,type,12,000000010,Atorvastatin,NA
3646,25670362,3,type of concomitant statin;rosuvastatin,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,369,type,12,000000010,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
3647,25670362,3,type of concomitant statin;simvastatin,lipid modifying agents,NA,C10,0,369,type,12,000000010,lipid modifying agents,NA
3648,25670362,3,use of concomitant lipid-modifying therapy,lipid modifying agents in combination with other drugs,NA,C10BX,0,369,any,2,000000000,lipid modifying agents in combination with other drugs,NA
3649,25681464,2,;diabetes mellitus,Diabetes Mellitus,D003920,NA,0,935,any,2,000000000,Diabetes Mellitus,NA
3650,25681464,2,;no diabetes mellitus,Diabetes Mellitus,D003920,NA,0,935,any,2,000000000,Diabetes Mellitus,NA
3651,25728587,2,';early crohn's disease*',Crohn Disease,D003424,NA,0,841,any,2,000000000,Crohn Disease,NA
3652,25728587,2,';non-early crohn's disease',Crohn Disease,D003424,NA,0,841,any,2,000000000,Crohn Disease,NA
3653,25728587,3,(a) aza treatment (ref),Immunosuppressive Agents,D007166,NA,0,1783,any,2,000000000,Immunosuppressive Agents,NA
3654,25728587,3,(b) aza treatment (ref),Immunosuppressive Agents,D007166,NA,0,1783,any,2,000000000,Immunosuppressive Agents,NA
3655,25728587,3,(d) aza treatment (ref),Immunosuppressive Agents,D007166,NA,0,1783,any,2,000000000,Immunosuppressive Agents,NA
3656,25728587,3,(e) aza treatment (ref),Immunosuppressive Agents,D007166,NA,0,1783,any,2,000000000,Immunosuppressive Agents,NA
3657,25728587,3,combination treatment ifx + aza,Tumor Necrosis Factor Inhibitors,D000079424,NA,0,1783,any,2,000000000,Tumor Necrosis Factor Inhibitors,NA
3658,25728587,3,history of bowel resection (ref),Digestive System Surgical Procedures,D013505,NA,0,1783,previous,8,100000000,Digestive System Surgical Procedures,NA
3659,25728587,3,history of extra-intestinal manifestations of ibd,Inflammatory Bowel Diseases,D015212,NA,0,1783,type,12,000000010,Inflammatory Bowel Diseases,NA
3660,25728587,3,hospitalization in the past 12 months prior to baseline,Patient Admission,D010343,NA,0,1783,previous,8,100000000,Patient Admission,NA
3661,25728587,3,ifx treatment,Tumor Necrosis Factor Inhibitors,D000079424,NA,0,1783,any,2,000000000,Tumor Necrosis Factor Inhibitors,NA
3662,25728587,3,no history of bowel resections,Digestive System Surgical Procedures,D013505,NA,0,1783,previous,8,100000000,Digestive System Surgical Procedures,NA
3663,25728587,3,no history of extra-intestinal manifestations of ibd (ref),Inflammatory Bowel Diseases,D015212,NA,0,1783,previous,8,100000000,Inflammatory Bowel Diseases,NA
3664,25728587,3,no hospitalization in the past 12 months prior to baseline (ref),Patient Admission,D010343,NA,0,1783,previous,8,100000000,Patient Admission,NA
3665,25728587,3,no previous cd related surgery3,"Surgical Procedures, Operative",D013514,NA,0,1783,previous,8,100000000,"Surgical Procedures, Operative",NA
3666,25728587,3,no steroid use at baseline (ref),Steroids,D013256,NA,0,1783,any,2,000000000,Steroids,NA
3667,25728587,3,on steroid at baseline,Steroids,D013256,NA,0,1783,any,2,000000000,Steroids,NA
3668,25736990,2,;ics no laba,"adrenergics, inhalants",NA,R03A,0,668,any,2,000000000,"adrenergics, inhalants",NA
3669,25736990,2,;ics plus laba,"adrenergics, inhalants",NA,R03A,0,668,any,2,000000000,"adrenergics, inhalants",NA
3670,25736990,2,;ocs at baseline,Steroids,D013256,NA,0,668,any,2,000000000,Steroids,NA
3671,25743173,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,15
3672,25743173,NA,baseline HDL,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,NA
3673,25743173,NA,baseline LDL,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,NA
3674,25743173,NA,baseline TG,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,NA
3675,25743173,NA,diabetes yes no,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
3676,25743173,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
3677,25743173,NA,"simvastatin, atorvastatin, rosovastatin",Atorvastatin,D000069059,NA,0,0,any,2,000000000,Atorvastatin,NA
3678,25743173,NA,statin,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,0,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
3679,25754414,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,211
3680,25754414,NA,baseline HbA1c,Glycated Hemoglobin A,D006442,NA,0,0,any,2,000000000,Glycated Hemoglobin A,217
3681,25754414,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,217
3682,25754414,NA,country,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,217
3683,25754414,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,217
3684,25758769,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
3685,25758769,NA,cv risk,Cardiovascular Diseases,D002318,NA,0,0,risk score,10,000000100,Cardiovascular Diseases,NA
3686,25758769,NA,renal function,Renal Insufficiency,D051437,NA,0,0,any,2,000000000,Renal Insufficiency,NA
3687,25765696,2,;history of heart failure at baseline,Heart Failure,D006333,NA,0,679,previous,8,100000000,Heart Failure,NA
3688,25765696,2,;no history of heart failure at baseline,Heart Failure,D006333,NA,0,679,previous,8,100000000,Heart Failure,NA
3689,25765696,2,history of heart failure at baseline,Heart Failure,D006333,NA,0,679,any,2,000000000,Heart Failure,NA
3690,25765696,3,;history of heart failure at baseline,Heart Failure,D006333,NA,0,1738,previous,8,100000000,Heart Failure,NA
3691,25765696,3,;no history of heart failure at baseline,Heart Failure,D006333,NA,0,1738,previous,8,100000000,Heart Failure,NA
3692,25765696,3,history of heart failure at baseline,Heart Failure,D006333,NA,0,1738,any,2,000000000,Heart Failure,NA
3693,25765696,3,no history of heart failure at baseline,Heart Failure,D006333,NA,0,1738,any,2,000000000,Heart Failure,NA
3694,25772548,NA,egfr,Renal Insufficiency,D051437,NA,0,0,any,2,000000000,Renal Insufficiency,NA
3695,25772548,NA,hba1c,Glycated Hemoglobin A,D006442,NA,0,0,any,2,000000000,Glycated Hemoglobin A,109
3696,25773268,2,age,Age Factors,D000367,NA,0,1409,any,2,000000000,Age Factors,NA
3697,25773268,2,aspirin dose,Aspirin,D001241,NA,0,1409,any,2,000000000,Aspirin,NA
3698,25773268,2,history of diabetes,Diabetes Mellitus,D003920,NA,0,1409,previous,8,100000000,Diabetes Mellitus,NA
3699,25773268,2,history of diabetes;diabetes,Diabetes Mellitus,D003920,NA,0,1409,previous,8,100000000,Diabetes Mellitus,NA
3700,25773268,2,history of diabetes;no diabetes,Diabetes Mellitus,D003920,NA,0,1409,any,2,000000000,Diabetes Mellitus,NA
3701,25773268,2,history of pci,Percutaneous Coronary Intervention,D062645,NA,0,1409,previous,8,100000000,Percutaneous Coronary Intervention,NA
3702,25773268,2,history of pci;no prior pci,Percutaneous Coronary Intervention,D062645,NA,0,1409,previous,8,100000000,Percutaneous Coronary Intervention,NA
3703,25773268,2,history of pci;prior pci,Percutaneous Coronary Intervention,D062645,NA,0,1409,previous,8,100000000,Percutaneous Coronary Intervention,NA
3704,25773268,2,mi,Myocardial Infarction,D009203,NA,0,1409,any,2,000000000,Myocardial Infarction,NA
3705,25773268,2,multivessel disease,Coronary Artery Disease,D003324,NA,0,1409,severity,11,000100000,Coronary Artery Disease,NA
3706,25773268,2,multivessel disease;no multivessel disease,Coronary Artery Disease,D003324,NA,0,1409,severity,11,000100000,Coronary Artery Disease,NA
3707,25773268,2,non-endstage renal dysfunction*,Renal Insufficiency,D051437,NA,0,1409,severity,11,000100000,Renal Insufficiency,NA
3708,25773268,2,non-endstage renal dysfunction*;no renal dysfunction,Renal Insufficiency,D051437,NA,0,1409,any,2,000000000,Renal Insufficiency,NA
3709,25773268,2,non-endstage renal dysfunction*;renal dysfunction,Renal Insufficiency,D051437,NA,0,1409,any,2,000000000,Renal Insufficiency,NA
3710,25773268,2,qualifying myocardial infarction,Myocardial Infarction,D009203,NA,0,1409,any,2,000000000,Myocardial Infarction,NA
3711,25773268,2,qualifying myocardial infarction;stemi,Myocardial Infarction,D009203,NA,0,1409,any,2,000000000,Myocardial Infarction,NA
3712,25773268,2,race,Racial Groups,D044469,NA,0,1409,any,2,000000000,Racial Groups,NA
3713,25773268,2,race;non-caucasian,Racial Groups,D044469,NA,0,1409,any,2,000000000,Racial Groups,NA
3714,25773268,2,region,Geographic Locations,D005842,NA,0,1409,any,2,000000000,Geographic Locations,NA
3715,25773268,2,second prior mi,Myocardial Infarction,D009203,NA,0,1409,previous,8,100010000,Myocardial Infarction,NA
3716,25773268,2,second prior mi;no second mi,Myocardial Infarction,D009203,NA,0,1409,previous,8,100000000,Myocardial Infarction,NA
3717,25773268,2,second prior mi;second mi,Myocardial Infarction,D009203,NA,0,1409,previous,8,100000000,Myocardial Infarction,NA
3718,25773268,2,sex,Gender Identity,D005783,NA,0,1409,any,2,000000000,Gender Identity,NA
3719,25773268,2,time from qualifying myocardial infarction,Myocardial Infarction,D009203,NA,0,1409,any,2,000000000,Myocardial Infarction,NA
3720,25773268,2,weight,Body Weight,D001835,NA,0,1409,any,2,000000000,Body Weight,NA
3721,25775052,3,> 65 years old,Age Factors,D000367,NA,0,222,any,2,000000000,Age Factors,NA
3722,25775052,3,anemia,Anemia,D000740,NA,0,222,any,2,000000000,Anemia,NA
3723,25775052,3,arterial access,Arteries,D001158,NA,0,222,any,2,000000000,Arteries,NA
3724,25775052,3,creatinine ciearance,Glomerular Filtration Rate,D005919,NA,0,222,any,2,000000000,Glomerular Filtration Rate,NA
3725,25775052,3,creatinine clearance,Glomerular Filtration Rate,D005919,NA,0,222,any,2,000000000,Glomerular Filtration Rate,NA
3726,25775052,3,creatinine clearance;<60 ml/min,Glomerular Filtration Rate,D005919,NA,0,222,any,2,000000000,Glomerular Filtration Rate,NA
3727,25775052,3,creatinine clearance;>60 ml/min,Glomerular Filtration Rate,D005919,NA,0,222,any,2,000000000,Glomerular Filtration Rate,NA
3728,25775052,3,crusade score;<30,Oral Hemorrhage,D006472,NA,0,222,severity,11,000100100,Oral Hemorrhage,NA
3729,25775052,3,crusade score;>30,Vitamin K Deficiency Bleeding,D006475,NA,0,222,severity,11,000100100,Vitamin K Deficiency Bleeding,NA
3730,25775052,3,diabetes,Diabetes Mellitus,D003920,NA,0,222,any,2,000000000,Diabetes Mellitus,NA
3731,25775052,3,gender,Gender Identity,D005783,NA,0,222,any,2,000000000,Gender Identity,NA
3732,25775052,3,killip ciass,Myocardial Infarction,D009203,NA,0,222,severity,11,000100000,Myocardial Infarction,NA
3733,25775052,3,killip class,Myocardial Infarction,D009203,NA,0,222,severity,11,000100000,Myocardial Infarction,NA
3734,25775052,3,killip class;class 1,Myocardial Infarction,D009203,NA,0,222,severity,11,000100000,Myocardial Infarction,NA
3735,25775052,3,killip class;class ll-iv,Myocardial Infarction,D009203,NA,0,222,severity,11,000100000,Myocardial Infarction,NA
3736,25775052,3,multivessel disease,Coronary Artery Disease,D003324,NA,0,222,any,2,000000000,Coronary Artery Disease,NA
3737,25775052,3,previous cv events,Cardiovascular Diseases,D002318,NA,0,222,previous,8,100000000,Cardiovascular Diseases,NA
3738,25775052,3,ST segment elevation myocardial infarction,Myocardial Infarction,D009203,NA,0,222,type,12,000000010,Myocardial Infarction,NA
3739,25775052,3,target vessel,Myocardial Revascularization,D009204,NA,0,222,any,2,000000000,Myocardial Revascularization,NA
3740,25775052,3,target vessel;lad artery,Arteries,D001158,NA,0,222,location,7,000000001,Arteries,NA
3741,25775052,3,target vessel;non-lad artery,Arteries,D001158,NA,0,222,location,7,000000001,Arteries,NA
3742,25775052,4,anemia,Anemia,D000740,NA,0,991,any,2,000000000,Anemia,NA
3743,25775052,4,arterial access,Arteries,D001158,NA,0,991,any,2,000000000,Arteries,NA
3744,25775052,4,creatinine ciearance,Glomerular Filtration Rate,D005919,NA,0,991,any,2,000000000,Glomerular Filtration Rate,NA
3745,25775052,4,creatinine clearance,Glomerular Filtration Rate,D005919,NA,0,991,any,2,000000000,Glomerular Filtration Rate,NA
3746,25775052,4,creatinine clearance;<60 ml/min,Glomerular Filtration Rate,D005919,NA,0,991,any,2,000000000,Glomerular Filtration Rate,NA
3747,25775052,4,creatinine clearance;>60 ml/min,Glomerular Filtration Rate,D005919,NA,0,991,any,2,000000000,Glomerular Filtration Rate,NA
3748,25775052,4,crusade score;<30,Oral Hemorrhage,D006472,NA,0,991,severity,11,000100100,Oral Hemorrhage,NA
3749,25775052,4,crusade score;>30,Vitamin K Deficiency Bleeding,D006475,NA,0,991,severity,11,000100100,Vitamin K Deficiency Bleeding,NA
3750,25775052,4,diabetes,Diabetes Mellitus,D003920,NA,0,991,any,2,000000000,Diabetes Mellitus,NA
3751,25775052,4,gender,Gender Identity,D005783,NA,0,991,any,2,000000000,Gender Identity,NA
3752,25775052,4,killip ciass,Myocardial Infarction,D009203,NA,0,991,severity,11,000100000,Myocardial Infarction,NA
3753,25775052,4,killip class,Myocardial Infarction,D009203,NA,0,991,severity,11,000100000,Myocardial Infarction,NA
3754,25775052,4,killip class;class 1,Myocardial Infarction,D009203,NA,0,991,severity,11,000100000,Myocardial Infarction,NA
3755,25775052,4,killip class;class ll-iv,Myocardial Infarction,D009203,NA,0,991,severity,11,000100000,Myocardial Infarction,NA
3756,25775052,4,multivessel disease,Coronary Artery Disease,D003324,NA,0,991,any,2,000000000,Coronary Artery Disease,NA
3757,25775052,4,previous cv events,Cardiovascular Diseases,D002318,NA,0,991,previous,8,100000000,Cardiovascular Diseases,NA
3758,25775052,4,ST segment elevation myocardial infarction,Myocardial Infarction,D009203,NA,0,991,type,12,000000010,Myocardial Infarction,NA
3759,25775052,4,target vessel,Myocardial Revascularization,D009204,NA,0,991,any,2,000000000,Myocardial Revascularization,NA
3760,25775052,4,target vessel;lad artery,Arteries,D001158,NA,0,991,location,7,000000001,Arteries,NA
3761,25775052,4,target vessel;non-lad artery,Arteries,D001158,NA,0,991,location,7,000000001,Arteries,NA
3762,25775052,5,> 65 years old,Age Factors,D000367,NA,0,1010,any,2,000000000,Age Factors,NA
3763,25775052,5,anemia,Anemia,D000740,NA,0,1010,any,2,000000000,Anemia,NA
3764,25775052,5,arterial access,Arteries,D001158,NA,0,1010,any,2,000000000,Arteries,NA
3765,25775052,5,creatinine ciearance,Glomerular Filtration Rate,D005919,NA,0,1010,any,2,000000000,Glomerular Filtration Rate,NA
3766,25775052,5,creatinine clearance,Glomerular Filtration Rate,D005919,NA,0,1010,any,2,000000000,Glomerular Filtration Rate,NA
3767,25775052,5,creatinine clearance;<60 ml/min,Glomerular Filtration Rate,D005919,NA,0,1010,any,2,000000000,Glomerular Filtration Rate,NA
3768,25775052,5,creatinine clearance;>60 ml/min,Glomerular Filtration Rate,D005919,NA,0,1010,any,2,000000000,Glomerular Filtration Rate,NA
3769,25775052,5,diabetes,Diabetes Mellitus,D003920,NA,0,1010,any,2,000000000,Diabetes Mellitus,NA
3770,25775052,5,gender,Gender Identity,D005783,NA,0,1010,any,2,000000000,Gender Identity,NA
3771,25775052,5,killip ciass,Myocardial Infarction,D009203,NA,0,1010,severity,11,000100000,Myocardial Infarction,NA
3772,25775052,5,killip class,Myocardial Infarction,D009203,NA,0,1010,severity,11,000100000,Myocardial Infarction,NA
3773,25775052,5,killip class;class 1,Myocardial Infarction,D009203,NA,0,1010,severity,11,000100000,Myocardial Infarction,NA
3774,25775052,5,killip class;class ll-iv,Myocardial Infarction,D009203,NA,0,1010,severity,11,000100000,Myocardial Infarction,NA
3775,25775052,5,previous cv events,Cardiovascular Diseases,D002318,NA,0,1010,previous,8,100000000,Cardiovascular Diseases,NA
3776,25775052,5,ST segment elevation myocardial infarction,Myocardial Infarction,D009203,NA,0,1010,any,2,000000000,Myocardial Infarction,NA
3777,25775052,5,target vessel,Myocardial Revascularization,D009204,NA,0,1010,any,2,000000000,Myocardial Revascularization,NA
3778,25775052,5,target vessel;lad artery,Arteries,D001158,NA,0,1010,location,7,000000001,Arteries,NA
3779,25775052,5,target vessel;non-lad artery,Arteries,D001158,NA,0,1010,location,7,000000001,Arteries,NA
3780,25779603,2,Baseline Methotrexate,Immunosuppressive Agents,D007166,NA,0,1360,any,2,000000000,Immunosuppressive Agents,NA
3781,25779603,2,No Baseline Methotrexate,Immunosuppressive Agents,D007166,NA,0,1360,any,2,000000000,Immunosuppressive Agents,NA
3782,25787199,NA,Medical History: MI,Myocardial Infarction,D009203,NA,0,0,previous,8,100000000,Myocardial Infarction,35
3783,25787199,NA,myocardial infarction,Myocardial Infarction,D009203,NA,0,0,any,2,000000000,Myocardial Infarction,282
3784,25792124,2,age,Age Factors,D000367,NA,0,661,any,2,000000000,Age Factors,NA
3785,25792124,2,diabetes,Diabetes Mellitus,D003920,NA,0,661,any,2,000000000,Diabetes Mellitus,NA
3786,25792124,2,egfr (ml/min/1.73m2),Glomerular Filtration Rate,D005919,NA,0,661,any,2,000000000,Glomerular Filtration Rate,NA
3787,25792124,2,planned thienopyridine at baseline,Thienopyridines,D058924,NA,0,661,any,2,000000000,Thienopyridines,NA
3788,25792124,2,prior stent,Stents,D015607,NA,0,661,previous,8,100000000,Stents,NA
3789,25792124,2,region,Geographic Locations,D005842,NA,0,661,any,2,000000000,Geographic Locations,NA
3790,25792124,2,sex,Gender Identity,D005783,NA,0,661,any,2,000000000,Gender Identity,NA
3791,25792124,2,weight,Body Weight,D001835,NA,0,661,any,2,000000000,Body Weight,NA
3792,25795432,3,";hba1c < 7.0%, bp < 130/80 mm hg, ldl-c < 100 mg /dl",complex,none,NA,0,853,any,2,000000000,complex,NA
3793,25795432,3,";hba1c < 8.0%, bp < 140/90 mm hg, ldl-c < 100 mg /dl",complex,none,NA,0,853,any,2,000000000,complex,NA
3794,25795432,3,glycosylated hemoglobin,Glycated Hemoglobin A,D006442,NA,0,853,any,2,000000000,Glycated Hemoglobin A,NA
3795,25795432,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,NA
3796,25805187,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,175
3797,25805187,NA,baseline HbA1c,Glycated Hemoglobin A,D006442,NA,0,0,any,2,000000000,Glycated Hemoglobin A,176
3798,25805187,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,176
3799,25805187,NA,geographical region,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,176
3800,25805187,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,176
3801,25805187,NA,renal function,Renal Insufficiency,D051437,NA,0,0,any,2,000000000,Renal Insufficiency,176
3802,25805187,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,176
3803,25805187,NA,time since diagnosis of diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,176
3804,25835002,NA,ambulatory monitoring,Ambulatory Care,D000553,NA,0,0,any,2,000000000,Ambulatory Care,153
3805,25852208,2,;age $65 yearsÂ§*,Age Factors,D000367,NA,0,1448,any,2,000000000,Age Factors,NA
3806,25852208,2,";age ,65 years",Age Factors,D000367,NA,0,1448,any,2,000000000,Age Factors,NA
3807,25881510,2,baseline HbA1c,Glycated Hemoglobin A,D006442,NA,0,1126,any,2,000000000,Glycated Hemoglobin A,NA
3808,25881510,2,race,Racial Groups,D044469,NA,0,1126,any,2,000000000,Racial Groups,NA
3809,26027630,2,age,Age Factors,D000367,NA,0,1060,any,2,000000000,Age Factors,NA
3810,26027630,2,bmi,Body Mass Index,D015992,NA,0,1060,any,2,000000000,Body Mass Index,NA
3811,26027630,2,diabetes at randomization,Diabetes Mellitus,D003920,NA,0,1060,any,2,000000000,Diabetes Mellitus,NA
3812,26027630,2,diabetes at randomization;diabetes,Diabetes Mellitus,D003920,NA,0,1060,any,2,000000000,Diabetes Mellitus,NA
3813,26027630,2,diabetes at randomization;no diabetes,Diabetes Mellitus,D003920,NA,0,1060,any,2,000000000,Diabetes Mellitus,NA
3814,26027630,2,ethnicity;hispanic/latino,Racial Groups,D044469,NA,0,1060,any,2,000000000,Racial Groups,NA
3815,26027630,2,gender,Gender Identity,D005783,NA,0,1060,any,2,000000000,Gender Identity,NA
3816,26027630,2,history of ml or ischemic stroke,Cardiovascular Diseases,D002318,NA,0,1060,previous,8,100000000,Cardiovascular Diseases,NA
3817,26027630,2,history of ml or ischemic stroke;no prior ml or stroke,Cardiovascular Diseases,D002318,NA,0,1060,previous,8,100000000,Cardiovascular Diseases,NA
3818,26027630,2,history of ml or ischemic stroke;prior history ml or stroke,Cardiovascular Diseases,D002318,NA,0,1060,previous,8,100000000,Cardiovascular Diseases,NA
3819,26027630,2,moderate ckd at randomization,Kidney Diseases,D007674,NA,0,1060,severity,11,000100000,Kidney Diseases,NA
3820,26027630,2,moderate ckd at randomization;moderate ckd,Kidney Diseases,D007674,NA,0,1060,severity,11,000100000,Kidney Diseases,NA
3821,26027630,2,moderate ckd at randomization;no moderate ckd,Kidney Diseases,D007674,NA,0,1060,severity,11,000100000,Kidney Diseases,NA
3822,26027630,2,other llt at randomization,lipid modifying agents,NA,C10,0,1060,any,2,000000000,lipid modifying agents,NA
3823,26027630,2,other llt at randomization;statin with other llt,lipid modifying agents,NA,C10,0,1060,any,2,000000000,lipid modifying agents,NA
3824,26027630,2,other llt at randomization;statin without other llt,lipid modifying agents,NA,C10,0,1060,any,2,000000000,lipid modifying agents,NA
3825,26027630,2,race,Racial Groups,D044469,NA,0,1060,any,2,000000000,Racial Groups,NA
3826,26027630,2,race;black/african american,Racial Groups,D044469,NA,0,1060,any,2,000000000,Racial Groups,NA
3827,26027630,2,statin treatment,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,1060,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
3828,26027630,2,statin treatment;high-intensity statin*,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,1060,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
3829,26027630,2,statin treatment;no high-intensity statin,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,1060,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
3830,26049552,NA,Baseline HbA1c,Glycated Hemoglobin A,D006442,NA,0,0,any,2,000000000,Glycated Hemoglobin A,NA
3831,26049552,NA,Gender,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
3832,26049552,NA,Location,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,NA
3833,26052984,2,ace inhibitors or angiotensin receptor blockers,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,235,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
3834,26052984,2,age,Age Factors,D000367,NA,0,235,any,2,000000000,Age Factors,NA
3835,26052984,2,aspirin,Aspirin,D001241,NA,0,235,any,2,000000000,Aspirin,NA
3836,26052984,2,beta blockers,Adrenergic beta-Antagonists,D000319,NA,0,235,any,2,000000000,Adrenergic beta-Antagonists,NA
3837,26052984,2,calcium channel blockers,Calcium Channel Blockers,D002121,NA,0,235,any,2,000000000,Calcium Channel Blockers,NA
3838,26052984,2,diabetes duration subgroups,Diabetes Mellitus,D003920,NA,0,235,duration,5,001000000,Diabetes Mellitus,NA
3839,26052984,2,diastolic blood pressure subgroups,Blood Pressure,D001794,NA,0,235,any,2,000000000,Blood Pressure,NA
3840,26052984,2,diuretics,Diuretics,D004232,NA,0,235,any,2,000000000,Diuretics,NA
3841,26052984,2,Hypertension,Hypertension,D006973,NA,0,235,any,2,000000000,Hypertension,NA
3842,26052984,2,insulin,Insulin,D007328,NA,0,235,any,2,000000000,Insulin,NA
3843,26052984,2,metformin,Hypoglycemic Agents,D007004,NA,0,235,any,2,000000000,Hypoglycemic Agents,NA
3844,26052984,2,prior congestive heart failure,Heart Failure,D006333,NA,0,235,previous,8,100000000,Heart Failure,NA
3845,26052984,2,race,Racial Groups,D044469,NA,0,235,any,2,000000000,Racial Groups,NA
3846,26052984,2,region,Geographic Locations,D005842,NA,0,235,any,2,000000000,Geographic Locations,NA
3847,26052984,2,renal function subgroups,Renal Insufficiency,D051437,NA,0,235,any,2,000000000,Renal Insufficiency,NA
3848,26052984,2,sex,Gender Identity,D005783,NA,0,235,any,2,000000000,Gender Identity,NA
3849,26052984,2,Smoker,Cigarette Smoking,D000073865,NA,0,235,any,2,000000000,Cigarette Smoking,NA
3850,26052984,2,sulfonylurea,Hypoglycemic Agents,D007004,NA,0,235,any,2,000000000,Hypoglycemic Agents,NA
3851,26052984,2,systolic blood pressure subgroups,Blood Pressure,D001794,NA,0,235,any,2,000000000,Blood Pressure,NA
3852,26052984,2,thiazolidinedione (includes pioglitazone),Hypoglycemic Agents,D007004,NA,0,235,any,2,000000000,Hypoglycemic Agents,NA
3853,26059896,1,;age =65 years,Age Factors,D000367,NA,0,345,any,2,000000000,Age Factors,NA
3854,26059896,1,;age =75 years,Age Factors,D000367,NA,0,345,any,2,000000000,Age Factors,NA
3855,26059896,1,;age Ã¢â€°Â¥65 years,Age Factors,D000367,NA,0,345,any,2,000000000,Age Factors,NA
3856,26059896,1,;age Ã¢â€°Â¥75 years,Age Factors,D000367,NA,0,345,any,2,000000000,Age Factors,NA
3857,26059896,1,;pci,Percutaneous Coronary Intervention,D062645,NA,0,345,any,2,000000000,Percutaneous Coronary Intervention,NA
3858,26059896,1,Hypertension,Hypertension,D006973,NA,0,345,any,2,000000000,Hypertension,NA
3859,26059896,1,index diagnosis;aspirin,Aspirin,D001241,NA,0,345,any,2,000000000,Aspirin,NA
3860,26059896,1,index diagnosis;clopidogrel,Fibrinolytic Agents,D005343,NA,0,345,any,2,000000000,Fibrinolytic Agents,NA
3861,26059896,1,index diagnosis;creatinine clearance <60 ml/min,Glomerular Filtration Rate,D005919,NA,0,345,any,2,000000000,Glomerular Filtration Rate,NA
3862,26059896,1,index diagnosis;diabetes,Diabetes Mellitus,D003920,NA,0,345,any,2,000000000,Diabetes Mellitus,NA
3863,26059896,1,index diagnosis;dyslipidemia,Dyslipidemias,D050171,NA,0,345,any,2,000000000,Dyslipidemias,NA
3864,26059896,1,index diagnosis;family history of cad,Coronary Artery Disease,D003324,NA,0,345,family history,6,000010000,Coronary Artery Disease,NA
3865,26059896,1,index diagnosis;history of chf,Heart Failure,D006333,NA,0,345,any,2,000000000,Heart Failure,NA
3866,26059896,1,index diagnosis;nste acs,Acute Coronary Syndrome,D054058,NA,0,345,any,2,000000000,Acute Coronary Syndrome,NA
3867,26059896,1,index diagnosis;prior cabg,Coronary Artery Bypass,D001026,NA,0,345,previous,8,100000000,Coronary Artery Bypass,NA
3868,26059896,1,index diagnosis;prior mi,Myocardial Infarction,D009203,NA,0,345,previous,8,100000000,Myocardial Infarction,NA
3869,26059896,1,index diagnosis;prior pci,Percutaneous Coronary Intervention,D062645,NA,0,345,previous,8,100000000,Percutaneous Coronary Intervention,NA
3870,26059896,1,index diagnosis;prior revascularization,Myocardial Revascularization,D009204,NA,0,345,previous,8,100000000,Myocardial Revascularization,NA
3871,26059896,1,index diagnosis;statin,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,345,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
3872,26059896,1,"index diagnosis;tni ultrapositive, =0.04 Âµg/l, n = 322 312",Troponin,D014336,NA,0,345,any,2,000000000,Troponin,NA
3873,26059896,1,"index diagnosis;tni ultrapositive, Ã¢â€°Â¥0.04 Ã‚Âµg/l, nÃ¢â‚¬â€°=Ã¢â‚¬â€°322Ã¢â‚¬â€°312",Troponin,D014336,NA,0,345,any,2,000000000,Troponin,NA
3874,26059896,1,male female,Gender Identity,D005783,NA,0,345,any,2,000000000,Gender Identity,NA
3875,26059896,1,Smoker,Cigarette Smoking,D000073865,NA,0,345,any,2,000000000,Cigarette Smoking,NA
3876,26059896,2,;age =65 years,Age Factors,D000367,NA,0,497,any,2,000000000,Age Factors,NA
3877,26059896,2,;age =75 years,Age Factors,D000367,NA,0,497,any,2,000000000,Age Factors,NA
3878,26059896,2,;age Ã¢â€°Â¥65 years,Age Factors,D000367,NA,0,497,any,2,000000000,Age Factors,NA
3879,26059896,2,;age Ã¢â€°Â¥75 years,Age Factors,D000367,NA,0,497,any,2,000000000,Age Factors,NA
3880,26059896,2,Hypertension,Hypertension,D006973,NA,0,497,any,2,000000000,Hypertension,NA
3881,26059896,2,index diagnosis;ace-i or arb,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,497,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
3882,26059896,2,index diagnosis;aceÃ¢â‚¬Âi or arb,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,497,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
3883,26059896,2,index diagnosis;aspirin,Aspirin,D001241,NA,0,497,any,2,000000000,Aspirin,NA
3884,26059896,2,"index diagnosis;bnp >80 pg/ml, n = 325 138","Natriuretic Peptide, Brain",D020097,NA,0,497,any,2,000000000,"Natriuretic Peptide, Brain",NA
3885,26059896,2,"index diagnosis;bnp >80 pg/ml, n = 975 1027","Natriuretic Peptide, Brain",D020097,NA,0,497,any,2,000000000,"Natriuretic Peptide, Brain",NA
3886,26059896,2,"index diagnosis;bnp >80 pg/ml, nÃ¢â‚¬â€°=Ã¢â‚¬â€°325Ã¢â‚¬Æ’138","Natriuretic Peptide, Brain",D020097,NA,0,497,any,2,000000000,"Natriuretic Peptide, Brain",NA
3887,26059896,2,"index diagnosis;bnp >80 pg/ml, nÃ¢â‚¬â€°=Ã¢â‚¬â€°975Ã¢â‚¬â€°1027","Natriuretic Peptide, Brain",D020097,NA,0,497,any,2,000000000,"Natriuretic Peptide, Brain",NA
3888,26059896,2,index diagnosis;clopidogrel,Fibrinolytic Agents,D005343,NA,0,497,any,2,000000000,Fibrinolytic Agents,NA
3889,26059896,2,index diagnosis;creatinine clearance <60 ml/min,Glomerular Filtration Rate,D005919,NA,0,497,any,2,000000000,Glomerular Filtration Rate,NA
3890,26059896,2,index diagnosis;diabetes,Diabetes Mellitus,D003920,NA,0,497,any,2,000000000,Diabetes Mellitus,NA
3891,26059896,2,index diagnosis;dyslipidemia,Dyslipidemias,D050171,NA,0,497,any,2,000000000,Dyslipidemias,NA
3892,26059896,2,index diagnosis;family history of cad,Coronary Artery Disease,D003324,NA,0,497,family history,6,000010000,Coronary Artery Disease,NA
3893,26059896,2,index diagnosis;history of chf,Heart Failure,D006333,NA,0,497,previous,8,100000000,Heart Failure,NA
3894,26059896,2,index diagnosis;ÃŽÂ²Ã¢â‚¬Âblocker,Adrenergic beta-Antagonists,D000319,NA,0,497,any,2,000000000,Adrenergic beta-Antagonists,NA
3895,26059896,2,"index diagnosis;lvef =40%, n = 917 947)a",Heart Failure,D006333,NA,0,497,any,2,000000000,Heart Failure,NA
3896,26059896,2,"index diagnosis;lvef Ã¢â€°Â¤40%, nÃ¢â‚¬â€°=Ã¢â‚¬â€°917Ã¢â‚¬Æ’947)a",Heart Failure,D006333,NA,0,497,any,2,000000000,Heart Failure,NA
3897,26059896,2,index diagnosis;nste acs,Acute Coronary Syndrome,D054058,NA,0,497,any,2,000000000,Acute Coronary Syndrome,NA
3898,26059896,2,"index diagnosis;prior angiography showing stenosis =50%, n = 521 09a",Coronary Stenosis,D023921,NA,0,497,previous,8,100000000,Coronary Stenosis,NA
3899,26059896,2,"index diagnosis;prior angiography showing stenosis Ã¢â€°Â¥50%, nÃ¢â‚¬â€°=Ã¢â‚¬â€°521Ã¢â‚¬â€°09a",Coronary Stenosis,D023921,NA,0,497,previous,8,100000000,Coronary Stenosis,NA
3900,26059896,2,index diagnosis;prior cabg,Coronary Artery Bypass,D001026,NA,0,497,previous,8,100000000,Coronary Artery Bypass,NA
3901,26059896,2,index diagnosis;prior mi,Myocardial Infarction,D009203,NA,0,497,previous,8,100010000,Myocardial Infarction,NA
3902,26059896,2,index diagnosis;prior pci,Percutaneous Coronary Intervention,D062645,NA,0,497,previous,8,100000000,Percutaneous Coronary Intervention,NA
3903,26059896,2,index diagnosis;prior revascularization,"Angioplasty, Balloon, Coronary",D015906,NA,0,497,previous,8,100000000,"Angioplasty, Balloon, Coronary",NA
3904,26059896,2,index diagnosis;ÃŸ-blocker,Adrenergic beta-Antagonists,D000319,NA,0,497,any,2,000000000,Adrenergic beta-Antagonists,NA
3905,26059896,2,index diagnosis;statin,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,497,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
3906,26059896,2,"index diagnosis;tni ultrapositive =0.04 Âµg/l, n = 970 1023",Troponin,D014336,NA,0,497,any,2,000000000,Troponin,NA
3907,26059896,2,"index diagnosis;tni ultrapositive Ã¢â€°Â¥0.04 Ã‚Âµg/l, nÃ¢â‚¬â€°=Ã¢â‚¬â€°970Ã¢â‚¬â€°1023",Troponin,D014336,NA,0,497,any,2,000000000,Troponin,NA
3908,26059896,2,index diagnosis;ua,Angina Pectoris,D000787,NA,0,497,any,2,000000000,Angina Pectoris,NA
3909,26059896,2,male female,Gender Identity,D005783,NA,0,497,any,2,000000000,Gender Identity,NA
3910,26059896,2,Smoker,Cigarette Smoking,D000073865,NA,0,497,any,2,000000000,Cigarette Smoking,NA
3911,26059896,3,;no pci,Percutaneous Coronary Intervention,D062645,NA,0,448,any,2,000000000,Percutaneous Coronary Intervention,NA
3912,26059896,3,;pci,Percutaneous Coronary Intervention,D062645,NA,0,448,any,2,000000000,Percutaneous Coronary Intervention,NA
3913,26059896,3,index diagnosis;prior pci,Percutaneous Coronary Intervention,D062645,NA,0,448,previous,8,100000000,Percutaneous Coronary Intervention,NA
3914,26059896,4,;no pci,Percutaneous Coronary Intervention,D062645,NA,0,1357,any,2,000000000,Percutaneous Coronary Intervention,NA
3915,26059896,4,;pci,Percutaneous Coronary Intervention,D062645,NA,0,1357,any,2,000000000,Percutaneous Coronary Intervention,NA
3916,26059896,4,index diagnosis;prior pci,Percutaneous Coronary Intervention,D062645,NA,0,1357,previous,8,100000000,Percutaneous Coronary Intervention,NA
3917,26066644,1,age (years),Age Factors,D000367,NA,0,1286,any,2,000000000,Age Factors,NA
3918,26072109,NA,biological therapy,complex,NA,NA,0,0,any,2,000000000,complex,5
3919,26082625,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
3920,26082625,NA,ics,Adrenal Cortex Hormones,D000305,NA,0,0,any,2,000000000,Adrenal Cortex Hormones,NA
3921,26082625,NA,severity of COPD,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,0,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
3922,26082625,NA,smoke,Cigarette Smoking,D000073865,NA,0,0,any,2,000000000,Cigarette Smoking,224
3923,26097039,2,baseline MTX use (yes/no),Immunosuppressive Agents,D007166,NA,0,395,previous,8,100000000,Immunosuppressive Agents,NA
3924,26097039,2,weight group (<= or >100 kg),Body Weight,D001835,NA,0,395,any,2,000000000,Body Weight,NA
3925,26097039,3,baseline MTX use (yes/no),Immunosuppressive Agents,D007166,NA,0,1092,any,2,000000000,Immunosuppressive Agents,NA
3926,26097039,3,weight group (<= or >100 kg),Body Weight,D001835,NA,0,1092,any,2,000000000,Body Weight,NA
3927,26100349,2,frequent exacerbator,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1088,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
3928,26100349,2,high risk,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1088,severity,11,000100100,"Pulmonary Disease, Chronic Obstructive",NA
3929,26100349,2,infrequent exacerbator,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1088,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
3930,26100349,2,low risk,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1088,severity,11,000100100,"Pulmonary Disease, Chronic Obstructive",NA
3931,26100349,2,salmeterol,long-acting beta agonist,NA,R03A,0,1088,any,2,000000000,long-acting beta agonist,NA
3932,26100349,2,tiotropium,Bronchodilator Agents,D001993,NA,0,1088,any,2,000000000,Bronchodilator Agents,NA
3933,26100349,2,tiotropium vs. salmeterol,Bronchodilator Agents,D001993,NA,0,1088,any,2,000000000,Bronchodilator Agents,NA
3934,26100349,3,high risk (-ics),Steroids,D013256,NA,0,1579,severity,11,000100100,Steroids,NA
3935,26100349,3,high risk (+ics),Steroids,D013256,NA,0,1579,severity,11,000100100,Steroids,NA
3936,26100349,3,low risk (-ics),Steroids,D013256,NA,0,1579,severity,11,000100100,Steroids,NA
3937,26100349,3,low risk (+ics),Steroids,D013256,NA,0,1579,severity,11,000100100,Steroids,NA
3938,26100349,3,salmeterol,long-acting beta agonist,NA,R03A,0,1579,any,2,000000000,long-acting beta agonist,NA
3939,26100349,3,tiotropium,Bronchodilator Agents,D001993,NA,0,1579,any,2,000000000,Bronchodilator Agents,NA
3940,26100349,3,tiotropium vs. salmeterol,Bronchodilator Agents,D001993,NA,0,1579,any,2,000000000,Bronchodilator Agents,NA
3941,26112656,3,;global initiative for chronic obstructive lung disease 2,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,760,any,2,000000000,"Pulmonary Disease, Chronic Obstructive",NA
3942,26112656,3,;global initiative for chronic obstructive lung disease 3-4,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,760,any,2,000000000,"Pulmonary Disease, Chronic Obstructive",NA
3943,26113687,NA,Age at baseline years,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
3944,26113687,NA,Baseline 6-min walk distance m,Exercise,D015444,NA,0,0,any,2,000000000,Exercise,NA
3945,26113687,NA,Baseline sildenafil dose mg,Sildenafil Citrate,D000068677,NA,0,0,any,2,000000000,Sildenafil Citrate,NA
3946,26113687,NA,Baseline WHO functional class,Pulmonary Arterial Hypertension,D000081029,NA,0,0,severity,11,000100000,Pulmonary Arterial Hypertension,NA
3947,26113687,NA,etiology,Pulmonary Arterial Hypertension,D000081029,NA,0,0,aetiological,1,000001000,Pulmonary Arterial Hypertension,NA
3948,26113687,NA,Geographical region,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,NA
3949,26113687,NA,Sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
3950,26121561,2,;black/african american,Racial Groups,D044469,NA,0,1297,any,2,000000000,Racial Groups,NA
3951,26121561,2,;other*,Racial Groups,D044469,NA,0,1297,any,2,000000000,Racial Groups,NA
3952,26121561,2,race,Racial Groups,D044469,NA,0,1297,any,2,000000000,Racial Groups,NA
3953,26132939,2,bmi (27.0Â 29.9),Body Mass Index,D015992,NA,0,821,any,2,000000000,Body Mass Index,NA
3954,26132939,2,bmi (30.0Â 34.9),Body Mass Index,D015992,NA,0,821,any,2,000000000,Body Mass Index,NA
3955,26132939,2,bmi (35.0Â 39.9),Body Mass Index,D015992,NA,0,821,any,2,000000000,Body Mass Index,NA
3956,26132939,2,bmi >=40,Body Mass Index,D015992,NA,0,821,any,2,000000000,Body Mass Index,NA
3957,26132939,2,bmi >40,Body Mass Index,D015992,NA,0,821,any,2,000000000,Body Mass Index,NA
3958,26132939,3,bmi (27.0Â 29.9),Body Mass Index,D015992,NA,0,1723,any,2,000000000,Body Mass Index,NA
3959,26132939,3,bmi (30.0Â 34.9),Body Mass Index,D015992,NA,0,1723,any,2,000000000,Body Mass Index,NA
3960,26132939,3,bmi (35.0Â 39.9),Body Mass Index,D015992,NA,0,1723,any,2,000000000,Body Mass Index,NA
3961,26132939,3,bmi >=40,Body Mass Index,D015992,NA,0,1723,any,2,000000000,Body Mass Index,NA
3962,26132939,3,bmi >40,Body Mass Index,D015992,NA,0,1723,any,2,000000000,Body Mass Index,NA
3963,26132939,4,bmi (27.0Â 29.9),Body Mass Index,D015992,NA,0,1099,any,2,000000000,Body Mass Index,NA
3964,26132939,4,bmi (30.0Â 34.9),Body Mass Index,D015992,NA,0,1099,any,2,000000000,Body Mass Index,NA
3965,26132939,4,bmi (35.0Â 39.9),Body Mass Index,D015992,NA,0,1099,any,2,000000000,Body Mass Index,NA
3966,26132939,4,bmi >=40,Body Mass Index,D015992,NA,0,1099,any,2,000000000,Body Mass Index,NA
3967,26132939,4,bmi >40,Body Mass Index,D015992,NA,0,1099,any,2,000000000,Body Mass Index,NA
3968,26135703,2,;anti-tnf-ir patients,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,921,any,2,000000000,Tumor Necrosis Factor Inhibitors,NA
3969,26135703,2,;anti-tnf-naive patients,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,921,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
3970,26139005,2,anti-ccp antibody (u/ml),Anti-Citrullinated Protein Antibodies,D000075422,NA,0,825,any,2,000000000,Anti-Citrullinated Protein Antibodies,NA
3971,26139005,2,concomitant mtxâ€”average dose (mg/week),Immunosuppressive Agents,D007166,NA,0,825,any,2,000000000,Immunosuppressive Agents,NA
3972,26139005,2,crp (mg/dl),C-Reactive Protein,D002097,NA,0,825,any,2,000000000,C-Reactive Protein,NA
3973,26139005,2,das28 (esr),"Arthritis, Rheumatoid",D001172,NA,0,825,severity,11,000100000,"Arthritis, Rheumatoid",NA
3974,26139005,2,haq-di,Quality of Life,D011788,NA,0,825,any,2,000000000,Quality of Life,NA
3975,26139005,2,mmp-3 (ng/ml),Matrix Metalloproteinases,D020782,NA,0,825,any,2,000000000,Matrix Metalloproteinases,NA
3976,26139005,2,mtss,"Arthritis, Rheumatoid",D001172,NA,0,825,severity,11,000100000,"Arthritis, Rheumatoid",NA
3977,26139005,2,rf (iu/ml),Rheumatoid Factor,D012217,NA,0,825,any,2,000000000,Rheumatoid Factor,NA
3978,26151264,2,accp score,Vitamin K Deficiency Bleeding,D006475,NA,1,23,severity,11,000100000,Vitamin K Deficiency Bleeding,NA
3979,26151264,2,age,Age Factors,D000367,NA,0,23,any,2,000000000,Age Factors,NA
3980,26151264,2,bmi,Body Mass Index,D015992,NA,0,23,any,2,000000000,Body Mass Index,NA
3981,26151264,2,bmi;<30 kg/m 2,Body Mass Index,D015992,NA,0,23,any,2,000000000,Body Mass Index,NA
3982,26151264,2,compression stockings and perfusion defect at inclusion,unclassifible,NA,NA,0,23,duration,5,001000000,unclassifible,NA
3983,26151264,2,d-dimer levelsatinclusion,Fibrin Fibrinogen Degradation Products,D005338,NA,0,23,risk score,10,000000100,Fibrin Fibrinogen Degradation Products,NA
3984,26151264,2,pe associated with dvt at diagnosis,Venous Thromboembolism,D054556,NA,0,23,type,12,000000010,Venous Thromboembolism,NA
3985,26151264,2,previous cancer,Neoplasms,D009369,NA,0,23,previous,8,100000000,Neoplasms,NA
3986,26151264,2,right ventriculardysfunction atinclusion,"Ventricular Dysfunction, Right",D018497,NA,0,23,any,2,000000000,"Ventricular Dysfunction, Right",NA
3987,26151264,2,sex,Gender Identity,D005783,NA,0,23,any,2,000000000,Gender Identity,NA
3988,26151264,2,thrombophilia,Thrombophilia,D019851,NA,0,23,any,2,000000000,Thrombophilia,NA
3989,26151264,2,time in therapeutic range before inclusion,International Normalized Ratio,D019934,NA,0,23,previous,8,100000000,International Normalized Ratio,NA
3990,26179619,2,;baseline hba1c <8.0%,Glycated Hemoglobin A,D006442,NA,0,1210,any,2,000000000,Glycated Hemoglobin A,NA
3991,26179619,2,;baseline hba1c >8.0%,Glycated Hemoglobin A,D006442,NA,0,1210,any,2,000000000,Glycated Hemoglobin A,NA
3992,26228097,NA,Type of reflux disease,Gastrointestinal Diseases,D005767,NA,0,0,type,12,000000010,Gastrointestinal Diseases,NA
3993,26233481,2,gold group,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1043,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
3994,26233481,3,GOLD COPD Severity Score,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1615,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
3995,26233481,4,;with concomitant ics,Adrenergic beta-2 Receptor Agonists,D058666,NA,0,1556,any,2,000000000,Adrenergic beta-2 Receptor Agonists,NA
3996,26233481,4,;without concomitant ics,Adrenergic beta-2 Receptor Agonists,D058666,NA,0,1556,any,2,000000000,Adrenergic beta-2 Receptor Agonists,NA
3997,26238672,1,mtx >10 and si 5 mg/week,Immunosuppressive Agents,D007166,NA,0,1488,any,2,000000000,Immunosuppressive Agents,NA
3998,26238672,1,mtx >15 mg/week,Immunosuppressive Agents,D007166,NA,0,1488,any,2,000000000,Immunosuppressive Agents,NA
3999,26238672,1,mtx sio mg/week,Immunosuppressive Agents,D007166,NA,0,1488,any,2,000000000,Immunosuppressive Agents,NA
4000,26246458,NA,NA,unclassifiable,NA,NA,0,0,any,2,000000000,unclassifiable,125
4001,26254019,NA,ACEi use,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,0,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
4002,26254019,NA,Beta blocker use,Adrenergic beta-Antagonists,D000319,NA,0,0,any,2,000000000,Adrenergic beta-Antagonists,NA
4003,26254019,NA,Congestive heart failure,Heart Failure,D006333,NA,0,0,any,2,000000000,Heart Failure,NA
4004,26254019,NA,multiple-vessel disease and single vessel disease,Coronary Artery Disease,D003324,NA,0,0,type,2,000000000,Coronary Artery Disease,NA
4005,26254019,NA,Nitrate use,Soluble Guanylyl Cyclase,D000071756,NA,0,0,any,2,000000000,Soluble Guanylyl Cyclase,NA
4006,26254019,NA,Obesity,Obesity,D009765,NA,0,0,any,2,000000000,Obesity,NA
4007,26254019,NA,Sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
4008,26254019,NA,Sirolimus eluting stent,Drug-Eluting Stents,D054855,NA,0,0,any,2,000000000,Drug-Eluting Stents,NA
4009,26271059,2,;aspirin 4 clopidogrel,Fibrinolytic Agents,D005343,NA,0,487,any,2,000000000,Fibrinolytic Agents,NA
4010,26271059,2,;aspirin only,Aspirin,D001241,NA,0,487,any,2,000000000,Aspirin,NA
4011,26275429,2,;bdmard-ir,Antirheumatic Agents,D018501,NA,0,812,disease response,4,000000000,Antirheumatic Agents,NA
4012,26275429,2,;bdmard-naive,Antirheumatic Agents,D018501,NA,0,812,previous,8,100000000,Antirheumatic Agents,NA
4013,26299520,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,41
4014,26299520,NA,antihypertensive,Antihypertensive Agents,D000959,NA,0,0,any,2,000000000,Antihypertensive Agents,41
4015,26299520,NA,arterial hypertension,Hypertension,D006973,NA,0,0,any,2,000000000,Hypertension,41
4016,26299520,NA,cardiac arrhythmia (defined from medical history and baseline adverse events);,Anti-Arrhythmia Agents,D000889,NA,0,0,previous,8,100000000,Anti-Arrhythmia Agents,41
4017,26299520,NA,"cardiac disorder (included ischaemic heart disease, cardiac arrhythmia, cardiac failure, cardiomyopathy or other cardiac disorders)",Cardiovascular Diseases,D002318,NA,0,0,any,2,000000000,Cardiovascular Diseases,41
4018,26299520,NA,"cardiovascular disorder (included ischaemic heart disease,
cardiac arrhythmia, cardiac failure, cardiomyopathy
or other cardiac disorders)",Cardiovascular Diseases,D002318,NA,0,0,any,2,000000000,Cardiovascular Diseases,41
4019,26299520,NA,"combined cardiac failure, cardiomyopathy or
other cardiac disorders",complex,none,NA,0,0,any,2,000000000,complex,41
4020,26299520,NA,"combined ischaemic
heart disease and/or cerebrovascular disorder
(included haemorrhagic, ischaemic or other cerebrovascular disorders)",complex,none,NA,0,0,any,2,000000000,complex,41
4021,26299520,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,41
4022,26299520,NA,hba1c,Glycated Hemoglobin A,D006442,NA,0,0,any,2,000000000,Glycated Hemoglobin A,41
4023,26299520,NA,hdl,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,41
4024,26299520,NA,insulin or oral use,Insulin,D007328,NA,0,0,any,2,000000000,Insulin,41
4025,26299520,NA,LUTS severity,Lower Urinary Tract Symptoms,D059411,NA,0,0,severity,11,000100000,Lower Urinary Tract Symptoms,277
4026,26299520,NA,number of antihypertensive medications used,Antihypertensive Agents,D000959,NA,0,0,any,2,000000000,Antihypertensive Agents,41
4027,26299520,NA,obesity,Obesity,D009765,NA,0,0,any,2,000000000,Obesity,41
4028,26299520,NA,smoke,Cigarette Smoking,D000073865,NA,0,0,any,2,000000000,Cigarette Smoking,41
4029,26299520,NA,statin  statin use or other lipid-lowering medication,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,0,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,41
4030,26308684,NA,6-minute walk distance,Exercise,D015444,NA,0,0,any,2,000000000,Exercise,22
4031,26308684,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,23
4032,26308684,NA,pulmonary arterial hypertension etiology,Hypertension,D006973,NA,0,0,aetiological,1,000001000,Hypertension,22
4033,26308684,NA,region,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,22
4034,26308684,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,22
4035,26308684,NA,World Health Organization functional class.,Pulmonary Arterial Hypertension,D000081029,NA,0,0,severity,11,000100000,Pulmonary Arterial Hypertension,22
4036,26321103,2,age,Age Factors,D000367,NA,0,1077,any,2,000000000,Age Factors,NA
4037,26321103,2,diabetes,Diabetes Mellitus,D003920,NA,0,1077,any,2,000000000,Diabetes Mellitus,NA
4038,26321103,2,dyslipidemia,Dyslipidemias,D050171,NA,0,1077,any,2,000000000,Dyslipidemias,NA
4039,26321103,2,ejection fraction,Stroke Volume,D013318,NA,0,1077,any,2,000000000,Stroke Volume,NA
4040,26321103,2,final timi flow,Thrombosis,D013927,NA,0,1077,any,2,000000000,Thrombosis,NA
4041,26321103,2,Hypertension,Hypertension,D006973,NA,0,1077,any,2,000000000,Hypertension,NA
4042,26321103,2,initial timi flow,Thrombosis,D013927,NA,0,1077,any,2,000000000,Thrombosis,NA
4043,26321103,2,killip at baseline,Heart Failure,D006333,NA,0,1077,severity,11,000100000,Heart Failure,NA
4044,26321103,2,male female,Gender Identity,D005783,NA,0,1077,any,2,000000000,Gender Identity,NA
4045,26321103,2,rentrop score,Coronary Vessel Anomalies,D003330,NA,0,1077,severity,11,000100000,Coronary Vessel Anomalies,NA
4046,26321103,2,symptom onset,Acute Coronary Syndrome,D054058,NA,0,1077,duration,5,001000000,Acute Coronary Syndrome,NA
4047,26321103,2,thrombus aspiration,Thrombosis,D013927,NA,0,1077,any,2,000000000,Thrombosis,NA
4048,26330422,2,age,Age Factors,D000367,NA,0,1427,any,2,000000000,Age Factors,NA
4049,26330422,2,bmi,Body Mass Index,D015992,NA,0,1427,any,2,000000000,Body Mass Index,NA
4050,26330422,2,diabetes mellitus,Diabetes Mellitus,D003920,NA,0,1427,any,2,000000000,Diabetes Mellitus,NA
4051,26330422,2,dose of atorvastatin,Atorvastatin,D000069059,NA,0,1427,any,2,000000000,Atorvastatin,NA
4052,26330422,2,dose of atorvastatin;40 mg,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,1427,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
4053,26330422,2,dose of rosuvastatin,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,1427,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
4054,26330422,2,ethnicity;hispanic or latino,Racial Groups,D044469,NA,0,1427,any,2,000000000,Racial Groups,NA
4055,26330422,2,gender,Gender Identity,D005783,NA,0,1427,any,2,000000000,Gender Identity,NA
4056,26330422,2,llt other than statin at randomization,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,1427,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
4057,26330422,2,moderate ckd,Renal Insufficiency,D051437,NA,0,1427,severity,11,000100000,Renal Insufficiency,NA
4058,26330422,2,prior history of ml or ischemic stroke,Cardiovascular Diseases,D002318,NA,0,1427,previous,8,100000000,Cardiovascular Diseases,NA
4059,26330422,2,race,Racial Groups,D044469,NA,0,1427,any,2,000000000,Racial Groups,NA
4060,26330422,2,race;black or african american,Racial Groups,D044469,NA,0,1427,any,2,000000000,Racial Groups,NA
4061,26330422,2,region,Geographic Locations,D005842,NA,0,1427,any,2,000000000,Geographic Locations,NA
4062,26330422,2,region;rest of world,Geographic Locations,D005842,NA,0,1427,any,2,000000000,Geographic Locations,NA
4063,26330422,2,statin treatment,lipid modifying agents,NA,C10,0,1427,any,2,000000000,lipid modifying agents,NA
4064,26338971,2,;no thienopyridine,Thienopyridines,D058924,NA,0,1482,any,2,000000000,Thienopyridines,NA
4065,26338971,2,;thienopyridine,Thienopyridines,D058924,NA,0,1482,any,2,000000000,Thienopyridines,NA
4066,26358285,2,cvd subjects,Cardiovascular Diseases,D002318,NA,0,1613,any,2,000000000,Cardiovascular Diseases,NA
4067,26358285,2,"race, non-white",Racial Groups,D044469,NA,0,1613,any,2,000000000,Racial Groups,NA
4068,26358285,2,"region, europe union",Geographic Locations,D005842,NA,0,1613,any,2,000000000,Geographic Locations,NA
4069,26358285,2,"renal function, moderate",Renal Insufficiency,D051437,NA,0,1613,severity,11,000100000,Renal Insufficiency,NA
4070,26358285,2,"renal function, normal- mild",Renal Insufficiency,D051437,NA,0,1613,severity,11,000100000,Renal Insufficiency,NA
4071,26358285,2,"renal function, severe",Renal Insufficiency,D051437,NA,0,1613,severity,11,000100000,Renal Insufficiency,NA
4072,26373629,2,age,Age Factors,D000367,NA,0,866,any,2,000000000,Age Factors,NA
4073,26373629,3,Gender,Gender Identity,D005783,NA,0,1595,any,2,000000000,Gender Identity,NA
4074,26374849,2,ejection fraction group,Stroke Volume,D013318,NA,0,239,any,2,000000000,Stroke Volume,NA
4075,26378978,2,acetylsalicylic acid,Aspirin,D001241,NA,0,533,any,2,000000000,Aspirin,NA
4076,26378978,2,age,Age Factors,D000367,NA,0,533,any,2,000000000,Age Factors,NA
4077,26378978,2,albuminuria,Albuminuria,D000419,NA,0,533,any,2,000000000,Albuminuria,NA
4078,26378978,2,angiotensin-converting enzyme inhibitors/ angiotensin receptor blockers,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,533,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
4079,26378978,2,antihypertensives,Antihypertensive Agents,D000959,NA,0,533,any,2,000000000,Antihypertensive Agents,NA
4080,26378978,2,beta blockers,Adrenergic beta-Antagonists,D000319,NA,0,533,any,2,000000000,Adrenergic beta-Antagonists,NA
4081,26378978,2,blood pressure control,Blood Pressure,D001794,NA,0,533,any,2,000000000,Blood Pressure,NA
4082,26378978,2,blood pressure control;sbp <140 mmhg and dbp <90 mmhg,Blood Pressure,D001794,NA,0,533,any,2,000000000,Blood Pressure,NA
4083,26378978,2,blood pressure control;sbp >140 mmhg and/or dbp >90 mmhg,Blood Pressure,D001794,NA,0,533,any,2,000000000,Blood Pressure,NA
4084,26378978,2,body mass index,Body Mass Index,D015992,NA,0,533,any,2,000000000,Body Mass Index,NA
4085,26378978,2,calcium channel blockers,Calcium Channel Blockers,D002121,NA,0,533,any,2,000000000,Calcium Channel Blockers,NA
4086,26378978,2,cardiovascular risk,Cardiovascular Diseases,D002318,NA,0,533,severity,11,000100100,Cardiovascular Diseases,NA
4087,26378978,2,cardiovascular risk;2 or 3 high cardiovascular risk categories,Cardiovascular Diseases,D002318,NA,0,533,severity,11,000100100,Cardiovascular Diseases,NA
4088,26378978,2,cardiovascular risk;only cerebrovascular disease,Stroke,D020521,NA,0,533,risk score,10,000000100,Stroke,NA
4089,26378978,2,cardiovascular risk;only coronary artery disease,Coronary Artery Disease,D003324,NA,0,533,risk score,10,000000100,Coronary Artery Disease,NA
4090,26378978,2,diuretics,Diuretics,D004232,NA,0,533,any,2,000000000,Diuretics,NA
4091,26378978,2,dpp-4 inhibitor,Hypoglycemic Agents,D007004,NA,0,533,any,2,000000000,Hypoglycemic Agents,NA
4092,26378978,2,estimated Glomerular Filtration Rate,Glomerular Filtration Rate,D005919,NA,0,533,any,2,000000000,Glomerular Filtration Rate,NA
4093,26378978,2,ethnicity;hispanic/latino,Racial Groups,D044469,NA,0,533,any,2,000000000,Racial Groups,NA
4094,26378978,2,glycated hemoglobin,Glycated Hemoglobin A,D006442,NA,0,533,any,2,000000000,Glycated Hemoglobin A,NA
4095,26378978,2,insulin,Insulin,D007328,NA,0,533,any,2,000000000,Insulin,NA
4096,26378978,2,metformin,Hypoglycemic Agents,D007004,NA,0,533,any,2,000000000,Hypoglycemic Agents,NA
4097,26378978,2,race,Racial Groups,D044469,NA,0,533,any,2,000000000,Racial Groups,NA
4098,26378978,2,region,Geographic Locations,D005842,NA,0,533,any,2,000000000,Geographic Locations,NA
4099,26378978,2,sex,Gender Identity,D005783,NA,0,533,any,2,000000000,Gender Identity,NA
4100,26378978,2,statins/ezetimibe,lipid modifying agents,NA,C10,0,533,any,2,000000000,lipid modifying agents,NA
4101,26378978,2,sulfonylurea,Hypoglycemic Agents,D007004,NA,0,533,any,2,000000000,Hypoglycemic Agents,NA
4102,26378978,2,thiazolidinediones,Hypoglycemic Agents,D007004,NA,0,533,any,2,000000000,Hypoglycemic Agents,NA
4103,26378978,3,acetylsalicylic acid,Aspirin,D001241,NA,0,986,any,2,000000000,Aspirin,NA
4104,26378978,3,age,Age Factors,D000367,NA,0,986,any,2,000000000,Age Factors,NA
4105,26378978,3,albuminuria,Albuminuria,D000419,NA,0,986,any,2,000000000,Albuminuria,NA
4106,26378978,3,angiotensin-converting enzyme inhibitors/ angiotensin receptor blockers,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,986,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
4107,26378978,3,antihypertensives,Antihypertensive Agents,D000959,NA,0,986,any,2,000000000,Antihypertensive Agents,NA
4108,26378978,3,beta blockers,Adrenergic beta-Antagonists,D000319,NA,0,986,any,2,000000000,Adrenergic beta-Antagonists,NA
4109,26378978,3,blood pressure control,Blood Pressure,D001794,NA,0,986,any,2,000000000,Blood Pressure,NA
4110,26378978,3,blood pressure control;sbp <140 mmhg and dbp <90 mmhg,Blood Pressure,D001794,NA,0,986,any,2,000000000,Blood Pressure,NA
4111,26378978,3,blood pressure control;sbp >140 mmhg and/or dbp >90 mmhg,Blood Pressure,D001794,NA,0,986,any,2,000000000,Blood Pressure,NA
4112,26378978,3,body mass index,Body Mass Index,D015992,NA,0,986,any,2,000000000,Body Mass Index,NA
4113,26378978,3,calcium channel blockers,Calcium Channel Blockers,D002121,NA,0,986,any,2,000000000,Calcium Channel Blockers,NA
4114,26378978,3,cardiovascular risk,Cardiovascular Diseases,D002318,NA,0,986,severity,11,000100100,Cardiovascular Diseases,NA
4115,26378978,3,cardiovascular risk;2 or 3 high cardiovascular risk categories,Cardiovascular Diseases,D002318,NA,0,986,severity,11,000100100,Cardiovascular Diseases,NA
4116,26378978,3,cardiovascular risk;only cerebrovascular disease,Stroke,D020521,NA,0,986,risk score,10,000000100,Stroke,NA
4117,26378978,3,cardiovascular risk;only coronary artery disease,Coronary Artery Disease,D003324,NA,0,986,risk score,10,000000100,Coronary Artery Disease,NA
4118,26378978,3,diuretics,Diuretics,D004232,NA,0,986,any,2,000000000,Diuretics,NA
4119,26378978,3,estimated Glomerular Filtration Rate,Glomerular Filtration Rate,D005919,NA,0,986,any,2,000000000,Glomerular Filtration Rate,NA
4120,26378978,3,ethnicity;hispanic/latino,Racial Groups,D044469,NA,0,986,any,2,000000000,Racial Groups,NA
4121,26378978,3,glycated hemoglobin,Glycated Hemoglobin A,D006442,NA,0,986,any,2,000000000,Glycated Hemoglobin A,NA
4122,26378978,3,insulin,Insulin,D007328,NA,0,986,any,2,000000000,Insulin,NA
4123,26378978,3,metformin,Hypoglycemic Agents,D007004,NA,0,986,any,2,000000000,Hypoglycemic Agents,NA
4124,26378978,3,region,Geographic Locations,D005842,NA,0,986,any,2,000000000,Geographic Locations,NA
4125,26378978,3,region;north america plus australia and new zealand,Geographic Locations,D005842,NA,0,986,any,2,000000000,Geographic Locations,NA
4126,26378978,3,sex,Gender Identity,D005783,NA,0,986,any,2,000000000,Gender Identity,NA
4127,26378978,3,statins/ezetimibe,lipid modifying agents,NA,C10,0,986,any,2,000000000,lipid modifying agents,NA
4128,26378978,3,sulfonylurea,Hypoglycemic Agents,D007004,NA,0,986,any,2,000000000,Hypoglycemic Agents,NA
4129,26400827,3,;femoral,Percutaneous Coronary Intervention,D062645,NA,0,745,location,7,000000001,Percutaneous Coronary Intervention,NA
4130,26422723,NA,previous anti-TNF therapy,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,0,previous,8,100000000,Tumor Necrosis Factor Inhibitors,224
4131,26446706,1,'level of renal impairment\'',Renal Insufficiency,D051437,NA,0,870,severity,11,000100000,Renal Insufficiency,NA
4132,26446706,1,age,Age Factors,D000367,NA,0,870,any,2,000000000,Age Factors,NA
4133,26446706,1,body weight*,Body Weight,D001835,NA,0,870,any,2,000000000,Body Weight,NA
4134,26446706,1,index event;dvt only,Venous Thromboembolism,D054556,NA,0,870,any,2,000000000,Venous Thromboembolism,NA
4135,26446706,1,index event;pe (with or without dvt),Venous Thromboembolism,D054556,NA,0,870,any,2,000000000,Venous Thromboembolism,NA
4136,26446706,1,level of renal impairment\,Renal Insufficiency,D051437,NA,0,870,severity,11,000100000,Renal Insufficiency,NA
4137,26446706,1,"Renal Insufficiency, Moderate (severity modifier),",Renal Insufficiency,D051437,NA,0,870,severity,11,000100000,Renal Insufficiency,NA
4138,26446706,1,sex,Gender Identity,D005783,NA,0,870,any,2,000000000,Gender Identity,NA
4139,26459421,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
4140,26459421,NA,obese,Obesity,D009765,NA,0,0,any,2,000000000,Obesity,NA
4141,26459421,NA,previous cardiovascular event,Cardiovascular Diseases,D002318,NA,0,0,previous,8,100000000,Cardiovascular Diseases,NA
4142,26459421,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
4143,26459421,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
4144,26471380,2,prior Levetiracetam,Anticonvulsants,D000927,NA,0,268,previous,8,100000000,Anticonvulsants,NA
4145,26475142,2,elevated natriuretic peptide level (n=92),"Natriuretic Peptide, Brain",D020097,NA,0,1856,any,2,000000000,"Natriuretic Peptide, Brain",NA
4146,26475142,2,prior hf hospitalization (n=147),Heart Failure,D006333,NA,0,1856,previous,8,100000000,Heart Failure,NA
4147,26475142,3,;enrolled in russia or georgia,Geographic Locations,D005842,NA,0,1413,any,2,000000000,Geographic Locations,NA
4148,26486868,NA,Rt-PA treatment,unclassifiable,NA,NA,0,0,any,2,000000000,unclassifiable,NA
4149,26486868,NA,time to treatment,Time-to-Treatment,D061665,NA,0,0,any,2,000000000,Time-to-Treatment,NA
4150,26486868,NA,vascular occlusion,Arterial Occlusive Diseases,D001157,NA,0,0,any,2,000000000,Arterial Occlusive Diseases,NA
4151,26491109,NA,Timing of P2Y12 withdrawal,unclassifiable,NA,NA,0,0,severity,11,000100000,unclassifiable,126
4152,26523993,2,;diabetes mellitus,Diabetes Mellitus,D003920,NA,0,726,any,2,000000000,Diabetes Mellitus,NA
4153,26523993,2,;no diabetes mellitus,Diabetes Mellitus,D003920,NA,0,726,any,2,000000000,Diabetes Mellitus,NA
4154,26523993,3,diabetes yes no,Diabetes Mellitus,D003920,NA,0,1212,any,2,000000000,Diabetes Mellitus,NA
4155,26524706,2,;hba1c 7-<=8%,Glycated Hemoglobin A,D006442,NA,0,58,any,2,000000000,Glycated Hemoglobin A,NA
4156,26524706,2,;hba1c 8-<=9%,Glycated Hemoglobin A,D006442,NA,0,58,any,2,000000000,Glycated Hemoglobin A,NA
4157,26524706,2,;hba1c<7%,Glycated Hemoglobin A,D006442,NA,0,58,any,2,000000000,Glycated Hemoglobin A,NA
4158,26524706,2,;hba1c>=9%,Glycated Hemoglobin A,D006442,NA,0,58,any,2,000000000,Glycated Hemoglobin A,NA
4159,26524706,2,HbA1C,Glycated Hemoglobin A,D006442,NA,0,58,any,2,000000000,Glycated Hemoglobin A,NA
4160,26524706,3,;hba1c 7-<=8%,Glycated Hemoglobin A,D006442,NA,0,1576,any,2,000000000,Glycated Hemoglobin A,NA
4161,26524706,3,;hba1c 8-<=9%,Glycated Hemoglobin A,D006442,NA,0,1576,any,2,000000000,Glycated Hemoglobin A,NA
4162,26524706,3,;hba1c<7%,Glycated Hemoglobin A,D006442,NA,0,1576,any,2,000000000,Glycated Hemoglobin A,NA
4163,26524706,3,;hba1c>=9%,Glycated Hemoglobin A,D006442,NA,0,1576,any,2,000000000,Glycated Hemoglobin A,NA
4164,26524706,3,HbA1C,Glycated Hemoglobin A,D006442,NA,0,1576,any,2,000000000,Glycated Hemoglobin A,NA
4165,26541915,2,"risk category (points);0-3 (n = 1,499)",Heart Failure,D006333,NA,1,1431,severity,11,000100000,Heart Failure,NA
4166,26541915,2,"risk category (points);4 (n = 1,314)",Heart Failure,D006333,NA,1,1431,severity,11,000100000,Heart Failure,NA
4167,26541915,2,"risk category (points);5 (n = 1,325)",Heart Failure,D006333,NA,1,1431,severity,11,000100000,Heart Failure,NA
4168,26541915,2,risk category (points);6 (n = 987),Heart Failure,D006333,NA,1,1431,severity,11,000100000,Heart Failure,NA
4169,26541915,2,risk category (points);7-12 (n = 987),Heart Failure,D006333,NA,1,1431,severity,11,000100000,Heart Failure,NA
4170,26541915,6,enalapril,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,1535,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
4171,26541915,6,LCZ696,Heart Failure,D006333,NA,1,1535,any,2,000000000,Heart Failure,NA
4172,26547918,2,lack of response to cyclosporine,Cyclosporins,D003524,NA,0,197,any,2,000000000,Cyclosporins,NA
4173,26547918,2,lack of response to methotrexate,Immunosuppressive Agents,D007166,NA,0,197,any,2,000000000,Immunosuppressive Agents,NA
4174,26547918,2,lack of response to systemic therapies,Psoriasis,D011565,NA,0,197,previous,8,100000000,Psoriasis,NA
4175,26547918,2,prior exposure to systemic therapies,Psoriasis,D011565,NA,0,197,previous,8,100000000,Psoriasis,NA
4176,26579834,1,race,Racial Groups,D044469,NA,0,375,any,2,000000000,Racial Groups,NA
4177,26580237,2,;<65 years of age,Age Factors,D000367,NA,0,13,any,2,000000000,Age Factors,NA
4178,26580237,2,;>65 years of age,Age Factors,D000367,NA,0,13,any,2,000000000,Age Factors,NA
4179,26580237,2,;egfr <60 ml/min/1.73 mz,Glomerular Filtration Rate,D005919,NA,0,13,any,2,000000000,Glomerular Filtration Rate,NA
4180,26580237,2,;egfr >60 ml/min/1.73 mz,Glomerular Filtration Rate,D005919,NA,0,13,any,2,000000000,Glomerular Filtration Rate,NA
4181,26580237,2,;fracture history,"Fractures, Bone",D050723,NA,0,13,previous,8,100000000,"Fractures, Bone",NA
4182,26580237,2,;no fracture history,"Fractures, Bone",D050723,NA,0,13,previous,8,100000000,"Fractures, Bone",NA
4183,26580237,2,duration of diabetes,Diabetes Mellitus,D003920,NA,0,13,duration,5,001000000,Diabetes Mellitus,NA
4184,26580237,2,male female,Gender Identity,D005783,NA,0,13,any,2,000000000,Gender Identity,NA
4185,26586780,2,age;< 75,Age Factors,D000367,NA,0,1694,any,2,000000000,Age Factors,NA
4186,26586780,2,age;> 75,Age Factors,D000367,NA,0,1694,any,2,000000000,Age Factors,NA
4187,26586780,2,aspirin dose at randomization,Aspirin,D001241,NA,0,1694,any,2,000000000,Aspirin,NA
4188,26586780,2,body mass index,Body Mass Index,D015992,NA,0,1694,any,2,000000000,Body Mass Index,NA
4189,26586780,2,body mass index;current tobacco use,Cigarette Smoking,D000073865,NA,0,1694,current,3,010000000,Cigarette Smoking,NA
4190,26586780,2,body mass index;diabetes,Diabetes Mellitus,D003920,NA,0,1694,any,2,000000000,Diabetes Mellitus,NA
4191,26586780,2,body mass index;history of cancer,Neoplasms,D009369,NA,0,1694,previous,8,100000000,Neoplasms,NA
4192,26586780,2,body mass index;no current tobacco use,Cigarette Smoking,D000073865,NA,0,1694,current,3,010000000,Cigarette Smoking,NA
4193,26586780,2,body mass index;no diabetes,Diabetes Mellitus,D003920,NA,0,1694,any,2,000000000,Diabetes Mellitus,NA
4194,26586780,2,body mass index;no history of cancer,Neoplasms,D009369,NA,0,1694,family history,6,000010000,Neoplasms,NA
4195,26586780,2,body mass index;no prior cabg,Coronary Artery Bypass,D001026,NA,0,1694,previous,8,100000000,Coronary Artery Bypass,NA
4196,26586780,2,body mass index;no prior mi,Myocardial Infarction,D009203,NA,0,1694,previous,8,100010000,Myocardial Infarction,NA
4197,26586780,2,body mass index;no prior pci,Percutaneous Coronary Intervention,D062645,NA,0,1694,previous,8,100000000,Percutaneous Coronary Intervention,NA
4198,26586780,2,body mass index;prior cabg,Coronary Artery Bypass,D001026,NA,0,1694,previous,8,100000000,Coronary Artery Bypass,NA
4199,26586780,2,body mass index;prior mi,Myocardial Infarction,D009203,NA,0,1694,previous,8,100010000,Myocardial Infarction,NA
4200,26586780,2,body mass index;prior pci,Percutaneous Coronary Intervention,D062645,NA,0,1694,previous,8,100001000,Percutaneous Coronary Intervention,NA
4201,26586780,2,indication for pci,Percutaneous Coronary Intervention,D062645,NA,0,1694,any,2,000000000,Percutaneous Coronary Intervention,NA
4202,26586780,2,indication for pci;mi,Myocardial Infarction,D009203,NA,0,1694,any,2,000000000,Myocardial Infarction,NA
4203,26586780,2,indication for pci;no mi,Myocardial Infarction,D009203,NA,0,1694,any,2,000000000,Myocardial Infarction,NA
4204,26586780,2,male female,Gender Identity,D005783,NA,0,1694,any,2,000000000,Gender Identity,NA
4205,26586780,2,race,Racial Groups,D044469,NA,0,1694,any,2,000000000,Racial Groups,NA
4206,26586780,2,race;non-white,Racial Groups,D044469,NA,0,1694,any,2,000000000,Racial Groups,NA
4207,26586780,2,region,Geographic Locations,D005842,NA,0,1694,any,2,000000000,Geographic Locations,NA
4208,26586780,2,region;european union,Geographic Locations,D005842,NA,0,1694,any,2,000000000,Geographic Locations,NA
4209,26586780,2,stent type,Stents,D015607,NA,0,1694,type,12,000000010,Stents,NA
4210,26586780,2,stent type;bare metal stent,Stents,D015607,NA,0,1694,type,12,000000010,Stents,NA
4211,26586780,2,thienopyridine at randomization,Platelet Aggregation Inhibitors,D010975,NA,0,1694,type,12,000000010,Platelet Aggregation Inhibitors,NA
4212,26589819,NA,Medical History: Baseline CHD,Coronary Artery Disease,D003324,NA,0,0,previous,8,100000000,Coronary Artery Disease,190
4213,26627989,2,;cha2ds2-vasc #4,Stroke,D020521,NA,0,1703,severity,11,000100100,Stroke,NA
4214,26627989,2,;cha2ds2-vasc >4,Stroke,D020521,NA,0,1703,severity,11,000100100,Stroke,NA
4215,26627989,2,;history of tia/stroke,Stroke,D020521,NA,0,1703,previous,8,100000000,Stroke,NA
4216,26627989,2,;modified has-bled $3,Hemorrhage,D006470,NA,1,1703,severity,11,000100000,Hemorrhage,NA
4217,26627989,2,;modified has-bled <3,Hemorrhage,D006470,NA,1,1703,severity,11,000100000,Hemorrhage,NA
4218,26627989,2,;no history of tia/stroke,Stroke,D020521,NA,0,1703,previous,8,100000000,Stroke,NA
4219,26627989,2,age,Age Factors,D000367,NA,0,1703,any,2,000000000,Age Factors,NA
4220,26627989,2,male female,Gender Identity,D005783,NA,0,1703,any,2,000000000,Gender Identity,NA
4221,26630143,2,ACE/ARB use Yes No,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,47,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
4222,26630143,2,ACS Event  NSTEMI  STEMI  UA,Acute Coronary Syndrome,D054058,NA,0,47,any,2,000000000,Acute Coronary Syndrome,NA
4223,26630143,2,Age  Less than 65 y ears  65 years or older,Age Factors,D000367,NA,0,47,any,2,000000000,Age Factors,NA
4224,26630143,2,BMI  Less than 30 kg/m2  30 kg/m2 or more,Body Mass Index,D015992,NA,0,47,any,2,000000000,Body Mass Index,NA
4225,26630143,2,Days between ACS and Rand  Less than 30  30 to less than 60  60 to less than 90  90 or greater,Coronary Artery Disease,D003324,NA,0,47,any,2,000000000,Coronary Artery Disease,NA
4226,26630143,2,DM Duration  Less than 10 y ears  10 years or more,Diabetes Mellitus,D003920,NA,0,47,duration,5,001000000,Diabetes Mellitus,NA
4227,26630143,2,eGFR  <60 ml/min/1.73m2  60-90 ml/min/1.73m2  >=90 ml/min/1.73m2,Glomerular Filtration Rate,D005919,NA,0,47,any,2,000000000,Glomerular Filtration Rate,NA
4228,26630143,2,Ethnicity  Hispanic  Not Hispanic,Racial Groups,D044469,NA,0,47,any,2,000000000,Racial Groups,NA
4229,26630143,2,Gender  Female  Male,Gender Identity,D005783,NA,0,47,any,2,000000000,Gender Identity,NA
4230,26630143,2,HbAlc  Less than 7.5%  7.5% or more,Hypoglycemia,D007003,NA,0,47,any,2,000000000,Hypoglycemia,NA
4231,26630143,2,History of HF  No  Yes,Heart Failure,D006333,NA,0,47,previous,8,100000000,Heart Failure,NA
4232,26630143,2,Racial category  White  Black  Asian  All Other,Racial Groups,D044469,NA,0,47,any,2,000000000,Racial Groups,NA
4233,26630143,2,Region  Africa ! Near East  Asia Pacific  Eastern Europe  Western Europe  North America  South! Central America,Geographic Locations,D005842,NA,0,47,any,2,000000000,Geographic Locations,NA
4234,26630143,2,Region (US)  United States  Non-US,Geographic Locations,D005842,NA,0,47,any,2,000000000,Geographic Locations,NA
4235,26653621,2,baseline sbp,Blood Pressure,D001794,NA,0,796,any,2,000000000,Blood Pressure,NA
4236,26653621,2,peak systolic pressure gradient,Blood Pressure,D001794,NA,0,796,any,2,000000000,Blood Pressure,NA
4237,26653621,2,percent stenosis [core lab],"Constriction, Pathologic",D003251,NA,0,796,any,2,000000000,"Constriction, Pathologic",NA
4238,26653621,2,percent stenosis [investigator],"Constriction, Pathologic",D003251,NA,0,796,any,2,000000000,"Constriction, Pathologic",NA
4239,26681720,2,;ace-i or arb use,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,1763,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
4240,26681720,2,;age<65,Age Factors,D000367,NA,0,1763,any,2,000000000,Age Factors,NA
4241,26681720,2,;age>:65,Age Factors,D000367,NA,0,1763,any,2,000000000,Age Factors,NA
4242,26681720,2,;betablocker use,Adrenergic beta-Antagonists,D000319,NA,0,1763,any,2,000000000,Adrenergic beta-Antagonists,NA
4243,26681720,2,;heart rate < 69 bpm,Heart Rate,D006339,NA,0,1763,any,2,000000000,Heart Rate,NA
4244,26681720,2,;heart rate > 69 bpm,Heart Rate,D006339,NA,0,1763,any,2,000000000,Heart Rate,NA
4245,26681720,2,;ifg/igt,Glucose Intolerance,D018149,NA,0,1763,any,2,000000000,Glucose Intolerance,NA
4246,26681720,2,;metformin use,Hypoglycemic Agents,D007004,NA,0,1763,any,2,000000000,Hypoglycemic Agents,NA
4247,26681720,2,;neither ace-i nor arb use,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,1763,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
4248,26681720,2,;new dm,Diabetes Mellitus,D003920,NA,0,1763,current,3,010000000,Diabetes Mellitus,NA
4249,26681720,2,;no betablocker use,Adrenergic beta-Antagonists,D000319,NA,0,1763,any,2,000000000,Adrenergic beta-Antagonists,NA
4250,26681720,2,;no metformin use,Hypoglycemic Agents,D007004,NA,0,1763,any,2,000000000,Hypoglycemic Agents,NA
4251,26681720,2,;no prior cv event,Cardiovascular Diseases,D002318,NA,0,1763,previous,8,100000000,Cardiovascular Diseases,NA
4252,26681720,2,;no statin use,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,1763,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
4253,26681720,2,;omega-3 fa intake 1st third,Fatty Acids,D005227,NA,0,1763,any,2,000000000,Fatty Acids,NA
4254,26681720,2,;omega-3 fa intake 2nd third,Fatty Acids,D005227,NA,0,1763,any,2,000000000,Fatty Acids,NA
4255,26681720,2,";omega-3 fa intake 3,d third",Fatty Acids,D005227,NA,0,1763,any,2,000000000,Fatty Acids,NA
4256,26681720,2,;omega 3 allocation,"Fatty Acids, Omega-3",D015525,NA,0,1763,any,2,000000000,"Fatty Acids, Omega-3",NA
4257,26681720,2,;prior cv event,Cardiovascular Diseases,D002318,NA,0,1763,previous,8,100000000,Cardiovascular Diseases,NA
4258,26681720,2,;prior dm,Diabetes Mellitus,D003920,NA,0,1763,previous,8,100000000,Diabetes Mellitus,NA
4259,26681720,2,;statin use,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,1763,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
4260,26681720,2,;triglycerides 1st third,Lipoproteins,D008074,NA,0,1763,any,2,000000000,Lipoproteins,NA
4261,26681720,2,;triglycerides 2nd third,Lipoproteins,D008074,NA,0,1763,any,2,000000000,Lipoproteins,NA
4262,26681720,2,";triglycerides 3,d third",Lipoproteins,D008074,NA,0,1763,any,2,000000000,Lipoproteins,NA
4263,26681720,2,age,Age Factors,D000367,NA,0,1763,any,2,000000000,Age Factors,NA
4264,26681720,2,BMI,Body Mass Index,D015992,NA,0,1763,any,2,000000000,Body Mass Index,NA
4265,26681720,2,Insulin glargine,Insulin,D007328,NA,0,1763,any,2,000000000,Insulin,NA
4266,26681720,2,male female,Gender Identity,D005783,NA,0,1763,any,2,000000000,Gender Identity,NA
4267,26699168,2,age at screening,Age Factors,D000367,NA,0,1158,any,2,000000000,Age Factors,NA
4268,26699168,2,geographical region,Geographic Locations,D005842,NA,0,1158,any,2,000000000,Geographic Locations,NA
4269,26699168,2,geographical region;western europe / australia,Geographic Locations,D005842,NA,0,1158,any,2,000000000,Geographic Locations,NA
4270,26699168,2,"pah etiology;assoc, with connective tissue disease",Connective Tissue Diseases,D003240,NA,0,1158,aetiological,1,000001000,Connective Tissue Diseases,NA
4271,26699168,2,"pah etiology;assoc, with corrected congenital shunts",Cardiovascular Abnormalities,D018376,NA,0,1158,aetiological,1,000001000,Cardiovascular Abnormalities,NA
4272,26699168,2,"pah etiology;ipah, hpah, hiv, drug or toxin induced",complex,none,NA,0,1158,aetiological,1,000001000,complex,NA
4273,26699168,2,pah therapy at baseline,antihypertensives for pulmonary arterial hypertension,NA,C02KX,0,1158,any,2,000000000,antihypertensives for pulmonary arterial hypertension,NA
4274,26699168,2,pah therapy at baseline;era and pde5 inhibitors,cardiac therapy,NA,C01,0,1158,any,2,000000000,cardiac therapy,NA
4275,26699168,2,pah therapy at baseline;era monotherapy,cardiac therapy,NA,C01,0,1158,any,2,000000000,cardiac therapy,NA
4276,26699168,2,pah therapy at baseline;pde5 inhibitor monotherapy,cardiac therapy,NA,C01,0,1158,any,2,000000000,cardiac therapy,NA
4277,26699168,2,"pulmonary arterial hypertension, etiology",Pulmonary Arterial Hypertension,D000081029,NA,0,1158,aetiological,1,000001010,Pulmonary Arterial Hypertension,NA
4278,26699168,2,sex,Gender Identity,D005783,NA,0,1158,any,2,000000000,Gender Identity,NA
4279,26699168,2,who functional class,Pulmonary Arterial Hypertension,D000081029,NA,0,1158,severity,11,000100000,Pulmonary Arterial Hypertension,NA
4280,26704701,2,japan,Geographic Locations,D005842,NA,0,1362,any,2,000000000,Geographic Locations,NA
4281,26704701,2,not-japan,Geographic Locations,D005842,NA,0,1362,any,2,000000000,Geographic Locations,NA
4282,26744025,2,asian,Racial Groups,D044469,NA,0,1165,any,2,000000000,Racial Groups,NA
4283,26744025,2,black/african- american,Racial Groups,D044469,NA,0,1165,any,2,000000000,Racial Groups,NA
4284,26744025,2,other,Racial Groups,D044469,NA,0,1165,any,2,000000000,Racial Groups,NA
4285,26744025,2,race,Racial Groups,D044469,NA,0,1165,any,2,000000000,Racial Groups,NA
4286,26744025,2,white,Racial Groups,D044469,NA,0,1165,any,2,000000000,Racial Groups,NA
4287,26744025,NA,Patient Variable: Race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,96
4288,26754626,2,;diabetes mellitus,Diabetes Mellitus,D003920,NA,0,305,any,2,000000000,Diabetes Mellitus,NA
4289,26754626,2,";diabetes mellitus, n=2907",Diabetes Mellitus,D003920,NA,0,305,any,2,000000000,Diabetes Mellitus,NA
4290,26754626,2,;preâ€“diabetes mellitus,Prediabetic State,D011236,NA,0,305,any,2,000000000,Prediabetic State,NA
4291,26754626,2,";preâ€“diabetes mellitus, n=2103",Prediabetic State,D011236,NA,0,305,any,2,000000000,Prediabetic State,NA
4292,26754626,2,;undiagnosed diabetes mellitus,Diabetes Mellitus,D003920,NA,0,305,any,2,000000000,Diabetes Mellitus,NA
4293,26754626,2,";undiagnosed diabetes mellitus, n=1106",Diabetes Mellitus,D003920,NA,0,305,any,2,000000000,Diabetes Mellitus,NA
4294,26754626,3,;diabetes mellitus,Diabetes Mellitus,D003920,NA,0,1572,any,2,000000000,Diabetes Mellitus,NA
4295,26754626,3,";diabetes mellitus, n=2907",Diabetes Mellitus,D003920,NA,0,1572,any,2,000000000,Diabetes Mellitus,NA
4296,26754626,3,";normal hba1c, n=2158",Glycated Hemoglobin A,D006442,NA,0,1572,any,2,000000000,Glycated Hemoglobin A,NA
4297,26754626,3,;preâ€“diabetes mellitus,Prediabetic State,D011236,NA,0,1572,any,2,000000000,Prediabetic State,NA
4298,26754626,3,";preâ€“diabetes mellitus, n=2103",Prediabetic State,D011236,NA,0,1572,any,2,000000000,Prediabetic State,NA
4299,26754626,3,;undiagnosed diabetes mellitus,Diabetes Mellitus,D003920,NA,0,1572,any,2,000000000,Diabetes Mellitus,NA
4300,26754626,3,";undiagnosed diabetes mellitus, n=1106",Diabetes Mellitus,D003920,NA,0,1572,any,2,000000000,Diabetes Mellitus,NA
4301,26762481,NA,Patient Variable: Gender,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,82
4302,26786577,NA,hba1c,Glycated Hemoglobin A,D006442,NA,0,0,any,2,000000000,Glycated Hemoglobin A,NA
4303,26792812,2,concomitant conventional dmard use,Antirheumatic Agents,D018501,NA,0,124,any,2,000000000,Antirheumatic Agents,NA
4304,26792812,2,prior biologic exposure,Biological Therapy,D001691,NA,0,124,previous,8,100000000,Biological Therapy,NA
4305,26826179,NA,peripheral artery disease history,Pulmonary Arterial Hypertension,D000081029,NA,0,0,previous,8,100000000,Pulmonary Arterial Hypertension,137
4306,26827074,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,203
4307,26827074,NA,age plus Gd status at baseline,complex,none,NA,0,0,any,2,000000000,complex,202
4308,26827074,NA,Expanded Disability Status Scale at baseline,Multiple Sclerosis,D009103,NA,0,0,severity,2,000000000,Multiple Sclerosis,202
4309,26827074,NA,Gd lesion status at baseline,Coronary Artery Disease,D003324,NA,0,0,any,2,000000000,Coronary Artery Disease,202
4310,26827074,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,202
4311,26833744,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,162
4312,26833744,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
4313,26886418,2,age,Age Factors,D000367,NA,0,1567,any,2,000000000,Age Factors,NA
4314,26886418,2,body-mass index,Body Mass Index,D015992,NA,0,1567,any,2,000000000,Body Mass Index,NA
4315,26886418,2,coronary artery disease,Coronary Artery Disease,D003324,NA,0,1567,any,2,000000000,Coronary Artery Disease,NA
4316,26886418,2,fasting glucose,Glucose,D005947,NA,0,1567,any,2,000000000,Glucose,NA
4317,26886418,2,glycated hemoglobin,Glycated Hemoglobin A,D006442,NA,0,1567,any,2,000000000,Glycated Hemoglobin A,NA
4318,26886418,2,HDL cholesterol,Lipoproteins,D008074,NA,0,1567,any,2,000000000,Lipoproteins,NA
4319,26886418,2,Hypertension,Hypertension,D006973,NA,0,1567,any,2,000000000,Hypertension,NA
4320,26886418,2,race,Racial Groups,D044469,NA,0,1567,any,2,000000000,Racial Groups,NA
4321,26886418,2,sex,Gender Identity,D005783,NA,0,1567,any,2,000000000,Gender Identity,NA
4322,26886418,2,triglycerides,Lipoproteins,D008074,NA,0,1567,any,2,000000000,Lipoproteins,NA
4323,26915374,2,enalapril,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,468,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
4324,26915374,2,sacubitril/valsartan,Angiotensin Receptor Antagonists,D057911,NA,0,468,any,2,000000000,Angiotensin Receptor Antagonists,NA
4325,26934128,NA,main meal,complex,NA,NA,0,0,any,2,000000000,complex,218
4326,26934128,NA,Patient Variable: consumed meal with the highest postprandial blood glucose level,Glucose,D005947,NA,0,0,any,2,000000000,Glucose,88
4327,26936426,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,102
4328,26949137,NA,Age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
4329,26949137,NA,level of asthma control at baseline (controlled or not controlled) previous asthma therapy (inhaled glucocorticoids or inhaled glucocorticoids plus LABA),Asthma,D001249,NA,0,0,any,2,000000000,Asthma,NA
4330,26994121,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,150
4331,27018175,NA,Eosinophil count (cells/microlitre),Eosinophilia,D004802,NA,0,0,any,2,000000000,Eosinophilia,NA
4332,27028914,2,# of prior bdmards,Antirheumatic Agents,D018501,NA,0,298,previous,8,100000000,Antirheumatic Agents,NA
4333,27028914,2,# of prior non-tnfi bdmards*,complex,none,NA,0,298,previous,8,100000000,complex,NA
4334,27028914,2,# of prior tnfi among non-tnfi naive,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,298,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
4335,27033025,2,ukpds 10-year risk score <20%,Diabetes Mellitus,D003920,NA,1,434,severity,11,000100000,Diabetes Mellitus,NA
4336,27033025,2,ukpds 10-year risk score >20%,Diabetes Mellitus,D003920,NA,1,434,severity,11,000100000,Diabetes Mellitus,NA
4337,27039236,NA,fixed airflow obstruction,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,0,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",71
4338,27039236,NA,Medical History: FAO status,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,0,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",18
4339,27043082,2,actual treatment strategy;cabg surgery,Coronary Artery Bypass,D001026,NA,0,543,any,2,000000000,Coronary Artery Bypass,NA
4340,27043082,2,actual treatment strategy;pci,Percutaneous Coronary Intervention,D062645,NA,0,543,any,2,000000000,Percutaneous Coronary Intervention,NA
4341,27043082,2,age,Age Factors,D000367,NA,0,543,any,2,000000000,Age Factors,NA
4342,27043082,2,chronic kidney disease,Kidney Diseases,D007674,NA,0,543,any,2,000000000,Kidney Diseases,NA
4343,27043082,2,diabetes mellitus,Diabetes Mellitus,D003920,NA,0,543,any,2,000000000,Diabetes Mellitus,NA
4344,27043082,2,no. of predictors of cardiovascular risk,Cardiovascular Diseases,D002318,NA,0,543,risk score,10,000000100,Cardiovascular Diseases,NA
4345,27043082,2,prior heart failure,Heart Failure,D006333,NA,0,543,previous,8,100000000,Heart Failure,NA
4346,27043082,2,prior mi,Myocardial Infarction,D009203,NA,0,543,previous,8,100010000,Myocardial Infarction,NA
4347,27043082,2,prior pci or cabg surgery,Coronary Artery Bypass,D001026,NA,0,543,previous,8,100000000,Coronary Artery Bypass,NA
4348,27043082,2,qualifying diagnosis;non-st-elevation mi,ST Elevation Myocardial Infarction,D000072657,NA,0,543,any,2,000000000,ST Elevation Myocardial Infarction,NA
4349,27043082,2,qualifying diagnosis;st-elevation mi,ST Elevation Myocardial Infarction,D000072657,NA,0,543,any,2,000000000,ST Elevation Myocardial Infarction,NA
4350,27043082,2,sex,Gender Identity,D005783,NA,0,543,any,2,000000000,Gender Identity,NA
4351,27043082,2,"time from randomization to pci (non-st-elevation mi), h",Percutaneous Coronary Intervention,D062645,NA,0,543,any,2,000000000,Percutaneous Coronary Intervention,NA
4352,27043082,2,"time from randomization to pci (st-elevation mi), min",Percutaneous Coronary Intervention,D062645,NA,0,543,any,2,000000000,Percutaneous Coronary Intervention,NA
4353,27046160,NA,Medical History: Diabetes at baseline,Diabetes Mellitus,D003920,NA,0,0,previous,8,100000000,Diabetes Mellitus,44
4354,27046162,NA,pad,Peripheral Vascular Diseases,D016491,NA,0,0,any,2,000000000,Peripheral Vascular Diseases,44
4355,27087007,NA,prior omalizumab treatment,Adrenergic beta-2 Receptor Agonists,D058666,NA,0,0,previous,8,100000000,Adrenergic beta-2 Receptor Agonists,283
4356,27098404,1,"randomised patients with basdai assessment at baseline and week 24, n",Spondylitis,D013166,NA,0,145,severity,11,000100000,Spondylitis,NA
4357,27098404,1,randomised patients with dactylitis at baseline,unclassifiable,NA,NA,0,145,any,2,000000000,unclassifiable,NA
4358,27098404,1,randomised patients with enthesitis at baselinet,"Arthritis, Juvenile",D001171,NA,0,145,any,2,000000000,"Arthritis, Juvenile",NA
4359,27098404,1,"randomised patients with spondylitis at baseline, n",Spondylitis,D013166,NA,0,145,any,2,000000000,Spondylitis,NA
4360,27102506,NA,ACEi or ARB post-randomisation,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,0,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
4361,27102506,NA,ACEi or ARB pre-randomisation,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,0,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
4362,27102506,NA,ACEi/ARB and BB after randomisation,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,0,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
4363,27102506,NA,Admission CrCl,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
4364,27102506,NA,"Admission K, mmol/l",Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
4365,27102506,NA,Age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
4366,27102506,NA,BB after randomisation,Adrenergic beta-Antagonists,D000319,NA,0,0,any,2,000000000,Adrenergic beta-Antagonists,NA
4367,27102506,NA,BMI,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,NA
4368,27102506,NA,Diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
4369,27102506,NA,Kilip Class,Myocardial Infarction,D009203,NA,0,0,severity,11,000100000,Myocardial Infarction,NA
4370,27102506,NA,"LVEF, %",Stroke Volume,D013318,NA,0,0,any,2,000000000,Stroke Volume,NA
4371,27102506,NA,Pulsed blood pressure,Blood Pressure,D001794,NA,0,0,any,2,000000000,Blood Pressure,NA
4372,27102506,NA,Received PCI,Percutaneous Coronary Intervention,D062645,NA,0,0,any,2,000000000,Percutaneous Coronary Intervention,NA
4373,27102506,NA,Sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
4374,27102506,NA,Type of MI,Myocardial Infarction,D009203,NA,0,0,type,12,000000010,Myocardial Infarction,NA
4375,27143684,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,264
4376,27143684,NA,heart failure medical history,Heart Failure,D006333,NA,0,0,previous,8,100000000,Heart Failure,264
4377,27143684,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,264
4378,27143684,NA,region,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,264
4379,27143684,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,264
4380,27144849,1,age,Age Factors,D000367,NA,0,325,any,2,000000000,Age Factors,NA
4381,27144849,1,duration of assigned regimen before surgery,Duration of Therapy,D000081206,NA,0,325,previous,8,101000000,Duration of Therapy,NA
4382,27144849,1,postoperative glucocorticoid use,Steroids,D013256,NA,0,325,any,2,000000000,Steroids,NA
4383,27144849,1,postoperative nsaid or glucocorticoid use,Steroids,D013256,NA,0,325,any,2,000000000,Steroids,NA
4384,27144849,1,previous statin use,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,325,previous,8,100000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
4385,27144849,1,procedure**;cabg,Cardiac Surgical Procedures,D006348,NA,0,325,type,12,000000010,Cardiac Surgical Procedures,NA
4386,27144849,1,procedure;aortic-valve replacement,Heart Valve Prosthesis Implantation,D019918,NA,0,325,any,2,000000000,Heart Valve Prosthesis Implantation,NA
4387,27144849,1,procedure;cabg,Coronary Artery Bypass,D001026,NA,0,325,any,2,000000000,Coronary Artery Bypass,NA
4388,27144849,1,sex,Gender Identity,D005783,NA,0,325,any,2,000000000,Gender Identity,NA
4389,27144849,1,surgical technique,"Surgical Procedures, Operative",D013514,NA,0,325,any,2,000000000,"Surgical Procedures, Operative",NA
4390,27144849,1,troponin 1 at baseline,Troponin,D014336,NA,0,325,any,2,000000000,Troponin,NA
4391,27144849,1,troponin 1 at baseline*,Troponin,D014336,NA,0,325,any,2,000000000,Troponin,NA
4392,27144849,2,age,Age Factors,D000367,NA,0,166,any,2,000000000,Age Factors,NA
4393,27144849,2,body-mass index,Body Mass Index,D015992,NA,0,166,any,2,000000000,Body Mass Index,NA
4394,27144849,2,duration of assigned regimen before surgery post-randomisation characteristic*,Duration of Therapy,D000081206,NA,0,166,previous,8,101000000,Duration of Therapy,NA
4395,27144849,2,ldl cholesterol,Lipoproteins,D008074,NA,0,166,any,2,000000000,Lipoproteins,NA
4396,27144849,2,lvef,Stroke Volume,D013318,NA,0,166,any,2,000000000,Stroke Volume,NA
4397,27144849,2,previous mi,Myocardial Infarction,D009203,NA,0,166,previous,8,100010000,Myocardial Infarction,NA
4398,27144849,2,previous ml,Myocardial Infarction,D009203,NA,0,166,previous,8,100010000,Myocardial Infarction,NA
4399,27144849,3,age,Age Factors,D000367,NA,0,609,any,2,000000000,Age Factors,NA
4400,27144849,3,duration of assigned regimen before surgery post-randomisation characteristic**,Duration of Therapy,D000081206,NA,0,609,previous,8,101000000,Duration of Therapy,NA
4401,27144849,3,postoperative glucocorticoid use post-randomisation characteristic**,Anti-Inflammatory Agents,D000893,NA,0,609,any,2,000000000,Anti-Inflammatory Agents,NA
4402,27144849,3,postoperative nsaid or glucocorticoid use post-randomisation characteristic**,Anti-Inflammatory Agents,D000893,NA,0,609,any,2,000000000,Anti-Inflammatory Agents,NA
4403,27144849,3,procedure**,"Surgical Procedures, Operative",D013514,NA,0,609,any,2,000000000,"Surgical Procedures, Operative",NA
4404,27144849,3,procedure**;avr,Heart Valve Prosthesis Implantation,D019918,NA,0,609,any,2,000000000,Heart Valve Prosthesis Implantation,NA
4405,27144849,3,procedure**;cabg,Coronary Artery Bypass,D001026,NA,0,609,any,2,000000000,Coronary Artery Bypass,NA
4406,27144849,3,procedure;cabg,Coronary Artery Bypass,D001026,NA,0,609,any,2,000000000,Coronary Artery Bypass,NA
4407,27144849,3,sex,Gender Identity,D005783,NA,0,609,any,2,000000000,Gender Identity,NA
4408,27144849,3,surgical technique post-randomisation characteristic**,"Surgical Procedures, Operative",D013514,NA,0,609,any,2,000000000,"Surgical Procedures, Operative",NA
4409,27144849,3,troponin 1 at baseline,Troponin,D014336,NA,0,609,any,2,000000000,Troponin,NA
4410,27144849,3,troponin 1 at baseline*,Troponin,D014336,NA,0,609,any,2,000000000,Troponin,NA
4411,27144849,4,age,Age Factors,D000367,NA,0,1122,any,2,000000000,Age Factors,NA
4412,27144849,4,body-mass index,Body Mass Index,D015992,NA,0,1122,any,2,000000000,Body Mass Index,NA
4413,27144849,4,duration of assigned regimen before surgery post-randomisation characteristic*,Duration of Therapy,D000081206,NA,0,1122,previous,8,101000000,Duration of Therapy,NA
4414,27144849,4,ldl cholesterol,Lipoproteins,D008074,NA,0,1122,any,2,000000000,Lipoproteins,NA
4415,27144849,4,lvef,Stroke Volume,D013318,NA,0,1122,any,2,000000000,Stroke Volume,NA
4416,27144849,4,previous mi,Myocardial Infarction,D009203,NA,0,1122,previous,8,100010000,Myocardial Infarction,NA
4417,27144849,4,previous ml,Myocardial Infarction,D009203,NA,0,1122,previous,8,100010000,Myocardial Infarction,NA
4418,27144849,5,age,Age Factors,D000367,NA,0,1108,any,2,000000000,Age Factors,NA
4419,27144849,5,body-mass index,Body Mass Index,D015992,NA,0,1108,any,2,000000000,Body Mass Index,NA
4420,27144849,5,ldl cholesterol,Lipoproteins,D008074,NA,0,1108,any,2,000000000,Lipoproteins,NA
4421,27144849,5,lvef,Stroke Volume,D013318,NA,0,1108,any,2,000000000,Stroke Volume,NA
4422,27144849,5,previous myocardial infarction,Myocardial Infarction,D009203,NA,0,1108,previous,8,100000000,Myocardial Infarction,NA
4423,27161178,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,33
4424,27161178,NA,Patient Variable: Age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,33
4425,27165179,2,CZP+MTX,Immunosuppressive Agents,D007166,NA,0,1697,duration,5,001000000,Immunosuppressive Agents,NA
4426,27181606,2,copd exacerbations during the previous year,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,446,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
4427,27181606,2,copd exacerbations during the previous year;>2 exacerbations,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,446,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
4428,27181606,2,copd exacerbations during the previous year;1 exacerbation,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,446,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
4429,27181606,2,inhaled glucocorticoid use at screening,Steroids,D013256,NA,0,446,any,2,000000000,Steroids,NA
4430,27181606,2,laba-inhaled glucocorticoid use at screening,Steroids,D013256,NA,0,446,any,2,000000000,Steroids,NA
4431,27181606,2,laba use at screening,long-acting beta agonist,NA,R03A,0,446,any,2,000000000,long-acting beta agonist,NA
4432,27181606,2,lama use at screening,lama,NA,R03BB,0,446,any,2,000000000,lama,NA
4433,27181606,2,race,Racial Groups,D044469,NA,0,446,any,2,000000000,Racial Groups,NA
4434,27181606,2,severity of airflow limitation,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,446,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
4435,27181606,2,severity of airflow limitation;moderate,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,446,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
4436,27181606,2,severity of airflow limitation;severe,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,446,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
4437,27181606,2,severity of airflow limitation;very severe,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,446,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
4438,27181606,2,severity of copd,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,446,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
4439,27181606,2,sex,Gender Identity,D005783,NA,0,446,any,2,000000000,Gender Identity,NA
4440,27181606,2,Smoker,Cigarette Smoking,D000073865,NA,0,446,any,2,000000000,Cigarette Smoking,NA
4441,27181606,2,smoking status at screening,Cigarette Smoking,D000073865,NA,0,446,any,2,000000000,Cigarette Smoking,NA
4442,27190009,2,;a,Genetic Profile,D000076610,NA,0,1135,type,12,000000010,Genetic Profile,NA
4443,27190009,2,;cc,Genetic Profile,D000076610,NA,0,1135,type,12,000000010,Genetic Profile,NA
4444,27193270,NA,body weight,Body Weight,D001835,NA,0,0,any,2,000000000,Body Weight,238
4445,27193270,NA,glycaemic status,unclassifible,NA,NA,0,0,any,2,000000000,unclassifible,NA
4446,27193270,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
4447,27215502,2,age (years),Age Factors,D000367,NA,0,1069,any,2,000000000,Age Factors,NA
4448,27215502,2,ccv history/condition at baseline,Cardiovascular Diseases,D002318,NA,0,1069,previous,8,100000000,Cardiovascular Diseases,NA
4449,27215502,2,history of atrial fibrillation/flutter,Atrial Fibrillation,D001281,NA,0,1069,previous,8,100000000,Atrial Fibrillation,NA
4450,27215502,2,History of cardiac arrhythmia No Yes,"Arrhythmias, Cardiac",D001145,NA,0,1069,previous,8,100000000,"Arrhythmias, Cardiac",NA
4451,27215502,2,ics use at baseline,Steroids,D013256,NA,0,1069,any,2,000000000,Steroids,NA
4452,27215502,2,long-acting bronchodilator use at screening,"adrenergics, inhalants",NA,R03A,0,1069,any,2,000000000,"adrenergics, inhalants",NA
4453,27215502,2,male female,Gender Identity,D005783,NA,0,1069,any,2,000000000,Gender Identity,NA
4454,27215502,2,race,Racial Groups,D044469,NA,0,1069,any,2,000000000,Racial Groups,NA
4455,27215502,2,severity of airflow obstruction,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1069,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
4456,27215502,2,severity of airflow obstruction;mild or moderate copd,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1069,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
4457,27215502,2,severity of airflow obstruction;severe or very severe copd,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1069,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
4458,27215749,3,GOLD stage,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,703,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
4459,27252787,2,;<65 years of age,Age Factors,D000367,NA,0,123,any,2,000000000,Age Factors,NA
4460,27252787,2,;>65 years of age,Age Factors,D000367,NA,0,123,any,2,000000000,Age Factors,NA
4461,27252787,2,;high (>25 kg/m^) baseline bmi,Body Mass Index,D015992,NA,0,123,any,2,000000000,Body Mass Index,NA
4462,27252787,2,;high (>8%) baseline hbalc,Glycated Hemoglobin A,D006442,NA,0,123,any,2,000000000,Glycated Hemoglobin A,NA
4463,27252787,2,;long (>10 years) duration of diabetes,Diabetes Mellitus,D003920,NA,0,123,duration,5,001000000,Diabetes Mellitus,NA
4464,27252787,2,;low (<25 kg/m^) baseline bmi,Body Mass Index,D015992,NA,0,123,any,2,000000000,Body Mass Index,NA
4465,27252787,2,;low (<8%) baseline hbalc,Glycated Hemoglobin A,D006442,NA,0,123,any,2,000000000,Glycated Hemoglobin A,NA
4466,27252787,2,;short (<10 years) duration of diabetes,Diabetes Mellitus,D003920,NA,0,123,duration,5,001000000,Diabetes Mellitus,NA
4467,27267268,NA,Medical History: SUIT Quartile,complex,NA,NA,0,0,previous,8,100000000,complex,103
4467,27267268,NA,Medical History: SUIT Quartile,unclassifiable,NA,NA,0,0,previous,8,100000000,unclassifiable,103
4468,27289121,2,asia/pacific,Geographic Locations,D005842,NA,0,778,any,2,000000000,Geographic Locations,NA
4469,27289121,2,baseline age,Age Factors,D000367,NA,0,778,any,2,000000000,Age Factors,NA
4470,27289121,2,baseline glycemic control,Glucose,D005947,NA,0,778,any,2,000000000,Glucose,NA
4471,27289121,2,biguanide use at baseline,Hypoglycemic Agents,D007004,NA,0,778,any,2,000000000,Hypoglycemic Agents,NA
4472,27289121,2,duration of diabetes,Diabetes Mellitus,D003920,NA,0,778,duration,5,001000000,Diabetes Mellitus,NA
4473,27289121,2,"eastern europe, africa",Geographic Locations,D005842,NA,0,778,any,2,000000000,Geographic Locations,NA
4474,27289121,2,ex-smoker,Cigarette Smoking,D000073865,NA,0,778,previous,8,100000000,Cigarette Smoking,NA
4475,27289121,2,geographic region,Geographic Locations,D005842,NA,0,778,any,2,000000000,Geographic Locations,NA
4476,27289121,2,history of chf before index event,Heart Failure,D006333,NA,0,778,previous,8,100000000,Heart Failure,NA
4477,27289121,2,history of ml before index event,Myocardial Infarction,D009203,NA,0,778,previous,8,100010000,Myocardial Infarction,NA
4478,27289121,2,history of pci or cabg before index event,Coronary Artery Bypass,D001026,NA,0,778,previous,8,100000000,Coronary Artery Bypass,NA
4479,27289121,2,insulin use at baseline,Insulin,D007328,NA,0,778,any,2,000000000,Insulin,NA
4480,27289121,2,"mexico, central/south america",Geographic Locations,D005842,NA,0,778,any,2,000000000,Geographic Locations,NA
4481,27289121,2,mi,Myocardial Infarction,D009203,NA,0,778,any,2,000000000,Myocardial Infarction,NA
4482,27289121,2,moderate or severe impairment,Renal Insufficiency,D051437,NA,0,778,severity,11,000100000,Renal Insufficiency,NA
4483,27289121,2,never smoked,Cigarette Smoking,D000073865,NA,0,778,any,2,000000000,Cigarette Smoking,NA
4484,27289121,2,non-white,Racial Groups,D044469,NA,0,778,any,2,000000000,Racial Groups,NA
4485,27289121,2,normal function or mild impairment,Renal Insufficiency,D051437,NA,0,778,severity,11,000100000,Renal Insufficiency,NA
4486,27289121,2,race,Racial Groups,D044469,NA,0,778,any,2,000000000,Racial Groups,NA
4487,27289121,2,renal function,Renal Insufficiency,D051437,NA,0,778,any,2,000000000,Renal Insufficiency,NA
4488,27289121,2,sex,Gender Identity,D005783,NA,0,778,any,2,000000000,Gender Identity,NA
4489,27289121,2,sulfonylurea use at baseline,Hypoglycemic Agents,D007004,NA,0,778,any,2,000000000,Hypoglycemic Agents,NA
4490,27289121,2,thiazolidinedione use at baseline,Hypoglycemic Agents,D007004,NA,0,778,any,2,000000000,Hypoglycemic Agents,NA
4491,27289121,2,"united states, canada",Geographic Locations,D005842,NA,0,778,any,2,000000000,Geographic Locations,NA
4492,27289121,2,unstable angina,Angina Pectoris,D000787,NA,0,778,any,2,000000000,Angina Pectoris,NA
4493,27289121,2,"western europe, australia, new zealand, middle eai",Geographic Locations,D005842,NA,0,778,any,2,000000000,Geographic Locations,NA
4494,27295427,NA,Age-Years,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
4495,27295427,NA,antidiabetic therapy,Hypoglycemic Agents,D007004,NA,0,0,any,2,000000000,Hypoglycemic Agents,NA
4496,27295427,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,NA
4497,27295427,NA,duration of diabetes,Diabetes Mellitus,D003920,NA,0,0,duration,5,001000000,Diabetes Mellitus,NA
4498,27295427,NA,egfr,Renal Insufficiency,D051437,NA,0,0,any,2,000000000,Renal Insufficiency,NA
4499,27295427,NA,hba1c,Glycated Hemoglobin A,D006442,NA,0,0,any,2,000000000,Glycated Hemoglobin A,NA
4500,27295427,NA,heart failure,Heart Failure,D006333,NA,0,0,any,2,000000000,Heart Failure,NA
4501,27295427,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
4502,27295427,NA,region,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,NA
4503,27295427,NA,renal function,Renal Insufficiency,D051437,NA,0,0,any,2,000000000,Renal Insufficiency,NA
4504,27295427,NA,risk of CVD,Cardiovascular Diseases,D002318,NA,0,0,risk score,10,000000100,Cardiovascular Diseases,NA
4505,27295427,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
4506,27299675,2,ace inhibitor and/or arb,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,1816,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
4507,27299675,2,age,Age Factors,D000367,NA,0,1816,any,2,000000000,Age Factors,NA
4508,27299675,2,albuminuria,Albuminuria,D000419,NA,0,1816,any,2,000000000,Albuminuria,NA
4509,27299675,2,anti-hypertensive therapy,Antihypertensive Agents,D000959,NA,0,1816,any,2,000000000,Antihypertensive Agents,NA
4510,27299675,2,beta-blocker,Adrenergic beta-Antagonists,D000319,NA,0,1816,any,2,000000000,Adrenergic beta-Antagonists,NA
4511,27299675,2,blood pressure control,Blood Pressure,D001794,NA,0,1816,any,2,000000000,Blood Pressure,NA
4512,27299675,2,blood pressure control;sbp <140 mmhg and dbp <90 mmhg,Blood Pressure,D001794,NA,0,1816,any,2,000000000,Blood Pressure,NA
4513,27299675,2,blood pressure control;sbp >140 mmhg and/or dbp >90 mmhg,Blood Pressure,D001794,NA,0,1816,any,2,000000000,Blood Pressure,NA
4514,27299675,2,body mass index,Body Mass Index,D015992,NA,0,1816,any,2,000000000,Body Mass Index,NA
4515,27299675,2,cardiovascular risk,Cardiovascular Diseases,D002318,NA,0,1816,severity,11,000100100,Cardiovascular Diseases,NA
4516,27299675,2,cardiovascular risk;2 or 3 high cardiovascular risk categories,Cardiovascular Diseases,D002318,NA,0,1816,severity,11,000100100,Cardiovascular Diseases,NA
4517,27299675,2,cardiovascular risk;only cerebrovascular disease,Stroke,D020521,NA,0,1816,risk score,10,000000100,Stroke,NA
4518,27299675,2,cardiovascular risk;only coronary artery disease,Coronary Artery Disease,D003324,NA,0,1816,risk score,10,000000100,Coronary Artery Disease,NA
4519,27299675,2,cardiovascular risk;only peripheral artery disease,Peripheral Vascular Diseases,D016491,NA,0,1816,risk score,10,000000100,Peripheral Vascular Diseases,NA
4520,27299675,2,diuretic,Diuretics,D004232,NA,0,1816,any,2,000000000,Diuretics,NA
4521,27299675,2,estimated Glomerular Filtration Rate,Glomerular Filtration Rate,D005919,NA,0,1816,any,2,000000000,Glomerular Filtration Rate,NA
4522,27299675,2,glycated hemoglobin,Glycated Hemoglobin A,D006442,NA,0,1816,any,2,000000000,Glycated Hemoglobin A,NA
4523,27299675,2,insulin,Insulin,D007328,NA,0,1816,any,2,000000000,Insulin,NA
4524,27299675,2,metformin,Hypoglycemic Agents,D007004,NA,0,1816,any,2,000000000,Hypoglycemic Agents,NA
4525,27299675,2,race,Racial Groups,D044469,NA,0,1816,any,2,000000000,Racial Groups,NA
4526,27299675,2,sex,Gender Identity,D005783,NA,0,1816,any,2,000000000,Gender Identity,NA
4527,27299675,2,statin and/or ezetimibe,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,1816,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
4528,27299675,2,time since diagnosis of type 2 diabetes,Diabetes Mellitus,D003920,NA,0,1816,duration,5,001000010,Diabetes Mellitus,NA
4529,27316465,2,GOLD stage,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1527,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
4530,27316465,3,GOLD stage,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1271,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
4531,27316465,5,ICS treatment at baseline,Steroids,D013256,NA,0,1254,any,2,000000000,Steroids,NA
4532,27316465,5,treatment naive at baseline,Steroids,D013256,NA,0,1254,previous,8,100000000,Steroids,NA
4533,27322571,NA,"Age, y",Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
4534,27322571,NA,"Disease duration, y",Parkinson Disease,D010300,NA,0,0,duration,5,001000000,Parkinson Disease,NA
4535,27322571,NA,Disease severity,"Arthritis, Rheumatoid",D001172,NA,0,0,severity,11,000100000,"Arthritis, Rheumatoid",NA
4536,27322571,NA,Disease stage,Parkinson Disease,D010300,NA,0,0,severity,11,000100000,Parkinson Disease,NA
4537,27322571,NA,Gender,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
4538,27335114,NA,AED inducer status and AED and number of prior AEDs,unclassifiable,NA,NA,0,0,previous severity,9,100100000,unclassifiable,167
4539,27354044,2,;central/easternÂ europe and russia,Geographic Locations,D005842,NA,0,236,any,2,000000000,Geographic Locations,NA
4540,27354044,2,Geographical variation,Geographic Locations,D005842,NA,0,236,any,2,000000000,Geographic Locations,NA
4541,27390130,NA,previous anti-TNF status (patients who were naive for anti-TNF therapy or those with a history of inadequate response to or intolerance of these agents),Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,0,previous,8,100000000,Tumor Necrosis Factor Inhibitors,78
4542,27395349,3,;no prior hf hospitalization,Heart Failure,D006333,NA,0,1794,previous severity,9,100100000,Heart Failure,NA
4543,27395349,3,Prior HF Hospitalization,Heart Failure,D006333,NA,0,1794,previous,8,110000000,Heart Failure,NA
4544,27418597,2,age,Age Factors,D000367,NA,0,1528,any,2,000000000,Age Factors,NA
4545,27418597,2,history of diabetes,Diabetes Mellitus,D003920,NA,0,1528,previous,8,100000000,Diabetes Mellitus,NA
4546,27418597,2,history of hypertension,Hypertension,D006973,NA,0,1528,previous,8,100000000,Hypertension,NA
4547,27418597,2,history of ischemic stroke,Stroke,D020521,NA,0,1528,previous,8,100000000,Stroke,NA
4548,27418597,2,hospital number of beds,Hospital Bed Capacity,D006742,NA,0,1528,any,2,000000000,Hospital Bed Capacity,NA
4549,27418597,2,hospital number of patients enrolled,unclassifiable,NA,NA,0,1528,any,2,000000000,unclassifiable,NA
4550,27418597,2,Hypercholesterolemia,Hypercholesterolemia,D006937,NA,0,1528,any,2,000000000,Hypercholesterolemia,NA
4551,27418597,2,lipid-lowering agents,Hypolipidemic Agents,D000960,NA,0,1528,any,2,000000000,Hypolipidemic Agents,NA
4552,27418597,2,sex,Gender Identity,D005783,NA,0,1528,any,2,000000000,Gender Identity,NA
4553,27418597,2,time to randomization,unclassifiable,NA,NA,0,1528,any,2,000000000,unclassifiable,NA
4554,27418597,2,time to randomization;anterior circulation,Stroke,D020521,NA,0,1528,location,7,000000001,Stroke,NA
4555,27418597,2,time to randomization;cortical only,Stroke,D020521,NA,0,1528,location,7,000000001,Stroke,NA
4556,27418597,2,time to randomization;mca,Stroke,D020521,NA,0,1528,location,7,000000001,Stroke,NA
4557,27418597,2,time to randomization;non-cortical,Stroke,D020521,NA,0,1528,location,7,000000001,Stroke,NA
4558,27418597,2,time to randomization;others,Stroke,D020521,NA,0,1528,location,7,000000001,Stroke,NA
4559,27418597,2,time to randomization;posterior circulation,Stroke,D020521,NA,0,1528,location,7,000000001,Stroke,NA
4560,27418597,2,time to treatment,Time-to-Treatment,D061665,NA,0,1528,any,2,000000000,Time-to-Treatment,NA
4561,27437883,2,ace inhibitor yes,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,1182,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
4562,27437883,2,age,Age Factors,D000367,NA,0,1182,any,2,000000000,Age Factors,NA
4563,27437883,2,angiotensin receptor blocker yes,Angiotensin Receptor Antagonists,D057911,NA,0,1182,any,2,000000000,Angiotensin Receptor Antagonists,NA
4564,27437883,2,baseline heart failure severity nyha class i,Heart Failure,D006333,NA,0,1182,severity,11,000100000,Heart Failure,NA
4565,27437883,2,body mass index < median,Body Mass Index,D015992,NA,0,1182,any,2,000000000,Body Mass Index,NA
4566,27437883,2,diabetes duration < median,Diabetes Mellitus,D003920,NA,0,1182,duration,5,001000000,Diabetes Mellitus,NA
4567,27437883,2,ethnicityÂ hispanic or latino,Racial Groups,D044469,NA,0,1182,any,2,000000000,Racial Groups,NA
4568,27437883,2,"glycated hemoglobin <median< p="""">",Glycated Hemoglobin A,D006442,NA,0,1182,any,2,000000000,Glycated Hemoglobin A,NA
4569,27437883,2,Hypertension,Hypertension,D006973,NA,0,1182,any,2,000000000,Hypertension,NA
4570,27437883,2,insulin yes,Insulin,D007328,NA,0,1182,any,2,000000000,Insulin,NA
4571,27437883,2,male female,Gender Identity,D005783,NA,0,1182,any,2,000000000,Gender Identity,NA
4572,27437883,2,nyha class >ii,Heart Failure,D006333,NA,0,1182,severity,11,000100000,Heart Failure,NA
4573,27437883,2,nyha class not reported,Heart Failure,D006333,NA,0,1182,severity,11,000100000,Heart Failure,NA
4574,27437883,2,p-blocker yes,beta blocking agents,NA,C07,0,1182,any,2,000000000,beta blocking agents,NA
4575,27437883,2,prior congestive heart failure yes,Heart Failure,D006333,NA,0,1182,previous,8,100000000,Heart Failure,NA
4576,27437883,2,prior coronary artery disease yes,Coronary Artery Disease,D003324,NA,0,1182,previous,8,100000000,Coronary Artery Disease,NA
4577,27437883,2,prior myocardial infarction yes,Myocardial Infarction,D009203,NA,0,1182,previous,8,100000000,Myocardial Infarction,NA
4578,27437883,2,race,Racial Groups,D044469,NA,0,1182,any,2,000000000,Racial Groups,NA
4579,27437883,2,raceÂ white,Racial Groups,D044469,NA,0,1182,any,2,000000000,Racial Groups,NA
4580,27437883,2,"renal function <60 egfr, ml/min/1.73 m2",Renal Insufficiency,D051437,NA,0,1182,any,2,000000000,Renal Insufficiency,NA
4581,27437883,2,"systolic blood pressure, mm hg <140",Blood Pressure,D001794,NA,0,1182,any,2,000000000,Blood Pressure,NA
4582,27437883,2,thiazolidinedione yes,Hypoglycemic Agents,D007004,NA,0,1182,any,2,000000000,Hypoglycemic Agents,NA
4583,27465265,2,abdominal obesity,Obesity,D009765,NA,0,631,any,2,000000000,Obesity,NA
4584,27465265,2,abdominal obesity;present,Obesity,D009765,NA,0,631,any,2,000000000,Obesity,NA
4585,27465265,2,ada impaired fasting glucose,Glucose Intolerance,D018149,NA,0,631,any,2,000000000,Glucose Intolerance,NA
4586,27465265,2,ada impaired fasting glucose;present (Â£100 mg/dl),Glucose Intolerance,D018149,NA,0,631,any,2,000000000,Glucose Intolerance,NA
4587,27465265,2,aerobic activity,Exercise,D015444,NA,0,631,any,2,000000000,Exercise,NA
4588,27465265,2,age,Age Factors,D000367,NA,0,631,any,2,000000000,Age Factors,NA
4589,27465265,2,body mass index,Body Mass Index,D015992,NA,0,631,any,2,000000000,Body Mass Index,NA
4590,27465265,2,coronary artery disease history,Coronary Artery Disease,D003324,NA,0,631,previous,8,100000000,Coronary Artery Disease,NA
4591,27465265,2,glycated hemoglobin,Glycated Hemoglobin A,D006442,NA,0,631,any,2,000000000,Glycated Hemoglobin A,NA
4592,27465265,2,HDL cholesterol,Lipoproteins,D008074,NA,0,631,any,2,000000000,Lipoproteins,NA
4593,27465265,2,hispanic ethnicity,Racial Groups,D044469,NA,0,631,any,2,000000000,Racial Groups,NA
4594,27465265,2,hypertension history,Hypertension,D006973,NA,0,631,previous,8,100000000,Hypertension,NA
4595,27465265,2,metabolic syndrome,Metabolic Syndrome,D024821,NA,0,631,any,2,000000000,Metabolic Syndrome,NA
4596,27465265,2,metabolic syndrome;present,Metabolic Syndrome,D024821,NA,0,631,any,2,000000000,Metabolic Syndrome,NA
4597,27465265,2,race,Racial Groups,D044469,NA,0,631,any,2,000000000,Racial Groups,NA
4598,27465265,2,sex,Gender Identity,D005783,NA,0,631,any,2,000000000,Gender Identity,NA
4599,27465265,2,triglycerides,Lipoproteins,D008074,NA,0,631,any,2,000000000,Lipoproteins,NA
4600,27465265,2,who/idf impaired fasting glucose,Glucose Intolerance,D018149,NA,0,631,any,2,000000000,Glucose Intolerance,NA
4601,27465265,2,who/idf impaired fasting glucose;present (Â£110 mg/dl),Glucose Intolerance,D018149,NA,0,631,any,2,000000000,Glucose Intolerance,NA
4602,27484756,2,age (years),Age Factors,D000367,NA,0,1478,any,2,000000000,Age Factors,NA
4603,27484756,2,age (years);<50,Age Factors,D000367,NA,0,1478,any,2,000000000,Age Factors,NA
4604,27484756,2,age (years);>75,Age Factors,D000367,NA,0,1478,any,2,000000000,Age Factors,NA
4605,27484756,2,age (years);51 to <65,Age Factors,D000367,NA,0,1478,any,2,000000000,Age Factors,NA
4606,27484756,2,age (years);65 to <75,Age Factors,D000367,NA,0,1478,any,2,000000000,Age Factors,NA
4607,27484756,2,bmi (kg/m),Body Mass Index,D015992,NA,0,1478,any,2,000000000,Body Mass Index,NA
4608,27484756,2,duration of t2dm (years),Diabetes Mellitus,D003920,NA,0,1478,duration,5,001000000,Diabetes Mellitus,NA
4609,27484756,2,gender,Gender Identity,D005783,NA,0,1478,any,2,000000000,Gender Identity,NA
4610,27484756,2,homa-ir (mu/l^mmol/l),Insulin Resistance,D007333,NA,0,1478,any,2,000000000,Insulin Resistance,NA
4611,27484756,2,presence of mets,Metabolic Syndrome,D024821,NA,0,1478,any,2,000000000,Metabolic Syndrome,NA
4612,27492833,NA,COPD exacerbations,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,0,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",123
4613,27492833,NA,prior ICS,Adrenal Cortex Hormones,D000305,NA,0,0,previous,8,100000000,Adrenal Cortex Hormones,123
4614,27493790,NA,Medical History: Rheumatoid arthritis duratio,"Arthritis, Rheumatoid",D001172,NA,0,0,previous,8,101000000,"Arthritis, Rheumatoid",168
4615,27493790,NA,Medical History: Rheumatoid arthritis duration,"Arthritis, Rheumatoid",D001172,NA,0,0,previous,8,101000000,"Arthritis, Rheumatoid",168
4616,27502307,2,;subset of patients not on metformin,Hypoglycemic Agents,D007004,NA,0,43,any,2,000000000,Hypoglycemic Agents,NA
4617,27502307,2,;subset of patients on metformin,Hypoglycemic Agents,D007004,NA,0,43,any,2,000000000,Hypoglycemic Agents,NA
4618,27502582,2,patient global assessment of pain,Pain,D010146,NA,0,1244,severity,11,000100000,Pain,NA
4619,27502582,2,swollen joint count,"Arthritis, Rheumatoid",D001172,NA,0,1244,severity,11,000100000,"Arthritis, Rheumatoid",NA
4620,27502582,2,tender joint count,"Arthritis, Rheumatoid",D001172,NA,0,1244,severity,11,000100000,"Arthritis, Rheumatoid",NA
4621,27502857,NA,Cardiac surgery type,"Specialties, Surgical",D013043,NA,0,0,type,12,000000010,"Specialties, Surgical",NA
4622,27502866,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,224
4623,27502866,NA,Patient Variable: Age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,31
4624,27506222,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,196
4625,27506222,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,64
4626,27506222,NA,duration of type 1 diabetes,Diabetes Mellitus,D003920,NA,0,0,duration,5,001000010,Diabetes Mellitus,NA
4627,27506222,NA,geographic region,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,64
4628,27506222,NA,HbA1c,Glycated Hemoglobin A,D006442,NA,0,0,any,2,000000000,Glycated Hemoglobin A,64
4629,27506222,NA,hypoglycemia unawareness status,unclassifible,NA,NA,0,0,any,2,000000000,unclassifible,64
4630,27506222,NA,method of insulin administration,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
4631,27506222,NA,renal function,Renal Insufficiency,D051437,NA,0,0,any,2,000000000,Renal Insufficiency,64
4632,27506222,NA,severe hypoglycemia within the last 12 months,Hypoglycemia,D007003,NA,0,0,severity,11,000100000,Hypoglycemia,64
4633,27506222,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,64
4634,27564409,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,197
4635,27564409,NA,comorbidities,Comorbidity,D015897,NA,0,0,any,2,000000000,Comorbidity,198
4636,27564409,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,198
4637,27564409,NA,renal function,Renal Insufficiency,D051437,NA,0,0,any,2,000000000,Renal Insufficiency,198
4638,27564409,NA,serum uric acid,Uric Acid,D014527,NA,0,0,any,2,000000000,Uric Acid,198
4639,27564409,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,198
4640,27564409,NA,thiazide diuretic use,Diuretics,D004232,NA,0,0,any,2,000000000,Diuretics,198
4641,27576559,2,tpasi 75,Psoriasis,D011565,NA,0,1005,severity,11,000100001,Psoriasis,NA
4642,27576559,2,ulpasi 75,Psoriasis,D011565,NA,0,1005,severity,11,000100001,Psoriasis,NA
4643,27576774,2,continued thienopyridine n (%),Thienopyridines,D058924,NA,0,980,any,2,000000000,Thienopyridines,NA
4644,27576774,2,on optimal medical therapy ;150 (4.2%),unclassifiable,NA,NA,0,NA,severity,11,000100000,unclassifiable,NA
4645,27576774,2,on optimal medical therapy ;45 (2.2%),unclassifiable,NA,NA,0,NA,severity,11,000100000,unclassifiable,NA
4646,27576774,2,on optimal medical therapy ;58 (2.8%),unclassifiable,NA,NA,0,NA,severity,11,000100000,unclassifiable,NA
4647,27576774,2,on optimal medical therapy;76 (2.1%),unclassifiable,NA,NA,0,NA,severity,11,000100000,unclassifiable,NA
4648,27576774,2,on optimal medical therapy;77 (2.2%),unclassifiable,NA,NA,0,NA,severity,11,000100000,unclassifiable,NA
4649,27576774,2,on optimal medical therapy;94 (4.5%),unclassifiable,NA,NA,0,NA,severity,11,000100000,unclassifiable,NA
4650,27576775,2,;diabetes,Diabetes Mellitus,D003920,NA,0,1753,any,2,000000000,Diabetes Mellitus,NA
4651,27576775,2,;history of af,Atrial Fibrillation,D001281,NA,0,1753,previous,8,100000000,Atrial Fibrillation,NA
4652,27576775,2,;history of chf,Heart Failure,D006333,NA,0,1753,previous,8,100000000,Heart Failure,NA
4653,27576775,2,;no diabetes,Diabetes Mellitus,D003920,NA,0,1753,any,2,000000000,Diabetes Mellitus,NA
4654,27576775,2,;no history of af,Atrial Fibrillation,D001281,NA,0,1753,previous,8,100000000,Atrial Fibrillation,NA
4655,27576775,2,;no history of chf,Heart Failure,D006333,NA,0,1753,previous,8,100000000,Heart Failure,NA
4656,27576775,2,;no prior stroke/tia,Cerebrovascular Disorders,D002561,NA,0,1753,previous,8,100000000,Cerebrovascular Disorders,NA
4657,27576775,2,;no renal dysfunction,Renal Insufficiency,D051437,NA,0,1753,any,2,000000000,Renal Insufficiency,NA
4658,27576775,2,;prior stroke/tia,Stroke,D020521,NA,0,1753,previous,8,100000000,Stroke,NA
4659,27576775,2,;renal dysfunction,Renal Insufficiency,D051437,NA,0,1753,any,2,000000000,Renal Insufficiency,NA
4660,27579635,NA,Age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
4661,27579635,NA,Ethnicity,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
4662,27579635,NA,Gender,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
4663,27585384,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,2
4664,27585384,NA,COPD severity,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,0,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
4665,27585384,NA,LABA/ICS therapy,"lama, long-acting beta agonist",NA,R03,0,0,any,2,000000000,"lama, long-acting beta agonist",NA
4666,27585384,NA,LAMA use,lama,NA,R03BB,0,0,any,2,000000000,lama,NA
4667,27585384,NA,previous exacerbations,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,0,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
4668,27585384,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
4669,27585384,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
4670,27585384,NA,smoking,Cigarette Smoking,D000073865,NA,0,0,any,2,000000000,Cigarette Smoking,NA
4671,27585384,NA,tiotropium,Bronchodilator Agents,D001993,NA,0,0,any,2,000000000,Bronchodilator Agents,NA
4672,27589414,2,older patients,Age Factors,D000367,NA,0,89,any,2,000000000,Age Factors,NA
4673,27600862,NA,Patient Variable: Ethnicity,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,43
4674,27600862,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,43
4675,27609406,2,age,Age Factors,D000367,NA,0,1594,any,2,000000000,Age Factors,NA
4676,27609406,2,atopic at baseline:,Hypersensitivity,D006967,NA,0,1594,any,2,000000000,Hypersensitivity,NA
4677,27609406,2,baseline ocs use:,Steroids,D013256,NA,0,1594,any,2,000000000,Steroids,NA
4678,27609406,2,BMI,Body Mass Index,D015992,NA,0,1594,any,2,000000000,Body Mass Index,NA
4679,27609406,2,exacerbations in the prev. year:,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1594,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
4680,27609406,2,geo graphic region:,Geographic Locations,D005842,NA,0,1594,any,2,000000000,Geographic Locations,NA
4681,27609406,2,ige at baseline:,Immunoglobulins,D007136,NA,0,1594,any,2,000000000,Immunoglobulins,NA
4682,27609406,2,nasal polyps at baseline:,Nasal Polyps,D009298,NA,0,1594,any,2,000000000,Nasal Polyps,NA
4683,27609406,2,prior therapy with omalizumab:,Adrenergic beta-2 Receptor Agonists,D058666,NA,0,1594,previous,8,100000000,Adrenergic beta-2 Receptor Agonists,NA
4684,27609406,2,race:,Racial Groups,D044469,NA,0,1594,any,2,000000000,Racial Groups,NA
4685,27609406,2,race:;black or african american,Racial Groups,D044469,NA,0,1594,any,2,000000000,Racial Groups,NA
4686,27609406,2,sex:,Gender Identity,D005783,NA,0,1594,any,2,000000000,Gender Identity,NA
4687,27609408,2,baseline atopy,Hypersensitivity,D006967,NA,0,513,any,2,000000000,Hypersensitivity,NA
4688,27609408,2,baseline IgE levels,Immunoglobulin E,D007073,NA,0,513,any,2,000000000,Immunoglobulin E,NA
4689,27609408,2,baseline oral corticosteroid use,Steroids,D013256,NA,0,513,any,2,000000000,Steroids,NA
4690,27609408,2,BMI,Body Mass Index,D015992,NA,0,513,any,2,000000000,Body Mass Index,NA
4691,27609408,2,gender,Gender Identity,D005783,NA,0,513,any,2,000000000,Gender Identity,NA
4692,27609408,2,geographic region,Geographic Locations,D005842,NA,0,513,any,2,000000000,Geographic Locations,NA
4693,27609408,2,nasal polyps,Nasal Polyps,D009298,NA,0,513,any,2,000000000,Nasal Polyps,NA
4694,27609408,2,number of asthma exacerbations in the past year,Asthma,D001249,NA,0,513,previous severity,9,100100000,Asthma,NA
4695,27609408,2,prior omalizumab therapy,Adrenergic beta-2 Receptor Agonists,D058666,NA,0,513,previous,8,100000000,Adrenergic beta-2 Receptor Agonists,NA
4696,27609408,2,race,Racial Groups,D044469,NA,0,513,any,2,000000000,Racial Groups,NA
4697,27612281,2,"age, years",Age Factors,D000367,NA,0,489,any,2,000000000,Age Factors,NA
4698,27612281,2,femoral neck bmd t-score,Osteoporosis,D010024,NA,0,489,severity,11,000100000,Osteoporosis,NA
4699,27612281,2,lumbar spine bmd t-score,Osteoporosis,D010024,NA,0,489,severity,11,000100000,Osteoporosis,NA
4700,27612281,2,prevalent vertebral fracture,"Fractures, Bone",D050723,NA,0,489,any,2,000000000,"Fractures, Bone",NA
4701,27612281,2,prior nonvertebral fracture,"Fractures, Bone",D050723,NA,0,489,previous,8,100000000,"Fractures, Bone",NA
4702,27612281,2,total hip bmd t-score,Osteoporosis,D010024,NA,0,489,severity,11,000100000,Osteoporosis,NA
4703,27612281,2,total hip bmdÂ t-score,Osteoporosis,D010024,NA,0,489,severity,11,000100000,Osteoporosis,NA
4704,27612281,3,"age, years",Age Factors,D000367,NA,0,787,any,2,000000000,Age Factors,NA
4705,27612281,3,femoral neck bmd t-score,Osteoporosis,D010024,NA,0,787,severity,11,000100000,Osteoporosis,NA
4706,27612281,3,lumbar spine bmd t-score,Osteoporosis,D010024,NA,0,787,severity,11,000100000,Osteoporosis,NA
4707,27612281,3,prevalent vertebral fracture,"Fractures, Bone",D050723,NA,0,787,any,2,000000000,"Fractures, Bone",NA
4708,27612281,3,prior nonvertebral fracture,"Fractures, Bone",D050723,NA,0,787,previous,8,100000000,"Fractures, Bone",NA
4709,27612281,3,total hip bmd t-score,Osteoporosis,D010024,NA,0,787,severity,11,000100000,Osteoporosis,NA
4710,27612281,3,total hip bmdÂ t-score,Osteoporosis,D010024,NA,0,787,severity,11,000100000,Osteoporosis,NA
4711,27612281,4,"age, years",Age Factors,D000367,NA,0,1014,any,2,000000000,Age Factors,NA
4712,27612281,4,lumbar spine bmd t-score,Osteoporosis,D010024,NA,0,1014,severity,11,000100000,Osteoporosis,NA
4713,27612281,4,prior nonvertebral fracture,"Fractures, Bone",D050723,NA,0,1014,previous,8,100000000,"Fractures, Bone",NA
4714,27612281,4,total hip bmd t-score,Osteoporosis,D010024,NA,0,1014,severity,11,000100000,Osteoporosis,NA
4715,27612281,4,total hip bmdÂ t-score,Osteoporosis,D010024,NA,0,1014,severity,11,000100000,Osteoporosis,NA
4716,27612281,5,"age, years",Age Factors,D000367,NA,0,1138,any,2,000000000,Age Factors,NA
4717,27612281,5,femoral neck bmd t-score,Osteoporosis,D010024,NA,0,1138,severity,11,000100000,Osteoporosis,NA
4718,27612281,5,lumbar spine bmd t-score,Osteoporosis,D010024,NA,0,1138,severity,11,000100000,Osteoporosis,NA
4719,27612281,5,prevalent vertebral fracture,"Fractures, Bone",D050723,NA,0,1138,any,2,000000000,"Fractures, Bone",NA
4720,27612281,5,total hip bmd t-score,Osteoporosis,D010024,NA,0,1138,severity,11,000100000,Osteoporosis,NA
4721,27612281,5,total hip bmdÂ t-score,Osteoporosis,D010024,NA,0,1138,severity,11,000100000,Osteoporosis,NA
4722,27612281,6,"age, years",Age Factors,D000367,NA,0,1202,any,2,000000000,Age Factors,NA
4723,27612281,6,femoral neck bmd t-score,Osteoporosis,D010024,NA,0,1202,severity,11,000100000,Osteoporosis,NA
4724,27612281,6,lumbar spine bmd t-score,Osteoporosis,D010024,NA,0,1202,severity,11,000100000,Osteoporosis,NA
4725,27612281,6,prevalent vertebral fracture,"Fractures, Bone",D050723,NA,0,1202,any,2,000000000,"Fractures, Bone",NA
4726,27612281,6,total hip bmd t-score,Osteoporosis,D010024,NA,0,1202,severity,11,000100000,Osteoporosis,NA
4727,27612281,6,total hip bmdÂ t-score,Osteoporosis,D010024,NA,0,1202,severity,11,000100000,Osteoporosis,NA
4728,27616196,2,;biomarker high,Eosinophilia,D004802,NA,0,532,any,2,000000000,Eosinophilia,NA
4729,27616196,2,;biomarker low,Eosinophilia,D004802,NA,0,532,any,2,000000000,Eosinophilia,NA
4730,27616196,3,periostin high,"POSTN protein, human",C512835,NA,0,1383,any,2,000000000,"POSTN protein, human",NA
4731,27616196,3,periostin low,"POSTN protein, human",C512835,NA,0,1383,any,2,000000000,"POSTN protein, human",NA
4732,27616196,4,eosinophil high,Eosinophilia,D004802,NA,0,1635,any,2,000000000,Eosinophilia,NA
4733,27616196,4,eosinophil low,Eosinophilia,D004802,NA,0,1635,any,2,000000000,Eosinophilia,NA
4734,27616196,5,;biomarker high,Eosinophilia,D004802,NA,0,396,any,2,000000000,Eosinophilia,NA
4735,27616196,5,;biomarker low,Eosinophilia,D004802,NA,0,396,any,2,000000000,Eosinophilia,NA
4736,27619750,2,dysglycaemia,Diabetes Mellitus,D003920,NA,0,1394,any,2,000000000,Diabetes Mellitus,NA
4737,27633186,NA,"Age, y",Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
4738,27633186,NA,BMI,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,NA
4739,27633186,NA,Cardiovascular status,Cardiovascular Diseases,D002318,NA,0,0,any,2,000000000,Cardiovascular Diseases,NA
4740,27633186,NA,Chronic heart failure class II-III,Heart Failure,D006333,NA,0,0,severity,11,000100000,Heart Failure,NA
4741,27633186,NA,"Duration of diabetes, y",Diabetes Mellitus,D003920,NA,0,0,duration,5,001000000,Diabetes Mellitus,NA
4742,27633186,NA,"eGFR, ml/min (MDRD)",Renal Insufficiency,D051437,NA,0,0,any,2,000000000,Renal Insufficiency,NA
4743,27633186,NA,Gender,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
4744,27633186,NA,HbA1c,Glycated Hemoglobin A,D006442,NA,0,0,any,2,000000000,Glycated Hemoglobin A,NA
4745,27633186,NA,Hispanic or latino,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
4746,27633186,NA,Insulin treatment,Insulin,D007328,NA,0,0,any,2,000000000,Insulin,NA
4747,27633186,NA,Prior MI/Stroke,Stroke,D020521,NA,0,0,previous,8,100000000,Stroke,NA
4748,27633186,NA,Race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
4749,27633186,NA,Region,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,NA
4750,27639327,2,;tnf-failure,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,1774,any,2,000000000,Tumor Necrosis Factor Inhibitors,NA
4751,27639327,2,;tnf-naive,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,1774,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
4752,27639753,2,age. years,Age Factors,D000367,NA,0,276,any,2,000000000,Age Factors,NA
4753,27639753,2,"bmi, kg/m2",Body Mass Index,D015992,NA,0,276,any,2,000000000,Body Mass Index,NA
4754,27639753,2,ethnicity;hispanic/latino,Racial Groups,D044469,NA,0,276,any,2,000000000,Racial Groups,NA
4755,27639753,2,gender,Gender Identity,D005783,NA,0,276,any,2,000000000,Gender Identity,NA
4756,27639753,2,race,Racial Groups,D044469,NA,0,276,any,2,000000000,Racial Groups,NA
4757,27639753,2,race;black/african american,Racial Groups,D044469,NA,0,276,any,2,000000000,Racial Groups,NA
4758,27639753,3,baseline free pcsk9 level,Proprotein Convertases,D043484,NA,0,1365,any,2,000000000,Proprotein Convertases,NA
4759,27639753,3,baseline total pcsk9 level,Proprotein Convertases,D043484,NA,0,1365,any,2,000000000,Proprotein Convertases,NA
4760,27639753,3,diabetes,Diabetes Mellitus,D003920,NA,0,1365,any,2,000000000,Diabetes Mellitus,NA
4761,27639753,3,moderate chronic kidney disease,Renal Insufficiency,D051437,NA,0,1365,severity,11,000100000,Renal Insufficiency,NA
4762,27639753,3,statin intolerant*,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,1365,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
4763,27639753,4,no statin group,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,1849,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
4764,27639753,4,statin group,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,1849,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
4765,27639753,4,"statin group;baseline hdl-c, mg/dl",Lipoproteins,D008074,NA,0,1849,any,2,000000000,Lipoproteins,NA
4766,27639753,4,"statin group;baseline ldl-c, mg/dl",Lipoproteins,D008074,NA,0,1849,any,2,000000000,Lipoproteins,NA
4767,27639753,4,"statin group;baseline lp(a), mg/dl",Lipoproteins,D008074,NA,0,1849,any,2,000000000,Lipoproteins,NA
4768,27647847,2,acr deciles,Albuminuria,D000419,NA,0,798,any,2,000000000,Albuminuria,NA
4769,27657471,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,255
4770,27657471,NA,blood pressure,Blood Pressure,D001794,NA,0,0,any,2,000000000,Blood Pressure,151
4771,27657471,NA,heart rate,Heart Rate,D006339,NA,0,0,any,2,000000000,Heart Rate,151
4772,27657471,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,151
4773,27657471,NA,the benefit of nicorandil in reducing the number of myocardial ischemia attacks,Nicorandil,D020108,NA,0,0,disease response,4,000000000,Nicorandil,151
4774,27672117,2,;fvc <90% predicted,Vital Capacity,D014797,NA,0,1272,any,2,000000000,Vital Capacity,NA
4775,27672117,2,;fvc >90% predicted,Vital Capacity,D014797,NA,0,1272,any,2,000000000,Vital Capacity,NA
4776,27684308,2,age (years),Age Factors,D000367,NA,0,1525,any,2,000000000,Age Factors,NA
4777,27684308,2,bmi (kg/m2),Body Mass Index,D015992,NA,0,1525,any,2,000000000,Body Mass Index,NA
4778,27684308,2,bmi (kg/m2);<25,Body Mass Index,D015992,NA,0,1525,any,2,000000000,Body Mass Index,NA
4779,27684308,2,bmi (kg/m2);>35,Body Mass Index,D015992,NA,0,1525,any,2,000000000,Body Mass Index,NA
4780,27684308,2,bmi (kg/m2);25-<30,Body Mass Index,D015992,NA,0,1525,any,2,000000000,Body Mass Index,NA
4781,27684308,2,bmi (kg/m2);30â€”<35,Body Mass Index,D015992,NA,0,1525,any,2,000000000,Body Mass Index,NA
4782,27684308,2,creatinine clearance (ml/min),Glomerular Filtration Rate,D005919,NA,0,1525,any,2,000000000,Glomerular Filtration Rate,NA
4783,27684308,2,creatinine clearance (ml/min);<90,Glomerular Filtration Rate,D005919,NA,0,1525,any,2,000000000,Glomerular Filtration Rate,NA
4784,27684308,2,creatinine clearance (ml/min);>90,Glomerular Filtration Rate,D005919,NA,0,1525,any,2,000000000,Glomerular Filtration Rate,NA
4785,27684308,2,ethnicity;hispanic/latino,Racial Groups,D044469,NA,0,1525,any,2,000000000,Racial Groups,NA
4786,27684308,2,race,Racial Groups,D044469,NA,0,1525,any,2,000000000,Racial Groups,NA
4787,27689735,NA,background csDMARD therapy,Antirheumatic Agents,D018501,NA,0,0,disease response,4,000000000,Antirheumatic Agents,224
4788,27708114,NA,statin users vs non-users,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,0,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
4789,27715335,2,COPD severity,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,326,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
4790,27715335,2,race,Racial Groups,D044469,NA,0,326,any,2,000000000,Racial Groups,NA
4791,27740719,NA,demographics,Demography,D003710,NA,0,0,any,2,000000000,Demography,249
4792,27740719,NA,disease-related and anthropometric characteristics,unclassifible,NA,NA,0,0,any,2,000000000,unclassifible,248
4793,27740719,NA,insulin stratum (premixed insulin or intermediate- and long-acting acting insulin),Insulin,D007328,NA,0,0,any,2,000000000,Insulin,248
4794,27742728,2,treatment by egfr stage,Glomerular Filtration Rate,D005919,NA,0,329,any,2,000000000,Glomerular Filtration Rate,NA
4795,27744141,2,age,Age Factors,D000367,NA,0,174,any,2,000000000,Age Factors,NA
4796,27744141,2,baseline disease activity score 28 (DAS28),"Arthritis, Rheumatoid",D001172,NA,0,174,severity,11,000100000,"Arthritis, Rheumatoid",NA
4797,27744141,2,c-reactive protein,C-Reactive Protein,D002097,NA,0,174,any,2,000000000,C-Reactive Protein,NA
4798,27744141,2,disease duration,"Arthritis, Rheumatoid",D001172,NA,0,174,duration,5,001000000,"Arthritis, Rheumatoid",NA
4799,27744141,2,Gender,Gender Identity,D005783,NA,0,174,any,2,000000000,Gender Identity,NA
4800,27744141,2,levels of cardiac troponin,Troponin,D014336,NA,0,174,any,2,000000000,Troponin,NA
4801,27744141,2,NT pro-Brain Natriuretric Peptide,"Natriuretic Peptide, Brain",D020097,NA,0,174,any,2,000000000,"Natriuretic Peptide, Brain",NA
4802,27744141,2,Smoker,Cigarette Smoking,D000073865,NA,0,174,any,2,000000000,Cigarette Smoking,NA
4803,27765312,NA,Age-Years,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
4804,27765312,NA,"antidiabetic therapy type (oral, insulin, none)",Hypoglycemic Agents,D007004,NA,0,0,type,12,000000010,Hypoglycemic Agents,NA
4805,27765312,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,NA
4806,27765312,NA,duration of diabetes,Diabetes Mellitus,D003920,NA,0,0,duration,5,001000000,Diabetes Mellitus,NA
4807,27765312,NA,hba1c,Glycated Hemoglobin A,D006442,NA,0,0,any,2,000000000,Glycated Hemoglobin A,NA
4808,27765312,NA,heart failure,Heart Failure,D006333,NA,0,0,any,2,000000000,Heart Failure,NA
4809,27765312,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
4810,27765312,NA,region,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,NA
4811,27765312,NA,renal function,Renal Insufficiency,D051437,NA,0,0,any,2,000000000,Renal Insufficiency,NA
4812,27765312,NA,risk of cardiovascular disease,Cardiovascular Diseases,D002318,NA,0,0,risk score,10,000000100,Cardiovascular Diseases,NA
4813,27765312,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
4814,27767328,1,% predicted fev1,Pulmonary Ventilation,D012123,NA,0,993,any,2,000000000,Pulmonary Ventilation,NA
4815,27767328,1,african-american/african heritage (n=129),Racial Groups,D044469,NA,0,993,any,2,000000000,Racial Groups,NA
4816,27767328,1,age group;<55 (n=824),Age Factors,D000367,NA,0,993,any,2,000000000,Age Factors,NA
4817,27767328,1,"age group;>55 to <65 (n=2,819)",Age Factors,D000367,NA,0,993,any,2,000000000,Age Factors,NA
4818,27767328,1,"age group;>65 to <75 (n=3,523)",Age Factors,D000367,NA,0,993,any,2,000000000,Age Factors,NA
4819,27767328,1,"age group;>75 (n=1,066)",Age Factors,D000367,NA,0,993,any,2,000000000,Age Factors,NA
4820,27767328,1,cv entry criteria,Cardiovascular Diseases,D002318,NA,0,993,risk score,10,000000100,Cardiovascular Diseases,NA
4821,27767328,1,"cv entry criteria;40-60, cv disease (n=1,761)",complex,none,NA,0,993,any,2,000000000,complex,NA
4822,27767328,1,"cv entry criteria;60-80, cv disease (n=4,096)",complex,none,NA,0,993,any,2,000000000,complex,NA
4823,27767328,1,"cv entry criteria;60-80, risk, not disease (n=2,285)",complex,none,NA,0,993,risk score,10,000000100,complex,NA
4824,27767328,1,ethnicity;hispanic/latino (n=588),Racial Groups,D044469,NA,0,993,any,2,000000000,Racial Groups,NA
4825,27767328,1,"ethnicity;not hispanic/latino (n=7,644)",Racial Groups,D044469,NA,0,993,any,2,000000000,Racial Groups,NA
4826,27767328,1,gender,Gender Identity,D005783,NA,0,993,any,2,000000000,Gender Identity,NA
4827,27767328,1,history of hospitalizationÂ for an exacerbation,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,993,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
4828,27767328,1,history of moderate/severe exacerbation,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,993,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
4829,27767328,1,race,Racial Groups,D044469,NA,0,993,any,2,000000000,Racial Groups,NA
4830,27767328,1,race;african-american/african heritage (n=129),Racial Groups,D044469,NA,0,993,any,2,000000000,Racial Groups,NA
4831,27767328,1,race;other (n=83),Racial Groups,D044469,NA,0,993,any,2,000000000,Racial Groups,NA
4832,27767328,1,region,Geographic Locations,D005842,NA,0,993,any,2,000000000,Geographic Locations,NA
4833,27767328,1,region;rest-of-world (n=645),Geographic Locations,D005842,NA,0,993,any,2,000000000,Geographic Locations,NA
4834,27767328,1,Smoker,Cigarette Smoking,D000073865,NA,0,993,any,2,000000000,Cigarette Smoking,NA
4835,27767328,1,"smoking status;former smoker (n=4,428)",Cigarette Smoking,D000073865,NA,0,993,previous,8,100000000,Cigarette Smoking,NA
4836,27767328,2,% predicted fev1,Pulmonary Ventilation,D012123,NA,0,1447,any,2,000000000,Pulmonary Ventilation,NA
4837,27767328,2,african-american/african heritage (n=129),Racial Groups,D044469,NA,0,1447,any,2,000000000,Racial Groups,NA
4838,27767328,2,age group;<55 (n=824),Age Factors,D000367,NA,0,1447,any,2,000000000,Age Factors,NA
4839,27767328,2,"age group;>55 to <65 (n=2,819)",Age Factors,D000367,NA,0,1447,any,2,000000000,Age Factors,NA
4840,27767328,2,"age group;>65 to <75 (n=3,523)",Age Factors,D000367,NA,0,1447,any,2,000000000,Age Factors,NA
4841,27767328,2,"age group;>75 (n=1,066)",Age Factors,D000367,NA,0,1447,any,2,000000000,Age Factors,NA
4842,27767328,2,cv entry criteria,Cardiovascular Diseases,D002318,NA,0,1447,risk score,10,000000100,Cardiovascular Diseases,NA
4843,27767328,2,"cv entry criteria;40-60, cv disease (n=1,761)",complex,none,NA,0,1447,any,2,000000000,complex,NA
4844,27767328,2,"cv entry criteria;60-80, cv disease (n=4,096)",complex,none,NA,0,1447,any,2,000000000,complex,NA
4845,27767328,2,"cv entry criteria;60-80, risk, not disease (n=2,285)",Cardiovascular Diseases,D002318,NA,0,1447,risk score,10,000000100,Cardiovascular Diseases,NA
4846,27767328,2,ethnicity;hispanic/latino (n=588),Racial Groups,D044469,NA,0,1447,any,2,000000000,Racial Groups,NA
4847,27767328,2,gender,Gender Identity,D005783,NA,0,1447,any,2,000000000,Gender Identity,NA
4848,27767328,2,history of hospitalizationÂ for an exacerbation,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1447,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
4849,27767328,2,"history of hospitalizationÂ for an exacerbation;>1 (n=1,132)","Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1447,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
4850,27767328,2,"history of hospitalizationÂ for an exacerbation;0 (n=7,100)","Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1447,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
4851,27767328,2,"history of hospitalized for an exacerbation;>= 1 (n=1,132)","Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1447,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
4852,27767328,2,history of moderate/severe exacerbation,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1447,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
4853,27767328,2,"history of moderate/severe exacerbation;>2 (n=1,215)","Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1447,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
4854,27767328,2,"history of moderate/severe exacerbation;0 (n=4,975)","Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1447,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
4855,27767328,2,"history of moderate/severe exacerbation;1 (n=2,042)","Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1447,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
4856,27767328,2,race,Racial Groups,D044469,NA,0,1447,any,2,000000000,Racial Groups,NA
4857,27767328,2,race;african-american/african heritage (n=129),Racial Groups,D044469,NA,0,1447,any,2,000000000,Racial Groups,NA
4858,27767328,2,"race;white (n=6,660)",Racial Groups,D044469,NA,0,1447,any,2,000000000,Racial Groups,NA
4859,27767328,2,region,Geographic Locations,D005842,NA,0,1447,any,2,000000000,Geographic Locations,NA
4860,27767328,2,region;rest-of-world (n=645),Geographic Locations,D005842,NA,0,1447,any,2,000000000,Geographic Locations,NA
4861,27767328,2,Smoker,Cigarette Smoking,D000073865,NA,0,1447,any,2,000000000,Cigarette Smoking,NA
4862,27767328,3,"% predicted fev,",Pulmonary Ventilation,D012123,NA,0,732,any,2,000000000,Pulmonary Ventilation,NA
4863,27767328,3,% predicted fev^,Pulmonary Ventilation,D012123,NA,0,732,any,2,000000000,Pulmonary Ventilation,NA
4864,27767328,3,african-american/african heritage (n=129),Racial Groups,D044469,NA,0,732,any,2,000000000,Racial Groups,NA
4865,27767328,3,age group;<55 (n=824),Age Factors,D000367,NA,0,732,any,2,000000000,Age Factors,NA
4866,27767328,3,"age group;>55 to <65 (n=2,819)",Age Factors,D000367,NA,0,732,any,2,000000000,Age Factors,NA
4867,27767328,3,"age group;>65 to <75 (n=3,523)",Age Factors,D000367,NA,0,732,any,2,000000000,Age Factors,NA
4868,27767328,3,"age group;>75 (n=1,066)",Age Factors,D000367,NA,0,732,any,2,000000000,Age Factors,NA
4869,27767328,3,cv entry criteria,Cardiovascular Diseases,D002318,NA,0,732,risk score,10,000000100,Cardiovascular Diseases,NA
4870,27767328,3,"cv entry criteria;40-60, cv disease (n=1,761)",complex,none,NA,0,732,any,2,000000000,complex,NA
4871,27767328,3,"cv entry criteria;60-80, cv disease (n=4,096)",complex,none,NA,0,732,any,2,000000000,complex,NA
4872,27767328,3,"cv entry criteria;60-80, risk, not disease (n=2,285)",complex,none,NA,0,732,risk score,10,000000100,complex,NA
4873,27767328,3,ethnicity;hispanic/latino (n=588),Racial Groups,D044469,NA,0,732,any,2,000000000,Racial Groups,NA
4874,27767328,3,"ethnicity;not hispanic/latino (n=7,644)",Racial Groups,D044469,NA,0,732,any,2,000000000,Racial Groups,NA
4875,27767328,3,gender,Gender Identity,D005783,NA,0,732,any,2,000000000,Gender Identity,NA
4876,27767328,3,history of hospitalized for an exacerbation,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,732,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
4877,27767328,3,history of moderate/severe exacerbation,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,732,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
4878,27767328,3,race,Racial Groups,D044469,NA,0,732,any,2,000000000,Racial Groups,NA
4879,27767328,3,race;african-american/african heritage (n=129),Racial Groups,D044469,NA,0,732,any,2,000000000,Racial Groups,NA
4880,27767328,3,region,Geographic Locations,D005842,NA,0,732,any,2,000000000,Geographic Locations,NA
4881,27767328,3,region;rest-of-world (n=645),Geographic Locations,D005842,NA,0,732,any,2,000000000,Geographic Locations,NA
4882,27767328,3,Smoker,Cigarette Smoking,D000073865,NA,0,732,any,2,000000000,Cigarette Smoking,NA
4883,27767328,3,"smoking status;former smoker (n=4,428)",Cigarette Smoking,D000073865,NA,0,732,previous,8,100000000,Cigarette Smoking,NA
4884,27767328,4,"% predicted fev,",Pulmonary Ventilation,D012123,NA,0,429,any,2,000000000,Pulmonary Ventilation,NA
4885,27767328,4,% predicted fev^,Pulmonary Ventilation,D012123,NA,0,429,any,2,000000000,Pulmonary Ventilation,NA
4886,27767328,4,african-american/african heritage (n=129),Racial Groups,D044469,NA,0,429,any,2,000000000,Racial Groups,NA
4887,27767328,4,age group,Age Factors,D000367,NA,0,429,any,2,000000000,Age Factors,NA
4888,27767328,4,age group;<55 (n=824),Age Factors,D000367,NA,0,429,any,2,000000000,Age Factors,NA
4889,27767328,4,"age group;>55 to <65 (n=2,819)",Age Factors,D000367,NA,0,429,any,2,000000000,Age Factors,NA
4890,27767328,4,"age group;>65 to <75 (n=3,523)",Age Factors,D000367,NA,0,429,any,2,000000000,Age Factors,NA
4891,27767328,4,"age group;>75 (n=1,066)",Age Factors,D000367,NA,0,429,any,2,000000000,Age Factors,NA
4892,27767328,4,cv entry criteria,Cardiovascular System,D002319,NA,0,429,any,2,000000000,Cardiovascular System,NA
4893,27767328,4,"cv entry criteria;40-60, cv disease (n=1,761)",complex,none,NA,0,429,any,2,000000000,complex,NA
4894,27767328,4,"cv entry criteria;60-80, cv disease (n=4,096)",complex,none,NA,0,429,any,2,000000000,complex,NA
4895,27767328,4,"cv entry criteria;60-80, risk, not disease (n=2,285)",complex,none,NA,0,429,risk score,10,000000100,complex,NA
4896,27767328,4,ethnicity;hispanic/latino (n=588),Racial Groups,D044469,NA,0,429,any,2,000000000,Racial Groups,NA
4897,27767328,4,"ethnicity;not hispanic/latino (n=7,644)",Racial Groups,D044469,NA,0,429,any,2,000000000,Racial Groups,NA
4898,27767328,4,gender,Gender Identity,D005783,NA,0,429,any,2,000000000,Gender Identity,NA
4899,27767328,4,hospitalized for an exacerbation,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,429,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
4900,27767328,4,moderate/severe exacerbation,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,429,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
4901,27767328,4,race,Racial Groups,D044469,NA,0,429,any,2,000000000,Racial Groups,NA
4902,27767328,4,race;african-american/african heritage (n=129),Racial Groups,D044469,NA,0,429,any,2,000000000,Racial Groups,NA
4903,27767328,4,"race;white (n=6,660)",Racial Groups,D044469,NA,0,429,any,2,000000000,Racial Groups,NA
4904,27767328,4,region,Geographic Locations,D005842,NA,0,429,any,2,000000000,Geographic Locations,NA
4905,27767328,4,region;rest-of-world (n=645),Geographic Locations,D005842,NA,0,429,any,2,000000000,Geographic Locations,NA
4906,27767328,4,Smoker,Cigarette Smoking,D000073865,NA,0,429,any,2,000000000,Cigarette Smoking,NA
4907,27796912,NA,Medical History: Maintenance-naïve,unclassifiable,NA,NA,0,0,previous,8,100000000,unclassifiable,28
4908,27799159,NA,biological DMARDs,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,194
4909,27799159,NA,tumour necrosis factor inhibitors,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,0,previous,8,100000000,Tumor Necrosis Factor Inhibitors,195
4910,27821644,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,199
4911,27821644,NA,comorbidities,Comorbidity,D015897,NA,0,0,any,2,000000000,Comorbidity,199
4912,27821644,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,199
4913,27821644,NA,renal function,Renal Insufficiency,D051437,NA,0,0,any,2,000000000,Renal Insufficiency,199
4914,27821644,NA,serum uric acid,Uric Acid,D014527,NA,0,0,any,2,000000000,Uric Acid,199
4915,27821644,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,199
4916,27821644,NA,thiazide diuretic use,Diuretics,D004232,NA,0,0,any,2,000000000,Diuretics,199
4917,27846344,2,agea,Age Factors,D000367,NA,0,998,any,2,000000000,Age Factors,NA
4918,27846344,2,agea;< median,Age Factors,D000367,NA,0,998,any,2,000000000,Age Factors,NA
4919,27846344,2,agea;> median,Age Factors,D000367,NA,0,998,any,2,000000000,Age Factors,NA
4920,27846344,2,baseline non-hdl-ca,Lipoproteins,D008074,NA,0,998,any,2,000000000,Lipoproteins,NA
4921,27846344,2,baseline non-hdl-ca;< median,Lipoproteins,D008074,NA,0,998,any,2,000000000,Lipoproteins,NA
4922,27846344,2,baseline non-hdl-ca;> median,Lipoproteins,D008074,NA,0,998,any,2,000000000,Lipoproteins,NA
4923,27846344,2,baseline pava,"Plaque, Atherosclerotic",D058226,NA,0,998,severity,11,000100000,"Plaque, Atherosclerotic",NA
4924,27846344,2,baseline pava;< median,"Plaque, Atherosclerotic",D058226,NA,0,998,severity,11,000100000,"Plaque, Atherosclerotic",NA
4925,27846344,2,baseline pava;> median,"Plaque, Atherosclerotic",D058226,NA,0,998,severity,11,000100000,"Plaque, Atherosclerotic",NA
4926,27846344,2,baseline tava,"Plaque, Atherosclerotic",D058226,NA,0,998,severity,11,000100000,"Plaque, Atherosclerotic",NA
4927,27846344,2,baseline tava;< median,"Plaque, Atherosclerotic",D058226,NA,0,998,severity,11,000100000,"Plaque, Atherosclerotic",NA
4928,27846344,2,baseline tava;> median,"Plaque, Atherosclerotic",D058226,NA,0,998,severity,11,000100000,"Plaque, Atherosclerotic",NA
4929,27846344,2,current cigarette use,Cigarette Smoking,D000073865,NA,0,998,current,3,010000000,Cigarette Smoking,NA
4930,27846344,2,current cigarette use;no,Cigarette Smoking,D000073865,NA,0,998,current,3,010000000,Cigarette Smoking,NA
4931,27846344,2,current cigarette use;yes,Cigarette Smoking,D000073865,NA,0,998,current,3,010000000,Cigarette Smoking,NA
4932,27846344,2,family history of premature chd,Coronary Artery Disease,D003324,NA,0,998,family history,6,000010000,Coronary Artery Disease,NA
4933,27846344,2,family history of premature chd;no,Coronary Artery Disease,D003324,NA,0,998,family history,6,000010000,Coronary Artery Disease,NA
4934,27846344,2,family history of premature chd;yes,Coronary Artery Disease,D003324,NA,0,998,family history,6,000010000,Coronary Artery Disease,NA
4935,27846344,2,prior myocardial infarction,Myocardial Infarction,D009203,NA,0,998,previous,8,100000000,Myocardial Infarction,NA
4936,27846344,2,prior myocardial infarction;no,Myocardial Infarction,D009203,NA,0,998,previous,8,100000000,Myocardial Infarction,NA
4937,27846344,2,prior myocardial infarction;yes,Myocardial Infarction,D009203,NA,0,998,previous,8,100000000,Myocardial Infarction,NA
4938,27846344,2,prior statin use,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,998,previous,8,100000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
4939,27846344,2,prior statin use;no,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,998,previous,8,100000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
4940,27846344,2,prior statin use;yes,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,998,previous,8,100000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
4941,27846344,2,race,Racial Groups,D044469,NA,0,998,any,2,000000000,Racial Groups,NA
4942,27846344,2,race;otherb,Racial Groups,D044469,NA,0,998,any,2,000000000,Racial Groups,NA
4943,27846344,2,race;white,Racial Groups,D044469,NA,0,998,any,2,000000000,Racial Groups,NA
4944,27846344,2,sex,Gender Identity,D005783,NA,0,998,any,2,000000000,Gender Identity,NA
4945,27846344,2,sex;men,Gender Identity,D005783,NA,0,998,any,2,000000000,Gender Identity,NA
4946,27846344,2,sex;women,Gender Identity,D005783,NA,0,998,any,2,000000000,Gender Identity,NA
4947,27846344,2,statin intensity per acc/ahac,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,998,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
4948,27846344,2,statin intensity per acc/ahac;high,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,998,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
4949,27846344,2,statin intensity per acc/ahac;moderate/low,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,998,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
4950,27846344,2,type 2 diabetes mellitus,Diabetes Mellitus,D003920,NA,0,998,type,12,000000010,Diabetes Mellitus,NA
4951,27846344,2,type 2 diabetes mellitus;no,Diabetes Mellitus,D003920,NA,0,998,type,12,000000010,Diabetes Mellitus,NA
4952,27846344,2,type 2 diabetes mellitus;yes,Diabetes Mellitus,D003920,NA,0,998,type,12,000000010,Diabetes Mellitus,NA
4953,27846344,NA,ACC+C2:C166/AHA statin background therapy high intensity at baseline,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,0,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
4954,27846344,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
4955,27846344,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
4956,27846344,NA,Family history of premature coronary heart disease,Coronary Artery Disease,D003324,NA,0,0,family history,6,000010000,Coronary Artery Disease,NA
4957,27846344,NA,hdl,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,NA
4958,27846344,NA,ldl,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,NA
4959,27846344,NA,pav,unclassifiable,NA,NA,0,0,any,2,000000000,unclassifiable,NA
4960,27846344,NA,pcsk9,Proprotein Convertases,D043484,NA,0,0,any,2,000000000,Proprotein Convertases,NA
4961,27846344,NA,prior mi,Myocardial Infarction,D009203,NA,0,0,previous,8,100000000,Myocardial Infarction,NA
4962,27846344,NA,Prior statin use,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,0,previous,8,100000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
4963,27846344,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
4964,27846344,NA,region,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,113
4965,27846344,NA,SCORE risk classification,Cardiovascular Diseases,D002318,NA,0,0,severity,11,000100100,Cardiovascular Diseases,NA
4966,27846344,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
4967,27846344,NA,smoking current,Cigarette Smoking,D000073865,NA,0,0,current,3,010000000,Cigarette Smoking,NA
4968,27846344,NA,tav,"Plaque, Atherosclerotic",D058226,NA,0,0,any,2,000000000,"Plaque, Atherosclerotic",NA
4969,27893045,2,age,Age Factors,D000367,NA,0,413,any,2,000000000,Age Factors,NA
4970,27893045,2,baseline ckd egfr <60 ml/min/1.73 m2,Glomerular Filtration Rate,D005919,NA,0,413,any,2,000000000,Glomerular Filtration Rate,NA
4971,27893045,2,baseline ckd egfr >60 ml/min/1.73 m2,Glomerular Filtration Rate,D005919,NA,0,413,any,2,000000000,Glomerular Filtration Rate,NA
4972,27893045,2,baseline mdrd egfr <60 ml/min/1.73 m2,Glomerular Filtration Rate,D005919,NA,0,413,any,2,000000000,Glomerular Filtration Rate,NA
4973,27893045,2,baseline mdrd egfr >60 ml/min/1.73 m2,Glomerular Filtration Rate,D005919,NA,0,413,any,2,000000000,Glomerular Filtration Rate,NA
4974,27893045,2,diabetes,Diabetes Mellitus,D003920,NA,0,413,any,2,000000000,Diabetes Mellitus,NA
4975,27893045,2,estrogen,Estrogens,D004967,NA,0,413,any,2,000000000,Estrogens,NA
4976,27893045,2,healthy weight,Body Weight,D001835,NA,0,413,any,2,000000000,Body Weight,NA
4977,27893045,2,male female,Gender Identity,D005783,NA,0,413,any,2,000000000,Gender Identity,NA
4978,27893045,2,no cvd,Cardiovascular Diseases,D002318,NA,0,413,any,2,000000000,Cardiovascular Diseases,NA
4979,27893045,2,no diabetes,Diabetes Mellitus,D003920,NA,0,413,any,2,000000000,Diabetes Mellitus,NA
4980,27893045,2,no estrogen,Estrogens,D004967,NA,0,413,any,2,000000000,Estrogens,NA
4981,27893045,2,non-black,Racial Groups,D044469,NA,0,413,any,2,000000000,Racial Groups,NA
4982,27893045,2,obese,Obesity,D009765,NA,0,413,any,2,000000000,Obesity,NA
4983,27893045,2,overweight,Overweight,D050177,NA,0,413,any,2,000000000,Overweight,NA
4984,27893045,2,prevalent cvd,Cardiovascular Diseases,D002318,NA,0,413,any,2,000000000,Cardiovascular Diseases,NA
4985,27893045,2,race,Racial Groups,D044469,NA,0,413,any,2,000000000,Racial Groups,NA
4986,27893045,2,Smoker,Cigarette Smoking,D000073865,NA,0,413,any,2,000000000,Cigarette Smoking,NA
4987,27912982,2,>2(n=1524),Asthma,D001249,NA,0,388,severity,11,000100000,Asthma,NA
4988,27912982,2,>2(n=15l6),Asthma,D001249,NA,0,388,severity,11,000100000,Asthma,NA
4989,27912982,2,>lto<2 (n=951),Asthma,D001249,NA,0,388,severity,11,000100000,Asthma,NA
4990,27912982,2,>lto<2 (n=963),Asthma,D001249,NA,0,388,severity,11,000100000,Asthma,NA
4991,27912982,2,0 to 1 (n=1102),Asthma,D001249,NA,0,388,severity,11,000100000,Asthma,NA
4992,27912982,2,0tol(n=1082),Asthma,D001249,NA,0,388,severity,11,000100000,Asthma,NA
4993,27912982,3,>lto £2 symptom days per week,Asthma,D001249,NA,0,411,severity,11,000100000,Asthma,NA
4994,27912982,3,>2 symptom days per week,Asthma,D001249,NA,0,411,severity,11,000100000,Asthma,NA
4995,27912982,3,0 to 1 symptom days per week,Asthma,D001249,NA,0,411,severity,11,000100000,Asthma,NA
4996,27935736,2,male female,Gender Identity,D005783,NA,0,594,any,2,000000000,Gender Identity,NA
4997,27956003,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
4998,27956003,NA,Baseline Cholesteryl ester transfer protein act,cholesterol ester transfer proteins,D053480,NA,0,0,any,2,000000000,cholesterol ester transfer proteins,NA
4999,27956003,NA,Baseline Cholesteryl ester transfer protein conc,cholesterol ester transfer proteins,D053480,NA,0,0,any,2,000000000,cholesterol ester transfer proteins,NA
5000,27956003,NA,Baseline HDL-C level,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,NA
5001,27956003,NA,Baseline LDL-C level,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,NA
5002,27956003,NA,Baseline TG level,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,NA
5003,27956003,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
5004,27956003,NA,gender,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
5005,27956003,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
5006,27956003,NA,Simvastatin,lipid modifying agents,NA,C10,0,0,any,2,000000000,lipid modifying agents,NA
5007,27956003,NA,"statin only, Statin + ezetimibe or Statin + fibrate",Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,0,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
5008,27959607,2,'crohn\'s disease duration',Crohn Disease,D003424,NA,0,1540,duration,5,001000000,Crohn Disease,NA
5009,27959607,2,age,Age Factors,D000367,NA,0,1540,any,2,000000000,Age Factors,NA
5010,27959607,2,cdai score,Crohn Disease,D003424,NA,0,1540,severity,11,000100000,Crohn Disease,NA
5011,27959607,2,geographic region,Geographic Locations,D005842,NA,0,1540,any,2,000000000,Geographic Locations,NA
5012,27959607,2,geographic region;rest of world,Geographic Locations,D005842,NA,0,1540,any,2,000000000,Geographic Locations,NA
5013,27959607,2,involved gastrointestinalÂ areas,Gastrointestinal Tract,D041981,NA,0,1540,severity,11,000100000,Gastrointestinal Tract,NA
5014,27959607,2,involved gastrointestinalÂ areas;colon only,Colon,D003106,NA,0,1540,any,2,000000000,Colon,NA
5015,27959607,2,involved gastrointestinalÂ areas;ileum and colon,Ileum,D007082,NA,0,1540,any,2,000000000,Ileum,NA
5016,27959607,2,involved gastrointestinalÂ areas;ileum only,Ileum,D007082,NA,0,1540,any,2,000000000,Ileum,NA
5017,27959607,2,race,Racial Groups,D044469,NA,0,1540,any,2,000000000,Racial Groups,NA
5018,27959607,2,race;non-white,Racial Groups,D044469,NA,0,1540,any,2,000000000,Racial Groups,NA
5019,27959607,2,sex,Gender Identity,D005783,NA,0,1540,any,2,000000000,Gender Identity,NA
5020,27959607,2,weight,Body Weight,D001835,NA,0,1540,any,2,000000000,Body Weight,NA
5021,27959607,2,y C-reactive protein;,C-Reactive Protein,D002097,NA,0,1540,any,2,000000000,C-Reactive Protein,NA
5022,27965257,2,male female,Gender Identity,D005783,NA,0,52,any,2,000000000,Gender Identity,NA
5023,27965257,2,non-smokers (at baseline),Cigarette Smoking,D000073865,NA,0,52,any,2,000000000,Cigarette Smoking,NA
5024,27965257,2,normal hscrp,C-Reactive Protein,D002097,NA,0,52,any,2,000000000,C-Reactive Protein,NA
5025,27965257,2,patients with syndesmophytes at baseline,Osteophyte,D054850,NA,0,52,any,2,000000000,Osteophyte,NA
5026,27965257,2,patients without syndesmophytes at baseline,Osteophyte,D054850,NA,0,52,any,2,000000000,Osteophyte,NA
5027,27965257,2,smokers (at baseline),Cigarette Smoking,D000073865,NA,0,52,any,2,000000000,Cigarette Smoking,NA
5028,27965257,2,y C-reactive protein;,C-Reactive Protein,D002097,NA,0,52,any,2,000000000,C-Reactive Protein,NA
5029,27977392,2,>2 antihypertensive medications,Antihypertensive Agents,D000959,NA,0,1228,any,2,000000000,Antihypertensive Agents,NA
5030,27977392,2,1 antihypertensive medication,Antihypertensive Agents,D000959,NA,0,1228,any,2,000000000,Antihypertensive Agents,NA
5031,27977392,2,no antihypertensive medication,Antihypertensive Agents,D000959,NA,0,1228,any,2,000000000,Antihypertensive Agents,NA
5032,27977392,3,ACE/ARB use Yes No,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,849,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
5033,27977392,3,Loop diuretics,Diuretics,D004232,NA,0,849,any,2,000000000,Diuretics,NA
5034,27977934,2,;baseline hbalc <8%,Glycated Hemoglobin A,D006442,NA,0,208,any,2,000000000,Glycated Hemoglobin A,NA
5035,27977934,2,;baseline hbalc >8% to <9%,Glycated Hemoglobin A,D006442,NA,0,208,any,2,000000000,Glycated Hemoglobin A,NA
5036,27977934,2,;baseline hbalc >9%,Glycated Hemoglobin A,D006442,NA,0,208,any,2,000000000,Glycated Hemoglobin A,NA
5037,27993292,2,cardiac rhythm disorder at baseline no,"Arrhythmias, Cardiac",D001145,NA,0,1091,any,2,000000000,"Arrhythmias, Cardiac",NA
5038,27993292,2,cardiac rhythm disorder at baseline yes,"Arrhythmias, Cardiac",D001145,NA,0,1091,any,2,000000000,"Arrhythmias, Cardiac",NA
5039,27993292,3,age,Age Factors,D000367,NA,0,1065,any,2,000000000,Age Factors,NA
5040,27993292,3,cardiac history,Cardiovascular Diseases,D002318,NA,0,1065,previous,8,100000000,Cardiovascular Diseases,NA
5041,27993292,3,cardiac rhythm disorders,"Arrhythmias, Cardiac",D001145,NA,0,1065,any,2,000000000,"Arrhythmias, Cardiac",NA
5042,27993292,3,copd disease severity,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1065,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
5043,27993292,3,diabetes mellitus,Diabetes Mellitus,D003920,NA,0,1065,any,2,000000000,Diabetes Mellitus,NA
5044,27993292,3,ics use at baseline,Steroids,D013256,NA,0,1065,any,2,000000000,Steroids,NA
5045,27993292,3,male female,Gender Identity,D005783,NA,0,1065,any,2,000000000,Gender Identity,NA
5046,27993292,3,race,Racial Groups,D044469,NA,0,1065,any,2,000000000,Racial Groups,NA
5047,28035868,2,;chinese subgroup,Racial Groups,D044469,NA,0,428,any,2,000000000,Racial Groups,NA
5048,28039187,NA,connective tissue assocaited pulmonary hypertension,Hypertension,D006973,NA,0,0,any,2,000000000,Hypertension,57
5049,28039187,NA,etiology pah,Pulmonary Arterial Hypertension,D000081029,NA,0,0,aetiological,1,000001000,Pulmonary Arterial Hypertension,NA
5050,28118533,2,corticosteroid use,Steroids,D013256,NA,0,1854,any,2,000000000,Steroids,NA
5051,28118533,2,race,Racial Groups,D044469,NA,0,1854,any,2,000000000,Racial Groups,NA
5052,28118533,2,race and ss at baseline,complex,none,NA,0,1854,any,2,000000000,complex,NA
5053,28118533,2,race;non-black race (n=496 vs 246),Racial Groups,D044469,NA,0,1854,any,2,000000000,Racial Groups,NA
5054,28118533,2,ss at baseline,"Lupus Erythematosus, Systemic",D008180,NA,0,1854,severity,11,000100000,"Lupus Erythematosus, Systemic",NA
5055,28118533,2,ss at baseline;ss >10(n=352vs 168),"Lupus Erythematosus, Systemic",D008180,NA,0,1854,severity,11,000100000,"Lupus Erythematosus, Systemic",NA
5056,28118533,2,ss at baseline;ss<9(n=202vs111),"Lupus Erythematosus, Systemic",D008180,NA,0,1854,severity,11,000100000,"Lupus Erythematosus, Systemic",NA
5057,28118533,2,steroid use at baseline,Steroids,D013256,NA,0,1854,any,2,000000000,Steroids,NA
5058,28118533,2,weight,Body Weight,D001835,NA,0,1854,any,2,000000000,Body Weight,NA
5059,28119763,NA,NERD Grade,unclassifiable,NA,NA,0,0,any,2,000000000,unclassifiable,NA
5060,28119763,NA,response to treatment at Week 2,unclassifiable,NA,NA,0,0,disease response,4,000000000,unclassifiable,NA
5061,28153828,2,baseline erosion,unclassifiable,none,NA,0,958,any,2,000000000,unclassifiable,NA
5062,28153828,2,baseline steroids,Steroids,D013256,NA,0,958,any,2,000000000,Steroids,NA
5063,28153828,2,crp (mg/dl),C-Reactive Protein,D002097,NA,0,958,any,2,000000000,C-Reactive Protein,NA
5064,28153828,2,das28,"Arthritis, Rheumatoid",D001172,NA,0,958,severity,11,000100000,"Arthritis, Rheumatoid",NA
5065,28153828,2,haq-di,Quality of Life,D011788,NA,0,958,any,2,000000000,Quality of Life,NA
5066,28153828,2,il-6 (pg/ml),Interleukin-6,D015850,NA,0,958,any,2,000000000,Interleukin-6,NA
5067,28153828,2,mmp-3 (ng/ml),Matrix Metalloproteinases,D020782,NA,0,958,any,2,000000000,Matrix Metalloproteinases,NA
5068,28153828,2,mtss,"Arthritis, Rheumatoid",D001172,NA,0,958,severity,11,000100000,"Arthritis, Rheumatoid",NA
5069,28153828,2,mtx exposure (mg/week),Immunosuppressive Agents,D007166,NA,0,958,any,2,000000000,Immunosuppressive Agents,NA
5070,28153828,2,ra duration (months)*,"Arthritis, Rheumatoid",D001172,NA,0,958,duration,5,001000000,"Arthritis, Rheumatoid",NA
5071,28153828,2,rf (iu/ml),Rheumatoid Factor,D012217,NA,0,958,any,2,000000000,Rheumatoid Factor,NA
5072,28153828,2,tnf-alpha (pg/ml),Tumor Necrosis Factor Inhibitors,D000079424,NA,0,958,any,2,000000000,Tumor Necrosis Factor Inhibitors,NA
5073,28159511,2,"Age of asthma onset, years",Asthma,D001249,NA,0,80,previous,8,100000000,Asthma,NA
5074,28188240,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,48
5075,28189475,2,diabetes,Diabetes Mellitus,D003920,NA,0,1072,any,2,000000000,Diabetes Mellitus,NA
5076,28197834,2,magnesium,magnesium,NA,A12CC,0,150,any,2,000000000,magnesium,NA
5077,28215362,2,prior anti-tnf therapy,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,1151,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
5078,28215362,2,prior biologic therapy (including anti-tnfs),Biological Therapy,D001691,NA,0,1151,previous,8,100000000,Biological Therapy,NA
5079,28217871,NA,hsCRP level,C-Reactive Protein,D002097,NA,0,0,any,2,000000000,C-Reactive Protein,24
5080,28228427,NA,Dual Antiplatelet Therapy score,Platelet Aggregation Inhibitors,D010975,NA,0,0,any,2,000000000,Platelet Aggregation Inhibitors,72
5081,28228427,NA,stent type,Stents,D015607,NA,0,0,type,12,000000010,Stents,253
5082,28231942,2,high risk (ri=3),Atherosclerosis,D050197,NA,0,623,risk score,10,000000100,Atherosclerosis,NA
5083,28231942,2,intermediate risk (ri=2),Atherosclerosis,D050197,NA,0,623,risk score,10,000000100,Atherosclerosis,NA
5084,28231942,2,low risk (ri=0-1),Atherosclerosis,D050197,NA,0,623,risk score,10,000000100,Atherosclerosis,NA
5085,28237263,2,bmi >=40,Body Mass Index,D015992,NA,0,1098,any,2,000000000,Body Mass Index,NA
5086,28237263,2,bmi 27-0-29-9,Body Mass Index,D015992,NA,0,1098,any,2,000000000,Body Mass Index,NA
5087,28237263,2,bmi 30 0-34 9,Body Mass Index,D015992,NA,0,1098,any,2,000000000,Body Mass Index,NA
5088,28237263,2,bmi 35-0-39 9,Body Mass Index,D015992,NA,0,1098,any,2,000000000,Body Mass Index,NA
5089,28237263,2,bmi 35 0-39 9,Body Mass Index,D015992,NA,0,1098,any,2,000000000,Body Mass Index,NA
5090,28237263,3,bmi >=40,Body Mass Index,D015992,NA,0,511,any,2,000000000,Body Mass Index,NA
5091,28237263,3,bmi 27-0-29-9,Body Mass Index,D015992,NA,0,511,any,2,000000000,Body Mass Index,NA
5092,28237263,3,bmi 30 0-34 9,Body Mass Index,D015992,NA,0,511,any,2,000000000,Body Mass Index,NA
5093,28237263,3,bmi 35-0-39 9,Body Mass Index,D015992,NA,0,511,any,2,000000000,Body Mass Index,NA
5094,28237263,3,bmi 35 0-39 9,Body Mass Index,D015992,NA,0,511,any,2,000000000,Body Mass Index,NA
5095,28246236,NA,hsTnI,Troponin,D014336,NA,0,0,any,2,000000000,Troponin,257
5096,28246237,2,ada impaired fasting glucose,Glucose Intolerance,D018149,NA,0,1105,any,2,000000000,Glucose Intolerance,NA
5097,28246237,2,age,Age Factors,D000367,NA,0,1105,any,2,000000000,Age Factors,NA
5098,28246237,2,arb/ace,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,1105,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
5099,28246237,2,aspirin,Aspirin,D001241,NA,0,1105,any,2,000000000,Aspirin,NA
5100,28246237,2,atrial fibrillation,Atrial Fibrillation,D001281,NA,0,1105,any,2,000000000,Atrial Fibrillation,NA
5101,28246237,2,body mass index,Body Mass Index,D015992,NA,0,1105,any,2,000000000,Body Mass Index,NA
5102,28246237,2,coronary artery disease history,Coronary Artery Disease,D003324,NA,0,1105,previous,8,100000000,Coronary Artery Disease,NA
5103,28246237,2,gender,Gender Identity,D005783,NA,0,1105,any,2,000000000,Gender Identity,NA
5104,28246237,2,glycated hemoglobin,Glycated Hemoglobin A,D006442,NA,0,1105,any,2,000000000,Glycated Hemoglobin A,NA
5105,28246237,2,hypertension history,Hypertension,D006973,NA,0,1105,previous,8,100000000,Hypertension,NA
5106,28246237,2,race,Racial Groups,D044469,NA,0,1105,any,2,000000000,Racial Groups,NA
5107,28246237,2,statin,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,1105,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
5108,28246237,2,triglycerides,Lipoproteins,D008074,NA,0,1105,any,2,000000000,Lipoproteins,NA
5109,28263812,2,COPD,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1074,any,2,000000000,"Pulmonary Disease, Chronic Obstructive",NA
5110,28263812,2,Heart Failure,Heart Failure,D006333,NA,0,1074,any,2,000000000,Heart Failure,NA
5111,28278391,2,blood eosinophils count,Eosinophilia,D004802,NA,0,288,any,2,000000000,Eosinophilia,NA
5112,28278391,2,blood eosinophils count;< 2 %,Eosinophilia,D004802,NA,0,288,any,2,000000000,Eosinophilia,NA
5113,28278391,2,blood eosinophils count;< 3 %,Eosinophilia,D004802,NA,0,288,any,2,000000000,Eosinophilia,NA
5114,28278391,2,blood eosinophils count;< 5 %,Eosinophilia,D004802,NA,0,288,any,2,000000000,Eosinophilia,NA
5115,28278391,2,blood eosinophils count;> 2%,Eosinophilia,D004802,NA,0,288,any,2,000000000,Eosinophilia,NA
5116,28278391,2,blood eosinophils count;> 3 %,Eosinophilia,D004802,NA,0,288,any,2,000000000,Eosinophilia,NA
5117,28278391,2,blood eosinophils count;> 5 %,Eosinophilia,D004802,NA,0,288,any,2,000000000,Eosinophilia,NA
5118,28279891,2,cbz-exposed,Anticonvulsants,D000927,NA,0,1627,any,2,000000000,Anticonvulsants,NA
5119,28279891,2,cbz-naive,Anticonvulsants,D000927,NA,0,1627,any,2,000000000,Anticonvulsants,NA
5120,28279891,2,lev-exposed,other antiepileptics,NA,N03AX,0,1627,any,2,000000000,other antiepileptics,NA
5121,28279891,2,lev-naive,other antiepileptics,NA,N03AX,0,1627,any,2,000000000,other antiepileptics,NA
5122,28279891,2,tpm-exposed,Anticonvulsants,D000927,NA,0,1627,any,2,000000000,Anticonvulsants,NA
5123,28279891,2,tpm-naive,Anticonvulsants,D000927,NA,0,1627,any,2,000000000,Anticonvulsants,NA
5124,28300867,2,diabetes and no dm,Diabetes Mellitus,D003920,NA,0,1716,any,2,000000000,Diabetes Mellitus,NA
5125,28316279,2,<50 ml/min,Glomerular Filtration Rate,D005919,NA,0,209,any,2,000000000,Glomerular Filtration Rate,NA
5126,28316279,2,>80 ml/min,Glomerular Filtration Rate,D005919,NA,0,209,any,2,000000000,Glomerular Filtration Rate,NA
5127,28316279,2,50-<80 ml/min,Glomerular Filtration Rate,D005919,NA,0,209,any,2,000000000,Glomerular Filtration Rate,NA
5128,28316279,2,active cancer,Neoplasms,D009369,NA,0,209,any,2,000000000,Neoplasms,NA
5129,28316279,2,age,Age Factors,D000367,NA,0,209,any,2,000000000,Age Factors,NA
5130,28316279,2,body mass index,Body Mass Index,D015992,NA,0,209,any,2,000000000,Body Mass Index,NA
5131,28316279,2,body weight,Body Weight,D001835,NA,0,209,any,2,000000000,Body Weight,NA
5132,28316279,2,creatinine clearance,Glomerular Filtration Rate,D005919,NA,0,209,any,2,000000000,Glomerular Filtration Rate,NA
5133,28316279,2,deep vein thrombosis only,Venous Thromboembolism,D054556,NA,0,209,type,12,000000010,Venous Thromboembolism,NA
5134,28316279,2,duration of pre-randomization anticoagulant therapy,Anticoagulants,D000925,NA,0,209,duration,5,001000000,Anticoagulants,NA
5135,28316279,2,extent of index DVT or PE,Venous Thromboembolism,D054556,NA,0,209,severity,11,000100000,Venous Thromboembolism,NA
5136,28316279,2,extent of index event,Venous Thromboembolism,D054556,NA,0,209,severity,11,000100000,Venous Thromboembolism,NA
5137,28316279,2,fragile,Frailty,D000073496,NA,0,209,any,2,000000000,Frailty,NA
5138,28316279,2,history of recurrent venous thromboembolism,Venous Thromboembolism,D054556,NA,0,209,previous,8,110000000,Venous Thromboembolism,NA
5139,28316279,2,intermediate,Venous Thromboembolism,D054556,NA,0,209,severity,11,000100100,Venous Thromboembolism,NA
5140,28316279,2,known thrombophilia,Thrombophilia,D019851,NA,0,209,any,2,000000000,Thrombophilia,NA
5141,28316279,2,limited,Venous Thromboembolism,D054556,NA,0,209,severity,11,000100000,Venous Thromboembolism,NA
5142,28316279,2,pulmonary embolism Â± deep vein thrombosis,Venous Thromboembolism,D054556,NA,0,209,any,2,000000000,Venous Thromboembolism,NA
5143,28316279,2,risk factor profile index event,Risk Factors,D012307,NA,0,209,risk score,10,000000100,Risk Factors,NA
5144,28316279,2,sex,Gender Identity,D005783,NA,0,209,any,2,000000000,Gender Identity,NA
5145,28327140,2,Hypertension,Hypertension,D006973,NA,0,1508,any,2,000000000,Hypertension,NA
5146,28327140,2,Prior CVD,Cardiovascular Diseases,D002318,NA,0,1508,previous,8,100000000,Cardiovascular Diseases,NA
5147,28332144,NA,Ethnicity,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
5148,28359411,2,bnp,"Natriuretic Peptide, Brain",D020097,NA,0,1668,any,2,000000000,"Natriuretic Peptide, Brain",NA
5149,28359411,2,bnp/ntbnp (n=687),"Natriuretic Peptide, Brain",D020097,NA,0,1668,any,2,000000000,"Natriuretic Peptide, Brain",NA
5150,28359411,2,Brain Natriuretic Peptide measurement,"Natriuretic Peptide, Brain",D020097,NA,0,1668,any,2,000000000,"Natriuretic Peptide, Brain",NA
5151,28359411,2,ntbnp (n=257),"Natriuretic Peptide, Brain",D020097,NA,0,1668,any,2,000000000,"Natriuretic Peptide, Brain",NA
5152,28382371,2,cangrelor dyspnoea vs no dyspnoea*,Dyspnea,D004417,NA,0,379,any,2,000000000,Dyspnea,NA
5153,28382371,2,clopidogrel dyspnoea vs no dyspnoea*,Dyspnea,D004417,NA,0,379,any,2,000000000,Dyspnea,NA
5154,28382371,2,with dyspnoea,Dyspnea,D004417,NA,0,379,any,2,000000000,Dyspnea,NA
5155,28382371,2,without dyspnoea,Dyspnea,D004417,NA,0,379,any,2,000000000,Dyspnea,NA
5156,28382371,3,with dyspnoea,Dyspnea,D004417,NA,0,526,any,2,000000000,Dyspnea,NA
5157,28382371,3,without dyspnoea,Dyspnea,D004417,NA,0,526,any,2,000000000,Dyspnea,NA
5158,28385353,2,>1 exacerbation in prev 12 m (n=316),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,898,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5159,28385353,2,>1 exacerbation in prev 12 m (n=333),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,898,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5160,28385353,2,>1 exacerbation in prev 12 m (n=443),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,898,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5161,28385353,2,1 exacerbation in prev 12 m (n=1279),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,898,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5162,28385353,2,1 exacerbation in prev 12 m (n=1299),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,898,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5163,28385353,2,1 exacerbation in prev 12 m (n=1708),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,898,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5164,28385353,2,age Â£75 years (itt) (n=154),Age Factors,D000367,NA,0,898,any,2,000000000,Age Factors,NA
5165,28385353,2,age Â£75 years (itt) (n=171),Age Factors,D000367,NA,0,898,any,2,000000000,Age Factors,NA
5166,28385353,2,age <65 years (itt) (n=895),Age Factors,D000367,NA,0,898,any,2,000000000,Age Factors,NA
5167,28385353,2,age <65 years (n=1192),Age Factors,D000367,NA,0,898,any,2,000000000,Age Factors,NA
5168,28385353,2,age <65 years (n=899),Age Factors,D000367,NA,0,898,any,2,000000000,Age Factors,NA
5169,28385353,2,age <65 years (n=905),Age Factors,D000367,NA,0,898,any,2,000000000,Age Factors,NA
5170,28385353,2,age >75 years (n=174),Age Factors,D000367,NA,0,898,any,2,000000000,Age Factors,NA
5171,28385353,2,age >75 years (n=222),Age Factors,D000367,NA,0,898,any,2,000000000,Age Factors,NA
5172,28385353,2,age 275 years (n=156),Age Factors,D000367,NA,0,898,any,2,000000000,Age Factors,NA
5173,28385353,2,age 65-74 years (itt) (n=538),Age Factors,D000367,NA,0,898,any,2,000000000,Age Factors,NA
5174,28385353,2,age 65-74 years (itt) (n=542),Age Factors,D000367,NA,0,898,any,2,000000000,Age Factors,NA
5175,28385353,2,age 65-74 years (n=542),Age Factors,D000367,NA,0,898,any,2,000000000,Age Factors,NA
5176,28385353,2,age 65-74 years (n=551),Age Factors,D000367,NA,0,898,any,2,000000000,Age Factors,NA
5177,28385353,2,age 65-74 years (n=737),Age Factors,D000367,NA,0,898,any,2,000000000,Age Factors,NA
5178,28385353,2,cardiovascular disease (n=1083),Cardiovascular Diseases,D002318,NA,0,898,any,2,000000000,Cardiovascular Diseases,NA
5179,28385353,2,cardiovascular disease (n=1101),Cardiovascular Diseases,D002318,NA,0,898,any,2,000000000,Cardiovascular Diseases,NA
5180,28385353,2,cardiovascular disease (n=1480),Cardiovascular Diseases,D002318,NA,0,898,any,2,000000000,Cardiovascular Diseases,NA
5181,28385353,2,chronic bronchitis (itt) (n=1088),Bronchitis,D001991,NA,0,898,any,2,000000000,Bronchitis,NA
5182,28385353,2,chronic bronchitis (itt) (n=792),Bronchitis,D001991,NA,0,898,any,2,000000000,Bronchitis,NA
5183,28385353,2,chronic bronchitis (itt) (n=800),Bronchitis,D001991,NA,0,898,any,2,000000000,Bronchitis,NA
5184,28385353,2,chronic bronchitis (itt) (n=824),Bronchitis,D001991,NA,0,898,any,2,000000000,Bronchitis,NA
5185,28385353,2,emphysema (itt) (n=433),Pulmonary Emphysema,D011656,NA,0,898,aetiological,1,000001000,Pulmonary Emphysema,NA
5186,28385353,2,emphysema (itt) (n=438),Pulmonary Emphysema,D011656,NA,0,898,aetiological,1,000001000,Pulmonary Emphysema,NA
5187,28385353,2,emphysema (itt) (n=444),Pulmonary Eosinophilia,D011657,NA,0,898,aetiological,1,000001000,Pulmonary Eosinophilia,NA
5188,28385353,2,emphysema (itt) (n=446),Pulmonary Fibrosis,D011658,NA,0,898,aetiological,1,000001000,Pulmonary Fibrosis,NA
5189,28385353,2,emphysema (itt) (n=582),Pulmonary Gas Exchange,D011659,NA,0,898,aetiological,1,000001000,Pulmonary Gas Exchange,NA
5190,28385353,2,male female,Gender Identity,D005783,NA,0,898,any,2,000000000,Gender Identity,NA
5191,28385353,2,no cardiovascular disease (n=514),Cardiovascular Diseases,D002318,NA,0,898,any,2,000000000,Cardiovascular Diseases,NA
5192,28385353,2,no cardiovascular disease (n=529),Cardiovascular Diseases,D002318,NA,0,898,any,2,000000000,Cardiovascular Diseases,NA
5193,28385353,2,no cardiovascular disease (n=671),Cardiovascular Diseases,D002318,NA,0,898,any,2,000000000,Cardiovascular Diseases,NA
5194,28385353,2,Prespecified subgroup analyses according to baseline blood eosinophil count,Eosinophilia,D004802,NA,0,898,any,2,000000000,Eosinophilia,NA
5195,28385353,2,severe (itt) (n=1257),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,898,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5196,28385353,2,severe (itt) (n=1265),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,898,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5197,28385353,2,severe (itt) (n=1270),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,898,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5198,28385353,2,severe (itt) (n=1274),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,898,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5199,28385353,2,severe (itt) (n=1694),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,898,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5200,28385353,2,Smoker,Cigarette Smoking,D000073865,NA,0,898,any,2,000000000,Cigarette Smoking,NA
5201,28385353,2,very severe (itt) (n=334),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,898,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5202,28385353,2,very severe (itt) (n=339),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,898,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5203,28385353,2,very severe (itt) (n=341),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,898,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5204,28385353,2,very severe (itt) (n=342),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,898,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5205,28385353,2,very severe (itt) (n=457),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,898,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5206,28385353,3,>1 exacerbation in prev 12 m (n=316),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,493,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5207,28385353,3,>1 exacerbation in prev 12 m (n=333),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,493,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5208,28385353,3,>1 exacerbation in prev 12 m (n=443),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,493,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5209,28385353,3,1 exacerbation in prev 12 m (n=1279),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,493,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5210,28385353,3,1 exacerbation in prev 12 m (n=1299),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,493,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5211,28385353,3,1 exacerbation in prev 12 m (n=1708),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,493,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5212,28385353,3,age Â£75 years (itt) (n=154),Age Factors,D000367,NA,0,493,any,2,000000000,Age Factors,NA
5213,28385353,3,age Â£75 years (itt) (n=171),Age Factors,D000367,NA,0,493,any,2,000000000,Age Factors,NA
5214,28385353,3,age <65 years (itt) (n=895),Age Factors,D000367,NA,0,493,any,2,000000000,Age Factors,NA
5215,28385353,3,age <65 years (n=1192),Age Factors,D000367,NA,0,493,any,2,000000000,Age Factors,NA
5216,28385353,3,age <65 years (n=899),Age Factors,D000367,NA,0,493,any,2,000000000,Age Factors,NA
5217,28385353,3,age <65 years (n=905),Age Factors,D000367,NA,0,493,any,2,000000000,Age Factors,NA
5218,28385353,3,age >75 years (n=174),Age Factors,D000367,NA,0,493,any,2,000000000,Age Factors,NA
5219,28385353,3,age >75 years (n=222),Age Factors,D000367,NA,0,493,any,2,000000000,Age Factors,NA
5220,28385353,3,age 275 years (n=156),Age Factors,D000367,NA,0,493,any,2,000000000,Age Factors,NA
5221,28385353,3,age 65-74 years (itt) (n=538),Age Factors,D000367,NA,0,493,any,2,000000000,Age Factors,NA
5222,28385353,3,age 65-74 years (itt) (n=542),Age Factors,D000367,NA,0,493,any,2,000000000,Age Factors,NA
5223,28385353,3,age 65-74 years (n=542),Age Factors,D000367,NA,0,493,any,2,000000000,Age Factors,NA
5224,28385353,3,age 65-74 years (n=551),Age Factors,D000367,NA,0,493,any,2,000000000,Age Factors,NA
5225,28385353,3,age 65-74 years (n=737),Age Factors,D000367,NA,0,493,any,2,000000000,Age Factors,NA
5226,28385353,3,cardiovascular disease (n=1083),Cardiovascular Diseases,D002318,NA,0,493,any,2,000000000,Cardiovascular Diseases,NA
5227,28385353,3,cardiovascular disease (n=1101),Cardiovascular Diseases,D002318,NA,0,493,any,2,000000000,Cardiovascular Diseases,NA
5228,28385353,3,cardiovascular disease (n=1480),Cardiovascular Diseases,D002318,NA,0,493,any,2,000000000,Cardiovascular Diseases,NA
5229,28385353,3,chronic bronchitis (itt) (n=1088),Bronchitis,D001991,NA,0,493,any,2,000000000,Bronchitis,NA
5230,28385353,3,chronic bronchitis (itt) (n=792),Bronchitis,D001991,NA,0,493,any,2,000000000,Bronchitis,NA
5231,28385353,3,chronic bronchitis (itt) (n=800),Bronchitis,D001991,NA,0,493,any,2,000000000,Bronchitis,NA
5232,28385353,3,chronic bronchitis (itt) (n=824),Bronchitis,D001991,NA,0,493,any,2,000000000,Bronchitis,NA
5233,28385353,3,emphysema (itt) (n=433),Subcutaneous Emphysema,D013352,NA,0,493,aetiological,1,000001000,Subcutaneous Emphysema,NA
5234,28385353,3,emphysema (itt) (n=438),Subcutaneous Emphysema,D013352,NA,0,493,aetiological,1,000001000,Subcutaneous Emphysema,NA
5235,28385353,3,emphysema (itt) (n=444),Subcutaneous Emphysema,D013352,NA,0,493,aetiological,1,000001000,Subcutaneous Emphysema,NA
5236,28385353,3,emphysema (itt) (n=446),Subcutaneous Emphysema,D013352,NA,0,493,aetiological,1,000001000,Subcutaneous Emphysema,NA
5237,28385353,3,emphysema (itt) (n=582),Subcutaneous Emphysema,D013352,NA,0,493,aetiological,1,000001000,Subcutaneous Emphysema,NA
5238,28385353,3,male female,Gender Identity,D005783,NA,0,493,any,2,000000000,Gender Identity,NA
5239,28385353,3,no cardiovascular disease (n=514),Cardiovascular Diseases,D002318,NA,0,493,any,2,000000000,Cardiovascular Diseases,NA
5240,28385353,3,no cardiovascular disease (n=529),Cardiovascular Diseases,D002318,NA,0,493,any,2,000000000,Cardiovascular Diseases,NA
5241,28385353,3,no cardiovascular disease (n=671),Cardiovascular Diseases,D002318,NA,0,493,any,2,000000000,Cardiovascular Diseases,NA
5242,28385353,3,Prespecified subgroup analyses according to baseline blood eosinophil count,Eosinophilia,D004802,NA,0,493,any,2,000000000,Eosinophilia,NA
5243,28385353,3,severe (itt) (n=1257),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,493,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5244,28385353,3,severe (itt) (n=1265),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,493,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5245,28385353,3,severe (itt) (n=1270),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,493,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5246,28385353,3,severe (itt) (n=1274),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,493,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5247,28385353,3,severe (itt) (n=1694),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,493,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5248,28385353,3,Smoker,Cigarette Smoking,D000073865,NA,0,493,any,2,000000000,Cigarette Smoking,NA
5249,28385353,3,very severe (itt) (n=334),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,493,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5250,28385353,3,very severe (itt) (n=339),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,493,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5251,28385353,3,very severe (itt) (n=341),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,493,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5252,28385353,3,very severe (itt) (n=342),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,493,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5253,28385353,3,very severe (itt) (n=457),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,493,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5254,28385353,4,>1 exacerbation in prev 12 m (n=316),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1480,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5255,28385353,4,>1 exacerbation in prev 12 m (n=333),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1480,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5256,28385353,4,>1 exacerbation in prev 12 m (n=443),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1480,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5257,28385353,4,1 exacerbation in prev 12 m (n=1279),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1480,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5258,28385353,4,1 exacerbation in prev 12 m (n=1299),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1480,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5259,28385353,4,1 exacerbation in prev 12 m (n=1708),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1480,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5260,28385353,4,age Â£75 years (itt) (n=154),Age Factors,D000367,NA,0,1480,any,2,000000000,Age Factors,NA
5261,28385353,4,age Â£75 years (itt) (n=171),Age Factors,D000367,NA,0,1480,any,2,000000000,Age Factors,NA
5262,28385353,4,age <65 years (itt) (n=895),Age Factors,D000367,NA,0,1480,any,2,000000000,Age Factors,NA
5263,28385353,4,age <65 years (n=1192),Age Factors,D000367,NA,0,1480,any,2,000000000,Age Factors,NA
5264,28385353,4,age <65 years (n=899),Age Factors,D000367,NA,0,1480,any,2,000000000,Age Factors,NA
5265,28385353,4,age <65 years (n=905),Age Factors,D000367,NA,0,1480,any,2,000000000,Age Factors,NA
5266,28385353,4,age >75 years (n=174),Age Factors,D000367,NA,0,1480,any,2,000000000,Age Factors,NA
5267,28385353,4,age >75 years (n=222),Age Factors,D000367,NA,0,1480,any,2,000000000,Age Factors,NA
5268,28385353,4,age 275 years (n=156),Age Factors,D000367,NA,0,1480,any,2,000000000,Age Factors,NA
5269,28385353,4,age 65-74 years (itt) (n=538),Age Factors,D000367,NA,0,1480,any,2,000000000,Age Factors,NA
5270,28385353,4,age 65-74 years (itt) (n=542),Age Factors,D000367,NA,0,1480,any,2,000000000,Age Factors,NA
5271,28385353,4,age 65-74 years (n=542),Age Factors,D000367,NA,0,1480,any,2,000000000,Age Factors,NA
5272,28385353,4,age 65-74 years (n=551),Age Factors,D000367,NA,0,1480,any,2,000000000,Age Factors,NA
5273,28385353,4,age 65-74 years (n=737),Age Factors,D000367,NA,0,1480,any,2,000000000,Age Factors,NA
5274,28385353,4,cardiovascular disease (n=1083),Cardiovascular Diseases,D002318,NA,0,1480,any,2,000000000,Cardiovascular Diseases,NA
5275,28385353,4,cardiovascular disease (n=1101),Cardiovascular Diseases,D002318,NA,0,1480,any,2,000000000,Cardiovascular Diseases,NA
5276,28385353,4,cardiovascular disease (n=1480),Cardiovascular Diseases,D002318,NA,0,1480,any,2,000000000,Cardiovascular Diseases,NA
5277,28385353,4,chronic bronchitis (itt) (n=1088),Bronchitis,D001991,NA,0,1480,any,2,000000000,Bronchitis,NA
5278,28385353,4,chronic bronchitis (itt) (n=792),Bronchitis,D001991,NA,0,1480,any,2,000000000,Bronchitis,NA
5279,28385353,4,chronic bronchitis (itt) (n=800),Bronchitis,D001991,NA,0,1480,any,2,000000000,Bronchitis,NA
5280,28385353,4,chronic bronchitis (itt) (n=824),Bronchitis,D001991,NA,0,1480,any,2,000000000,Bronchitis,NA
5281,28385353,4,emphysema (itt) (n=433),Subcutaneous Emphysema,D013352,NA,0,1480,aetiological,1,000001000,Subcutaneous Emphysema,NA
5282,28385353,4,emphysema (itt) (n=438),Subcutaneous Emphysema,D013352,NA,0,1480,aetiological,1,000001000,Subcutaneous Emphysema,NA
5283,28385353,4,emphysema (itt) (n=444),Subcutaneous Emphysema,D013352,NA,0,1480,aetiological,1,000001000,Subcutaneous Emphysema,NA
5284,28385353,4,emphysema (itt) (n=446),Subcutaneous Emphysema,D013352,NA,0,1480,aetiological,1,000001000,Subcutaneous Emphysema,NA
5285,28385353,4,emphysema (itt) (n=582),Subcutaneous Emphysema,D013352,NA,0,1480,aetiological,1,000001000,Subcutaneous Emphysema,NA
5286,28385353,4,male female,Gender Identity,D005783,NA,0,1480,any,2,000000000,Gender Identity,NA
5287,28385353,4,no cardiovascular disease (n=514),Cardiovascular Diseases,D002318,NA,0,1480,any,2,000000000,Cardiovascular Diseases,NA
5288,28385353,4,no cardiovascular disease (n=529),Cardiovascular Diseases,D002318,NA,0,1480,any,2,000000000,Cardiovascular Diseases,NA
5289,28385353,4,no cardiovascular disease (n=671),Cardiovascular Diseases,D002318,NA,0,1480,any,2,000000000,Cardiovascular Diseases,NA
5290,28385353,4,Prespecified subgroup analyses according to baseline blood eosinophil count,Eosinophilia,D004802,NA,0,1480,any,2,000000000,Eosinophilia,NA
5291,28385353,4,severe (itt) (n=1257),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1480,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5292,28385353,4,severe (itt) (n=1265),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1480,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5293,28385353,4,severe (itt) (n=1270),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1480,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5294,28385353,4,severe (itt) (n=1274),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1480,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5295,28385353,4,severe (itt) (n=1694),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1480,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5296,28385353,4,Smoker,Cigarette Smoking,D000073865,NA,0,1480,any,2,000000000,Cigarette Smoking,NA
5297,28385353,4,very severe (itt) (n=334),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1480,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5298,28385353,4,very severe (itt) (n=339),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1480,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5299,28385353,4,very severe (itt) (n=341),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1480,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5300,28385353,4,very severe (itt) (n=342),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1480,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5301,28385353,4,very severe (itt) (n=457),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1480,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5302,28385353,5,male female,Gender Identity,D005783,NA,0,93,any,2,000000000,Gender Identity,NA
5303,28385353,5,Prespecified subgroup analyses according to baseline blood eosinophil count,Eosinophilia,D004802,NA,0,93,any,2,000000000,Eosinophilia,NA
5304,28385353,5,Smoker,Cigarette Smoking,D000073865,NA,0,93,any,2,000000000,Cigarette Smoking,NA
5305,28385353,6,age Â£75 years (itt) (n=154),Age Factors,D000367,NA,0,685,any,2,000000000,Age Factors,NA
5306,28385353,6,age Â£75 years (itt) (n=171),Age Factors,D000367,NA,0,685,any,2,000000000,Age Factors,NA
5307,28385353,6,age <65 years (itt) (n=895),Age Factors,D000367,NA,0,685,any,2,000000000,Age Factors,NA
5308,28385353,6,age <65 years (n=1192),Age Factors,D000367,NA,0,685,any,2,000000000,Age Factors,NA
5309,28385353,6,age <65 years (n=899),Age Factors,D000367,NA,0,685,any,2,000000000,Age Factors,NA
5310,28385353,6,age <65 years (n=905),Age Factors,D000367,NA,0,685,any,2,000000000,Age Factors,NA
5311,28385353,6,age >75 years (n=174),Age Factors,D000367,NA,0,685,any,2,000000000,Age Factors,NA
5312,28385353,6,age >75 years (n=222),Age Factors,D000367,NA,0,685,any,2,000000000,Age Factors,NA
5313,28385353,6,age 275 years (n=156),Age Factors,D000367,NA,0,685,any,2,000000000,Age Factors,NA
5314,28385353,6,age 65-74 years (itt) (n=538),Age Factors,D000367,NA,0,685,any,2,000000000,Age Factors,NA
5315,28385353,6,age 65-74 years (itt) (n=542),Age Factors,D000367,NA,0,685,any,2,000000000,Age Factors,NA
5316,28385353,6,age 65-74 years (n=542),Age Factors,D000367,NA,0,685,any,2,000000000,Age Factors,NA
5317,28385353,6,age 65-74 years (n=551),Age Factors,D000367,NA,0,685,any,2,000000000,Age Factors,NA
5318,28385353,6,age 65-74 years (n=737),Age Factors,D000367,NA,0,685,any,2,000000000,Age Factors,NA
5319,28385353,6,chronic bronchitis (itt) (n=817),Bronchitis,D001991,NA,0,685,any,2,000000000,Bronchitis,NA
5320,28385353,6,emphysema (itt) (n=433),Subcutaneous Emphysema,D013352,NA,0,685,aetiological,1,000001000,Subcutaneous Emphysema,NA
5321,28385353,6,emphysema (itt) (n=438),Subcutaneous Emphysema,D013352,NA,0,685,aetiological,1,000001000,Subcutaneous Emphysema,NA
5322,28385353,6,emphysema (itt) (n=444),Subcutaneous Emphysema,D013352,NA,0,685,aetiological,1,000001000,Subcutaneous Emphysema,NA
5323,28385353,6,emphysema (itt) (n=446),Subcutaneous Emphysema,D013352,NA,0,685,aetiological,1,000001000,Subcutaneous Emphysema,NA
5324,28385353,6,emphysema (itt) (n=582),Subcutaneous Emphysema,D013352,NA,0,685,aetiological,1,000001000,Subcutaneous Emphysema,NA
5325,28385353,6,male female,Gender Identity,D005783,NA,0,685,any,2,000000000,Gender Identity,NA
5326,28385353,6,Prespecified subgroup analyses according to baseline blood eosinophil count,Eosinophilia,D004802,NA,0,685,any,2,000000000,Eosinophilia,NA
5327,28385353,6,Smoker,Cigarette Smoking,D000073865,NA,0,685,any,2,000000000,Cigarette Smoking,NA
5328,28385353,7,age Â£75 years (itt) (n=154),Age Factors,D000367,NA,0,500,any,2,000000000,Age Factors,NA
5329,28385353,7,age Â£75 years (itt) (n=171),Age Factors,D000367,NA,0,500,any,2,000000000,Age Factors,NA
5330,28385353,7,age <65 years (itt) (n=895),Age Factors,D000367,NA,0,500,any,2,000000000,Age Factors,NA
5331,28385353,7,age <65 years (n=1192),Age Factors,D000367,NA,0,500,any,2,000000000,Age Factors,NA
5332,28385353,7,age <65 years (n=899),Age Factors,D000367,NA,0,500,any,2,000000000,Age Factors,NA
5333,28385353,7,age <65 years (n=905),Age Factors,D000367,NA,0,500,any,2,000000000,Age Factors,NA
5334,28385353,7,age >75 years (n=174),Age Factors,D000367,NA,0,500,any,2,000000000,Age Factors,NA
5335,28385353,7,age >75 years (n=222),Age Factors,D000367,NA,0,500,any,2,000000000,Age Factors,NA
5336,28385353,7,age 275 years (n=156),Age Factors,D000367,NA,0,500,any,2,000000000,Age Factors,NA
5337,28385353,7,age 65-74 years (itt) (n=538),Age Factors,D000367,NA,0,500,any,2,000000000,Age Factors,NA
5338,28385353,7,age 65-74 years (itt) (n=542),Age Factors,D000367,NA,0,500,any,2,000000000,Age Factors,NA
5339,28385353,7,age 65-74 years (n=542),Age Factors,D000367,NA,0,500,any,2,000000000,Age Factors,NA
5340,28385353,7,age 65-74 years (n=551),Age Factors,D000367,NA,0,500,any,2,000000000,Age Factors,NA
5341,28385353,7,age 65-74 years (n=737),Age Factors,D000367,NA,0,500,any,2,000000000,Age Factors,NA
5342,28385353,7,chronic bronchitis (itt) (n=1088),Bronchitis,D001991,NA,0,500,any,2,000000000,Bronchitis,NA
5343,28385353,7,chronic bronchitis (itt) (n=792),Bronchitis,D001991,NA,0,500,any,2,000000000,Bronchitis,NA
5344,28385353,7,chronic bronchitis (itt) (n=800),Bronchitis,D001991,NA,0,500,any,2,000000000,Bronchitis,NA
5345,28385353,7,chronic bronchitis (itt) (n=824),Bronchitis,D001991,NA,0,500,any,2,000000000,Bronchitis,NA
5346,28385353,7,emphysema (itt) (n=433),Subcutaneous Emphysema,D013352,NA,0,500,aetiological,1,000001000,Subcutaneous Emphysema,NA
5347,28385353,7,emphysema (itt) (n=438),Subcutaneous Emphysema,D013352,NA,0,500,aetiological,1,000001000,Subcutaneous Emphysema,NA
5348,28385353,7,emphysema (itt) (n=444),Subcutaneous Emphysema,D013352,NA,0,500,aetiological,1,000001000,Subcutaneous Emphysema,NA
5349,28385353,7,emphysema (itt) (n=446),Subcutaneous Emphysema,D013352,NA,0,500,aetiological,1,000001000,Subcutaneous Emphysema,NA
5350,28385353,7,emphysema (itt) (n=582),Subcutaneous Emphysema,D013352,NA,0,500,aetiological,1,000001000,Subcutaneous Emphysema,NA
5351,28385353,7,male female,Gender Identity,D005783,NA,0,500,any,2,000000000,Gender Identity,NA
5352,28385353,7,Prespecified subgroup analyses according to baseline blood eosinophil count,Eosinophilia,D004802,NA,0,500,any,2,000000000,Eosinophilia,NA
5353,28385353,7,Smoker,Cigarette Smoking,D000073865,NA,0,500,any,2,000000000,Cigarette Smoking,NA
5354,28386035,1,'egfr;>90 ml min-1 1.73 m'2',Glomerular Filtration Rate,D005919,NA,0,828,any,2,000000000,Glomerular Filtration Rate,NA
5355,28386035,1,'egfr;60 to <90 ml minâ€™1 1.73 m'2',Glomerular Filtration Rate,D005919,NA,0,828,any,2,000000000,Glomerular Filtration Rate,NA
5356,28386035,1,ace inhibitor or arb,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,828,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
5357,28386035,1,acetylsalicylic acid,Aspirin,D001241,NA,0,828,any,2,000000000,Aspirin,NA
5358,28386035,1,age,Age Factors,D000367,NA,0,828,any,2,000000000,Age Factors,NA
5359,28386035,1,albuminuria,Albuminuria,D000419,NA,0,828,any,2,000000000,Albuminuria,NA
5360,28386035,1,atrial fibrillation,Atrial Fibrillation,D001281,NA,0,828,any,2,000000000,Atrial Fibrillation,NA
5361,28386035,1,beta-blocker,Adrenergic beta-Antagonists,D000319,NA,0,828,any,2,000000000,Adrenergic beta-Antagonists,NA
5362,28386035,1,blood pressure control,Blood Pressure,D001794,NA,0,828,any,2,000000000,Blood Pressure,NA
5363,28386035,1,blood pressure control;sbp >140 mm hg and/or dbp >90 mm hg 83/1780,Blood Pressure,D001794,NA,0,828,any,2,000000000,Blood Pressure,NA
5364,28386035,1,body mass index,Body Mass Index,D015992,NA,0,828,any,2,000000000,Body Mass Index,NA
5365,28386035,1,calcium channel blocker,Calcium Channel Blockers,D002121,NA,0,828,any,2,000000000,Calcium Channel Blockers,NA
5366,28386035,1,cardiovascular risk,Cardiovascular Diseases,D002318,NA,0,828,severity,11,000100100,Cardiovascular Diseases,NA
5367,28386035,1,cardiovascular risk;2 or 3 high-risk categories,Cardiovascular Diseases,D002318,NA,0,828,risk score,10,000000100,Cardiovascular Diseases,NA
5368,28386035,1,cardiovascular risk;only cerebrovascular disease,Stroke,D020521,NA,0,828,risk score,10,000000100,Stroke,NA
5369,28386035,1,cardiovascular risk;only coronary artery disease,Coronary Artery Disease,D003324,NA,0,828,risk score,10,000000100,Coronary Artery Disease,NA
5370,28386035,1,cardiovascular risk;only peripheral artery disease,Peripheral Vascular Diseases,D016491,NA,0,828,risk score,10,000000100,Peripheral Vascular Diseases,NA
5371,28386035,1,diuretic,Diuretics,D004232,NA,0,828,any,2,000000000,Diuretics,NA
5372,28386035,1,egfr,Glomerular Filtration Rate,D005919,NA,0,828,any,2,000000000,Glomerular Filtration Rate,NA
5373,28386035,1,"egfr;<60 ml minâ€™1 1.73 m""2",Glomerular Filtration Rate,D005919,NA,0,828,any,2,000000000,Glomerular Filtration Rate,NA
5374,28386035,1,ethnicity;hispanic/latino,Racial Groups,D044469,NA,0,828,any,2,000000000,Racial Groups,NA
5375,28386035,1,hba1c,Glycated Hemoglobin A,D006442,NA,0,828,any,2,000000000,Glycated Hemoglobin A,NA
5376,28386035,1,heart failure,Heart Failure,D006333,NA,0,828,any,2,000000000,Heart Failure,NA
5377,28386035,1,Hypertension,Hypertension,D006973,NA,0,828,any,2,000000000,Hypertension,NA
5378,28386035,1,insulin,Insulin,D007328,NA,0,828,any,2,000000000,Insulin,NA
5379,28386035,1,insulin;thiazolidinedione,Hypoglycemic Agents,D007004,NA,0,828,any,2,000000000,Hypoglycemic Agents,NA
5380,28386035,1,metformin,Hypoglycemic Agents,D007004,NA,0,828,any,2,000000000,Hypoglycemic Agents,NA
5381,28386035,1,race,Racial Groups,D044469,NA,0,828,any,2,000000000,Racial Groups,NA
5382,28386035,1,region,Geographic Locations,D005842,NA,0,828,any,2,000000000,Geographic Locations,NA
5383,28386035,1,region;north america (plus australia and new zealand),Geographic Locations,D005842,NA,0,828,any,2,000000000,Geographic Locations,NA
5384,28386035,1,sbp,Blood Pressure,D001794,NA,0,828,any,2,000000000,Blood Pressure,NA
5385,28386035,1,sex,Gender Identity,D005783,NA,0,828,any,2,000000000,Gender Identity,NA
5386,28386035,1,Smoker,Cigarette Smoking,D000073865,NA,0,828,any,2,000000000,Cigarette Smoking,NA
5387,28386035,1,statin or ezetimibe,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,828,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
5388,28386035,1,statin or ezetimibe;antihypertensive therapy,Antihypertensive Agents,D000959,NA,0,828,any,2,000000000,Antihypertensive Agents,NA
5389,28386035,1,sulfonylurea,Hypoglycemic Agents,D007004,NA,0,828,any,2,000000000,Hypoglycemic Agents,NA
5390,28386035,1,time since diagnosis of type 2 diabetes,Diabetes Mellitus,D003920,NA,0,828,duration,5,001000010,Diabetes Mellitus,NA
5391,28386035,1,vitamin k antagonist,Anticoagulants,D000925,NA,0,828,any,2,000000000,Anticoagulants,NA
5392,28386035,2,'egfr;>90 ml min-1 1.73 m'2',Glomerular Filtration Rate,D005919,NA,0,1132,any,2,000000000,Glomerular Filtration Rate,NA
5393,28386035,2,'egfr;60 to <90 ml minâ€™1 1.73 m'2',Glomerular Filtration Rate,D005919,NA,0,1132,any,2,000000000,Glomerular Filtration Rate,NA
5394,28386035,2,ace inhibitor or arb,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,1132,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
5395,28386035,2,acetylsalicylic acid,Aspirin,D001241,NA,0,1132,any,2,000000000,Aspirin,NA
5396,28386035,2,age,Age Factors,D000367,NA,0,1132,any,2,000000000,Age Factors,NA
5397,28386035,2,albuminuria,Albuminuria,D000419,NA,0,1132,any,2,000000000,Albuminuria,NA
5398,28386035,2,atrial fibrillation,Atrial Fibrillation,D001281,NA,0,1132,any,2,000000000,Atrial Fibrillation,NA
5399,28386035,2,blood pressure control,Blood Pressure,D001794,NA,0,1132,any,2,000000000,Blood Pressure,NA
5400,28386035,2,blood pressure control;sbp >140 mm hg and/or dbp >90 mm hg 83/1780,Blood Pressure,D001794,NA,0,1132,any,2,000000000,Blood Pressure,NA
5401,28386035,2,body mass index,Body Mass Index,D015992,NA,0,1132,any,2,000000000,Body Mass Index,NA
5402,28386035,2,cardiovascular risk,Cardiovascular Diseases,D002318,NA,0,1132,severity,11,000100100,Cardiovascular Diseases,NA
5403,28386035,2,cardiovascular risk;2 or 3 high-risk categories,Cardiovascular Diseases,D002318,NA,0,1132,risk score,10,000000100,Cardiovascular Diseases,NA
5404,28386035,2,cardiovascular risk;only cerebrovascular disease,Stroke,D020521,NA,0,1132,risk score,10,000000100,Stroke,NA
5405,28386035,2,cardiovascular risk;only coronary artery disease,Coronary Artery Disease,D003324,NA,0,1132,risk score,10,000000100,Coronary Artery Disease,NA
5406,28386035,2,diuretic,Diuretics,D004232,NA,0,1132,any,2,000000000,Diuretics,NA
5407,28386035,2,egfr,Glomerular Filtration Rate,D005919,NA,0,1132,any,2,000000000,Glomerular Filtration Rate,NA
5408,28386035,2,"egfr;<60 ml minâ€™1 1.73 m""2",Glomerular Filtration Rate,D005919,NA,0,1132,any,2,000000000,Glomerular Filtration Rate,NA
5409,28386035,2,hba1c,Glycated Hemoglobin A,D006442,NA,0,1132,any,2,000000000,Glycated Hemoglobin A,NA
5410,28386035,2,heart failure,Heart Failure,D006333,NA,0,1132,any,2,000000000,Heart Failure,NA
5411,28386035,2,insulin,Insulin,D007328,NA,0,1132,any,2,000000000,Insulin,NA
5412,28386035,2,previous stroke,Stroke,D020521,NA,0,1132,previous,8,100000000,Stroke,NA
5413,28386035,2,region,Geographic Locations,D005842,NA,0,1132,any,2,000000000,Geographic Locations,NA
5414,28386035,2,sbp,Blood Pressure,D001794,NA,0,1132,any,2,000000000,Blood Pressure,NA
5415,28386035,2,sex,Gender Identity,D005783,NA,0,1132,any,2,000000000,Gender Identity,NA
5416,28386035,2,Smoker,Cigarette Smoking,D000073865,NA,0,1132,any,2,000000000,Cigarette Smoking,NA
5417,28386035,2,statin or ezetimibe,lipid modifying agents,NA,C10,0,1132,any,2,000000000,lipid modifying agents,NA
5418,28386035,2,vitamin k antagonist,Fibrinolytic Agents,D005343,NA,0,1132,any,2,000000000,Fibrinolytic Agents,NA
5419,28386990,1,;hba1c <8%,Glycated Hemoglobin A,D006442,NA,0,109,any,2,000000000,Glycated Hemoglobin A,NA
5420,28386990,1,;hbalc <8%,Glycated Hemoglobin A,D006442,NA,0,109,any,2,000000000,Glycated Hemoglobin A,NA
5421,28386990,1,;hbalc >8%,Glycated Hemoglobin A,D006442,NA,0,109,any,2,000000000,Glycated Hemoglobin A,NA
5422,28386990,2,T2DM Duration,Diabetes Mellitus,D003920,NA,0,1434,duration,5,001000000,Diabetes Mellitus,NA
5423,28386990,3,BMI,Body Mass Index,D015992,NA,0,1428,any,2,000000000,Body Mass Index,NA
5424,28391886,2,bmi,Body Mass Index,D015992,NA,0,1055,any,2,000000000,Body Mass Index,NA
5425,28391886,2,distance to ldl-c goal,Lipoproteins,D008074,NA,0,1055,any,2,000000000,Lipoproteins,NA
5426,28391886,2,ltt other than statin,lipid modifying agents,NA,C10,0,1055,any,2,000000000,lipid modifying agents,NA
5427,28402745,2,age at screening,Age Factors,D000367,NA,0,788,any,2,000000000,Age Factors,NA
5428,28402745,2,baseline systolic bp,Blood Pressure,D001794,NA,0,788,any,2,000000000,Blood Pressure,NA
5429,28402745,2,Coronary heart disease,Coronary Artery Disease,D003324,NA,0,788,any,2,000000000,Coronary Artery Disease,NA
5430,28402745,2,diabetes,Diabetes Mellitus,D003920,NA,0,788,any,2,000000000,Diabetes Mellitus,NA
5431,28402745,2,ejection fraction,Stroke Volume,D013318,NA,0,788,any,2,000000000,Stroke Volume,NA
5432,28402745,2,gender,Gender Identity,D005783,NA,0,788,any,2,000000000,Gender Identity,NA
5433,28402745,2,gfr as assessed by mdrd,Glomerular Filtration Rate,D005919,NA,0,788,any,2,000000000,Glomerular Filtration Rate,NA
5434,28402745,2,gfr as assessed by mdrd;<60 ml/min,Glomerular Filtration Rate,D005919,NA,0,788,any,2,000000000,Glomerular Filtration Rate,NA
5435,28402745,2,gfr as assessed by mdrd;>=60 ml/min,Glomerular Filtration Rate,D005919,NA,0,788,any,2,000000000,Glomerular Filtration Rate,NA
5436,28402745,2,history of chronic hf,Heart Failure,D006333,NA,0,788,previous,8,100000000,Heart Failure,NA
5437,28402745,2,levels of cardiac troponin,Troponin,D014336,NA,0,788,any,2,000000000,Troponin,NA
5438,28402745,2,nt-pro bnp,"Natriuretic Peptide, Brain",D020097,NA,0,788,any,2,000000000,"Natriuretic Peptide, Brain",NA
5439,28402745,2,race,Racial Groups,D044469,NA,0,788,any,2,000000000,Racial Groups,NA
5440,28402745,2,race;all others,Racial Groups,D044469,NA,0,788,any,2,000000000,Racial Groups,NA
5441,28402745,2,region,Geographic Locations,D005842,NA,0,788,any,2,000000000,Geographic Locations,NA
5442,28402745,2,time from first evaluation,"Infusions, Intravenous",D007262,NA,0,788,any,2,000000000,"Infusions, Intravenous",NA
5443,28402745,2,time from first evaluation;<=6 hrs,"Infusions, Intravenous",D007262,NA,0,788,any,2,000000000,"Infusions, Intravenous",NA
5444,28402745,2,time from first evaluation;>6 hrs,"Infusions, Intravenous",D007262,NA,0,788,any,2,000000000,"Infusions, Intravenous",NA
5445,28405473,2,background csdmard category,Antirheumatic Agents,D018501,NA,0,1536,any,2,000000000,Antirheumatic Agents,NA
5446,28405473,2,background csdmard category;mtx + other csdmards,Immunosuppressive Agents,D007166,NA,0,1536,any,2,000000000,Immunosuppressive Agents,NA
5447,28405473,2,background csdmard category;mtx + other csomards,Immunosuppressive Agents,D007166,NA,0,1536,any,2,000000000,Immunosuppressive Agents,NA
5448,28405473,2,background csdmard category;mtx + othetcsdmards,Immunosuppressive Agents,D007166,NA,0,1536,any,2,000000000,Immunosuppressive Agents,NA
5449,28405473,2,background csdmard category;mtx only,Immunosuppressive Agents,D007166,NA,0,1536,any,2,000000000,Immunosuppressive Agents,NA
5450,28405473,2,background csdmard category;non-mtx csdmards,Immunosuppressive Agents,D007166,NA,0,1536,any,2,000000000,Immunosuppressive Agents,NA
5451,28416587,2,60-80 with cv risk but not disease (n=2285),complex,none,NA,0,509,risk score,10,000000100,complex,NA
5452,28416587,2,african-american / african heritage (n=129),Racial Groups,D044469,NA,0,509,any,2,000000000,Racial Groups,NA
5453,28416587,2,african-american / african heritage (n=129);other(n=83),Racial Groups,D044469,NA,0,509,any,2,000000000,Racial Groups,NA
5454,28416587,2,age group,Age Factors,D000367,NA,0,509,any,2,000000000,Age Factors,NA
5455,28416587,2,age group;<55 years (n=824),Age Factors,D000367,NA,0,509,any,2,000000000,Age Factors,NA
5456,28416587,2,age group;>55 years to <65 years (n=2819),Age Factors,D000367,NA,0,509,any,2,000000000,Age Factors,NA
5457,28416587,2,age group;>65 years to <75 years (n=3523),Age Factors,D000367,NA,0,509,any,2,000000000,Age Factors,NA
5458,28416587,2,age group;>75 years (n=1066),Age Factors,D000367,NA,0,509,any,2,000000000,Age Factors,NA
5459,28416587,2,cv entry criteria,Cardiovascular System,D002319,NA,0,509,any,2,000000000,Cardiovascular System,NA
5460,28416587,2,cv entry criteria;40-60 with cv disease (n=1761),complex,none,NA,0,509,any,2,000000000,complex,NA
5461,28416587,2,cv entry criteria;60-80 with cv disease (n=4096),complex,none,NA,0,509,any,2,000000000,complex,NA
5462,28416587,2,ethnicity;hispanic or latino (n=588),Racial Groups,D044469,NA,0,509,any,2,000000000,Racial Groups,NA
5463,28416587,2,ethnicity;not hispanic or latino (n=7644),Racial Groups,D044469,NA,0,509,any,2,000000000,Racial Groups,NA
5464,28416587,2,gender,Gender Identity,D005783,NA,0,509,any,2,000000000,Gender Identity,NA
5465,28416587,2,gender;female (n=2049),Gender Identity,D005783,NA,0,509,any,2,000000000,Gender Identity,NA
5466,28416587,2,race,Racial Groups,D044469,NA,0,509,any,2,000000000,Racial Groups,NA
5467,28416587,2,region,Geographic Locations,D005842,NA,0,509,any,2,000000000,Geographic Locations,NA
5468,28416587,2,region;rest-of-world (n=645),Geographic Locations,D005842,NA,0,509,any,2,000000000,Geographic Locations,NA
5469,28416587,2,Smoker,Cigarette Smoking,D000073865,NA,0,509,any,2,000000000,Cigarette Smoking,NA
5470,28416587,2,smoking status;former smoker (n=4428),Cigarette Smoking,D000073865,NA,0,509,previous,8,100000000,Cigarette Smoking,NA
5471,28430947,NA,NA,unclassifiable,NA,NA,0,0,any,2,000000000,unclassifiable,46
5472,28432746,1,Glycosylated HbA1c,Glycated Hemoglobin A,D006442,NA,0,1405,any,2,000000000,Glycated Hemoglobin A,NA
5473,28432746,2,baseline glycated haemoglobin,Glycated Hemoglobin A,D006442,NA,0,1229,any,2,000000000,Glycated Hemoglobin A,NA
5474,28432746,2,body mass index,Body Mass Index,D015992,NA,0,1229,any,2,000000000,Body Mass Index,NA
5475,28432746,2,diabetes duration,Diabetes Mellitus,D003920,NA,0,1229,duration,5,001000000,Diabetes Mellitus,NA
5476,28467869,2,corticosteroid use at baseline-no,Steroids,D013256,NA,0,35,any,2,000000000,Steroids,NA
5477,28467869,2,corticosteroid use at baseline-yes,Steroids,D013256,NA,0,35,any,2,000000000,Steroids,NA
5478,28467869,2,geographic region-europe,Geographic Locations,D005842,NA,0,35,any,2,000000000,Geographic Locations,NA
5479,28467869,2,geographic region-north america,Geographic Locations,D005842,NA,0,35,any,2,000000000,Geographic Locations,NA
5480,28467869,2,geographic region-other,Geographic Locations,D005842,NA,0,35,any,2,000000000,Geographic Locations,NA
5481,28467869,2,prior tnf antagonist failure-no,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,35,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
5482,28467869,2,prior tnf antagonist failure-yes,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,35,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
5483,28467869,2,prior tnf antagonist treatment-no,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,35,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
5484,28467869,2,prior tnf antagonist treatment-yes,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,35,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
5485,28467869,3,corticosteroid use at baseline-no,Steroids,D013256,NA,0,1224,any,2,000000000,Steroids,NA
5486,28467869,3,corticosteroid use at baseline-yes,Steroids,D013256,NA,0,1224,any,2,000000000,Steroids,NA
5487,28467869,3,geographic region-europe,Geographic Locations,D005842,NA,0,1224,any,2,000000000,Geographic Locations,NA
5488,28467869,3,geographic region-north america,Geographic Locations,D005842,NA,0,1224,any,2,000000000,Geographic Locations,NA
5489,28467869,3,geographic region-other,Geographic Locations,D005842,NA,0,1224,any,2,000000000,Geographic Locations,NA
5490,28467869,3,prior tnf antagonist failure-no,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,1224,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
5491,28467869,3,prior tnf antagonist failure-yes,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,1224,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
5492,28467869,3,prior tnf antagonist treatment-no,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,1224,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
5493,28467869,3,prior tnf antagonist treatment-yes,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,1224,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
5494,28473423,2,;tnfi exposed,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,620,any,2,000000000,Tumor Necrosis Factor Inhibitors,NA
5495,28473423,2,;tnfi naive,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,620,any,2,000000000,Tumor Necrosis Factor Inhibitors,NA
5496,28498975,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,61
5497,28498975,NA,axial spondyloarthritis duration,Axial Spondyloarthritis,D000089183,NA,0,0,duration,5,001000000,Axial Spondyloarthritis,61
5498,28498975,NA,Disease-modifying antirheumatic drugs,Antirheumatic Agents,D018501,NA,0,0,any,2,000000000,Antirheumatic Agents,60
5499,28498975,NA,prior anti-TNF exposure,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,0,previous,8,100000000,Tumor Necrosis Factor Inhibitors,61
5500,28498975,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,61
5501,28531241,2,;65-74 y,Age Factors,D000367,NA,0,1485,any,2,000000000,Age Factors,NA
5502,28544533,NA,Patient Variable: Race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,40
5503,28558833,2,prior LABA and/ or LAMA use,lama,NA,R03BB,0,867,previous,8,100000000,lama,NA
5504,28558833,3,moderate copd,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,251,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
5505,28558833,3,severe copd,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,251,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
5506,28605608,2,age,Age Factors,D000367,NA,0,62,any,2,000000000,Age Factors,NA
5507,28605608,2,antithrombotic use,Platelet Aggregation Inhibitors,D010975,NA,0,62,any,2,000000000,Platelet Aggregation Inhibitors,NA
5508,28605608,2,beta-blocker use,Adrenergic beta-Antagonists,D000319,NA,0,62,any,2,000000000,Adrenergic beta-Antagonists,NA
5509,28605608,2,blood pressure control,Blood Pressure,D001794,NA,0,62,any,2,000000000,Blood Pressure,NA
5510,28605608,2,blood pressure control;systolic blood pressure <140 mm hg and diastolic blood pressure <90 mm hg,Blood Pressure,D001794,NA,0,62,any,2,000000000,Blood Pressure,NA
5511,28605608,2,blood pressure control;systolic blood pressure >140 mm hg or diastolic blood pressure >90 mm hg,Blood Pressure,D001794,NA,0,62,any,2,000000000,Blood Pressure,NA
5512,28605608,2,bmi,Body Mass Index,D015992,NA,0,62,any,2,000000000,Body Mass Index,NA
5513,28605608,2,diuretic use,Diuretics,D004232,NA,0,62,any,2,000000000,Diuretics,NA
5514,28605608,2,duration of diabetes,Diabetes Mellitus,D003920,NA,0,62,duration,5,001000000,Diabetes Mellitus,NA
5515,28605608,2,egfr,Glomerular Filtration Rate,D005919,NA,0,62,any,2,000000000,Glomerular Filtration Rate,NA
5516,28605608,2,glycated hemoglobin,Glycated Hemoglobin A,D006442,NA,0,62,any,2,000000000,Glycated Hemoglobin A,NA
5517,28605608,2,history of amputation,Amputation,D000671,NA,0,62,previous,8,100000000,Amputation,NA
5518,28605608,2,history of heart failure,Heart Failure,D006333,NA,0,62,any,2,000000000,Heart Failure,NA
5519,28605608,2,history of peripheral vascular disease,Peripheral Vascular Diseases,D016491,NA,0,62,previous,8,100000000,Peripheral Vascular Diseases,NA
5520,28605608,2,Insulin glargine,Insulin,D007328,NA,0,62,any,2,000000000,Insulin,NA
5521,28605608,2,Prior CVD,Cardiovascular Diseases,D002318,NA,0,62,previous,8,100000000,Cardiovascular Diseases,NA
5522,28605608,2,raas inhibitor use,agents acting on the renin-angiotensin system,NA,C09,0,62,any,2,000000000,agents acting on the renin-angiotensin system,NA
5523,28605608,2,race,Racial Groups,D044469,NA,0,62,any,2,000000000,Racial Groups,NA
5524,28605608,2,region,Geographic Locations,D005842,NA,0,62,any,2,000000000,Geographic Locations,NA
5525,28605608,2,region;rest of the world,Geographic Locations,D005842,NA,0,62,any,2,000000000,Geographic Locations,NA
5526,28605608,2,sex,Gender Identity,D005783,NA,0,62,any,2,000000000,Gender Identity,NA
5527,28605608,2,statin use,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,62,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
5528,28605608,2,study;canvas,unclassifiable,none,NA,0,62,any,2,000000000,unclassifiable,NA
5529,28636754,NA,hba1c,Glycated Hemoglobin A,D006442,NA,0,0,any,2,000000000,Glycated Hemoglobin A,224
5530,28636754,NA,region,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,NA
5531,28636754,NA,urinary albumin to creatinine ratio,Albuminuria,D000419,NA,0,0,any,2,000000000,Albuminuria,NA
5532,28637881,NA,Patient Variable: Physical Activity Level,Exercise,D015444,NA,0,0,any,2,000000000,Exercise,26
5533,28666775,2,;patients with macroalbuminuria at baseline,Proteinuria,D011507,NA,0,766,any,2,000000000,Proteinuria,NA
5534,28666775,2,;patients with microalbuminuria at baseline,Proteinuria,D011507,NA,0,766,any,2,000000000,Proteinuria,NA
5535,28666775,2,;patients with normoalbuminuria at baseline,Albuminuria,D000419,NA,0,766,any,2,000000000,Albuminuria,NA
5536,28666775,3,;uric acid tertile 1 (<5.2 mg/dl),Uric Acid,D014527,NA,0,868,any,2,000000000,Uric Acid,NA
5537,28666775,3,;uric acid tertile 2 (5.2 to <6.51 mg/dl),Uric Acid,D014527,NA,0,868,any,2,000000000,Uric Acid,NA
5538,28666775,3,;uric acid tertile 3 (>6.51 mg/dl),Uric Acid,D014527,NA,0,868,any,2,000000000,Uric Acid,NA
5539,28679611,NA,Medical History: Prior Hospitalisation,Patient Admission,D010343,NA,0,0,previous,8,100000000,Patient Admission,58
5540,28720132,2,;current,Cigarette Smoking,D000073865,NA,0,338,current,3,010000000,Cigarette Smoking,NA
5541,28720132,2,age,Age Factors,D000367,NA,0,338,any,2,000000000,Age Factors,NA
5542,28720132,2,baseline therapy;form/bud,Steroids,D013256,NA,0,338,any,2,000000000,Steroids,NA
5543,28720132,2,exacerbations in the previous year,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,338,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5544,28720132,2,Smoker,Cigarette Smoking,D000073865,NA,0,338,any,2,000000000,Cigarette Smoking,NA
5545,28720132,2,smoking status;current,Cigarette Smoking,D000073865,NA,0,338,current,3,010000000,Cigarette Smoking,NA
5546,28720132,3,;current,Cigarette Smoking,D000073865,NA,0,657,current,3,010000000,Cigarette Smoking,NA
5547,28720132,3,age,Age Factors,D000367,NA,0,657,any,2,000000000,Age Factors,NA
5548,28720132,3,"age, years",Age Factors,D000367,NA,0,657,any,2,000000000,Age Factors,NA
5549,28720132,3,"age, years;<75",Age Factors,D000367,NA,0,657,any,2,000000000,Age Factors,NA
5550,28720132,3,"age, years;265",Age Factors,D000367,NA,0,657,any,2,000000000,Age Factors,NA
5551,28720132,3,"age, years;275",Age Factors,D000367,NA,0,657,any,2,000000000,Age Factors,NA
5552,28720132,3,baseline therapy;laba,long-acting beta agonist,NA,R03A,0,657,any,2,000000000,long-acting beta agonist,NA
5553,28720132,3,exacerbations in the previous year,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,657,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
5554,28720132,3,"fev, at baseline",Pulmonary Ventilation,D012123,NA,0,657,any,2,000000000,Pulmonary Ventilation,NA
5555,28720132,3,mmrc at baseline,Dyspnea,D004417,NA,0,657,severity,11,000100000,Dyspnea,NA
5556,28720132,3,sex,Gender Identity,D005783,NA,0,657,any,2,000000000,Gender Identity,NA
5557,28720132,3,Smoker,Cigarette Smoking,D000073865,NA,0,657,any,2,000000000,Cigarette Smoking,NA
5558,28720132,3,smoking status;current,Cigarette Smoking,D000073865,NA,0,657,current,3,010000000,Cigarette Smoking,NA
5559,28720336,2,cat >= 10,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1353,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
5560,28720336,2,cat >=15,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1353,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
5561,28720336,2,cat >=20,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1353,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
5562,28753486,2,BMI,Body Mass Index,D015992,NA,0,1230,any,2,000000000,Body Mass Index,NA
5563,28753486,3,Age,Age Factors,D000367,NA,0,45,any,2,000000000,Age Factors,NA
5564,28801539,3,age <75 years (n=,Age Factors,D000367,NA,0,604,any,2,000000000,Age Factors,NA
5565,28801539,3,age <75 years (n=8932),Age Factors,D000367,NA,0,604,any,2,000000000,Age Factors,NA
5566,28801539,3,age >75 years (n=2010),Age Factors,D000367,NA,0,604,any,2,000000000,Age Factors,NA
5567,28801539,4,age <75 years (n=,Age Factors,D000367,NA,0,1809,any,2,000000000,Age Factors,NA
5568,28801539,4,age <75 years (n=8932),Age Factors,D000367,NA,0,1809,any,2,000000000,Age Factors,NA
5569,28801539,4,age >75 years (n=2010),Age Factors,D000367,NA,0,1809,any,2,000000000,Age Factors,NA
5570,28801539,5,age <75 years (n=,Age Factors,D000367,NA,0,1117,any,2,000000000,Age Factors,NA
5571,28801539,5,age <75 years (n=8932),Age Factors,D000367,NA,0,1117,any,2,000000000,Age Factors,NA
5572,28801539,5,age >75 years (n=2010),Age Factors,D000367,NA,0,1117,any,2,000000000,Age Factors,NA
5573,28818881,2,ctd population subgroup,Connective Tissue Diseases,D003240,NA,0,1148,any,2,000000000,Connective Tissue Diseases,NA
5574,28818881,2,ctd population subgroup;pah-sleÂ systemic lupus erythematosus,"Lupus Erythematosus, Systemic",D008180,NA,0,1148,any,2,000000000,"Lupus Erythematosus, Systemic",NA
5575,28818881,2,overall ctd,Connective Tissue Diseases,D003240,NA,0,1148,any,2,000000000,Connective Tissue Diseases,NA
5576,28818881,2,pah therapy at baseline,cardiac therapy,NA,C01,0,1148,any,2,000000000,cardiac therapy,NA
5577,28818881,2,pah therapy at baseline;era and pde-5i,cardiac therapy,NA,C01,0,1148,any,2,000000000,cardiac therapy,NA
5578,28818881,2,pah therapy at baseline;era monotherapy,cardiac therapy,NA,C01,0,1148,any,2,000000000,cardiac therapy,NA
5579,28818881,2,pah therapy at baseline;pde-5i monotherapy,cardiac therapy,NA,C01,0,1148,any,2,000000000,cardiac therapy,NA
5580,28818881,2,pooled pah-mctd and pah,complex,none,NA,0,1148,any,2,000000000,complex,NA
5581,28838685,NA,background LABA use,Adrenal Cortex Hormones,D000305,R03,0,0,any,2,000000000,Adrenal Cortex Hormones,209
5582,28842165,2,ckd rate (#events),Renal Insufficiency,D051437,NA,0,971,previous,8,100000000,Renal Insufficiency,NA
5583,28842165,2,no ckd rate (#events),Renal Insufficiency,D051437,NA,0,971,previous,8,100000000,Renal Insufficiency,NA
5584,28842165,3,age;< 65 yrs,Age Factors,D000367,NA,0,942,any,2,000000000,Age Factors,NA
5585,28842165,3,age;65 yrs or more,Age Factors,D000367,NA,0,942,any,2,000000000,Age Factors,NA
5586,28842165,3,dcct a1c,Glycated Hemoglobin A,D006442,NA,0,942,any,2,000000000,Glycated Hemoglobin A,NA
5587,28842165,3,diabetes melitus,Diabetes Mellitus,D003920,NA,0,942,any,2,000000000,Diabetes Mellitus,NA
5588,28842165,3,Hypertension,Hypertension,D006973,NA,0,942,any,2,000000000,Hypertension,NA
5589,28842165,3,previous cv event,Cardiovascular Diseases,D002318,NA,0,942,previous,8,100000000,Cardiovascular Diseases,NA
5590,28842165,3,race,Racial Groups,D044469,NA,0,942,any,2,000000000,Racial Groups,NA
5591,28842165,3,race;non white,Racial Groups,D044469,NA,0,942,any,2,000000000,Racial Groups,NA
5592,28842165,3,sex,Gender Identity,D005783,NA,0,942,any,2,000000000,Gender Identity,NA
5593,28842165,3,treatment glargine,Insulin,D007328,NA,0,942,any,2,000000000,Insulin,NA
5594,28844192,2,age,Age Factors,D000367,NA,0,1236,any,2,000000000,Age Factors,NA
5595,28844192,2,baseline diabetes,Diabetes Mellitus,D003920,NA,0,1236,any,2,000000000,Diabetes Mellitus,NA
5596,28844192,2,baseline dyslipidemia,Dyslipidemias,D050171,NA,0,1236,any,2,000000000,Dyslipidemias,NA
5597,28844192,2,baseline tobacco use,Cigarette Smoking,D000073865,NA,0,1236,any,2,000000000,Cigarette Smoking,NA
5598,28844192,2,body weight,Body Weight,D001835,NA,0,1236,any,2,000000000,Body Weight,NA
5599,28844192,2,coronary artery disease,Coronary Artery Disease,D003324,NA,0,1236,any,2,000000000,Coronary Artery Disease,NA
5600,28844192,2,estimated gfr,Glomerular Filtration Rate,D005919,NA,0,1236,any,2,000000000,Glomerular Filtration Rate,NA
5601,28844192,2,geographic region,Geographic Locations,D005842,NA,0,1236,any,2,000000000,Geographic Locations,NA
5602,28844192,2,history of hypertension,Hypertension,D006973,NA,0,1236,previous,8,100000000,Hypertension,NA
5603,28844192,2,peripheral arterial disease,Peripheral Vascular Diseases,D016491,NA,0,1236,any,2,000000000,Peripheral Vascular Diseases,NA
5604,28844192,2,race,Racial Groups,D044469,NA,0,1236,any,2,000000000,Racial Groups,NA
5605,28844192,2,sex,Gender Identity,D005783,NA,0,1236,any,2,000000000,Gender Identity,NA
5606,28844508,2,diabetes,Diabetes Mellitus,D003920,NA,0,1205,any,2,000000000,Diabetes Mellitus,NA
5607,28844508,2,high risk for diabetes*,Diabetes Mellitus,D003920,NA,0,1205,risk score,10,000000100,Diabetes Mellitus,NA
5608,28844508,2,high risk of diabetes,Diabetes Mellitus,D003920,NA,0,1205,risk score,10,000000100,Diabetes Mellitus,NA
5609,28844508,2,no diabetes,Diabetes Mellitus,D003920,NA,0,1205,any,2,000000000,Diabetes Mellitus,NA
5610,28844508,3,diabetes,Diabetes Mellitus,D003920,NA,0,1399,any,2,000000000,Diabetes Mellitus,NA
5611,28844508,3,high risk for diabetes*,Diabetes Mellitus,D003920,NA,0,1399,risk score,10,000000100,Diabetes Mellitus,NA
5612,28844508,3,high risk of diabetes,Diabetes Mellitus,D003920,NA,0,1399,risk score,10,000000100,Diabetes Mellitus,NA
5613,28844508,3,no diabetes,Diabetes Mellitus,D003920,NA,0,1399,any,2,000000000,Diabetes Mellitus,NA
5614,28844508,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,21
5615,28844990,2,age at randomization (years),Age Factors,D000367,NA,0,1649,any,2,000000000,Age Factors,NA
5616,28844990,2,diabetes,Diabetes Mellitus,D003920,NA,0,1649,any,2,000000000,Diabetes Mellitus,NA
5617,28844990,2,Hypertension,Hypertension,D006973,NA,0,1649,any,2,000000000,Hypertension,NA
5618,28844990,2,killip class,Heart Failure,D006333,NA,0,1649,severity,11,000100000,Heart Failure,NA
5619,28844990,2,killip class;i,Heart Failure,D006333,NA,0,1649,severity,11,000100000,Heart Failure,NA
5620,28844990,2,male female,Gender Identity,D005783,NA,0,1649,any,2,000000000,Gender Identity,NA
5621,28844990,2,systolic blood pressure,Blood Pressure,D001794,NA,0,1649,any,2,000000000,Blood Pressure,NA
5622,28844990,2,weight,Body Weight,D001835,NA,0,1649,any,2,000000000,Body Weight,NA
5623,28847206,2,age at randomization (years),Age Factors,D000367,NA,0,698,any,2,000000000,Age Factors,NA
5624,28847206,2,albuminuria,Albuminuria,D000419,NA,0,698,any,2,000000000,Albuminuria,NA
5625,28847206,2,alcohol intake,Alcohol Drinking,D000428,NA,0,698,any,2,000000000,Alcohol Drinking,NA
5626,28847206,2,alcohol intake;current drinker,Alcohol Drinking,D000428,NA,0,698,current,3,010000000,Alcohol Drinking,NA
5627,28847206,2,alcohol intake;former/non-drinker,Alcohol Drinking,D000428,NA,0,698,previous,8,100000000,Alcohol Drinking,NA
5628,28847206,2,apolipoprotein a1 (mg/dl),Apolipoprotein A-I,D016632,NA,0,698,any,2,000000000,Apolipoprotein A-I,NA
5629,28847206,2,apolipoprotein b (mg/dl),Apolipoprotein A-I,D016632,NA,0,698,any,2,000000000,Apolipoprotein A-I,NA
5630,28847206,2,atorvastatin dose,Atorvastatin,D000069059,NA,0,698,any,2,000000000,Atorvastatin,NA
5631,28847206,2,body mass index (kg/m1),Body Mass Index,D015992,NA,0,698,any,2,000000000,Body Mass Index,NA
5632,28847206,2,diastolic blood pressure (mmhg),Blood Pressure,D001794,NA,0,698,any,2,000000000,Blood Pressure,NA
5633,28847206,2,gender,Gender Identity,D005783,NA,0,698,any,2,000000000,Gender Identity,NA
5634,28847206,2,"Glomerular Filtration Rate (ml/min/1.73ma,",Glomerular Filtration Rate,D005919,NA,0,698,any,2,000000000,Glomerular Filtration Rate,NA
5635,28847206,2,HDL cholesterol,Lipoproteins,D008074,NA,0,698,any,2,000000000,Lipoproteins,NA
5636,28847206,2,ldl cholesterol (mg/dl),Lipoproteins,D008074,NA,0,698,any,2,000000000,Lipoproteins,NA
5637,28847206,2,lipoprotein (a) (nmol/l),Lipoproteins,D008074,NA,0,698,any,2,000000000,Lipoproteins,NA
5638,28847206,2,medication;ace inhibitor or arb,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,698,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
5639,28847206,2,medication;anti platelet therapy,Platelet Aggregation Inhibitors,D010975,NA,0,698,any,2,000000000,Platelet Aggregation Inhibitors,NA
5640,28847206,2,medication;beta-blocker,Adrenergic beta-Antagonists,D000319,NA,0,698,any,2,000000000,Adrenergic beta-Antagonists,NA
5641,28847206,2,medication;calcium channel blocker,Calcium Channel Blockers,D002121,NA,0,698,any,2,000000000,Calcium Channel Blockers,NA
5642,28847206,2,medication;diuretic,Diuretics,D004232,NA,0,698,any,2,000000000,Diuretics,NA
5643,28847206,2,Peripheral artery disease Yes No,Peripheral Vascular Diseases,D016491,NA,0,698,any,2,000000000,Peripheral Vascular Diseases,NA
5644,28847206,2,prior disease,Peripheral Vascular Diseases,D016491,NA,0,698,previous,8,100000000,Peripheral Vascular Diseases,NA
5645,28847206,2,prior disease;cerebrovascular disease,Stroke,D020521,NA,0,698,previous,8,100000000,Stroke,NA
5646,28847206,2,prior disease;coronary heart disease,Coronary Artery Disease,D003324,NA,0,698,previous,8,100000000,Coronary Artery Disease,NA
5647,28847206,2,prior disease;diabetes,Diabetes Mellitus,D003920,NA,0,698,previous,8,100000000,Diabetes Mellitus,NA
5648,28847206,2,prior disease;heart failure,Heart Failure,D006333,NA,0,698,previous,8,100000000,Heart Failure,NA
5649,28847206,2,region,Geographic Locations,D005842,NA,0,698,any,2,000000000,Geographic Locations,NA
5650,28847206,2,Smoker,Cigarette Smoking,D000073865,NA,0,698,any,2,000000000,Cigarette Smoking,NA
5651,28847206,2,systolic blood pressure (mmhg),Blood Pressure,D001794,NA,0,698,any,2,000000000,Blood Pressure,NA
5652,28847206,2,total cholesterol (mg/dl),Lipoproteins,D008074,NA,0,698,any,2,000000000,Lipoproteins,NA
5653,28847206,2,triglycerides (mg/dl),Lipoproteins,D008074,NA,0,698,any,2,000000000,Lipoproteins,NA
5654,28847206,2,urinary albumimcreatinine ratio;macro-albuminuria,Albuminuria,D000419,NA,0,698,any,2,000000000,Albuminuria,NA
5655,28847206,2,urinary albumimcreatinine ratio;micro-albuminuria,Albuminuria,D000419,NA,0,698,any,2,000000000,Albuminuria,NA
5656,28847206,2,waisthip ratio,Waist-Hip Ratio,D049629,NA,0,698,any,2,000000000,Waist-Hip Ratio,NA
5657,28848879,2,age,Age Factors,D000367,NA,0,1839,any,2,000000000,Age Factors,NA
5658,28848879,2,gold 2,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1839,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
5659,28848879,2,gold 3,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1839,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
5660,28848879,2,ics use no,Steroids,D013256,NA,0,1839,any,2,000000000,Steroids,NA
5661,28848879,2,male female,Gender Identity,D005783,NA,0,1839,any,2,000000000,Gender Identity,NA
5662,28848879,2,Smoker,Cigarette Smoking,D000073865,NA,0,1839,any,2,000000000,Cigarette Smoking,NA
5663,28854085,2,combined estimated gfr and albuminuria status,Albuminuria,D000419,NA,0,905,any,2,000000000,Albuminuria,NA
5664,28854085,2,combined estimated gfr and albuminuria status;estimated gfr <60 ml/min/1.73 m2Â and microalbuminuria or macroalbuminuria,Glomerular Filtration Rate,D005919,NA,0,905,any,2,000000000,Glomerular Filtration Rate,NA
5665,28854085,2,combined estimated gfr and albuminuria status;estimated gfr >60 ml/min/1.73 m2Â or no microalbuminuria or macroalbuminuria,Glomerular Filtration Rate,D005919,NA,0,905,any,2,000000000,Glomerular Filtration Rate,NA
5666,28854085,2,estimated gfr,Glomerular Filtration Rate,D005919,NA,0,905,any,2,000000000,Glomerular Filtration Rate,NA
5667,28854085,2,microalbuminuria or macroalbuminuria,Albuminuria,D000419,NA,0,905,any,2,000000000,Albuminuria,NA
5668,28877027,2,;cat<10,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,516,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
5669,28877027,2,;cat>10,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,516,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
5670,28879052,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,1
5671,28882235,3,by Time from MI at randomisation,Myocardial Infarction,D009203,NA,0,112,any,2,000000000,Myocardial Infarction,NA
5672,28893134,NA,blood eosinophil count,Eosinophilia,D004802,NA,0,0,any,2,000000000,Eosinophilia,174
5673,28899222,2,patients who did not use insulin pump,Insulin,D007328,NA,0,1264,any,2,000000000,Insulin,NA
5674,28899222,2,patients who used insulin pump,Insulin,D007328,NA,0,1264,any,2,000000000,Insulin,NA
5675,28902593,2,age at randomisation,Age Factors,D000367,NA,0,707,any,2,000000000,Age Factors,NA
5676,28902593,2,age at randomisation;<44.6,Age Factors,D000367,NA,0,707,any,2,000000000,Age Factors,NA
5677,28902593,2,gender,Gender Identity,D005783,NA,0,707,any,2,000000000,Gender Identity,NA
5678,28902593,2,history of cv disease,Cardiovascular Diseases,D002318,NA,0,707,previous,8,100000000,Cardiovascular Diseases,NA
5679,28902593,2,patent foramen ovale,"Foramen Ovale, Patent",D054092,NA,0,707,any,2,000000000,"Foramen Ovale, Patent",NA
5680,28902593,2,patent foramen ovale;large shunt,Cardiovascular Abnormalities,D018376,NA,0,707,any,2,000000000,Cardiovascular Abnormalities,NA
5681,28902593,2,rope score,Stroke,D020521,NA,1,707,type,12,000000010,Stroke,NA
5682,28903864,2,ACT total score at baseline,Asthma,D001249,NA,0,949,severity,11,000100000,Asthma,NA
5683,28903864,2,Asthma maintenance therapy at baseline,Asthma,D001249,NA,0,949,any,2,000000000,Asthma,NA
5684,28903864,2,Asthma symptoms at baseline,Asthma,D001249,NA,0,949,any,2,000000000,Asthma,NA
5685,28903864,2,number of asthma exacerbations in past 1 year,Asthma,D001249,NA,0,949,previous severity,9,100100000,Asthma,NA
5686,28904068,2,;patients with egfr <60 ml/min/1.73m2 at baseline,Glomerular Filtration Rate,D005919,NA,0,1215,any,2,000000000,Glomerular Filtration Rate,NA
5687,28904068,2,;patients with egfr >60 ml/min/1.73m2 at baseline,Glomerular Filtration Rate,D005919,NA,0,1215,any,2,000000000,Glomerular Filtration Rate,NA
5688,28905478,2,;t1d,Diabetes Mellitus,D003920,NA,0,1705,type,12,000000010,Diabetes Mellitus,NA
5689,28905478,2,;t2d,Diabetes Mellitus,D003920,NA,0,1705,type,12,000000010,Diabetes Mellitus,NA
5690,28905478,3,age,Age Factors,D000367,NA,0,850,any,2,000000000,Age Factors,NA
5691,28905478,3,age in 2 classes;<65 years,Age Factors,D000367,NA,0,850,severity,11,000100000,Age Factors,NA
5692,28905478,3,age in 2 classes;=65 years,Age Factors,D000367,NA,0,850,severity,11,000100000,Age Factors,NA
5693,28905478,3,age in 2 classes;Ã¢â€°Â¥65 years,Age Factors,D000367,NA,0,850,severity,11,000100000,Age Factors,NA
5694,28905478,3,age in 3 classes;<65 years,Age Factors,D000367,NA,0,850,severity,11,000100000,Age Factors,NA
5695,28905478,3,age in 3 classes;=65 to <75 years,Age Factors,D000367,NA,0,850,severity,11,000100000,Age Factors,NA
5696,28905478,3,age in 3 classes;Ã¢â€°Â¥65 to <75 years,Age Factors,D000367,NA,0,850,severity,11,000100000,Age Factors,NA
5697,28905478,3,albuminuria,Albuminuria,D000419,NA,0,850,any,2,000000000,Albuminuria,NA
5698,28905478,3,any statin versus no statin at randomization,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,850,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
5699,28905478,3,any statin versus no statin at randomization;any statin (with/without llt),Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,850,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
5700,28905478,3,any statin versus no statin at randomization;no statin,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,850,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
5701,28905478,3,ascvd as per protocol,Cardiovascular Diseases,D002318,NA,0,850,any,2,000000000,Cardiovascular Diseases,NA
5702,28905478,3,ascvd including tia,Cardiovascular Diseases,D002318,NA,0,850,any,2,000000000,Cardiovascular Diseases,NA
5703,28905478,3,baseline albumin/creatinine ratio in 3 classes;=30 to <300 mg/g,Albuminuria,D000419,NA,0,850,severity,11,000100000,Albuminuria,NA
5704,28905478,3,baseline albumin/creatinine ratio in 3 classes;=300 mg/g,Albuminuria,D000419,NA,0,850,severity,11,000100000,Albuminuria,NA
5705,28905478,3,baseline albumin/creatinine ratio in 3 classes;Ã¢â€°Â¥30 to <300 mg/g,Albuminuria,D000419,NA,0,850,severity,11,000100000,Albuminuria,NA
5706,28905478,3,baseline albumin/creatinine ratio in 3 classes;Ã¢â€°Â¥300 mg/g,Albuminuria,D000419,NA,0,850,severity,11,000100000,Albuminuria,NA
5707,28905478,3,baseline free pcsk9 level by median,Proprotein Convertases,D043484,NA,0,850,any,2,000000000,Proprotein Convertases,NA
5708,28905478,3,baseline free pcsk9 level by median;<242 ng/ml,Proprotein Convertases,D043484,NA,0,850,any,2,000000000,Proprotein Convertases,NA
5709,28905478,3,baseline free pcsk9 level by median;=242 ng/ml,Proprotein Convertases,D043484,NA,0,850,any,2,000000000,Proprotein Convertases,NA
5710,28905478,3,baseline free pcsk9 level by median;Ã¢â€°Â¥242 ng/ml,Proprotein Convertases,D043484,NA,0,850,any,2,000000000,Proprotein Convertases,NA
5711,28905478,3,baseline hba1c in 3 classes,Glycated Hemoglobin A,D006442,NA,0,850,severity,11,000100000,Glycated Hemoglobin A,NA
5712,28905478,3,baseline hba1c in 3 classes;<7 %,Glycated Hemoglobin A,D006442,NA,0,850,severity,11,000100000,Glycated Hemoglobin A,NA
5713,28905478,3,baseline hba1c in 3 classes;=9%,Glycated Hemoglobin A,D006442,NA,0,850,severity,11,000100000,Glycated Hemoglobin A,NA
5714,28905478,3,baseline hba1c in 3 classes;Ã¢â€°Â¥9%,Glycated Hemoglobin A,D006442,NA,0,850,severity,11,000100000,Glycated Hemoglobin A,NA
5715,28905478,3,baseline hdl-c in 2 classes,Lipoproteins,D008074,NA,0,850,severity,11,000100000,Lipoproteins,NA
5716,28905478,3,baseline hdl-c in 2 classes;high hdl-c (for men Ã¢â€°Â¥40Ã‚Â mg/dl / for women Ã¢â€°Â¥50Ã‚Â mg/dl),Lipoproteins,D008074,NA,0,850,severity,11,000100000,Lipoproteins,NA
5717,28905478,3,baseline hdl-c in 2 classes;low hdl-c (for men <40Â mg/dl / for women <50Â mg/dl),complex,none,NA,0,850,severity,11,000100000,complex,NA
5718,28905478,3,baseline insulin daily dose/kg,Insulin,D007328,NA,0,850,any,2,000000000,Insulin,NA
5719,28905478,3,baseline insulin daily dose/kg;=1 u/kg/day,Insulin,D007328,NA,0,850,any,2,000000000,Insulin,NA
5720,28905478,3,baseline insulin daily dose/kg;>1 u/kg/day,Insulin,D007328,NA,0,850,any,2,000000000,Insulin,NA
5721,28905478,3,baseline insulin daily dose/kg;Ã¢â€°Â¤1 u/kg/day,Insulin,D007328,NA,0,850,any,2,000000000,Insulin,NA
5722,28905478,3,baseline lp(a) in 2 classes,Lipoproteins,D008074,NA,0,850,severity,11,000100000,Lipoproteins,NA
5723,28905478,3,baseline lp(a) in 2 classes;<30 mg/dl,Lipoproteins,D008074,NA,0,850,severity,11,000100000,Lipoproteins,NA
5724,28905478,3,baseline lp(a) in 2 classes;=30 mg/dl,Lipoproteins,D008074,NA,0,850,severity,11,000100000,Lipoproteins,NA
5725,28905478,3,baseline lp(a) in 2 classes;Ã¢â€°Â¥30 mg/dl,Lipoproteins,D008074,NA,0,850,severity,11,000100000,Lipoproteins,NA
5726,28905478,3,baseline lp(a) in 3 classes,Lipoproteins,D008074,NA,0,850,severity,11,000100000,Lipoproteins,NA
5727,28905478,3,baseline lp(a) in 3 classes;<30 mg/dl,Lipoproteins,D008074,NA,0,850,severity,11,000100000,Lipoproteins,NA
5728,28905478,3,baseline lp(a) in 3 classes;=30 to <50 mg/dl,Lipoproteins,D008074,NA,0,850,severity,11,000100000,Lipoproteins,NA
5729,28905478,3,baseline lp(a) in 3 classes;=50 mg/dl,Lipoproteins,D008074,NA,0,850,severity,11,000100000,Lipoproteins,NA
5730,28905478,3,baseline lp(a) in 3 classes;Ã¢â€°Â¥30 to <50 mg/dl,Lipoproteins,D008074,NA,0,850,severity,11,000100000,Lipoproteins,NA
5731,28905478,3,baseline lp(a) in 3 classes;Ã¢â€°Â¥50 mg/dl,Lipoproteins,D008074,NA,0,850,severity,11,000100000,Lipoproteins,NA
5732,28905478,3,baseline total pcsk9 level by median,Proprotein Convertases,D043484,NA,0,850,any,2,000000000,Proprotein Convertases,NA
5733,28905478,3,baseline total pcsk9 level by median;<508 ng/ml,Proprotein Convertases,D043484,NA,0,850,any,2,000000000,Proprotein Convertases,NA
5734,28905478,3,baseline total pcsk9 level by median;=508 ng/ml,Proprotein Convertases,D043484,NA,0,850,any,2,000000000,Proprotein Convertases,NA
5735,28905478,3,baseline total pcsk9 level by median;Ã¢â€°Â¥508 ng/ml,Proprotein Convertases,D043484,NA,0,850,any,2,000000000,Proprotein Convertases,NA
5736,28905478,3,baseline triglycerides by quintiles,Lipoproteins,D008074,NA,0,850,any,2,000000000,Lipoproteins,NA
5737,28905478,3,baseline triglycerides by quintiles;<97 mg/dl,Lipoproteins,D008074,NA,0,850,any,2,000000000,Lipoproteins,NA
5738,28905478,3,baseline triglycerides by quintiles;=133 to <165 mg/dl,Lipoproteins,D008074,NA,0,850,any,2,000000000,Lipoproteins,NA
5739,28905478,3,baseline triglycerides by quintiles;=165 to <226 mg/dl,Lipoproteins,D008074,NA,0,850,any,2,000000000,Lipoproteins,NA
5740,28905478,3,baseline triglycerides by quintiles;=226 mg/dl,Lipoproteins,D008074,NA,0,850,any,2,000000000,Lipoproteins,NA
5741,28905478,3,baseline triglycerides by quintiles;=97 to <133 mg/dl,Lipoproteins,D008074,NA,0,850,any,2,000000000,Lipoproteins,NA
5742,28905478,3,baseline triglycerides by quintiles;Ã¢â€°Â¥133 to <165 mg/dl,Lipoproteins,D008074,NA,0,850,any,2,000000000,Lipoproteins,NA
5743,28905478,3,baseline triglycerides by quintiles;Ã¢â€°Â¥165 to <226 mg/dl,Lipoproteins,D008074,NA,0,850,any,2,000000000,Lipoproteins,NA
5744,28905478,3,baseline triglycerides by quintiles;Ã¢â€°Â¥226 mg/dl,Lipoproteins,D008074,NA,0,850,any,2,000000000,Lipoproteins,NA
5745,28905478,3,baseline triglycerides by quintiles;Ã¢â€°Â¥97 to <133 mg/dl,Lipoproteins,D008074,NA,0,850,any,2,000000000,Lipoproteins,NA
5746,28905478,3,baseline triglycerides in 2 classes,Lipoproteins,D008074,NA,0,850,severity,11,000100000,Lipoproteins,NA
5747,28905478,3,baseline triglycerides in 2 classes;<150 mg/dl,Lipoproteins,D008074,NA,0,850,severity,11,000100000,Lipoproteins,NA
5748,28905478,3,baseline triglycerides in 2 classes;=150 mg/dl,Lipoproteins,D008074,NA,0,850,severity,11,000100000,Lipoproteins,NA
5749,28905478,3,baseline triglycerides in 2 classes;Ã¢â€°Â¥150 mg/dl,Lipoproteins,D008074,NA,0,850,severity,11,000100000,Lipoproteins,NA
5750,28905478,3,baseline triglycerides in 3 classes,Lipoproteins,D008074,NA,0,850,severity,11,000100000,Lipoproteins,NA
5751,28905478,3,baseline triglycerides in 3 classes;<150 mg/dl,Lipoproteins,D008074,NA,0,850,severity,11,000100000,Lipoproteins,NA
5752,28905478,3,baseline triglycerides in 3 classes;=150 to <200 mg/dl,Lipoproteins,D008074,NA,0,850,severity,11,000100000,Lipoproteins,NA
5753,28905478,3,baseline triglycerides in 3 classes;=200 mg/dl,Lipoproteins,D008074,NA,0,850,severity,11,000100000,Lipoproteins,NA
5754,28905478,3,baseline triglycerides in 3 classes;Ã¢â€°Â¥150 to <200 mg/dl,Lipoproteins,D008074,NA,0,850,severity,11,000100000,Lipoproteins,NA
5755,28905478,3,baseline triglycerides in 3 classes;Ã¢â€°Â¥200 mg/dl,Lipoproteins,D008074,NA,0,850,severity,11,000100000,Lipoproteins,NA
5756,28905478,3,BMI,Body Mass Index,D015992,NA,0,850,any,2,000000000,Body Mass Index,NA
5757,28905478,3,calculated ldl-c in 4 classes,Lipoproteins,D008074,NA,0,850,severity,11,000100000,Lipoproteins,NA
5758,28905478,3,calculated ldl-c in 4 classes;<100 mg/dl,Lipoproteins,D008074,NA,0,850,severity,11,000100000,Lipoproteins,NA
5759,28905478,3,calculated ldl-c in 4 classes;=100 to <130 mg/dl,Lipoproteins,D008074,NA,0,850,severity,11,000100000,Lipoproteins,NA
5760,28905478,3,calculated ldl-c in 4 classes;=130 to <160 mg/dl,Lipoproteins,D008074,NA,0,850,severity,11,000100000,Lipoproteins,NA
5761,28905478,3,calculated ldl-c in 4 classes;=160 mg/dl,Lipoproteins,D008074,NA,0,850,severity,11,000100000,Lipoproteins,NA
5762,28905478,3,calculated ldl-c in 4 classes;Ã¢â€°Â¥100 to <130 mg/dl,Lipoproteins,D008074,NA,0,850,severity,11,000100000,Lipoproteins,NA
5763,28905478,3,calculated ldl-c in 4 classes;Ã¢â€°Â¥130 to <160 mg/dl,Lipoproteins,D008074,NA,0,850,severity,11,000100000,Lipoproteins,NA
5764,28905478,3,calculated ldl-c in 4 classes;Ã¢â€°Â¥160 mg/dl,Lipoproteins,D008074,NA,0,850,severity,11,000100000,Lipoproteins,NA
5765,28905478,3,ckd,Renal Insufficiency,D051437,NA,0,850,any,2,000000000,Renal Insufficiency,NA
5766,28905478,3,diabetes mellitus status,Diabetes Mellitus,D003920,NA,0,850,any,2,000000000,Diabetes Mellitus,NA
5767,28905478,3,diabetes mellitus status;controlled,Disease Attributes,D020969,NA,0,850,any,2,000000000,Disease Attributes,NA
5768,28905478,3,diabetes mellitus status;uncontrolled,Diabetes Mellitus,D003920,NA,0,850,type,12,000000010,Diabetes Mellitus,NA
5769,28905478,3,diabetic kidney disease,Diabetic Nephropathies,D003928,NA,0,850,any,2,000000000,Diabetic Nephropathies,NA
5770,28905478,3,duration of diabetes by tertiles,Diabetes Mellitus,D003920,NA,0,850,duration,5,001000000,Diabetes Mellitus,NA
5771,28905478,3,egfr in 3 classes,Glomerular Filtration Rate,D005919,NA,0,850,severity,11,000100000,Glomerular Filtration Rate,NA
5772,28905478,3,egfr in 3 classes;<60 ml/min/1.73 m2,Glomerular Filtration Rate,D005919,NA,0,850,severity,11,000100000,Glomerular Filtration Rate,NA
5773,28905478,3,egfr in 3 classes;=60 to <90 ml/min/1.73 m2,Glomerular Filtration Rate,D005919,NA,0,850,severity,11,000100000,Glomerular Filtration Rate,NA
5774,28905478,3,egfr in 3 classes;=90 ml/min/1.73 m2,Glomerular Filtration Rate,D005919,NA,0,850,severity,11,000100000,Glomerular Filtration Rate,NA
5775,28905478,3,egfr in 3 classes;Ã¢â€°Â¥60 to <90 ml/min/1.73 m2,Glomerular Filtration Rate,D005919,NA,0,850,severity,11,000100000,Glomerular Filtration Rate,NA
5776,28905478,3,egfr in 3 classes;Ã¢â€°Â¥90 ml/min/1.73 m2,Glomerular Filtration Rate,D005919,NA,0,850,severity,11,000100000,Glomerular Filtration Rate,NA
5777,28905478,3,gender,Gender Identity,D005783,NA,0,850,any,2,000000000,Gender Identity,NA
5778,28905478,3,high-intensity statin vs medium- or low-intensity statin at randomization,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,850,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
5779,28905478,3,high-intensity statin vs medium- or low-intensity statin at randomization;high-intensity statin,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,850,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
5780,28905478,3,high-intensity statin vs medium- or low-intensity statin at randomization;medium- or low-intensity statin,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,850,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
5781,28905478,3,no statin vs statin alone vs any statin plus other llt,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,850,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
5782,28905478,3,no statin vs statin alone vs any statin plus other llt;any statin + other llt,lipid modifying agents,NA,C10,0,850,any,2,000000000,lipid modifying agents,NA
5783,28905478,3,no statin vs statin alone vs any statin plus other llt;no statin (+/-llt),Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,850,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
5784,28905478,3,no statin vs statin alone vs any statin plus other llt;statin alone,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,850,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
5785,28905478,3,non-hdl-c in 4 classes,Lipoproteins,D008074,NA,0,850,severity,11,000100000,Lipoproteins,NA
5786,28905478,3,non-hdl-c in 4 classes;<130 mg/dl,Lipoproteins,D008074,NA,0,850,severity,11,000100000,Lipoproteins,NA
5787,28905478,3,non-hdl-c in 4 classes;=130 to <160 mg/dl,Lipoproteins,D008074,NA,0,850,severity,11,000100000,Lipoproteins,NA
5788,28905478,3,non-hdl-c in 4 classes;=160 to <190 mg/dl,Lipoproteins,D008074,NA,0,850,severity,11,000100000,Lipoproteins,NA
5789,28905478,3,non-hdl-c in 4 classes;=190 mg/dl,Lipoproteins,D008074,NA,0,850,severity,11,000100000,Lipoproteins,NA
5790,28905478,3,non-hdl-c in 4 classes;Ã¢â€°Â¥130 to <160 mg/dl,Lipoproteins,D008074,NA,0,850,severity,11,000100000,Lipoproteins,NA
5791,28905478,3,non-hdl-c in 4 classes;Ã¢â€°Â¥160 to <190 mg/dl,Lipoproteins,D008074,NA,0,850,severity,11,000100000,Lipoproteins,NA
5792,28905478,3,non-hdl-c in 4 classes;Ã¢â€°Â¥190 mg/dl,Lipoproteins,D008074,NA,0,850,severity,11,000100000,Lipoproteins,NA
5793,28905478,3,prior history of mi or ischaemic stroke,Cardiovascular Diseases,D002318,NA,0,850,previous,8,100000000,Cardiovascular Diseases,NA
5794,28905478,3,race,Racial Groups,D044469,NA,0,850,any,2,000000000,Racial Groups,NA
5795,28905478,3,race;non-white,Racial Groups,D044469,NA,0,850,any,2,000000000,Racial Groups,NA
5796,28905478,3,region,Geographic Locations,D005842,NA,0,850,any,2,000000000,Geographic Locations,NA
5797,28910237,2,antihyperglycaemic oral agent therapy,Hypoglycemic Agents,D007004,NA,0,1277,any,2,000000000,Hypoglycemic Agents,NA
5798,28910237,2,antihyperglycemic oral agent therapy,Hypoglycemic Agents,D007004,NA,0,1277,any,2,000000000,Hypoglycemic Agents,NA
5799,28910237,2,body-mass index,Body Mass Index,D015992,NA,0,1277,any,2,000000000,Body Mass Index,NA
5800,28910237,2,dpp-4 inhibitor therapy,Hypoglycemic Agents,D007004,NA,0,1277,any,2,000000000,Hypoglycemic Agents,NA
5801,28910237,2,DPP-4 inhibitor therapy,Hypoglycemic Agents,D007004,NA,0,1277,any,2,000000000,Hypoglycemic Agents,NA
5802,28910237,2,duration of diabetes,Diabetes Mellitus,D003920,NA,0,1277,duration,5,001000000,Diabetes Mellitus,NA
5803,28910237,2,estimated gfr,Glomerular Filtration Rate,D005919,NA,0,1277,any,2,000000000,Glomerular Filtration Rate,NA
5804,28910237,2,estimated GFR,Glomerular Filtration Rate,D005919,NA,0,1277,any,2,000000000,Glomerular Filtration Rate,NA
5805,28910237,2,estimated gfr renal function stage,Glomerular Filtration Rate,D005919,NA,0,1277,severity,11,000100000,Glomerular Filtration Rate,NA
5806,28910237,2,glycated haemoglobin level,Glycated Hemoglobin A,D006442,NA,0,1277,any,2,000000000,Glycated Hemoglobin A,NA
5807,28910237,2,glycated hemoglobin level,Glycated Hemoglobin A,D006442,NA,0,1277,any,2,000000000,Glycated Hemoglobin A,NA
5808,28910237,2,history of congestive heart failure,Heart Failure,D006333,NA,0,1277,previous,8,100000000,Heart Failure,NA
5809,28910237,2,insulin therapy,Insulin,D007328,NA,0,1277,any,2,000000000,Insulin,NA
5810,28910237,2,previous cardiovascular event,Cardiovascular Diseases,D002318,NA,0,1277,previous,8,100000000,Cardiovascular Diseases,NA
5811,28910237,2,previous cardiovascular event at randomization,Cardiovascular Diseases,D002318,NA,0,1277,previous,8,100000000,Cardiovascular Diseases,NA
5812,28910237,2,race,Racial Groups,D044469,NA,0,1277,any,2,000000000,Racial Groups,NA
5813,28910237,2,race or ethnic group,Racial Groups,D044469,NA,0,1277,any,2,000000000,Racial Groups,NA
5814,28910237,2,race or ethnic group;indian (american) or alaskan native,Racial Groups,D044469,NA,0,1277,any,2,000000000,Racial Groups,NA
5815,28910237,2,race or ethnic group;native hawaiian or other pacific islander,Racial Groups,D044469,NA,0,1277,any,2,000000000,Racial Groups,NA
5816,28910237,2,region,Geographic Locations,D005842,NA,0,1277,any,2,000000000,Geographic Locations,NA
5817,28910237,2,sex,Gender Identity,D005783,NA,0,1277,any,2,000000000,Gender Identity,NA
5818,28917545,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,140
5819,28917545,NA,BMI,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,140
5820,28917545,NA,Chinese region,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,140
5821,28917545,NA,"coronary heart disease inclusion criteria (previous MI, previous UA, current SA, >1 of the above)",Coronary Artery Disease,D003324,NA,0,0,severity,2,000000000,Coronary Artery Disease,140
5822,28917545,NA,eGFR,Renal Insufficiency,D051437,NA,0,0,any,2,000000000,Renal Insufficiency,140
5823,28917545,NA,fasting plasma glucose,Glucose,D005947,NA,0,0,any,2,000000000,Glucose,NA
5824,28917545,NA,HbA1c,Glycated Hemoglobin A,D006442,NA,0,0,any,2,000000000,Glycated Hemoglobin A,140
5825,28917545,NA,plasma glucose,Glucose,D005947,NA,0,0,any,2,000000000,Glucose,NA
5826,28917545,NA,previous heart failure,Heart Failure,D006333,NA,0,0,previous,8,100000000,Heart Failure,140
5827,28917545,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,139
5828,28917545,NA,systolic blood pressure,Blood Pressure,D001794,NA,0,0,any,2,000000000,Blood Pressure,140
5829,28921862,3,n = 79,Glycated Hemoglobin A,D006442,NA,0,452,any,2,000000000,Glycated Hemoglobin A,NA
5830,28921862,3,n = 82,Glycated Hemoglobin A,D006442,NA,0,452,any,2,000000000,Glycated Hemoglobin A,NA
5831,28921862,3,n = 83,Glycated Hemoglobin A,D006442,NA,0,452,any,2,000000000,Glycated Hemoglobin A,NA
5832,28924103,NA,Medical History: Time since initial stroke event,Stroke,D020521,NA,0,0,previous,8,100000000,Stroke,189
5833,28939567,2,female,Gender Identity,D005783,NA,0,988,any,2,000000000,Gender Identity,NA
5834,28939567,2,male,Gender Identity,D005783,NA,0,988,any,2,000000000,Gender Identity,NA
5835,28947039,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,267
5836,28947039,NA,BMI,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,267
5837,28947039,NA,diabetes history,Diabetes Mellitus,D003920,NA,0,0,previous,8,100000000,Diabetes Mellitus,267
5838,28947039,NA,FEV1,Pulmonary Ventilation,D012123,NA,0,0,any,2,000000000,Pulmonary Ventilation,267
5839,28947039,NA,prior copd excerbations,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,0,previous,8,100000000,"Pulmonary Disease, Chronic Obstructive",267
5840,28947039,NA,region,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,267
5841,28947039,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,267
5842,28947039,NA,smoking current vs former,Cigarette Smoking,D000073865,NA,0,0,previous,8,110000000,Cigarette Smoking,258
5843,28948656,2,;diabetes,Diabetes Mellitus,D003920,NA,0,983,any,2,000000000,Diabetes Mellitus,NA
5844,28948656,2,;non-diabetes,Diabetes Mellitus,D003920,NA,0,983,any,2,000000000,Diabetes Mellitus,NA
5845,28968735,NA,Dactylitis,"Arthritis, Juvenile",D001171,NA,0,0,any,2,000000000,"Arthritis, Juvenile",NA
5846,28968735,NA,enthesitis,"Arthritis, Juvenile",D001171,NA,0,0,any,2,000000000,"Arthritis, Juvenile",NA
5847,28968735,NA,MTX treatment,Immunosuppressive Agents,D007166,NA,0,0,any,2,000000000,Immunosuppressive Agents,NA
5848,28968735,NA,previous anti-TNF-a,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,0,any,2,000000000,Tumor Necrosis Factor Inhibitors,NA
5849,28968735,NA,Psoriasis Area Severity Index at least 3% of the BSA affected by psoriatic skin involvement,Psoriasis,D011565,NA,0,0,severity,11,000100000,Psoriasis,NA
5850,28972004,1,;current smoking,Cigarette Smoking,D000073865,NA,0,1771,current,3,010000000,Cigarette Smoking,NA
5851,28972004,1,;diabetes,Diabetes Mellitus,D003920,NA,0,1771,any,2,000000000,Diabetes Mellitus,NA
5852,28972004,1,;prior stroke,Stroke,D020521,NA,0,1771,previous,8,100000000,Stroke,NA
5853,28972004,1,;stemi,Myocardial Infarction,D009203,NA,0,1771,any,2,000000000,Myocardial Infarction,NA
5854,28972004,1,age,Age Factors,D000367,NA,0,1771,any,2,000000000,Age Factors,NA
5855,28972004,1,at index acs event,Acute Coronary Syndrome,D054058,NA,0,1771,any,2,000000000,Acute Coronary Syndrome,NA
5856,28972004,1,at index acs event;stemi,Myocardial Infarction,D009203,NA,0,1771,any,2,000000000,Myocardial Infarction,NA
5857,28972004,1,at index acs event;unstable angina,Angina Pectoris,D000787,NA,0,1771,any,2,000000000,Angina Pectoris,NA
5858,28972004,1,before index acs event,Acute Coronary Syndrome,D054058,NA,0,1771,previous,8,100000000,Acute Coronary Syndrome,NA
5859,28972004,1,before index acs event;aspirin,Aspirin,D001241,NA,0,1771,previous,8,100000000,Aspirin,NA
5860,28972004,1,before index acs event;lipid-lowering agent,lipid modifying agents,NA,C10,0,1771,previous,8,100000000,lipid modifying agents,NA
5861,28972004,1,before index acs event;statin,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,1771,previous,8,100000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
5862,28972004,1,coexisting conditions;atrial fibrillation,Atrial Fibrillation,D001281,NA,0,1771,any,2,000000000,Atrial Fibrillation,NA
5863,28972004,1,"coexisting conditions;cha2ds2-vasc score (median, iqr)",Stroke,D020521,NA,0,1771,severity,11,000100100,Stroke,NA
5864,28972004,1,coexisting conditions;current smoking,Cigarette Smoking,D000073865,NA,0,1771,current,3,010000000,Cigarette Smoking,NA
5865,28972004,1,coexisting conditions;diabetes mellitus,Diabetes Mellitus,D003920,NA,0,1771,any,2,000000000,Diabetes Mellitus,NA
5866,28972004,1,coexisting conditions;heart failure,Heart Failure,D006333,NA,0,1771,any,2,000000000,Heart Failure,NA
5867,28972004,1,coexisting conditions;prior cabg (before index acs),Coronary Artery Bypass,D001026,NA,0,1771,previous,8,100000000,Coronary Artery Bypass,NA
5868,28972004,1,coexisting conditions;prior ml (before index acs),Acute Coronary Syndrome,D054058,NA,0,1771,previous,8,100000000,Acute Coronary Syndrome,NA
5869,28972004,1,coexisting conditions;prior stroke,Stroke,D020521,NA,0,1771,previous,8,100000000,Stroke,NA
5870,28972004,1,coexisting conditions;score 1-3,Stroke,D020521,NA,0,1771,severity,11,000100100,Stroke,NA
5871,28972004,1,coexisting conditions;score 4-9,Stroke,D020521,NA,0,1771,severity,11,000100100,Stroke,NA
5872,28972004,1,Creatinine,Glomerular Filtration Rate,D005919,NA,0,1771,any,2,000000000,Glomerular Filtration Rate,NA
5873,28972004,1,"demographics;age (median, iqr), y",Age Factors,D000367,NA,0,1771,any,2,000000000,Age Factors,NA
5874,28972004,1,"demographics;bmi (median, iqr), kg/m2",Body Mass Index,D015992,NA,0,1771,any,2,000000000,Body Mass Index,NA
5875,28972004,1,Hypertension,Hypertension,D006973,NA,0,1771,any,2,000000000,Hypertension,NA
5876,28972004,1,labs at the index acs event,Acute Coronary Syndrome,D054058,NA,0,1771,any,2,000000000,Acute Coronary Syndrome,NA
5877,28972004,1,labs at the index acs event;acei/arb,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,1771,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
5878,28972004,1,labs at the index acs event;aspirin,Aspirin,D001241,NA,0,1771,any,2,000000000,Aspirin,NA
5879,28972004,1,"labs at the index acs event;egfr (median, iqr), ml/min/1,73m2",Glomerular Filtration Rate,D005919,NA,0,1771,any,2,000000000,Glomerular Filtration Rate,NA
5880,28972004,1,labs at the index acs event;egfr <60 ml/ min/1.73m2,Glomerular Filtration Rate,D005919,NA,0,1771,any,2,000000000,Glomerular Filtration Rate,NA
5881,28972004,1,"labs at the index acs event;hdl-c (median, iqr), mg/dl",Lipoproteins,D008074,NA,0,1771,any,2,000000000,Lipoproteins,NA
5882,28972004,1,"labs at the index acs event;hs-crp (median, iqr), mg/l",C-Reactive Protein,D002097,NA,0,1771,any,2,000000000,C-Reactive Protein,NA
5883,28972004,1,"labs at the index acs event;ldl-c (median, iqr), mg/dl",Lipoproteins,D008074,NA,0,1771,any,2,000000000,Lipoproteins,NA
5884,28972004,1,labs at the index acs event;p blocker,Adrenergic beta-Antagonists,D000319,NA,0,1771,any,2,000000000,Adrenergic beta-Antagonists,NA
5885,28972004,1,labs at the index acs event;thienopyridine,Thienopyridines,D058924,NA,0,1771,any,2,000000000,Thienopyridines,NA
5886,28972004,1,"labs at the index acs event;time from acs to randomization (median, iqr)",Acute Coronary Syndrome,D054058,NA,0,1771,any,2,000000000,Acute Coronary Syndrome,NA
5887,28972004,1,"labs at the index acs event;total cholesterol (median, iqr), mg/dl",Lipoproteins,D008074,NA,0,1771,any,2,000000000,Lipoproteins,NA
5888,28972004,1,"labs at the index acs event;triglycerides (median, iqr), mg/dl",Lipoproteins,D008074,NA,0,1771,any,2,000000000,Lipoproteins,NA
5889,28972004,1,male female,Gender Identity,D005783,NA,0,1771,any,2,000000000,Gender Identity,NA
5890,28972004,1,mi,Myocardial Infarction,D009203,NA,0,1771,any,2,000000000,Myocardial Infarction,NA
5891,28972004,1,Peripheral artery disease Yes No,Peripheral Vascular Diseases,D016491,NA,0,1771,any,2,000000000,Peripheral Vascular Diseases,NA
5892,28972004,1,prior stroke,Stroke,D020521,NA,0,1771,previous,8,100000000,Stroke,NA
5893,28972004,1,race,Racial Groups,D044469,NA,0,1771,any,2,000000000,Racial Groups,NA
5894,28972004,2,;crci>60-<90,Glomerular Filtration Rate,D005919,NA,0,380,any,2,000000000,Glomerular Filtration Rate,NA
5895,28972004,2,;crci>90,Glomerular Filtration Rate,D005919,NA,0,380,any,2,000000000,Glomerular Filtration Rate,NA
5896,28972004,2,;current smoking,Cigarette Smoking,D000073865,NA,0,380,current,3,010000000,Cigarette Smoking,NA
5897,28972004,2,;diabetes,Diabetes Mellitus,D003920,NA,0,380,any,2,000000000,Diabetes Mellitus,NA
5898,28972004,2,;ldl-c>median,Lipoproteins,D008074,NA,0,380,any,2,000000000,Lipoproteins,NA
5899,28972004,2,;ldl-csmedian,Lipoproteins,D008074,NA,0,380,any,2,000000000,Lipoproteins,NA
5900,28972004,2,;no diabetes,Diabetes Mellitus,D003920,NA,0,380,any,2,000000000,Diabetes Mellitus,NA
5901,28972004,2,;no htn,Hypertension,D006973,NA,0,380,any,2,000000000,Hypertension,NA
5902,28972004,2,;no prior llt,lipid modifying agents,NA,C10,0,380,previous,8,100000000,lipid modifying agents,NA
5903,28972004,2,;no prior stroke,Stroke,D020521,NA,0,380,previous,8,100000000,Stroke,NA
5904,28972004,2,;no smoking,Cigarette Smoking,D000073865,NA,0,380,any,2,000000000,Cigarette Smoking,NA
5905,28972004,2,;non-caucasian,Racial Groups,D044469,NA,0,380,any,2,000000000,Racial Groups,NA
5906,28972004,2,;nste-acs,Acute Coronary Syndrome,D054058,NA,0,380,any,2,000000000,Acute Coronary Syndrome,NA
5907,28972004,2,;prior llt,lipid modifying agents,NA,C10,0,380,previous,8,100000000,lipid modifying agents,NA
5908,28972004,2,;prior stroke,Stroke,D020521,NA,0,380,previous,8,100000000,Stroke,NA
5909,28972004,2,;stemi,Myocardial Infarction,D009203,NA,0,380,any,2,000000000,Myocardial Infarction,NA
5910,28972004,2,age,Age Factors,D000367,NA,0,380,any,2,000000000,Age Factors,NA
5911,28972004,2,at index acs event;stemi,Myocardial Infarction,D009203,NA,0,380,any,2,000000000,Myocardial Infarction,NA
5912,28972004,2,coexisting conditions;current smoking,Cigarette Smoking,D000073865,NA,0,380,current,3,010000000,Cigarette Smoking,NA
5913,28972004,2,coexisting conditions;diabetes mellitus,Diabetes Mellitus,D003920,NA,0,380,any,2,000000000,Diabetes Mellitus,NA
5914,28972004,2,coexisting conditions;prior stroke,Stroke,D020521,NA,0,380,previous,8,100000000,Stroke,NA
5915,28972004,2,Creatinine,Glomerular Filtration Rate,D005919,NA,0,380,any,2,000000000,Glomerular Filtration Rate,NA
5916,28972004,2,male female,Gender Identity,D005783,NA,0,380,any,2,000000000,Gender Identity,NA
5917,28972004,2,mi,Myocardial Infarction,D009203,NA,0,380,any,2,000000000,Myocardial Infarction,NA
5918,28972004,2,no prior stroke,Stroke,D020521,NA,0,380,previous,8,100000000,Stroke,NA
5919,28972004,2,prior stroke,Stroke,D020521,NA,0,380,previous,8,100000000,Stroke,NA
5920,28972004,3,;no prior stroke,Stroke,D020521,NA,0,635,previous,8,100000000,Stroke,NA
5921,28972004,3,;prior stroke,Stroke,D020521,NA,0,635,previous,8,100000000,Stroke,NA
5922,28972004,3,coexisting conditions;prior stroke,Stroke,D020521,NA,0,635,previous,8,100000000,Stroke,NA
5923,28972004,3,mi,Myocardial Infarction,D009203,NA,0,635,any,2,000000000,Myocardial Infarction,NA
5924,28972004,3,no prior stroke,Stroke,D020521,NA,0,635,previous,8,100000000,Stroke,NA
5925,28972004,3,prior stroke,Stroke,D020521,NA,0,635,previous,8,100000000,Stroke,NA
5926,28975241,2,age,Age Factors,D000367,NA,0,1304,any,2,000000000,Age Factors,NA
5927,28975241,2,aphasia,Aphasia,D001037,NA,0,1304,any,2,000000000,Aphasia,NA
5928,28975241,2,prior stroke,Stroke,D020521,NA,0,1304,previous,8,100000000,Stroke,NA
5929,28975241,2,Smoker,Cigarette Smoking,D000073865,NA,0,1304,any,2,000000000,Cigarette Smoking,NA
5930,29028981,2,corticosteroid use at baseline,Steroids,D013256,NA,0,963,any,2,000000000,Steroids,NA
5931,29028981,2,gender,Gender Identity,D005783,NA,0,963,any,2,000000000,Gender Identity,NA
5932,29028981,2,prior anti-tnf therapy,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,963,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
5933,29028981,3,corticosteroid use at baseline,Steroids,D013256,NA,0,410,any,2,000000000,Steroids,NA
5934,29028981,3,gender,Gender Identity,D005783,NA,0,410,any,2,000000000,Gender Identity,NA
5935,29028981,3,prior anti-tnf therapy,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,410,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
5936,29045207,NA,the number of TNF inhibitors that had failed in the patients owing to an inadequate response,unclassifible,NA,NA,0,0,disease response,4,000000000,unclassifible,232
5937,29064626,2,high-sensitivity c-reactive protein stratification,C-Reactive Protein,D002097,NA,0,1808,any,2,000000000,C-Reactive Protein,NA
5938,29064626,2,p value *;<1 mg/l (n = 1278),C-Reactive Protein,D002097,NA,0,1808,any,2,000000000,C-Reactive Protein,NA
5939,29064626,2,p value *;>3 mg/l (n = 2139),C-Reactive Protein,D002097,NA,0,1808,any,2,000000000,C-Reactive Protein,NA
5940,29064626,2,p value *;1 to 3 mg/l (n = 1963),C-Reactive Protein,D002097,NA,0,1808,any,2,000000000,C-Reactive Protein,NA
5941,29073947,NA,Complex lesion,Coronary Artery Disease,D003324,NA,0,0,severity,2,000000000,Coronary Artery Disease,35
5942,29084736,2,age,Age Factors,D000367,NA,0,1441,any,2,000000000,Age Factors,NA
5943,29084736,2,atrial fibrillation,Atrial Fibrillation,D001281,NA,0,1441,any,2,000000000,Atrial Fibrillation,NA
5944,29084736,2,body mass index,Body Mass Index,D015992,NA,0,1441,any,2,000000000,Body Mass Index,NA
5945,29084736,2,carotid stenosis,"Constriction, Pathologic",D003251,NA,0,1441,any,2,000000000,"Constriction, Pathologic",NA
5946,29084736,2,gender,Gender Identity,D005783,NA,0,1441,any,2,000000000,Gender Identity,NA
5947,29084736,2,glycated hemoglobin,Glycated Hemoglobin A,D006442,NA,0,1441,any,2,000000000,Glycated Hemoglobin A,NA
5948,29084736,2,glycated hemoglobin;6.5-6.9%f,Glycated Hemoglobin A,D006442,NA,0,1441,any,2,000000000,Glycated Hemoglobin A,NA
5949,29084736,2,hypertension history,Hypertension,D006973,NA,0,1441,previous,8,100000000,Hypertension,NA
5950,29084736,2,ldl-cholesterol,Lipoproteins,D008074,NA,0,1441,any,2,000000000,Lipoproteins,NA
5951,29084736,2,prior stroke,Stroke,D020521,NA,0,1441,previous,8,100000000,Stroke,NA
5952,29084736,2,race,Racial Groups,D044469,NA,0,1441,any,2,000000000,Racial Groups,NA
5953,29103664,2,;age < 65 years,Age Factors,D000367,NA,0,992,any,2,000000000,Age Factors,NA
5954,29103664,2,;age > 65 years,Age Factors,D000367,NA,0,992,any,2,000000000,Age Factors,NA
5955,29103664,2,;baseline bmi < 30 kg/m2,Body Mass Index,D015992,NA,0,992,any,2,000000000,Body Mass Index,NA
5956,29103664,2,;baseline bmi > 30 kg/m2,Body Mass Index,D015992,NA,0,992,any,2,000000000,Body Mass Index,NA
5957,29103664,2,;baseline egfr < 60 ml/min/1.73 m2,Glomerular Filtration Rate,D005919,NA,0,992,any,2,000000000,Glomerular Filtration Rate,NA
5958,29103664,2,;baseline egfr > 60 ml/min/1.73 m2,Glomerular Filtration Rate,D005919,NA,0,992,any,2,000000000,Glomerular Filtration Rate,NA
5959,29103664,2,;baseline hba1c < 9.0%,Glycated Hemoglobin A,D006442,NA,0,992,any,2,000000000,Glycated Hemoglobin A,NA
5960,29103664,2,;baseline hba1c > 9.0%,Glycated Hemoglobin A,D006442,NA,0,992,any,2,000000000,Glycated Hemoglobin A,NA
5961,29103664,2,;baseline su dose < 1/2 maximal,Hypoglycemic Agents,D007004,NA,0,992,any,2,000000000,Hypoglycemic Agents,NA
5962,29103664,2,;baseline su dose > 1/2 maximal,Hypoglycemic Agents,D007004,NA,0,992,any,2,000000000,Hypoglycemic Agents,NA
5963,29103664,2,;duration of diabetes < 10 years,Diabetes Mellitus,D003920,NA,0,992,duration,5,001000000,Diabetes Mellitus,NA
5964,29103664,2,;duration of diabetes > 10 years,Diabetes Mellitus,D003920,NA,0,992,duration,5,001000000,Diabetes Mellitus,NA
5965,29128192,3,japanese subgroup (n = 83),Geographic Locations,D005842,NA,0,1602,any,2,000000000,Geographic Locations,NA
5966,29132879,2,age (years),Age Factors,D000367,NA,0,1349,any,2,000000000,Age Factors,NA
5967,29132879,2,baseline diabetes,Diabetes Mellitus,D003920,NA,0,1349,any,2,000000000,Diabetes Mellitus,NA
5968,29132879,2,baseline total cholesterol,Lipoproteins,D008074,NA,0,1349,any,2,000000000,Lipoproteins,NA
5969,29132879,2,history of cabg,Coronary Artery Bypass,D001026,NA,0,1349,previous,8,100000000,Coronary Artery Bypass,NA
5970,29132879,2,history of cabg;myocardial infarction/cabg/pci,complex,none,NA,0,1349,any,2,000000000,complex,NA
5971,29132879,2,history of myocardial infarction,Myocardial Infarction,D009203,NA,0,1349,previous,8,100010000,Myocardial Infarction,NA
5972,29132879,2,history of myocardial infarction;no previous myocardial infarction,Myocardial Infarction,D009203,NA,0,1349,previous,8,100010000,Myocardial Infarction,NA
5973,29132879,2,history of myocardial infarction;no previous myocardial infarction 117/2659,Myocardial Infarction,D009203,NA,0,1349,previous,8,100010000,Myocardial Infarction,NA
5974,29132879,2,history of myocardial infarction;no previous myocardial infarction 87/2659,Myocardial Infarction,D009203,NA,0,1349,previous,8,100010000,Myocardial Infarction,NA
5975,29132879,2,history of pci/ptca,Percutaneous Coronary Intervention,D062645,NA,0,1349,previous,8,100000000,Percutaneous Coronary Intervention,NA
5976,29132879,2,myocardial infarction/cabg/pci <2 years,complex,none,NA,0,1349,any,2,000000000,complex,NA
5977,29132879,2,"non-smokers receiving lipid-lowering drugs, p blockers, and either an ace inhibitor or angiotension receptor blocker",complex,none,NA,0,1349,any,2,000000000,complex,NA
5978,29132879,2,"non-smokers receiving lipid lowering drugs, (5 blockers, and either an ace inhibitor or angiotension receptor blocker",complex,none,NA,0,1349,any,2,000000000,complex,NA
5979,29132879,2,Peripheral artery disease Yes No,Peripheral Vascular Diseases,D016491,NA,0,1349,any,2,000000000,Peripheral Vascular Diseases,NA
5980,29132879,2,race,Racial Groups,D044469,NA,0,1349,any,2,000000000,Racial Groups,NA
5981,29132879,2,region,Geographic Locations,D005842,NA,0,1349,any,2,000000000,Geographic Locations,NA
5982,29132879,2,sex,Gender Identity,D005783,NA,0,1349,any,2,000000000,Gender Identity,NA
5983,29132879,2,sex;f emale,Gender Identity,D005783,NA,0,1349,any,2,000000000,Gender Identity,NA
5984,29132879,2,timi risk score!,Myocardial Infarction,D009203,NA,1,1349,severity,11,000100000,Myocardial Infarction,NA
5985,29132879,2,timi risk scoret,Myocardial Infarction,D009203,NA,1,1349,severity,11,000100000,Myocardial Infarction,NA
5986,29132879,3,age (years),Age Factors,D000367,NA,0,481,any,2,000000000,Age Factors,NA
5987,29132879,3,baseline diabetes,Diabetes Mellitus,D003920,NA,0,481,any,2,000000000,Diabetes Mellitus,NA
5988,29132879,3,baseline total cholesterol,Lipoproteins,D008074,NA,0,481,any,2,000000000,Lipoproteins,NA
5989,29132879,3,history of cabg,Coronary Artery Bypass,D001026,NA,0,481,previous,8,100000000,Coronary Artery Bypass,NA
5990,29132879,3,history of cabg;myocardial infarction/cabg/pci,complex,none,NA,0,481,any,2,000000000,complex,NA
5991,29132879,3,history of myocardial infarction,Myocardial Infarction,D009203,NA,0,481,previous,8,100010000,Myocardial Infarction,NA
5992,29132879,3,history of myocardial infarction;no previous myocardial infarction,Myocardial Infarction,D009203,NA,0,481,previous,8,100010000,Myocardial Infarction,NA
5993,29132879,3,history of myocardial infarction;no previous myocardial infarction 117/2659,Myocardial Infarction,D009203,NA,0,481,previous,8,100010000,Myocardial Infarction,NA
5994,29132879,3,history of myocardial infarction;no previous myocardial infarction 87/2659,Myocardial Infarction,D009203,NA,0,481,previous,8,100010000,Myocardial Infarction,NA
5995,29132879,3,history of pci/ptca,Percutaneous Coronary Intervention,D062645,NA,0,481,previous,8,100000000,Percutaneous Coronary Intervention,NA
5996,29132879,3,myocardial infarction/cabg/pci <2 years,complex,none,NA,0,481,any,2,000000000,complex,NA
5997,29132879,3,"non-smokers receiving lipid-lowering drugs, p blockers, and either an ace inhibitor or angiotension receptor blocker",complex,none,NA,0,481,any,2,000000000,complex,NA
5998,29132879,3,"non-smokers receiving lipid lowering drugs, (5 blockers, and either an ace inhibitor or angiotension receptor blocker",complex,none,NA,0,481,any,2,000000000,complex,NA
5999,29132879,3,Peripheral artery disease Yes No,Peripheral Vascular Diseases,D016491,NA,0,481,any,2,000000000,Peripheral Vascular Diseases,NA
6000,29132879,3,race,Racial Groups,D044469,NA,0,481,any,2,000000000,Racial Groups,NA
6001,29132879,3,region,Geographic Locations,D005842,NA,0,481,any,2,000000000,Geographic Locations,NA
6002,29132879,3,sex,Gender Identity,D005783,NA,0,481,any,2,000000000,Gender Identity,NA
6003,29132879,3,sex;f emale,Gender Identity,D005783,NA,0,481,any,2,000000000,Gender Identity,NA
6004,29132879,3,timi risk score!,Thrombosis,D013927,NA,0,481,severity,11,000100100,Thrombosis,NA
6005,29132879,3,timi risk scoret,Thrombosis,D013927,NA,0,481,severity,11,000100100,Thrombosis,NA
6006,29132879,4,age (years),Age Factors,D000367,NA,0,1040,any,2,000000000,Age Factors,NA
6007,29132879,4,baseline diabetes,Diabetes Mellitus,D003920,NA,0,1040,any,2,000000000,Diabetes Mellitus,NA
6008,29132879,4,baseline total cholesterol,Lipoproteins,D008074,NA,0,1040,any,2,000000000,Lipoproteins,NA
6009,29132879,4,history of cabg,Coronary Artery Bypass,D001026,NA,0,1040,previous,8,100000000,Coronary Artery Bypass,NA
6010,29132879,4,history of cabg;myocardial infarction/cabg/pci,complex,none,NA,0,1040,any,2,000000000,complex,NA
6011,29132879,4,history of myocardial infarction,Myocardial Infarction,D009203,NA,0,1040,previous,8,100010000,Myocardial Infarction,NA
6012,29132879,4,history of myocardial infarction;no previous myocardial infarction,Myocardial Infarction,D009203,NA,0,1040,previous,8,100010000,Myocardial Infarction,NA
6013,29132879,4,history of myocardial infarction;no previous myocardial infarction 117/2659,Myocardial Infarction,D009203,NA,0,1040,previous,8,100010000,Myocardial Infarction,NA
6014,29132879,4,history of myocardial infarction;no previous myocardial infarction 87/2659,Myocardial Infarction,D009203,NA,0,1040,previous,8,100010000,Myocardial Infarction,NA
6015,29132879,4,history of pci/ptca,Percutaneous Coronary Intervention,D062645,NA,0,1040,previous,8,100000000,Percutaneous Coronary Intervention,NA
6016,29132879,4,myocardial infarction/cabg/pci <2 years,complex,none,NA,0,1040,any,2,000000000,complex,NA
6017,29132879,4,"non-smokers receiving lipid-lowering drugs, p blockers, and either an ace inhibitor or angiotension receptor blocker",complex,none,NA,0,1040,any,2,000000000,complex,NA
6018,29132879,4,"non-smokers receiving lipid lowering drugs, (5 blockers, and either an ace inhibitor or angiotension receptor blocker",complex,none,NA,0,1040,any,2,000000000,complex,NA
6019,29132879,4,Peripheral artery disease Yes No,Peripheral Vascular Diseases,D016491,NA,0,1040,any,2,000000000,Peripheral Vascular Diseases,NA
6020,29132879,4,race,Racial Groups,D044469,NA,0,1040,any,2,000000000,Racial Groups,NA
6021,29132879,4,region,Geographic Locations,D005842,NA,0,1040,any,2,000000000,Geographic Locations,NA
6022,29132879,4,sex,Gender Identity,D005783,NA,0,1040,any,2,000000000,Gender Identity,NA
6023,29132879,4,sex;f emale,Gender Identity,D005783,NA,0,1040,any,2,000000000,Gender Identity,NA
6024,29132879,4,timi risk score!,Thrombosis,D013927,NA,0,1040,severity,11,000100100,Thrombosis,NA
6025,29132879,4,timi risk scoret,Thrombosis,D013927,NA,0,1040,severity,11,000100100,Thrombosis,NA
6026,29132880,2,abi,Ankle Brachial Index,D055109,NA,0,1279,any,2,000000000,Ankle Brachial Index,NA
6027,29132880,2,Coronary heart disease,Coronary Artery Disease,D003324,NA,0,1279,any,2,000000000,Coronary Artery Disease,NA
6028,29132880,2,diabetes,Diabetes Mellitus,D003920,NA,0,1279,any,2,000000000,Diabetes Mellitus,NA
6029,29132880,2,egfr,Glomerular Filtration Rate,D005919,NA,0,1279,any,2,000000000,Glomerular Filtration Rate,NA
6030,29132880,2,egfr;overall pad,Peripheral Vascular Diseases,D016491,NA,0,1279,any,2,000000000,Peripheral Vascular Diseases,NA
6031,29132880,2,pad lower extremities,Peripheral Vascular Diseases,D016491,NA,0,1279,any,2,000000000,Peripheral Vascular Diseases,NA
6032,29132880,2,Smoker,Cigarette Smoking,D000073865,NA,0,1279,any,2,000000000,Cigarette Smoking,NA
6033,29132880,2,smoking status;current,Cigarette Smoking,D000073865,NA,0,1279,current,3,010000000,Cigarette Smoking,NA
6034,29132880,2,smoking status;former or never,Cigarette Smoking,D000073865,NA,0,1279,previous,8,100000000,Cigarette Smoking,NA
6035,29132880,2,symptomatic pad,Peripheral Vascular Diseases,D016491,NA,0,1279,any,2,000000000,Peripheral Vascular Diseases,NA
6036,29143919,NA,Medical History: Baseline Hemoglobin A1c,Glycated Hemoglobin A,D006442,NA,0,0,previous,8,100000000,Glycated Hemoglobin A,38
6037,29143919,NA,Medical History: hba1c,Glycated Hemoglobin A,D006442,NA,0,0,previous,8,100000000,Glycated Hemoglobin A,224
6038,29144061,NA,metformin use,Hypoglycemic Agents,D007004,NA,0,0,any,2,000000000,Hypoglycemic Agents,193
6039,29145215,2,baseline bmi,Body Mass Index,D015992,NA,0,1331,any,2,000000000,Body Mass Index,NA
6040,29145215,2,"baseline bmi > 35 kg/m2, n = 2,383 change from baseline to 56 weeks",Body Mass Index,D015992,NA,0,1331,any,2,000000000,Body Mass Index,NA
6041,29145215,2,"baseline bmi 27 to <35 kg/m2, n = 1,279 change from baseline to 56 weeks",Body Mass Index,D015992,NA,0,1331,any,2,000000000,Body Mass Index,NA
6042,29145215,2,"individuals with diabetes, n = 632",Diabetes Mellitus,D003920,NA,0,1331,any,2,000000000,Diabetes Mellitus,NA
6043,29145215,2,"individuals without diabetes, n = 3,662",Diabetes Mellitus,D003920,NA,0,1331,any,2,000000000,Diabetes Mellitus,NA
6044,29145215,3,"baseline bmi > 35 kg/m2, n = 350 change from baseline to 56 weeks",Body Mass Index,D015992,NA,0,173,any,2,000000000,Body Mass Index,NA
6045,29145215,3,"baseline bmi 27 to <35 kg/m2, n = 273 change from baseline to 56 weeks",Body Mass Index,D015992,NA,0,173,any,2,000000000,Body Mass Index,NA
6046,29145215,3,"individuals with diabetes, n = 632",Diabetes Mellitus,D003920,NA,0,173,any,2,000000000,Diabetes Mellitus,NA
6047,29145215,3,"individuals without diabetes, n = 3,662",Diabetes Mellitus,D003920,NA,0,173,any,2,000000000,Diabetes Mellitus,NA
6048,29145215,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,96
6049,29145215,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,96
6050,29146124,2,age <60 years,Age Factors,D000367,NA,0,847,any,2,000000000,Age Factors,NA
6051,29146124,2,age >60 years,Age Factors,D000367,NA,0,847,any,2,000000000,Age Factors,NA
6052,29146124,2,bmi <30 kg/m2,Body Mass Index,D015992,NA,0,847,any,2,000000000,Body Mass Index,NA
6053,29146124,2,diabetes,Diabetes Mellitus,D003920,NA,0,847,any,2,000000000,Diabetes Mellitus,NA
6054,29146124,2,hdl cholesterol <1-17 mmol/l,Lipoproteins,D008074,NA,0,847,any,2,000000000,Lipoproteins,NA
6055,29146124,2,hdl cholesterol >1-17 mmol/l,Lipoproteins,D008074,NA,0,847,any,2,000000000,Lipoproteins,NA
6056,29146124,2,hscrp >2 to <4 mg/l,C-Reactive Protein,D002097,NA,0,847,any,2,000000000,C-Reactive Protein,NA
6057,29146124,2,hscrp >4 mg/l,C-Reactive Protein,D002097,NA,0,847,any,2,000000000,C-Reactive Protein,NA
6058,29146124,2,ldl cholesterol <2-07 mmol/l,Lipoproteins,D008074,NA,0,847,any,2,000000000,Lipoproteins,NA
6059,29146124,2,ldl cholesterol >2-07 mmol/l,Lipoproteins,D008074,NA,0,847,any,2,000000000,Lipoproteins,NA
6060,29146124,2,male female,Gender Identity,D005783,NA,0,847,any,2,000000000,Gender Identity,NA
6061,29146124,2,no diabetes,Diabetes Mellitus,D003920,NA,0,847,any,2,000000000,Diabetes Mellitus,NA
6062,29146124,2,smoker,Cigarette Smoking,D000073865,NA,0,847,any,2,000000000,Cigarette Smoking,NA
6063,29146124,2,triglycerides <1-69 mmol/l,Lipoproteins,D008074,NA,0,847,any,2,000000000,Lipoproteins,NA
6064,29146124,2,triglycerides >1-69 mmol/l,Lipoproteins,D008074,NA,0,847,any,2,000000000,Lipoproteins,NA
6065,29146124,3,Women Men Age <60 years Age =60 years No diabetes Diabetes Non-smoker Smoker BMI <30 kg/m2 BMI =30 kg/m2 LDL cholesterol <2Â·07 mmol/L LDL cholesterol =2Â·07 mmol/L hsCRP >2 to <4 mg/L hsCRP =4 mg/L HDL cholesterol >1Â·17 mmol/L HDL cholesterol =1Â·17 mmol/L Triglycerides <1Â·69 mmol/L Triglycerides =1Â·69 mmol/L Overall,complex,none,NA,0,200,any,2,000000000,complex,NA
6066,29146124,3,Women Men Age <60 years Age Ã¢â€°Â¥60 years No diabetes Diabetes Non-smoker Smoker BMI <30 kg/m2 BMI Ã¢â€°Â¥30 kg/m2 LDL cholesterol <2Ã‚Â·07 mmol/L LDL cholesterol Ã¢â€°Â¥2Ã‚Â·07 mmol/L hsCRP >2 to <4 mg/L hsCRP Ã¢â€°Â¥4 mg/L HDL cholesterol >1Ã‚Â·17 mmol/L HDL cholesterol Ã¢â€°Â¤1Ã‚Â·17 mmol/L Triglycerides <1Ã‚Â·69 mmol/L Triglycerides Ã¢â€°Â¥1Ã‚Â·69 mmol/L Overall,complex,none,NA,0,200,any,2,000000000,complex,NA
6067,29148144,2,;128< sbp< 138 mmhg n = 403,Blood Pressure,D001794,NA,0,69,any,2,000000000,Blood Pressure,NA
6068,29148144,2,sbp,Blood Pressure,D001794,NA,0,69,any,2,000000000,Blood Pressure,NA
6069,29151034,2,cardiovascular death/myocardial infarction/stroke,Myocardial Infarction,D009203,NA,0,1822,any,2,000000000,Myocardial Infarction,NA
6070,29151034,2,men,Gender Identity,D005783,NA,0,1822,any,2,000000000,Gender Identity,NA
6071,29151034,2,myocardial infarction,Myocardial Infarction,D009203,NA,0,1822,any,2,000000000,Myocardial Infarction,NA
6072,29151034,2,primary endpoint,Gender Identity,D005783,NA,0,1822,any,2,000000000,Gender Identity,NA
6073,29151034,2,women,Gender Identity,D005783,NA,0,1822,any,2,000000000,Gender Identity,NA
6074,29151034,3,women men,Gender Identity,D005783,NA,0,1247,any,2,000000000,Gender Identity,NA
6075,29151034,4,men,Gender Identity,D005783,NA,0,1285,any,2,000000000,Gender Identity,NA
6076,29151034,4,women,Gender Identity,D005783,NA,0,1285,any,2,000000000,Gender Identity,NA
6077,29151034,5,men,Gender Identity,D005783,NA,0,1797,any,2,000000000,Gender Identity,NA
6078,29151034,5,women,Gender Identity,D005783,NA,0,1797,any,2,000000000,Gender Identity,NA
6079,29159457,2,stage 3a ckd cohort (secondary analysis),Renal Insufficiency,D051437,NA,0,1578,any,2,000000000,Renal Insufficiency,NA
6080,29228101,2,no rhtn,Hypertension,D006973,NA,0,156,any,2,000000000,Hypertension,NA
6081,29228101,2,rhtn,Hypertension,D006973,NA,0,156,any,2,000000000,Hypertension,NA
6082,29242349,NA,patients not receiving sulfonylureas,Hypoglycemic Agents,D007004,NA,0,0,any,2,000000000,Hypoglycemic Agents,53
6083,29248384,NA,Chronic kidney disease,Kidney Diseases,D007674,NA,0,0,any,2,000000000,Kidney Diseases,NA
6084,29248384,NA,Diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
6085,29263150,2,age,Age Factors,D000367,NA,0,650,any,2,000000000,Age Factors,NA
6086,29263150,2,ezetimibe/simvastatin,lipid modifying agents,NA,C10,0,650,any,2,000000000,lipid modifying agents,NA
6087,29263150,3,diabetes,Diabetes Mellitus,D003920,NA,0,1461,any,2,000000000,Diabetes Mellitus,NA
6088,29263150,3,dm absent,Diabetes Mellitus,D003920,NA,0,1461,previous,8,100000000,Diabetes Mellitus,NA
6089,29263150,3,dm present,Diabetes Mellitus,D003920,NA,0,1461,any,2,000000000,Diabetes Mellitus,NA
6090,29266675,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,117
6091,29266675,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,NA
6092,29266675,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
6093,29279300,2,male female,Gender Identity,D005783,NA,0,1741,any,2,000000000,Gender Identity,NA
6094,29299340,2,IXEQ2W + cDMARD,Immunosuppressive Agents,D007166,NA,0,956,any,2,000000000,Immunosuppressive Agents,NA
6095,29299340,2,IXEQ2W + cDMARD naive or past use,Immunosuppressive Agents,D007166,NA,0,956,previous,8,100000000,Immunosuppressive Agents,NA
6096,29299340,2,IXEQ2W + MTX,Immunosuppressive Agents,D007166,NA,0,956,any,2,000000000,Immunosuppressive Agents,NA
6097,29299340,2,IXEQ4W + cDMARD,Immunosuppressive Agents,D007166,NA,0,956,any,2,000000000,Immunosuppressive Agents,NA
6098,29299340,2,IXEQ4W + cDMARD naive or past use,Immunosuppressive Agents,D007166,NA,0,956,previous,8,100000000,Immunosuppressive Agents,NA
6099,29299340,2,IXEQ4W + MTX,Immunosuppressive Agents,D007166,NA,0,956,any,2,000000000,Immunosuppressive Agents,NA
6100,29299340,2,PBO + cDMARD naive or past use,complex,none,NA,0,956,previous,8,100000000,complex,NA
6101,29307087,2,overall;who fc ii symptoms at baseline,Pulmonary Arterial Hypertension,D000081029,NA,0,1501,severity,11,000100000,Pulmonary Arterial Hypertension,NA
6102,29307087,2,overall;who fc iii symptoms at baseline,Pulmonary Arterial Hypertension,D000081029,NA,0,1501,severity,11,000100000,Pulmonary Arterial Hypertension,NA
6103,29338762,2,";bmi, kg/m2",Body Mass Index,D015992,NA,0,573,any,2,000000000,Body Mass Index,NA
6104,29338762,2,ACPA,Anti-Citrullinated Protein Antibodies,D000075422,NA,0,573,any,2,000000000,Anti-Citrullinated Protein Antibodies,NA
6105,29338762,2,age,Age Factors,D000367,NA,0,573,any,2,000000000,Age Factors,NA
6106,29338762,2,cdai,"Arthritis, Rheumatoid",D001172,NA,0,573,severity,11,000100000,"Arthritis, Rheumatoid",NA
6107,29338762,2,das28,"Arthritis, Rheumatoid",D001172,NA,0,573,duration,5,001100000,"Arthritis, Rheumatoid",NA
6108,29338762,2,disease duration,"Arthritis, Rheumatoid",D001172,NA,0,573,duration,5,001000000,"Arthritis, Rheumatoid",NA
6109,29338762,2,ESR,Blood Sedimentation,D001799,NA,0,573,any,2,000000000,Blood Sedimentation,NA
6110,29338762,2,HAQ,Quality of Life,D011788,NA,0,573,any,2,000000000,Quality of Life,NA
6111,29338762,2,prior/current smoker,Cigarette Smoking,D000073865,NA,0,573,previous,8,110000000,Cigarette Smoking,NA
6112,29338762,2,RF,Rheumatoid Factor,D012217,NA,0,573,any,2,000000000,Rheumatoid Factor,NA
6113,29338762,2,SDAI,"Arthritis, Rheumatoid",D001172,NA,0,573,severity,11,000100000,"Arthritis, Rheumatoid",NA
6114,29338762,2,sex,Gender Identity,D005783,NA,0,573,any,2,000000000,Gender Identity,NA
6115,29338762,2,y C-reactive protein;,C-Reactive Protein,D002097,NA,0,573,any,2,000000000,C-Reactive Protein,NA
6116,29406853,NA,Medical History: Multivessel Coronary Disease,Coronary Artery Disease,D003324,NA,0,0,previous,8,100000000,Coronary Artery Disease,44
6116,29406853,NA,Medical History: Multivessel Coronary Disease,Coronary Artery Disease,D003324,NA,0,0,previous,8,100000000,Coronary Artery Disease,111
6117,29409133,1,Anti-TNF-IR,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,737,any,2,000000000,Tumor Necrosis Factor Inhibitors,NA
6118,29409133,1,Anti-TNF-naÃ¯ve,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,737,any,2,000000000,Tumor Necrosis Factor Inhibitors,NA
6119,29409951,2,";ige high (>150 ku/l; n = 1,204)",Immunoglobulin E,D007073,NA,0,518,any,2,000000000,Immunoglobulin E,NA
6120,29409951,2,";igelow(<150ku/l; n=1,053)",Immunoglobulin E,D007073,NA,0,518,any,2,000000000,Immunoglobulin E,NA
6121,29409951,2,IgE levels,Immunoglobulin E,D007073,NA,0,518,any,2,000000000,Immunoglobulin E,NA
6122,29409951,3,";ige high (>150 ku/l; n = 1,204)",Immunoglobulin E,D007073,NA,0,781,any,2,000000000,Immunoglobulin E,NA
6123,29409951,3,";igelow(<150ku/l; n=1,053)",Immunoglobulin E,D007073,NA,0,781,any,2,000000000,Immunoglobulin E,NA
6124,29409951,3,IgE levels,Immunoglobulin E,D007073,NA,0,781,any,2,000000000,Immunoglobulin E,NA
6125,29413502,2,high blood eosinophil counts,Eosinophilia,D004802,NA,0,1801,any,2,000000000,Eosinophilia,NA
6126,29413502,2,high serum periostin,"POSTN protein, human",C512835,NA,0,1801,any,2,000000000,"POSTN protein, human",NA
6127,29414542,NA,use of lamotrigine,Lamotrigine,D000077213,NA,0,0,any,2,000000000,Lamotrigine,275
6128,29414542,NA,use of topiramate,Topiramate,D000077236,NA,0,0,any,2,000000000,Topiramate,86
6129,29415145,1,"age, years",Age Factors,D000367,NA,0,928,any,2,000000000,Age Factors,NA
6130,29415145,1,"age, years;<65",Age Factors,D000367,NA,0,928,any,2,000000000,Age Factors,NA
6131,29415145,1,"age, years;=>65",Age Factors,D000367,NA,0,928,any,2,000000000,Age Factors,NA
6132,29415145,1,"baseline weight, kg",Body Weight,D001835,NA,0,928,any,2,000000000,Body Weight,NA
6133,29415145,1,corticosteroid use,Steroids,D013256,NA,0,928,any,2,000000000,Steroids,NA
6134,29415145,1,disease Duration rheumatoid arthritis,"Arthritis, Rheumatoid",D001172,NA,0,928,duration,5,001000000,"Arthritis, Rheumatoid",NA
6135,29415145,1,region (pooled),Geographic Locations,D005842,NA,0,928,any,2,000000000,Geographic Locations,NA
6136,29415145,1,region (pooled);rest of world,Geographic Locations,D005842,NA,0,928,any,2,000000000,Geographic Locations,NA
6137,29415145,1,region (pooled);usa and canada,Geographic Locations,D005842,NA,0,928,any,2,000000000,Geographic Locations,NA
6138,29415145,1,seropositivity,"Arthritis, Rheumatoid",D001172,NA,0,928,risk score,10,000000100,"Arthritis, Rheumatoid",NA
6139,29415145,1,seropositivity;rf and acpa negative,Rheumatoid Factor,D012217,NA,0,928,any,2,000000000,Rheumatoid Factor,NA
6140,29415145,1,seropositivity;rf or acpa positive,Rheumatoid Factor,D012217,NA,0,928,any,2,000000000,Rheumatoid Factor,NA
6141,29415145,2,no. of non-tnfi,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,180,any,2,000000000,Tumor Necrosis Factor Inhibitors,NA
6142,29415145,2,no. of prior bdmards,Antirheumatic Agents,D018501,NA,0,180,previous,8,100000000,Antirheumatic Agents,NA
6143,29415145,2,no. of prior tnfi,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,180,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
6144,29415145,2,no. of tnfi among non-tnfi naive,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,180,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
6145,29415145,2,prior tnfi treatment,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,180,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
6146,29415145,2,"prior tnfi treatment;ada, no",Tumor Necrosis Factor Inhibitors,D000079424,NA,0,180,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
6147,29415145,2,"prior tnfi treatment;ada, yes",Tumor Necrosis Factor Inhibitors,D000079424,NA,0,180,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
6148,29415145,2,"prior tnfi treatment;etn, no",Tumor Necrosis Factor Inhibitors,D000079424,NA,0,180,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
6149,29415145,2,"prior tnfi treatment;etn, yes",Tumor Necrosis Factor Inhibitors,D000079424,NA,0,180,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
6150,29415145,2,"prior tnfi treatment;inflix, no",Tumor Necrosis Factor Inhibitors,D000079424,NA,0,180,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
6151,29415145,2,"prior tnfi treatment;inflix, yes",Tumor Necrosis Factor Inhibitors,D000079424,NA,0,180,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
6152,29429593,2,<30% (n=314),Pulmonary Ventilation,D012123,NA,0,359,previous severity,9,100100000,Pulmonary Ventilation,NA
6153,29429593,2,>1 exacerbation in prev 12 m (n=294),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,359,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
6154,29429593,2,>30%(n=1218),Pulmonary Ventilation,D012123,NA,0,359,previous severity,9,100100000,Pulmonary Ventilation,NA
6155,29429593,2,1 exacerbation in prev 12 m (n=1238),"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,359,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
6156,29429593,2,chronic bronchitis (n=855),Bronchitis,D001991,NA,0,359,any,2,000000000,Bronchitis,NA
6157,29429593,2,emphysema (n=462),Pulmonary Emphysema,D011656,NA,0,359,aetiological,1,000001000,Pulmonary Emphysema,NA
6158,29429593,2,male female,Gender Identity,D005783,NA,0,359,any,2,000000000,Gender Identity,NA
6159,29429593,2,Prespecified subgroup analyses according to baseline blood eosinophil count,Eosinophilia,D004802,NA,0,359,any,2,000000000,Eosinophilia,NA
6160,29429593,2,Smoker,Cigarette Smoking,D000073865,NA,0,359,any,2,000000000,Cigarette Smoking,NA
6161,29430796,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,276
6162,29430801,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
6163,29430801,NA,duration of diabetes,Diabetes Mellitus,D003920,NA,0,0,duration,5,001000000,Diabetes Mellitus,NA
6164,29430801,NA,hba1c,Glycated Hemoglobin A,D006442,NA,0,0,any,2,000000000,Glycated Hemoglobin A,79
6165,29431256,2,Ejection Fraction,Stroke Volume,D013318,NA,0,102,any,2,000000000,Stroke Volume,NA
6166,29445520,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,79
6167,29445520,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
6168,29445520,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
6169,29447769,NA,Medical History: Prior Stroke,Stroke,D020521,NA,0,0,previous,8,100000000,Stroke,67
6170,29463520,2,non-statin (n=1054),Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,1395,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
6171,29463520,2,non-statin (n=704),Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,1395,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
6172,29463520,2,statin (n=137),Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,1395,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
6173,29463520,2,statin (n=84),Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,1395,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
6174,29471381,NA,perianal fistula,Fistula,D005402,NA,0,0,any,2,000000000,Fistula,186
6175,29490509,2,severe disease subgroup,Prostatic Hyperplasia,D011470,NA,0,624,severity,11,000100000,Prostatic Hyperplasia,NA
6176,29526832,2,h/o of heart failure,Heart Failure,D006333,NA,0,742,previous,8,100000000,Heart Failure,NA
6177,29544534,NA,concomitant MTX use,Immunosuppressive Agents,D007166,NA,0,0,any,2,000000000,Immunosuppressive Agents,214
6178,29544534,NA,previous anti-TNF use (ACR20/50 and DAS28-CRP assessments) concomitant MTX use,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,0,previous,8,100000000,Tumor Necrosis Factor Inhibitors,77
6179,29544870,2,"Baseline Diabetes, Baseline PreDiabetes,Baseline Normoglycemia",Diabetes Mellitus,D003920,NA,0,1053,any,2,000000000,Diabetes Mellitus,NA
6180,29544870,3,"Baseline Diabetes, Baseline PreDiabetes,Baseline Normoglycemia",Diabetes Mellitus,D003920,NA,0,885,any,2,000000000,Diabetes Mellitus,NA
6181,29556416,2,<4.5 (n=140),"Arthritis, Psoriatic",D015535,NA,0,968,severity,11,000100000,"Arthritis, Psoriatic",NA
6182,29556416,2,<4.5 (n=29),"Arthritis, Psoriatic",D015535,NA,0,968,severity,11,000100000,"Arthritis, Psoriatic",NA
6183,29556416,2,<4.5 (n=31),"Arthritis, Psoriatic",D015535,NA,0,968,severity,11,000100000,"Arthritis, Psoriatic",NA
6184,29556416,2,<4.5 (n=65),"Arthritis, Psoriatic",D015535,NA,0,968,severity,11,000100000,"Arthritis, Psoriatic",NA
6185,29556416,2,<4.5 (n=75),"Arthritis, Psoriatic",D015535,NA,0,968,severity,11,000100000,"Arthritis, Psoriatic",NA
6186,29556416,2,>4.5 (n=129),"Arthritis, Psoriatic",D015535,NA,0,968,severity,11,000100000,"Arthritis, Psoriatic",NA
6187,29556416,2,>4.5 (n=26),"Arthritis, Psoriatic",D015535,NA,0,968,severity,11,000100000,"Arthritis, Psoriatic",NA
6188,29556416,2,>4.5 (n=30),"Arthritis, Psoriatic",D015535,NA,0,968,severity,11,000100000,"Arthritis, Psoriatic",NA
6189,29556416,2,>4.5 (n=58),"Arthritis, Psoriatic",D015535,NA,0,968,severity,11,000100000,"Arthritis, Psoriatic",NA
6190,29556416,2,>4.5 (n=71),"Arthritis, Psoriatic",D015535,NA,0,968,severity,11,000100000,"Arthritis, Psoriatic",NA
6191,29556416,2,Baseline mTSS,"Arthritis, Rheumatoid",D001172,NA,0,968,severity,11,000100000,"Arthritis, Rheumatoid",NA
6192,29563108,NA,urinary protein:creatinine ratio,Albuminuria,D000419,NA,0,0,any,2,000000000,Albuminuria,154
6193,29661699,2,with diabetes,Diabetes Mellitus,D003920,NA,0,1614,any,2,000000000,Diabetes Mellitus,NA
6194,29661699,2,without diabetes,Diabetes Mellitus,D003920,NA,0,1614,any,2,000000000,Diabetes Mellitus,NA
6195,29664406,2,;nonblack (n=1465),Racial Groups,D044469,NA,0,1562,any,2,000000000,Racial Groups,NA
6196,29664406,2,race,Racial Groups,D044469,NA,0,1562,any,2,000000000,Racial Groups,NA
6197,29671280,2,hypocomplementemic (C3 <90 mg/dl and/or C4 <10 mg/dl) and anti-double-stranded DNA (anti-dsDNA) positive (=30 IU/ml) at baseline.,Autoantibodies,D001323,NA,0,1317,any,2,000000000,Autoantibodies,NA
6198,29671280,2,hypocomplementemic (C3 <90 mg/dl and/or C4 <10 mg/dl) and anti-double-stranded DNA (anti-dsDNA) positive (Ã¢â€°Â¥30 IU/ml) at baseline.,Autoantibodies,D001323,NA,0,1317,any,2,000000000,Autoantibodies,NA
6199,29680881,NA,region,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,281
6200,29685860,1,-¦-;accord acr <3-4,Albuminuria,D000419,NA,0,1310,any,2,000000000,Albuminuria,NA
6201,29685860,1,;sprint acr <3-4,Albuminuria,D000419,NA,0,1310,any,2,000000000,Albuminuria,NA
6202,29685860,1,;sprint acr >3-4,Albuminuria,D000419,NA,0,1310,any,2,000000000,Albuminuria,NA
6203,29685860,1,age (years),Age Factors,D000367,NA,0,1078,any,2,000000000,Age Factors,NA
6204,29685860,1,antihypertensive agents (n per patient),Antihypertensive Agents,D000959,NA,0,1078,any,2,000000000,Antihypertensive Agents,NA
6205,29685860,1,body-mass index (kg/m2),Body Mass Index,D015992,NA,0,1078,any,2,000000000,Body Mass Index,NA
6206,29685860,1,clinical atherosclerotic disease*,Atherosclerosis,D050197,NA,0,1078,any,2,000000000,Atherosclerosis,NA
6207,29685860,1,diastolic blood pressure (mm hg),Blood Pressure,D001794,NA,0,1078,any,2,000000000,Blood Pressure,NA
6208,29685860,1,duration of diabetes (years),Diabetes Mellitus,D003920,NA,0,1078,duration,5,001000000,Diabetes Mellitus,NA
6209,29685860,1,egfrâ€¡ (ml/min per 1Â·73 m2),Glomerular Filtration Rate,D005919,NA,0,1078,any,2,000000000,Glomerular Filtration Rate,NA
6210,29685860,1,fasting plasma glucose (mmol/l),Glucose,D005947,NA,0,1078,any,2,000000000,Glucose,NA
6211,29685860,1,male female,Gender Identity,D005783,NA,0,1078,any,2,000000000,Gender Identity,NA
6212,29685860,1,never smoked,Cigarette Smoking,D000073865,NA,0,1078,any,2,000000000,Cigarette Smoking,NA
6213,29685860,1,race,Racial Groups,D044469,NA,0,1078,any,2,000000000,Racial Groups,NA
6214,29685860,1,systolic blood pressure (mm hg),Blood Pressure,D001794,NA,0,1078,any,2,000000000,Blood Pressure,NA
6215,29685860,1,urinary acr (mg/mmol),Albuminuria,D000419,NA,0,1078,any,2,000000000,Albuminuria,NA
6216,29685860,1,-¦-;accord acr >3-4,Albuminuria,D000419,NA,0,1310,any,2,000000000,Albuminuria,NA
6217,29685860,1,-¦-,Albuminuria,D000419,NA,0,1310,any,2,000000000,Albuminuria,NA
6218,29685860,NA,Albuminuria,Albuminuria,D000419,NA,0,0,any,2,000000000,Albuminuria,NA
6219,29687620,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,280
6220,29713156,2,"age, years",Age Factors,D000367,NA,0,226,any,2,000000000,Age Factors,NA
6221,29713156,2,ccq total score,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,226,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
6222,29713156,2,"dyspnea â€“ mmrc grade, n (%)",Dyspnea,D004417,NA,0,226,severity,11,000100000,Dyspnea,NA
6223,29713156,2,"number of patients with exacerbations in the previous 12 months, n (%)","Pulmonary Disease, Chronic Obstructive",D029424,NA,0,226,previous severity,9,100100000,"Pulmonary Disease, Chronic Obstructive",NA
6224,29713156,2,"post-bronchodilator fev1, % predicted",Bronchodilator Agents,D001993,NA,0,226,any,2,000000000,Bronchodilator Agents,NA
6225,29713156,2,"post-bronchodilator fev1, l",Bronchodilator Agents,D001993,NA,0,226,any,2,000000000,Bronchodilator Agents,NA
6226,29743836,NA,Patient Variable: Ethnicity,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,32
6227,29743836,NA,race,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,32
6228,29748996,1,";hba1c, %d",Glycated Hemoglobin A,D006442,NA,0,1152,any,2,000000000,Glycated Hemoglobin A,NA
6229,29748996,1,";weight, kg",Body Weight,D001835,NA,0,1152,any,2,000000000,Body Weight,NA
6230,29748996,1,male female,Gender Identity,D005783,NA,0,1152,any,2,000000000,Gender Identity,NA
6231,29766634,2,";age, years",Age Factors,D000367,NA,0,711,any,2,000000000,Age Factors,NA
6232,29766634,2,";weight, kg",Body Weight,D001835,NA,0,711,any,2,000000000,Body Weight,NA
6233,29766634,2,male female,Gender Identity,D005783,NA,0,711,any,2,000000000,Gender Identity,NA
6234,29768149,NA,uncontrolled on as-needed inhaled short-acting bronchodilator(s) vs well-controlled on maintenance low-dose inhaled glucocorticoid or LTRA plus as-needed short-acting bronchodilator(s).,Adrenal Cortex Hormones,D000305,NA,0,0,any,2,000000000,Adrenal Cortex Hormones,16
6235,29777264,1,";age, years",Age Factors,D000367,NA,0,294,any,2,000000000,Age Factors,NA
6236,29777264,1,;anti-hypertensive therapy,Antihypertensive Agents,D000959,NA,0,294,any,2,000000000,Antihypertensive Agents,NA
6237,29777264,1,;anticoagulant,Anticoagulants,D000925,NA,0,294,any,2,000000000,Anticoagulants,NA
6238,29777264,1,";bmi, kg/m2",Body Mass Index,D015992,NA,0,294,any,2,000000000,Body Mass Index,NA
6239,29777264,1,;cardiac failurec,Heart Failure,D006333,NA,0,294,any,2,000000000,Heart Failure,NA
6240,29777264,1,";egfr (mdrd), ml min-1 1.73Â m-2",Glomerular Filtration Rate,D005919,NA,0,294,any,2,000000000,Glomerular Filtration Rate,NA
6241,29777264,1,";egfr (mdrd), ml minÃ¢Ë†â€™1 1.73Ã‚Â mÃ¢Ë†â€™2",Glomerular Filtration Rate,D005919,NA,0,294,any,2,000000000,Glomerular Filtration Rate,NA
6242,29777264,1,";hba1c, %d",Glycated Hemoglobin A,D006442,NA,0,294,any,2,000000000,Glycated Hemoglobin A,NA
6243,29777264,1,";hba1c, mmol/mold",Glycated Hemoglobin A,D006442,NA,0,294,any,2,000000000,Glycated Hemoglobin A,NA
6244,29777264,1,;lipid-lowering therapy,lipid modifying agents,NA,C10,0,294,any,2,000000000,lipid modifying agents,NA
6245,29777264,1,";total cholesterol, mmol/le",Lipoproteins,D008074,NA,0,294,any,2,000000000,Lipoproteins,NA
6246,29777264,1,";triacylglycerol, mmol/le",Lipoproteins,D008074,NA,0,294,any,2,000000000,Lipoproteins,NA
6247,29777264,1,";weight, kg",Body Weight,D001835,NA,0,294,any,2,000000000,Body Weight,NA
6248,29777264,1,Diastolic blood pressure,Blood Pressure,D001794,NA,0,294,any,2,000000000,Blood Pressure,NA
6249,29777264,1,HDL cholesterol,Lipoproteins,D008074,NA,0,294,any,2,000000000,Lipoproteins,NA
6250,29777264,1,LDL cholesterol,Lipoproteins,D008074,NA,0,294,any,2,000000000,Lipoproteins,NA
6251,29777264,1,male female,Gender Identity,D005783,NA,0,294,any,2,000000000,Gender Identity,NA
6252,29777264,1,sbp,Blood Pressure,D001794,NA,0,294,any,2,000000000,Blood Pressure,NA
6253,29782217,2,fraction of exhaled nitric oxide,Soluble Guanylyl Cyclase,D000071756,NA,0,424,any,2,000000000,Soluble Guanylyl Cyclase,NA
6254,29782217,2,fraction of exhaled nitric oxide;<25 ppb,Soluble Guanylyl Cyclase,D000071756,NA,0,424,any,2,000000000,Soluble Guanylyl Cyclase,NA
6255,29782217,2,fraction of exhaled nitric oxide;>25 to <50 ppb,Soluble Guanylyl Cyclase,D000071756,NA,0,424,any,2,000000000,Soluble Guanylyl Cyclase,NA
6256,29782217,2,fraction of exhaled nitric oxide;>50 ppb,Soluble Guanylyl Cyclase,D000071756,NA,0,424,any,2,000000000,Soluble Guanylyl Cyclase,NA
6257,29782217,2,Prespecified subgroup analyses according to baseline blood eosinophil count,Eosinophilia,D004802,NA,0,424,any,2,000000000,Eosinophilia,NA
6258,29782217,3,fraction of exhaled nitric oxide,Soluble Guanylyl Cyclase,D000071756,NA,0,78,any,2,000000000,Soluble Guanylyl Cyclase,NA
6259,29782217,3,fraction of exhaled nitric oxide;<25 ppb,Soluble Guanylyl Cyclase,D000071756,NA,0,78,any,2,000000000,Soluble Guanylyl Cyclase,NA
6260,29782217,3,fraction of exhaled nitric oxide;>25 to <50 ppb,Soluble Guanylyl Cyclase,D000071756,NA,0,78,any,2,000000000,Soluble Guanylyl Cyclase,NA
6261,29782217,3,fraction of exhaled nitric oxide;>50 ppb,Soluble Guanylyl Cyclase,D000071756,NA,0,78,any,2,000000000,Soluble Guanylyl Cyclase,NA
6262,29782217,3,Prespecified subgroup analyses according to baseline blood eosinophil count,Eosinophilia,D004802,NA,0,78,any,2,000000000,Eosinophilia,NA
6263,29790415,1,gene type,Genetic Profile,D000076610,NA,0,1309,type,12,000000010,Genetic Profile,NA
6264,29793629,2,;egfrÂ <60Â ml/min/1.73 m2,Glomerular Filtration Rate,D005919,NA,0,1766,any,2,000000000,Glomerular Filtration Rate,NA
6265,29793629,2,;egfrÂ =60Â ml/min/1.73 m2,Glomerular Filtration Rate,D005919,NA,0,1766,any,2,000000000,Glomerular Filtration Rate,NA
6266,29793629,2,;egfrÃ‚Â Ã¢â€°Â¥60Ã‚Â ml/min/1.73 m2,Glomerular Filtration Rate,D005919,NA,0,1766,any,2,000000000,Glomerular Filtration Rate,NA
6267,29793629,2,;uacrÂ <3Â mg/mmol*,Albuminuria,D000419,NA,0,1766,any,2,000000000,Albuminuria,NA
6268,29793629,2,;uacrÂ =3Â mg/mmol*,Albuminuria,D000419,NA,0,1766,any,2,000000000,Albuminuria,NA
6269,29793629,2,;uacrÃ‚Â <3Ã‚Â mg/mmolÃ¢Ë†â€”,Albuminuria,D000419,NA,0,1766,any,2,000000000,Albuminuria,NA
6270,29793629,2,;uacrÃ‚Â Ã¢â€°Â¥3Ã‚Â mg/mmolÃ¢Ë†â€”,Albuminuria,D000419,NA,0,1766,any,2,000000000,Albuminuria,NA
6271,29797519,1,anti-TNF treatment failure,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,465,any,2,000000000,Tumor Necrosis Factor Inhibitors,NA
6272,29797519,1,anti-TNF treatment non-failure,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,465,any,2,000000000,Tumor Necrosis Factor Inhibitors,NA
6273,29857145,3,TNF antagonistâ€“exposed,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,450,any,2,000000000,Tumor Necrosis Factor Inhibitors,NA
6274,29857145,3,TNF antagonistâ€“naive,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,450,any,2,000000000,Tumor Necrosis Factor Inhibitors,NA
6275,29857145,3,TNF antagonist exposed,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,450,any,2,000000000,Tumor Necrosis Factor Inhibitors,NA
6276,29857145,3,TNF antagonist naive,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,450,any,2,000000000,Tumor Necrosis Factor Inhibitors,NA
6277,29857145,4,TNF antagonistâ€“exposed,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,1292,any,2,000000000,Tumor Necrosis Factor Inhibitors,NA
6278,29857145,4,TNF antagonistâ€“naive,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,1292,any,2,000000000,Tumor Necrosis Factor Inhibitors,NA
6279,29857145,4,TNF antagonist exposed,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,1292,any,2,000000000,Tumor Necrosis Factor Inhibitors,NA
6280,29857145,4,TNF antagonist naive,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,1292,any,2,000000000,Tumor Necrosis Factor Inhibitors,NA
6281,29857145,5,TNF antagonistâ€“exposed,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,105,any,2,000000000,Tumor Necrosis Factor Inhibitors,NA
6282,29857145,5,TNF antagonistâ€“naive,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,105,any,2,000000000,Tumor Necrosis Factor Inhibitors,NA
6283,29857145,5,TNF antagonist exposed,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,105,any,2,000000000,Tumor Necrosis Factor Inhibitors,NA
6284,29857145,5,TNF antagonist naive,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,105,any,2,000000000,Tumor Necrosis Factor Inhibitors,NA
6285,29857145,6,TNF antagonistâ€“exposed,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,1064,any,2,000000000,Tumor Necrosis Factor Inhibitors,NA
6286,29857145,6,TNF antagonistâ€“naive,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,1064,any,2,000000000,Tumor Necrosis Factor Inhibitors,NA
6287,29857145,6,TNF antagonist exposed,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,1064,any,2,000000000,Tumor Necrosis Factor Inhibitors,NA
6288,29857145,6,TNF antagonist naive,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,1064,any,2,000000000,Tumor Necrosis Factor Inhibitors,NA
6289,29857145,7,TNF antagonistâ€“exposed,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,771,any,2,000000000,Tumor Necrosis Factor Inhibitors,NA
6290,29857145,7,TNF antagonistâ€“naive,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,771,any,2,000000000,Tumor Necrosis Factor Inhibitors,NA
6291,29857145,7,TNF antagonist exposed,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,771,any,2,000000000,Tumor Necrosis Factor Inhibitors,NA
6292,29857145,7,TNF antagonist naive,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,771,any,2,000000000,Tumor Necrosis Factor Inhibitors,NA
6293,29880010,1,;tnf-ir,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,677,any,2,000000000,Tumor Necrosis Factor Inhibitors,NA
6294,29880010,1,prior exposure to anti TNF,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,677,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
6295,29903515,3,"nonalcoholic fatty liver disease fibrosis score, severity",Non-alcoholic Fatty Liver Disease,D065626,NA,0,NA,severity,11,000100000,Non-alcoholic Fatty Liver Disease,NA
6296,29903515,3,"nonalcoholic fatty liver disease fibrosis score, severity/risk",Non-alcoholic Fatty Liver Disease,D065626,NA,0,NA,severity,11,000100100,Non-alcoholic Fatty Liver Disease,NA
6297,29908670,1,age,Age Factors,D000367,NA,0,671,any,2,000000000,Age Factors,NA
6298,29908670,1,BMI,Body Mass Index,D015992,NA,0,671,any,2,000000000,Body Mass Index,NA
6299,29908670,1,gender,Gender Identity,D005783,NA,0,671,any,2,000000000,Gender Identity,NA
6300,29908670,1,race,Racial Groups,D044469,NA,0,671,any,2,000000000,Racial Groups,NA
6301,29908670,1,race;non-white,Racial Groups,D044469,NA,0,671,any,2,000000000,Racial Groups,NA
6302,29908670,1,region,Geographic Locations,D005842,NA,0,671,any,2,000000000,Geographic Locations,NA
6303,29908670,1,weight,Body Weight,D001835,NA,0,671,any,2,000000000,Body Weight,NA
6304,29909019,2,induction study population,unclassifiable,NA,NA,0,1689,previous,8,100000000,unclassifiable,NA
6305,29909019,2,randomized patients with eligible SES-CD score or ulcerations at induction baseline,Endoscopy,D004724,NA,0,1689,severity,11,000100000,Endoscopy,NA
6306,29910024,NA,albuminuria,Albuminuria,D000419,NA,0,0,any,2,000000000,Albuminuria,80
6307,29925383,2,;age <65years,Age Factors,D000367,NA,0,1421,any,2,000000000,Age Factors,NA
6308,29925383,2,;age =65years,Age Factors,D000367,NA,0,1421,any,2,000000000,Age Factors,NA
6309,29925383,2,;age Ã¢â€°Â¥65years,Age Factors,D000367,NA,0,1421,any,2,000000000,Age Factors,NA
6310,29925383,2,;baseline eosinophil <300 cells/Âµl,Eosinophilia,D004802,NA,0,1421,any,2,000000000,Eosinophilia,NA
6311,29925383,2,;baseline eosinophil <300 cells/ÃŽÂ¼l,Eosinophilia,D004802,NA,0,1421,any,2,000000000,Eosinophilia,NA
6312,29925383,2,;baseline eosinophil =300 cells/Âµl,Eosinophilia,D004802,NA,0,1421,any,2,000000000,Eosinophilia,NA
6313,29925383,2,;baseline eosinophil Ã¢â€°Â¥300 cells/ÃŽÂ¼l,Eosinophilia,D004802,NA,0,1421,any,2,000000000,Eosinophilia,NA
6314,29925383,2,;moderate copd,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1421,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
6315,29925383,2,;severe copd,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1421,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
6316,29925383,2,;very severe copd,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1421,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
6317,29925383,2,male female,Gender Identity,D005783,NA,0,1421,any,2,000000000,Gender Identity,NA
6318,29925383,2,Smoker,Cigarette Smoking,D000073865,NA,0,1421,any,2,000000000,Cigarette Smoking,NA
6319,29937267,2,;age (years),Age Factors,D000367,NA,0,1464,any,2,000000000,Age Factors,NA
6320,29937267,2,;baseline albuminuria,Albuminuria,D000419,NA,0,1464,any,2,000000000,Albuminuria,NA
6321,29937267,2,;black or african-american,Racial Groups,D044469,NA,0,1464,any,2,000000000,Racial Groups,NA
6322,29937267,2,;blood pressure control,Blood Pressure,D001794,NA,0,1464,any,2,000000000,Blood Pressure,NA
6323,29937267,2,;bmi (kg/m^),Body Mass Index,D015992,NA,0,1464,any,2,000000000,Body Mass Index,NA
6324,29937267,2,;central or south america,Geographic Locations,D005842,NA,0,1464,any,2,000000000,Geographic Locations,NA
6325,29937267,2,;duration of diabetes (years),Diabetes Mellitus,D003920,NA,0,1464,duration,5,001000000,Diabetes Mellitus,NA
6326,29937267,2,;ecfr (ml/min per 1-73 mâ€™),Glomerular Filtration Rate,D005919,NA,0,1464,any,2,000000000,Glomerular Filtration Rate,NA
6327,29937267,2,;race,Racial Groups,D044469,NA,0,1464,any,2,000000000,Racial Groups,NA
6328,29937267,2,;region,Geographic Locations,D005842,NA,0,1464,any,2,000000000,Geographic Locations,NA
6329,29937267,2,;renin-angiotensin system inhibitor use,agents acting on the renin-angiotensin system,NA,C09,0,1464,any,2,000000000,agents acting on the renin-angiotensin system,NA
6330,29937267,2,;rest ofthe world,Geographic Locations,D005842,NA,0,1464,any,2,000000000,Geographic Locations,NA
6331,29937267,2,;sex,Gender Identity,D005783,NA,0,1464,any,2,000000000,Gender Identity,NA
6332,29937267,2,;statin use,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,1464,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
6333,29937267,2,;systolic blood pressure <140 mm hg and diastolic,Blood Pressure,D001794,NA,0,1464,any,2,000000000,Blood Pressure,NA
6334,29937267,2,;systolic blood pressure >140 mm hg or diastolic,Blood Pressure,D001794,NA,0,1464,any,2,000000000,Blood Pressure,NA
6335,29937267,2,Loop diuretics,Diuretics,D004232,NA,0,1464,any,2,000000000,Diuretics,NA
6336,29937267,2,Prior CVD,Cardiovascular Diseases,D002318,NA,0,1464,previous,8,100000000,Cardiovascular Diseases,NA
6337,29937431,NA,hba1c,Glycated Hemoglobin A,D006442,NA,0,0,any,2,000000000,Glycated Hemoglobin A,161
6338,29941478,1,eGFR,Glomerular Filtration Rate,D005919,NA,0,1812,any,2,000000000,Glomerular Filtration Rate,NA
6339,29941478,1,estimated Glomerular Filtration Rate,Glomerular Filtration Rate,D005919,NA,0,1812,any,2,000000000,Glomerular Filtration Rate,NA
6340,29941478,2,eGFR,Glomerular Filtration Rate,D005919,NA,0,1850,any,2,000000000,Glomerular Filtration Rate,NA
6341,29941478,2,estimated Glomerular Filtration Rate,Glomerular Filtration Rate,D005919,NA,0,1850,any,2,000000000,Glomerular Filtration Rate,NA
6342,29945203,NA,psoriasis affecting ?3% body surface area at baseline,Psoriasis,D011565,NA,0,0,severity,2,000000000,Psoriasis,9
6343,30012431,NA,anti-tumor necrosis factor therapy,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,0,any,2,000000000,Tumor Necrosis Factor Inhibitors,13
6344,30012431,NA,corticosteroid use,Adrenal Cortex Hormones,D000305,NA,0,0,any,2,000000000,Adrenal Cortex Hormones,213
6345,30012431,NA,crp,C-Reactive Protein,D002097,NA,0,0,any,2,000000000,C-Reactive Protein,213
6346,30026335,2,;for patients not using personal cgm,Glucose,D005947,NA,0,412,any,2,000000000,Glucose,NA
6347,30026335,2,;for patients using personal cgm,Glucose,D005947,NA,0,412,any,2,000000000,Glucose,NA
6348,30026335,3,csii,Insulin,D007328,NA,0,753,any,2,000000000,Insulin,NA
6349,30026335,3,mdi,Insulin,D007328,NA,0,753,any,2,000000000,Insulin,NA
6350,30053967,1,;act total score =Â 20,Asthma,D001249,NA,0,894,severity,11,000100000,Asthma,NA
6351,30053967,1,;act total score Ã¢â€°Â¥Ã¢â‚¬Â¯20,Asthma,D001249,NA,0,894,severity,11,000100000,Asthma,NA
6352,30053967,1,;act total scoreÂ =Â 20 and/or improvement from baselineÂ =Â 3,Asthma,D001249,NA,0,894,severity,11,000100000,Asthma,NA
6353,30053967,1,;act total scoreÃ‚Â Ã¢â€°Â¥Ã¢â‚¬Â¯20 and/or improvement from baselineÃ¢â‚¬Â¯Ã¢â€°Â¥Ã¢â‚¬Â¯3,Asthma,D001249,NA,0,894,severity,11,000100000,Asthma,NA
6354,30053967,1,ICS/LABA subsets,Steroids,D013256,NA,0,894,any,2,000000000,Steroids,NA
6355,30053967,1,inhaled corticosteroid,Steroids,D013256,NA,0,894,any,2,000000000,Steroids,NA
6356,30053967,2,;ics subset,Steroids,D013256,NA,0,862,any,2,000000000,Steroids,NA
6357,30053967,2,;ics/laba subset,Steroids,D013256,R03,0,862,any,2,000000000,Steroids,NA
6358,30121827,3,;tnf-alpha inhibitor inadequate response,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,1468,disease response,4,000000000,Tumor Necrosis Factor Inhibitors,NA
6359,30121827,3,;tnf-alpha inhibitor naive,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,1468,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
6360,30139780,2,;2 exacerbations,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1736,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
6361,30139780,2,;age at diagnosis <18 years,Age Factors,D000367,NA,0,1736,any,2,000000000,Age Factors,NA
6362,30139780,2,;age at diagnosis s18 years,Age Factors,D000367,NA,0,1736,any,2,000000000,Age Factors,NA
6363,30139780,2,";either ocs use, nasal polyps, pre-bd fvc <65% of predicted or age at diagnosis sl8 years",complex,none,NA,0,1736,any,2,000000000,complex,NA
6364,30139780,2,;nasal polyps,Nasal Polyps,D009298,NA,0,1736,any,2,000000000,Nasal Polyps,NA
6365,30139780,2,;no nasal polyps,Nasal Polyps,D009298,NA,0,1736,any,2,000000000,Nasal Polyps,NA
6366,30139780,2,;no ocs,Steroids,D013256,NA,0,1736,any,2,000000000,Steroids,NA
6367,30139780,2,";no ocs use, no nasal polyps, pre-bd fvc s65% of predicted and age at diagnosis <18 years",complex,none,NA,0,1736,any,2,000000000,complex,NA
6368,30139780,2,;ocs,Steroids,D013256,NA,0,1736,any,2,000000000,Steroids,NA
6369,30139780,2,;pre-bd fvc <65% of predicted,Bronchodilator Agents,D001993,NA,0,1736,any,2,000000000,Bronchodilator Agents,NA
6370,30139780,2,;pre-bd fvc s65% of predicted,Bronchodilator Agents,D001993,NA,0,1736,any,2,000000000,Bronchodilator Agents,NA
6371,30139780,2,;s3 exacerbations,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,1736,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",NA
6372,30146931,2,age at baseline (years),Age Factors,D000367,NA,0,1792,any,2,000000000,Age Factors,NA
6373,30146931,2,body mass index (kg/mâ€™)^,Body Mass Index,D015992,NA,0,1792,any,2,000000000,Body Mass Index,NA
6374,30146931,2,body mass index (kg/mâ€œ)^,Body Mass Index,D015992,NA,0,1792,any,2,000000000,Body Mass Index,NA
6375,30146931,2,duration of diabetes (years),Diabetes Mellitus,D003920,NA,0,1792,duration,5,001000000,Diabetes Mellitus,NA
6376,30146931,2,other treatment assignment;omega-3 fatty acids,Fatty Acids,D005227,NA,0,1792,any,2,000000000,Fatty Acids,NA
6377,30146931,2,prior aspirin use,Aspirin,D001241,NA,0,1792,previous,8,100000000,Aspirin,NA
6378,30146931,2,sex,Gender Identity,D005783,NA,0,1792,any,2,000000000,Gender Identity,NA
6379,30146931,2,statin use,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,1792,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
6380,30146931,2,weight at randomization (kg),Body Weight,D001835,NA,0,1792,any,2,000000000,Body Weight,NA
6381,30146931,3,age at baseline (years),Age Factors,D000367,NA,0,820,any,2,000000000,Age Factors,NA
6382,30146931,3,body mass index (kg/mâ€™)^,Body Mass Index,D015992,NA,0,820,any,2,000000000,Body Mass Index,NA
6383,30146931,3,body mass index (kg/mâ€œ)^,Body Mass Index,D015992,NA,0,820,any,2,000000000,Body Mass Index,NA
6384,30146931,3,duration of diabetes (years),Diabetes Mellitus,D003920,NA,0,820,duration,5,001000000,Diabetes Mellitus,NA
6385,30146931,3,other treatment assignment;omega-3 fatty acids,Fatty Acids,D005227,NA,0,820,any,2,000000000,Fatty Acids,NA
6386,30146931,3,prior aspirin use,Aspirin,D001241,NA,0,820,previous,8,100000000,Aspirin,NA
6387,30146931,3,sex,Gender Identity,D005783,NA,0,820,any,2,000000000,Gender Identity,NA
6388,30146931,3,statin use,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,820,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
6389,30146932,2,age at baseline (years),Age Factors,D000367,NA,0,1666,any,2,000000000,Age Factors,NA
6390,30146932,2,body mass index (kg/m^)^,Body Mass Index,D015992,NA,0,1666,any,2,000000000,Body Mass Index,NA
6391,30146932,2,Diabetes,Diabetes Mellitus,D003920,NA,0,1666,duration,5,001000000,Diabetes Mellitus,NA
6392,30146932,2,duration of diabetes (years),Diabetes Mellitus,D003920,NA,0,1666,duration,5,001000000,Diabetes Mellitus,NA
6393,30146932,2,prior aspirin use,Aspirin,D001241,NA,0,1666,previous,8,100000000,Aspirin,NA
6394,30146932,2,sex,Gender Identity,D005783,NA,0,1666,any,2,000000000,Gender Identity,NA
6395,30146932,2,statin use,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,1666,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
6396,30166073,3,age;>75 years,Age Factors,D000367,NA,0,295,any,2,000000000,Age Factors,NA
6397,30166073,3,age;s75 years,Age Factors,D000367,NA,0,295,any,2,000000000,Age Factors,NA
6398,30166073,3,diabetes mellitus,Diabetes Mellitus,D003920,NA,0,295,any,2,000000000,Diabetes Mellitus,NA
6399,30166073,3,indication;acute coronary syndrome,Acute Coronary Syndrome,D054058,NA,0,295,any,2,000000000,Acute Coronary Syndrome,NA
6400,30166073,3,indication;stable coronary artery disease,Coronary Artery Disease,D003324,NA,0,295,any,2,000000000,Coronary Artery Disease,NA
6401,30166073,3,main treated or not,Percutaneous Coronary Intervention,D062645,NA,0,295,any,2,000000000,Percutaneous Coronary Intervention,NA
6402,30166073,3,peripheral vascular disease,Peripheral Vascular Diseases,D016491,NA,0,295,any,2,000000000,Peripheral Vascular Diseases,NA
6403,30166073,3,region,Geographic Locations,D005842,NA,0,295,any,2,000000000,Geographic Locations,NA
6404,30166073,3,region;rest of the world,Geographic Locations,D005842,NA,0,295,any,2,000000000,Geographic Locations,NA
6405,30166073,3,renal failure,Renal Insufficiency,D051437,NA,0,295,any,2,000000000,Renal Insufficiency,NA
6406,30166073,3,sex,Gender Identity,D005783,NA,0,295,any,2,000000000,Gender Identity,NA
6407,30166073,3,type of reference treatment strategy;use of ticagrelor,Platelet Aggregation Inhibitors,D010975,NA,0,295,type,12,000000010,Platelet Aggregation Inhibitors,NA
6408,30175930,2,"age, years",Age Factors,D000367,NA,0,1294,any,2,000000000,Age Factors,NA
6409,30175930,2,"baseline 24-hour mean sbp, mm hg",Blood Pressure,D001794,NA,0,1294,any,2,000000000,Blood Pressure,NA
6410,30175930,2,"bmi, kg/m^",Body Mass Index,D015992,NA,0,1294,any,2,000000000,Body Mass Index,NA
6411,30175930,2,"cgfr, ml/min/1.73m2",Glomerular Filtration Rate,D005919,NA,0,1294,any,2,000000000,Glomerular Filtration Rate,NA
6412,30175930,2,race,Racial Groups,D044469,NA,0,1294,any,2,000000000,Racial Groups,NA
6413,30175930,2,sex,Gender Identity,D005783,NA,0,1294,any,2,000000000,Gender Identity,NA
6414,30183102,2,dm,Diabetes Mellitus,D003920,NA,0,201,any,2,000000000,Diabetes Mellitus,NA
6415,30183102,2,non-dm,Diabetes Mellitus,D003920,NA,0,201,any,2,000000000,Diabetes Mellitus,NA
6416,30191421,2,dmard- (n = 74),Antirheumatic Agents,D018501,NA,0,1130,any,2,000000000,Antirheumatic Agents,NA
6417,30191421,2,dmard+ (n = 199),Antirheumatic Agents,D018501,NA,0,1130,any,2,000000000,Antirheumatic Agents,NA
6418,30191421,2,dmard+ (nÃ¢â‚¬â€°=Ã¢â‚¬â€°199),Antirheumatic Agents,D018501,NA,0,1130,any,2,000000000,Antirheumatic Agents,NA
6419,30191421,2,dmardÃ¢Ë†â€™ (nÃ¢â‚¬â€°=Ã¢â‚¬â€°74),Antirheumatic Agents,D018501,NA,0,1130,any,2,000000000,Antirheumatic Agents,NA
6420,30200078,NA,Patient Variable: Ethnicity,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,92
6421,30203005,2,'patients with Crohn's disease',Crohn Disease,D003424,NA,0,995,any,2,000000000,Crohn Disease,NA
6422,30203005,2,patients with ulcerative colitis,"Colitis, Ulcerative",D003093,NA,0,995,any,2,000000000,"Colitis, Ulcerative",NA
6423,30203580,2,;anti-gad negative,anti-GAD65 autoantibody,C000719275,NA,0,1344,any,2,000000000,anti-GAD65 autoantibody,NA
6424,30203580,2,;anti-gad positive,anti-GAD65 autoantibody,C000719275,NA,0,1344,any,2,000000000,anti-GAD65 autoantibody,NA
6425,30218434,1,Insulin glargine,Insulin,D007328,NA,0,652,any,2,000000000,Insulin,NA
6426,30218434,1,insulin glargine/lixisenatide (iGlarLixi),Insulin,D007328,NA,0,652,any,2,000000000,Insulin,NA
6427,30218434,1,patients with T2DM,Diabetes Mellitus,D003920,NA,0,652,any,2,000000000,Diabetes Mellitus,NA
6428,30248105,2,male female,Gender Identity,D005783,NA,0,483,any,2,000000000,Gender Identity,NA
6429,30248105,3,;carrier (n=194),Genetic Profile,D000076610,NA,0,1342,any,2,000000000,Genetic Profile,NA
6430,30248105,3,Apolipoprotein E gene carriers and non carriers,Genetic Profile,D000076610,NA,0,1342,any,2,000000000,Genetic Profile,NA
6431,30248105,4,;mild (n=187),Alzheimer Disease,D000544,NA,0,1335,severity,11,000100000,Alzheimer Disease,NA
6432,30248105,4,;moderate (n=311),Alzheimer Disease,D000544,NA,0,1335,severity,11,000100000,Alzheimer Disease,NA
6433,30248105,4,standardized mini mental state examination dementia severity,Dementia,D003704,NA,0,1335,severity,11,000100000,Dementia,NA
6434,30261995,NA,Age-Years,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,115
6435,30261995,NA,bmi,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,115
6436,30261995,NA,COPD severity,"Pulmonary Disease, Chronic Obstructive",D029424,NA,0,0,severity,11,000100000,"Pulmonary Disease, Chronic Obstructive",115
6437,30261995,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,115
6438,30287422,2,Baseline HbA1c,Glycated Hemoglobin A,D006442,NA,0,1632,any,2,000000000,Glycated Hemoglobin A,NA
6439,30290801,2,;fp versus no ics,Steroids,D013256,NA,0,1248,type,12,000000010,Steroids,NA
6440,30290801,2,;fp versus other ics,Steroids,D013256,NA,0,1248,type,12,000000010,Steroids,NA
6441,30290801,2,;other ics versus no ics,Steroids,D013256,NA,0,1248,any,2,000000000,Steroids,NA
6442,30290801,2,type of inhaled corticosteroid,Steroids,D013256,NA,0,1248,type,12,000000010,Steroids,NA
6443,30291013,2,age,Age Factors,D000367,NA,0,1095,any,2,000000000,Age Factors,NA
6444,30291013,2,baseline antiplatelet,Platelet Aggregation Inhibitors,D010975,NA,0,1095,any,2,000000000,Platelet Aggregation Inhibitors,NA
6445,30291013,2,baseline insulin,Insulin,D007328,NA,0,1095,any,2,000000000,Insulin,NA
6446,30291013,2,baseline metformin,Hypoglycemic Agents,D007004,NA,0,1095,any,2,000000000,Hypoglycemic Agents,NA
6447,30291013,2,baseline statin,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,1095,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
6448,30291013,2,cerebrovascular disease,Cerebrovascular Disorders,D002561,NA,0,1095,previous,8,100000000,Cerebrovascular Disorders,NA
6449,30291013,2,Coronary heart disease,Coronary Artery Disease,D003324,NA,0,1095,any,2,000000000,Coronary Artery Disease,NA
6450,30291013,2,dpp-4 inhibitor,Hypoglycemic Agents,D007004,NA,0,1095,any,2,000000000,Hypoglycemic Agents,NA
6451,30291013,2,duration of diabetes,Diabetes Mellitus,D003920,NA,0,1095,duration,5,001000000,Diabetes Mellitus,NA
6452,30291013,2,eGFR,Glomerular Filtration Rate,D005919,NA,0,1095,any,2,000000000,Glomerular Filtration Rate,NA
6453,30291013,2,heart failure history,Heart Failure,D006333,NA,0,1095,any,2,000000000,Heart Failure,NA
6454,30291013,2,number of arterial beds involved,unclassifiable,NA,NA,0,1095,any,2,000000000,unclassifiable,NA
6455,30291013,2,Peripheral artery disease Yes No,Peripheral Vascular Diseases,D016491,NA,0,1095,any,2,000000000,Peripheral Vascular Diseases,NA
6456,30291013,2,race,Racial Groups,D044469,NA,0,1095,any,2,000000000,Racial Groups,NA
6457,30291013,2,race or ethnicity;non-hispanic black,Racial Groups,D044469,NA,0,1095,any,2,000000000,Racial Groups,NA
6458,30291013,2,region,Geographic Locations,D005842,NA,0,1095,any,2,000000000,Geographic Locations,NA
6459,30291013,2,sex,Gender Identity,D005783,NA,0,1095,any,2,000000000,Gender Identity,NA
6460,30291013,2,Smoker,Cigarette Smoking,D000073865,NA,0,1095,any,2,000000000,Cigarette Smoking,NA
6461,30292589,NA,albuminuria,Albuminuria,D000419,NA,0,0,any,2,000000000,Albuminuria,188
6462,30302940,4,diabetes,Diabetes Mellitus,D003920,NA,0,508,any,2,000000000,Diabetes Mellitus,NA
6463,30302940,4,no diabetes,Diabetes Mellitus,D003920,NA,0,508,any,2,000000000,Diabetes Mellitus,NA
6464,30302940,4,univariate logistic modela,Diabetes Mellitus,D003920,NA,0,508,any,2,000000000,Diabetes Mellitus,NA
6465,30336824,2,evolocumab (n = 164),lipid modifying agents,NA,C10,0,1664,any,2,000000000,lipid modifying agents,NA
6466,30336824,2,evolocumab (n = 35),lipid modifying agents,NA,C10,0,1664,any,2,000000000,lipid modifying agents,NA
6467,30336824,3,evolocumab (n = 164),lipid modifying agents,NA,C10,0,244,any,2,000000000,lipid modifying agents,NA
6468,30336824,3,evolocumab (n = 35),lipid modifying agents,NA,C10,0,244,any,2,000000000,lipid modifying agents,NA
6469,30336824,NA,ldl,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,229
6470,30341453,1,baseline symptom duration,"Arthritis, Rheumatoid",D001172,NA,0,803,duration,5,001000000,"Arthritis, Rheumatoid",NA
6471,30341453,2,baseline symptom duration,"Arthritis, Rheumatoid",D001172,NA,0,705,duration,5,001000000,"Arthritis, Rheumatoid",NA
6472,30352894,1,baseline hba1c,Glycated Hemoglobin A,D006442,NA,0,223,any,2,000000000,Glycated Hemoglobin A,NA
6473,30352894,1,cgm use,Glucose,D005947,NA,0,223,any,2,000000000,Glucose,NA
6474,30352894,1,insulin administration;csii,Insulin,D007328,NA,0,223,any,2,000000000,Insulin,NA
6475,30352894,1,insulin administration;mdi,Insulin,D007328,NA,0,223,any,2,000000000,Insulin,NA
6476,30352894,1,Insulin glargine,Insulin,D007328,NA,0,223,any,2,000000000,Insulin,NA
6477,30352894,2,baseline bmi,Body Mass Index,D015992,NA,0,1251,any,2,000000000,Body Mass Index,NA
6478,30352894,2,baseline hba1c,Glycated Hemoglobin A,D006442,NA,0,1251,any,2,000000000,Glycated Hemoglobin A,NA
6479,30354517,1,;ldl-c <50 mg/dl,Lipoproteins,D008074,NA,0,376,any,2,000000000,Lipoproteins,NA
6480,30354517,1,;ldl-c >70 mg/dl,Lipoproteins,D008074,NA,0,376,any,2,000000000,Lipoproteins,NA
6481,30354517,1,;ldl-c 50-70 mg/dl,Lipoproteins,D008074,NA,0,376,any,2,000000000,Lipoproteins,NA
6482,30354781,2,gender,Gender Identity,D005783,NA,0,1370,any,2,000000000,Gender Identity,NA
6483,30371334,6,genotype,Genetic Profile,D000076610,NA,0,918,type,12,000000010,Genetic Profile,NA
6484,30383495,NA,Age-Years,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,34
6485,30392095,2,HbA1c at baseline,Glycated Hemoglobin A,D006442,NA,0,321,any,2,000000000,Glycated Hemoglobin A,NA
6486,30393950,NA,hba1c,Glycated Hemoglobin A,D006442,NA,0,0,any,2,000000000,Glycated Hemoglobin A,118
6487,30403574,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
6488,30403574,NA,Apolipoprotein A-I,Apolipoprotein A-I,D016632,NA,0,0,any,2,000000000,Apolipoprotein A-I,NA
6489,30403574,NA,hdl,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,NA
6490,30403574,NA,hsCRP,C-Reactive Protein,D002097,NA,0,0,any,2,000000000,C-Reactive Protein,NA
6491,30403574,NA,"index event type (NSTEMI, STEMI, UA)",Myocardial Infarction,D009203,NA,0,0,type,12,000000010,Myocardial Infarction,NA
6492,30403574,NA,index to randomisation,complex,NA,NA,0,0,any,2,000000000,complex,NA
6493,30403574,NA,ldl,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,NA
6494,30403574,NA,region,Geographic Locations,D005842,NA,0,0,any,2,000000000,Geographic Locations,NA
6495,30403574,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
6496,30403574,NA,statin treatment,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,0,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
6497,30415602,2,<60 ml/min/1.73 m^,Glomerular Filtration Rate,D005919,NA,0,664,any,2,000000000,Glomerular Filtration Rate,NA
6498,30415602,2,>90 ml/min/1.73,Glomerular Filtration Rate,D005919,NA,0,664,any,2,000000000,Glomerular Filtration Rate,NA
6499,30415602,2,>90 ml/min/1.73 m^,Glomerular Filtration Rate,D005919,NA,0,664,any,2,000000000,Glomerular Filtration Rate,NA
6500,30415602,2,60 to <90 ml/min/1-73,Glomerular Filtration Rate,D005919,NA,0,664,any,2,000000000,Glomerular Filtration Rate,NA
6501,30415602,2,60 to <90 ml/min/1.73 m^,Glomerular Filtration Rate,D005919,NA,0,664,any,2,000000000,Glomerular Filtration Rate,NA
6502,30415602,2,ascvd,Cardiovascular Diseases,D002318,NA,0,664,any,2,000000000,Cardiovascular Diseases,NA
6503,30415602,2,egfr,Glomerular Filtration Rate,D005919,NA,0,664,any,2,000000000,Glomerular Filtration Rate,NA
6504,30415602,2,history of heart failure,Heart Failure,D006333,NA,0,664,previous,8,100000000,Heart Failure,NA
6505,30415602,2,mrf,Risk Factors,D012307,NA,0,664,risk score,10,000000100,Risk Factors,NA
6506,30415628,1,age,Age Factors,D000367,NA,0,1047,any,2,000000000,Age Factors,NA
6507,30415628,1,baseline estimated gfr,Glomerular Filtration Rate,D005919,NA,0,1047,any,2,000000000,Glomerular Filtration Rate,NA
6508,30415628,1,"baseline estimated gfr;<60 ml/min/1,73 m^",Glomerular Filtration Rate,D005919,NA,0,1047,any,2,000000000,Glomerular Filtration Rate,NA
6509,30415628,1,baseline estimated gfr;>60 to <90 ml/min/1.73 m^,Glomerular Filtration Rate,D005919,NA,0,1047,any,2,000000000,Glomerular Filtration Rate,NA
6510,30415628,1,baseline high-sensitivity crp,C-Reactive Protein,D002097,NA,0,1047,any,2,000000000,C-Reactive Protein,NA
6511,30415628,1,baseline high-sensitivity crp;<2 mg/liter,C-Reactive Protein,D002097,NA,0,1047,any,2,000000000,C-Reactive Protein,NA
6512,30415628,1,baseline high-sensitivity crp;>2 mg/liter,C-Reactive Protein,D002097,NA,0,1047,any,2,000000000,C-Reactive Protein,NA
6513,30415628,1,baseline ldl cholesterol (derived),Lipoproteins,D008074,NA,0,1047,any,2,000000000,Lipoproteins,NA
6514,30415628,1,baseline statin intensity,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,1047,any,2,000000000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
6515,30415628,1,baseline statin intensity;moderate,Hydroxymethylglutaryl-CoA Reductase Inhibitors,D019161,NA,0,1047,severity,11,000100000,Hydroxymethylglutaryl-CoA Reductase Inhibitors,NA
6516,30415628,1,baseline triglycerides,Lipoproteins,D008074,NA,0,1047,any,2,000000000,Lipoproteins,NA
6517,30415628,1,baseline triglycerides >200 mg/dl and,Lipoproteins,D008074,NA,0,1047,any,2,000000000,Lipoproteins,NA
6518,30415628,1,diabetes at baseline,Diabetes Mellitus,D003920,NA,0,1047,any,2,000000000,Diabetes Mellitus,NA
6519,30415628,1,ezetimibe use,lipid modifying agents,NA,C10,0,1047,any,2,000000000,lipid modifying agents,NA
6520,30415628,1,primary vs secondary prevention,unclassifiable,NA,NA,0,1047,any,2,000000000,unclassifiable,NA
6521,30415628,1,race,Racial Groups,D044469,NA,0,1047,any,2,000000000,Racial Groups,NA
6522,30415628,1,region,Geographic Locations,D005842,NA,0,1047,any,2,000000000,Geographic Locations,NA
6523,30415628,1,sex,Gender Identity,D005783,NA,0,1047,any,2,000000000,Gender Identity,NA
6524,30418475,2,linagliptin (n = 3494),Hypoglycemic Agents,D007004,NA,0,777,any,2,000000000,Hypoglycemic Agents,NA
6525,30425095,1,age &65,Age Factors,D000367,NA,0,422,any,2,000000000,Age Factors,NA
6526,30425095,1,age <65,Age Factors,D000367,NA,0,422,any,2,000000000,Age Factors,NA
6527,30425095,1,cvd,Cardiovascular Diseases,D002318,NA,0,422,any,2,000000000,Cardiovascular Diseases,NA
6528,30425095,1,dm,Diabetes Mellitus,D003920,NA,0,422,any,2,000000000,Diabetes Mellitus,NA
6529,30425095,1,educ >12y,Educational Status,D004522,NA,0,422,any,2,000000000,Educational Status,NA
6530,30425095,1,educ 9-12y,Educational Status,D004522,NA,0,422,any,2,000000000,Educational Status,NA
6531,30425095,1,educ ssy,Educational Status,D004522,NA,0,422,any,2,000000000,Educational Status,NA
6532,30425095,1,female,Gender Identity,D005783,NA,0,422,any,2,000000000,Gender Identity,NA
6533,30425095,1,giargine,Insulin,D007328,NA,0,422,any,2,000000000,Insulin,NA
6534,30425095,1,male,Gender Identity,D005783,NA,0,422,any,2,000000000,Gender Identity,NA
6535,30425095,1,no prior cvd,Cardiovascular Diseases,D002318,NA,0,422,previous,8,100000000,Cardiovascular Diseases,NA
6536,30425095,1,no prior dm,Diabetes Mellitus,D003920,NA,0,422,previous,8,100000000,Diabetes Mellitus,NA
6537,30425095,1,standard,Insulin,D007328,NA,0,422,any,2,000000000,Insulin,NA
6538,30425095,2,age,Age Factors,D000367,NA,0,234,any,2,000000000,Age Factors,NA
6539,30425095,2,diabetes,Diabetes Mellitus,D003920,NA,0,234,any,2,000000000,Diabetes Mellitus,NA
6540,30425095,2,Insulin glargine,Insulin,D007328,NA,0,234,any,2,000000000,Insulin,NA
6541,30425095,2,severe hypoglycemia,Hypoglycemia,D007003,NA,0,234,severity,11,000100000,Hypoglycemia,NA
6542,30425195,NA,Patient Variable: Ethnicity,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,166
6543,30465321,NA,Medical History: Baseline Itch NRS,Pruritus,D011537,NA,0,0,previous severity,9,100100000,Pruritus,30
6544,30465321,NA,Medical History: Baseline Itch Numeric Rating Scale (NRS),Pruritus,D011537,NA,0,0,previous,8,100000000,Pruritus,30
6545,30474818,2,elderly Japanese,Racial Groups,D044469,NA,0,1740,any,2,000000000,Racial Groups,NA
6546,30474818,NA,Age-Years,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,100
6547,30522501,1,;crp = uln,C-Reactive Protein,D002097,NA,0,1845,any,2,000000000,C-Reactive Protein,NA
6548,30522501,1,;crp > uln,C-Reactive Protein,D002097,NA,0,1845,any,2,000000000,C-Reactive Protein,NA
6549,30522501,1,;crpÃ¢â‚¬â€°>Ã¢â‚¬â€°uln,C-Reactive Protein,D002097,NA,0,1845,any,2,000000000,C-Reactive Protein,NA
6550,30522501,1,;crpÃ¢â‚¬â€°Ã¢â€°Â¤Ã¢â‚¬â€°uln,C-Reactive Protein,D002097,NA,0,1845,any,2,000000000,C-Reactive Protein,NA
6551,30522501,1,;tnfi-exposedâ€ ,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,1845,any,2,000000000,Tumor Necrosis Factor Inhibitors,NA
6552,30522501,1,;tnfi-naÃ¯ve,Tumor Necrosis Factor Inhibitors,D000079424,L04AB,0,1845,previous,8,100000000,Tumor Necrosis Factor Inhibitors,NA
6553,30525116,2,race,Racial Groups,D044469,NA,0,1384,any,2,000000000,Racial Groups,NA
6554,30547388,2,;bmi Â£30 kg/m* (n=64/61),Body Mass Index,D015992,NA,0,304,any,2,000000000,Body Mass Index,NA
6555,30547388,2,";bmi <25 kg/m"" (n=144/129)",Body Mass Index,D015992,NA,0,304,any,2,000000000,Body Mass Index,NA
6556,30547388,2,;bmi <25 kg/m* (n=10/19),Body Mass Index,D015992,NA,0,304,any,2,000000000,Body Mass Index,NA
6557,30547388,2,;bmi <25 kg/m* (n=144/129),Body Mass Index,D015992,NA,0,304,any,2,000000000,Body Mass Index,NA
6558,30547388,2,;bmi <25 kg/m^ (n=10/19),Body Mass Index,D015992,NA,0,304,any,2,000000000,Body Mass Index,NA
6559,30547388,2,;bmi <25 kg/m^ (n=144/129),Body Mass Index,D015992,NA,0,304,any,2,000000000,Body Mass Index,NA
6560,30547388,2,;bmi <25 kg/m^ (n=32/35),Body Mass Index,D015992,NA,0,304,any,2,000000000,Body Mass Index,NA
6561,30547388,2,;bmi >30 kg/m^ (n=203/199),Body Mass Index,D015992,NA,0,304,any,2,000000000,Body Mass Index,NA
6562,30547388,2,;bmi >30 kg/m^ (n=69/77),Body Mass Index,D015992,NA,0,304,any,2,000000000,Body Mass Index,NA
6563,30547388,2,;bmi 25-<30 kg/m^ (n=106/107),Body Mass Index,D015992,NA,0,304,any,2,000000000,Body Mass Index,NA
6564,30547388,2,;bmi 25-<30 kg/m^ (n=46/35),Body Mass Index,D015992,NA,0,304,any,2,000000000,Body Mass Index,NA
6565,30547388,2,;bmi 25-<30 kg/ni- (n=168/1074),Body Mass Index,D015992,NA,0,304,any,2,000000000,Body Mass Index,NA
6566,30547388,2,;bmi>30kg/m* (n=64/61),Body Mass Index,D015992,NA,0,304,any,2,000000000,Body Mass Index,NA
6567,30547388,2,;bmi>30kg/m2 (n =203/199),Body Mass Index,D015992,NA,0,304,any,2,000000000,Body Mass Index,NA
6568,30547388,2,;hbalc Â£58 mmol/mol (Â£7.5%) (n=38/36),Glycated Hemoglobin A,D006442,NA,0,304,any,2,000000000,Glycated Hemoglobin A,NA
6569,30547388,2,;hbalc Â£58 mmol/mol (<7.5%) (n=188/201),Glycated Hemoglobin A,D006442,NA,0,304,any,2,000000000,Glycated Hemoglobin A,NA
6570,30547388,2,;hbalc Â£64 mmol/mol (Â£8.0%) (n=163/148),Glycated Hemoglobin A,D006442,NA,0,304,any,2,000000000,Glycated Hemoglobin A,NA
6571,30547388,2,;hbalc Â£64 mmol/mol (Â£8.0%) (n=51/54),Glycated Hemoglobin A,D006442,NA,0,304,any,2,000000000,Glycated Hemoglobin A,NA
6572,30547388,2,;hbalc Â£64 mmol/mol (>8.0%) (n=110/95),Glycated Hemoglobin A,D006442,NA,0,304,any,2,000000000,Glycated Hemoglobin A,NA
6573,30547388,2,;hbalc <58 mmol/mol (Â£7.5%) (n=108/120),Glycated Hemoglobin A,D006442,NA,0,304,any,2,000000000,Glycated Hemoglobin A,NA
6574,30547388,2,;hbalc <58 mmol/mol (<7.5%) (n=108/120),Glycated Hemoglobin A,D006442,NA,0,304,any,2,000000000,Glycated Hemoglobin A,NA
6575,30547388,2,;hbalc <58 mmol/mol (<7.5%) (n=188/201),Glycated Hemoglobin A,D006442,NA,0,304,any,2,000000000,Glycated Hemoglobin A,NA
6576,30547388,2,;hbalc <58 mmol/mol (<7.5%) (n=38/36),Glycated Hemoglobin A,D006442,NA,0,304,any,2,000000000,Glycated Hemoglobin A,NA
6577,30547388,2,;hbalc >58-<64 mmol/mol (>7.5-<8.0%) (n=31/25),Glycated Hemoglobin A,D006442,NA,0,304,any,2,000000000,Glycated Hemoglobin A,NA
6578,30547388,2,;hbalc >58-<64 mmol/mol (>7.5-<8.0%) (n=70/73),Glycated Hemoglobin A,D006442,NA,0,304,any,2,000000000,Glycated Hemoglobin A,NA
6579,30547388,2,;hbalc >58-<64 mmol/mol (>7.5-<8.0%) (n=83/84),Glycated Hemoglobin A,D006442,NA,0,304,any,2,000000000,Glycated Hemoglobin A,NA
6580,30547388,2,;hbalc >64 mmol/mol (>8.0%) (n=110/95),Glycated Hemoglobin A,D006442,NA,0,304,any,2,000000000,Glycated Hemoglobin A,NA
6581,30547388,2,;hbalc >64 mmol/mol (>8.0%) (n=163/148),Glycated Hemoglobin A,D006442,NA,0,304,any,2,000000000,Glycated Hemoglobin A,NA
6582,30547388,2,;hbalc >64 mmol/mol (>8.0%) (n=51/54),Glycated Hemoglobin A,D006442,NA,0,304,any,2,000000000,Glycated Hemoglobin A,NA
6583,30547388,3,;bmi Â£30 kg/m* (n=64/61),Body Mass Index,D015992,NA,0,1415,any,2,000000000,Body Mass Index,NA
6584,30547388,3,";bmi <25 kg/m"" (n=144/129)",Body Mass Index,D015992,NA,0,1415,any,2,000000000,Body Mass Index,NA
6585,30547388,3,;bmi <25 kg/m* (n=10/19),Body Mass Index,D015992,NA,0,1415,any,2,000000000,Body Mass Index,NA
6586,30547388,3,;bmi <25 kg/m* (n=144/129),Body Mass Index,D015992,NA,0,1415,any,2,000000000,Body Mass Index,NA
6587,30547388,3,;bmi <25 kg/m^ (n=10/19),Body Mass Index,D015992,NA,0,1415,any,2,000000000,Body Mass Index,NA
6588,30547388,3,;bmi <25 kg/m^ (n=144/129),Body Mass Index,D015992,NA,0,1415,any,2,000000000,Body Mass Index,NA
6589,30547388,3,;bmi <25 kg/m^ (n=32/35),Body Mass Index,D015992,NA,0,1415,any,2,000000000,Body Mass Index,NA
6590,30547388,3,;bmi >30 kg/m^ (n=203/199),Body Mass Index,D015992,NA,0,1415,any,2,000000000,Body Mass Index,NA
6591,30547388,3,;bmi >30 kg/m^ (n=69/77),Body Mass Index,D015992,NA,0,1415,any,2,000000000,Body Mass Index,NA
6592,30547388,3,;bmi 25-<30 kg/m^ (n=106/107),Body Mass Index,D015992,NA,0,1415,any,2,000000000,Body Mass Index,NA
6593,30547388,3,;bmi 25-<30 kg/m^ (n=46/35),Body Mass Index,D015992,NA,0,1415,any,2,000000000,Body Mass Index,NA
6594,30547388,3,;bmi 25-<30 kg/ni- (n=168/1074),Body Mass Index,D015992,NA,0,1415,any,2,000000000,Body Mass Index,NA
6595,30547388,3,;bmi>30kg/m* (n=64/61),Body Mass Index,D015992,NA,0,1415,any,2,000000000,Body Mass Index,NA
6596,30547388,3,;bmi>30kg/m2 (n =203/199),Body Mass Index,D015992,NA,0,1415,any,2,000000000,Body Mass Index,NA
6597,30547388,4,;bmi Â£30 kg/m* (n=64/61),Body Mass Index,D015992,NA,0,51,any,2,000000000,Body Mass Index,NA
6598,30547388,4,";bmi <25 kg/m"" (n=144/129)",Body Mass Index,D015992,NA,0,51,any,2,000000000,Body Mass Index,NA
6599,30547388,4,;bmi <25 kg/m* (n=10/19),Body Mass Index,D015992,NA,0,51,any,2,000000000,Body Mass Index,NA
6600,30547388,4,;bmi <25 kg/m* (n=144/129),Body Mass Index,D015992,NA,0,51,any,2,000000000,Body Mass Index,NA
6601,30547388,4,;bmi <25 kg/m^ (n=10/19),Body Mass Index,D015992,NA,0,51,any,2,000000000,Body Mass Index,NA
6602,30547388,4,;bmi <25 kg/m^ (n=144/129),Body Mass Index,D015992,NA,0,51,any,2,000000000,Body Mass Index,NA
6603,30547388,4,;bmi <25 kg/m^ (n=32/35),Body Mass Index,D015992,NA,0,51,any,2,000000000,Body Mass Index,NA
6604,30547388,4,;bmi >30 kg/m^ (n=203/199),Body Mass Index,D015992,NA,0,51,any,2,000000000,Body Mass Index,NA
6605,30547388,4,;bmi >30 kg/m^ (n=69/77),Body Mass Index,D015992,NA,0,51,any,2,000000000,Body Mass Index,NA
6606,30547388,4,;bmi 25-<30 kg/m^ (n=106/107),Body Mass Index,D015992,NA,0,51,any,2,000000000,Body Mass Index,NA
6607,30547388,4,;bmi 25-<30 kg/m^ (n=46/35),Body Mass Index,D015992,NA,0,51,any,2,000000000,Body Mass Index,NA
6608,30547388,4,;bmi 25-<30 kg/ni- (n=168/1074),Body Mass Index,D015992,NA,0,51,any,2,000000000,Body Mass Index,NA
6609,30547388,4,;bmi>30kg/m* (n=64/61),Body Mass Index,D015992,NA,0,51,any,2,000000000,Body Mass Index,NA
6610,30547388,4,;bmi>30kg/m2 (n =203/199),Body Mass Index,D015992,NA,0,51,any,2,000000000,Body Mass Index,NA
6611,30547388,4,;hbalc Â£58 mmol/mol (Â£7.5%) (n=38/36),Glycated Hemoglobin A,D006442,NA,0,51,any,2,000000000,Glycated Hemoglobin A,NA
6612,30547388,4,;hbalc Â£58 mmol/mol (<7.5%) (n=188/201),Glycated Hemoglobin A,D006442,NA,0,51,any,2,000000000,Glycated Hemoglobin A,NA
6613,30547388,4,;hbalc Â£64 mmol/mol (Â£8.0%) (n=163/148),Glycated Hemoglobin A,D006442,NA,0,51,any,2,000000000,Glycated Hemoglobin A,NA
6614,30547388,4,;hbalc Â£64 mmol/mol (Â£8.0%) (n=51/54),Glycated Hemoglobin A,D006442,NA,0,51,any,2,000000000,Glycated Hemoglobin A,NA
6615,30547388,4,;hbalc Â£64 mmol/mol (>8.0%) (n=110/95),Glycated Hemoglobin A,D006442,NA,0,51,any,2,000000000,Glycated Hemoglobin A,NA
6616,30547388,4,;hbalc <58 mmol/mol (Â£7.5%) (n=108/120),Glycated Hemoglobin A,D006442,NA,0,51,any,2,000000000,Glycated Hemoglobin A,NA
6617,30547388,4,;hbalc <58 mmol/mol (<7.5%) (n=108/120),Glycated Hemoglobin A,D006442,NA,0,51,any,2,000000000,Glycated Hemoglobin A,NA
6618,30547388,4,;hbalc <58 mmol/mol (<7.5%) (n=188/201),Glycated Hemoglobin A,D006442,NA,0,51,any,2,000000000,Glycated Hemoglobin A,NA
6619,30547388,4,;hbalc <58 mmol/mol (<7.5%) (n=38/36),Glycated Hemoglobin A,D006442,NA,0,51,any,2,000000000,Glycated Hemoglobin A,NA
6620,30547388,4,;hbalc >58-<64 mmol/mol (>7.5-<8.0%) (n=31/25),Glycated Hemoglobin A,D006442,NA,0,51,any,2,000000000,Glycated Hemoglobin A,NA
6621,30547388,4,;hbalc >58-<64 mmol/mol (>7.5-<8.0%) (n=70/73),Glycated Hemoglobin A,D006442,NA,0,51,any,2,000000000,Glycated Hemoglobin A,NA
6622,30547388,4,;hbalc >58-<64 mmol/mol (>7.5-<8.0%) (n=83/84),Glycated Hemoglobin A,D006442,NA,0,51,any,2,000000000,Glycated Hemoglobin A,NA
6623,30547388,4,;hbalc >64 mmol/mol (>8.0%) (n=110/95),Glycated Hemoglobin A,D006442,NA,0,51,any,2,000000000,Glycated Hemoglobin A,NA
6624,30547388,4,;hbalc >64 mmol/mol (>8.0%) (n=163/148),Glycated Hemoglobin A,D006442,NA,0,51,any,2,000000000,Glycated Hemoglobin A,NA
6625,30547388,4,;hbalc >64 mmol/mol (>8.0%) (n=51/54),Glycated Hemoglobin A,D006442,NA,0,51,any,2,000000000,Glycated Hemoglobin A,NA
6626,30564451,2,baseline crp levels <10 mg/l,C-Reactive Protein,D002097,NA,0,1262,any,2,000000000,C-Reactive Protein,NA
6627,30564451,2,baseline crp levels =10 mg/l,C-Reactive Protein,D002097,NA,0,1262,any,2,000000000,C-Reactive Protein,NA
6628,30564451,2,baseline crp levels Ã¢â€°Â¥10 mg/l,C-Reactive Protein,D002097,NA,0,1262,any,2,000000000,C-Reactive Protein,NA
6629,30566004,NA,Medical History: Prior MI or Stroke,Stroke,D020521,NA,0,0,previous,8,100000000,Stroke,25
6630,30566004,NA,Medical History: Prior MI or Stroke,Myocardial Infarction,D009203,NA,0,0,previous,8,100000000,Myocardial Infarction,228
6631,30566006,1,;egfr <30 ml/min/1.73,Glomerular Filtration Rate,D005919,NA,0,740,any,2,000000000,Glomerular Filtration Rate,NA
6632,30566006,1,;egfr 290 ml/min/1.73,Glomerular Filtration Rate,D005919,NA,0,740,any,2,000000000,Glomerular Filtration Rate,NA
6633,30566006,1,;egfr 30 to <45 ml/min/1.73,Glomerular Filtration Rate,D005919,NA,0,740,any,2,000000000,Glomerular Filtration Rate,NA
6634,30566006,1,;egfr 45 to <60 ml/min/1.73 m*,Glomerular Filtration Rate,D005919,NA,0,740,any,2,000000000,Glomerular Filtration Rate,NA
6635,30566006,1,;egfr 60 to <75 ml/min/1.73 mâ€™,Glomerular Filtration Rate,D005919,NA,0,740,any,2,000000000,Glomerular Filtration Rate,NA
6636,30566006,1,;egfr 75 to <90 ml/min/1.73 m^,Glomerular Filtration Rate,D005919,NA,0,740,any,2,000000000,Glomerular Filtration Rate,NA
6637,30566006,1,;micro/macroalbuminuria,Proteinuria,D011507,NA,0,740,any,2,000000000,Proteinuria,NA
6638,30566006,1,age,Age Factors,D000367,NA,0,740,any,2,000000000,Age Factors,NA
6639,30566006,1,"bmi, kg/m2 (sd)",Body Mass Index,D015992,NA,0,740,any,2,000000000,Body Mass Index,NA
6640,30566006,1,"body weight, kg (sd)",Body Weight,D001835,NA,0,740,any,2,000000000,Body Weight,NA
6641,30566006,1,"creatinine, mg/dl (sd)",Glomerular Filtration Rate,D005919,NA,0,740,any,2,000000000,Glomerular Filtration Rate,NA
6642,30566006,1,"dbp, mm hg (sd)",Blood Pressure,D001794,NA,0,740,any,2,000000000,Blood Pressure,NA
6643,30566006,1,"dbp, mmÃ¢â‚¬â€°hg (sd)",Blood Pressure,D001794,NA,0,740,any,2,000000000,Blood Pressure,NA
6644,30566006,1,"diabetes mellitus duration, y (sd)",Diabetes Mellitus,D003920,NA,0,740,duration,5,001000000,Diabetes Mellitus,NA
6645,30566006,1,"egfr, ml/min/1.73 m2 (sd)",Glomerular Filtration Rate,D005919,NA,0,740,any,2,000000000,Glomerular Filtration Rate,NA
6646,30566006,1,"hba1c, % (sd)",Glycated Hemoglobin A,D006442,NA,0,740,any,2,000000000,Glycated Hemoglobin A,NA
6647,30566006,1,"hr, bpm (sd)",Heart Rate,D006339,NA,0,740,any,2,000000000,Heart Rate,NA
6648,30566006,1,Hypertension,Hypertension,D006973,NA,0,740,any,2,000000000,Hypertension,NA
6649,30566006,1,"ldl-c, mmol/l (sd)",Lipoproteins,D008074,NA,0,740,any,2,000000000,Lipoproteins,NA
6650,30566006,1,male female,Gender Identity,D005783,NA,0,740,any,2,000000000,Gender Identity,NA
6651,30566006,1,patients with eGFR,Glomerular Filtration Rate,D005919,NA,0,740,any,2,000000000,Glomerular Filtration Rate,NA
6652,30566006,1,"prior stroke/mi, n (%)",Stroke,D020521,NA,0,740,previous,8,100000000,Stroke,NA
6653,30566006,1,"race, n (%)",Racial Groups,D044469,NA,0,740,any,2,000000000,Racial Groups,NA
6654,30566006,1,"region, n (%)",Geographic Locations,D005842,NA,0,740,any,2,000000000,Geographic Locations,NA
6655,30566006,1,sbp,Blood Pressure,D001794,NA,0,740,any,2,000000000,Blood Pressure,NA
6656,30566006,1,Smoker,Cigarette Smoking,D000073865,NA,0,740,any,2,000000000,Cigarette Smoking,NA
6657,30566006,1,"total cholesterol, mmol/l (sd)",Lipoproteins,D008074,NA,0,740,any,2,000000000,Lipoproteins,NA
6658,30566006,1,with micro- and macroalbuminuria versus those without albuminuria,Albuminuria,D000419,NA,0,740,any,2,000000000,Albuminuria,NA
6659,30566006,2,;egfr <30 ml/min/1.73,Glomerular Filtration Rate,D005919,NA,0,596,any,2,000000000,Glomerular Filtration Rate,NA
6660,30566006,2,;egfr 290 ml/min/1.73,Glomerular Filtration Rate,D005919,NA,0,596,any,2,000000000,Glomerular Filtration Rate,NA
6661,30566006,2,;egfr 30 to <45 ml/min/1.73,Glomerular Filtration Rate,D005919,NA,0,596,any,2,000000000,Glomerular Filtration Rate,NA
6662,30566006,2,;egfr 45 to <60 ml/min/1.73 m*,Glomerular Filtration Rate,D005919,NA,0,596,any,2,000000000,Glomerular Filtration Rate,NA
6663,30566006,2,;egfr 60 to <75 ml/min/1.73 mâ€™,Glomerular Filtration Rate,D005919,NA,0,596,any,2,000000000,Glomerular Filtration Rate,NA
6664,30566006,2,;egfr 75 to <90 ml/min/1.73 m^,Glomerular Filtration Rate,D005919,NA,0,596,any,2,000000000,Glomerular Filtration Rate,NA
6665,30566006,2,"egfr, ml/min/1.73 m2 (sd)",Glomerular Filtration Rate,D005919,NA,0,596,any,2,000000000,Glomerular Filtration Rate,NA
6666,30571332,NA,Age-Years,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,130
6667,30571332,NA,antithrombotic therapy,Fibrinolytic Agents,D005343,NA,0,0,any,2,000000000,Fibrinolytic Agents,130
6668,30571332,NA,cardiopulmonary bypass use,Cardiopulmonary Bypass,D002315,NA,0,0,any,2,000000000,Cardiopulmonary Bypass,130
6669,30571332,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,130
6670,30571332,NA,type of surgery,"Specialties, Surgical",D013043,NA,0,0,type,12,000000010,"Specialties, Surgical",130
6671,30571562,NA,serum creatinine,Glomerular Filtration Rate,D005919,NA,0,0,any,2,000000000,Glomerular Filtration Rate,NA
6672,30584583,2,age,Age Factors,D000367,NA,0,1787,any,2,000000000,Age Factors,NA
6673,30584583,2,background laba use,long-acting beta agonist,NA,R03A,0,1787,any,2,000000000,long-acting beta agonist,NA
6674,30584583,2,"fev, % predicted",Pulmonary Ventilation,D012123,NA,0,1787,any,2,000000000,Pulmonary Ventilation,NA
6675,30584583,3,age,Age Factors,D000367,NA,0,804,any,2,000000000,Age Factors,NA
6676,30584583,3,background laba use,long-acting beta agonist,NA,R03A,0,804,any,2,000000000,long-acting beta agonist,NA
6677,30584583,3,"fev, % predicted",Pulmonary Ventilation,D012123,NA,0,804,any,2,000000000,Pulmonary Ventilation,NA
6678,30584583,3,pifr l/min;< 60 l/min,Pulmonary Ventilation,D012123,NA,0,804,any,2,000000000,Pulmonary Ventilation,NA
6679,30584583,3,pifr l/min;>= 60 l_/min,Pulmonary Ventilation,D012123,NA,0,804,any,2,000000000,Pulmonary Ventilation,NA
6680,30586723,2,history of heart failure,Heart Failure,D006333,NA,0,1118,any,2,000000000,Heart Failure,NA
6681,30586723,3,'ckd prognosis by kdigo''',Renal Insufficiency,D051437,NA,1,582,severity,11,000100000,Renal Insufficiency,NA
6682,30586723,3,age,Age Factors,D000367,NA,0,582,any,2,000000000,Age Factors,NA
6683,30586723,3,albuminuria,Albuminuria,D000419,NA,0,582,any,2,000000000,Albuminuria,NA
6684,30586723,3,angiotensin-eonverting enzyme inhibitors,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,582,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
6685,30586723,3,angiotensin-eonverting enzyme inhibitors/ angiotensin reeeptor bloekers,Angiotensin-Converting Enzyme Inhibitors,D000806,NA,0,582,any,2,000000000,Angiotensin-Converting Enzyme Inhibitors,NA
6686,30586723,3,antiplatelet drugs,Platelet Aggregation Inhibitors,D010975,NA,0,582,any,2,000000000,Platelet Aggregation Inhibitors,NA
6687,30586723,3,atrial fibrillation,Atrial Fibrillation,D001281,NA,0,582,any,2,000000000,Atrial Fibrillation,NA
6688,30586723,3,beta blocker,Adrenergic beta-Antagonists,D000319,NA,0,582,any,2,000000000,Adrenergic beta-Antagonists,NA
6689,30586723,3,blood pressure control,Blood Pressure,D001794,NA,0,582,any,2,000000000,Blood Pressure,NA
6690,30586723,3,blood pressure control;sbp <140 mmhg,Blood Pressure,D001794,NA,0,582,any,2,000000000,Blood Pressure,NA
6691,30586723,3,blood pressure control;sbp <160 mmhg,Blood Pressure,D001794,NA,0,582,any,2,000000000,Blood Pressure,NA
6692,30586723,3,blood pressure control;sbp >140 mmhg,Blood Pressure,D001794,NA,0,582,any,2,000000000,Blood Pressure,NA
6693,30586723,3,blood pressure control;sbp >160 mmhg,Blood Pressure,D001794,NA,0,582,any,2,000000000,Blood Pressure,NA
6694,30586723,3,body mass index,Body Mass Index,D015992,NA,0,582,any,2,000000000,Body Mass Index,NA
6695,30586723,3,body mass index;<30 ky/nr,Body Mass Index,D015992,NA,0,582,any,2,000000000,Body Mass Index,NA
6696,30586723,3,body mass index;>30 ky/nr,Body Mass Index,D015992,NA,0,582,any,2,000000000,Body Mass Index,NA
6697,30586723,3,cardio-renal risk,Cardio-Renal Syndrome,D059347,NA,1,582,severity,11,000100000,Cardio-Renal Syndrome,NA
6698,30586723,3,diuretics,Diuretics,D004232,NA,0,582,any,2,000000000,Diuretics,NA
6699,30586723,3,duration of type 2 diabetes,Diabetes Mellitus,D003920,NA,0,582,duration,5,001000010,Diabetes Mellitus,NA
6700,30586723,3,established macrovascular disease and albuminuria,complex,none,NA,0,582,any,2,000000000,complex,NA
6701,30586723,3,established renal disease*,Kidney Diseases,D007674,NA,0,582,any,2,000000000,Kidney Diseases,NA
6702,30586723,3,estimated Glomerular Filtration Rate,Glomerular Filtration Rate,D005919,NA,0,582,any,2,000000000,Glomerular Filtration Rate,NA
6703,30586723,3,glycated haemoglobin,Glycated Hemoglobin A,D006442,NA,0,582,any,2,000000000,Glycated Hemoglobin A,NA
6704,30586723,3,history of heart failure,Heart Failure,D006333,NA,0,582,any,2,000000000,Heart Failure,NA
6705,30586723,3,insulin,Insulin,D007328,NA,0,582,any,2,000000000,Insulin,NA
6706,30586723,3,ischaemicÂ heart disease,Coronary Artery Disease,D003324,NA,0,582,any,2,000000000,Coronary Artery Disease,NA
6707,30586723,3,lipid lowering drugs,Hypolipidemic Agents,D000960,NA,0,582,any,2,000000000,Hypolipidemic Agents,NA
6708,30586723,3,metformin,Hypoglycemic Agents,D007004,NA,0,582,any,2,000000000,Hypoglycemic Agents,NA
6709,30586723,3,metformin-dose,Hypoglycemic Agents,D007004,NA,0,582,any,2,000000000,Hypoglycemic Agents,NA
6710,30586723,3,metformin-dose;<1500 mg,Hypoglycemic Agents,D007004,NA,0,582,any,2,000000000,Hypoglycemic Agents,NA
6711,30586723,3,metformin-dose;>1500 mg,Hypoglycemic Agents,D007004,NA,0,582,any,2,000000000,Hypoglycemic Agents,NA
6712,30586723,3,metformin-dose;not on metformin,Hypoglycemic Agents,D007004,NA,0,582,any,2,000000000,Hypoglycemic Agents,NA
6713,30586723,3,prevalent kidney disease (egfr< 60 ml/min/usm^ or maeroalbuminuria uacr >300 mg/g),Kidney Diseases,D007674,NA,0,582,any,2,000000000,Kidney Diseases,NA
6714,30586723,3,race,Racial Groups,D044469,NA,0,582,any,2,000000000,Racial Groups,NA
6715,30586723,3,race;hispanie/latino,Racial Groups,D044469,NA,0,582,any,2,000000000,Racial Groups,NA
6716,30586723,3,region,Geographic Locations,D005842,NA,0,582,any,2,000000000,Geographic Locations,NA
6717,30586723,3,sex,Gender Identity,D005783,NA,0,582,any,2,000000000,Gender Identity,NA
6718,30586723,3,sulfonylurea,Hypoglycemic Agents,D007004,NA,0,582,any,2,000000000,Hypoglycemic Agents,NA
6719,30586757,3,prior miÂ or stroke at baseline,Stroke,D020521,NA,0,762,previous,8,100000000,Stroke,NA
6720,30587959,3,;fev1% predicted =50%,Pulmonary Ventilation,D012123,NA,0,1599,any,2,000000000,Pulmonary Ventilation,NA
6721,30587959,3,;fev1% predicted Ã¢â€°Â¥50%,Pulmonary Ventilation,D012123,NA,0,1599,any,2,000000000,Pulmonary Ventilation,NA
6722,30587959,3,fev1% predicted <50%,Pulmonary Ventilation,D012123,NA,0,1599,any,2,000000000,Pulmonary Ventilation,NA
6723,30587959,3,fev1% predicted =50%,Pulmonary Ventilation,D012123,NA,0,1599,any,2,000000000,Pulmonary Ventilation,NA
6724,30587959,3,fev1% predicted Ã¢â€°Â¥50%,Pulmonary Ventilation,D012123,NA,0,1599,any,2,000000000,Pulmonary Ventilation,NA
6725,30587959,4,;age <65 years,Age Factors,D000367,NA,0,581,any,2,000000000,Age Factors,NA
6726,30587959,4,;age =65 years,Age Factors,D000367,NA,0,581,any,2,000000000,Age Factors,NA
6727,30587959,4,;age Ã¢â€°Â¥65 years,Age Factors,D000367,NA,0,581,any,2,000000000,Age Factors,NA
6728,30587959,5,;fev1% predicted <50%,Pulmonary Ventilation,D012123,NA,0,1303,any,2,000000000,Pulmonary Ventilation,NA
6729,30587959,5,;fev1% predicted =50%,Pulmonary Ventilation,D012123,NA,0,1303,any,2,000000000,Pulmonary Ventilation,NA
6730,30587959,5,;fev1% predicted Ã¢â€°Â¥50%,Pulmonary Ventilation,D012123,NA,0,1303,any,2,000000000,Pulmonary Ventilation,NA
6731,30587959,5,fev1% predicted =50%,Pulmonary Ventilation,D012123,NA,0,1303,any,2,000000000,Pulmonary Ventilation,NA
6732,30587959,5,fev1% predicted Ã¢â€°Â¥50%,Pulmonary Ventilation,D012123,NA,0,1303,any,2,000000000,Pulmonary Ventilation,NA
6733,30590387,2,grs,Genetic Profile,D000076610,NA,0,91,severity,11,000100000,Genetic Profile,NA
6734,30590387,2,grs,complex,none,NA,0,91,severity,11,000100100,complex,NA
6735,30591006,3,;with cerebrovascular disease,Stroke,D020521,NA,0,1366,any,2,000000000,Stroke,NA
6736,30591006,3,;without cerebrovascular disease,Stroke,D020521,NA,0,1366,any,2,000000000,Stroke,NA
6737,30609212,2,age,Age Factors,D000367,NA,0,66,any,2,000000000,Age Factors,NA
6738,30609212,2,anti-hyperglycaemic agents,"blood glucose lowering drugs, excl. insulins",NA,A10B,0,66,any,2,000000000,"blood glucose lowering drugs, excl. insulins",NA
6739,30609212,2,baseline HbA1c,Glycated Hemoglobin A,D006442,NA,0,66,any,2,000000000,Glycated Hemoglobin A,NA
6740,30609212,2,gender,Gender Identity,D005783,NA,0,66,any,2,000000000,Gender Identity,NA
6741,30609212,3,;baseline hbalc >69 mmol/mol (>8.5%),Glycated Hemoglobin A,D006442,NA,0,340,any,2,000000000,Glycated Hemoglobin A,NA
6742,30614616,2,;female participants who are =3 years postmenopausal,Menopause,D008593,NA,0,801,any,2,000000000,Menopause,NA
6743,30614616,2,;female participants who are Ã¢â€°Â¥3 years postmenopausal,Menopause,D008593,NA,0,801,any,2,000000000,Menopause,NA
6744,30654882,1,peri-operative cabg participants:,Coronary Artery Bypass,D001026,NA,0,1181,any,2,000000000,Coronary Artery Bypass,NA
6745,30659410,NA,Medical History: 25(OH)D Sufficiency category,unclassifiable,NA,NA,0,0,previous,8,100000000,unclassifiable,172
6746,30667279,1,age,Age Factors,D000367,NA,0,1172,any,2,000000000,Age Factors,NA
6747,30667279,1,diabetes,Diabetes Mellitus,D003920,NA,0,1172,any,2,000000000,Diabetes Mellitus,NA
6748,30667279,1,Hypertension,Hypertension,D006973,NA,0,1172,any,2,000000000,Hypertension,NA
6749,30667279,1,previous stroke,Stroke,D020521,NA,0,1172,previous,8,100000000,Stroke,NA
6750,30667279,1,race,Racial Groups,D044469,NA,0,1172,any,2,000000000,Racial Groups,NA
6751,30667279,1,systolic blood pressure,Blood Pressure,D001794,NA,0,1172,any,2,000000000,Blood Pressure,NA
6752,30696483,2,Leeds Dactylitis Index-Basic =0,unclassifiable,NA,NA,0,48,any,2,000000000,unclassifiable,NA
6753,30696483,2,Leeds Dactylitis Index-Basic >0,unclassifiable,NA,NA,0,48,any,2,000000000,unclassifiable,NA
6754,30696483,2,Leeds Enthesitis Index =0,unclassifiable,NA,NA,0,48,any,2,000000000,unclassifiable,NA
6755,30696483,2,Leeds Enthesitis Index >0,unclassifiable,NA,NA,0,48,any,2,000000000,unclassifiable,NA
6756,30729456,NA,Patient Variable: Ethnicity,Racial Groups,D044469,NA,0,0,any,2,000000000,Racial Groups,20
6757,30734043,2,;adherence >80%,unclassifiable,NA,NA,0,NA,severity,11,000100000,unclassifiable,NA
6758,30734043,2,;intention to treat,unclassifiable,NA,NA,0,NA,severity,11,000100000,unclassifiable,NA
6759,30815468,2,subjects who did not receive labd prior to the study,long-acting beta agonist,NA,R03A,0,291,previous,8,100000000,long-acting beta agonist,NA
6760,30815468,2,subjects who did receive labd prior to the study,long-acting beta agonist,NA,R03A,0,291,previous,8,100000000,long-acting beta agonist,NA
6761,30815468,3,a) those receiving no inhaled pre-treatment maintenance medication,complex,none,NA,0,84,previous,8,100000000,complex,NA
6762,30815468,3,previous ics alone,Steroids,D013256,NA,0,84,previous,8,100000000,Steroids,NA
6763,30815468,3,previous labd alone,long-acting beta agonist,NA,R03A,0,84,previous,8,100000000,long-acting beta agonist,NA
6764,30830724,2,"age =65 years, n (%)",Age Factors,D000367,NA,0,982,any,2,000000000,Age Factors,NA
6765,30830724,2,"age Ã¢â€°Â¥65 years, n (%)",Age Factors,D000367,NA,0,982,any,2,000000000,Age Factors,NA
6766,30830724,2,"age, years",Age Factors,D000367,NA,0,982,any,2,000000000,Age Factors,NA
6767,30830724,2,"baseline egfr, ml/min/1.73 m2",Glomerular Filtration Rate,D005919,NA,0,982,any,2,000000000,Glomerular Filtration Rate,NA
6768,30830724,2,"baseline fpg, mg/dl",Glycemic Control,D000085002,NA,0,982,any,2,000000000,Glycemic Control,NA
6769,30830724,2,"baseline hba1c, %",Glycated Hemoglobin A,D006442,NA,0,982,any,2,000000000,Glycated Hemoglobin A,NA
6770,30830724,2,"bmi, kg/m2",Body Mass Index,D015992,NA,0,982,any,2,000000000,Body Mass Index,NA
6771,30830724,2,"body weight, kg",Body Weight,D001835,NA,0,982,any,2,000000000,Body Weight,NA
6772,30830724,2,"distribution of metformin dose at randomization, n (%)",Hypoglycemic Agents,D007004,NA,0,982,any,2,000000000,Hypoglycemic Agents,NA
6773,30830724,2,"duration of t2dm, years",Diabetes Mellitus,D003920,NA,0,982,duration,5,001000000,Diabetes Mellitus,NA
6774,30830724,2,male female,Gender Identity,D005783,NA,0,982,any,2,000000000,Gender Identity,NA
6775,30830724,2,n (%),Racial Groups,D044469,NA,0,982,any,2,000000000,Racial Groups,NA
6776,30830724,3,n (%),Racial Groups,D044469,NA,0,1700,any,2,000000000,Racial Groups,NA
6777,30830724,4,n (%),Racial Groups,D044469,NA,0,152,any,2,000000000,Racial Groups,NA
6778,30830724,5,male female,Gender Identity,D005783,NA,0,65,any,2,000000000,Gender Identity,NA
6779,30830724,5,n (%),Racial Groups,D044469,NA,0,65,any,2,000000000,Racial Groups,NA
6780,30830724,6,male female,Gender Identity,D005783,NA,0,445,any,2,000000000,Gender Identity,NA
6781,30830724,6,n (%),Racial Groups,D044469,NA,0,445,any,2,000000000,Racial Groups,NA
6782,30851070,3,Duration of diabetes,Diabetes Mellitus,D003920,NA,0,277,duration,5,001000000,Diabetes Mellitus,NA
6783,30865796,2,age,Age Factors,D000367,NA,0,1586,any,2,000000000,Age Factors,NA
6784,30865796,2,Atherosclerotic cardiovascular disease,Atherosclerosis,D050197,NA,0,1586,any,2,000000000,Atherosclerosis,NA
6785,30865796,2,background lipid-lowering therapy ezetimibe,lipid modifying agents,NA,C10,0,1586,any,2,000000000,lipid modifying agents,NA
6786,30865796,2,background lipid-lowering therapy fibrate,lipid modifying agents,NA,C10,0,1586,any,2,000000000,lipid modifying agents,NA
6787,30865796,2,background lipid-lowering therapy intensity of statin therapy,lipid modifying agents,NA,C10,0,1586,any,2,000000000,lipid modifying agents,NA
6788,30865796,2,background lipid-lowering therapy intensity of statin therapy;low or moderate,lipid modifying agents,NA,C10,0,1586,severity,11,000100000,lipid modifying agents,NA
6789,30865796,2,baseline ldl cholesterol,Lipoproteins,D008074,NA,0,1586,any,2,000000000,Lipoproteins,NA
6790,30865796,2,body-mass index,Body Mass Index,D015992,NA,0,1586,any,2,000000000,Body Mass Index,NA
6791,30865796,2,fibrate,lipid modifying agents,NA,C10,0,1586,any,2,000000000,lipid modifying agents,NA
6792,30865796,2,geographic region,Geographic Locations,D005842,NA,0,1586,any,2,000000000,Geographic Locations,NA
6793,30865796,2,high intensity statin therapy,lipid modifying agents,NA,C10,0,1586,any,2,000000000,lipid modifying agents,NA
6794,30865796,2,history of diabetes,Diabetes Mellitus,D003920,NA,0,1586,previous,8,100000000,Diabetes Mellitus,NA
6795,30865796,2,Hypercholesterolemia,Hypercholesterolemia,D006937,NA,0,1586,type,12,000000010,Hypercholesterolemia,NA
6796,30865796,2,race,Racial Groups,D044469,NA,0,1586,any,2,000000000,Racial Groups,NA
6797,30865796,2,sex,Gender Identity,D005783,NA,0,1586,any,2,000000000,Gender Identity,NA
6798,30871355,3,clopidogrel,Fibrinolytic Agents,D005343,NA,0,1217,any,2,000000000,Fibrinolytic Agents,NA
6799,30871355,4,clopidogrel,Fibrinolytic Agents,D005343,NA,0,1162,any,2,000000000,Fibrinolytic Agents,NA
6800,30882238,2,hf 'without known reduced ef,Heart Failure,D006333,NA,0,1166,type,12,000000010,Heart Failure,NA
6801,30882238,2,hf without known reduced ef,Heart Failure,D006333,NA,0,1166,type,12,000000010,Heart Failure,NA
6802,30882238,2,hfref,Heart Failure,D006333,NA,0,1166,type,12,000000010,Heart Failure,NA
6803,30882238,2,nothfref,Heart Failure,D006333,NA,0,1166,type,12,000000010,Heart Failure,NA
6804,30882238,2,without hx of hf,Heart Failure,D006333,NA,0,1166,type,12,000000010,Heart Failure,NA
6805,30882239,2,mrf,Risk Factors,D012307,NA,0,1094,risk score,10,000000100,Risk Factors,NA
6806,30882239,2,no prior mi,Myocardial Infarction,D009203,NA,0,1094,previous,8,100010000,Myocardial Infarction,NA
6807,30882239,2,patients with ascvd but noÂ ml,complex,none,NA,0,1094,any,2,000000000,complex,NA
6808,30882239,2,patients with only mrf,Risk Factors,D012307,NA,0,1094,risk score,10,000000100,Risk Factors,NA
6809,30882239,2,patients with prior ml,Myocardial Infarction,D009203,NA,0,1094,previous,8,100000000,Myocardial Infarction,NA
6810,30882239,2,prior ml,Myocardial Infarction,D009203,NA,0,1094,previous,8,100010000,Myocardial Infarction,NA
6811,30882239,3,no prior mi (arr),Myocardial Infarction,D009203,NA,0,1382,previous,8,100000000,Myocardial Infarction,NA
6812,30882239,3,no prior ml (hr (95%ci)),Myocardial Infarction,D009203,NA,0,1382,previous,8,100000000,Myocardial Infarction,NA
6813,30882239,3,no prior ml hr (95% cl),Myocardial Infarction,D009203,NA,0,1382,previous,8,100000000,Myocardial Infarction,NA
6814,30882239,3,patients with ascvd but no prior ml hr (95% cl),Cardiovascular Diseases,D002318,NA,0,1382,previous,8,100000000,Cardiovascular Diseases,NA
6815,30882239,3,"patients with only mrf, no prior mi hr (95% cl)",Myocardial Infarction,D009203,NA,0,1382,previous,8,100010100,Myocardial Infarction,NA
6816,30882239,3,patients with prior ml hr (95% cl),Myocardial Infarction,D009203,NA,0,1382,previous,8,100000000,Myocardial Infarction,NA
6817,30882239,3,prior ml (arr),Myocardial Infarction,D009203,NA,0,1382,previous,8,100000000,Myocardial Infarction,NA
6818,30882239,3,prior ml (hr (95%ci)),Myocardial Infarction,D009203,NA,0,1382,previous,8,100000000,Myocardial Infarction,NA
6819,30882239,3,prior ml hr (95% cl),Myocardial Infarction,D009203,NA,0,1382,previous,8,100000000,Myocardial Infarction,NA
6820,30882239,4,no prior mi (arr),Myocardial Infarction,D009203,NA,0,1266,previous,8,100000000,Myocardial Infarction,NA
6821,30882239,4,no prior ml (hr (95%ci)),Myocardial Infarction,D009203,NA,0,1266,previous,8,100000000,Myocardial Infarction,NA
6822,30882239,4,no prior ml hr (95% cl),Myocardial Infarction,D009203,NA,0,1266,previous,8,100000000,Myocardial Infarction,NA
6823,30882239,4,patients with prior ml hr (95% cl),Myocardial Infarction,D009203,NA,0,1266,previous,8,100000000,Myocardial Infarction,NA
6824,30882239,4,prior ml (arr),Myocardial Infarction,D009203,NA,0,1266,previous,8,100000000,Myocardial Infarction,NA
6825,30882239,4,prior ml (hr (95%ci)),Myocardial Infarction,D009203,NA,0,1266,previous,8,100000000,Myocardial Infarction,NA
6826,30882239,4,prior ml hr (95% cl),Myocardial Infarction,D009203,NA,0,1266,previous,8,100000000,Myocardial Infarction,NA
6827,30882239,5,no prior mi (arr),Myocardial Infarction,D009203,NA,0,255,previous,8,100000000,Myocardial Infarction,NA
6828,30882239,5,no prior ml (hr (95%ci)),Myocardial Infarction,D009203,NA,0,255,previous,8,100000000,Myocardial Infarction,NA
6829,30882239,5,no prior ml hr (95% cl),Myocardial Infarction,D009203,NA,0,255,previous,8,100000000,Myocardial Infarction,NA
6830,30882239,5,patients with prior ml hr (95% cl),Myocardial Infarction,D009203,NA,0,255,previous,8,100000000,Myocardial Infarction,NA
6831,30882239,5,prior ml (arr),Myocardial Infarction,D009203,NA,0,255,previous,8,100000000,Myocardial Infarction,NA
6832,30882239,5,prior ml (hr (95%ci)),Myocardial Infarction,D009203,NA,0,255,previous,8,100000000,Myocardial Infarction,NA
6833,30882239,5,prior ml hr (95% cl),Myocardial Infarction,D009203,NA,0,255,previous,8,100000000,Myocardial Infarction,NA
6834,30936738,2,age,Age Factors,D000367,NA,0,669,any,2,000000000,Age Factors,NA
6835,30936738,2,diabetes,Diabetes Mellitus,D003920,NA,0,669,any,2,000000000,Diabetes Mellitus,NA
6836,30936738,2,pain,Pain,D010146,NA,0,669,severity,11,000100000,Pain,NA
6837,30936738,3,diabetes,Diabetes Mellitus,D003920,NA,0,702,any,2,000000000,Diabetes Mellitus,NA
6838,30936738,4,diabetes,Diabetes Mellitus,D003920,NA,0,1511,any,2,000000000,Diabetes Mellitus,NA
6839,30936738,5,diabetes,Diabetes Mellitus,D003920,NA,0,630,any,2,000000000,Diabetes Mellitus,NA
6840,30953107,2,baseline tg <1.8 mmol/l,Lipoproteins,D008074,NA,0,865,any,2,000000000,Lipoproteins,NA
6841,30953107,2,baseline tg > 1.8 mmol/l,Lipoproteins,D008074,NA,0,865,any,2,000000000,Lipoproteins,NA
6842,30953107,2,baseline triglyceride levels,Lipoproteins,D008074,NA,0,865,any,2,000000000,Lipoproteins,NA
6843,7997016,1,age <60 yr,Age Factors,D000367,NA,0,1731,any,2,000000000,Age Factors,NA
6844,7997016,1,age 3*60 yr,Age Factors,D000367,NA,0,1731,any,2,000000000,Age Factors,NA
6845,7997016,1,age s*60 yr,Age Factors,D000367,NA,0,1731,any,2,000000000,Age Factors,NA
6846,7997016,1,men,Gender Identity,D005783,NA,0,1731,any,2,000000000,Gender Identity,NA
6847,7997016,1,women,Gender Identity,D005783,NA,0,1731,any,2,000000000,Gender Identity,NA
6848,8121459,2,age (yr),Age Factors,D000367,NA,0,1656,any,2,000000000,Age Factors,NA
6849,8121459,2,angina or acute mi,Myocardial Infarction,D009203,NA,0,1656,severity,11,000100000,Myocardial Infarction,NA
6850,8121459,2,angina or acute mi;high-risk,Myocardial Infarction,D009203,NA,0,1656,severity,11,000100100,Myocardial Infarction,NA
6851,8121459,2,entry category;unstable,Myocardial Infarction,D009203,NA,0,1656,risk score,10,000000100,Myocardial Infarction,NA
6852,8121459,2,sex,Gender Identity,D005783,NA,0,1656,any,2,000000000,Gender Identity,NA
6853,8121459,2,weight (kg),Body Weight,D001835,NA,0,1656,any,2,000000000,Body Weight,NA
6854,8596317,NA,Age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
6855,8596317,NA,Body mass index,Body Mass Index,D015992,NA,0,0,any,2,000000000,Body Mass Index,NA
6856,8596317,NA,Bodyweight (kg),Body Weight,D001835,NA,0,0,any,2,000000000,Body Weight,NA
6857,8596317,NA,"High-risk criterion (more than one of: age >70, previous myocardial infarction, medically treated heart failure, or diabetes mellitus)",complex,NA,NA,0,0,previous,8,100000100,complex,NA
6858,8596317,NA,Inclusion diagnosis,Angina Pectoris,D000787,NA,0,0,any,2,000000000,Angina Pectoris,NA
6859,8596317,NA,Inclusion diagnosis,Myocardial Infarction,D009203,NA,0,0,any,2,000000000,Myocardial Infarction,NA
6860,8596317,NA,Medication,Cardiovascular Agents,D002317,NA,0,0,any,2,000000000,Cardiovascular Agents,NA
6861,8596317,NA,"Modified Braunwald class, type",Angina Pectoris,D000787,NA,0,0,severity,11,000100010,Angina Pectoris,NA
6862,8596317,NA,Sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
6863,8596317,NA,Smoking status,Cigarette Smoking,D000073865,NA,0,0,any,2,000000000,Cigarette Smoking,NA
6864,8950879,NA,vertebral fracture frequency,"Fractures, Bone",D050723,NA,0,0,any,2,000000000,"Fractures, Bone",279
6865,9036306,NA,Cardiothoracic ratio,unclassifiable,NA,NA,0,0,any,2,000000000,unclassifiable,NA
6866,9036306,NA,Cause of heart failure,Heart Failure,D006333,NA,0,0,aetiological,1,000001000,Heart Failure,NA
6867,9036306,NA,Ejection fraction,Stroke Volume,D013318,NA,0,0,any,2,000000000,Stroke Volume,NA
6868,9036306,NA,NYHA class,Heart Failure,D006333,NA,0,0,severity,11,000100000,Heart Failure,NA
6869,9036306,NA,Previous use of digoxin,Diuretics,D004232,NA,0,0,previous,8,100000000,Diuretics,NA
6870,9164316,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,245
6871,9164316,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
6872,9164316,NA,ECG findings at enrolment,Electrocardiography,D004562,NA,0,0,any,2,000000000,Electrocardiography,NA
6873,9164316,NA,peripheral vascular disease,Peripheral Vascular Diseases,D016491,NA,0,0,any,2,000000000,Peripheral Vascular Diseases,NA
6874,9164316,NA,renal dysfunction,Renal Insufficiency,D051437,NA,0,0,any,2,000000000,Renal Insufficiency,NA
6875,9164316,NA,sex,Gender Identity,D005783,NA,0,0,any,2,000000000,Gender Identity,NA
6876,9250846,NA,age,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,105
6877,9250846,NA,any echocardiographic changes at base line,unclassifiable,NA,NA,0,0,any,2,000000000,unclassifiable,104
6878,9250846,NA,previous long-term aspirin use,Aspirin,D001241,NA,0,0,previous,8,100000000,Aspirin,104
6879,9250846,NA,previous percutaneous transluminal coronary angioplasty,Percutaneous Coronary Intervention,D062645,NA,0,0,previous,8,100000000,Percutaneous Coronary Intervention,104
6880,9250846,NA,ST-segment depression,ST Elevation Myocardial Infarction,D000072657,NA,0,0,any,2,000000000,ST Elevation Myocardial Infarction,104
6881,9603532,1,;tertile 1: 4.78 (0.016),Lipoproteins,D008074,NA,0,645,any,2,000000000,Lipoproteins,NA
6882,9603532,1,;tertile 2: 5.66 (0.19),Lipoproteins,D008074,NA,0,645,any,2,000000000,Lipoproteins,NA
6883,9603532,1,;tertile 3: 6.58 (0.44),Lipoproteins,D008074,NA,0,645,any,2,000000000,Lipoproteins,NA
6884,9841303,2,diabetes,Diabetes Mellitus,D003920,NA,0,1197,any,2,000000000,Diabetes Mellitus,NA
6885,9841303,2,diabetes;no,Diabetes Mellitus,D003920,NA,0,1197,any,2,000000000,Diabetes Mellitus,NA
6886,9841303,2,diabetes;yes,Diabetes Mellitus,D003920,NA,0,1197,any,2,000000000,Diabetes Mellitus,NA
6887,9841303,2,hdl cholesterol,Lipoproteins,D008074,NA,0,1197,any,2,000000000,Lipoproteins,NA
6888,9841303,2,HDL cholesterol,Lipoproteins,D008074,NA,0,1197,any,2,000000000,Lipoproteins,NA
6889,9841303,2,hdl cholesterol;<39 mg/dl,Lipoproteins,D008074,NA,0,1197,any,2,000000000,Lipoproteins,NA
6890,9841303,2,hdl cholesterol;539 mg/dl,Lipoproteins,D008074,NA,0,1197,any,2,000000000,Lipoproteins,NA
6891,9841303,2,Hypertension,Hypertension,D006973,NA,0,1197,any,2,000000000,Hypertension,NA
6892,9841303,2,hypertension!,Hypertension,D006973,NA,0,1197,any,2,000000000,Hypertension,NA
6893,9841303,2,hypertension!;no,Hypertension,D006973,NA,0,1197,any,2,000000000,Hypertension,NA
6894,9841303,2,hypertension!;yes,Hypertension,D006973,NA,0,1197,any,2,000000000,Hypertension,NA
6895,9841303,2,ldl cholesterol,Lipoproteins,D008074,NA,0,1197,any,2,000000000,Lipoproteins,NA
6896,9841303,2,ldl cholesterol;<135 mg/dl,Lipoproteins,D008074,NA,0,1197,any,2,000000000,Lipoproteins,NA
6897,9841303,2,ldl cholesterol;135-173 mg/dl,Lipoproteins,D008074,NA,0,1197,any,2,000000000,Lipoproteins,NA
6898,9841303,2,ldl cholesterol;5174 mg/dl,Lipoproteins,D008074,NA,0,1197,any,2,000000000,Lipoproteins,NA
6899,9841303,2,qualifying event,Medical History Taking,D008487,NA,0,1197,any,2,000000000,Medical History Taking,NA
6900,9841303,2,qualifying event;hospitalization for,Angina Pectoris,D000787,NA,0,1197,any,2,000000000,Angina Pectoris,NA
6901,9841303,2,qualifying event;myocardial infarction,Myocardial Infarction,D009203,NA,0,1197,any,2,000000000,Myocardial Infarction,NA
6902,9841303,2,sex,Gender Identity,D005783,NA,0,1197,any,2,000000000,Gender Identity,NA
6903,9841303,2,sex;female,Gender Identity,D005783,NA,0,1197,any,2,000000000,Gender Identity,NA
6904,9841303,2,sex;male,Gender Identity,D005783,NA,0,1197,any,2,000000000,Gender Identity,NA
6905,9841303,2,Smoker,Cigarette Smoking,D000073865,NA,0,1197,any,2,000000000,Cigarette Smoking,NA
6906,9841303,2,smoking,Cigarette Smoking,D000073865,NA,0,1197,any,2,000000000,Cigarette Smoking,NA
6907,9841303,2,smoking;current smoker,Cigarette Smoking,D000073865,NA,0,1197,current,3,010000000,Cigarette Smoking,NA
6908,9841303,2,smoking;former smoker,Cigarette Smoking,D000073865,NA,0,1197,previous,8,100000000,Cigarette Smoking,NA
6909,9841303,2,smoking;nonsmoker,Cigarette Smoking,D000073865,NA,0,1197,any,2,000000000,Cigarette Smoking,NA
6910,9841303,2,total cholesterol,Lipoproteins,D008074,NA,0,1197,any,2,000000000,Lipoproteins,NA
6911,9841303,2,total cholesterol;<213 mg/dl,Lipoproteins,D008074,NA,0,1197,any,2,000000000,Lipoproteins,NA
6912,9841303,2,total cholesterol;213-250 mg/dl,Lipoproteins,D008074,NA,0,1197,any,2,000000000,Lipoproteins,NA
6913,9841303,2,total cholesterol;5251 mg/dl,Lipoproteins,D008074,NA,0,1197,any,2,000000000,Lipoproteins,NA
6914,9841303,2,triglycerides,Lipoproteins,D008074,NA,0,1197,any,2,000000000,Lipoproteins,NA
6915,9841303,2,triglycerides;<133 mg/dl,Lipoproteins,D008074,NA,0,1197,any,2,000000000,Lipoproteins,NA
6916,9841303,2,triglycerides;133-230 mg/dl,Lipoproteins,D008074,NA,0,1197,any,2,000000000,Lipoproteins,NA
6917,9841303,2,triglycerides;5 231 mg/dl,Lipoproteins,D008074,NA,0,1197,any,2,000000000,Lipoproteins,NA
6918,9841303,2,unstable angina age,complex,none,NA,0,1197,any,2,000000000,complex,NA
6919,9841303,2,unstable angina age;<55 yr,complex,none,NA,0,1197,any,2,000000000,complex,NA
6920,9841303,2,unstable angina age;55-64 yr,complex,none,NA,0,1197,any,2,000000000,complex,NA
6921,9841303,2,unstable angina age;570 yr,complex,none,NA,0,1197,any,2,000000000,complex,NA
6922,9841303,2,unstable angina age;65-69 yr,complex,none,NA,0,1197,any,2,000000000,complex,NA
6923,9841303,NA,Age-Years,Age Factors,D000367,NA,0,0,any,2,000000000,Age Factors,NA
6924,9841303,NA,cholesterol,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,NA
6925,9841303,NA,diabetes,Diabetes Mellitus,D003920,NA,0,0,any,2,000000000,Diabetes Mellitus,NA
6926,9841303,NA,hypertension,Hypertension,D006973,NA,0,0,any,2,000000000,Hypertension,NA
6927,9841303,NA,ldl,Lipoproteins,D008074,NA,0,0,any,2,000000000,Lipoproteins,NA
6928,9841303,NA,"sexm qualifying event (MI, hospitalisation for UA)",complex,none,NA,0,0,any,2,000000000,complex,NA
6929,9841303,NA,smoking,Cigarette Smoking,D000073865,NA,0,0,any,2,000000000,Cigarette Smoking,NA
6930,9848888,2,pretreatment hdl-c,Lipoproteins,D008074,NA,0,271,any,2,000000000,Lipoproteins,NA
6931,9848888,2,pretreatment hdl-c;<0.94 mmol/l,Lipoproteins,D008074,NA,0,271,any,2,000000000,Lipoproteins,NA
6932,9848888,2,pretreatment hdl-c;>0.94 mmol/l,Lipoproteins,D008074,NA,0,271,any,2,000000000,Lipoproteins,NA
6933,9848888,2,pretreatment triglycerides,Lipoproteins,D008074,NA,0,271,any,2,000000000,Lipoproteins,NA
6934,9848888,2,pretreatment triglycerides;<1.58 mmol/l,Lipoproteins,D008074,NA,0,271,any,2,000000000,Lipoproteins,NA
6935,9848888,2,pretreatment triglycerides;>1.58 mmol/l,Lipoproteins,D008074,NA,0,271,any,2,000000000,Lipoproteins,NA
6936,9875874,NA,bone mineral density,Osteoporosis,D010024,NA,0,0,any,2,000000000,Osteoporosis,19
6937,9875874,NA,in subgroups stratified by tertile of baseline Bone mineral density; in this analysis we use femoral neck BMD,Osteoporosis,D010024,NA,0,0,any,2,000000000,Osteoporosis,NA
6938,9892586,3,"cholesterol, mg/dl",Lipoproteins,D008074,NA,0,355,any,2,000000000,Lipoproteins,NA
6939,9892586,3,"cholesterol, mg/dl;<209",Lipoproteins,D008074,NA,0,355,any,2,000000000,Lipoproteins,NA
6940,9892586,3,"cholesterol, mg/dl;>209",Lipoproteins,D008074,NA,0,355,any,2,000000000,Lipoproteins,NA
6941,9892586,3,HDL cholesterol,Lipoproteins,D008074,NA,0,355,any,2,000000000,Lipoproteins,NA
6942,9892586,3,ldl:hdl ratio,Lipoproteins,D008074,NA,0,355,any,2,000000000,Lipoproteins,NA
6943,9892586,3,ldl:hdl ratio;<3.7,Lipoproteins,D008074,NA,0,355,any,2,000000000,Lipoproteins,NA
6944,9892586,3,ldl:hdl ratio;>3.7,Lipoproteins,D008074,NA,0,355,any,2,000000000,Lipoproteins,NA
6945,9892586,3,"triglycerides, mg/dl",Lipoproteins,D008074,NA,0,355,any,2,000000000,Lipoproteins,NA
6946,9892586,4,"cholesterol, mg/dl",Lipoproteins,D008074,NA,0,211,any,2,000000000,Lipoproteins,NA
6947,9892586,4,"cholesterol, mg/dl;<209",Lipoproteins,D008074,NA,0,211,any,2,000000000,Lipoproteins,NA
6948,9892586,4,"cholesterol, mg/dl;>209",Lipoproteins,D008074,NA,0,211,any,2,000000000,Lipoproteins,NA
6949,9892586,4,ldl:hdl ratio,Lipoproteins,D008074,NA,0,211,any,2,000000000,Lipoproteins,NA
6950,9892586,4,ldl:hdl ratio;<3.7,Lipoproteins,D008074,NA,0,211,any,2,000000000,Lipoproteins,NA
6951,9892586,4,ldl:hdl ratio;>3.7,Lipoproteins,D008074,NA,0,211,any,2,000000000,Lipoproteins,NA
6952,9892586,4,"triglycerides, mg/dl",Lipoproteins,D008074,NA,0,211,any,2,000000000,Lipoproteins,NA
